PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ring, A; Dowrick, C; Humphris, G; Salmon, P				Ring, A; Dowrick, C; Humphris, G; Salmon, P			Do patients with unexplained physical symptoms pressurise general practitioners for somatic treatment? A qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE; DOCTORS; GYNECOLOGISTS; STRATEGIES; DISORDER	Objectives To identify the ways in which patients with medically unexplained symptoms present their problems and needs to general practitioners and to identify the forms of presentation that might lead general practitioners to feel pressurised to deliver somatic mterventions. Design Qualitative analysis of audiorecorded consultations between patients and general practitioners. Setting 7 general practices in Merseyside, England. Participants 36 patients selected consecutively from 21 general practices, in Whom doctors considered that patients' symptoms were medically unexplained. Main outcome measures Inductive qualitative analysis of ways in which patients presented their symptoms to general practitioners. Results Although 34 patients received somatic interventions (27 received drug prescriptions, 12 underwent investigations, and four were referred), only 10 requested them. However, patients presented in other ways that had the potential to pressurise general practitioners, including graphic and emotional language; complex patterns of symptoms that resisted explanation; description of emotional and social effects of symptoms; reference to other individuals as authority for the severity of symptoms; and biomedical explanations. Conclusions Most patients with unexplained symptoms received somatic interventions from their general practitioners but had not requested diem. Though such patients apparently seek to engage the general practitioner by conveying the reality of their suffering, general practitioners respond symptomatically.	Univ Liverpool, Dept Clin Psychol, Liverpool L69 3GB, Merseyside, England; Univ Liverpool, Dept Primary Care, Liverpool L69 3GB, Merseyside, England; Univ St Andrews, Bute Med Sch, St Andrews KY16 9ST, Fife, Scotland	University of Liverpool; University of Liverpool; University of St Andrews	Salmon, P (corresponding author), Univ Liverpool, Dept Clin Psychol, Whelan Bldg,Brownlow HIll, Liverpool L69 3GB, Merseyside, England.	psalmon@liv.ac.uk	Humphris, Gerry/AAX-8013-2020; Salmon, Peter/H-5289-2018	Humphris, Gerry/0000-0002-4601-8834; Salmon, Peter/0000-0001-6450-5209				ARMSTRONG D, 1991, BRIT MED J, V302, P1186, DOI 10.1136/bmj.302.6786.1186; Echlin D, 2002, BJOG-INT J OBSTET GY, V109, P1335, DOI 10.1016/S1470-0328(02)01974-2; Escobar JI, 1998, BRIT J PSYCHIAT, V173, P262, DOI 10.1192/bjp.173.3.262; Garcia-Campayo J, 1998, AUST NZ J PSYCHIAT, V32, P528, DOI 10.3109/00048679809068327; GUBA F, 1989, 4 GENERATION EVALUAT; Hartz AJ, 2000, GEN HOSP PSYCHIAT, V22, P144, DOI 10.1016/S0163-8343(00)00060-8; Kouyanou K, 1998, PAIN, V76, P417, DOI 10.1016/S0304-3959(98)00074-8; MarchantHaycox S, 1997, PSYCHOSOMATICS, V38, P440, DOI 10.1016/S0033-3182(97)71421-X; MATHERS N, 1995, BRIT J GEN PRACT, V45, P293; MCDONALD PS, 1991, FAM PRACT, V8, P112, DOI 10.1093/fampra/8.2.112; Morriss RK, 1999, BRIT J GEN PRACT, V49, P263; Peters S, 1998, SOC SCI MED, V46, P559, DOI 10.1016/S0277-9536(97)00200-1; Peveler R, 1997, J PSYCHOSOM RES, V42, P245, DOI 10.1016/S0022-3999(96)00292-9; Reid S, 2001, FAM PRACT, V18, P519, DOI 10.1093/fampra/18.5.519; Salmon P, 2000, J PSYCHOSOM RES, V49, P119, DOI 10.1016/S0022-3999(00)00103-3; SALMON P, 1994, SOC SCI MED, V38, P585, DOI 10.1016/0277-9536(94)90255-0; Salmon P, 1995, INT J PSYCHIAT MED, V25, P319, DOI 10.2190/JUNY-QCER-GWLF-H60R; Stanley IM, 2002, INT J PSYCHIAT MED, V32, P125, DOI 10.2190/AVM3-8GU8-JW70-5RX5; Steinmetz D, 2001, FAM PRACT, V18, P495, DOI 10.1093/fampra/18.5.495; Wileman L, 2002, FAM PRACT, V19, P178, DOI 10.1093/fampra/19.2.178; WILLIAMS S, 1995, FAM PRACT, V12, P193, DOI 10.1093/fampra/12.2.193; Zaballa P, 2001, BRIT J GEN PRACT, V51, P182	22	119	121	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 1	2004	328	7447					1057	1060		10.1136/bmj.38057.622639.EE	http://dx.doi.org/10.1136/bmj.38057.622639.EE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817JT	15056592	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000221174500020
J	Sargent, RP; Shepard, RM; Glantz, SA				Sargent, RP; Shepard, RM; Glantz, SA			Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; ACUTE CORONARY SYNDROMES; CARDIO2000 CASE-CONTROL; HEALTHY-YOUNG ADULTS; PASSIVE SMOKING; HEART-DISEASE; SECONDHAND SMOKE; ENDOTHELIUM; EXPOSURE; RISK	Objective To determine whether there was a change in hospital admissions for acute myocardial infarction while a local law banning smoking in public and in workplaces was in effect. Design Analysis of admissions front December 1997 through November 2003 using Poisson analysis. Setting Helena, Montana, a geographical]), isolated community with one hospital serving a population of 68140. Participants All patients admitted for acute myocardial infarction. Main outcome measures Number of monthly admissions for acute myocardial infarction for people living in mid outside Helena. Results During the six months the law was enforced the number of admissions fell significantly (-16 admissions, 95% confidence interval -31.7 to -0.3), from an average of 40 admissions during the same 0 months in die years before and after the law to a total of 24 admissions during die six months the law was in effect. There was a non-significant increase of 5.6 (-5.2 to 16.4) in the number of admissions from outside Helena during the same period, from 12.4 in the years before and after the law to 18 while the law was in effect. Conclusions Laws to enforce smoke-free workplaces and public places may be associated with art effect on morbidity from heart disease.	Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA; St Peters Community Hosp, HealthCare Qual Performance Council, Helena, MT 59601 USA	University of California System; University of California San Francisco	Glantz, SA (corresponding author), Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA.	glantz@medicine.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Celermajer DS, 1996, NEW ENGL J MED, V334, P150, DOI 10.1056/NEJM199601183340303; DAVIS JW, 1989, ARCH INTERN MED, V149, P386, DOI 10.1001/archinte.149.2.386; Fichtenberg CM, 2000, NEW ENGL J MED, V343, P1772, DOI 10.1056/NEJM200012143432406; Fichtenberg CM, 2002, BMJ-BRIT MED J, V325, P188, DOI 10.1136/bmj.325.7357.188; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; Glantz SA, 2001, JAMA-J AM MED ASSOC, V286, P462, DOI 10.1001/jama.286.4.462; He J, 1999, NEW ENGL J MED, V340, P920, DOI 10.1056/NEJM199903253401204; Law MR, 1997, BMJ-BRIT MED J, V315, P973, DOI 10.1136/bmj.315.7114.973; Lightwood JM, 1997, CIRCULATION, V96, P1089, DOI 10.1161/01.CIR.96.4.1089; ONG M, IN PRESS AM J MED; Otsuka R, 2001, JAMA-J AM MED ASSOC, V286, P436, DOI 10.1001/jama.286.4.436; Panagiotakos DB, 2002, BMC PUBLIC HEALTH, V2, DOI 10.1186/1471-2458-2-9; Pierce JP, 1994, TOBACCO USE CALIFORN; Pierce JP, 1994, TOB CONTROL, V3, P15, DOI DOI 10.1136/TC.3.1.15; Pitsavos C, 2002, TOB CONTROL, V11, P220, DOI 10.1136/tc.11.3.220; Pope CA, 2001, ENVIRON HEALTH PERSP, V109, P711, DOI 10.2307/3454788; Rosenlund M, 2001, EPIDEMIOLOGY, V12, P558, DOI 10.1097/00001648-200109000-00016; SCHACHINGER V, 2000, CIRCULATION, V100, P2153; Stefanadis C, 1998, ANN INTERN MED, V128, P426, DOI 10.7326/0003-4819-128-6-199803150-00002; Sumida H, 1998, J AM COLL CARDIOL, V31, P811, DOI 10.1016/S0735-1097(98)00010-2; *TOB CONTR SECT, MOD CHANG CAL EXP TO; Valkonen M, 1998, CIRCULATION, V97, P2012, DOI 10.1161/01.CIR.97.20.2012	23	343	349	1	29	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 24	2004	328	7446					977	980		10.1136/bmj.38055.715683.55	http://dx.doi.org/10.1136/bmj.38055.715683.55			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	816SR	15066887	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000221130100011
J	Dunham, A; Matthews, LH; Burton, J; Ashurst, JL; Howe, KL; Ashcroft, KJ; Beare, DM; Burford, DC; Hunt, SE; Griffiths-Jones, S; Jones, MC; Keenan, SJ; Oliver, K; Scott, CE; Ainscough, R; Almeida, JP; Ambrose, KD; Andrews, DT; Ashwell, RIS; Babbage, AK; Bagguley, CL; Bailey, J; Bannerjee, R; Barlow, KF; Bates, K; Beasley, H; Bird, CP; Bray-Allen, S; Brown, AJ; Brown, JY; Burrill, W; Carder, C; Carter, NP; Chapman, JC; Clamp, ME; Clark, SY; Clarke, G; Clee, CM; Clegg, SCM; Cobley, V; Collins, JE; Corby, N; Coville, GJ; Deloukas, P; Dhami, P; Dunham, I; Dunn, M; Earthrowl, ME; Ellington, AG; Faulkner, L; Frankish, AG; Frankland, J; French, L; Garner, P; Garnett, J; Gilbert, JGR; Gilson, CJ; Ghori, J; Grafham, DV; Gribble, SM; Griffiths, C; Hall, RE; Hammond, S; Harley, JL; Hart, EA; Heath, PD; Howden, PJ; Huckle, EJ; Hunt, PJ; Hunt, AR; Johnson, C; Johnson, D; Kay, M; Kimberley, AM; King, A; Laird, GK; Langford, CJ; Lawlor, S; Leongamornlert, DA; Lloyd, DM; Lloyd, C; Loveland, JE; Lovell, J; Martin, S; Mashreghi-Mohammadi, M; McLaren, SJ; McMurray, A; Milne, S; Moore, MJF; Nickerson, T; Palmer, SA; Pearce, AV; Peck, AI; Pelan, S; Phillimore, B; Porter, KM; Rice, CM; Searle, S; Sehra, HK; Shownkeen, R; Skuce, CD; Smith, M; Steward, CA; Sycamore, N; Tester, J; Thomas, DW; Tracey, A; Tromans, A; Tubby, B; Wall, M; Wallis, JM; West, AP; Whitehead, SL; Willey, DL; Wilming, L; Wray, PW; Wright, MW; Young, L; Coulson, A; Durbin, R; Hubbard, T; Sulston, JE; Beck, S; Bentley, DR; Rogers, J; Ross, MT				Dunham, A; Matthews, LH; Burton, J; Ashurst, JL; Howe, KL; Ashcroft, KJ; Beare, DM; Burford, DC; Hunt, SE; Griffiths-Jones, S; Jones, MC; Keenan, SJ; Oliver, K; Scott, CE; Ainscough, R; Almeida, JP; Ambrose, KD; Andrews, DT; Ashwell, RIS; Babbage, AK; Bagguley, CL; Bailey, J; Bannerjee, R; Barlow, KF; Bates, K; Beasley, H; Bird, CP; Bray-Allen, S; Brown, AJ; Brown, JY; Burrill, W; Carder, C; Carter, NP; Chapman, JC; Clamp, ME; Clark, SY; Clarke, G; Clee, CM; Clegg, SCM; Cobley, V; Collins, JE; Corby, N; Coville, GJ; Deloukas, P; Dhami, P; Dunham, I; Dunn, M; Earthrowl, ME; Ellington, AG; Faulkner, L; Frankish, AG; Frankland, J; French, L; Garner, P; Garnett, J; Gilbert, JGR; Gilson, CJ; Ghori, J; Grafham, DV; Gribble, SM; Griffiths, C; Hall, RE; Hammond, S; Harley, JL; Hart, EA; Heath, PD; Howden, PJ; Huckle, EJ; Hunt, PJ; Hunt, AR; Johnson, C; Johnson, D; Kay, M; Kimberley, AM; King, A; Laird, GK; Langford, CJ; Lawlor, S; Leongamornlert, DA; Lloyd, DM; Lloyd, C; Loveland, JE; Lovell, J; Martin, S; Mashreghi-Mohammadi, M; McLaren, SJ; McMurray, A; Milne, S; Moore, MJF; Nickerson, T; Palmer, SA; Pearce, AV; Peck, AI; Pelan, S; Phillimore, B; Porter, KM; Rice, CM; Searle, S; Sehra, HK; Shownkeen, R; Skuce, CD; Smith, M; Steward, CA; Sycamore, N; Tester, J; Thomas, DW; Tracey, A; Tromans, A; Tubby, B; Wall, M; Wallis, JM; West, AP; Whitehead, SL; Willey, DL; Wilming, L; Wray, PW; Wright, MW; Young, L; Coulson, A; Durbin, R; Hubbard, T; Sulston, JE; Beck, S; Bentley, DR; Rogers, J; Ross, MT			The DNA sequence and analysis of human chromosome 13	NATURE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN GENOME SEQUENCE; SEGMENTAL DUPLICATIONS; PHYSICAL MAPS; RNA GENES; DATABASE; FAMILY; POLYMORPHISMS; RECOMBINATION; LOCALIZATION	Chromosome 13 is the largest acrocentric human chromosome. It carries genes involved in cancer including the breast cancer type 2 (BRCA2) and retinoblastoma (RB1) genes, is frequently rearranged in B-cell chronic lymphocytic leukaemia, and contains the DAOA locus associated with bipolar disorder and schizophrenia. We describe completion and analysis of 95.5 megabases (Mb) of sequence from chromosome 13, which contains 633 genes and 296 pseudogenes. We estimate that more than 95.4% of the protein-coding genes of this chromosome have been identified, on the basis of comparison with other vertebrate genome sequences. Additionally, 105 putative non-coding RNA genes were found. Chromosome 13 has one of the lowest gene densities (6.5 genes per Mb) among human chromosomes, and contains a central region of 38 Mb where the gene density drops to only 3.1 genes per Mb.	Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England; Galton Lab, HUGO Gene Nomenclature Comm, London NW1 2HE, England	Wellcome Trust Sanger Institute; University of London; University College London	Dunham, A (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Hinxton CB10 1SA, Cambs, England.	ad1@sanger.ac.uk	Frankish, Adam/G-6545-2011; Hubbard, Tim J/C-2567-2008; Hubbard, Tim J.P./AAT-4571-2020; Deloukas, Panos/B-2922-2013; Johnson, David/A-3907-2011; Durbin, Richard/AAE-7178-2019; Wright, Mathew/H-5394-2012; Griffiths-Jones, Sam/H-2998-2014	Hubbard, Tim J/0000-0002-1767-9318; Hubbard, Tim J.P./0000-0002-1767-9318; Deloukas, Panos/0000-0001-9251-070X; Johnson, David/0000-0003-0887-3343; Durbin, Richard/0000-0002-9130-1006; Wright, Mathew/0000-0002-2650-2426; Loveland, Jane/0000-0002-7669-2934; Andrews, Dan/0000-0003-3922-6376; Kay, Mike/0000-0002-3282-0834; Griffiths-Jones, Sam/0000-0001-6043-807X; Howe, Kevin/0000-0002-1751-9226; Wass, Elizabeth/0000-0002-8605-9921; Hunt, Sarah/0000-0002-8350-1235; Wilming, Laurens/0000-0002-4154-7358; Martin, Sancha/0000-0001-6213-5259; Davidson, Claire/0000-0002-4910-8202; Hunt, Adrienne/0000-0002-1227-0310; Fosker, Christine/0000-0002-3799-9474; Gilbert, James/0000-0001-8079-3159; Keenan, Stephen/0000-0002-9141-7690; Steward, Charles/0000-0001-8829-5349; Frankish, Adam/0000-0002-4333-628X; Leongamornlert, Daniel/0000-0002-3486-3168; Dunham, Ian/0000-0003-2525-5598				Armitage JO, 1998, J CLIN ONCOL, V16, P2780, DOI 10.1200/JCO.1998.16.8.2780; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; Bentley DR, 2001, NATURE, V409, P942, DOI 10.1038/35057165; Beyer K, 2000, J INVEST DERMATOL, V115, P906, DOI 10.1046/j.1523-1747.2000.00096.x; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Cheung J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r25; Chumakov I, 2002, P NATL ACAD SCI USA, V99, P13675, DOI 10.1073/pnas.182412499; Collins JE, 2003, GENOME RES, V13, P27, DOI 10.1101/gr.695703; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; Deloukas P, 2001, NATURE, V414, P865, DOI 10.1038/414865a; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Down TA, 2002, GENOME RES, V12, P458, DOI 10.1101/gr.216102; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Felsenfeld A, 1999, GENOME RES, V9, P1; Glazko GV, 2003, TRENDS GENET, V19, P119, DOI 10.1016/S0168-9525(03)00016-7; Griffiths-Jones S, 2003, NUCLEIC ACIDS RES, V31, P439, DOI 10.1093/nar/gkg006; Guipponi M, 2001, HUM GENET, V109, P569, DOI 10.1007/s004390100607; Hattori E, 2003, AM J HUM GENET, V72, P1131, DOI 10.1086/374822; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Heilig R, 2003, NATURE, V421, P601, DOI 10.1038/nature01348; Hillier LW, 2003, NATURE, V424, P157, DOI 10.1038/nature01782; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Kehrer-Sawatzki H, 1998, CHROMOSOME RES, V6, P429, DOI 10.1023/A:1009287223826; Kimura K, 1999, HUM MOL GENET, V8, P1487, DOI 10.1093/hmg/8.8.1487; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157; Mungall AJ, 2003, NATURE, V425, P805, DOI 10.1038/nature02055; Neat MJ, 2001, GENE CHROMOSOME CANC, V32, P236, DOI 10.1002/gcc.1187; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Osoegawa K, 2001, GENOME RES, V11, P483, DOI 10.1101/gr.169601; Roest Crollius H, 2000, NAT GENET, V25, P235, DOI 10.1038/76118; Rowntree C, 2002, LEUKEMIA, V16, P1267, DOI 10.1038/sj.leu.2402551; SACCONE S, 1993, P NATL ACAD SCI USA, V90, P11929, DOI 10.1073/pnas.90.24.11929; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Schuler GD, 1997, GENOME RES, V7, P541, DOI 10.1101/gr.7.5.541; Schwartz S, 2003, NUCLEIC ACIDS RES, V31, P3518, DOI 10.1093/nar/gkg579; Schwartz S, 2003, GENOME RES, V13, P103, DOI 10.1101/gr.809403; Stoesser G, 2003, NUCLEIC ACIDS RES, V31, P17, DOI 10.1093/nar/gkg021; Wain HM, 2002, NUCLEIC ACIDS RES, V30, P169, DOI 10.1093/nar/30.1.169; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yu A, 2001, NATURE, V409, P951, DOI 10.1038/35057185; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166	50	65	387	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					522	528		10.1038/nature02379	http://dx.doi.org/10.1038/nature02379			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15057823	Green Accepted, Bronze			2022-12-28	WOS:000220540100033
J	Li, DH; Xie, KP; Wolff, R; Abbruzzese, JL				Li, DH; Xie, KP; Wolff, R; Abbruzzese, JL			Pancreatic cancer	LANCET			English	Review							ENDOTHELIAL GROWTH-FACTOR; K-RAS MUTATIONS; PHASE-II TRIAL; COOPERATIVE-ONCOLOGY-GROUP; TUMOR-SUPPRESSOR GENE; INTRAEPITHELIAL NEOPLASIA; RESECTABLE ADENOCARCINOMA; ENHANCES TUMORIGENICITY; CURATIVE RESECTION; SOMATIC MUTATIONS	Pancreatic cancer remains a major unsolved health problem, with conventional cancer treatments having little impact on disease course. Almost all patients who have pancreatic cancer develop metastases and die. The main risk factors are smoking, age, and some genetic disorders, although the primary causes are poorly understood. Advances in molecular biology have, however, greatly improved understanding of the pathogenesis of pancreatic cancer. Many patients have mutations of the K-ras oncogene, and various tumour-suppressor genes are also inactivated. Growth factors also play an important part. However, disease prognosis is extremely poor. Around 15-20% of patients have resectable disease, but only around 20% of these survive to 5 years. For locally advanced, unresectable, and metastatic disease, treatment is palliative, although fluorouracil chemoradiation for locally advanced and gemcitabine chemotherapy for metastatic disease can provide palliative benefits. Despite pancreatic cancer's resistance to currently available treatments, new methods are being investigated. Preoperative chemoradiation is being advocated, with seemingly sound reasoning, and a wider role for gemcitabine is being explored. However, new therapeutic strategies based on the molecular biology of pancreatic cancer seem to hold the greatest promise.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Abbruzzese, JL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd,Box 426, Houston, TX 77030 USA.	jabbruzz@mdanderson.org	qiao, zhixin/I-3408-2012					ABBRUZZESE JL, 2001, P AN M AM SOC CLIN, V20, P518; Abrams RA, 2001, LANCET, V358, P1565, DOI 10.1016/S0140-6736(01)06666-1; Alguacil J, 2002, CARCINOGENESIS, V23, P101, DOI 10.1093/carcin/23.1.101; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Anderson KE PJ, 1996, CANC EPIDEMIOLOGY PR, P725; Bartsch H, 1998, EUR J CANCER PREV, V7, P215, DOI 10.1097/00008469-199806000-00006; Berger DH, 1999, CANCER, V85, P326, DOI 10.1002/(SICI)1097-0142(19990115)85:2<326::AID-CNCR9>3.0.CO;2-O; Berlin JD, 2002, J CLIN ONCOL, V20, P3270, DOI 10.1200/JCO.2002.11.149; Blackstock AW, 1999, J CLIN ONCOL, V17, P2208, DOI 10.1200/JCO.1999.17.7.2208; Blanchard JA, 2000, DIGEST DIS SCI, V45, P927, DOI 10.1023/A:1005573024448; Bramhall SR, 2002, BRIT J CANCER, V87, P161, DOI 10.1038/sj.bjc.6600446; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Colucci G, 2002, CANCER, V94, P902, DOI 10.1002/cncr.10323.abs; DAVIDS PHP, 1992, LANCET, V340, P1488, DOI 10.1016/0140-6736(92)92752-2; Di Stasi M, 1998, AM J GASTROENTEROL, V93, P1329; DOUGLASS HO, 1987, CANCER, V59, P2006; Duell EJ, 2002, CANCER RES, V62, P4630; Duell EJ, 2002, JNCI-J NATL CANCER I, V94, P297, DOI 10.1093/jnci/94.4.297; Evans DB, 2002, ANN SURG, V236, P694, DOI 10.1097/00000658-200211000-00023; Evans Douglas B., 1997, P1054; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; Fryzek JP, 1997, INT J CANCER, V72, P62, DOI 10.1002/(SICI)1097-0215(19970703)72:1&lt;62::AID-IJC9&gt;3.0.CO;2-2; Fryzek JP, 1997, GI CANCER, V2, P99; FUHRMAN GM, 1994, AM J SURG, V167, P104, DOI 10.1016/0002-9610(94)90060-4; GARABRANT DH, 1992, J NATL CANCER I, V84, P764, DOI 10.1093/jnci/84.10.764; GHADIRIAN P, 1995, CANCER EPIDEM BIOMAR, V4, P895; Goggins M, 2000, AM J PATHOL, V156, P1767, DOI 10.1016/S0002-9440(10)65047-X; Goggins M, 1996, CANCER RES, V56, P5360; Gouma DJ, 2003, ANN SURG, V237, P595, DOI 10.1097/00000658-200304000-00025; Gress F, 2001, ANN INTERN MED, V134, P459, DOI 10.7326/0003-4819-134-6-200103200-00010; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hoffman JP, 1998, J CLIN ONCOL, V16, P317, DOI 10.1200/JCO.1998.16.1.317; Hruban R H, 1998, Surg Oncol Clin N Am, V7, P1; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; JI BT, 1995, CANCER EPIDEM BIOMAR, V4, P885; JIAO L, 2001, P AM ASSOC CANC RES, V42, pA1844; Jimenez R E, 2000, J Hepatobiliary Pancreat Surg, V7, P15, DOI 10.1007/s005340050148; Kadlubar FF, 1998, MUTAT RES-FUND MOL M, V405, P125, DOI 10.1016/S0027-5107(98)00129-8; KAUPPINEN T, 1995, EPIDEMIOLOGY, V6, P498, DOI 10.1097/00001648-199509000-00006; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006; Korc M, 1998, Surg Oncol Clin N Am, V7, P25; LE X, 2000, J INTERFERON CYTOKIN, V20, P1532; Li DH, 2002, MUTAT RES-GEN TOX EN, V513, P37, DOI 10.1016/S1383-5718(01)00291-1; LIEBERMAN MD, 1995, ANN SURG, V222, P638, DOI 10.1097/00000658-199511000-00006; Lima CMSR, 2002, J CLIN ONCOL, V20, P1182, DOI 10.1200/JCO.20.5.1182; LIN A, 1990, ANN INTERN MED, V113, P166, DOI 10.7326/0003-4819-113-2-166; Liu G, 2000, BRIT J CANCER, V82, P1646; Louvet C, 2002, J CLIN ONCOL, V20, P1512, DOI 10.1200/JCO.20.6.1512; Louvet C, 2001, ANN ONCOL, V12, P675, DOI 10.1023/A:1011139808426; Luo JY, 2001, INT J CANCER, V92, P361, DOI 10.1002/ijc.1202; Malats N, 1997, INT J CANCER, V70, P661, DOI 10.1002/(SICI)1097-0215(19970317)70:6<661::AID-IJC6>3.0.CO;2-T; McGinn CJ, 2001, J CLIN ONCOL, V19, P4202, DOI 10.1200/JCO.2001.19.22.4202; Millikan KW, 1999, AM SURGEON, V65, P618; Minsky B D, 1988, J Pain Symptom Manage, V3, P199, DOI 10.1016/0885-3924(88)90031-0; MOERTEL CG, 1981, CANCER, V48, P1705, DOI 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4; Neoptolemos JP, 2003, ANN ONCOL, V14, P675, DOI 10.1093/annonc/mdg207; Neoptolemos JP, 2002, ANN SURG, V236, P694, DOI 10.1097/00000658-200211000-00024; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OZKELIK H, 1997, NAT GENET, V16, P17; Philip PA, 2001, CANCER-AM CANCER SOC, V92, P569, DOI 10.1002/1097-0142(20010801)92:3<569::AID-CNCR1356>3.0.CO;2-D; Pisters PWT, 2003, ANN SURG, V237, P594, DOI 10.1097/00000658-200304000-00024; Pisters PWT, 2002, J CLIN ONCOL, V20, P2537, DOI 10.1200/JCO.2002.11.064; Pisters PWT, 2001, ANN SURG, V234, P47, DOI 10.1097/00000658-200107000-00008; Porta M, 1999, LANCET, V354, P2125, DOI 10.1016/S0140-6736(99)04232-4; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Rothenberg ML, 1996, ANN ONCOL, V7, P347; Rozenblum E, 1997, CANCER RES, V57, P1731; Ryan DP, 2002, CANCER-AM CANCER SOC, V94, P97, DOI 10.1002/cncr.10202; SAFRAN H, 2001, P AN M AM SOC CLIN, V20, pA130; Saito K, 1998, INT J CANCER, V75, P284, DOI 10.1002/(SICI)1097-0215(19980119)75:2<284::AID-IJC18>3.3.CO;2-E; Sakorafas GH, 2001, BIODRUGS, V15, P439, DOI 10.2165/00063030-200115070-00003; Schenk M, 2001, JNCI-J NATL CANCER I, V93, P640, DOI 10.1093/jnci/93.8.640; Schutte M, 1997, CANCER RES, V57, P3126; Sewnath ME, 2002, ANN SURG, V236, P17, DOI 10.1097/00000658-200207000-00005; Sharma S, 2001, CLIN CANCER RES, V7, P3963; Shi Q, 1999, CLIN CANCER RES, V5, P3711; Shi Q, 2001, ONCOGENE, V20, P3751, DOI 10.1038/sj.onc.1204500; Shi Q, 2001, CANCER RES, V61, P4143; Sohn TA, 2000, SURG ONCOL, V9, P95, DOI 10.1016/S0960-7404(00)00041-4; Spitz FR, 1997, J CLIN ONCOL, V15, P928, DOI 10.1200/JCO.1997.15.3.928; Stehlin JS, 1999, INT J ONCOL, V14, P821; Stolzenberg-Solomon RZ, 2001, AM J EPIDEMIOL, V153, P680, DOI 10.1093/aje/153.7.680; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Thompson PA, 1999, MUTAT RES-FUND MOL M, V424, P263, DOI 10.1016/S0027-5107(99)00024-X; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Uehara H, 1999, AM J GASTROENTEROL, V94, P2513; VANCUTSEM E, 2002, P AN M AM SOC CLIN, V21, P130; Wang MY, 1998, CANCER RES, V58, P38; Watanabe N, 1997, CHEMOTHERAPY, V43, P406, DOI 10.1159/000239599; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; Wenger FA, 1999, LANGENBECK ARCH SURG, V384, P181, DOI 10.1007/s004230050189; White R, 1999, ANN SURG ONCOL, V6, P38, DOI 10.1007/s10434-999-0038-z; Wilentz RE, 2000, CANCER RES, V60, P2002; Wolfe K, 2000, NAT REV GENET, V1, P7, DOI 10.1038/35049607; WOLFF RA, 2002, P AN M AM SOC CLIN, V21, pA130; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; YAMANAKA Y, 1993, CANCER RES, V53, P5289; YEO CJ, 1995, ANN SURG, V221, P721, DOI 10.1097/00000658-199506000-00011	103	1604	1709	12	265	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	2004	363	9414					1049	1057		10.1016/S0140-6736(04)15841-8	http://dx.doi.org/10.1016/S0140-6736(04)15841-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15051286				2022-12-28	WOS:000220497300020
J	Lotery, HE; McClure, N; Galask, RP				Lotery, HE; McClure, N; Galask, RP			Vulvoldynia	LANCET			English	Review							VULVAR VESTIBULITIS SYNDROME; CONTACT-DERMATITIS; PAIN-SYNDROME; VULVODYNIA; WOMEN; FEATURES; DYSESTHESIA; INNERVATION; INTERFERON; PREVALENCE	Context Vulvodynia is a term used to describe chronic burning and/or pain in the vulva without objective physical findings to explain the symptoms. The terminology and classification of vulvodynia continue to evolve, and much remains to be understood about the prevalence, pathogenesis, natural history, and management of this distressing condition. Starting point James Aikens and colleagues showed that chronic vulva] pain (vulvodynia or vulvar dysaesthesia) is associated with worse depressive symptoms (Am J Obstet Gynecol 2003; 189: 462-66). However, the increased: scores for depression in this case-control study were attributed to sexual disinterest and experience of chronic pain rather than to features of depressive disorder. These results lend weight to the increasing need for better understanding of the pathogenesis of vulval pain and how to manage it appropriately. Where next? The aetiology of vulvodynia and effectiveness; of treatments need further study. Appraising the available I literature, we have formulated a useful approach to patients with chronic vulval pain. There is a pressing need for further case-control studies of potential causes of vulvodynia and for randomised trials of interventions.	Royal S Hants Hosp, Dept Dermatol, Southampton SO14 0YG, Hants, England; Queens Univ Belfast, Sch Med Obstet & Gynaecol, Belfast, Antrim, North Ireland; Univ Iowa Hosp & Clin, Dept Obstet & Gynecol, Iowa City, IA 52242 USA; Univ Iowa Hosp & Clin, Dept Dermatol, Iowa City, IA 52242 USA; Univ Iowa Hosp & Clin, Dept Microbiol, Iowa City, IA 52242 USA	University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; Queens University Belfast; University of Iowa; University of Iowa; University of Iowa	Lotery, HE (corresponding author), Royal S Hants Hosp, Dept Dermatol, Southampton SO14 0YG, Hants, England.	hlotery@doctors.org.uk						ACOG educational bulletin, 1998, INT J GYNAECOL OBSTE, V60, P181; Aikens JE, 2003, AM J OBSTET GYNECOL, V189, P462, DOI 10.1067/S0002-9378(03)00521-0; Baggish MS, 1997, AM J OBSTET GYNECOL, V177, P507, DOI 10.1016/S0002-9378(97)70137-6; BAZIN S, 1994, OBSTET GYNECOL, V83, P47; BERGERON C, 1994, J REPROD MED, V39, P936; Bergeron S, 2001, OBSTET GYNECOL, V98, P45, DOI 10.1016/S0029-7844(01)01389-8; Bodden-Heidrich R, 1999, J REPROD MED, V44, P411; Bohm-Starke N, 2001, ACTA OBSTET GYN SCAN, V80, P638, DOI 10.1034/j.1600-0412.2001.800709.x; Bohm-Starke N, 1998, GYNECOL OBSTET INVES, V46, P256, DOI 10.1159/000010045; Chadha S, 1998, INT J GYNECOL PATHOL, V17, P7, DOI 10.1097/00004347-199801000-00002; Danielsson I, 2000, ACTA OBSTET GYN SCAN, V79, P872, DOI 10.1034/j.1600-0412.2000.079010872.x; Denbow ML, 1998, INT J STD AIDS, V9, P88, DOI 10.1258/0956462981921738; Eason EL, 1996, CAN MED ASSOC J, V154, P1173; Edwards L, 1997, J REPROD MED, V42, P135; FISCHER G, 1995, BRIT J OBSTET GYNAEC, V102, P773, DOI 10.1111/j.1471-0528.1995.tb10841.x; FRIEDRICH EG, 1987, J REPROD MED, V32, P110; Gerber S, 2002, AM J OBSTET GYNECOL, V186, P361, DOI 10.1067/mob.2002.121091; Gerber S, 2002, AM J OBSTET GYNECOL, V186, P696, DOI 10.1067/mob.2002.121869; Glazer HI, 2000, J REPROD MED, V45, P798; GOETSCH MF, 1991, AM J OBSTET GYNECOL, V164, P1609, DOI 10.1016/0002-9378(91)91444-2; Granot M, 2002, BJOG-INT J OBSTET GY, V109, P863, DOI 10.1111/j.1471-0528.2002.01416.x; Harlow Bernard L, 2003, J Am Med Womens Assoc (1972), V58, P82; Jeremias J, 2000, AM J OBSTET GYNECOL, V182, P283, DOI 10.1016/S0002-9378(00)70212-2; KAUFMAN RH, 1994, BENIGN DIS VULVA VAG; KENT HL, 1990, J REPROD MED, V35, P1138; Lundqvist EN, 1997, ACTA DERM-VENEREOL, V77, P319; Lynch P.J., 1994, GENITAL DERMATOLOGY; MARREN P, 1992, BRIT J DERMATOL, V126, P52, DOI 10.1111/j.1365-2133.1992.tb08403.x; Masterson BJ, 1996, J REPROD MED, V41, P562; MCKAY M, 1988, J REPROD MED, V33, P695; MCKAY M, 1993, J REPROD MED, V38, P9; MCKAY M, 1984, J REPROD MED, V29, P457; Neill SM, 2000, ANN DERMATOL VENER, V127, P368; Nunns D, 2000, BRIT J OBSTET GYNAEC, V107, P1185, DOI 10.1111/j.1471-0528.2000.tb11606.x; PECKHAM BM, 1986, AM J OBSTET GYNECOL, V154, P855, DOI 10.1016/0002-9378(86)90472-2; Powell J, 1999, J ROY SOC MED, V92, P579, DOI 10.1177/014107689909201110; Pukall CF, 2002, PAIN, V96, P163, DOI 10.1016/S0304-3959(01)00442-0; PYKA RE, 1988, INT J GYNECOL PATHOL, V7, P249, DOI 10.1097/00004347-198809000-00005; Reed BD, 2003, J REPROD MED, V48, P409; RIDLEY CM, 1999, VULVA; Scheinfeld N, 2003, INT J DERMATOL, V42, P491, DOI 10.1046/j.1365-4362.2003.01831.x; SOBEL JD, 1992, CLIN INFECT DIS   S1, V14, P148; STEWART DE, 1994, OBSTET GYNECOL, V84, P587; TURNER MLC, 1991, AM J OBSTET GYNECOL, V165, P1233, DOI 10.1016/S0002-9378(12)90733-4; Tympanidis P, 2003, BRIT J DERMATOL, V148, P1021, DOI 10.1046/j.1365-2133.2003.05308.x; Wesselmann U, 1996, SEMIN NEUROL, V16, P63, DOI 10.1055/s-2008-1040961; Westrom LV, 1998, OBSTET GYNECOL, V91, P572, DOI 10.1016/S0029-7844(97)00719-9; Zolnoun DA, 2003, OBSTET GYNECOL, V102, P84, DOI 10.1016/S0029-7844(03)00368-5	48	27	30	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	2004	363	9414					1058	1060		10.1016/S0140-6736(04)15842-X	http://dx.doi.org/10.1016/S0140-6736(04)15842-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15065562				2022-12-28	WOS:000220497300021
J	Lai, W; Dowell, J				Lai, W; Dowell, J			Diffuse subcutaneous air due to a perforated colonic diverticulum	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Vet Affairs N Texas Hlth Care Syst, Dallas, TX 75216 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System	Lai, W (corresponding author), Vet Affairs N Texas Hlth Care Syst, Dallas, TX 75216 USA.								0	5	5	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2004	350	13					E12	E12		10.1056/ENEJMicm020108	http://dx.doi.org/10.1056/ENEJMicm020108			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VN	15044655				2022-12-28	WOS:000220393900013
J	Rajshekhar, V				Rajshekhar, V			Purging the worm: management of Taenia solium taeniasis	LANCET			English	Editorial Material							CYSTICERCOSIS; VILLAGE; MEXICO		Christian Med Coll & Hosp, Dept Neurol Sci, Vellore 632004, Tamil Nadu, India	Christian Medical College & Hospital (CMCH) Vellore	Rajshekhar, V (corresponding author), Christian Med Coll & Hosp, Dept Neurol Sci, Vellore 632004, Tamil Nadu, India.	rajshekhar@cmcvellore.ac.in						ALLAN JC, 1990, PARASITOLOGY, V101, P473, DOI 10.1017/S0031182000060686; Allan JC, 2003, ACTA TROP, V87, P87, DOI 10.1016/S0001-706X(03)00059-7; Eddi C, 2003, ACTA TROP, V87, P145, DOI 10.1016/S0001-706X(03)00037-8; SARTI E, 1992, AM J TROP MED HYG, V46, P677, DOI 10.4269/ajtmh.1992.46.677; SARTI E, 1994, T ROY SOC TROP MED H, V88, P49, DOI 10.1016/0035-9203(94)90493-6; Sarti E, 2000, T ROY SOC TROP MED H, V94, P85, DOI 10.1016/S0035-9203(00)90451-6	6	5	5	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	2004	363	9413					912	912		10.1016/S0140-6736(04)15820-0	http://dx.doi.org/10.1016/S0140-6736(04)15820-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043955				2022-12-28	WOS:000220308600004
J	Hoekstra, HE; Price, T				Hoekstra, HE; Price, T			Parallel evolution is in the genes	SCIENCE			English	Editorial Material							CONVERGENCE		Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of California System; University of California San Diego; University of Chicago	Hoekstra, HE (corresponding author), Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.	hoekstra@ucsd.edu; pricet@uchicago.edu	Hoekstra, Hopi E/I-6690-2012	Hoekstra, Hopi E/0000-0003-1431-1769				Allen ES, 2003, AUK, V120, P961; Endler JA, 1996, AM NAT, V148, P421, DOI 10.1086/285934; Majerus MEN, 2003, TRENDS GENET, V19, P585, DOI 10.1016/j.tig.2003.09.003; Mundy NI, 2004, SCIENCE, V303, P1870, DOI 10.1126/science.1093834; Omland KE, 2000, EVOLUTION, V54, P2119; Sibley CG, 1990, DISTRIBUTION TAXONOM; West-Eberhard Mary Jane, 2003, pi	7	20	21	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1779	+		10.1126/science.1096413	http://dx.doi.org/10.1126/science.1096413			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031483				2022-12-28	WOS:000220281600031
J	Pielke, RA; Chase, TN				Pielke, RA; Chase, TN			Comment on "Contributions of anthropogenic and natural forcing to recent tropopause height changes"	SCIENCE			English	Editorial Material							TROPOSPHERIC TEMPERATURES; REANALYSIS; TRENDS		Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA; Univ Colorado, Cooperat Inst Res Environm Sci, Boulder, CO 80309 USA; Univ Colorado, Dept Geog, Boulder, CO 80309 USA	Colorado State University; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Pielke, RA (corresponding author), Colorado State Univ, Dept Atmospher Sci, 1371 Campus Delivery, Ft Collins, CO 80523 USA.	pielke@atmos.colostate.edu	Pielke, Roger A/A-5015-2009					Basist AN, 1997, B AM METEOROL SOC, V78, P1431, DOI 10.1175/1520-0477(1997)078<1431:COTTDF>2.0.CO;2; Chase TN, 2000, INT J CLIMATOL, V20, P503, DOI 10.1002/(SICI)1097-0088(200004)20:5<503::AID-JOC491>3.0.CO;2-0; Christy JR, 2003, J ATMOS OCEAN TECH, V20, P613, DOI 10.1175/1520-0426(2003)20<613:EEOVOM>2.0.CO;2; Christy JR, 1998, J CLIMATE, V11, P2016, DOI 10.1175/1520-0442-11.8.2016; Gedzelman S. D., 1980, SCI WONDERS ATMOSPHE, P535; Haynes P, 2001, GEOPHYS RES LETT, V28, P4179, DOI 10.1029/2001GL013485; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; KALNAY E, COMMUNICATION; Pielke RA, 1998, J GEOPHYS RES-ATMOS, V103, P16927, DOI 10.1029/98JD01645; Pielke RA, 2003, B AM METEOROL SOC, V84, P331, DOI 10.1175/BAMS-84-3-331; Pielke RA, 2001, J GEOPHYS RES-ATMOS, V106, P27287, DOI 10.1029/2000JD000299; Pielke RA, 1998, J GEOPHYS RES-ATMOS, V103, P28909, DOI 10.1029/1998JD200023; RIAL J, IN PRESS CLIM CHANGE; Santer B.D., 2003, J GEOPHYS RES, V108, pD1, DOI DOI 10.1029/2002JD002258; Santer BD, 2003, SCIENCE, V301, P479, DOI 10.1126/science.1084123	15	4	4	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	2004	303	5665												2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031480				2022-12-28	WOS:000220281600026
J	Cooper, DJ; Myles, PS; McDermott, FT; Murray, LJ; Laidlaw, J; Cooper, G; Tremayne, AB; Bernard, SS; Ponsford, J				Cooper, DJ; Myles, PS; McDermott, FT; Murray, LJ; Laidlaw, J; Cooper, G; Tremayne, AB; Bernard, SS; Ponsford, J		HTS Study Investigators	Prehospital hypertonic saline resuscitation of patients with hypotension and severe traumatic brain injury - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Scientific Meeting of the Australian-and-New Zealand-Intensive-Care-Society	SEP   13, 2003	Cairns, AUSTRALIA	Australia & New Zealand Intens Care Soc			SEVERE HEAD-INJURY; CRITICALLY ILL PATIENTS; GLASGOW OUTCOME SCALE; STRUCTURED INTERVIEWS; FLUID RESUSCITATION; MULTICENTER TRIAL; REHABILITATION; RELIABILITY; DEXTRAN-70; DISABILITY	Context Prehospital hypertonic saline (HTS) resuscitation of patients with traumatic brain injury (TBI) may increase survival but whether HTS improves neurological outcomes is unknown. Objective To determine whether prehospital resuscitation with intravenous HTS improves long-term neurological outcome in patients with severe TBI compared with resuscitation with conventional fluids. Design, Setting, and Patients Double-blind, randomized controlled trial of 229 patients with TBI who were comatose (Glasgow Coma Scale score, <9) and hypotensive (systolic blood pressure, <100 mm Hg). The patients were enrolled between December 14, 1998, and April 9, 2002, in Melbourne, Australia. Interventions Patients were randomly assigned to receive a rapid intravenous infusion of either 250 mL of 7.5% saline (n = 114) or 250 mL of Ringer's lactate solution (n = 115; controls) in addition to conventional intravenous fluid and resuscitation protocols administered by paramedics. Treatment allocation was concealed. Main Outcome Measure Neurological function at 6 months, measured by the extended Glasgow Outcome Score (GOSE). Results Primary outcomes were obtained in 226 (99%) of 229 patients enrolled. Baseline characteristics of the groups were equivalent. At hospital admission, the mean serum sodium level was 149 mEq/L for HTS patients vs 141 mEq/L for controls (P<.001). The proportion of patients surviving to hospital discharge was similar in both groups (n =63 [55%] for HTS group and n =57 [50%] for controls; P=32); at 6 months, survival rates were n =62 (55%) in the HTS group and n =53 (47%) in the control group (P=.23). At 6 months, the median (interquartile range) GOSE was 5 (3-6) in the HTS group vs 5 (5-6) in the control group (P=.45). There was no significant difference between the groups in favorable outcomes (moderate disability and good outcome survivors [GOSE of 5-8]) (risk ratio, 0.99; 95% confidence interval, 0.76-1.30; P=.96) or in any other measure of postinjury neurological function. Conclusion In this study, patients with hypotension and severe TBI who received prehospital resuscitation with HTS had almost identical neurological function 6 months after injury as patients who received conventional fluid.	Monash Univ, Alfred Hosp, Dept Intens Care, Melbourne, Vic 3004, Australia; Monash Univ, Alfred Hosp, Dept Anaesthesia, Melbourne, Vic 3004, Australia; Monash Univ, Dept Psychol, Melbourne, Vic 3004, Australia; Metropolitan Ambulance Serv, Melbourne, Vic, Australia; Consulat Comm Rd Traff Fatil Victoria, Melbourne, Vic, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; Florey Institute of Neuroscience & Mental Health; Monash University; Monash University	Cooper, DJ (corresponding author), Monash Univ, Alfred Hosp, Dept Intens Care, Commercial Rd, Melbourne, Vic 3004, Australia.	j.cooper@alfred.org.au	Morley, Peter/G-5280-2017; Myles, Paul/AAU-9524-2020; Cooper, D. James/G-7961-2013	Morley, Peter/0000-0003-2653-090X; Myles, Paul/0000-0002-3324-5456; Cooper, D. James/0000-0002-5872-9051				*AM COLL SURG COMM, 2003, ADV TRAUM LIF SUPP P; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Choi PTL, 1999, CRIT CARE MED, V27, P200, DOI 10.1097/00003246-199901000-00053; *COMM AUSTR, 1999, NAT STAT ETH COND RE; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; DUBICK MA, 1994, J TRAUMA, V36, P323, DOI 10.1097/00005373-199403000-00007; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GABRIEL EJ, 2000, GUIDELINES PREHOSPIT, P7; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HAGEN C, 1982, COGNITIVE REHABILITA, P131; HUNT J, 1995, AUST NZ J SURG, V65, P83, DOI 10.1111/j.1445-2197.1995.tb07266.x; JENNETT B, 1975, LANCET, V1, P480; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kramer GC, 2003, J TRAUMA, V54, pS89, DOI 10.1097/01.TA.0000065609.82142.F1; Liberman M, 2000, J TRAUMA, V49, P584, DOI 10.1097/00005373-200010000-00003; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; Schierhout G, 1998, BMJ-BRIT MED J, V316, P961, DOI 10.1136/bmj.316.7136.961; SVENSEN CH, 2002, TRAUMA CARE J INT TR, P6; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; *US NIH, 1998, REH PERS TRAUM BRAIN; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; WADE CE, 1997, J TRAUMA, V42, P561; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478	32	283	302	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	2004	291	11					1350	1357		10.1001/jama.291.11.1350	http://dx.doi.org/10.1001/jama.291.11.1350			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	802PF	15026402	Bronze			2022-12-28	WOS:000220174700029
J	Fernandez, JM; Li, HB				Fernandez, JM; Li, HB			Force-clamp spectroscopy monitors the folding trajectory of a single protein	SCIENCE			English	Article							TITIN IMMUNOGLOBULIN DOMAINS; KINETIC-ANALYSIS; FLEXIBLE COIL; COLLAPSE; MICROSCOPY; UBIQUITIN; MOLECULE; PATHWAY; MODEL; FUNNELS	We used force-clamp atomic force micoscopy to measure the end-to-end length of the small protein ubiquitin during its folding reaction at the single-molecule level. Ubiquitin was first unfolded and extended at a high force, then the stretching force was quenched and protein folding was observed. The folding trajectories were continuous and marked by several distinct stages. The time taken to fold was dependent on the contour length of the unfolded protein and the stretching force applied during folding. The folding collapse was marked by large fluctuations in the end-to-end length of the protein, but these fluctuations vanished upon the final folding contraction. These direct observations of the complete folding trajectory of a protein provide a benchmark to determine the physical basis of the folding reaction.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Fernandez, JM (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	jfernandez@columbia.edu	Li, Hongbin/G-2949-2012	Li, Hongbin/0000-0001-7813-1332				Buguin A, 1996, CR ACAD SCI II B, V322, P741; CAMACHO CJ, 1993, P NATL ACAD SCI USA, V90, P6369, DOI 10.1073/pnas.90.13.6369; Carrion-Vazquez M, 2003, NAT STRUCT BIOL, V10, P738, DOI 10.1038/nsb965; Carrion-Vazquez M, 1999, P NATL ACAD SCI USA, V96, P3694, DOI 10.1073/pnas.96.7.3694; CHU B, 1995, MACROMOLECULES, V28, P180, DOI 10.1021/ma00105a024; DEGENNES PG, 1985, J PHYS LETT-PARIS, V46, pL639, DOI 10.1051/jphyslet:019850046014063900; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; Frisch T, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.041801; Gao M, 2001, BIOPHYS J, V81, P2268, DOI 10.1016/S0006-3495(01)75874-2; GROSBERG AY, 1988, J PHYS-PARIS, V49, P2095, DOI 10.1051/jphys:0198800490120209500; Halperin A, 2000, PHYS REV E, V61, P565, DOI 10.1103/PhysRevE.61.565; Hardin C, 2002, J COMPUT CHEM, V23, P138, DOI 10.1002/jcc.1162; Khorasanizadeh S, 1996, NAT STRUCT BIOL, V3, P193, DOI 10.1038/nsb0296-193; Klimov DK, 1997, PHYS REV LETT, V79, P317, DOI 10.1103/PhysRevLett.79.317; Li HB, 2000, P NATL ACAD SCI USA, V97, P6527, DOI 10.1073/pnas.120048697; Liphardt J, 2001, SCIENCE, V292, P733, DOI 10.1126/science.1058498; MATOUSCHEK A, 1989, NATURE, V340, P122, DOI 10.1038/340122a0; Mayor U, 2003, NATURE, V421, P863, DOI 10.1038/nature01428; Nauli S, 2001, NAT STRUCT BIOL, V8, P602, DOI 10.1038/89638; NISHIO I, 1982, NATURE, V300, P243, DOI 10.1038/300243a0; Oberhauser AF, 2001, P NATL ACAD SCI USA, V98, P468, DOI 10.1073/pnas.021321798; Pande VS, 2000, REV MOD PHYS, V72, P259, DOI 10.1103/RevModPhys.72.259; Rhoades E, 2003, P NATL ACAD SCI USA, V100, P3197, DOI 10.1073/pnas.2628068100; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rief M, 1997, SCIENCE, V275, P1295, DOI 10.1126/science.275.5304.1295; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; Schuler B, 2002, NATURE, V419, P743, DOI 10.1038/nature01060; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; WILLIAMS C, 1981, ANNU REV PHYS CHEM, V32, P433, DOI 10.1146/annurev.pc.32.100181.002245; Zhou YQ, 1999, NATURE, V401, P400, DOI 10.1038/43940; Zhou YQ, 1999, J MOL BIOL, V293, P917, DOI 10.1006/jmbi.1999.2936	32	446	459	0	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 12	2004	303	5664					1674	1678		10.1126/science.1092497	http://dx.doi.org/10.1126/science.1092497			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15017000				2022-12-28	WOS:000220151400045
J	Worrall, A; O'Herlihy, A; Banerjee, S; Jaffa, T; Lelliott, P; Hill, P; Scott, A; Brook, H				Worrall, A; O'Herlihy, A; Banerjee, S; Jaffa, T; Lelliott, P; Hill, P; Scott, A; Brook, H			Inappropriate admission of young people with mental disorder to adult psychiatric wards and paediatric wards: cross sectional study of six months' activity	BRITISH MEDICAL JOURNAL			English	Article									Royal Coll Psychiatrists, Res Unit, London SW1H 0HW, England; Univ London Kings Coll, Inst Psychiat, Hlth Serv Res Dept, London, England; Fulbourne Hosp, Phoenix Ctr, Cambridge, England; Great Ormond St Hosp Children, Dept Psychol Med, London, England	University of London; King's College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Worrall, A (corresponding author), Royal Coll Psychiatrists, Res Unit, 6th Floor,83 Victoria St, London SW1H 0HW, England.	aworrall@cru.rcpsych.ac.uk	Banerjee, Sube/E-3757-2010	Banerjee, Sube/0000-0002-8083-7649				Barker S, 2000, ENV UNFRIENDLY PATIE; *MILMIS PROJ GROUP, 1995, PSYCHIAT B, V19, P276; OHERLIHY A, 2001, UNPUB NATL IN PATIEN; Scott D., 2001, MENTAL HLTH LEARNING, V4, P305; Worrall A., 2001, PSYCHIAT B, V25, P219, DOI [10.1192/pb.25.6.219, DOI 10.1192/PB.25.6.219]	5	19	19	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 10	2004	328	7444					867	868		10.1136/bmj.38058.605787.AE	http://dx.doi.org/10.1136/bmj.38058.605787.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	812XE	15066888	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000220871400016
J	Friedrich, MJ				Friedrich, MJ			Institute probes music's therapeutic potential	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Coleman J., 1997, INT J ARTS MED, V5, P4; 2003, PAIN MANAG NURS, V4, P54	2	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2004	291	13					1554	1555		10.1001/jama.291.13.1554	http://dx.doi.org/10.1001/jama.291.13.1554			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809PQ	15069033				2022-12-28	WOS:000220649000005
J	Aaron, R; Joseph, A; Abraham, S; Muliyil, J; George, K; Prasad, J; Minz, S; Abraham, VJ; Bose, A				Aaron, R; Joseph, A; Abraham, S; Muliyil, J; George, K; Prasad, J; Minz, S; Abraham, VJ; Bose, A			Suicides in young people in rural southern India	LANCET			English	Article							RATES	Different rates of suicide have been reported in India. In Vellore, southern India, we have noted that the rates of suicides are several fold higher than those reported anywhere in the world, especially in young women. The department of community health at the Christian Medical College, Vellore, has obtained data prospectively on births, deaths, and morbidity in a population of 108000. We used the verbal autopsy method to assign cause of death. The mortality rates were analysed for 10 years, from 1992 to 2001, for the age-group 10-19 years. Suicides accounted for about a quarter of all deaths in young men and between 50% and 75% of all deaths in young women. The average suicide rate for young women was 148 per 100000, and for young men 58 per 100000. We believe that our findings are reliable. The system of surveillance is well established and the verbal autopsy method has been validated. These very high rates of suicide need urgent intervention.	Christian Med Coll & Hosp, Dept Community Hlth, Vellore 632002, Tamil Nadu, India; Schieffelin Leprosy Res & Training Ctr, Vellore, Tamil Nadu, India	Christian Medical College & Hospital (CMCH) Vellore	Bose, A (corresponding author), Christian Med Coll & Hosp, Dept Community Hlth, Vellore 632002, Tamil Nadu, India.	bose@cmcvellore.ac.in						Gururaj G, 2001, EPIDEMIOLOGY SUICIDE; Joseph A, 2003, BRIT MED J, V326, P1121, DOI 10.1136/bmj.326.7399.1121; McClure GMG, 2001, BRIT J PSYCHIAT, V178, P469, DOI 10.1192/bjp.178.5.469; Phillips MR, 2002, LANCET, V359, P835, DOI 10.1016/S0140-6736(02)07954-0; World Health Organization, 1999, WHOHSCPVI9911	5	158	159	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	2004	363	9415					1117	1118		10.1016/S0140-6736(04)15896-0	http://dx.doi.org/10.1016/S0140-6736(04)15896-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	808VB	15064031				2022-12-28	WOS:000220595500012
J	Stubblefield, PG				Stubblefield, PG			Antenatal day care or admission to hospital: a mother's choice?	LANCET			English	Editorial Material							BED REST; WOMEN		Boston Univ, Med Ctr, Sch Med, Dept Obstet & Gynecol, Boston, MA 02118 USA	Boston University	Stubblefield, PG (corresponding author), Boston Univ, Med Ctr, Sch Med, Dept Obstet & Gynecol, Boston, MA 02118 USA.	Phillip.stubblefield@bmc.org						Adelson PL, 1999, MED J AUSTRALIA, V170, P211, DOI 10.5694/j.1326-5377.1999.tb140319.x; FRANKS AL, 1992, AM J OBSTET GYNECOL, V166, P1339, DOI 10.1016/0002-9378(92)91601-6; Heaman M, 1998, BIRTH-ISS PERINAT C, V25, P252, DOI 10.1046/j.1523-536X.1998.00252.x; Maloni JA, 2002, NURS RES, V51, P92, DOI 10.1097/00006199-200203000-00005; MALONI JA, 2000, MCN AM J MATERN CHIL, V256, P204	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	2004	363	9415					1089	1089		10.1016/S0140-6736(04)15930-8	http://dx.doi.org/10.1016/S0140-6736(04)15930-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808VB	15064022				2022-12-28	WOS:000220595500003
J	de la Cova, C; Abril, M; Bellosta, P; Gallant, P; Johnston, LA				de la Cova, C; Abril, M; Bellosta, P; Gallant, P; Johnston, LA			Drosophila Myc regulates organ size by inducing cell competition	CELL			English	Article							WING DEVELOPMENT; TNF SUPERFAMILY; GROWTH; PROLIFERATION; COMPARTMENTS; DIVISION; SURVIVAL; PROTEIN; APOPTOSIS; ENCODES	Experiments in both vertebrates and invertebrates have illustrated the competitive nature of growth and led to the idea that competition is a mechanism of regulating organ and tissue size. We have assessed competitive interactions between cells in a developing organ and examined their effect on its final size. We show that local expression of the Drosophila growth regulator dMyc, a homolog of the c-myc protooncogene, induces cell competition and leads to the death of nearby wildtype cells in developing wings. We demonstrate that cell competition is executed via induction of the proapoptotic gene hid and that both competition and hid function are required for the wing to reach an appropriate size when dMyc is expressed. Moreover, we provide evidence that reproducible wing size during normal development requires apoptosis. Modulating dmyc levels to create cell competition and hid-dependent cell death may be a mechanism used during normal development to control organ size.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland	Columbia University; University of Zurich	Johnston, LA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 701 W 168th St,Room 704, New York, NY 10032 USA.	lj180@columbia.edu	Bellosta, Paola/AAA-3413-2020; Johnston, Laura A/ABC-1945-2021	Bellosta, Paola/0000-0003-1913-5661; JOHNSTON, LAURA A/0000-0001-9477-7897; de la Cova, Claire/0000-0001-8719-6883	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078464, T32GM007088] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD042770-01A1, R01 HD042770, R01 HD042770-03, R01 HD042770-04, R01 HD042770-05, R01 HD042770-02] Funding Source: Medline; NIGMS NIH HHS [R01 GM078464, R01 GM078464-04, R01 GM078464-02, R01 GM078464-03, T32 GM007088, R01 GM078464-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; BRYANT PJ, 1984, Q REV BIOL, V59, P387, DOI 10.1086/414040; BRYANT PJ, 1970, DEV BIOL, V22, P389, DOI 10.1016/0012-1606(70)90160-0; Burke R, 1996, DEVELOPMENT, V122, P2261; Datar SA, 2000, EMBO J, V19, P4543, DOI 10.1093/emboj/19.17.4543; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; HAY BA, 1994, DEVELOPMENT, V120, P2121; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Johnston LA, 2003, NAT CELL BIOL, V5, P827, DOI 10.1038/ncb1041; Johnston LA, 1998, NATURE, V394, P82, DOI 10.1038/27925; Johnston LA, 2002, BIOESSAYS, V24, P54, DOI 10.1002/bies.10021; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Martin-Castellanos C, 2002, DEVELOPMENT, V129, P1003; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; Moreno E, 2002, NATURE, V416, P755, DOI 10.1038/416755a; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Plas DR, 2002, NAT IMMUNOL, V3, P515, DOI 10.1038/ni0602-515; Prober DA, 2000, CELL, V100, P435, DOI 10.1016/S0092-8674(00)80679-0; Prober DA, 2002, GENE DEV, V16, P2286, DOI 10.1101/gad.991102; SaeboeLarssen S, 1997, MOL GEN GENET, V255, P141, DOI 10.1007/s004380050482; SIMPSON P, 1979, DEV BIOL, V69, P182, DOI 10.1016/0012-1606(79)90284-7; Simpson P, 1980, Basic Life Sci, V16, P129; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Stern DL, 1999, DEVELOPMENT, V126, P1091; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Weigmann K, 1999, DEVELOPMENT, V126, P3823; Weigmann K, 1997, DEVELOPMENT, V124, P3555; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; ZECCA M, 1995, DEVELOPMENT, V121, P2265	39	431	437	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	2004	117	1					107	116		10.1016/S0092-8674(04)00214-4	http://dx.doi.org/10.1016/S0092-8674(04)00214-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YV	15066286	Bronze			2022-12-28	WOS:000221500300012
J	Lo, MC; Gay, F; Odom, R; Shi, Y; Lin, F				Lo, MC; Gay, F; Odom, R; Shi, Y; Lin, F			Phosphorylation by the beta-catenin/MAPK complex promotes 14-3-3-mediated nuclear export of TCF/POP-1 in signal-responsive cells in C-elegans	CELL			English	Article							C-ELEGANS; POLARITY SIGNALS; 14-3-3 PROTEINS; MAP KINASE; POP-1; EMBRYOS; GENE; TRANSCRIPTION; ENDODERM; PATHWAY	In C. elegans embryos, a Wnt/MAPK signaling pathway downregulates the TCF/LEF transcription factor POP-1, resulting in a lower nuclear level in signal-responsive cells compared to their sisters. Although the beta-catenin WRM-1 is required for POP-1 down-regulation, a direct interaction between these two proteins does not seem to be required, as the beta-catenin-interacting domain of POP-1 is dispensable for both POP-1 downregulation and function in early embryos. We show here that WRM-1 downregulates POP-1 by promoting its phosphorylation by the MAP kinase LIT-1 and subsequent nuclear export via a 14-3-3 protein, PAR-5. In signal-responsive cells, we also detect a concurrent upregulation of nuclear LIT-1 that is dependent on Wnt/MAPK signaling. Our results suggest a model whereby Wnt/MAPK signaling downregulates POP-1 levels in responsive cells, in part by increasing nuclear LIT-1 levels, thereby increasing POP-1 phosphorylation and PAR-5-mediated nuclear export.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard Medical School	Lin, F (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	rueyling.lin@utsouthwestern.edu			NICHD NIH HHS [HD37933] Funding Source: Medline; NIGMS NIH HHS [GM58012] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD037933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058012] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler PN, 2001, CURR OPIN CELL BIOL, V13, P635, DOI 10.1016/S0955-0674(00)00263-5; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Calvo D, 2001, EMBO J, V20, P7197, DOI 10.1093/emboj/20.24.7197; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gay F, 2003, GENE DEV, V17, P717, DOI 10.1101/gad.1042403; Gay F, 2002, MOL ENDOCRINOL, V16, P1332, DOI 10.1210/me.16.6.1332; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; Herman MA, 2001, DEVELOPMENT, V128, P581; Hermann GJ, 2000, DEVELOPMENT, V127, P3429; Hyodo-Miura J, 2002, GENES CELLS, V7, P487, DOI 10.1046/j.1365-2443.2002.00536.x; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Kaletta T, 1997, NATURE, V390, P294, DOI 10.1038/36869; Lin RL, 1998, CELL, V92, P229, DOI 10.1016/S0092-8674(00)80917-4; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Maduro MF, 2002, DEV BIOL, V248, P128, DOI 10.1006/dbio.2002.0721; Maduro MF, 2001, MOL CELL, V7, P475, DOI 10.1016/S1097-2765(01)00195-2; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Morton DG, 2002, DEV BIOL, V241, P47, DOI 10.1006/dbio.2001.0489; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pandur P, 2001, BIOESSAYS, V23, P207, DOI 10.1002/1521-1878(200103)23:3<207::AID-BIES1029>3.0.CO;2-0; Polakis P, 2000, GENE DEV, V14, P1837; Praitis V, 2001, GENETICS, V157, P1217; Rocheleau CE, 1999, CELL, V97, P717, DOI 10.1016/S0092-8674(00)80784-9; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rogers E, 2002, J CELL BIOL, V157, P219, DOI 10.1083/jcb.200110045; Schroeder DF, 1998, DEVELOPMENT, V125, P4877; Shin TH, 1999, MOL CELL, V4, P275, DOI 10.1016/S1097-2765(00)80375-5; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Wang WF, 1997, J MOL BIOL, V268, P619, DOI 10.1006/jmbi.1997.1002	38	109	138	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	2004	117	1					95	106		10.1016/S0092-8674(04)00203-X	http://dx.doi.org/10.1016/S0092-8674(04)00203-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YV	15066285	Bronze			2022-12-28	WOS:000221500300011
J	Tijsterman, M; Plasterk, RHA				Tijsterman, M; Plasterk, RHA			Dicers at RISC: The mechanism of RNAi	CELL			English	Editorial Material									Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Tijsterman, M (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands.		Tijsterman, Marcel/H-5663-2018	Tijsterman, Marcel/0000-0001-8465-9002				Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; Finnegan EJ, 2003, CURR BIOL, V13, P236, DOI 10.1016/S0960-9822(03)00010-1; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2	10	214	290	2	64	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	2004	117	1					1	3		10.1016/S0092-8674(04)00293-4	http://dx.doi.org/10.1016/S0092-8674(04)00293-4			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YV	15066275	Bronze			2022-12-28	WOS:000221500300001
J	Mohr, DC; Hart, SL; Julian, L; Cox, D; Pelletier, D				Mohr, DC; Hart, SL; Julian, L; Cox, D; Pelletier, D			Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PSYCHOLOGICAL STRESS; EMOTIONAL-STRESS; DISORDER; DISEASE; MS; LESIONS; ONSET	Objective To quantify the association between stressful life events and exacerbations of multiple sclerosis. Data sources PubMed, PsychInfo, and Psychological Abstracts searched for empirical papers from 1965 to February 2003 with terms "stress," "trauma," and, "multiple sclerosis." Review methods Three investigators independently reviewed papers for inclusion/exclusion criteria and extracted the relevant data, including methods, sample statistics, and outcomes. Results Of 20 studies identified, 14 were included. The meta-analysis showed a significant increase in risk of exacerbation in multiple sclerosis after stressful life events, with a weighted average effect size of d = 0.53 (95% confidence interval 0.40 to 0.65), P < 0.0001. The studies were homogenous, Q = 16.62, P = 0.22, I-2 = 21.8%. Neither sampling nor study methods had any effect on study outcomes. Conclusions There is a consistent association between stressful life events and subsequent exacerbation in multiple sclerosis. However these data do not allow the linking of specific stressors to exacerbations nor should they be used to infer that patients are responsible for their exacerbations. Investigation of the psychological, neuroendocrine, and immune mediators of stressful life events on exacerbation may lead to new behavioural and pharmacological strategies targeting potential links between stress and exacerbation.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94142 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Mohr, DC (corresponding author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94142 USA.	dmohr@itsa.ucsf.edu	Hart, Stacey L/E-4819-2011	Mohr, David/0000-0002-5443-7596	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD043323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059708] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD043323-01] Funding Source: Medline; NIMH NIH HHS [R01 MH59708-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ackerman KD, 2003, BRAIN BEHAV IMMUN, V17, P141, DOI 10.1016/S0889-1591(03)00047-3; Ackerman KD, 2000, PSYCHOSOM MED, V62, P147; ANTONOVS.A, 1968, AM J PUBLIC HEALTH N, V58, P836, DOI 10.2105/AJPH.58.5.836; Buljevac D, 2003, BMJ-BRIT MED J, V327, P646, DOI 10.1136/bmj.327.7416.646; Charcot J., 1877, NEW SYDENHAM SOC, V1, P157; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Correa SG, 1998, BRAIN BEHAV IMMUN, V12, P134, DOI 10.1006/brbi.1998.0519; Filippini G, 2003, LANCET, V361, P545, DOI 10.1016/S0140-6736(03)12512-3; Franklin GM, 1988, J NEUROL REHABIL, V2, P7; GAIATTO C, 1992, MED PSICOSOMATICA, V37, P19; GASPERINI C, 1995, J NEUROL NEUROSUR PS, V59, P303, DOI 10.1136/jnnp.59.3.303; Goodin DS, 1999, NEUROLOGY, V52, P1737, DOI 10.1212/WNL.52.9.1737; Goodkin DE, 1998, NEUROLOGY, V51, P1689, DOI 10.1212/WNL.51.6.1689; GRANT I, 1989, J NEUROL NEUROSUR PS, V52, P8, DOI 10.1136/jnnp.52.1.8; HOHLFELD R, 1995, NEUROLOGY, V45, pS33, DOI 10.1212/WNL.45.6_Suppl_6.S33; Kino T, 2001, J ENDOCRINOL, V169, P437, DOI 10.1677/joe.0.1690437; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; MEITAL V, 1970, PSYCHOSOM MED, V32, P67; Mohr DC, 2001, ARCH NEUROL-CHICAGO, V58, P1081, DOI 10.1001/archneur.58.7.1081; Mohr DC, 2000, NEUROLOGY, V55, P55, DOI 10.1212/WNL.55.1.55; Moller HJ, 2001, PSYCHOPHARMAKOTHERAP, V8, P1; Morrison W, 1994, Axone, V16, P23; MUNCK A, 1994, ANN NY ACAD SCI, V746, P115, DOI 10.1111/j.1749-6632.1994.tb39221.x; MUNCK A, 1994, ANN NY ACAD SCI, V746, P131; NISIPEANU P, 1993, NEUROLOGY, V43, P1311, DOI 10.1212/WNL.43.7.1311; Palumbo R, 1998, ITAL J NEUROL SCI, V19, P259, DOI 10.1007/BF02427615; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; PRATT RTC, 1951, J NEUROL NEUROSUR PS, V14, P326, DOI 10.1136/jnnp.14.4.326; RABINS PV, 1986, BRAIN, V109, P585, DOI 10.1093/brain/109.4.585; SCHUMACHER GA, 1965, ANN NY ACAD SCI, V122, P552; Schwartz CE, 1999, BEHAV MED, V25, P110, DOI 10.1080/08964289909596740; SIBLEY WA, 1997, MULTIPLE SCLEROSIS C, P141; STIP E, 1994, CAN J PSYCHIAT, V39, P27, DOI 10.1177/070674379403900107; WARREN S, 1982, J CHRON DIS, V35, P821, DOI 10.1016/0021-9681(82)90047-9; WARREN S, 1991, J PSYCHOSOM RES, V35, P37, DOI 10.1016/0022-3999(91)90005-9; Whitacre CC, 1998, ANN NY ACAD SCI, V840, P705, DOI 10.1111/j.1749-6632.1998.tb09609.x; Wilson D.B, 2001, PRACTICAL METAANALYS, V1; Zappulla JP, 2002, J NEUROIMMUNOL, V131, P5, DOI 10.1016/S0165-5728(02)00250-3; 1877, LECT DIS NERVOUS SYS; 2000, N ENGL J MED, V343, P938	40	229	234	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 27	2004	328	7442					731	733		10.1136/bmj.38041.724421.55	http://dx.doi.org/10.1136/bmj.38041.724421.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809WH	15033880	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000220666300012
J	Mouillet, D				Mouillet, D			Nearby planetary disks	SCIENCE			English	Editorial Material									Observ Midi Pyrenees, Astrophys Lab, F-65008 Tarbes, France		Mouillet, D (corresponding author), Observ Midi Pyrenees, Astrophys Lab, 57 Av Azereix,BP826, F-65008 Tarbes, France.	mouillet@bagn.obs-mip.fr						BECKWITH SVW, 1999, NATO ASI SER C, P579; Evans NJ, 2003, PUBL ASTRON SOC PAC, V115, P965, DOI 10.1086/376697; Kalas P, 2004, SCIENCE, V303, P1990, DOI 10.1126/science.1093420; Lagrange A.-M., 2000, Protostars and planets 4, P639; Mouillet D, 2001, ASTRON ASTROPHYS, V372, pL61, DOI 10.1051/0004-6361:20010660; SMITH BA, 1984, SCIENCE, V226, P1421, DOI 10.1126/science.226.4681.1421; Udry S, 2003, ASTRON ASTROPHYS, V407, P369, DOI 10.1051/0004-6361:20030843	8	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	2004	303	5666					1982	1983		10.1126/science.1095851	http://dx.doi.org/10.1126/science.1095851			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044792				2022-12-28	WOS:000220429800027
J	Frost, DJ; Liebske, C; Langenhorst, F; McCammon, CA; Tronnes, RG; Rubie, DC				Frost, DJ; Liebske, C; Langenhorst, F; McCammon, CA; Tronnes, RG; Rubie, DC			Experimental evidence for the existence of iron-rich metal in the Earth's lower mantle	NATURE			English	Article							MAGNESIUM-SILICATE PEROVSKITE; SPINEL OXYGEN GEOBAROMETER; FERRIC IRON; OXIDATION-STATE; SPECTROSCOPY; MOSSBAUER; PRESSURE; FUGACITY; HISTORY; MELTS	The oxidation state recorded by rocks from the Earth's upper mantle can be calculated from measurements of the distribution of Fe3+ and Fe2+ between the constituent minerals(1-3). The capacity for minerals to incorporate Fe3+ may also be a significant factor controlling the oxidation state of the mantle(4,5), and high-pressure experimental measurements of this property might provide important insights into the redox state of the more inaccessible deeper mantle. Here we show experimentally that the Fe3+ content of aluminous silicate perovskite, the dominant lower-mantle mineral, is independent of oxygen fugacity. High levels of Fe3+ are present in perovskite even when it is in chemical equilibrium with metallic iron. Silicate perovskite in the lower mantle will, therefore, have an Fe3+/total Fe ratio of at least 0.6, resulting in a whole-rock ratio of over ten times that of the upper mantle(5,6). Consequently, the lower mantle must either be enriched in Fe3+ or Fe3+ must form by the disproportionation of Fe2+ to produce Fe3+ plus iron metal. We argue that the lower mantle contains approximately 1 wt% of a metallic iron-rich alloy. The mantle's oxidation state and siderophile element budget have probably been influenced by the presence of this alloy.	Univ Bayreuth, Bayer Geoinst, D-95440 Bayreuth, Germany; Univ Iceland, Nord Volcanol Inst, IS-101 Reykjavik, Iceland	University of Bayreuth; University of Iceland	Frost, DJ (corresponding author), Univ Bayreuth, Bayer Geoinst, POB 101251, D-95440 Bayreuth, Germany.	dan.frost@uni-bayreuth.de	Frost, Daniel J/B-7526-2016; McCammon, Catherine/B-4983-2010	Frost, Daniel J/0000-0002-4443-8149; McCammon, Catherine/0000-0001-5680-9106; Langenhorst, Falko/0000-0003-4892-7713				AGEE CB, 1997, LUN PLAN SCI ABSTR, V28, P7; ASAHARA Y, IN PRESS PHYS EARTH; BALLHAUS C, 1995, EARTH PLANET SC LETT, V132, P75, DOI 10.1016/0012-821X(95)00047-G; BALLHAUS C, 1991, CONTRIB MINERAL PETR, V107, P27, DOI 10.1007/BF00311183; BALLHAUS C, 1994, GEOCHIM COSMOCHIM AC, V58, P4931, DOI 10.1016/0016-7037(94)90222-4; Canil D, 1997, NATURE, V389, P842, DOI 10.1038/39860; Canil D, 1996, J PETROL, V37, P609, DOI 10.1093/petrology/37.3.609; Delano JW, 2001, ORIGINS LIFE EVOL B, V31, P311, DOI 10.1023/A:1011895600380; Frost DJ, 2002, EARTH PLANET SC LETT, V199, P227, DOI 10.1016/S0012-821X(02)00558-7; IRIFUNE T, 1994, NATURE, V370, P131, DOI 10.1038/370131a0; Kesson SE, 1998, NATURE, V393, P252, DOI 10.1038/30466; Lauterbach S, 2000, CONTRIB MINERAL PETR, V138, P17, DOI 10.1007/PL00007658; LUTH RW, 1990, CONTRIB MINERAL PETR, V104, P56, DOI 10.1007/BF00310646; McCammon C, 1997, NATURE, V387, P694, DOI 10.1038/42685; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; O'Neill H.S.C., 1998, EARTHS MANTLE COMPOS, P3; ONEILL HS, 1987, J PETROL, V28, P1169, DOI 10.1093/petrology/28.6.1169; ONEILL HS, 1993, IUGG, V14, P73; ONEILL HSC, 1993, AM MINERAL, V78, P456; Richmond NC, 1998, AM MINERAL, V83, P947; Righter K, 1997, PHYS EARTH PLANET IN, V100, P115, DOI 10.1016/S0031-9201(96)03235-9; RINGWOOD AE, 1966, GEOCHIM COSMOCHIM AC, V30, P41, DOI 10.1016/0016-7037(66)90090-1; Shannon MC, 1998, SCIENCE, V280, P1059, DOI 10.1126/science.280.5366.1059; Stevenson DJ., 1990, ORIGIN EARTH, P231; van Aken PA, 1998, PHYS CHEM MINER, V25, P323, DOI 10.1007/s002690050122; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0; WALTER MJ, 2000, ORIGIN EARTH MOON, P285; Wood BJ, 1996, PHILOS T R SOC A, V354, P1495, DOI 10.1098/rsta.1996.0060; Xu YS, 1998, SCIENCE, V282, P922, DOI 10.1126/science.282.5390.922	30	441	458	2	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 25	2004	428	6981					409	412		10.1038/nature02413	http://dx.doi.org/10.1038/nature02413			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042086				2022-12-28	WOS:000220404300038
J	Cook, HA; Koppetsch, BS; Wu, J; Theurkauf, WE				Cook, HA; Koppetsch, BS; Wu, J; Theurkauf, WE			The Drosophila SDE3 homolog armitage is required for oskar mRNA silencing and embryonic axis specification	CELL			English	Review							RESTRICTS POLE PLASM; DOUBLE-STRANDED-RNA; BINDING-PROTEIN; CAENORHABDITIS-ELEGANS; POSTERIOR LOCALIZATION; GERM PLASM; KINESIN-I; TRANSLATIONAL REGULATION; ANTERIOR-POSTERIOR; PATTERN-FORMATION	Polarization of the microtubule cytoskeleton during early oogenesis is required to specify the posterior of the Drosophila oocyte, which is essential for asymmetric mRNA localization during mid-oogenesis and for embryonic axis specification. The posterior determinant oskar mRNA is translationally silent until mid-oogenesis. We show that mutations in armitage and three components of the RNAi pathway disrupt oskar mRNA translational silencing, polarization of the microtubule cytoskeleton, and posterior localization of oskar mRNA. armitage encodes a homolog of SDE3, a presumptive RNA helicase involved in posttranscriptional gene silencing (RNAi) in Arabidopsis, and is required for RNAi in Drosophila ovaries. Armitage forms an asymmetric network associated with the polarized microtubule cytoskeleton and is concentrated with translationally silent oskar mRNA in the oocyte. We conclude that RNA silencing is essential for establishment of the cytoskeletal polarity that initiates embryonic axis specification and for translational control of oskar mRNA.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Cell Dynam, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Theurkauf, WE (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	William.Theurkauf@umassmed.edu		Theurkauf, William/0000-0001-7342-1912	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007312] Funding Source: NIH RePORTER; NICHD NIH HHS [T32 HD 07312] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aravin AA, 2001, CURR BIOL, V11, P1017, DOI 10.1016/S0960-9822(01)00299-8; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; Bassell GJ, 1999, FASEB J, V13, P447, DOI 10.1096/fasebj.13.3.447; BERIETH T, 1988, EMBO J, V7, P1749; Bernstein E, 2001, RNA, V7, P1509; Brendza RP, 2000, SCIENCE, V289, P2120, DOI 10.1126/science.289.5487.2120; Brendza RP, 2002, CURR BIOL, V12, P1541, DOI 10.1016/S0960-9822(02)01108-9; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Castagnetti S, 2003, DEVELOPMENT, V130, P835, DOI 10.1242/dev.00309; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Celotto AM, 2002, RNA, V8, P718, DOI 10.1017/S1355838202021064; Cha BJ, 2002, NAT CELL BIOL, V4, P592, DOI 10.1038/ncb832; Cha BJ, 2001, CELL, V106, P35, DOI 10.1016/S0092-8674(01)00419-6; Chou TB, 1996, GENETICS, V144, P1673; Clegg NJ, 1997, DEVELOPMENT, V124, P4661; Clegg NJ, 2001, DEV GENES EVOL, V211, P44, DOI 10.1007/s004270000114; CONSORTIUM TF, 2003, NUCLEIC ACIDS RES, V31, P172; Cooperstock RL, 2001, INT REV CYTOL, V203, P541; Dalmay T, 2001, EMBO J, V20, P2069, DOI 10.1093/emboj/20.8.2069; Deng W, 1997, DEV BIOL, V189, P79, DOI 10.1006/dbio.1997.8669; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; Duncan JE, 2002, CURR BIOL, V12, P1982, DOI 10.1016/S0960-9822(02)01303-9; EDDY EM, 1975, INT REV CYTOL, V43, P229; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; Findley SD, 2003, DEVELOPMENT, V130, P859, DOI 10.1242/dev.00310; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GILLESPIE DE, 1995, GENE DEV, V9, P2495, DOI 10.1101/gad.9.20.2495; Gonzalez-Reyes A, 1997, DEVELOPMENT, V124, P4927; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; HAMILTON BA, 1994, METHOD CELL BIOL, V44, P81, DOI 10.1016/S0091-679X(08)60907-3; HARLOW E, 1999, USING ANTIBODIES LAB, P70; Himber C, 2003, EMBO J, V22, P4523, DOI 10.1093/emboj/cdg431; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Ikenishi K, 1998, DEV GROWTH DIFFER, V40, P1; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Januschke J, 2002, CURR BIOL, V12, P1971, DOI 10.1016/S0960-9822(02)01302-7; Kennerdell JR, 2002, GENE DEV, V16, P1884, DOI 10.1101/gad.990802; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Kim-Ha Jeongsil, 1993, Development (Cambridge), V119, P169; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KIMHA J, 1995, CELL, V81, P403, DOI 10.1016/0092-8674(95)90393-3; Kolonin MG, 2000, DEV BIOL, V227, P661, DOI 10.1006/dbio.2000.9916; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90338-A; Kooter JM, 1999, TRENDS PLANT SCI, V4, P340, DOI 10.1016/S1360-1385(99)01467-3; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LIANG L, 1994, DEVELOPMENT, V120, P1201; Lieberfarb ME, 1996, DEVELOPMENT, V122, P579; LIN HF, 1994, DEVELOPMENT, V120, P947; Linder P, 2000, NAT STRUCT BIOL, V7, P97, DOI 10.1038/72464; MARKUSSEN FH, 1995, DEVELOPMENT, V121, P3723; Micklem DR, 1997, CURR BIOL, V7, P468, DOI 10.1016/S0960-9822(06)00218-1; Mohr E, 2001, INT J BIOCHEM CELL B, V33, P669, DOI 10.1016/S1357-2725(01)00047-4; MOOSLEHNER K, 1991, MOL CELL BIOL, V11, P886, DOI 10.1128/MCB.11.2.886; Nakamura A, 2004, DEV CELL, V6, P69, DOI 10.1016/S1534-5807(03)00400-3; NeumanSilberberg FS, 1996, MECH DEVELOP, V59, P105, DOI 10.1016/0925-4773(96)00567-9; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; O'Connor Mark, 1993, V18, P75; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Palacios IM, 2002, DEVELOPMENT, V129, P5473, DOI 10.1242/dev.00119; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; Riechmann V, 2002, NAT CELL BIOL, V4, P337, DOI 10.1038/ncb782; Riechmann V, 2001, CURR OPIN GENET DEV, V11, P374, DOI 10.1016/S0959-437X(00)00207-0; Roignant JY, 2003, RNA, V9, P299, DOI 10.1261/rna.2154103; RONGO C, 1995, DEVELOPMENT, V121, P2737; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; Saffman EE, 1998, MOL CELL BIOL, V18, P4855, DOI 10.1128/MCB.18.8.4855; SALLES FJ, 1994, SCIENCE, V266, P1996, DOI 10.1126/science.7801127; Schmidt A, 1999, GENETICS, V151, P749; SCHUPBACH T, 1991, GENETICS, V129, P1119; Schwarz DS, 2002, MOL CELL, V10, P537, DOI 10.1016/S1097-2765(02)00651-2; Seggerson K, 2002, DEV BIOL, V243, P215, DOI 10.1006/dbio.2001.0563; Shulman JM, 2000, CELL, V101, P377, DOI 10.1016/S0092-8674(00)80848-X; Stapleton W, 2001, CHROMOSOMA, V110, P228, DOI 10.1007/s004120100136; STARK A, 2003, PLOS BIOL, V1, pE61, DOI DOI 10.1371/JOURNAL.PBIO.0000061; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Theodosiou NA, 1998, METHODS, V14, P355, DOI 10.1006/meth.1998.0591; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; THEURKAUF WE, 1994, METHOD CELL BIOL, V44, P489, DOI 10.1016/S0091-679X(08)60928-0; Tijsterman M, 2002, ANNU REV GENET, V36, P489, DOI 10.1146/annurev.genet.36.043002.091619; Tomari Y, 2004, CELL, V116, P831, DOI 10.1016/S0092-8674(04)00218-1; Tracey WD, 2000, GENETICS, V154, P273; van Eeden F, 1999, CURR OPIN GENET DEV, V9, P396, DOI 10.1016/S0959-437X(99)80060-4; Vanzo NF, 2002, DEVELOPMENT, V129, P3705; Vaucheret H, 2001, TRENDS GENET, V17, P29, DOI 10.1016/S0168-9525(00)02166-1; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; Webster PJ, 1997, GENE DEV, V11, P2510, DOI 10.1101/gad.11.19.2510; Weng YM, 1996, MOL CELL BIOL, V16, P5477; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Wilhelm JE, 2003, J CELL BIOL, V163, P1197, DOI 10.1083/jcb.200309088; Willmann MR, 2001, TRENDS PLANT SCI, V6, P450, DOI 10.1016/S1360-1385(01)02147-1; Wilson JE, 1996, DEVELOPMENT, V122, P1631; Winston WM, 2002, SCIENCE, V295, P2456, DOI 10.1126/science.1068836; Zaccai M, 1996, DEV GENET, V19, P249, DOI 10.1002/(SICI)1520-6408(1996)19:3<249::AID-DVG8>3.0.CO;2-9	101	188	200	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 19	2004	116	6					817	829		10.1016/S0092-8674(04)00250-8	http://dx.doi.org/10.1016/S0092-8674(04)00250-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YS	15035984	Bronze			2022-12-28	WOS:000221499900008
J	Turelli, P; Mangeat, B; Jost, S; Vianin, S; Trono, D				Turelli, P; Mangeat, B; Jost, S; Vianin, S; Trono, D			Inhibition of hepatitis B virus replication by APOBEC3G	SCIENCE			English	Article									Univ Geneva, Dept Microbiol & Mol Med, CH-1211 Geneva 4, Switzerland; Univ Geneva, Frontiers Genet Res Program, CH-1211 Geneva 4, Switzerland	University of Geneva; University of Geneva	Trono, D (corresponding author), Univ Geneva, Dept Microbiol & Mol Med, CH-1211 Geneva 4, Switzerland.	Didier.Trono@medecine.unige.ch		Mangeat, Bastien/0000-0003-2592-0236				Biermer M, 2003, J VIROL, V77, P4033, DOI 10.1128/JVI.77.7.4033-4042.2003; Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65; KewalRamani VN, 2003, SCIENCE, V301, P923, DOI 10.1126/science.1088965; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Ngui SL, 1999, REV MED VIROL, V9, P183, DOI 10.1002/(SICI)1099-1654(199907/09)9:3&lt;183::AID-RMV248&gt;3.0.CO;2-P; OON CJ, 1995, VACCINE, V13, P699, DOI 10.1016/0264-410X(94)00080-7; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591	7	359	395	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1829	1829		10.1126/science.1092066	http://dx.doi.org/10.1126/science.1092066			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031497				2022-12-28	WOS:000220281600045
J	Lebrun, F; Terrier, R; Bazzano, A; Belanger, G; Bird, A; Bouchet, L; Dean, A; Del Santo, M; Goldwurm, A; Lund, N; Morand, H; Parmar, A; Paul, J; Roques, JP; Schonfelder, V; Strong, AW; Ubertini, P; Walter, R; Winkler, C				Lebrun, F; Terrier, R; Bazzano, A; Belanger, G; Bird, A; Bouchet, L; Dean, A; Del Santo, M; Goldwurm, A; Lund, N; Morand, H; Parmar, A; Paul, J; Roques, JP; Schonfelder, V; Strong, AW; Ubertini, P; Walter, R; Winkler, C			Compact sources as the origin of the soft gamma-ray emission of the Milky Way	NATURE			English	Article							GALACTIC RIDGE; IMAGER; GALAXY	The Milky Way is known to be an abundant source of gamma-ray photons(1), now determined to be mainly diffuse in nature and resulting from interstellar processes(2). In the soft gamma-ray domain, point sources are expected to dominate, but the lack of sensitive high-resolution observations did not allow for a clear estimate of the contribution from such sources(3,4). Even the best imaging experiment(5) revealed only a few point sources, accounting for about 50% of the total Galactic flux(6). Theoretical studies were unable to explain the remaining intense diffuse emission(7,8). Investigating the origin of the soft gamma-rays is therefore necessary to determine the dominant particle acceleration processes and to gain insights into the physical and chemical equilibrium of the interstellar medium(7). Here we report observations in the soft gamma-ray domain that reveal numerous compact sources. We show that these sources account for the entirety of the Milky Way's emission in soft gamma-rays, leaving at most a minor role for diffuse processes.	CEA Saclay, DAPNIA, Serv Astrophys, F-91191 Gif Sur Yvette, France; Coll France, Federat Rech APC, F-75231 Paris, France; CNR, IASF, I-00133 Rome, Italy; Univ Southampton, Sch Phys & Astron, Southampton SO17 1BJ, Hants, England; CESR, F-31028 Toulouse 4, France; DSRI, DK-2100 Copenhagen O, Denmark; ESA, RSSD, NL-2201 AZ Noordwijk, Netherlands; MPE, D-85748 Garching, Germany; ISDC, CH-1290 Versoix, Switzerland	CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; College de France; Consiglio Nazionale delle Ricerche (CNR); University of Southampton; Max Planck Society; University of Geneva	Lebrun, F (corresponding author), CEA Saclay, DAPNIA, Serv Astrophys, F-91191 Gif Sur Yvette, France.	flebrun@cea.fr		Del Santo, Melania/0000-0002-1793-1050; Belanger, Guillaume/0000-0003-4810-1268				Dogiel VA, 2002, ASTROPHYS J, V581, P1061, DOI 10.1086/344246; Goldwurm A, 2003, ASTRON ASTROPHYS, V411, pL223, DOI 10.1051/0004-6361:20031395; Gros A, 2003, ASTRON ASTROPHYS, V411, pL179, DOI 10.1051/0004-6361:20031584; Kinzer RL, 1999, ASTROPHYS J, V515, P215, DOI 10.1086/306997; Lebrun F, 1999, ASTROPHYS LETT COMM, V38, P457; Lebrun F, 2003, ASTRON ASTROPHYS, V411, pL141, DOI 10.1051/0004-6361:20031367; PAUL J, 1991, ADV SPACE RES-SERIES, V11, P289, DOI 10.1016/0273-1177(91)90181-I; Pohl M, 1998, ASTRON ASTROPHYS, V339, P587; Purcell W.R., 1996, A A, V120, P389; SCHONFELDER V, 2001, UNIVERSE GAMMA RAYS; SKIBO JG, 1996, A AS, V120, P403; Strong AW, 2000, ASTROPHYS J, V537, P763, DOI 10.1086/309038; Strong AW, 2003, ASTRON ASTROPHYS, V411, pL447, DOI 10.1051/0004-6361:20031256; Ubertini P, 2003, ASTRON ASTROPHYS, V411, pL131, DOI 10.1051/0004-6361:20031224; Valinia A, 2000, ASTROPHYS J, V534, P277, DOI 10.1086/308755; Vedrenne G, 2003, ASTRON ASTROPHYS, V411, pL63, DOI 10.1051/0004-6361:20031482; Walter R, 2003, ASTRON ASTROPHYS, V411, pL427, DOI 10.1051/0004-6361:20031369; Wang QD, 2002, NATURE, V415, P148, DOI 10.1038/415148a; Webber W. R., 1983, Composition and Origin of Cosmic Rays. Proceedings of the NATO Advanced Study Institute, P83; Winkler C, 2003, ASTRON ASTROPHYS, V411, pL1, DOI 10.1051/0004-6361:20031288	20	63	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 18	2004	428	6980					293	296		10.1038/nature02407	http://dx.doi.org/10.1038/nature02407			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15029189				2022-12-28	WOS:000220250200036
J	Foustoukos, DI; Seyfried, WE				Foustoukos, DI; Seyfried, WE			Hydrocarbons in hydrothermal vent fluids: The role of chromium-bearing catalysts	SCIENCE			English	Article							MID-ATLANTIC RIDGE; ORGANIC-ACIDS; SERPENTINIZATION; GEOCHEMISTRY; CONSTRAINTS; REDUCTION; ROCKS; FIELD; CO2	Fischer-Tropsch type (FTT) synthesis has long been proposed to account for the existence of hydrocarbons in hydrothermal fluids. We show that iron- and chromium-bearing minerals catalyze the abiotic formation of hydrocarbons. In addition to production of methane (CH4aq), we report abiotic generation of ethane (C2H6aq) and propane (C3H8aq) by mineral-catalyzed hydrothermal reactions at 390degreesC and 400 bars. Results suggest that the chromium component in ultramafic rocks could be an important factor for FTT synthesis during water-rock interaction in mid-ocean ridge hydrothermal systems. This in turn could help to support microbial communities now recognized in the subsurface at deep-sea vents.	Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Foustoukos, DI (corresponding author), Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA.	fous0009@umn.edu						Allen DE, 2003, GEOCHIM COSMOCHIM AC, V67, P1531, DOI 10.1016/S0016-7037(02)01173-0; Berndt ME, 1996, GEOLOGY, V24, P351, DOI 10.1130/0091-7613(1996)024<0351:ROCDSO>2.3.CO;2; BONATTI E, 1981, SEA, V7, P241; BRADY RC, 1980, J AM CHEM SOC, V102, P6181, DOI 10.1021/ja00539a053; Brocks JJ, 2003, GEOCHIM COSMOCHIM AC, V67, P4321, DOI 10.1016/S0016-7037(03)00209-6; CANNAT M, 1992, EARTH PLANET SC LETT, V109, P87, DOI 10.1016/0012-821X(92)90076-8; Charlou JL, 2002, CHEM GEOL, V191, P345, DOI 10.1016/S0009-2541(02)00134-1; Charlou JL, 2000, CHEM GEOL, V171, P49, DOI 10.1016/S0009-2541(00)00244-8; COLEMAN RG, 1977, MINERALS ROCKS, V12; COLLOM TM, 2003, GEOCHIM COSMOCHIM AC, V67, P3625; Dias RF, 2002, GEOCHIM COSMOCHIM AC, V66, P2755, DOI 10.1016/S0016-7037(02)00871-2; DIAS RF, 2000, THESIS PENNSYLVANIA; DING K, 1992, GEOCHIM COSMOCHIM AC, V56, P3681, DOI 10.1016/0016-7037(92)90161-B; FU Q, 2004, 11 INT S WAT ROCK IN; Holm NG, 2001, EARTH PLANET SC LETT, V191, P1, DOI 10.1016/S0012-821X(01)00397-1; Horita J, 1999, SCIENCE, V285, P1055, DOI 10.1126/science.285.5430.1055; Kelley DS, 2001, NATURE, V412, P145, DOI 10.1038/35084000; McCollom TM, 2003, GEOCHIM COSMOCHIM AC, V67, P3645, DOI 10.1016/S0016-7037(03)00135-2; McCollom TM, 2001, GEOCHIM COSMOCHIM AC, V65, P3769, DOI 10.1016/S0016-7037(01)00655-X; NOVAK S, 1984, IND ENG CHEM FUND, V23, P274, DOI 10.1021/i100015a002; ORBERGER B, 1999, NUCL INSTRUM METH B, V158, P575; ROBIE RA, 1995, US GEOL SURV B, V2131, P462; RONA PA, 1987, J GEOPHYS RES-SOLID, V92, P1417, DOI 10.1029/JB092iB02p01417; SEEWALD J, COMMUNICATION; Seewald JS, 2001, GEOCHIM COSMOCHIM AC, V65, P1641, DOI 10.1016/S0016-7037(01)00544-0; SEYFRIED WE, 1987, HYDROTHERMAL EXPT TE, V9, P216; Stein S, 1998, NIST MASS SPECTRAL S; SUGISAKI R, 1994, GEOCHIM COSMOCHIM AC, V58, P2527, DOI 10.1016/0016-7037(94)90029-9; Taylor K.C., 1969, ADV CATAL, V20, P1; Weckhuysen BM, 1996, CHEM REV, V96, P3327, DOI 10.1021/cr940044o	30	260	279	7	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	2004	304	5673					1002	1005		10.1126/science.1096033	http://dx.doi.org/10.1126/science.1096033			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15060286				2022-12-28	WOS:000221383300046
J	Larson, EB; Shadlen, MF; Wang, L; McCormick, WC; Bowen, JD; Teri, L; Kukull, WA				Larson, EB; Shadlen, MF; Wang, L; McCormick, WC; Bowen, JD; Teri, L; Kukull, WA			Survival after initial diagnosis of Alzheimer disease	ANNALS OF INTERNAL MEDICINE			English	Article							BEHAVIOR PROBLEMS CHECKLIST; MULTIINFARCT DEMENTIA; GENDER-DIFFERENCES; REVISED MEMORY; FOLLOW-UP; PREDICTORS; MORTALITY; DEATH; INSTITUTIONALIZATION; PROGRESSION	Background: Alzheimer disease is an increasingly common condition in older people. Knowledge of life expectancy after the diagnosis of Alzheimer disease and of associations of patient characteristics with survival may help planning for future care. Objective: To investigate the course of Alzheimer disease after initial diagnosis and examine associations hypothesized to correlate with survival among community-dwelling patients with Alzheimer disease. Design: Prospective observational study. Setting: An Alzheimer disease patient registry from a base population of 23 000 persons age 60 years and older in the Group Health Cooperative, Seattle, Washington. Patients: 521 newly recognized persons with Alzheimer disease enrolled from 1987 to 1996 in an Alzheimer disease patient registry. Measurements: Baseline measurements included patient demographic features, Mini-Mental State Examination score, Blessed Dementia Rating Scale score, duration since reported onset of symptoms, associated symptoms, comorbid conditions, and selected signs. Survival was the outcome of interest. Results: The median survival from initial diagnosis was 4.2 years for men and 5.7 years for women with Alzheimer disease. Men had poorer survival across all age groups compared with females. Survival was decreased in all age groups compared with the life expectancy of the U.S. population. Predictors of mortality based on proportional hazards models included a baseline Mini-Mental State Examination score of 17 or less, baseline Blessed Dementia Rating Scale score of 5.0 or greater, presence of frontal lobe release signs, presence of extrapyramidal signs, gait disturbance, history of falls, congestive heart failure, ischemic heart disease, and diabetes at baseline. Limitations: The base population, although typical of the surrounding Seattle community, may not be representative of other, more diverse populations. Conclusions: In this sample of community-dwelling elderly persons who received a diagnosis of Alzheimer disease, survival duration was shorter than predicted on the basis of U.S. population data, especially for persons with onset at relatively younger ages. Features significantly associated with reduced survival at diagnosis were increased severity of cognitive impairment, decreased functional level, history of falls, physical examination findings of frontal release signs, and abnormal gait. The variables most strongly associated with survival were measures of disease severity at the time of diagnosis. These results should be useful to patients and families experiencing Alzheimer disease, other caregivers, clinicians, and policymakers when planning for future care needs.	Univ Washington, Seattle, WA 98195 USA; Grp Hlth Cooperat Puget Sound, Seattle, WA USA	University of Washington; University of Washington Seattle; Group Health Cooperative	Larson, EB (corresponding author), Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.	larson.e@ghz.org		Kukull, Walter/0000-0001-8761-9014	NATIONAL INSTITUTE ON AGING [U01AG006781] Funding Source: NIH RePORTER; NIA NIH HHS [AG 06781-13S1, AG 06781] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aguero-Torres H, 1998, INT J GERIATR PSYCH, V13, P755, DOI 10.1002/(SICI)1099-1166(1998110)13:11<755::AID-GPS862>3.0.CO;2-Y; BELLONISONZOGNI A, 1989, ARCH GERONTOL GERIAT, V9, P193, DOI 10.1016/0167-4943(89)90039-3; BIANCHETTI A, 1995, DEMENTIA, V6, P108, DOI 10.1159/000106930; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; Bowen JD, 1996, NEUROLOGY, V47, P433, DOI 10.1212/WNL.47.2.433; Claus JJ, 1998, DEMENT GERIATR COGN, V9, P284, DOI 10.1159/000017073; COX DR, 1972, J R STAT SOC B, V34, P187; Doody RS, 2001, ARCH NEUROL-CHICAGO, V58, P449, DOI 10.1001/archneur.58.3.449; Ewbank DC, 1999, AM J PUBLIC HEALTH, V89, P90, DOI 10.2105/AJPH.89.1.90; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gambassi G, 1999, NEUROLOGY, V53, P508, DOI 10.1212/WNL.53.3.508; Ganguli M, 1999, J AM GERIATR SOC, V47, P842, DOI 10.1111/j.1532-5415.1999.tb03842.x; Geerlings MI, 1997, NEUROLOGY, V49, P798, DOI 10.1212/WNL.49.3.798; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Heyman A, 1996, NEUROLOGY, V46, P656, DOI 10.1212/WNL.46.3.656; HIER DB, 1989, ARCH NEUROL-CHICAGO, V46, P1213, DOI 10.1001/archneur.1989.00520470073030; JAGGER C, 1995, PSYCHOL MED, V25, P171, DOI 10.1017/S0033291700028191; KNOPMAN DS, 1988, J AM GERIATR SOC, V36, P108, DOI 10.1111/j.1532-5415.1988.tb01778.x; Lapane KL, 2001, NEUROLOGY, V56, P650, DOI 10.1212/WNL.56.5.650; Larson E B, 1990, Aging (Milano), V2, P404; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MOLSA PK, 1995, ACTA NEUROL SCAND, V91, P159; MOLSA PK, 1986, ACTA NEUROL SCAND, V74, P103; NIELSEN H, 1991, ACTA PSYCHIAT SCAND, V84, P277, DOI 10.1111/j.1600-0447.1991.tb03144.x; Ostbye T, 1999, NEUROLOGY, V53, P521, DOI 10.1212/WNL.53.3.521; Piccininni M, 1998, ALZHEIMERS REP, V1, P321; STERN Y, 1994, NEUROLOGY, V44, P2300, DOI 10.1212/WNL.44.12.2300; TERI L, 1992, PSYCHOL AGING, V7, P622, DOI 10.1037/0882-7974.7.4.622; WALSH JS, 1990, ANN INTERN MED, V113, P429, DOI 10.7326/0003-4819-113-6-429; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2750, DOI 10.1001/jama.285.21.2750; Wilson RS, 2002, NEUROLOGY, V58, P1815, DOI 10.1212/WNL.58.12.1815; Wolfson C, 2001, NEW ENGL J MED, V344, P1111, DOI 10.1056/NEJM200104123441501	32	391	398	0	35	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 6	2004	140	7					501	509		10.7326/0003-4819-140-7-200404060-00008	http://dx.doi.org/10.7326/0003-4819-140-7-200404060-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	808OE	15068977				2022-12-28	WOS:000220577600001
J	Nakata, T; Hattori, A; Shimamoto, K				Nakata, T; Hattori, A; Shimamoto, K			Double chambered right ventricle	LANCET			English	Editorial Material									Sapporo Med Univ, Dept Internal Med Cardiol, Sapporo, Hokkaido 0600061, Japan; Sapporo Med Univ, Dept Pathol, Sapporo, Hokkaido 0600061, Japan	Sapporo Medical University; Sapporo Medical University	Nakata, T (corresponding author), Sapporo Med Univ, Dept Internal Med Cardiol, Sapporo, Hokkaido 0600061, Japan.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	2004	363	9415					1137	1137		10.1016/S0140-6736(04)15898-4	http://dx.doi.org/10.1016/S0140-6736(04)15898-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808VB	15064033				2022-12-28	WOS:000220595500022
J	Clack, JA				Clack, JA			From fins to fingers	SCIENCE			English	Editorial Material							TETRAPOD; EVOLUTION		Univ Cambridge, Univ Museum Zool, Cambridge CB2 3EJ, England	University of Cambridge	Clack, JA (corresponding author), Univ Cambridge, Univ Museum Zool, Downing St, Cambridge CB2 3EJ, England.	j.a.clack@zoo.cam.ac.uk						ANDREWS S M, 1985, Transactions of the Royal Society of Edinburgh Earth Sciences, V76, P67; ANDREWS S M, 1970, Transactions of the Royal Society of Edinburgh, V68, P207; Clack JA, 2003, J VERTEBR PALEONTOL, V23, p41A; Clack JA, 2003, NATURE, V425, P65, DOI 10.1038/nature01904; Clack JA., 2012, GAINING GROUND ORIGI; Coates MI, 1996, T ROY SOC EDIN-EARTH, V87, P363, DOI 10.1017/S0263593300006787; Daeschler EB, 1998, NATURE, V391, P133, DOI 10.1038/34317; Daeschler Edward B., 2003, Records of the Australian Museum, V55, P45; Jarvik Erik, 1996, Fossils and Strata, V40, P1; Jeffery JE, 2001, BIOL J LINN SOC, V74, P217, DOI 10.1006/bijl.2001.0572; LEBEDEV OA, 1990, RECHERCHE, V21, P1274; Shubin NH, 2004, SCIENCE, V304, P90, DOI 10.1126/science.1094295; Vorobyeva E. I., 2000, PALEONTOL J, V34, P632; Vorobyeva EI, 1975, NEUES JB GEOL PAL, V1975, P315	14	9	9	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 2	2004	304	5667					57	58		10.1126/science.1096415	http://dx.doi.org/10.1126/science.1096415			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15060312				2022-12-28	WOS:000220567900031
J	Dynek, JN; Smith, S				Dynek, JN; Smith, S			Resolution of sister telomere association is required for progression through mitosis	SCIENCE			English	Article							POLY(ADP-RIBOSE) POLYMERASE; MAMMALIAN-CELLS; TANKYRASE; ANAPHASE; COHESIN; SEPARATION; COMPLEXES; TRF1; IDENTIFICATION; CENTROMERES	Cohesins keep sister chromatids associated from the time of their replication in S phase until the onset of anaphase. In vertebrate cells, two distinct pathways dissociate cohesins, one acts on chromosome arms and the other on centromeres. Here, we describe a third pathway that acts on telomeres. Knockdown of tankyrase 1, a telomeric poly(ADP-ribose) polymerase caused mitotic arrest. Chromosomes aligned normally on the metaphase plate but were unable to segregate. Sister chromatids separated at centromeres and arms but remained associated at telomeres, apparently through proteinaceous bridges. Thus, telomeres may require a unique tankyrase 1-dependent mechanism for sister chromatid resolution before anaphase.	NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA	New York University	Smith, S (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, 450 1st Ave, New York, NY 10016 USA.	smithsu@saturn.med.nyu.edu		Smith, Susan/0000-0002-8213-5915	NATIONAL CANCER INSTITUTE [R01CA095099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007238] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA95099-01, R01 CA095099] Funding Source: Medline; NIGMS NIH HHS [GM07238-28] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chang W, 2003, GENE DEV, V17, P1328, DOI 10.1101/gad.1077103; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; Cook BD, 2002, MOL CELL BIOL, V22, P332, DOI 10.1128/MCB.22.1.332-342.2002; Donaldson MM, 2001, J CELL BIOL, V153, P663, DOI 10.1083/jcb.153.4.663; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Ofir R, 2002, CHROMOSOMA, V111, P147, DOI 10.1007/s00412-002-0199-z; OHNUKI Y, 1968, CHROMOSOMA, V25, P402, DOI 10.1007/BF02327721; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Seimiya H, 2002, J BIOL CHEM, V277, P14116, DOI 10.1074/jbc.M112266200; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0	24	215	230	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					97	100		10.1126/science.1094754	http://dx.doi.org/10.1126/science.1094754			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15064417				2022-12-28	WOS:000220567900045
J	Rizzoli, SO; Betz, WJ				Rizzoli, SO; Betz, WJ			The structural organization of the readily releasable pool of synaptic vesicles	SCIENCE			English	Article							FROG NEUROMUSCULAR-JUNCTION; MOTOR-NERVE TERMINALS; TRANSMITTER RELEASE; HIPPOCAMPAL SYNAPSES; EXOCYTOSIS; DEPLETION; ACTIN; KISS; RUN	The defining morphological feature of chemical synapses is the vesicle cluster in the presynaptic nerve terminal. It has generally been assumed that vesicles closest to release sites are recruited first during nerve activity. We tested this by selectively labeling the "readily releasable" pool, those vesicles released first during physiological stimulation. The readily releasable vesicles were not clustered close to the presynaptic membrane but instead were dispersed almost randomly throughout the vesicle cluster. Thus, vesicles are not recruited according to proximity to release sites but are mobilized differently, perhaps by being peeled from the surface of the cluster.	Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Betz, WJ (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, 4200 E 9th Ave, Denver, CO 80262 USA.	bill.betz@uchsc.edu	Rizzoli, Silvio/ABG-2227-2020	Rizzoli, Silvio/0000-0002-1667-7839	NINDS NIH HHS [5 RO1 NS023466] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023466] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BETZ WJ, 1994, J CELL BIOL, V124, P843, DOI 10.1083/jcb.124.5.843; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; Dunaevsky A, 2000, J NEUROSCI, V20, P6007, DOI 10.1523/JNEUROSCI.20-16-06007.2000; ELMQVIST D, 1965, J PHYSIOL-LONDON, V178, P505, DOI 10.1113/jphysiol.1965.sp007639; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; Gandhi SP, 2003, NATURE, V423, P607, DOI 10.1038/nature01677; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; KATZ B, 1979, PROC R SOC SER B-BIO, V205, P369, DOI 10.1098/rspb.1979.0070; Kuromi H, 1998, NEURON, V20, P917, DOI 10.1016/S0896-6273(00)80473-0; MOLGO J, 1988, NEUROSCIENCE, V24, P695, DOI 10.1016/0306-4522(88)90362-4; Richards DA, 2003, NEURON, V39, P529, DOI 10.1016/S0896-6273(03)00405-7; Richards DA, 2000, NEURON, V27, P551, DOI 10.1016/S0896-6273(00)00065-9; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Rosenmund C, 1997, J NEUROSCI METH, V76, P1, DOI 10.1016/S0165-0270(97)00061-7; Sakaba T, 2001, J NEUROSCI, V21, P462, DOI 10.1523/JNEUROSCI.21-02-00462.2001; Shupliakov O, 2002, P NATL ACAD SCI USA, V99, P14476, DOI 10.1073/pnas.212381799; SMITH JE, 1980, J EXP BIOL, V89, P19; Stevens CF, 2000, P NATL ACAD SCI USA, V97, P12828, DOI 10.1073/pnas.230438697; Trommershauser J, 2003, BIOPHYS J, V84, P1563, DOI 10.1016/S0006-3495(03)74967-4; vonGersdorff H, 1997, J NEUROSCI, V17, P1919; Wolfel M, 2003, J NEUROSCI, V23, P7059, DOI 10.1523/JNEUROSCI.23-18-07059.2003	22	219	222	2	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	2004	303	5666					2037	2039		10.1126/science.1094682	http://dx.doi.org/10.1126/science.1094682			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044806				2022-12-28	WOS:000220429800047
J	Stedman, HH; Kozyak, BW; Nelson, A; Thesier, DM; Su, LT; Low, DW; Bridges, CR; Shrager, JB; Minugh-Purvis, N; Mitchell, MA				Stedman, HH; Kozyak, BW; Nelson, A; Thesier, DM; Su, LT; Low, DW; Bridges, CR; Shrager, JB; Minugh-Purvis, N; Mitchell, MA			Myosin gene mutation correlates with anatomical changes in the human lineage	NATURE			English	Article							MIDDLE AWASH; MIOCENE; HOMINID; GROWTH; SKULL; MICE	Powerful masticatory muscles are found in most primates, including chimpanzees and gorillas, and were part of a prominent adaptation of Australopithecus and Paranthropus, extinct genera of the family Hominidae(1,2). In contrast, masticatory muscles are considerably smaller in both modern and fossil members of Homo. The evolving hominid masticatory apparatus - traceable to a Late Miocene, chimpanzee-like morphology(3) - shifted towards a pattern of gracilization nearly simultaneously with accelerated encephalization in early Homo(4). Here, we show that the gene encoding the predominant myosin heavy chain (MYH) expressed in these muscles was inactivated by a frameshifting mutation after the lineages leading to humans and chimpanzees diverged. Loss of this protein isoform is associated with marked size reductions in individual muscle fibres and entire masticatory muscles. Using the coding sequence for the myosin rod domains as a molecular clock, we estimate that this mutation appeared approximately 2.4 million years ago, predating the appearance of modern human body size(5) and emigration of Homo from Africa(6). This represents the first proteomic distinction between humans and chimpanzees that can be correlated with a traceable anatomic imprint in the fossil record.	Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Muscle Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Dent Med, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Plast Surg, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Stedman, HH (corresponding author), Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA.	hstedman@mail.med.upenn.edu						AcakpoSatchivi LJR, 1997, J CELL BIOL, V139, P1219, DOI 10.1083/jcb.139.5.1219; AIELLO L, 1998, INTRO HUMAN EVOLUTIO; Allen DL, 2001, AM J PHYSIOL-CELL PH, V280, pC637, DOI 10.1152/ajpcell.2001.280.3.C637; Asfaw B, 1999, SCIENCE, V284, P629, DOI 10.1126/science.284.5414.629; Bamman MM, 1999, ELECTROPHORESIS, V20, P466, DOI 10.1002/(SICI)1522-2683(19990301)20:3<466::AID-ELPS466>3.0.CO;2-7; Brennan M, 1996, PLAST RECONSTR SURG, V97, P13, DOI 10.1097/00006534-199601000-00002; Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; Chou HH, 2002, P NATL ACAD SCI USA, V99, P11736, DOI 10.1073/pnas.182257399; Desjardins PR, 2002, MOL BIOL EVOL, V19, P375, DOI 10.1093/oxfordjournals.molbev.a004093; Haile-Selassie Y, 2001, NATURE, V412, P178, DOI 10.1038/35084063; Hamrick MW, 2000, BONE, V27, P343, DOI 10.1016/S8756-3282(00)00339-2; HOHL TH, 1983, J MAXILLOFAC SURG, V11, P149, DOI 10.1016/S0301-0503(83)80038-1; Korfage JAM, 2003, J HISTOCHEM CYTOCHEM, V51, P113, DOI 10.1177/002215540305100113; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Leakey MG, 1998, NATURE, V393, P62, DOI 10.1038/29972; Levine S, 1997, NEW ENGL J MED, V337, P1799, DOI 10.1056/NEJM199712183372503; Lockwood CA, 2000, J HUM EVOL, V39, P23, DOI 10.1006/jhev.2000.0401; MacCoss MJ, 2002, ANAL CHEM, V74, P5593, DOI 10.1021/ac025826t; Martinsson T, 2000, P NATL ACAD SCI USA, V97, P14614, DOI 10.1073/pnas.250289597; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Messler W, 1997, NATURE, V385, P151, DOI 10.1038/385151a0; Rak Y., 1983, AUSTRALOPITHECINE FA, DOI [10.1016/B978-0-12-576280-9.50006-7, DOI 10.1016/B978-0-12-576280-9.50006-7]; Swofford D. L., 1998, PAUP PHYLOGENETIC AN; Tobias PV., 1992, S AFR ARCHAEOL B, V47, P137, DOI [10.2307/3889219, DOI 10.2307/3889219]; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; Vekua A, 2002, SCIENCE, V297, P85, DOI 10.1126/science.1072953; Walker A., 1993, NARIOKOTOME HOMO ERE; Warren SM, 2003, NATURE, V422, P625, DOI 10.1038/nature01545; White TD, 2000, AM J PHYS ANTHROPOL, V111, P45, DOI 10.1002/(SICI)1096-8644(200001)111:1<45::AID-AJPA4>3.0.CO;2-I; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555	30	264	280	0	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	2004	428	6981					415	418		10.1038/nature02358	http://dx.doi.org/10.1038/nature02358			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042088				2022-12-28	WOS:000220404300040
J	Tanaka, M; Chien, P; Naber, N; Cooke, R; Weissman, JS				Tanaka, M; Chien, P; Naber, N; Cooke, R; Weissman, JS			Conformational variations in an infectious protein determine prion strain differences	NATURE			English	Article							SUP35 PROTEIN; PSI+ PRION; YEAST; PSI(+); GENERATION; INDUCTION; DIVERSITY; VITRO	A remarkable feature of prion biology is the strain phenomenon wherein prion particles apparently composed of the same protein lead to phenotypically distinct transmissible states(1-4). To reconcile the existence of strains with the 'protein-only' hypothesis of prion transmission, it has been proposed that a single protein can misfold into multiple distinct infectious forms, one for each different strain(1-3,5). Several studies have found correlations between strain phenotypes and conformations of prion particles(6-10); however, whether such differences cause or are simply a secondary manifestation of prion strains remains unclear, largely due to the difficulty of creating infectious material from pure protein(3,5). Here we report a high-efficiency protocol for infecting yeast with the [PSI+] prion using amyloids composed of a recombinant Sup35 fragment (Sup-NM). Using thermal stability and electron paramagnetic resonance spectroscopy, we demonstrate that Sup-NM amyloids formed at different temperatures adopt distinct, stably propagating conformations. Infection of yeast with these different amyloid conformations leads to different [PSI+] strains. These results establish that Sup-NM adopts an infectious conformation before entering the cell fulfilling a key prediction of the prion hypothesis(5)-and directly demonstrate that differences in the conformation of the infectious protein determine prion strain variation.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weissman, JS (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	jsw1@itsa.ucsf.edu	Tanaka, Motomasa/N-5064-2015	Tanaka, Motomasa/0000-0002-2994-7703; Weissman, Jonathan/0000-0003-2445-670X				Aguzzi A, 2003, SCIENCE, V302, P814, DOI 10.1126/science.1087348; Baxa U, 2002, P NATL ACAD SCI USA, V99, P5253, DOI 10.1073/pnas.082097899; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Chernoff YO, 2000, MOL MICROBIOL, V35, P865, DOI 10.1046/j.1365-2958.2000.01761.x; Chien P, 2003, NATURE, V424, P948, DOI 10.1038/nature01894; Chien P, 2001, NATURE, V410, P223, DOI 10.1038/35065632; CHIEN P, IN PRESS ANN REV BIO; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; DePace AH, 2002, NAT STRUCT BIOL, V9, P389, DOI 10.1038/nsb786; Derkatch IL, 1997, GENETICS, V147, P507; Derkatch IL, 1996, GENETICS, V144, P1375; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; King CY, 2001, J MOL BIOL, V307, P1247, DOI 10.1006/jmbi.2001.4542; Kochneva-Pervukhova NV, 2001, YEAST, V18, P489, DOI 10.1002/yea.700; Kushnirov VV, 2000, EMBO J, V19, P324, DOI 10.1093/emboj/19.3.324; Kushnirov VV, 2000, CURR BIOL, V10, P1443, DOI 10.1016/S0960-9822(00)00802-2; Liebman SW, 2002, P NATL ACAD SCI USA, V99, P9098, DOI 10.1073/pnas.152318899; Maddelein ML, 2002, P NATL ACAD SCI USA, V99, P7402, DOI 10.1073/pnas.072199199; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Rice S, 2003, BIOPHYS J, V84, P1844, DOI 10.1016/S0006-3495(03)74992-3; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Uptain SM, 2002, ANNU REV MICROBIOL, V56, P703, DOI 10.1146/annurev.micro.56.013002.100603; Uptain SM, 2001, EMBO J, V20, P6236, DOI 10.1093/emboj/20.22.6236; Zhou P, 1999, EMBO J, V18, P1182, DOI 10.1093/emboj/18.5.1182	30	655	683	0	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	2004	428	6980					323	328		10.1038/nature02392	http://dx.doi.org/10.1038/nature02392			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15029196				2022-12-28	WOS:000220250200045
J	Smetana, GW; Cohn, SL; Lawrence, VA				Smetana, GW; Cohn, SL; Lawrence, VA			Update in perioperative medicine	ANNALS OF INTERNAL MEDICINE			English	Review							POSTOPERATIVE PULMONARY COMPLICATIONS; MAJOR NONCARDIAC SURGERY; CARDIAC RISK; MYOCARDIAL-INFARCTION; VASCULAR-SURGERY; SMOKING; DISEASE; INDEX		Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; SUNY Hlth Sci Ctr, Med Ctr, Brooklyn, NY USA; S Texas Vet Hlth Care Syst, VERDICT, San Antonio, TX USA; Univ Texas, Ctr Hlth, San Antonio, TX 78285 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System	Smetana, GW (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Shapiro 621D,330 Brookline Ave, Boston, MA 02215 USA.							Arozullah AM, 2000, ANN SURG, V232, P242, DOI 10.1097/00000658-200008000-00015; Back MR, 2002, J VASC SURG, V36, P526, DOI 10.1067/mva.2002.126560; Bergqvist D, 2002, NEW ENGL J MED, V346, P975, DOI 10.1056/NEJMoa012385; Bluman LG, 1998, CHEST, V113, P883, DOI 10.1378/chest.113.4.883; Eagle KA, 1997, CIRCULATION, V96, P1882, DOI 10.1161/01.CIR.96.6.1882; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; Kaluza GL, 2000, J AM COLL CARDIOL, V35, P1288, DOI 10.1016/S0735-1097(00)00521-0; Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; Polanczyk CA, 2001, JAMA-J AM MED ASSOC, V286, P309, DOI 10.1001/jama.286.3.309; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; Reilly DF, 1999, ARCH INTERN MED, V159, P2185, DOI 10.1001/archinte.159.18.2185; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Smetana GW, 1999, NEW ENGL J MED, V340, P937, DOI 10.1056/NEJM199903253401207; Sorensen Lars Tue, 2003, Colorectal Dis, V5, P347, DOI 10.1046/j.1463-1318.2003.00450.x; Straus SE, 2000, JAMA-J AM MED ASSOC, V283, P1853, DOI 10.1001/jama.283.14.1853; WARNER MA, 1989, MAYO CLIN PROC, V64, P609, DOI 10.1016/S0025-6196(12)65337-3; Wijeysundera DN, 2003, AM J MED, V114, P742, DOI 10.1016/S0002-9343(03)00165-7	18	11	12	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 16	2004	140	6					452	461		10.7326/0003-4819-140-6-200403160-00012	http://dx.doi.org/10.7326/0003-4819-140-6-200403160-00012			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803AU	15023711				2022-12-28	WOS:000220204800006
J	Kalberer, M; Paulsen, D; Sax, M; Steinbacher, M; Dommen, J; Prevot, ASH; Fisseha, R; Weingartner, E; Frankevich, V; Zenobi, R; Baltensperger, U				Kalberer, M; Paulsen, D; Sax, M; Steinbacher, M; Dommen, J; Prevot, ASH; Fisseha, R; Weingartner, E; Frankevich, V; Zenobi, R; Baltensperger, U			Identification of polymers as major components of atmospheric organic aerosols	SCIENCE			English	Article							MOLECULAR COMPOSITION; PHOTOOXIDATION; 1,3,5-TRIMETHYLBENZENE; HYDROCARBONS; GLYOXAL; TOLUENE; XYLENE; MODEL; WATER	Results from photooxidation of aromatic compounds in a reaction chamber show that a substantial fraction of the organic aerosol mass is composed of polymers. This polymerization results from reactions of carbonyls and their hydrates. After aging for more than 20 hours, about 50% of the particle mass consists of polymers with a molecular mass up to 1000 daltons. This results in a lower volatility of this secondary organic aerosol and a higher aerosol yield than a model using vapor pressures of individual organic species would predict.	Swiss Fed Inst Technol, Dept Chem & Appl Biosci, CH-8053 Zurich, Switzerland; Paul Scherrer Inst, Lab Atmospher Chem, CH-5232 Villigen, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Kalberer, M (corresponding author), Swiss Fed Inst Technol, Dept Chem & Appl Biosci, CH-8053 Zurich, Switzerland.	kalberer@org.chem.ethz.ch; urs.baltensperger@psi.ch	Prevot, Andre S. H./C-6677-2008; Frankevich, Vladimir E/E-3004-2016; Zenobi, Renato/F-1113-2010; Steinbacher, Martin/B-7424-2009; Weingartner, Ernest/B-6793-2009	Prevot, Andre S. H./0000-0002-9243-8194; Frankevich, Vladimir E/0000-0002-9780-4579; Steinbacher, Martin/0000-0002-7195-8115; Weingartner, Ernest/0000-0002-2427-4634				Calvert J. G., 2002, MECH ATMOSPHERIC OXI; CHASTRETTE F, 1983, B SOC CHIM FR II-CH, P33; CHASTRETTE F, 1985, B SOC CHIM FR, P66; Cocker DR, 2001, ATMOS ENVIRON, V35, P6073, DOI 10.1016/S1352-2310(01)00405-8; Dechapanya W, 2003, ENVIRON SCI TECHNOL, V37, P3662, DOI 10.1021/es0209058; Forstner HJL, 1997, ENVIRON SCI TECHNOL, V31, P1345, DOI 10.1021/es9605376; Griffin RJ, 1999, J GEOPHYS RES-ATMOS, V104, P3555, DOI 10.1029/1998JD100049; Grosjean E, 1996, ENVIRON SCI TECHNOL, V30, P2687, DOI 10.1021/es950758w; Hoffmann T, 1998, J GEOPHYS RES-ATMOS, V103, P25569, DOI 10.1029/98JD01816; Holes A, 1997, AEROSOL SCI TECH, V26, P516, DOI 10.1080/02786829708965450; Hurley MD, 2001, ENVIRON SCI TECHNOL, V35, P1358, DOI 10.1021/es0013733; Jang MS, 2002, SCIENCE, V298, P814, DOI 10.1126/science.1075798; Jang MS, 2001, ENVIRON SCI TECHNOL, V35, P3626, DOI 10.1021/es010676+; Koo BY, 2003, ATMOS ENVIRON, V37, P4757, DOI 10.1016/j.atmosenv.2003.08.016; Lim HJ, 2002, ENVIRON SCI TECHNOL, V36, P4489, DOI 10.1021/es0206487; Odum JR, 1997, SCIENCE, V276, P96, DOI 10.1126/science.276.5309.96; PANDIS SN, 1992, ATMOS ENVIRON A-GEN, V26, P2269, DOI 10.1016/0960-1686(92)90358-R; PANKOW JF, 1994, ATMOS ENVIRON, V28, P189, DOI 10.1016/1352-2310(94)90094-9; Pun BK, 2003, ENVIRON SCI TECHNOL, V37, P3647, DOI 10.1021/es0341541; RADER DJ, 1986, J AEROSOL SCI, V17, P771, DOI 10.1016/0021-8502(86)90031-5; ROGGE WF, 1993, ATMOS ENVIRON A-GEN, V27, P1309, DOI 10.1016/0960-1686(93)90257-Y; Seinfeld J. H., 1998, ATMOSPHERIC CHEM PHY; Sheehan PE, 2001, ENVIRON SCI TECHNOL, V35, P2129, DOI 10.1021/es001547g; Smith DF, 1999, J ATMOS CHEM, V34, P339, DOI 10.1023/A:1006277328628; TURPIN BJ, 1991, ATMOS ENVIRON A-GEN, V25, P207, DOI 10.1016/0960-1686(91)90291-E; WHIPPLE EB, 1970, J AM CHEM SOC, V92, P7183, DOI 10.1021/ja00727a027; Yu JZ, 1997, ATMOS ENVIRON, V31, P2261, DOI 10.1016/S1352-2310(97)00011-3	27	744	753	6	321	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1659	1662		10.1126/science.1092185	http://dx.doi.org/10.1126/science.1092185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016998				2022-12-28	WOS:000220151400041
J	Legg, L; Langhorne, P; Andersen, HE; Corr, S; Drummond, A; Duncan, P; Gershkoff, A; Gilbertson, L; Gladman, J; Hui, E; Jongbloed, L; Leonardi-Bee, J; Logan, P; Meade, T; de Vet, R; Stoker-Yates, J; Tilling, K; Walker, M; Wolfe, C				Legg, L; Langhorne, P; Andersen, HE; Corr, S; Drummond, A; Duncan, P; Gershkoff, A; Gilbertson, L; Gladman, J; Hui, E; Jongbloed, L; Leonardi-Bee, J; Logan, P; Meade, T; de Vet, R; Stoker-Yates, J; Tilling, K; Walker, M; Wolfe, C		Outpatient Serv Trialists	Rehabilitation therapy services for stroke patients living at home: systematic review of randomised trials	LANCET			English	Review							OCCUPATIONAL-THERAPY	Background Stroke-unit care can be valuable for stroke patients in hospital, but effectiveness of outpatient care is less certain. We aimed to assess the effects of therapy-based rehabilitation services targeted at stroke patients resident in the community within 1 year of stroke onset or discharge from hospital. Methods We did a systematic review of randomised trials of outpatient services, including physiotherapy, occupational therapy, and multidisciplinary teams. We used Cochrane collaboration methodology. Findings We identified a heterogeneous group of 14 trials (1617 patients). Therapy-based rehabilitation services for stroke patients living at home reduced the odds of deteriorating in personal activities of daily living (odds ratio 0.72 [95% CI 0.57-0.92], p=0.009) and increased ability of patients to do personal activities of daily living (standardised mean difference 0.14 [95% CI 0.02-0.25], p=0.02). For every 100 stroke patients resident in the community receiving therapy-based rehabilitation services, seven (95% CI 2-11) would not deteriorate. Interpretation Therapy-based rehabilitation services targeted at selected patients resident in the community after stroke improve ability to undertake personal activities of daily living and reduce risk of deterioration in ability. These findings should be considered in future service planning.	Glasgow Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland	University of Glasgow	Legg, L (corresponding author), Glasgow Royal Infirm, Acad Sect Geriatr Med, Level 3,Ctr Block, Glasgow G4 0SF, Lanark, Scotland.	Lynn@Legg80.freeserve.co.uk	Tilling, Kate/AAY-1578-2021	Tilling, Kate/0000-0002-1010-8926				Andersen HE, 2000, STROKE, V31, P1038, DOI 10.1161/01.STR.31.5.1038; [Anonymous], 2001, IMPR STROK SERV PAT; Corr S, 1995, CLIN REHABIL, V9, P291; Department of Health, 2001, NAT SERV FRAM OLD PE; Drummond A, 1995, CLIN REHABIL, V9, P283, DOI DOI 10.1177/026921559500900402; Duncan P, 1998, STROKE, V29, P2055, DOI 10.1161/01.STR.29.10.2055; EBRAHIM S, 1999, STROKE CARE MATTER C; Gilbertson L, 2000, BRIT MED J, V320, P603, DOI 10.1136/bmj.320.7235.603; GILBERTSON L, 1998, THESIS U GLASGOW; Goldberg G, 1997, Top Stroke Rehabil, V4, P64, DOI 10.1310/L9B9-6TB8-N4NQ-YRVH; HUI E, 1995, STROKE, V26, P1616, DOI 10.1161/01.STR.26.9.1616; JONGBLOED L, 1991, AM J OCCUP THER, V45, P420, DOI 10.5014/ajot.45.5.420; Logan PA, 1997, CLIN REHABIL, V11, P107, DOI 10.1177/026921559701100203; Mulrow CD, 1994, COCHRANE LIB; *OUTP SERV TRIAL, 1999, P 7 COCHR C OCT 5 8; *OUTP SERV TRIAL, 2003, COCHR LIB; Parker CJ, 2001, CLIN REHABIL, V15, P42, DOI 10.1191/026921501666968247; SANDERCOCK P, 2003, COCHRANE LIB; SMITH DS, 1981, BMJ-BRIT MED J, V282, P517, DOI 10.1136/bmj.282.6263.517; *STROK UN TRIAL CO, 2004, COCHR LIB; Wade DT, 2001, CLIN REHABIL, V15, P1, DOI 10.1191/026921501675961253; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5; WALKER MF, 1996, CLIN REHABIL, V10, P23, DOI DOI 10.1177/026921559601000105; Warlow CP., 2001, STROKE PRACTICAL GUI; Wolfe CDA, 2000, CLIN REHABIL, V14, P563, DOI 10.1191/0269215500cr362oa	25	158	170	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	2004	363	9406					352	356						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768TQ	15070563				2022-12-28	WOS:000188590900008
J	Leitzmann, MF; Platz, EA; Stampfer, MJ; Willett, WC; Giovannucci, E				Leitzmann, MF; Platz, EA; Stampfer, MJ; Willett, WC; Giovannucci, E			Ejaculation frequency and subsequent risk of prostate cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEXUAL-BEHAVIOR; SEMINAL PLASMA; INTRALUMINAL CRYSTALLOIDS; ERECTILE DYSFUNCTION; CIGARETTE-SMOKING; MEN; CARCINOMA; EPIDEMIOLOGY; QUESTIONNAIRE; METAANALYSIS	Context Sexual activity has been hypothesized to play a role in the development of prostate cancer, but epidemiological data are virtually limited to case-control studies, which may be prone to bias because recall among individuals with prostate cancer could be distorted as a consequence of prostate malignancy or ongoing therapy. Objective To examine the association between ejaculation frequency, which includes sexual intercourse, nocturnal emission, and masturbation and risk of prostate cancer. Design, Setting, and Participants Prospective study using follow-up data from the Health Professionals Follow-up Study (February 1, 1992, through January 31, 2000) of 29342 US men aged 46 to 81 years, who provided information on history of ejaculation frequency on a self-administered questionnaire in 1992 and responded to follow-up questionnaires every 2 years to 2000. Ejaculation frequency was assessed by asking participants to report the average number of ejaculations they had per month during the ages of 20 to 29 years, 40 to 49 years, and during the past year (1991). Main Outcome Measure Incidence of total prostate cancer. Results During 222426 person-years of follow-up, there were 1449 new cases of total prostate cancer, 953 organ-confined cases, and 147 advanced cases of prostate cancer. Most categories of ejaculation frequency were unrelated to risk of prostate cancer. However, high ejaculation frequency was related to decreased risk of total prostate cancer. The multivariate relative risks for men reporting 21 or more ejaculations per month compared with men reporting 4 to 7 ejaculations per month at ages 20 to 29 years were 0.89 (95% confidence interval [CI], 0.73-1.10); ages 40 to 49 years, 0.68 (95% CI, 0.53-0.86); previous year, 0.49 (95% CI, 0.27-0.88); and averaged across a lifetime, 0.67(95% CI, 051-0.89). Similar associations were observed for organ-confined prostate cancer. Ejaculation frequency was not statistically significantly associated with risk of advanced prostate cancer. Conclusions Our results suggest that ejaculation frequency is not related to increased risk of prostate cancer.	NCI, Div Canc Epidemiol & Genet, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Johns Hopkins Bloomerg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Leitzmann, MF (corresponding author), NCI, Div Canc Epidemiol & Genet, NIH, Dept Hlth & Human Serv, EPS-MSC 7232,6120 Execut Blvd, Bethesda, MD 20892 USA.	leitzmann@mail.nih.gov			NCI NIH HHS [CA055075, 5T32 CA09001-26] Funding Source: Medline; NHLBI NIH HHS [HL035464] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009001, Z01CP010127] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn HS, 2002, BJU INT, V89, P526, DOI 10.1046/j.1464-410X.2002.02650.x; Anton RC, 1998, AM J SURG PATHOL, V22, P446, DOI 10.1097/00000478-199804000-00009; AUMULLER G, 1991, Bulletin de l'Association des Anatomistes, V75, P39; BAKER LH, 1981, J UROLOGY, V125, P370, DOI 10.1016/S0022-5347(17)55039-9; BANERJEE AK, 1986, UROLOGY, V28, P159, DOI 10.1016/0090-4295(86)90112-3; Binks S, 1999, IMMUNOL INVEST, V28, P353, DOI 10.3109/08820139909062269; Bortz WM, 1999, J GERONTOL A-BIOL, V54, pM237, DOI 10.1093/gerona/54.5.M237; CHAKLIN AV, 1984, UROL NEFROL MOSK, V4, P46; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; COX DR, 1972, J R STAT SOC B, V34, P187; DELROSARIO AD, 1993, HUM PATHOL, V24, P1159, DOI 10.1016/0046-8177(93)90210-8; Dennis LK, 2002, EPIDEMIOLOGY, V13, P72, DOI 10.1097/00001648-200201000-00012; DJAKIEW D, 1992, J ANDROL, V13, P476; Du S F, 1996, Zhonghua Liu Xing Bing Xue Za Zhi, V17, P343; Feldman HA, 2000, PREV MED, V30, P328, DOI 10.1006/pmed.2000.0643; Giles GG, 2003, BJU INT, V92, P211, DOI 10.1046/j.1464-410X.2003.04319.x; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; Hayes R B, 1992, Eur J Cancer Prev, V1, P239, DOI 10.1097/00008469-199204000-00005; Hayes RB, 2000, BRIT J CANCER, V82, P718, DOI 10.1054/bjoc.1999.0986; HOLMES EJ, 1977, CANCER, V39, P2073, DOI 10.1002/1097-0142(197705)39:5<2073::AID-CNCR2820390525>3.0.CO;2-C; HONDA GD, 1988, BRIT J CANCER, V57, P326, DOI 10.1038/bjc.1988.74; Hsieh CC, 1999, INT J CANCER, V80, P699, DOI 10.1002/(SICI)1097-0215(19990301)80:5<699::AID-IJC12>3.3.CO;2-Z; Ilic M, 1996, BRIT J CANCER, V74, P1682, DOI 10.1038/bjc.1996.610; ISAACS JT, 1983, PROSTATE, V4, P351, DOI 10.1002/pros.2990040405; Jackson M A, 1981, Prog Clin Biol Res, V53, P111; Jakobsson L, 2001, J CLIN NURS, V10, P573, DOI 10.1046/j.1365-2702.2001.00499.x; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; KELLY RW, 1997, HUMAN REPROD, V12, P220; KRAIN LS, 1974, PREV MED, V3, P154, DOI 10.1016/0091-7435(74)90070-X; LAVECCHIA C, 1993, J EPIDEMIOL COMMUN H, V47, P450, DOI 10.1136/jech.47.6.450; LEIGH BC, 1993, AM J PUBLIC HEALTH, V83, P1400, DOI 10.2105/AJPH.83.10.1400; MANDEL JS, 1987, J GERONTOL, V42, P259, DOI 10.1093/geronj/42.3.259; MANTZOROS CS, 1995, BRIT MED J, V310, P1289, DOI 10.1136/bmj.310.6990.1289; MARSIGLIO W, 1991, J GERONTOL, V46, P338; Matthias RE, 1997, GERONTOLOGIST, V37, P6, DOI 10.1093/geront/37.1.6; MCVARY KT, 1994, BIOL REPROD, V51, P99, DOI 10.1095/biolreprod51.1.99; MILLS PK, 1989, CANCER, V64, P598, DOI 10.1002/1097-0142(19890801)64:3&lt;598::AID-CNCR2820640306&gt;3.0.CO;2-6; Mirone V, 2002, EUR UROL, V41, P294, DOI 10.1016/S0302-2838(02)00005-2; MISHINA T, 1985, PROSTATE, V6, P423, DOI 10.1002/pros.2990060411; NEWMAN HF, 1982, UROLOGY, V19, P341, DOI 10.1016/0090-4295(82)90186-8; OISHI K, 1990, PROSTATE, V17, P269, DOI 10.1002/pros.2990170403; Okamoto M, 2002, AIDS RES HUM RETROV, V18, P797, DOI 10.1089/08892220260139549; PICHINI S, 1994, CLIN PHARMACOKINET, V26, P356, DOI 10.2165/00003088-199426050-00004; RO JY, 1986, CANCER, V57, P2397, DOI 10.1002/1097-0142(19860615)57:12<2397::AID-CNCR2820571226>3.0.CO;2-1; Rosenblatt KA, 2001, AM J EPIDEMIOL, V153, P1152, DOI 10.1093/aje/153.12.1152; ROSS RK, 1987, JNCI-J NATL CANCER I, V78, P869; ROSS RK, 1983, PROSTATE, V4, P333, DOI 10.1002/pros.2990040403; ROTKIN ID, 1977, CANCER TREAT REP, V61, P173; SCHIAVI RC, 1990, AM J PSYCHIAT, V147, P766; SEVERSON RK, 1989, CANCER RES, V49, P1857; Shaneyfelt T, 2000, J CLIN ONCOL, V18, P847, DOI 10.1200/JCO.2000.18.4.847; Smith E R, 1981, Prog Clin Biol Res, V75B, P131; STEELE R, 1971, J CHRON DIS, V24, P29, DOI 10.1016/0021-9681(71)90056-7; Strickler HD, 2001, EPIDEMIOL REV, V23, P144, DOI 10.1093/oxfordjournals.epirev.a000781; TARTER TH, 1992, J INVEST ALLERG CLIN, V2, P106; WHITE JR, 1990, ARCH SEX BEHAV, V19, P193, DOI 10.1007/BF01541546	56	72	73	6	34	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2004	291	13					1578	1586		10.1001/jama.291.13.1578	http://dx.doi.org/10.1001/jama.291.13.1578			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	809PQ	15069045	Bronze			2022-12-28	WOS:000220649000022
J	Shubin, NH; Daeschler, EB; Coates, MI				Shubin, NH; Daeschler, EB; Coates, MI			The early evolution of the tetrapod humerus	SCIENCE			English	Article							DEVONIAN TETRAPOD; MORPHOLOGY; FINS	A tetrapod humerus from the Late Devonian of Pennsylvania has a novel mix of primitive and derived characters. A comparative analysis of this fossil and other relevant humeri from the Devonian shows that the role of the limb in propping the body arose first in fish fins, not tetrapod limbs. The functional diversity of the earliest known limbs includes several different kinds of appendage design. This functional diversity was achieved with a humeral architecture that was remarkably conserved during the Devonian.	Univ Chicago, Dept Organismal Biol & Anat, Chicago, IL 60637 USA; Acad Nat Sci Philadelphia, Philadelphia, PA 19103 USA	University of Chicago; Drexel University	Shubin, NH (corresponding author), Univ Chicago, Dept Organismal Biol & Anat, 1025 E 57th St, Chicago, IL 60637 USA.	nshubin@uchicago.edu	Coates, Michael/AAO-3810-2020	Coates, Michael/0000-0003-2843-1075				AHLBERG PE, 1991, NATURE, V354, P298, DOI 10.1038/354298a0; Ahlberg PE, 1998, NATURE, V395, P792, DOI 10.1038/27421; ANDREWS S M, 1970, Transactions of the Royal Society of Edinburgh, V68, P207; Carroll RL, 1988, VERTEBRATE PALEONTOL; Clack JA., 2012, GAINING GROUND ORIGI; Coates MI, 1996, T ROY SOC EDIN-EARTH, V87, P363, DOI 10.1017/S0263593300006787; COATES MI, 1990, NATURE, V347, P66, DOI 10.1038/347066a0; Daeschler EB, 2000, J PALEONTOL, V74, P301, DOI 10.1666/0022-3360(2000)074<0301:ETJFTL>2.0.CO;2; DAESCHLER EB, 1994, SCIENCE, V265, P639, DOI 10.1126/science.265.5172.639; Goto T, 1999, ICHTHYOL RES, V46, P281, DOI 10.1007/BF02678514; Gregory W. K., 1941, Annals of the New York Academy of Sciences, V42, P273; Jarvik Erik, 1996, Fossils and Strata, V40, P1; LEBEDEV OA, 1995, ZOOL J LINN SOC-LOND, V114, P307, DOI 10.1006/zjls.1995.0027; ROMER AS, 1958, EVOLUTION, V12, P365, DOI 10.2307/2405858; Traverse A, 2002, COUR FOR SEKENBG, V241, P19; VOROBYEVA E, 1992, FOSSIL FISHES LIVING; Vorobyeva E. I., 2000, PALEONTOL J, V34, P632; Wilga CD, 2001, J MORPHOL, V249, P195, DOI 10.1002/jmor.1049	18	79	80	2	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					90	93		10.1126/science.1094295	http://dx.doi.org/10.1126/science.1094295			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15064415				2022-12-28	WOS:000220567900043
J	Murphy, SM; Murray, D; Smith, S; Orr, DJA				Murphy, SM; Murray, D; Smith, S; Orr, DJA			Lesson of the week - Burns caused by steam inhalation for respiratory tract infections in children	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Our Ladys Hosp Sick Children, Dept Plast & Reconstruct Surg, Dublin 12, Ireland; Univ Dublin Trinity Coll, Dept Community Hlth & Gen Practice, Dublin 2, Ireland	Our Ladys Children Hospital Crumlin; Trinity College Dublin	Murphy, SM (corresponding author), Our Ladys Hosp Sick Children, Dept Plast & Reconstruct Surg, Dublin 12, Ireland.	siunm@hotmail.com	Orr, David/T-1779-2019; Smith, Susan/D-1872-2012	Orr, David/0000-0002-1935-1412; Smith, Susan/0000-0001-6027-2727				BALSLEV T, 1990, Ugeskrift for Laeger, V152, P1384; Jeffery SLA, 2000, BRIT MED J, V320, P235, DOI 10.1136/bmj.320.7229.235; MODELL M, 1996, PAEDIAT PROBLEMS GEN, P199; SINGH M, 2001, COCHRANE DB SYST REV, P1728	4	9	10	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 27	2004	328	7442					757	757		10.1136/bmj.328.7442.757	http://dx.doi.org/10.1136/bmj.328.7442.757			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809WH	15044293	Green Published			2022-12-28	WOS:000220666300021
J	White, NJ				White, NJ			Sharing malarias	LANCET			English	Editorial Material									Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand	Mahidol University	White, NJ (corresponding author), Mahidol Univ, Fac Trop Med, 420-6 Rajvithi Rd, Bangkok 10400, Thailand.	nickw@tropmedres.ac	White, Nick/AAC-6527-2019; White, Nicholas J/I-4629-2012	White, Nick/0000-0002-1897-1978; 				GARNHAM PCC, 1966, MALARIA OTHER HAEMOS; Rathore D, 2001, MOL BIOCHEM PARASIT, V114, P89, DOI 10.1016/S0166-6851(01)00241-9; Rich SM, 2003, ADV PARASIT, V54, P255, DOI 10.1016/S0065-308X(03)54005-2	3	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	2004	363	9414					1006	1006		10.1016/S0140-6736(04)15879-0	http://dx.doi.org/10.1016/S0140-6736(04)15879-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15051279	Green Published, Bronze			2022-12-28	WOS:000220497300005
J	Wonderling, D; Vickers, AJ; Grieve, R; McCarney, R				Wonderling, D; Vickers, AJ; Grieve, R; McCarney, R			Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TENSION-TYPE HEADACHE; PROPHYLACTIC TREATMENT; NEEDLE ACUPUNCTURE; MIGRAINE; HEALTH; PLACEBO; SUMATRIPTAN; ACCESS	Objective To evaluate the cost effectiveness of acupuncture in the management of chronic headache. Design Cost effectiveness analysis of a randomised controlled trial. Setting General practices in England and Wales. Participants 401 patients with chronic headache, predominantly migraine. Interventions Patients were randomly allocated to receive up to 12 acupuncture treatments over three months from appropriately trained physiotherapists, or to usual care alone. Main outcome measure Incremental cost per quality adjusted life year (QALY) gained. Results Total costs during the one year period of the study were on average higher for the acupuncture group (1,103; $768; E598) than for controls (A:217) because of the acupuncture practitioners' costs. The mean health gain from acupuncture during the one year of the trial was 0.021 quality adjusted life years (QALYs), leading to a base case estimate of 9180 per QALY gained. This result was robust to sensitivity analysis. Cost per QALY dropped substantially when the analysis incorporated likely QALY differences for the years after the trial. Conclusions Acupuncture for chronic headache improves health related quality of life at a small additional cost; it is relatively cost effective compared with a number of other interventions provided by the NHS.	Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England; Mem Sloan Kettering Canc Ctr, Biostat Serv, Integrat Med Serv, New York, NY 10021 USA; Univ London Imperial Coll Sci Technol & Med, Dept Psychol Med, London W2 1PD, England	University of London; London School of Hygiene & Tropical Medicine; Memorial Sloan Kettering Cancer Center; Imperial College London	Wonderling, D (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, Keppel St, London WC1E 7HT, England.	David.Wonderling@lshtm.ac.uk		Vickers, Andrew/0000-0003-1525-6503; Grieve, Richard/0000-0001-8899-1301; Wonderling, David/0000-0003-0315-6273				Allais G, 2002, HEADACHE, V42, P855, DOI 10.1046/j.1526-4610.2002.02203.x; BLAU JN, 1991, MIGRAINE; BOSANQUET N, 1992, BR J MED EC, V2, P81; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; CULL RE, 1992, BR J MED EC, V2, P81; Evans KW, 1997, PHARMACOECONOMICS, V12, P565, DOI 10.2165/00019053-199712050-00007; Goadsby PJ, 2002, NEW ENGL J MED, V346, P257, DOI 10.1056/NEJMra010917; Karakurum B, 2001, CEPHALALGIA, V21, P813, DOI 10.1046/j.1468-2982.2001.218238.x; Karst M, 2000, PAIN, V88, P199, DOI 10.1016/S0304-3959(00)00315-8; Karst M, 2001, CEPHALALGIA, V21, P637, DOI 10.1046/j.1468-2982.2001.00198.x; Kee W. G., 1998, AM J PAIN MANAGEMENT, V8, P83; LENHARD L, 1983, NEW ZEAL MED J, V96, P663; Lipton RB, 2003, NEUROLOGY, V60, P441, DOI 10.1212/WNL.60.3.441; McCarney R, 2002, COMPLEMENT THER MED, V10, P63, DOI 10.1054/ctim.2002.0516; Melchart D, 2003, J INTERN MED, V253, P181, DOI 10.1046/j.1365-2796.2003.01081.x; MELCHART D, 2001, COCHRANE DATABASE SY; Melchart D., 2001, COCHRANE DATABASE SY; NETTEN A, 2002, UNIT COSTS HLTH SOCI; *OFF NAT STAT, 2003, 1 REL CONS PRIC IND; Raftery J, 2001, BRIT MED J, V323, P1300, DOI 10.1136/bmj.323.7324.1300; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Solomon GD, 1997, PHARMACOECONOMICS, V11, P1, DOI 10.2165/00019053-199700111-00003; Solomon GD, 1997, NEUROLOGY, V48, pS10, DOI 10.1212/WNL.48.3_Suppl_3.10S; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; STEEDMAN SM, 1992, CLIN J PAIN, V8, P204, DOI 10.1097/00002508-199209000-00004; STEWART WF, 1994, EUR NEUROL, V34, P12, DOI 10.1159/000119527; Stinnett AA, 1998, MED DECIS MAKING, V18, pS68, DOI 10.1177/0272989X98018002S09; Tfelt-Hansen P, 2000, CEPHALALGIA, V20, P765; Thomas KJ, 2001, BRIT J GEN PRACT, V51, P25; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; VICKERS A, 1999, COMPLEMENT THER MED, V7, P8; Vickers A. J., 2004, BMJ, V328; VINCENT CA, 1989, CLIN J PAIN, V5, P305, DOI 10.1097/00002508-198912000-00006; Wadlow G., 1996, COMPLEMENT THER MED, V4, P1, DOI [10.1016/S0965-2299(96)80048-3, DOI 10.1016/S0965-2299(96)80048-3]; WHITE A, 2001, BRIT MED J, V323, P4485; Whittaker SJ, 1996, BT TECHNOL J, V14, P11	37	82	87	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 27	2004	328	7442					747	749		10.1136/bmj.38033.896505.EB	http://dx.doi.org/10.1136/bmj.38033.896505.EB			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809WH	15023830	Bronze, Green Published, Green Accepted, Green Submitted			2022-12-28	WOS:000220666300018
J	Jia, CL; Urban, K				Jia, CL; Urban, K			Atomic-resolution measurement of oxygen concentration in oxide materials	SCIENCE			English	Article							TRANSMISSION ELECTRON-MICROSCOPY; GRAIN-BOUNDARIES; BARIUM-TITANATE; THIN-FILMS; BATIO3; IMAGE; NONSTOICHIOMETRY; NANOTWINS; CERAMICS; SRTIO3	Using high-resolution imaging at negative spherical aberration of the objective lens in an aberration-corrected transmission electron microscope, we measure the concentration of oxygen in Sigma3{111} twin boundaries in BaTiO(3) thin films at atomic resolution. On average, 68% of the boundary oxygen sites are occupied, and the others are left vacant. The modified Ti(2)O(9) group unit thus formed reduces the grain boundary energy and provides a way of accommodating oxygen vacancies occurring in oxygen-deficient material by the formation of a nanotwin lamellae structure. The atomically resolved measurement technique offers the potential for studies on oxide materials in which the electronic properties sensitively depend on the local oxygen content.	Forschungszentrum Julich, Inst Solid State Res, D-52425 Julich, Germany	Helmholtz Association; Research Center Julich	Urban, K (corresponding author), Forschungszentrum Julich, Inst Solid State Res, Postfach 1913, D-52425 Julich, Germany.	k.urban@fz-juelich.de						Astala R, 2002, J PHYS-CONDENS MAT, V14, P6455, DOI 10.1088/0953-8984/14/25/313; BURBANK RD, 1948, ACTA CRYSTALLOGR, V1, P330, DOI 10.1107/S0365110X48000867; COWLEY JM, 1957, ACTA CRYSTALLOGR, V10, P609, DOI 10.1107/S0365110X57002194; FAHEY KP, 1995, APPL PHYS LETT, V67, P2480, DOI 10.1063/1.114614; Grey IE, 1998, J SOLID STATE CHEM, V135, P312, DOI 10.1006/jssc.1997.7652; Haider M, 1998, NATURE, V392, P768, DOI 10.1038/33823; HUXFORD NP, 1987, NATURE, V329, P812, DOI 10.1038/329812a0; HYTCH MJ, 1994, ULTRAMICROSCOPY, V53, P63, DOI 10.1016/0304-3991(94)90105-8; Jia CL, 1998, PHILOS MAG A, V77, P923, DOI 10.1080/01418619808221220; Jia CL, 1999, PHYS REV LETT, V82, P5052, DOI 10.1103/PhysRevLett.82.5052; Jia CL, 2003, SCIENCE, V299, P870, DOI 10.1126/science.1079121; JIA CL, IN PRESS MICROSC MIC; Kim M, 2001, PHYS REV LETT, V86, P4056, DOI 10.1103/PhysRevLett.86.4056; KING WE, 1994, ULTRAMICROSCOPY, V56, P46, DOI 10.1016/0304-3991(94)90145-7; KISIELOWSKI C, 1995, ULTRAMICROSCOPY, V58, P131, DOI 10.1016/0304-3991(94)00202-X; Klie RF, 2001, ULTRAMICROSCOPY, V86, P289, DOI 10.1016/S0304-3991(00)00120-0; Lentzen M, 2002, ULTRAMICROSCOPY, V92, P233, DOI 10.1016/S0304-3991(02)00139-0; LICHTE H, 1991, ULTRAMICROSCOPY, V38, P13, DOI 10.1016/0304-3991(91)90105-F; OKEEFE MA, 1988, SCANNING MICROSCOPY, P225; OURMAZD A, 1990, ULTRAMICROSCOPY, V34, P237, DOI 10.1016/0304-3991(90)90018-H; OURMAZD A, 1987, NATURE, V329, P425, DOI 10.1038/329425a0; Poole C.P., 1995, SUPERCONDUCTIVITY, V1st; RECNIK A, 1994, PHILOS MAG B, V70, P1021, DOI 10.1080/01418639408240270; Setter N, 2000, ACTA MATER, V48, P151, DOI 10.1016/S1359-6454(99)00293-1; STENKAMP D, 1993, ULTRAMICROSCOPY, V50, P321, DOI 10.1016/0304-3991(93)90200-H; Suzuki T, 2000, J AM CERAM SOC, V83, P3185, DOI 10.1111/j.1151-2916.2000.tb01702.x; Tagantsev AK, 2001, J APPL PHYS, V90, P1387, DOI 10.1063/1.1381542; THUST A, 1992, ULTRAMICROSCOPY, V45, P23, DOI 10.1016/0304-3991(92)90035-I; Tokura Y., 2000, COLOSSAL MAGNETORESI; VANTENDELOO G, 2000, CHARACTERIZATION HIG, P161; WASER R, 1995, SOLID STATE IONICS, V75, P89, DOI 10.1016/0167-2738(94)00152-I; Waser R, 1997, INTEGR FERROELECTR, V15, P39, DOI 10.1080/10584589708015695; Yoo HI, 2002, J ELECTROCERAM, V8, P5, DOI 10.1023/A:1015570717935; Zhang ZL, 2003, SCIENCE, V302, P846, DOI 10.1126/science.1089785; Zhang ZL, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.094108	35	238	265	11	281	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	2004	303	5666					2001	2004		10.1126/science.1093617	http://dx.doi.org/10.1126/science.1093617			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044799				2022-12-28	WOS:000220429800037
J	Ungless, MA; Magill, PJ; Bolam, JP				Ungless, MA; Magill, PJ; Bolam, JP			Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli	SCIENCE			English	Article							SUBSTANTIA NIGRA; DISCHARGE RATE; RELEASE; RAT; MODULATION; ACTIVATION; RESPONSES; SYSTEM; REWARD; STRESS	Dopamine neurons play a key role in reward-related behaviors. Reward coding theories predict that dopamine neurons will be inhibited by or will not respond to aversive stimuli. Paradoxically, between 3 and 49% of presumed dopamine neurons are excited by aversive stimuli. We found that, in the ventral tegmental area of anesthetized rats, the population of presumed dopamine neurons that are excited by aversive stimuli is actually not dopaminergic. The identified dopamine neurons were inhibited by the aversive stimulus. These findings suggest that dopamine neurons are specifically excited by reward and that a population of nondopamine neurons is excited by aversive stimuli.	Univ Oxford, Dept Pharmacol, MRC, Anat Neuropharmacol Unit, Oxford OX1 3TH, England	University of Oxford	Ungless, MA (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	mark.ungless@zoo.ox.ac.uk	Ungless, Mark/A-1985-2009	Ungless, Mark/0000-0002-1730-3353; Bolam, J Paul/0000-0002-5008-8405; Magill, Peter/0000-0001-7141-7071				Cameron DL, 1997, NEUROSCIENCE, V77, P155, DOI 10.1016/S0306-4522(96)00444-7; CHIODO LA, 1980, BRAIN RES, V189, P544, DOI 10.1016/0006-8993(80)90366-2; Fa M, 2003, SYNAPSE, V48, P1, DOI 10.1002/syn.10177; Floresco SB, 2003, NAT NEUROSCI, V6, P968, DOI 10.1038/nn1103; FREEMAN AS, 1987, BRAIN RES, V405, P46, DOI 10.1016/0006-8993(87)90988-7; GONON FG, 1988, NEUROSCIENCE, V24, P19, DOI 10.1016/0306-4522(88)90307-7; GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U; GRACE AA, 1984, J NEUROSCI, V4, P2877; GRACE AA, 1983, NEUROSCIENCE, V10, P301, DOI 10.1016/0306-4522(83)90135-5; Guarraci FA, 1999, BEHAV BRAIN RES, V99, P169, DOI 10.1016/S0166-4328(98)00102-8; Horvitz JC, 2000, NEUROSCIENCE, V96, P651, DOI 10.1016/S0306-4522(00)00019-1; JEDEMA HP, 1994, J NEUROCHEM, V63, P785, DOI 10.1046/j.1471-4159.1994.63020785.x; KEEFE KA, 1993, J NEUROCHEM, V61, P1943, DOI 10.1111/j.1471-4159.1993.tb09837.x; MAEDA H, 1982, BRAIN RES BULL, V8, P7, DOI 10.1016/0361-9230(82)90021-1; MANTZ J, 1989, BRAIN RES, V476, P377, DOI 10.1016/0006-8993(89)91263-8; McClure SM, 2003, TRENDS NEUROSCI, V26, P423, DOI 10.1016/S0166-2236(03)00177-2; Mirenowicz J, 1996, NATURE, V379, P449, DOI 10.1038/379449a0; Overton PG, 1997, BRAIN RES REV, V25, P312, DOI 10.1016/S0165-0173(97)00039-8; PALIJ P, 1990, BRAIN RES, V509, P172, DOI 10.1016/0006-8993(90)90329-A; Pinault D, 1996, J NEUROSCI METH, V65, P113, DOI 10.1016/0165-0270(95)00144-1; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SALAMONE JD, 1994, BEHAV BRAIN RES, V61, P117, DOI 10.1016/0166-4328(94)90153-8; Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4; SCHULTZ W, 1987, J NEUROPHYSIOL, V57, P201, DOI 10.1152/jn.1987.57.1.201; Steffensen SC, 1998, J NEUROSCI, V18, P8003	25	572	578	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	2004	303	5666					2040	2042		10.1126/science.1093360	http://dx.doi.org/10.1126/science.1093360			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044807	Green Submitted			2022-12-28	WOS:000220429800048
J	Sourjik, V; Berg, HC				Sourjik, V; Berg, HC			Functional interactions between receptors in bacterial chemotaxis	NATURE			English	Article							ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; COVALENT MODIFICATION; MODEL; CHEMORECEPTOR; SENSITIVITY; COMPLEX; BINDING; METHYLATION; COMPONENTS	Bacterial chemotaxis is a model system for signal transduction, noted for its relative simplicity, high sensitivity, wide dynamic range and robustness. Changes in ligand concentrations are sensed by a protein assembly consisting of transmembrane receptors, a coupling protein ( CheW) and a histidine kinase (CheA)(1-4). In Escherichia coli, these components are organized at the cell poles in tight clusters that contain several thousand copies of each protein(1,4-6). Here we studied the effects of variation in the composition of clusters on the activity of the kinase and its sensitivity to attractant stimuli, monitoring responses in vivo using fluorescence resonance energy transfer. Our results indicate that assemblies of bacterial chemoreceptors work in a highly cooperative manner, mimicking the behaviour of allosteric proteins. Conditions that favour steep responses to attractants in mutants with homogeneous receptor populations also enhance the sensitivity of the response in wild-type cells. This is consistent with a number of models(7-11) that assume long-range cooperative interactions between receptors as a general mechanism for signal integration and amplification.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Rowland Inst, Cambridge, MA 02142 USA	Harvard University; Harvard University	Berg, HC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.	hberg@biosun.harvard.edu						Ames P, 2002, P NATL ACAD SCI USA, V99, P7060, DOI 10.1073/pnas.092071899; AMES P, 1994, J BACTERIOL, V176, P6340, DOI 10.1128/jb.176.20.6340-6348.1994; ASAKURA S, 1984, J MOL BIOL, V176, P349, DOI 10.1016/0022-2836(84)90494-7; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; Bornhorst JA, 2000, BIOCHEMISTRY-US, V39, P9486, DOI 10.1021/bi0002737; Boukhvalova MS, 2002, J BIOL CHEM, V277, P22251, DOI 10.1074/jbc.M110908200; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; Duke TAJ, 1999, P NATL ACAD SCI USA, V96, P10104, DOI 10.1073/pnas.96.18.10104; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; Gestwicki JE, 2002, NATURE, V415, P81, DOI 10.1038/415081a; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; Kim SH, 2002, P NATL ACAD SCI USA, V99, P11611, DOI 10.1073/pnas.132376499; Levit MN, 2002, J BIOL CHEM, V277, P36748, DOI 10.1074/jbc.M204317200; Levit MN, 2002, J BIOL CHEM, V277, P36760, DOI 10.1074/jbc.M204325200; Li GY, 2000, CELL, V100, P357, DOI 10.1016/S0092-8674(00)80671-6; MADDOCK JR, 1993, SCIENCE, V259, P1717; Mello BA, 2003, P NATL ACAD SCI USA, V100, P8223, DOI 10.1073/pnas.1330839100; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Morton-Firth CJ, 1999, J MOL BIOL, V286, P1059, DOI 10.1006/jmbi.1999.2535; NINFA EG, 1991, J BIOL CHEM, V266, P9764; Shi Y, 1998, PHYS REV E, V58, P6399, DOI 10.1103/PhysRevE.58.6399; Shimizu TS, 2000, NAT CELL BIOL, V2, P792, DOI 10.1038/35041030; Shimizu TS, 2003, J MOL BIOL, V329, P291, DOI 10.1016/S0022-2836(03)00437-6; Sourjik V, 2002, P NATL ACAD SCI USA, V99, P123, DOI 10.1073/pnas.011589998; Sourjik V, 2002, P NATL ACAD SCI USA, V99, P12669, DOI 10.1073/pnas.192463199; Sourjik V, 2000, MOL MICROBIOL, V37, P740, DOI 10.1046/j.1365-2958.2000.02044.x	28	351	359	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	2004	428	6981					437	441		10.1038/nature02406	http://dx.doi.org/10.1038/nature02406			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042093				2022-12-28	WOS:000220404300045
J	Chang, JT; Morton, SC; Rubenstein, LZ; Mojica, WA; Maglione, M; Suttorp, MJ; Roth, EA; Shekelle, PG				Chang, JT; Morton, SC; Rubenstein, LZ; Mojica, WA; Maglione, M; Suttorp, MJ; Roth, EA; Shekelle, PG			Interventions for the prevention of falls in older adults: systematic review and meta-analysis of randomised clinical trials	BRITISH MEDICAL JOURNAL			English	Article							NURSING-HOME RESIDENTS; RISK-FACTORS; MULTIFACTORIAL INTERVENTION; ELDERLY-PATIENTS; COMMUNITY; PEOPLE; BALANCE; FRAILTY; QUALITY; INJURY	Objective To assess the relative effectiveness of interventions to prevent falls in older adults to either a usual care group or control group. Design Systematic review and meta-analyses. Data sources Medline, HealthSTAR, Embase, the Cochrane Library, other health related databases, and the reference lists from review articles and systematic reviews. Data extraction Components of falls intervention: multifactorial falls risk assessment with management programme, exercise, environmental modifications, or education. Results 40 trials were identified. A random effects analysis combining trials with risk ratio data showed a reduction in the risk of falling (risk ratio 0.88, 95% confidence interval 0.82 to 0.95), whereas combining trials with incidence rate data showed a reduction in the monthly rate of failing (incidence rate ratio 0.80, 0.72 to 0.88). The effect of individual components was assessed by meta-regression. A multifactorial falls risk assessment and management programme was the most effective component on risk of falling (0.82,0.72 to 0.94, number needed to treat 11) and monthly fall rate (0.63, 0.49 to 0.83; 11.8 fewer falls in treatment group per 100 patients per month). Exercise interventions also had a beneficial effect on the risk of falling (0.86, 0.75 to 0.99, number needed to treat 16) and monthly fall rate (0.86, 0.73 to 1.01; 2.7). Conclusions Interventions to prevent falls in older adults are effective in reducing both the risk of falling and the monthly rate of falling. The most effective intervention was a multifactorial falls risk assessment and management programme. Exercise programmes were also effective in reducing the risk of falling.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA; RAND Corp, Hlth, So Calif Evidence Based Practice Ctr, Santa Monica, CA 90407 USA; Greater Los Angeles VA Med Ctr, Sepulveda, CA 91343 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Chang, JT (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, 911 Broxton Ave, Los Angeles, CA 90095 USA.	johnchang@mednet.ucla.edu	Chang, John T./L-7840-2019; Roth, Elizabeth/AAD-9380-2021	Rubenstein, Laurence/0000-0001-5910-0266	BHP HRSA HHS [PE-19001] Funding Source: Medline	BHP HRSA HHS		ALEXANDER BH, 1992, AM J PUBLIC HEALTH, V82, P1020, DOI 10.2105/AJPH.82.7.1020; Becker C, 2003, J AM GERIATR SOC, V51, P306, DOI 10.1046/j.1532-5415.2003.51103.x; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; Buchner DM, 1997, J GERONTOL A-BIOL, V52, pM218, DOI 10.1093/gerona/52A.4.M218; Cumming Robert G., 1990, Annals of Epidemiology, V1, P49; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dunn J E, 1993, J Aging Health, V5, P194, DOI 10.1177/089826439300500203; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Englander F, 1996, J FORENSIC SCI, V41, P733; FIATARONE MA, 1993, J AM GERIATR SOC, V41, P333, DOI 10.1111/j.1532-5415.1993.tb06714.x; GILLESPIE LD, 2003, COCHRANE LIB; Hedges LV, 2014, STAT METHODS META AN; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; HORNBROOK MC, 1994, GERONTOLOGIST, V34, P16, DOI 10.1093/geront/34.1.16; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jensen J, 2003, J AM GERIATR SOC, V51, P627, DOI 10.1034/j.1600-0579.2003.00206.x; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; Latham NK, 2003, J AM GERIATR SOC, V51, P291, DOI 10.1046/j.1532-5415.2003.51101.x; MULROW CD, 1994, JAMA-J AM MED ASSOC, V271, P519, DOI 10.1001/jama.271.7.519; NEVITT MC, 1991, J GERONTOL, V46, P164; Nikolaus T, 2003, J AM GERIATR SOC, V51, P300, DOI 10.1046/j.1532-5415.2003.51102.x; Oliver D, 2000, J AM GERIATR SOC, V48, P1679, DOI 10.1111/j.1532-5415.2000.tb03883.x; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; Peden M, 2002, INJURY CHART BOOK GR; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; Rothman K., 1998, MODERN EPIDEMIOLOGY; Sackett D. L., 1997, EVIDENCE BASED MED P; SATTIN RW, 1990, AM J EPIDEMIOL, V131, P1028, DOI 10.1093/oxfordjournals.aje.a115594; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sharp S, 1998, STATA TECH B, V7, DOI DOI 10.1002/SIM.1187/FULL); Shaw FE, 2003, BRIT MED J, V326, P73, DOI 10.1136/bmj.326.7380.73; Statacorp, 2001, STAT STAT SOFTW REL; Steadman J, 2003, J AM GERIATR SOC, V51, P847, DOI 10.1046/j.1365-2389.2003.51268.x; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1995, J AM GERIATR SOC, V43, P1214, DOI 10.1111/j.1532-5415.1995.tb07396.x; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; WOLFSON L, 1993, J AM GERIATR SOC, V41, P341, DOI 10.1111/j.1532-5415.1993.tb06716.x	40	731	762	1	100	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 20	2004	328	7441					680	683		10.1136/bmj.328.7441.680	http://dx.doi.org/10.1136/bmj.328.7441.680			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	805VB	15031239	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000220392700019
J	Fung, JC; Rockmill, B; Odell, M; Roeder, GS				Fung, JC; Rockmill, B; Odell, M; Roeder, GS			Imposition of crossover interference through the nonrandom distribution of synapsis initiation complexes	CELL			English	Article							MEIOTIC RECIPROCAL RECOMBINATION; SIZE-DEPENDENT CONTROL; CHROMOSOME SYNAPSIS; SACCHAROMYCES-CEREVISIAE; SYNAPTONEMAL COMPLEX; BUDDING YEAST; CROSSING-OVER; CHIASMA INTERFERENCE; FISSION YEAST; MUTS HOMOLOG	Meiotic crossovers (COs) are nonrandomly distributed along chromosomes such that two COs seldom occur close together, a phenomenon known as CO interference. We have used genetic and cytological methods to investigate interference mechanisms in budding yeast. Assembly of the synaptonemal complex (SC) initiates at a few sites along each chromosome, triggered by a complex of proteins (including Zip2 and Zip3) called the synapsis initiation complex (SIC). We found that SICs, like COs, display interference, supporting the hypothesis that COs occur at synapsis initiation sites. Unexpectedly, we found that SICs show interference in mutants in which CO interference is abolished; one explanation is that these same mutations eliminate the subset of COs that normally occur at SICs. Since SICs are assembled in advance of SC and they are properly positioned even in the absence of SC formation, these data clearly demonstrate an aspect of interference that is independent of synapsis.	Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Genet, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University	Roeder, GS (corresponding author), Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA.	shirleen.roeder@yale.edu						Agarwal S, 2000, CELL, V102, P245, DOI 10.1016/S0092-8674(00)00029-5; BAHLER J, 1993, J CELL BIOL, V121, P241, DOI 10.1083/jcb.121.2.241; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; Chua PR, 1997, GENE DEV, V11, P1786, DOI 10.1101/gad.11.14.1786; Chua PR, 1998, CELL, V93, P349, DOI 10.1016/S0092-8674(00)81164-2; Conrad MN, 1997, SCIENCE, V276, P1252, DOI 10.1126/science.276.5316.1252; de los Santos T, 2003, GENETICS, V164, P81; de los Santos T, 2001, GENETICS, V159, P1511; EGEL R, 1978, HEREDITY, V41, P233, DOI 10.1038/hdy.1978.92; EGELMITANI M, 1982, HEREDITAS, V97, P179, DOI 10.1111/j.1601-5223.1982.tb00870.x; FOSS E, 1993, GENETICS, V133, P681; Havekes FWJ, 1994, CHROMOSOME RES, V2, P315, DOI 10.1007/BF01552725; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; KABACK DB, 1989, P NATL ACAD SCI USA, V86, P3694, DOI 10.1073/pnas.86.10.3694; KABACK DB, 1992, SCIENCE, V256, P228, DOI 10.1126/science.1566070; Kaback DB, 1999, GENETICS, V152, P1475; KING JS, 1990, GENETICS, V126, P1127; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; LAMBIE EJ, 1988, CELL, V52, P863, DOI 10.1016/0092-8674(88)90428-X; LAMBIE EJ, 1986, GENETICS, V114, P769; LOIDL J, 1990, GENOME, V33, P759, DOI 10.1139/g90-115; MAGUIRE MP, 1988, J THEOR BIOL, V134, P565, DOI 10.1016/S0022-5193(88)80058-4; MOENS PB, 1969, CAN J GENET CYTOL, V11, P857, DOI 10.1139/g69-101; Mortimer R.R., 1974, MECH RECOMBINATION, P263, DOI [10.1007/978-1-4684-2133-0_23, DOI 10.1007/978-1-4684-2133-0_23]; MUNZ P, 1994, GENETICS, V137, P701; Novak JE, 2001, GENETICS, V158, P1013; ROCKMILL B, 1995, GENE DEV, V9, P2684, DOI 10.1101/gad.9.21.2684; Rockmill B, 2003, CURR BIOL, V13, P1954, DOI 10.1016/j.cub.2003.10.059; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Shonn MA, 2000, SCIENCE, V289, P300, DOI 10.1126/science.289.5477.300; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1995, J CELL BIOL, V128, P455, DOI 10.1083/jcb.128.4.455; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; Tung KS, 1998, GENETICS, V149, P817; Zar JH., 1999, BIOSTAT ANAL, V663rd	38	163	166	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 19	2004	116	6					795	802		10.1016/S0092-8674(04)00249-1	http://dx.doi.org/10.1016/S0092-8674(04)00249-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YS	15035982	Bronze			2022-12-28	WOS:000221499900006
J	Viscusi, ER; Reynolds, L; Chung, F; Atkinson, LE; Khanna, S				Viscusi, ER; Reynolds, L; Chung, F; Atkinson, LE; Khanna, S			Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED ANALGESIA; EFFICACY; MANAGEMENT; SAFETY	Context Patient-controlled analgesia (PCA) with morphine is commonly used to provide acute postoperative pain control after major surgery. The fentanyl hydrochloride patient-controlled transdermal system eliminates the need for venous access and complicated programming of pumps. Objective To assess the efficacy and safety of an investigational patient-controlled iontophoretic transdermal system using fentanyl hydrochloride compared with a standard intravenous morphine patient-controlled pump. Design, Setting, and Patients Prospective randomized controlled parallel-group trial conducted between September 2000 and March 2001 at 33 North American hospitals, enrolling 636 adult patients who had just undergone major surgery. Interventions In surgical recovery rooms, patients were randomly assigned to intravenous morphine (1-mg bolus every 5 minutes; maximum of 10 mg/h) by a patient-controlled analgesia pump (n=320) or iontophoretic fentanyl hydrochloride (40-mug infusion over 10 minutes) by a patient-controlled transdermal system (n =316). Supplemental analgesia (morphine or fentanyl intravenous boluses) was administered as needed before and for the first 3 hours after activation of the PCA treatments. Patients then used the PCA treatments without additional analgesics for up to 72 hours. Main Outcome Measures The primary efficacy variable was patient global assessment of the method of pain control during the first 24 hours. Additional efficacy measures were the proportion of patients discontinuing the study because of inadequate analgesia for any reason, patient-reported pain intensity scores on a 100-mm visual analog scale WAS), and patient global assessments at 48 and 72 hours. Adverse effects were also recorded. Results Ratings of good or excellent after 24 hours of treatment for the method of pain control were given by 73.7% of patients (233/316) who used transdermal fentanyl PCA and 76.9% of patients (246/320) who used intravenous morphine PCA-1 treatment difference was -3.2% (95% confidence interval, -9.9% to 3.5%; P=36). Early patient discontinuations (25.9% fentanyl vs 25.0% morphine; P=.78) and last pain intensity scores (32.7 fentanyl vs 31.1 morphine on the VAS; P=.45) were not different between the 2 treatments. With continued treatment for up to 48 or 72 hours, more than 80% of patient assessments in each treatment group were good or excellent. The incidence of opioid-related adverse events was similar between the Conclusion An investigational PCA transclermal system using iontophoresis to deliver fentanyl provided postsurgical pain control equivalent to that of a standard intravenous morphine regimen delivered by a PCA pump.	Thomas Jefferson Univ, Dept Anesthesiol, Philadelphia, PA 19107 USA; Loma Linda Univ, Ctr Pain Management, Loma Linda, CA 92350 USA; Univ Toronto, Toronto Western Hosp, Dept Anesthesiol, Toronto, ON, Canada; ALZA Corp, Stat & Data Management, Mountain View, CA USA; ALZA Corp, Clin Dev, Mountain View, CA USA	Jefferson University; Loma Linda University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Johnson & Johnson; Johnson & Johnson USA; Johnson & Johnson; Johnson & Johnson USA	Viscusi, ER (corresponding author), Thomas Jefferson Univ, Dept Anesthesiol, 111 S 11th St,Suite G 8490, Philadelphia, PA 19107 USA.	eugene.viscusi@jefferson.edu	Chung, Frances/F-5618-2015	Chung, Frances/0000-0001-9576-3606				*AC PAIN MAN PAN, 1992, AC PAIN MAN OP MED P; *AM PAIN SOC, 1999, PRINC AN US TREATM A; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Byrom B., 2002, APPL CLIN TRIALS, V2002, P36; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; GINSBERG B, 1995, PAIN, V62, P95, DOI 10.1016/0304-3959(94)00255-D; GLASS PSA, 1992, ANESTH ANALG, V74, P345; HOWELL PR, 1995, CAN J ANAESTH, V42, P41, DOI 10.1007/BF03010570; Lehmann KA, 1999, EUR SURG RES, V31, P112, DOI 10.1159/000008629; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; OWEN H, 1989, ANAESTHESIA, V44, P7, DOI 10.1111/j.1365-2044.1989.tb11087.x; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; ROWBOTHAM DJ, 1989, ANAESTHESIA, V44, P922, DOI 10.1111/j.1365-2044.1989.tb09151.x; Schumann R, 2003, ANESTH ANALG, V96, P469, DOI 10.1097/00000539-200302000-00032; SINATRA RS, 1989, ANESTHESIOLOGY, V70, P585, DOI 10.1097/00000542-198904000-00005; WELCHEW EA, 1983, ANAESTHESIA, V38, P19, DOI 10.1111/j.1365-2044.1983.tb10367.x; Woodhouse A, 1996, PAIN, V64, P115, DOI 10.1016/0304-3959(95)00082-8	19	143	166	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	2004	291	11					1333	1341		10.1001/jama.291.11.1333	http://dx.doi.org/10.1001/jama.291.11.1333			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	802PF	15026400	Bronze			2022-12-28	WOS:000220174700027
J	Wertheim, HFL; Vos, MC; Ott, A; Voss, A; Kluytmans, JAJW; Vandenbroucke-Grauls, CMJE; Meester, MHM; van Keulen, PHJ; Verbrugh, HA				Wertheim, HFL; Vos, MC; Ott, A; Voss, A; Kluytmans, JAJW; Vandenbroucke-Grauls, CMJE; Meester, MHM; van Keulen, PHJ; Verbrugh, HA			Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients	ANNALS OF INTERNAL MEDICINE			English	Article							SURGICAL-SITE INFECTIONS; NASAL CARRIAGE; HEMODIALYSIS-PATIENTS; CLINICAL-TRIAL; DOUBLE-BLIND; OINTMENT; SURVEILLANCE; DEFINITIONS; ELIMINATION; CRITERIA	Background: Staphylococcus aureus nasal carriage is a major risk factor for nosocomial S. aureus infection. Studies show that intranasal mupirocin can prevent nosocomial surgical site infections. No data are available on the efficacy of mupirocin in nonsurgical patients. Objective: To assess the efficacy of mupirocin prophylaxis in preventing nosocomial S. aureus infections in nonsurgical patients. Design: Randomized, double-blind, placebo-controlled trial. Setting: 3 tertiary care academic hospitals and 1 nonacademic hospital. Patients: 1602 culture-proven S. aureus carriers hospitalized in nonsurgical departments. Intervention: Therapy with mupirocin 2% nasal ointment (n = 793) or placebo ointment (n = 809), twice daily for 5 days, started 1 to 3 days after admission. Measurements: Nosocomial S. aureus infections according to defined criteria, in-hospital mortality, duration of hospitalization, and time to nosocomial S. aureus infection. Staphylococcus aureus isolates were genotyped to assess whether infection was caused by endogenous strains. Results: The mupirocin and placebo groups did not statistically differ in the rates of nosocomial S. aureus infections (mupirocin, 2.6%; placebo, 2.8%; risk difference, 0.2 percentage point [95% CI, -1.5 to 1.9 percentage points]), mortality (mupirocin, 3.0%; placebo, 2.8%; risk difference, -0.2 percentage point [CI, -1.9 to 1.5 percentage points]), or duration of hospitalization (median for both, 8 days). However, time to nosocomial S. aureus infection was decreased in the mupirocin group from 12 to 25 days (P > 0.2). A total of 77% of S. aureus nosocomial infections were endogenous. Limitations: A few infections in both groups may have been missed because investigators assessed a patient for infection only if microbiology culture results were positive for S. aureus. Conclusion: Routine culture for S. aureus nasal carriage at admission and subsequent mupirocin application does not provide effective prophylaxis against nosocomial S. aureus infections in nonsurgical patients.	Erasmus MC, Dept Med Microbiol & Infect Dis, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Wertheim, HFL (corresponding author), Erasmus MC, Dept Med Microbiol & Infect Dis, POB 2040, NL-3000 CA Rotterdam, Netherlands.	h.wertheim@erasmusmc.nl	Vandenbroucke-Grauls, Christina/AAO-7953-2020; Wertheim, Heiman FL/F-3338-2016; Voss, A./H-8111-2014	Vandenbroucke-Grauls, Christina/0000-0003-2074-1597; Wertheim, Heiman FL/0000-0002-5003-5565; 				Bending M, 1996, J AM SOC NEPHROL, V7, P2403; BOELAERT JR, 1989, NEPHROL DIAL TRANSPL, V4, P278, DOI 10.1093/oxfordjournals.ndt.a091872; Boelaert JR, 1996, INFECT CONT HOSP EP, V17, P809; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Cookson BD, 1998, J ANTIMICROB CHEMOTH, V41, P11, DOI 10.1093/jac/41.1.11; Corbella X, 1997, EUR J CLIN MICROBIOL, V16, P351, DOI 10.1007/BF01726362; FERNANDEZ C, 1995, J ANTIMICROB CHEMOTH, V35, P399, DOI 10.1093/jac/35.3.399; Finlay JE, 1997, ANTIMICROB AGENTS CH, V41, P1137, DOI 10.1128/AAC.41.5.1137; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GROSS PA, 1980, INFECT CONT HOSP EP, V1, P233, DOI 10.1017/S0195941700053078; Johnson DW, 2002, NEPHROL DIAL TRANSPL, V17, P1802, DOI 10.1093/ndt/17.10.1802; Kalmeijer MD, 2002, CLIN INFECT DIS, V35, P353, DOI 10.1086/341025; Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505, DOI 10.1128/CMR.10.3.505; Kluytmans JAJW, 1996, INFECT CONT HOSP EP, V17, P780; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Martin JN, 1999, J INFECT DIS, V180, P896, DOI 10.1086/314949; Mintjes-de Groot AJ, 2000, J HOSP INFECT, V46, P36, DOI 10.1053/jhin.2000.0755; Perl TM, 2002, NEW ENGL J MED, V346, P1871, DOI 10.1056/NEJMoa003069; PITTET D, 1995, ARCH INTERN MED, V155, P1177, DOI 10.1001/archinte.155.11.1177; Pujol M, 1996, AM J MED, V100, P509, DOI 10.1016/S0002-9343(96)00014-9; Raz R, 1996, ARCH INTERN MED, V156, P1109, DOI 10.1001/archinte.156.10.1109; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; Richards MJ, 2000, INFECT CONT HOSP EP, V21, P510, DOI 10.1086/501795; Sesso R, 1998, J AM SOC NEPHROL, V9, P1085; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; VandenBergh MFQ, 1996, INFECT CONT HOSP EP, V17, P786; von Eiff C, 2001, NEW ENGL J MED, V344, P11, DOI 10.1056/NEJM200101043440102	27	91	92	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 16	2004	140	6					419	425		10.7326/0003-4819-140-6-200403160-00007	http://dx.doi.org/10.7326/0003-4819-140-6-200403160-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803AU	15023707				2022-12-28	WOS:000220204800002
J	Lee, WL; Watauchi, S; Miller, VL; Cava, RJ; Ong, NP				Lee, WL; Watauchi, S; Miller, VL; Cava, RJ; Ong, NP			Dissipationless anomalous Hall current in the ferromagnetic spinel CuCr2Se4-xBrx	SCIENCE			English	Article							BERRY PHASE; SIDE-JUMP; MECHANISM; METAL	In a ferromagnet, an applied electric field E invariably produces an anomalous Hall current J(H) that flows perpendicular to the plane defined by E and M (the magnetization). For decades, the question of whether J(H) is dissipationless (independent of the scattering rate) has been debated without experimental resolution. In the ferromagnetic spinel CuCr2Se4-xBrx, the resistivity rho (at low temperature) may be increased by several decades by varying x (Br) without degrading M. We show that J(H)/E (normalized per carrier, at 5 kelvin) remains unchanged throughout. In addition to confirming the dissipationless nature of J(H), our finding has implications for the generation and study of spin-Hall currents in bulk samples.	Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Princeton Univ, Princeton Mat Inst, Princeton, NJ 08544 USA	Princeton University; Princeton University; Princeton University	Ong, NP (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.	npo@princeton.edu	Lee, Wei-Li/AAP-3926-2021; Ong, N. Phuan/Z-1626-2019	Lee, Wei-Li/0000-0001-7207-1607; Ong, N. Phuan/0000-0001-7166-1058				ADAMS EN, 1959, J PHYS CHEM SOLIDS, V10, P286, DOI 10.1016/0022-3697(59)90004-6; Berger L., 1980, Hall effect and its applications. Proceedings of the commemorative symposium, P55; Berger L, 1970, PHYS REV B-SOLID ST, V2, P4559, DOI 10.1103/PhysRevB.2.4559; GOODENOUGH JB, 1969, J PHYS CHEM SOLIDS, V30, P261, DOI 10.1016/0022-3697(69)90308-4; Hirsch JE, 1999, PHYS REV LETT, V83, P1834, DOI 10.1103/PhysRevLett.83.1834; Hurd C. M., 1972, HALL EFFECT METALS A, P153; Jellinghaus W., 1961, ANN PHYS-BERLIN, V462, P189; Jungwirth T, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.207208; KARPLUS R, 1954, PHYS REV, V95, P1154, DOI 10.1103/PhysRev.95.1154; KOOI C, 1954, PHYS REV, V95, P843, DOI 10.1103/PhysRev.95.843; LUTTINGER JM, 1958, PHYS REV, V112, P739, DOI 10.1103/PhysRev.112.739; LYO SK, 1973, PHYS REV B, V8, P1185, DOI 10.1103/PhysRevB.8.1185; LYO SK, 1974, PHYS REV B, V9, P2412, DOI 10.1103/PhysRevB.9.2412; Matl P, 1998, PHYS REV B, V57, P10248, DOI 10.1103/PhysRevB.57.10248; MIYATANI K, 1971, J PHYS CHEM SOLIDS, V32, P1429, DOI 10.1016/S0022-3697(71)80037-9; Murakami S, 2003, SCIENCE, V301, P1348, DOI 10.1126/science.1087128; NOZIERES P, 1973, J PHYS-PARIS, V34, P901, DOI 10.1051/jphys:019730034010090100; OGATA F, 1982, J PHYS C SOLID STATE, V15, P3483, DOI 10.1088/0022-3719/15/16/009; Ohno H, 1998, SCIENCE, V281, P951, DOI 10.1126/science.281.5379.951; Onoda M, 2002, J PHYS SOC JPN, V71, P19, DOI 10.1143/JPSJ.71.19; Schmidt G, 2000, PHYS REV B, V62, pR4790, DOI 10.1103/PhysRevB.62.R4790; SMIT J, 1973, PHYS REV B, V8, P2349, DOI 10.1103/PhysRevB.8.2349; SMIT J, 1955, PHYSICA, V21, P877, DOI 10.1016/S0031-8914(55)92596-9; Soulen RJ, 1998, SCIENCE, V282, P85, DOI 10.1126/science.282.5386.85; Taguchi Y, 2001, SCIENCE, V291, P2573, DOI 10.1126/science.1058161; Ye JW, 1999, PHYS REV LETT, V83, P3737, DOI 10.1103/PhysRevLett.83.3737	26	185	188	4	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1647	1649		10.1126/science.1094383	http://dx.doi.org/10.1126/science.1094383			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016994	Green Submitted			2022-12-28	WOS:000220151400037
J	Abrahamsen, MS; Templeton, TJ; Enomoto, S; Abrahante, JE; Zhu, G; Lancto, CA; Deng, MQ; Liu, C; Widmer, G; Tzipori, S; Buck, GA; Xu, P; Bankier, AT; Dear, PH; Konfortov, BA; Spriggs, HF; Iyer, L; Anantharaman, V; Aravind, L; Kapur, V				Abrahamsen, MS; Templeton, TJ; Enomoto, S; Abrahante, JE; Zhu, G; Lancto, CA; Deng, MQ; Liu, C; Widmer, G; Tzipori, S; Buck, GA; Xu, P; Bankier, AT; Dear, PH; Konfortov, BA; Spriggs, HF; Iyer, L; Anantharaman, V; Aravind, L; Kapur, V			Complete genome sequence of the apicomplexan, Cryptosporidium parvum	SCIENCE			English	Article							PROTEIN	The apicomplexan Cryptosporidium parvum is an intestinal parasite that affects healthy humans and animals, and causes an unrelenting infection in immunocompromised individuals such as AIDS patients. We report the complete genome sequence of C. parvum, type II isolate. Genome analysis identifies extremely streamlined metabolic pathways and a reliance on the host for nutrients. In contrast to Plasmodium and Toxoplasma, the parasite lacks an apicoplast and its genome, and possesses a degenerate mitochondrion that has lost its genome. Several novel classes of cell-surface and secreted proteins with a potential role in host interactions and pathogenesis were also detected. Elucidation of the core metabolism, including enzymes with high similarities to bacterial and plant counterparts, opens new avenues for drug development.	Univ Minnesota, Coll Vet Med, Dept Vet & Biomed Sci, St Paul, MN 55108 USA; Univ Minnesota, Biomed Genom Ctr, St Paul, MN 55108 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Program Immunol, New York, NY 10021 USA; Texas A&M Univ, Coll Vet Med, Dept Vet Pathobiol, College Stn, TX 77843 USA; Tufts Univ, Sch Vet Med, Div Infect Dis, North Grafton, MA 01536 USA; Virginia Commonwealth Univ, Ctr Study Biol Complex, Richmond, VA 23198 USA; Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23198 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Cornell University; Cornell University; Texas A&M University System; Texas A&M University College Station; Tufts University; Virginia Commonwealth University; Virginia Commonwealth University; MRC Laboratory Molecular Biology; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); University of Minnesota System; University of Minnesota Twin Cities	Abrahamsen, MS (corresponding author), Univ Minnesota, Coll Vet Med, Dept Vet & Biomed Sci, St Paul, MN 55108 USA.	abe@umn.edu	Iyer, Lakshminarayan M./H-2996-2019; Zhu, Guan/AFJ-2945-2022; ZHU, GUAN/D-8147-2011; Kapur, Vivek/F-7610-2013; Dear, Paul H/A-1162-2012; Anantharaman, Vivek/ABB-9991-2021; ZHU, GUAN/GQB-0299-2022	Zhu, Guan/0000-0003-3888-0659; Anantharaman, Vivek/0000-0001-8395-0009; ZHU, GUAN/0000-0003-3888-0659; Abrahante, Juan/0000-0002-9074-4307; Aravind, L/0000-0003-0771-253X; Kapur, Vivek/0000-0002-9648-0138	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI046397] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [Z01LM092504] Funding Source: NIH RePORTER; NIAID NIH HHS [U01 AI 46397] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrahamsen MS, 1999, MOL BIOCHEM PARASIT, V104, P141, DOI 10.1016/S0166-6851(99)00081-X; Bankier AT, 2003, GENOME RES, V13, P1787, DOI 10.1101/gr.1555203; Barnes DA, 1998, MOL BIOCHEM PARASIT, V96, P93, DOI 10.1016/S0166-6851(98)00119-4; Cai XM, 2003, GENE, V321, P39, DOI 10.1016/j.gene.2003.08.008; Cevallos AM, 2000, INFECT IMMUN, V68, P5167, DOI 10.1128/IAI.68.9.5167-5175.2000; Coombs GH, 1999, PARASITOL TODAY, V15, P333, DOI 10.1016/S0169-4758(99)01474-X; Doyle PS, 1998, EXP PARASITOL, V89, P9, DOI 10.1006/expr.1998.4263; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; Foth BJ, 2003, SCIENCE, V299, P705, DOI 10.1126/science.1078599; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Katinka MD, 2001, NATURE, V414, P450, DOI 10.1038/35106579; KORICH DG, 1990, APPL ENVIRON MICROB, V56, P1423, DOI 10.1128/AEM.56.5.1423-1428.1990; KRAMER RA, 1993, MOL BIOCHEM PARASIT, V60, P327, DOI 10.1016/0166-6851(93)90144-M; Nihei C, 2002, BBA-MOL BASIS DIS, V1587, P234, DOI 10.1016/S0925-4439(02)00086-8; Rosenthal B, 1997, J BACTERIOL, V179, P3736, DOI 10.1128/jb.179.11.3736-3745.1997; Rotte C, 2001, MOL BIOL EVOL, V18, P710, DOI 10.1093/oxfordjournals.molbev.a003853; Schmatz DM, 1997, PARASITOLOGY, V114, pS81; Striepen B, 2002, P NATL ACAD SCI USA, V99, P6304, DOI 10.1073/pnas.092525699; Templeton TJ, 2004, INFECT IMMUN, V72, P980, DOI 10.1128/IAI.72.2.980-987.2004; WILLIAMSON JD, 1995, P NATL ACAD SCI USA, V92, P7148, DOI 10.1073/pnas.92.16.7148; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Wood V, 2001, COMP FUNCT GENOM, V2, P143, DOI 10.1002/cfg.86; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; YANG WG, 1994, MOL BIOCHEM PARASIT, V64, P253, DOI 10.1016/0166-6851(93)00020-A; Zhu G, 2000, MICROBIOL-SGM, V146, P315, DOI 10.1099/00221287-146-2-315; Zhu G, 2000, MOL BIOCHEM PARASIT, V105, P253, DOI 10.1016/S0166-6851(99)00183-8; Zhu G, 2002, GENE, V298, P79, DOI 10.1016/S0378-1119(02)00931-9	27	692	746	3	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	2004	304	5669					441	445		10.1126/science.1094786	http://dx.doi.org/10.1126/science.1094786			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	812NE	15044751				2022-12-28	WOS:000220845400049
J	Numans, ME; Lau, J; de Wit, NJ; Bonis, PA				Numans, ME; Lau, J; de Wit, NJ; Bonis, PA			Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease - A meta-analysis of diagnostic test characteristics	ANNALS OF INTERNAL MEDICINE			English	Article							DOUBLE-BLIND; GENERAL-PRACTICE; FUNCTIONAL DYSPEPSIA; NEGATIVE PATIENTS; OMEPRAZOLE TEST; PRIMARY-CARE; SYMPTOMS; ESOPHAGITIS; STRATEGY; LANSOPRAZOLE	Background: A response to proton-pump inhibitors (PPIs) is commonly considered to support the diagnosis of gastroesophageal reflux disease (GERD). However, the accuracy of this diagnostic strategy has not been well established. Objective: To estimate the diagnostic test characteristics of successful PPI treatment with objective measures of GERD by performing a meta-analysis based on the published literature. Data Sources: English-language studies were identified by searching the Cochrane Clinical Trial Register and MEDLINE from 1 January 1980 through 1 July 2003. Study Selection: Studies in which the clinical response to a short course (1 to 4 weeks) of normal- or high-dose PPI therapy could be compared with objective measures of GERD (24-hour pH monitoring, endoscopy findings, symptom questionnaires). Data Extraction: Studies were screened for inclusion by 1 author. Final decisions on exclusion were made by consensus with 2 of the other authors. Two investigators independently extracted the data. Information extracted included patient characteristics, study design, setting, specific type and dose of medication, duration of treatment, and definitions of outcomes. Data Synthesis: Sensitivity and specificity were determined by comparing a clinical response to PPIs with objective measures for GERD. The summary receiver-operating characteristic curve method was used to summarize test characteristics across studies. Sensitivity and specificity were also combined independently by using a random-effects model. Fifteen studies met the inclusion criteria and provided sufficient data. With 24-hour pH monitoring as the reference standard, the positive likelihood ratio ranged from 1.63 to 1.87, and combined estimates of sensitivity and specificity were 0.78 (95% Cl, 0.66 to 0.86) and 0.54 (Cl, 0.44 to 0.65), respectively. These values were lower with the other reference standards. Limitations: Data were insufficient to determine the effect of various doses of PPIs and duration of therapy on test characteristics. Conclusion: Successful short-term treatment with a PPI in patients suspected of having GERD does not confidently establish the diagnosis when GERD is defined by currently accepted reference standards.	Univ Utrecht, Ctr Med, Utrecht, Netherlands; Tufts Univ New England Med Ctr, Boston, MA USA	Utrecht University; Tufts Medical Center	Numans, ME (corresponding author), Univ Utrecht, Ctr Med, Utrecht, Netherlands.	m.e.numans@med.uu.nl			AHRQ HHS [R01 HS013328] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS013328] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bate CM, 1999, ALIMENT PHARM THERAP, V13, P59; Bonis PAL, 1997, HEPATOLOGY, V26, P1035, DOI 10.1053/jhep.1997.v26.pm0009328332; Brun J, 2000, FAM PRACT, V17, P401, DOI 10.1093/fampra/17.5.401; Bytzer P, 1997, SCAND J GASTROENTERO, V32, P118, DOI 10.3109/00365529709000181; Carlsson R, 1998, EUR J GASTROEN HEPAT, V10, P119, DOI 10.1097/00042737-199802000-00004; DEMEESTER TR, 1976, ANN SURG, V184, P459, DOI 10.1097/00000658-197610000-00009; Dent J, 1999, GUT, V44, pS1, DOI 10.1136/gut.44.2008.S1; DeVault KR, 1999, AM J GASTROENTEROL, V94, P1434; Deville WLJM, 2000, J CLIN EPIDEMIOL, V53, P65, DOI 10.1016/S0895-4356(99)00144-4; Dupas JL, 2001, GASTROEN CLIN BIOL, V25, P245; Farup PG, 1999, SCAND J GASTROENTERO, V34, P575; Fass R, 1999, ARCH INTERN MED, V159, P2161, DOI 10.1001/archinte.159.18.2161; Fass R, 2000, ALIMENT PHARM THER, V14, P389; Fass R, 2000, DIGEST DIS, V18, P20, DOI 10.1159/000016930; Galmiche JP, 1997, ALIMENT PHARM THER, V11, P765, DOI 10.1046/j.1365-2036.1997.00185.x; HATLEBAKK JG, 1993, SCAND J GASTROENTERO, V28, P224, DOI 10.3109/00365529309096076; Hatlebakk JG, 1999, BMJ-BRIT MED J, V319, P550, DOI 10.1136/bmj.319.7209.550; HETZEL DJ, 1988, GASTROENTEROLOGY, V95, P903, DOI 10.1016/0016-5085(88)90162-X; Ioannidis JPA, 2002, J CLIN EPIDEMIOL, V55, P619, DOI 10.1016/S0895-4356(02)00393-1; Johnsson F, 1998, SCAND J GASTROENTERO, V33, P15; Johnsson F, 2003, SCAND J GASTROENTERO, V38, P354, DOI 10.1080/0036552031002139; Juul-Hansen P, 2001, SCAND J GASTROENTERO, V36, P806, DOI 10.1080/003655201750313315; Kahrilas PJ, 1996, GASTROENTEROLOGY, V110, P1982, DOI 10.1053/gast.1996.1101982; KLAUSER AG, 1990, LANCET, V335, P205, DOI 10.1016/0140-6736(90)90287-F; Kroes RM, 1999, EUR J GEN PRACT, V5, P88; LAU J, 1997, META TEST VERSION 0; Lewin-van den Broek NT, 2001, BRIT J GEN PRACT, V51, P619; LITTENBERG B, 1993, MED DECIS MAKING, V13, P313, DOI 10.1177/0272989X9301300408; Locke GR, 1997, GASTROENTEROLOGY, V112, P1448, DOI 10.1016/S0016-5085(97)70025-8; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; MULROW CD, 1989, J GEN INTERN MED, V4, P288, DOI 10.1007/BF02597398; NUMANS ME, 1994, FAM PRACT, V11, P382, DOI 10.1093/fampra/11.4.382; Numans ME, 2003, ALIMENT PHARM THER, V17, P1049, DOI 10.1046/j.1365-2036.2003.01549.x; OLLYO J B, 1990, Gastroenterology, V98, pA100; ORLANDO RC, 1994, AM J GASTROENTEROL, V89, pS48; SAVARY M, 1977, OESOPHAGUS; Schenk BE, 1997, AM J GASTROENTEROL, V92, P1997; SCHINDLBECK NE, 1995, ARCH INTERN MED, V155, P1808, DOI 10.1001/archinte.155.16.1808; Shapiro D E, 1995, Acad Radiol, V2 Suppl 1, pS37; SHAPIRO DE, 1995, ACAD RADIOL, V2, pS65; SHAPIRO DE, 1995, ACAD RADIOL, V2, pS83; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Talley NJ, 1998, ALIMENT PHARM THER, V12, P1055; van Bommel MJJ, 2001, POSTGRAD MED J, V77, P514, DOI 10.1136/pmj.77.910.514; van Herwaarden MA, 2000, BEST PRACT RES CL GA, V14, P759, DOI 10.1053/bega.2000.0123; van Pinxteren B, 2003, J GEN INTERN MED, V18, P755, DOI 10.1046/j.1525-1497.2003.20833.x; Venables TL, 1997, SCAND J GASTROENTERO, V32, P965, DOI 10.3109/00365529709011211; Watson RGP, 1997, GUT, V40, P587, DOI 10.1136/gut.40.5.587; WEUSTEN BLAM, 1994, GASTROENTEROLOGY, V107, P1741, DOI 10.1016/0016-5085(94)90815-X	49	210	224	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 6	2004	140	7					518	527		10.7326/0003-4819-140-7-200404060-00011	http://dx.doi.org/10.7326/0003-4819-140-7-200404060-00011			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808OE	15068979				2022-12-28	WOS:000220577600003
J	Gattorno, M; Di Rocco, M; Buoncompagni, A; Picco, P; Meroni, PL; Martini, A				Gattorno, M; Di Rocco, M; Buoncompagni, A; Picco, P; Meroni, PL; Martini, A			Neonatal lupus and a seronegative mother	LANCET			English	Editorial Material							LYSINURIC PROTEIN INTOLERANCE		Univ Genoa, G Gaslini Inst, Dept Paediat, Div Paediat 2, Genoa, Italy; Univ Milan, IRCCS, Ist Auxol Italiano, Dept Internal Med, Milan, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini; IRCCS Istituto Auxologico Italiano; University of Milan	Gattorno, M (corresponding author), Univ Genoa, G Gaslini Inst, Dept Paediat, Div Paediat 2, Genoa, Italy.	marcogattorno@ospedale-gaslini.ge.it	meroni, pier luigi/K-8473-2016; Gattorno, Marco/AAL-2974-2020	meroni, pier luigi/0000-0002-3394-1451; Gattorno, Marco/0000-0003-0704-1916; Picco, Paolo/0000-0003-0686-0725				Aoki M, 2001, EUR J PEDIATR, V160, P522, DOI 10.1007/PL00008455; Cimaz R, 2000, ARTHRITIS RHEUM, V43, P1049, DOI 10.1002/1529-0131(200005)43:5<1049::AID-ANR13>3.0.CO;2-X; Di Rocco M, 1998, J INHERIT METAB DIS, V21, P675, DOI 10.1023/A:1005440802688; Duval M, 1999, J PEDIATR-US, V134, P236, DOI 10.1016/S0022-3476(99)70423-3; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809	5	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	2004	363	9414					1038	1038		10.1016/S0140-6736(04)15839-X	http://dx.doi.org/10.1016/S0140-6736(04)15839-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15051284				2022-12-28	WOS:000220497300010
J	Lantz, PE; Sinal, SH; Stanton, CA; Weaver, RG				Lantz, PE; Sinal, SH; Stanton, CA; Weaver, RG			Evidence based case report - Perimacular retinal folds from childhood head trauma	BRITISH MEDICAL JOURNAL			English	Review							SHAKEN BABY SYNDROME; OCULAR FINDINGS; CHILDREN; ABUSE		Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Paediat, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Ophthalmol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Lantz, PE (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	plantz@wfubmc.edu						BUYS YM, 1992, OPHTHALMOLOGY, V99, P1718; Donohoe M, 2003, AM J FOREN MED PATH, V24, P239, DOI 10.1097/01.paf.0000083635.85457.97; ELNER SG, 1990, ARCH OPHTHALMOL-CHIC, V108, P1094, DOI 10.1001/archopht.1990.01070100050033; GAYNON MW, 1988, AM J OPHTHALMOL, V106, P423, DOI 10.1016/0002-9394(88)90877-X; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; GREENWALD MJ, 1986, OPHTHALMOLOGY, V93, P618; Han D P, 1990, J Pediatr Ophthalmol Strabismus, V27, P299; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; Marshall DH, 2001, CAN J OPHTHALMOL, V36, P377, DOI 10.1016/S0008-4182(01)80081-8; MASSICOTTE SJ, 1991, OPHTHALMOLOGY, V98, P1124; Mills M, 1998, J AAPOS, V2, P67, DOI 10.1016/S1091-8531(98)90066-0; MUNGER CE, 1993, AM J FOREN MED PATH, V14, P193, DOI 10.1097/00000433-199309000-00004	12	98	102	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 27	2004	328	7442					754	756		10.1136/bmj.328.7442.754	http://dx.doi.org/10.1136/bmj.328.7442.754			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809WH	15044292	Green Published			2022-12-28	WOS:000220666300020
J	Shaw, J; Amos, T; Hunt, IM; Flynn, S; Turnbull, P; Kapur, N; Appleby, L				Shaw, J; Amos, T; Hunt, IM; Flynn, S; Turnbull, P; Kapur, N; Appleby, L			Mental illness in people who kill strangers: longitudinal study and national clinical survey	BRITISH MEDICAL JOURNAL			English	Article							HOMICIDE	Objectives To establish changes over time in the frequency of homicides committed by strangers, and to describe the personal and clinical characteristics of perpetrators of stranger homicides. Design Longitudinal study and national clinical survey. Participants People convicted of homicide in England and Wales between 1996 and 1999 and whether the victim was known to the perpetrator. Setting England and Wales. Main outcome measure Characteristics of perpetrators of homicides according to whether victims were strangers or not. Results Stranger homicides increased between 1967 and 1997, both in number and as a proportion of all homicides. No increase was found, however, in the number of perpetrators placed under a hospital order after homicide, whether all homicides or stranger homicides only. 358 of 1594 (22%) homicides were stranger homicides. In these cases the perpetrator was more likely to be male and young. The method of killing was more likely to be by hitting, kicking, or pushing (36% (130 of 358) for victims who were strangers to the perpetrator compared with 14% (145 of 1074) for victims who were known). Perpetrators were less likely to have a history of mental disorder (34%, n = 80 v 50%, n = 142), a history of contact with mental health services (16%, 37 of 234 v 24%, 200 of 824), and Psychiatric symptoms at the time of the offence (6%, n 14 v 18%, n = 143). They were more likely to have a history of drug misuse (47%, n = 93 v 37%, n = 272); alcohol (56%, n = 94 v 41%, n = 285) or drugs (24% n = 44 v 12%, n = 86). were more likely to have contributed to the offence. Conclusions Stranger homicides have increased, but the increase is not the result of homicides by mentally ill people and therefore the "care in the community" policy. Stranger homicides are more likely to be related to alcohol or drug misuse by young men.	Univ Manchester, Sch Psychiat & Behav Sci, Ctr Suicide Prevent, Natl Confidential Inquiry Suicide & Homicide Peop, Manchester M13 9PL, Lancs, England	University of Manchester	Shaw, J (corresponding author), Univ Manchester, Sch Psychiat & Behav Sci, Ctr Suicide Prevent, Natl Confidential Inquiry Suicide & Homicide Peop, Manchester M13 9PL, Lancs, England.	Jennifer.J.Shaw@man.ac.uk	Hunt, Isabelle/AAM-4281-2021	Turnbull, Pauline/0000-0003-0708-0608; shaw, jennifer/0000-0003-2569-7687; Flynn, Sandra/0000-0003-1413-0992; Hunt, Isabelle/0000-0003-4875-8593				APPLEBY I, 2001, SAFETY 1 NATL CONFID; Petch E, 1997, J FORENSIC PSYCHIATR, V8, P161, DOI 10.1080/09585189708412002; Phelan JC, 1998, SOC PSYCH PSYCH EPID, V33, pS7, DOI 10.1007/s001270050204; RITCHIE JH, 1994, REPORT INUIRY CARE T; Shaw J, 1999, BRIT MED J, V318, P1240; Taylor PJ, 1999, BRIT J PSYCHIAT, V174, P9, DOI 10.1192/bjp.174.1.9; THORNICROFT G, 1994, BRIT MED J, V308, P816; 2000, CRIMINAL STAT ENGLAN	8	25	27	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 27	2004	328	7442					734	737		10.1136/bmj.328.7442.734	http://dx.doi.org/10.1136/bmj.328.7442.734			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	809WH	15044289	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000220666300013
J	Schlingmann, KP; Konrad, M; Jeck, N; Waldegger, P; Reinalter, SC; Holder, M; Seyberth, HW; Waldegger, S				Schlingmann, KP; Konrad, M; Jeck, N; Waldegger, P; Reinalter, SC; Holder, M; Seyberth, HW; Waldegger, S			Salt wasting and deafness resulting from mutations in two chloride channels	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BARTTERS-SYNDROME; SENSORINEURAL DEAFNESS; HYPOKALEMIC ALKALOSIS; KIDNEY; HYPERCALCIURIA; COTRANSPORTER; VARIANT; CLCNKB; GENE		Univ Marburg, Dept Pediat, D-35033 Marburg, Germany; Olgahosp Stuttgart, Dept Pediat Nephrol, Stuttgart, Germany	Philipps University Marburg; Klinikum Stuttgart	Seyberth, HW (corresponding author), Univ Marburg, Dept Pediat, Deutschhausstr 12, D-35033 Marburg, Germany.	seyberth@staff.uni-marburg.de						Akizuki N, 2001, AM J PHYSIOL-RENAL, V280, pF79, DOI 10.1152/ajprenal.2001.280.1.F79; BARTTER FC, 1962, AM J MED, V33, P811, DOI 10.1016/0002-9343(62)90214-0; Birkenhager R, 2001, NAT GENET, V29, P310, DOI 10.1038/ng752; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; Gitelman H J, 1966, Trans Assoc Am Physicians, V79, P221; Haas Nikolaus A, 2003, Pediatr Crit Care Med, V4, P249; Jeck N, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.1.e5; Konrad M, 2000, J AM SOC NEPHROL, V11, P1449, DOI 10.1681/ASN.V1181449; LANDAU D, 1995, AM J MED GENET, V59, P454, DOI 10.1002/ajmg.1320590411; Matsumura Y, 1999, NAT GENET, V21, P95, DOI 10.1038/5036; Peters M, 2002, AM J MED, V112, P183, DOI 10.1016/S0002-9343(01)01086-5; SEYBERTH HW, 1985, J PEDIATR-US, V107, P694, DOI 10.1016/S0022-3476(85)80395-4; SEYBERTH HW, 1998, OXFORD TXB CLIN NEPH, V2, P1085; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; UCHIDA S, 1995, J CLIN INVEST, V95, P104, DOI 10.1172/JCI117626; Van Naarden K, 1999, PEDIATRICS, V104, P905, DOI 10.1542/peds.104.4.905; Waldegger S, 2002, PFLUG ARCH EUR J PHY, V444, P411, DOI 10.1007/s00424-002-0819-8; Yoshikawa M, 1999, AM J PHYSIOL-RENAL, V276, pF552, DOI 10.1152/ajprenal.1999.276.4.F552	21	183	194	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2004	350	13					1314	1319		10.1056/NEJMoa032843	http://dx.doi.org/10.1056/NEJMoa032843			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VN	15044642				2022-12-28	WOS:000220393900009
J	Rutherford, AW; Boussac, A				Rutherford, AW; Boussac, A			Water photolysis in biology	SCIENCE			English	Editorial Material							AMINO-ACID-RESIDUES; PHOTOSYSTEM-II; OXIDIZING COMPLEX; MANGANESE CLUSTER; CRYSTAL-STRUCTURE; OXIDATION; OXYGEN; PHOTOSYNTHESIS; RESOLUTION; MECHANISM		CEA Saclay, Dept Biol Joliot Curie, CNRS,URA 2096, Serv Bioenerget, F-91191 Gif Sur Yvette, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Rutherford, AW (corresponding author), CEA Saclay, Dept Biol Joliot Curie, CNRS,URA 2096, Serv Bioenerget, F-91191 Gif Sur Yvette, France.	rutherford@dsvidf.cea.fr	Rutherford, Alfred W/A-7831-2019	Rutherford, Alfred W/0000-0002-3124-154X				BOUSSAC A, 1988, FEBS LETT, V236, P432, DOI 10.1016/0014-5793(88)80071-1; Carrell TG, 2002, J BIOL INORG CHEM, V7, P2, DOI 10.1007/s00775-001-0305-3; Debus RJ, 2001, BBA-BIOENERGETICS, V1503, P164, DOI 10.1016/S0005-2728(00)00221-8; Diner BA, 2001, BIOCHEMISTRY-US, V40, P9265, DOI 10.1021/bi010121r; Diner BA, 2001, BBA-BIOENERGETICS, V1503, P147, DOI 10.1016/S0005-2728(00)00220-6; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Fromme P, 2002, PHILOS T R SOC B, V357, P1337, DOI 10.1098/rstb.2002.1143; Goussias C, 2002, PHILOS T R SOC B, V357, P1369, DOI 10.1098/rstb.2002.1134; Hoganson CW, 1997, SCIENCE, V277, P1953, DOI 10.1126/science.277.5334.1953; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; PELLOQUIN JM, 2001, BIOCHIM BIOPHYS ACTA, V1503, P96; Rutherford AW, 2001, TRENDS BIOCHEM SCI, V26, P341, DOI 10.1016/S0968-0004(01)01874-6; Vrettos JS, 2002, PHILOS T R SOC B, V357, P1395, DOI 10.1098/rstb.2002.1136; Yachandra VK, 2002, PHILOS T R SOC B, V357, P1347, DOI 10.1098/rstb.2002.1133; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	16	108	111	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1782	1784		10.1126/science.1096767	http://dx.doi.org/10.1126/science.1096767			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031485				2022-12-28	WOS:000220281600033
J	Siemens, J; Lillo, C; Dumont, RA; Reynolds, A; Williams, DS; Gillespie, PG; Muller, U				Siemens, J; Lillo, C; Dumont, RA; Reynolds, A; Williams, DS; Gillespie, PG; Muller, U			Cadherin 23 is a component of the tip link in hair-cell stereocilia	NATURE			English	Article							SYNDROME TYPE 1D; MECHANICAL TRANSDUCTION; CALCIUM CHELATION; INNER-EAR; ADAPTATION; CDH23; MUTATIONS; HARMONIN; ADHESION; ANTIGEN	Mechanoelectrical transduction, the conversion of mechanical force into electrochemical signals, underlies a range of sensory phenomena, including touch, hearing and balance. Hair cells of the vertebrate inner ear are specialized mechanosensors that transduce mechanical forces arising from sound waves and head movement to provide our senses of hearing and balance(1,2); however, the mechanotransduction channel of hair cells and the molecules that regulate channel activity have remained elusive. One molecule that might participate in mechanoelectrical transduction is cadherin 23 (CDH23), as mutations in its gene cause deafness and age-related hearing loss(3-6). Furthermore, CDH23 is large enough to be the tip link, the extracellular filament proposed to gate the mechanotransduction channel(7). Here we show that antibodies against CDH23 label the tip link, and that CDH23 has biochemical properties similar to those of the tip link. Moreover, CDH23 forms a complex with myosin-1c, the only known component of the mechanotransduction apparatus(8), suggesting that CDH23 and myosin-1c cooperate to regulate the activity of mechanically gated ion channels in hair cells.	Scripps Res Inst, Dept Cell Biol, Inst Childhood & Neglected Dis, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, Dept Pharmacol & Neurosci, La Jolla, CA 92093 USA; Oregon Hlth & Sci Univ, Oregon Hearing Res Ctr, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA	Scripps Research Institute; University of California System; University of California San Diego; Oregon Health & Science University; Oregon Health & Science University	Muller, U (corresponding author), Scripps Res Inst, Dept Cell Biol, Inst Childhood & Neglected Dis, La Jolla, CA 92037 USA.	umueller@scripps.edu	Lillo, Concepcion/A-6321-2009	Lillo, Concepcion/0000-0001-5814-9826; Barr-Gillespie, Peter/0000-0002-9787-5860; Siemens, Jan/0000-0001-9051-9217	NATIONAL EYE INSTITUTE [R01EY007042] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY007042, R01 EY007042-18] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASSAD JA, 1991, NEURON, V7, P985, DOI 10.1016/0896-6273(91)90343-X; Boeda B, 2002, EMBO J, V21, P6689, DOI 10.1093/emboj/cdf689; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Bolz H, 2001, NAT GENET, V27, P108, DOI 10.1038/83667; Bork JM, 2001, AM J HUM GENET, V68, P26, DOI 10.1086/316954; COREY DP, 1983, J NEUROSCI, V3, P962; Di Palma F, 2001, NAT GENET, V27, P103, DOI 10.1038/83660; Furness DN, 2002, HEARING RES, V173, P10, DOI 10.1016/S0378-5955(02)00584-1; Garcia JA, 1998, J NEUROSCI, V18, P8637; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; Goodyear R, 1999, J NEUROSCI, V19, P3761; Goodyear RJ, 2003, J NEUROSCI, V23, P4878; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Holt JR, 2002, CELL, V108, P371, DOI 10.1016/S0092-8674(02)00629-3; HUDSPETH AJ, 1994, NEURON, V12, P1, DOI 10.1016/0896-6273(94)90147-3; Kachar B, 2000, P NATL ACAD SCI USA, V97, P13336, DOI 10.1073/pnas.97.24.13336; LITTLE KF, 1985, CELL TISSUE RES, V242, P427; Muller U, 2001, TRENDS CELL BIOL, V11, P334, DOI 10.1016/S0962-8924(01)02046-3; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Noben-Trauth K, 2003, NAT GENET, V35, P21, DOI 10.1038/ng1226; OSBORNE MP, 1990, ACTA OTO-LARYNGOL, V110, P37, DOI 10.3109/00016489009122513; PICKLES JO, 1991, SCANNING MICROSCOPY, V5, P1115; PICKLES JO, 1984, HEARING RES, V15, P103, DOI 10.1016/0378-5955(84)90041-8; SHEPHERD GMG, 1991, J GEN PHYSIOL, V98, pA25; Siemens J, 2002, P NATL ACAD SCI USA, V99, P14946, DOI 10.1073/pnas.232579599; SOLLNER C, 2004, NATURE          0331; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Zhao YD, 1996, P NATL ACAD SCI USA, V93, P15469, DOI 10.1073/pnas.93.26.15469	29	330	349	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 29	2004	428	6986					950	955		10.1038/nature02483	http://dx.doi.org/10.1038/nature02483			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	816AO	15057245				2022-12-28	WOS:000221083000043
J	Ashworth, A; Chopra, M; McCoy, D; Sanders, D; Jackson, D; Karaolis, N; Sogaula, N; Schofield, C				Ashworth, A; Chopra, M; McCoy, D; Sanders, D; Jackson, D; Karaolis, N; Sogaula, N; Schofield, C			WHO guidelines for management of severe malnutrition in rural South African hospitals: effect on case fatality and the influence of operational factors	LANCET			English	Article							MALNOURISHED CHILDREN; CLINICAL-PRACTICE; CARE; MORTALITY; QUALITY; IMPACT	Background WHO case-management guidelines for severe malnutrition aim to improve the quality of hospital care and reduce mortality. We aimed to assess whether these guidelines are feasible and effective in under-resourced hospitals. Methods All children admitted with a diagnosis of severe malnutrition to two rural hospitals in Eastern Cape Province from April, 2000 to April, 2001, were studied and their case-fatality rates were compared with the rates in a period before guidelines were implemented (March, 1997 to February, 1998). Quality of care was assessed by observation of medical and nursing practices, review of medical records, and interviews with carers and staff. A mortality audit was used to identify cause of death and avoidable contributory factors. Findings At Mary Theresa Hospital, case-fatality rates fell from 46% before implementation to 21% after implementation. At Sipetu Hospital, the rates fell from 25% preimplementation to 18% during 2000, but then rose to 38% during 2001, when inexperienced doctors who were not trained in the treatment of malnutrition were deployed. This rise coincided with less frequent prescribing of potassium (13% vs 77%, p < 0.0001), antibiotics with gram-negative cover (15% vs 46%, p = 0.0003), and vitamin A (76% vs 91%, p = 0.018). Most deaths were attributed to sepsis. For the two hospitals combined, 50% of deaths in 2000-01 were due to doctor error and 28% to nurse error. Weaknesses within the health system-especially doctor training, and nurse supervision and support-compromised quality of care. Interpretation Quality of care improved with implementation of the WHO guidelines and case-fatality rates fell. Although major changes in medical and nursing practice were achieved in these under-resourced hospitals, not all tasks were done with adequate care and errors led to unnecessary deaths.	Univ London London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, London WC1E 7HT, England; Univ Western Cape, Sch Publ Hlth, ZA-7535 Bellville, South Africa; Hlth Syst Trust, Cape Town, South Africa	University of London; London School of Hygiene & Tropical Medicine; University of the Western Cape	Ashworth, A (corresponding author), Univ London London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, Keppel St, London WC1E 7HT, England.	ann.hill@lshtm.ac.uk		Jackson, Debra/0000-0003-3307-632X				Ahmed T, 1999, LANCET, V353, P1919, DOI 10.1016/S0140-6736(98)07499-6; Alleyne GAO, 1977, PROTEIN ENERGY MALNU; BROWN KL, 1998, RRD INORG CHEM, V1, P1; CHOPRA M, 1995, LANCET, V345, P788; Collins S, 2002, LANCET, V360, P1824, DOI 10.1016/S0140-6736(02)11770-3; Davis DA, 1997, CAN MED ASSOC J, V157, P408; DENEN JL, 2003, B WORLD HEALTH ORGAN, V81, P237; Duke Trevor, 2002, Indian Pediatr, V39, P523; Firth-Cozens J, 1997, QUAL HEALTH CARE, V6, P205, DOI 10.1136/qshc.6.4.205; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; KHANUM S, 1994, LANCET, V344, P1728; LOMAS J, 1991, ANNU REV PUBL HEALTH, V12, P41, DOI 10.1146/annurev.pu.12.050191.000353; Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X; OBRIEN MA, 2003, COCHRANE DATABASE SY; PADARATH A, HLTH PERSONNEL SO AF; Puoane T, 2004, INT J QUAL HEALTH C, V16, P31, DOI 10.1093/intqhc/mzh002; Puoane T, 2001, S AFR MED J, V91, P137; *S AFR DEM HLTH SU, 1999, PREL REP; *S AFR DEP HLTH, 2001, NAT HIV SYPH SER SUR; *S AFR DEP HLTH, 2002, SAV BAB 2001 2 PER C; *S AFR DEP HLTH, 1999, SAV MOTH REP CONF EN; Schofield C, 1996, B WORLD HEALTH ORGAN, V74, P223; SCHOFIELD EC, 2001, FIELD EXCHANGE, V14, P21; Shortell SM, 1998, MILBANK Q, V76, P593, DOI 10.1111/1468-0009.00107; Tamburlini G, 1999, ARCH DIS CHILD, V81, P478, DOI 10.1136/adc.81.6.478; WATERSTON T, 1987, MED EDUC, V21, P4, DOI 10.1111/j.1365-2923.1987.tb00506.x; *WHO, 2000, MAN CHILD SER INF MA; *WHO, 2002, WHOFCHCAH0212; World Health Organization, 1999, MAN SEV MALN MAN PHY	29	147	153	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	2004	363	9415					1110	1115		10.1016/S0140-6736(04)15894-7	http://dx.doi.org/10.1016/S0140-6736(04)15894-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808VB	15064029				2022-12-28	WOS:000220595500010
J	Wallace, GL; Treffert, DA				Wallace, GL; Treffert, DA			Head size and autism	LANCET			English	Editorial Material							CIRCUMFERENCE; DISORDER; CHILDREN; GROWTH; LIFE; AGE		NIMH, Child Psychiat Branch, Bethesda, MD 20892 USA; St Agnes Hosp, Fond Du Lac, WI USA; Univ Wisconsin, Sch Med, Dept Psychiat, Madison, WI USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Wisconsin System; University of Wisconsin Madison	Wallace, GL (corresponding author), NIMH, Child Psychiat Branch, Bethesda, MD 20892 USA.	gregwallace@mail.nih.gov	Wallace, Gregory/A-4789-2008; Wallace, Gregory/H-2158-2018	Wallace, Gregory/0000-0003-0329-5054				Aylward EH, 2002, NEUROLOGY, V59, P175, DOI 10.1212/WNL.59.2.175; BAILEY A, 1993, LANCET, V341, P1225, DOI 10.1016/0140-6736(93)91065-T; Carper RA, 2002, NEUROIMAGE, V16, P1038, DOI 10.1006/nimg.2002.1099; Conciatori M, 2004, BIOL PSYCHIAT, V55, P413, DOI 10.1016/j.biopsych.2003.10.005; Courchesne E, 2003, JAMA-J AM MED ASSOC, V290, P337, DOI 10.1001/jama.290.3.337; Courchesne E, 2001, NEUROLOGY, V57, P245, DOI 10.1212/WNL.57.2.245; DeLong GR, 1999, NEUROLOGY, V52, P911, DOI 10.1212/WNL.52.5.911; Deutsch CK, 2003, J AUTISM DEV DISORD, V33, P209, DOI 10.1023/A:1022903913547; Happe F, 1999, TRENDS COGN SCI, V3, P216, DOI 10.1016/S1364-6613(99)01318-2; Kanner L, 1943, NERV CHILD, V2, P217; Lainhart JE, 2003, JAMA-J AM MED ASSOC, V290, P393, DOI 10.1001/jama.290.3.393; Miles JH, 2000, AM J MED GENET, V95, P339, DOI 10.1002/1096-8628(20001211)95:4<339::AID-AJMG9>3.3.CO;2-2; Sparks BF, 2002, NEUROLOGY, V59, P184, DOI 10.1212/WNL.59.2.184; Stevenson RE, 1997, LANCET, V349, P1744, DOI 10.1016/S0140-6736(05)62956-X	14	5	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	2004	363	9414					1003	1004		10.1016/S0140-6736(04)15877-7	http://dx.doi.org/10.1016/S0140-6736(04)15877-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15051277				2022-12-28	WOS:000220497300003
J	Derry, LA; Murray, RW				Derry, LA; Murray, RW			Continental margins and the sulfur cycle	SCIENCE			English	Editorial Material							SEAWATER		Cornell Univ, Dept Earth & Atmospher Sci, Ithaca, NY 14853 USA; Boston Univ, Dept Earth Sci, Boston, MA 02215 USA	Cornell University; Boston University	Derry, LA (corresponding author), Cornell Univ, Dept Earth & Atmospher Sci, Ithaca, NY 14853 USA.	lad9@cornell.edu	Derry, Louis A/H-5637-2016	Derry, Louis A/0000-0001-7062-7333				Bertrand P, 1996, MAR GEOL, V130, P1, DOI 10.1016/0025-3227(95)00166-2; Ganeshram RS, 2003, GEOCHIM COSMOCHIM AC, V67, P2599, DOI 10.1016/S0016-7037(03)00164-9; Paytan A, 1998, SCIENCE, V282, P1459, DOI 10.1126/science.282.5393.1459; Turchyn AV, 2004, SCIENCE, V303, P2004, DOI 10.1126/science.1092296	4	12	13	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	2004	303	5666					1981	1982						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044791				2022-12-28	WOS:000220429800026
J	Holt, M; Jahn, R				Holt, M; Jahn, R			Synaptic vesicles in the fast lane	SCIENCE			English	Editorial Material							FROG NEUROMUSCULAR JUNCTION; TRANSMITTER; EXOCYTOSIS; MEMBRANE; MODES		Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany	Max Planck Society	Holt, M (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany.	rjahn@gwdg.de	Holt, Matthew/AAJ-1813-2020	Holt, Matthew/0000-0002-8958-4027; Jahn, Reinhard/0000-0003-1542-3498				Aravanis AM, 2003, NATURE, V423, P643, DOI 10.1038/nature01686; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; De Camilli P, 2001, SYNAPSES, P89; de Lange RPJ, 2003, J NEUROSCI, V23, P10164; Gandhi SP, 2003, NATURE, V423, P607, DOI 10.1038/nature01677; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; Holt M, 2004, CURR BIOL, V14, P173, DOI 10.1016/j.cub.2003.12.053; Rizzoli SO, 2004, SCIENCE, V303, P2037, DOI 10.1126/science.1094682; SCHWARZENFELD IV, 1979, NEUROSCIENCE, V4, P477, DOI 10.1016/0306-4522(79)90125-8; Zenisek D, 2002, NEURON, V35, P1085, DOI 10.1016/S0896-6273(02)00896-6	10	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	2004	303	5666					1986	1987		10.1126/science.1096747	http://dx.doi.org/10.1126/science.1096747			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044796	Green Submitted, Green Published			2022-12-28	WOS:000220429800031
J	Myers, RA; Levin, SA; Lande, R; James, FC; Murdoch, WW; Paine, RT				Myers, RA; Levin, SA; Lande, R; James, FC; Murdoch, WW; Paine, RT			Hatcheries and endangered salmon	SCIENCE			English	Editorial Material									Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada; Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA; Univ Calif Santa Barbara, Dept Ecol Evolut & Marine Biol, Santa Barbara, CA 93106 USA; Univ Washington, Dept Biol, Seattle, WA 98195 USA	Dalhousie University; Princeton University; University of California System; University of California San Diego; State University System of Florida; Florida State University; University of California System; University of California Santa Barbara; University of Washington; University of Washington Seattle	Myers, RA (corresponding author), Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada.	ransom.myers@dal.ca; slevin@princeton.edu; rlande@ucsd.edu; james@bio.fsu.edu; murdoch@lifesci.ucsb.edu; painert@u.washington.edu	Ebersole, Joseph L/A-8371-2009; Levin, Simon A/J-1218-2014	Levin, Simon A/0000-0002-8216-5639				Allendorf Fred W., 1996, P238; Einum Sigurd, 2001, Nordic Journal of Freshwater Research, V75, P56; Gibson A. J. F., 2003, 1123 FISH AQ SCI; HILBORN R, 1993, CAN J FISH AQUAT SCI, V50, P2043, DOI 10.1139/f93-228; LENT R, 2002, FED REGISTER, V67, P6215; LICHATWICH J, 1999, SALMON RIVERS; McGinnity P, 2003, P ROY SOC B-BIOL SCI, V270, P2443, DOI 10.1098/rspb.2003.2520; *NAT RES COUNC, 1996, UPSTR SALM SOC PAC; REISENBICHLER R, 2003, ASSESSING EXTINCTION, P147; Waples R.S., 1991, MAR FISH REV, V53, P11; Waples RS, 1999, FISHERIES, V24, P12, DOI 10.1577/1548-8446(1999)024<0012:DSMAH>2.0.CO;2	11	64	68	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	2004	303	5666					1980	1980		10.1126/science.1095410	http://dx.doi.org/10.1126/science.1095410			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044790				2022-12-28	WOS:000220429800025
J	Barsky, AJ; Ahern, DK				Barsky, AJ; Ahern, DK			Cognitive behavior therapy for hypochondriasis - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOMATOSENSORY AMPLIFICATION SCALE; FUNCTIONAL STATUS QUESTIONNAIRE; SOMATIZATION DISORDER PATIENTS; III-R HYPOCHONDRIASIS; PRIMARY-CARE; MEDICAL OUTPATIENTS; TRANSIENT HYPOCHONDRIASIS; PSYCHIATRIC-CONSULTATION; HEALTH; VALIDITY	Context Hypochondriasis is a chronic, distressing, and disabling condition that is prevalent in ambulatory medical practice. Until recently, no specific treatment has been clearly demonstrated to be effective. Objective To assess the efficacy of a cognitive behavior therapy (CBT) for hypochondriasis. Design A randomized, usual care control group design, conducted between September 1997 and November 2001. The individual primary care physician was the unit of randomization, and all patients clustered within each physician's practice were assigned to the experimental treatment (individual CBT and a consultation letter to the primary care physician) or to the control condition. Subjects were assessed immediately before and 6 and 12 months after the completion of treatment. Setting and Participants Participants were 80 patients from primary care practices and 107 volunteers responding to public announcements, all of whom exceeded a predetermined cutoff score on a hypochondriasis self-report questionnaire on 2 successive occasions. Intervention A scripted, 6-session, individual CBT intervention was compared with medical care as usual. The CBT was accompanied by a consultation letter sent to the patient's primary care physician. Main Outcome Measures Hypochondriacal beliefs, fears, attitudes, and somatic symptoms; role function and impairment. Results A total of 102 individuals were assigned to CBT and 85 were assigned to medical care as usual. The sociodemographic and clinical characteristics of the 2 groups were similar at baseline. Using an intent-to-treat analytic strategy, a consistent pattern of statistically and clinically significant treatment effects was found at both 6- and 12-month follow-up, adjusting for baseline covariates that included educational level, generalized psychiatric distress, and participant status (patient vs volunteer). At 12-month follow-up, CBT patients had significantly lower levels of hypochondriacal symptoms, beliefs, and attitudes (P < .001) and health-related anxiety (P = .009). They also had significantly less impairment of social role functioning (P = .05) and intermediate activities of daily living (P < .001). Hypochondriacal somatic symptoms were not improved significantly by treatment. Conclusion This brief, individual CBT intervention, developed specifically to alter hypochondriacal thinking and restructure hypochondriacal beliefs, appears to have significant beneficial long-term effects on the symptoms of hypochondriasis.	Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Barsky, AJ (corresponding author), Brigham & Womens Hosp, Dept Psychiat, 75 Francis St, Boston, MA 02115 USA.	abarsky@partners.org			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040487] Funding Source: NIH RePORTER; NIMH NIH HHS [MH40487] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Avia MD, 1996, BEHAV RES THER, V34, P23, DOI 10.1016/0005-7967(95)00052-Y; BARSKY AJ, 1990, SOC PSYCH PSYCH EPID, V25, P89; BARSKY AJ, 1986, MED CARE, V24, P548, DOI 10.1097/00005650-198606000-00009; BARSKY AJ, 1986, ARCH GEN PSYCHIAT, V43, P493; BARSKY AJ, 1992, J NERV MENT DIS, V180, P20, DOI 10.1097/00005053-199201000-00006; BARSKY AJ, 1990, ARCH GEN PSYCHIAT, V47, P746; BARSKY AJ, 1990, J PSYCHIAT RES, V24, P323, DOI 10.1016/0022-3956(90)90004-A; Barsky AJ, 1998, ARCH GEN PSYCHIAT, V55, P737, DOI 10.1001/archpsyc.55.8.737; Barsky AJ, 1997, JAMA-J AM MED ASSOC, V278, P673, DOI 10.1001/jama.278.8.673; BARSKY AJ, 1990, BRIT J PSYCHIAT, V157, P404, DOI 10.1192/bjp.157.3.404; BARSKY AJ, 1991, J GEN INTERN MED, V6, P413, DOI 10.1007/BF02598162; BARSKY AJ, 1993, AM J PSYCHIAT, V150, P484; Barsky AJ, 2001, HYPOCHONDRIASIS MODE, P223; Bouman TK, 1998, PSYCHOTHER PSYCHOSOM, V67, P214, DOI 10.1159/000012283; Clark DM, 1998, BRIT J PSYCHIAT, V173, P218, DOI 10.1192/bjp.173.3.218; Cleary PD, 2000, QUAL LIFE RES, V9, P747, DOI 10.1023/A:1008977923785; Derogatis L.R, 1983, SCL 90 R ADM SCORING, VII; Derogatis L.R., 1994, SCL90 R ADM SCORING, V3rd; Escobar JI, 1998, GEN HOSP PSYCHIAT, V20, P155, DOI 10.1016/S0163-8343(98)00018-8; Gramling SE, 1996, PSYCHOSOM MED, V58, P423, DOI 10.1097/00006842-199609000-00005; JETTE AM, 1986, J GEN INTERN MED, V1, P143, DOI 10.1007/BF02602324; KASHNER TM, 1995, PSYCHOSOMATICS, V36, P462, DOI 10.1016/S0033-3182(95)71627-9; KELLNER R, 1983, INT J PSYCHIAT MED, V13, P127, DOI 10.2190/9JPT-A66K-72BH-C3MY; Kellner R., 1986, SOMATIZATION HYPOCHO; Kroenke K, 1998, PSYCHOSOMATICS, V39, P263, DOI 10.1016/S0033-3182(98)71343-X; LIPSITT DR, 2001, HYPOCHONDRIASIS MODE; NOYES R, 1994, PSYCHOSOMATICS, V35, P533, DOI 10.1016/S0033-3182(94)71722-9; Noyes R, 1999, PSYCHOSOMATICS, V40, P461, DOI 10.1016/S0033-3182(99)71183-7; NOYES R, 1993, ARCH GEN PSYCHIAT, V50, P961; Papageorgiou C, 1998, PSYCHOL MED, V28, P193, DOI 10.1017/S0033291797005825; PARKERSON GR, 1992, J CLIN EPIDEMIOL, V45, P1303, DOI 10.1016/0895-4356(92)90171-I; PARKERSON GR, 1989, J CLIN EPIDEMIOL, V42, P217, DOI 10.1016/0895-4356(89)90058-9; PILOWSKY I, 1978, BRIT J MED PSYCHOL, V51, P131, DOI 10.1111/j.2044-8341.1978.tb02457.x; PILOWSKY I, 1967, BRIT J PSYCHIAT, V113, P89, DOI 10.1192/bjp.113.494.89; ROST K, 1994, GEN HOSP PSYCHIAT, V16, P381, DOI 10.1016/0163-8343(94)90113-9; Salkovskis PM, 2002, PSYCHOL MED, V32, P843, DOI 10.1017/S0033291702005822; SMITH GR, 1986, NEW ENGL J MED, V314, P1407, DOI 10.1056/NEJM198605293142203; SMITH GR, 1995, ARCH GEN PSYCHIAT, V52, P238; Speckens AEM, 1996, J PSYCHOSOM RES, V40, P95, DOI 10.1016/0022-3999(95)00561-7; STERN R, 1991, BRIT MED J, V303, P1229, DOI 10.1136/bmj.303.6812.1229; WARWICK HMC, 1988, BRIT J PSYCHIAT, V152, P239, DOI 10.1192/bjp.152.2.239; Warwick HMC, 1996, BRIT J PSYCHIAT, V169, P189, DOI 10.1192/bjp.169.2.189; WEINSTEIN MC, 1989, MED CARE, V27, P593, DOI 10.1097/00005650-198906000-00003; WISE TN, 1994, J PSYCHOSOM RES, V38, P515, DOI 10.1016/0022-3999(94)90048-5	44	208	218	0	34	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	2004	291	12					1464	1470		10.1001/jama.291.12.1464	http://dx.doi.org/10.1001/jama.291.12.1464			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	805UI	15039413	Bronze			2022-12-28	WOS:000220390800027
J	Gale, EAM; Bingley, PJ; Knip, M; Emmett, CL; Swankie, H; Fewell, S; Kearsey, P; Schober, E; Gorus, FK; Dupre, J; Mahon, JL; Profozic, V; Reimers, JI; Mandrup-Poulsen, T; Levy-Marchal, C; Jaeger, C; Bartsocas, C; Vazeou, A; Gyorko, M; Soltesz, G; Madacsy, L; Pastore, MR; Pozzilli, P; Dahl-Jorgensen, K; Joner, G; Kinalska, I; Mrozikiewicz, A; Vaykhonsky, Y; de Leiva, A; Martinez-Larrad, MT; Mauricio, D; Serrano-Rios, M; Ludvigsson, J; Schoenle, EJ; Yilmaz, MT; Carson, DJ; Tennet, H; Robertson, K; Gillespie, KM; Gillmor, H; Moore, WPT; Norcross, A; Williams, AJK; Dinesen, B; Kjellberg, S; Akelsen, HE; Thorsby, E; Undlien, DE; Collier, T; Hardy, P; Sharpe, S; Pocock, S; Ollier, S; Ollier, D; Keynes, M; Drash, AL; Aagenes, O; Dahlquist, G; Laupacis, A; McLean, AEM; Nerup, J; Weber, B; Gale, EAM				Gale, EAM; Bingley, PJ; Knip, M; Emmett, CL; Swankie, H; Fewell, S; Kearsey, P; Schober, E; Gorus, FK; Dupre, J; Mahon, JL; Profozic, V; Reimers, JI; Mandrup-Poulsen, T; Levy-Marchal, C; Jaeger, C; Bartsocas, C; Vazeou, A; Gyorko, M; Soltesz, G; Madacsy, L; Pastore, MR; Pozzilli, P; Dahl-Jorgensen, K; Joner, G; Kinalska, I; Mrozikiewicz, A; Vaykhonsky, Y; de Leiva, A; Martinez-Larrad, MT; Mauricio, D; Serrano-Rios, M; Ludvigsson, J; Schoenle, EJ; Yilmaz, MT; Carson, DJ; Tennet, H; Robertson, K; Gillespie, KM; Gillmor, H; Moore, WPT; Norcross, A; Williams, AJK; Dinesen, B; Kjellberg, S; Akelsen, HE; Thorsby, E; Undlien, DE; Collier, T; Hardy, P; Sharpe, S; Pocock, S; Ollier, S; Ollier, D; Keynes, M; Drash, AL; Aagenes, O; Dahlquist, G; Laupacis, A; McLean, AEM; Nerup, J; Weber, B; Gale, EAM		ENDIT Grp	European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes	LANCET			English	Article							ISLET-CELL ANTIBODIES; DOSE NICOTINAMIDE; INSULIN-RESPONSE; AUTOANTIBODIES; PREVENTION; RELATIVES; MELLITUS; RISK; IDDM; PROGRESSION	Background Results of studies in animals and human beings suggest that type 1 diabetes is preventable. Nicotinamide prevents autoimmune diabetes in animal models, possibly through inhibition of the DNA repair enzyme poly-ADP-ribose polymerase and prevention of beta-cell NAD depletion. We aimed to assess whether high dose nicotinamide prevents or delays clinical onset of diabetes in people with a first-degree family history of type 1 diabetes. Method We did a randomised double-blind placebo-controlled trial of nicotinamide in 552 relatives with confirmed islet cell antibody (ICA) levels of 20 Juvenile Diabetes Federation (JDF) units or more, and a non-diabetic oral glucose tolerance test. Participants were recruited from 18 European countries, Canada, and the USA, and were randomly allocated oral modified release nicotinamide (1.2 g/m(2)) or placebo for 5 years. Random allocation was done with a pseudorandom number generator and we used size balanced blocks of four and stratified by age and national group. Primary outcome was development of diabetes, as defined by WHO criteria. Analysis was done on an intention-to-treat basis. Findings There was no difference in the development of diabetes between the treatment groups. Of 159 participants who developed diabetes in the course of the trial, 82 were taking nicotinamide and 77 were on placebo. The unadjusted hazard ratio for development of diabetes was 1.07 (95% Cl 0.78-1.45; p=0.69), and the hazard ratio adjusted for age-at-entry, baseline glucose tolerance, and number of islet autoantibodies detected was 1.01 (0.73-1.38; p=0.97). Of 168 (30.4%) participants who withdrew from the trial, 83 were on placebo. The number of serious adverse events did not differ between treatment groups. Nicotinamide treatment did not affect growth in children or first-phase insulin secretion. Interpretation Large-scale controlled trials of interventions designed to prevent the onset of type 1 diabetes are feasible, but nicotinamide was ineffective at the dose we used.	Univ Bristol, Bristol BS8 1TH, Avon, England; Univ Helsinki Hosp, Helsinki, Finland; Steno Diabet Ctr, DK-2820 Gentofte, Denmark; Natl Hosp, Oslo, Norway; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; QED Partnership, Milton Keynes, Bucks, England	University of Bristol; University of Helsinki; Helsinki University Central Hospital; Steno Diabetes Center; University of Oslo; National Hospital Norway; University of London; London School of Hygiene & Tropical Medicine	Gale, EAM (corresponding author), Southmead Gen Hosp, Diabet & Metab Med Sch Unit, Bristol BS10 5NB, Avon, England.	edwin.gale@bristol.ac.uk	Mauricio, Didac/B-7951-2009; Pozzilli, Paolo/A-5235-2010; Ludvigsson, Johnny/AAI-2051-2020	Mauricio, Didac/0000-0002-2868-0250; Ludvigsson, Johnny/0000-0003-1695-5234; Knip, Mikael/0000-0003-0474-0033; Gorus, Frans/0000-0002-9007-6177				ANDERSEN L, 1993, CLIN CHEM, V39, P578; Atkinson MA, 1999, NAT MED, V5, P601, DOI 10.1038/9442; Atkinson MA, 2001, LANCET, V358, P221, DOI 10.1016/S0140-6736(01)05415-0; Bingley PJ, 1996, DIABETES, V45, P1720, DOI 10.2337/diabetes.45.12.1720; Bingley PJ, 1997, DIABETES, V46, P1701, DOI 10.2337/diabetes.46.11.1701; Bingley PJ, 2001, DIABETES CARE, V24, P398, DOI 10.2337/diacare.24.2.398; Bingley PJ, 1999, DIABETES CARE, V22, P1796, DOI 10.2337/diacare.22.11.1796; BINGLEY PJ, 1992, DIABETES CARE, V15, P93; BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U; *DIAB PREV TRIAL T, 2002, NEW ENGL J MED, V346, P1658; DULIN WE, 1969, DIABETES, V18, P459, DOI 10.2337/diab.18.7.459; Elliott RB, 1996, J PEDIATR ENDOCR MET, V9, P501; ELLIOTT RB, 1991, DIABETOLOGIA, V34, P362, DOI 10.1007/BF00405010; Freeman JV, 1990, ARCH DIS CHILD, V1995, P17; Gale EAM, 2003, DIABETOLOGIA, V46, P339, DOI 10.1007/s00125-003-1033-8; Gale EAM, 2002, NEW ENGL J MED, V346, P1740, DOI 10.1056/NEJM200205303462211; Gardner SG, 1999, DIABETES CARE, V22, P2049, DOI 10.2337/diacare.22.12.2049; GORSUCH AN, 1981, LANCET, V2, P1363; Hoorens A, 1999, DIABETOLOGIA, V42, P55, DOI 10.1007/s001250051113; Knip M, 2000, DIABETOLOGIA, V43, P1337, DOI 10.1007/s001250051536; Lampeter EF, 1998, DIABETES, V47, P980, DOI 10.2337/diabetes.47.6.980; MANDRUPPOULSEN T, 1993, DIABETES METAB REV, V9, P295, DOI 10.1002/dmr.5610090410; MCCULLOCH DK, 1993, DIABETES CARE, V16, P911, DOI 10.2337/diacare.16.6.911; PETLEY A, 1995, DIABETES, V44, P152, DOI 10.2337/diabetes.44.2.152; POCIOT F, 1993, DIABETOLOGIA, V36, P574, DOI 10.1007/BF02743277; Pozzilli P, 1996, DIABETES CARE, V19, P1357, DOI 10.2337/diacare.19.12.1357; RILEY WJ, 1990, NEW ENGL J MED, V323, P1167, DOI 10.1056/NEJM199010253231704; Verge CF, 1998, DIABETES, V47, P1857, DOI 10.2337/diabetes.47.12.1857; Wilson JMG, 1968, PRINCIPLES PRACTICE; World Health Organization, 1985, DIAB MELL REP WHO ST; YAMADA K, 1982, DIABETES, V31, P749, DOI 10.2337/diabetes.31.9.749	31	349	362	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 20	2004	363	9413					925	931		10.1016/S0140-6736(04)15786-3	http://dx.doi.org/10.1016/S0140-6736(04)15786-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043959				2022-12-28	WOS:000220308600008
J	Colman, DR				Colman, DR			Obedient and wayward synaptic behavior	CELL			English	Editorial Material							AXONS	Synapse formation is a complex process that culminates in the linking up and locking in of pre- and postsynaptic membranes. Shen et al. (2004 [this issue of Cell]) begin to dissect the molecular instructions that govern target selection of pre- and postsynaptic membrane interactions.	McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	McGill University	Colman, DR (corresponding author), McGill Univ, Montreal Neurol Inst, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.							Benson DL, 2001, NAT REV NEUROSCI, V2, P899, DOI 10.1038/35104078; BURRY RW, 1982, BRAIN RES, V247, P1, DOI 10.1016/0006-8993(82)91022-8; Holt CE, 1998, CURR OPIN NEUROBIOL, V8, P98, DOI 10.1016/S0959-4388(98)80013-5; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Shen K, 2003, CELL, V112, P619, DOI 10.1016/S0092-8674(03)00113-2; Shen K, 2004, CELL, V116, P869, DOI 10.1016/S0092-8674(04)00251-X; von Melchner L, 2000, NATURE, V404, P871, DOI 10.1038/35009102; ZWIMPFER TJ, 1992, J NEUROSCI, V12, P1144	8	1	1	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 19	2004	116	6					766	767		10.1016/S0092-8674(04)00257-0	http://dx.doi.org/10.1016/S0092-8674(04)00257-0			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YS	15035979	Bronze			2022-12-28	WOS:000221499900003
J	Niethammer, P; Bastiaens, P; Karsenti, E				Niethammer, P; Bastiaens, P; Karsenti, E			Stathmin-tubulin interaction gradients in motile and mitotic cells	SCIENCE			English	Article							XENOPUS EGG EXTRACTS; SMALL G-PROTEINS; MICROTUBULE DYNAMICS; IN-VITRO; PHOSPHORYLATION; IDENTIFICATION; CHROMATIN; FAMILY; KINASE; RHO	The spatial organization of the microtubule cytoskeleton is thought to be directed by steady-state activity gradients of diffusible regulatory molecules. We visualized such intracellular gradients by monitoring the interaction between tubulin and a regulator of microtubule dynamics, stathmin, using a fluorescence resonance energy transfer (FRET) biosensor. These gradients were observed both during interphase in motile membrane protrusions and during mitosis around chromosomes, which suggests that a similar mechanism may contribute to the creation of polarized microtubule structures. These interaction patterns are likely to reflect phosphorylation of stathmin in these areas.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Bastiaens, P (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	bastiaen@embl-heidelberg.de; karsenti@embl-heidelberg.de						Amayed P, 2002, J BIOL CHEM, V277, P22718, DOI 10.1074/jbc.M111605200; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Andersen SSL, 1997, NATURE, V389, P640, DOI 10.1038/39382; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1993, J BIOL CHEM, V268, P20076; Brown GC, 1999, FEBS LETT, V457, P452, DOI 10.1016/S0014-5793(99)01058-3; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Carazo-Salas RE, 2003, CURR BIOL, V13, P1728, DOI 10.1016/j.cub.2003.09.006; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; CHNEIWEISS H, 1992, J NEUROCHEM, V58, P282, DOI 10.1111/j.1471-4159.1992.tb09308.x; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; DiPaolo G, 1997, FEBS LETT, V416, P149, DOI 10.1016/S0014-5793(97)01188-5; Drouva SV, 1998, ENDOCRINOLOGY, V139, P2235, DOI 10.1210/en.139.5.2235; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Kuntziger T, 2001, J BIOL CHEM, V276, P22979, DOI 10.1074/jbc.M101466200; LEIGHTON IA, 1993, MOL CELL BIOCHEM, V128, P151, DOI 10.1007/BF01076766; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; SOBEL A, 1989, J BIOL CHEM, V264, P3765; Steinmetz MO, 2000, EMBO J, V19, P572, DOI 10.1093/emboj/19.4.572; Stukenberg PT, 2003, CURR BIOL, V13, pR848, DOI 10.1016/j.cub.2003.10.020; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200; Wittmann T, 2003, J CELL BIOL, V161, P845, DOI 10.1083/jcb.200303082	30	168	172	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1862	1866		10.1126/science.1094108	http://dx.doi.org/10.1126/science.1094108			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031504				2022-12-28	WOS:000220281600054
J	Nayak, KR; Daly, RG				Nayak, KR; Daly, RG			Images in clinical medicine - Eruptive xanthomas associated with hypertriglyceridemia and new-onset diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									USN, Med Ctr, San Diego, CA 92134 USA	United States Department of Defense; United States Navy	Nayak, KR (corresponding author), USN, Med Ctr, San Diego, CA 92134 USA.								0	17	20	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	2004	350	12					1235	1235		10.1056/NEJMicm030676	http://dx.doi.org/10.1056/NEJMicm030676			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803PG	15028827				2022-12-28	WOS:000220242400010
J	Macpherson, AJ; Uhr, T				Macpherson, AJ; Uhr, T			Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria	SCIENCE			English	Article							RESPONSES; PHAGOCYTOSIS	The enormous number of commensal bacteria in the lower intestine of vertebrates share abundant molecular patterns used for innate immune recognition of pathogenic bacteria. We show that, even though commensals are rapidly killed by macrophages, intestinal dendritic cells (DCs) can retain small numbers of live commensals for several days. This allows DCs to selectively induce IgA, which helps protect against mucosal penetration by commensals. The commensal-loaded DCs are restricted to the mucosal immune compartment by the mesenteric lymph nodes, which ensures that immune responses to commensal bacteria are induced locally, without potentially damaging systemic immune responses.	Univ Spital Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Macpherson, AJ (corresponding author), Univ Spital Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland.	amacpher@pathol.unizh.ch	Eckhardt, Erik/G-1567-2010					Berg RD, 1996, TRENDS MICROBIOL, V4, P430, DOI 10.1016/0966-842X(96)10057-3; Fagarasan S, 2002, SCIENCE, V298, P1424, DOI 10.1126/science.1077336; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Hamada H, 2002, J IMMUNOL, V168, P57, DOI 10.4049/jimmunol.168.1.57; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Huang FP, 2000, J EXP MED, V191, P435, DOI 10.1084/jem.191.3.435; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; Macpherson AJ, 2001, MICROBES INFECT, V3, P1021, DOI 10.1016/S1286-4579(01)01460-5; MACPHERSON AJ, UNPUB; Nagl M, 2002, CLIN DIAGN LAB IMMUN, V9, P1165, DOI 10.1128/CDLI.9.6.1165-1168.2002; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; POST LE, 1980, J BIOL CHEM, V255, P4653; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Sansonetti P, 2001, SEMIN IMMUNOL, V13, P381, DOI 10.1006/smim.2001.0335; WELLS CL, 1988, REV INFECT DIS, V10, P958	15	1064	1163	6	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1662	1665		10.1126/science.1091334	http://dx.doi.org/10.1126/science.1091334			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016999				2022-12-28	WOS:000220151400042
J	Sundar, VC; Zaumseil, J; Podzorov, V; Menard, E; Willett, RL; Someya, T; Gershenson, ME; Rogers, JA				Sundar, VC; Zaumseil, J; Podzorov, V; Menard, E; Willett, RL; Someya, T; Gershenson, ME; Rogers, JA			Elastomeric transistor stamps: Reversible probing of charge transport in organic crystals	SCIENCE			English	Article							FIELD-EFFECT TRANSISTORS; SINGLE-CRYSTALS; MOBILITY; FILMS; SOFT; SEMICONDUCTORS; TEMPERATURE; LAMINATION; CIRCUITS; SURFACE	We introduce a method to fabricate high-performance field-effect transistors on the surface of freestanding organic single crystals. The transistors are constructed by laminating a monolithic elastomeric transistor stamp against the surface of a crystal. This method, which eliminates exposure of the fragile organic surface to the hazards of conventional processing, enables fabrication of rubrene transistors with charge carrier mobilities as high as similar to15 cm(2)/V.s and subthreshold slopes as low as 2 nF.V/decade.cm(2). Multiple relamination of the transistor stamp against the same crystal does not affect the transistor characteristics; we exploit this reversibility to reveal anisotropic charge transport at the basal plane of rubrene.	Univ Illinois, Beckman Inst, Dept Mat Sci & Engn, Urbana, IL 61801 USA; Univ Illinois, Beckman Inst, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Seitz Mat Res Lab, Urbana, IL 61801 USA; Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; Rutgers State Univ, Dept Phys & Astron, Piscataway, NJ 08854 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Alcatel-Lucent; Lucent Technologies; AT&T; Rutgers State University New Brunswick	Rogers, JA (corresponding author), Univ Illinois, Beckman Inst, Dept Mat Sci & Engn, Urbana, IL 61801 USA.	jrogers@uiuc.edu	Rogers, John/L-2798-2016; Podzorov, Vitaly/I-2639-2016; , Michael/AAL-5083-2021; Zaumseil, Jana/C-1731-2018; Someya, Takao/H-3052-2015	Zaumseil, Jana/0000-0002-2048-217X; Someya, Takao/0000-0003-3051-1138; Podzorov, Vitaly/0000-0001-8276-882X				Butko VY, 2003, APPL PHYS LETT, V83, P4773, DOI 10.1063/1.1631736; Cheng YC, 2003, J CHEM PHYS, V118, P3764, DOI 10.1063/1.1539090; Childs WR, 2002, J AM CHEM SOC, V124, P13583, DOI 10.1021/ja020942z; Chwang AB, 2001, J APPL PHYS, V90, P1342, DOI 10.1063/1.1376404; de Boer RWI, 2003, APPL PHYS LETT, V83, P4345, DOI 10.1063/1.1629144; Gundlach DJ, 2002, APPL PHYS LETT, V80, P2925, DOI 10.1063/1.1471378; Horowitz G, 1998, ADV MATER, V10, P365, DOI 10.1002/(SICI)1521-4095(199803)10:5<365::AID-ADMA365>3.0.CO;2-U; Hull D, 1981, INTRO COMPOSITE MAT; Jacobs HO, 2001, SCIENCE, V291, P1763, DOI 10.1126/science.1057061; KATZ HE, 1998, OLIGO POLYTHIOPHENE; Laudise RA, 1998, J CRYST GROWTH, V187, P449, DOI 10.1016/S0022-0248(98)00034-7; Loo YL, 2002, P NATL ACAD SCI USA, V99, P10252, DOI 10.1073/pnas.162128299; Nelson SF, 1998, APPL PHYS LETT, V72, P1854, DOI 10.1063/1.121205; Perutz S, 1998, MACROMOLECULES, V31, P4272, DOI 10.1021/ma9700993; Podzorov V, 2003, APPL PHYS LETT, V83, P3504, DOI 10.1063/1.1622799; Podzorov V, 2003, APPL PHYS LETT, V82, P1739, DOI 10.1063/1.1560869; Pope M., 1999, ELECT PROCESSES ORGA; Rogers JA, 2001, SCIENCE, V291, P1502, DOI 10.1126/science.291.5508.1502; Sirringhaus H, 2000, SCIENCE, V290, P2123, DOI 10.1126/science.290.5499.2123; SMITH AC, 1967, ELECT CONDUCTION SOL, P257; Sze S., 1981, PHYS SEMICONDUCTOR D, V2nd ed., P85; Takeya J, 2003, J APPL PHYS, V94, P5800, DOI 10.1063/1.1618919; Vrijmoeth J, 1998, J APPL PHYS, V83, P3816, DOI 10.1063/1.367145; Wu MW, 1997, CHEM PHYS LETT, V266, P363, DOI 10.1016/S0009-2614(97)00022-5; Zaumseil J, 2003, J APPL PHYS, V93, P6117, DOI 10.1063/1.1568157	25	1474	1531	8	615	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1644	1646		10.1126/science.1094196	http://dx.doi.org/10.1126/science.1094196			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016993				2022-12-28	WOS:000220151400036
J	O'Keeffe, ST				O'Keeffe, ST			Down with bedrails?	LANCET			English	Editorial Material									Merlin Pk Reg Hosp, Dept Geriatr Med, Galway, Ireland	Ollscoil na Gaillimhe-University of Galway	O'Keeffe, ST (corresponding author), Merlin Pk Reg Hosp, Dept Geriatr Med, Galway, Ireland.	s.okeeffe@whb.ie		O'Keeffe, Shaun/0000-0002-7682-5004				[Anonymous], 1984, LANCET, V2, P383; Braun U., 2000, SCHLECHTENDALIA, V4, P1; Capezuti E, 2002, J AM GERIATR SOC, V50, P90, DOI 10.1046/j.1532-5415.2002.50013.x; Hanger HC, 1999, J AM GERIATR SOC, V47, P529, DOI 10.1111/j.1532-5415.1999.tb02565.x; HOFFMAN S, BEDSAFE BED SAFETY A; Hospital Bed Safety Workgroup, 2003, CLIN GUID ASS IMPL B; *MED DEV BUR, 2001, HOSP BED HAZ; MEIKLE J, 2001, GUARDIAN        0531; MYINT S, 1999, GERONTOLOGIST, V39, P611; OKEEFFE S, 1996, J AM GERIATR SOC, V41, P1226; Parker KP, 1997, J AM GERIATR SOC, V45, P797, DOI 10.1111/j.1532-5415.1997.tb01504.x; POWELLCOPE G, 2003, BED SAFETY EVALUATIO; Rubin B S, 1993, Arch Fam Med, V2, P405, DOI 10.1001/archfami.2.4.405; *US FDA, 2000, GUID BED SAF	14	13	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	2004	363	9406					343	344		10.1016/S0140-6736(04)15473-1	http://dx.doi.org/10.1016/S0140-6736(04)15473-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768TQ	15070560				2022-12-28	WOS:000188590900005
J	Silberstein, SD				Silberstein, SD			Migraine	LANCET			English	Review							FAMILIAL HEMIPLEGIC MIGRAINE; PLASMA-PROTEIN EXTRAVASATION; SUPERIOR SAGITTAL SINUS; GENE-RELATED PEPTIDE; TRANSCRANIAL MAGNETIC STIMULATION; FOS-LIKE IMMUNOREACTIVITY; BRAIN-STEM ACTIVATION; DOUBLE-BLIND TRIAL; DURA-MATER; PHARMACOLOGICAL PROFILE	Migraine is a very common neurobiological headache disorder that is caused by increased excitability of the CNS. It ranks among the world's most disabling medical illnesses. Diagnosis is based on the headache's characteristics and associated symptoms. The economic and societal effect of migraine is substantial: it affects patients' quality of life and impairs work, social activities, and family life. There are many acute and preventive migraine treatments. Acute treatment is either specific (triptans and ergots) or non-specific (analgesics). Disabling migraine should be treated with triptans. Increased headache frequency is an indication for preventive treatment. Preventive treatment decreases migraine frequency and improves quality of life. More treatments are being developed, which provides hope to the many patients whose migraines remain uncontrolled.	Thomas Jefferson Univ Hosp, Jefferson Headache Ctr, Philadelphia, PA 19107 USA	Jefferson University	Silberstein, SD (corresponding author), Thomas Jefferson Univ Hosp, Jefferson Headache Ctr, Philadelphia, PA 19107 USA.	Stephen.Silberstein@jefferson.edu						Afra J, 1998, ANN NEUROL, V44, P209, DOI 10.1002/ana.410440211; AMADAN NM, 1999, EVIDENCE BASED GUIDE; ANDERSEN AR, 1988, ARCH NEUROL-CHICAGO, V45, P154, DOI 10.1001/archneur.1988.00520260040017; Aurora SK, 1999, HEADACHE, V39, P469, DOI 10.1046/j.1526-4610.1999.3907469.x; Bahra A, 2001, LANCET, V357, P1016, DOI 10.1016/S0140-6736(00)04250-1; BARKLEY GL, 1990, HEADACHE, V30, P428, DOI 10.1111/j.1526-4610.1990.hed3007428.x; BATES D, 1994, NEUROLOGY, V44, P1587, DOI 10.1212/WNL.44.9.1587; Bolay H, 2002, NAT MED, V8, P136, DOI 10.1038/nm0202-136; Bowyer SM, 2001, ANN NEUROL, V50, P582, DOI 10.1002/ana.1293; Brandes Jan L., 2003, Neurology, V60, pA238; Burstein R, 2000, BRAIN, V123, P1703, DOI 10.1093/brain/123.8.1703; BURSTEIN R, 2002, HEADACHE, V42, P390; BUZZI MG, 1989, EUR J PHARMACOL, V165, P251; BUZZI MG, 1991, NEUROPHARMACOLOGY, V30, P1193, DOI 10.1016/0028-3908(91)90165-8; Cady RK, 2000, CLIN THER, V22, P1035, DOI 10.1016/S0149-2918(00)80083-1; CALLAHAM M, 1986, HEADACHE, V26, P168, DOI 10.1111/j.1526-4610.1986.hed2604168.x; CAMPBELL JK, 2000, EVIDENCED BASED GUID; Cao Y, 1999, ARCH NEUROL-CHICAGO, V56, P548, DOI 10.1001/archneur.56.5.548; CHABRIAT H, 1995, LANCET, V346, P934, DOI 10.1016/S0140-6736(95)91557-5; Charlesworth BR, 2003, CNS DRUGS, V17, P653, DOI 10.2165/00023210-200317090-00005; CRITCHLEY M, 1967, MIGRAINE CAPPADOCIA; Cutrer FM, 1995, BRIT J PHARMACOL, V116, P3199, DOI 10.1111/j.1476-5381.1995.tb15124.x; Cutrer FM, 1998, ANN NEUROL, V43, P25, DOI 10.1002/ana.410430108; Cutrer FM, 1999, CURR OPIN NEUROL, V12, P255, DOI 10.1097/00019052-199906000-00003; Dahlof C, 1999, CEPHALALGIA, V19, P769, DOI 10.1046/j.1468-2982.1999.1909769.x; Dahlof C, 2001, CEPHALALGIA, V21, P9, DOI 10.1046/j.1468-2982.2001.021s1009.x; De Fusco M, 2003, NAT GENET, V33, P192, DOI 10.1038/ng1081; del Rio MS, 1999, CEPHALALGIA, V19, P701, DOI 10.1046/j.1468-2982.1999.019008701.x; DIMITRIADOU V, 1992, NEUROSCIENCE, V48, P187, DOI 10.1016/0306-4522(92)90348-6; Doods H, 2000, BRIT J PHARMACOL, V129, P420, DOI 10.1038/sj.bjp.0703110; Ducros A, 2001, NEW ENGL J MED, V345, P17, DOI 10.1056/NEJM200107053450103; Duquesnoy C, 1998, EUR J PHARM SCI, V6, P99, DOI 10.1016/S0928-0987(97)00073-0; Edvinsson L, 1998, EUR J NEUROL, V5, P329, DOI 10.1046/j.1468-1331.1998.540329.x; FARKKILA M, 1996, CEPHALALGIA, V16, P387; Ferrari MD, 1998, LANCET, V351, P1043, DOI 10.1016/S0140-6736(97)11370-8; Ferrari MD, 2001, LANCET, V358, P1668, DOI 10.1016/S0140-6736(01)06711-3; Ferrari MD, 2001, WOLFFS HEADACHE OTHE, P73; FISHER CM, 1986, STROKE, V17, P1033, DOI 10.1161/01.STR.17.5.1033; Giffin NJ, 2003, NEUROLOGY, V60, P935, DOI 10.1212/01.WNL.0000052998.58526.A9; GOADSBY PJ, 1993, ANN NEUROL, V33, P48, DOI 10.1002/ana.410330109; Goadsby PJ, 1997, J ANAT, V190, P367, DOI 10.1046/j.1469-7580.1997.19030367.x; GOADSBY PJ, 1991, ANN NEUROL, V29, P91, DOI 10.1002/ana.410290116; GOADSBY PJ, 1990, ANN NEUROL, V28, P183, DOI 10.1002/ana.410280213; GOSLIN RE, 1999, 127946 HLTH CAR POL; GRAY RN, 1999, 127854 NAT TECHN INF; GRAY RN, 1999, 127953 NAT TECHN INF; GRAY RN, 1999, 1278862 NAT TECHN IN; Gunasekara NS, 1997, CNS DRUGS, V8, P402, DOI 10.2165/00023210-199708050-00006; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Hartig PR, 1996, TRENDS PHARMACOL SCI, V17, P103, DOI 10.1016/0165-6147(96)30002-3; HOYER D, 1994, PHARMACOL REV, V46, P157; Iadecola C, 2002, NAT MED, V8, P110, DOI 10.1038/nm0202-110; JONES J, 1989, JAMA-J AM MED ASSOC, V261, P1174, DOI 10.1001/jama.261.8.1174; JOUTEL A, 1993, NAT GENET, V5, P40, DOI 10.1038/ng0993-40; Joutel A, 1997, LANCET, V350, P1511, DOI 10.1016/S0140-6736(97)08083-5; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; KAUBE H, 1993, BRAIN RES, V629, P95, DOI 10.1016/0006-8993(93)90486-7; Lashley KS, 1941, ARCH NEURO PSYCHIATR, V46, P331, DOI 10.1001/archneurpsyc.1941.02280200137007; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; LEE WS, 1994, BRIT J PHARMACOL, V112, P920, DOI 10.1111/j.1476-5381.1994.tb13168.x; LEE WS, 1995, BRIT J PHARMACOL, V116, P1661, DOI 10.1111/j.1476-5381.1995.tb16388.x; Limmroth V, 1996, BRIT J PHARMACOL, V117, P99, DOI 10.1111/j.1476-5381.1996.tb15160.x; Lipton RB, 2000, JAMA-J AM MED ASSOC, V284, P2599, DOI 10.1001/jama.284.20.2599; Lipton RB, 2001, HEADACHE, V41, P638, DOI 10.1046/j.1526-4610.2001.041007638.x; Lipton RB, 2000, ARCH INTERN MED, V160, P3486, DOI 10.1001/archinte.160.22.3486; Lipton RB, 1998, ARCH NEUROL-CHICAGO, V55, P210, DOI 10.1001/archneur.55.2.210; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; Lipton RB, 2002, NEUROLOGY, V58, pA472; LIPTON RB, 1994, NEUROLOGY, V44, P4; Lipton RB, 2000, HEADACHE, V40, P783, DOI 10.1046/j.1526-4610.2000.00143.x; Lipton RB., 2001, WOLFFS HEADACHES OTH, V85, P107; Longmore J, 1997, CEPHALALGIA, V17, P833, DOI 10.1046/j.1468-2982.1997.1708833.x; Mark AS, 1998, AM J NEURORADIOL, V19, P1887; MARKOWITZ S, 1988, CEPHALALGIA, V8, P83, DOI 10.1046/j.1468-2982.1988.0802083.x; Matchar DB., 2000, NEUROLOGY, V54, P58, DOI [10.1212/WNL.54.1.58, DOI 10.1212/WNL.54.1.58]; Mathew Ninan T., 2003, Neurology, V60, pA336; Mathew NT, 2001, HEADACHE, V41, P119, DOI 10.1046/j.1526-4610.2001.111006119.x; May A, 1996, PAIN, V67, P375, DOI 10.1016/0304-3959(96)03137-5; MILNER PM, 1958, ELECTROEN CLIN NEURO, V10, P705, DOI 10.1016/0013-4694(58)90073-7; MOSKOWITZ MA, 1993, ANNU REV MED, V44, P145, DOI 10.1146/annurev.med.44.1.145; NOZAKI K, 1992, NEUROSCIENCE, V49, P669, DOI 10.1016/0306-4522(92)90235-T; OCONNOR TP, 1986, J NEUROSCI, V6, P2200; OCONNOR TP, 1988, J NEUROSCI, V8, P2468; OLESEN J, 1991, CEREBROVAS BRAIN MET, V3, P1; OLESEN J, 1990, ANN NEUROL, V28, P791, DOI 10.1002/ana.410280610; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; Olesen J, 2003, CEPHALALGIA, V23, P579; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; PAPPAGALO M, 2002, NEUROLOGY, V52, P274; Pietrobon D, 2003, NAT REV NEUROSCI, V4, P386, DOI 10.1038/nrn1102; Russell MB, 1996, BRAIN, V119, P355, DOI 10.1093/brain/119.2.355; Sandor PS, 2003, CEPHALALGIA, V23, P577; SAPER JR, 1994, HEADACHE, V34, P497, DOI 10.1111/j.1526-4610.1994.hed3409497.x; Schoenen J, 1998, NEUROLOGY, V50, P466, DOI 10.1212/WNL.50.2.466; SCHOENEN J, 2000, HEADACHES, P301; SETO H, 1994, CLIN NUCL MED, V19, P215, DOI 10.1097/00003072-199403000-00010; Shakra S, 2002, NEUROLOGY, V58, pA414; Shakra S, 2002, NEUROLOGY, V58, pA91; Silberstein S, 2000, HEADACHE, V40, P445, DOI 10.1046/j.1526-4610.2000.00066.x; Silberstein S D, 2001, WOLFFS HEADACHE OTHE, P121; Silberstein SD, 2000, NEUROLOGY, V55, P754, DOI 10.1212/WNL.55.6.754; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Silberstein SD, 1996, HEADACHE, V36, P547, DOI 10.1046/j.1526-4610.1996.3609547.x; SILBERSTEIN SD, 1995, HEADACHE, V35, P387, DOI 10.1111/j.1526-4610.1995.hed3507387.x; Silberstein SD, 2003, NEUROLOGY, V60, P315, DOI 10.1212/01.WNL.0000042477.63516.B2; Silberstein SD, 2003, HEADACHE, V43, P144, DOI 10.1046/j.1526-4610.2003.03034.x; SILBERSTEIN SD, 1990, HEADACHE, V30, P334, DOI 10.1111/j.1526-4610.1990.hed3006334.x; Silberstein SD, 2002, HEADACHE, V42, pS45; Silberstein SD, 2002, CEPHALALGIA, V22, P491, DOI 10.1046/j.1468-2982.2002.00386.x; Silberstein SD, 2001, HEADACHE, V41, P953, DOI 10.1046/j.1526-4610.2001.01189.x; SILBERSTEIN SD, 1995, SEMIN NEUROL, V15, P175, DOI 10.1055/s-2008-1041021; Silberstein SD, 1997, NEUROL CLIN, V15, P209, DOI 10.1016/S0733-8619(05)70305-4; Silberstein SD, 2000, CEPHALALGIA, V20, P854, DOI 10.1046/j.1468-2982.2000.00149.x; SILBERSTEIN SD, 1994, NEUROLOGY, V44, P6; Silberstein SD, 1998, CEPHALALGIA, V18, P421, DOI 10.1046/j.1468-2982.1998.1807421.x; Silberstein Stephen D., 1999, Headache, V39, P633, DOI 10.1046/j.1526-4610.1999.3909633.x; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; STEIN DJ, 1994, CNS DRUGS, V2, P78, DOI 10.2165/00023210-199402010-00006; STEWART WF, 1994, NEUROLOGY, V44, P24; Stewart WF, 2000, PAIN, V88, P41, DOI 10.1016/S0304-3959(00)00305-5; STEWART WF, 1994, NEUROLOGY, V44, P17; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Strassman AM, 1996, NATURE, V384, P560, DOI 10.1038/384560a0; TATSUTA T, 1992, J BIOL CHEM, V267, P20383; Tfelt-Hansen P, 1998, CEPHALALGIA, V18, P532, DOI 10.1046/j.1468-2982.1998.1808532.x; Tfelt-Hansen P, 2000, BRAIN, V123, P9, DOI 10.1093/brain/123.1.9; *THOMS PDR, 2003, THOMS HEALTHC PHYS D; Thomsen LL, 2002, BRAIN, V125, P1379, DOI 10.1093/brain/awf132; TOURNIERLASSERVE E, 1993, NAT GENET, V3, P256, DOI 10.1038/ng0393-256; UDDMAN R, 1985, NEUROSCI LETT, V62, P131, DOI 10.1016/0304-3940(85)90296-4; Vogler BK, 1998, CEPHALALGIA, V18, P704, DOI 10.1046/j.1468-2982.1998.1810704.x; Ware JE, 2000, MED CARE, V38, P73; WEILLER C, 1995, NAT MED, V1, P658, DOI 10.1038/nm0795-658; WHITTY CWM, 1967, LANCET, V2, P283; Wijman CAC, 1998, STROKE, V29, P1539, DOI 10.1161/01.STR.29.8.1539; Wolff H. G., 1963, HEADACHE OTHER HEAD; WOODS RP, 1994, NEW ENGL J MED, V331, P1689, DOI 10.1056/NEJM199412223312505; World Health Organization, 2001, WORLD HLTH REP; Young WB, 2001, CEPHALALGIA, V21, P842, DOI 10.1046/j.1468-2982.2001.00254.x; Young WB, 2000, HEADACHE, V40, P587, DOI 10.1046/j.1526-4610.2000.00091.x; Young WB, 2001, NEUROLOGY, V56, pA142; ZAGAMI AS, 1990, NEUROPEPTIDES, V16, P69, DOI 10.1016/0143-4179(90)90114-E	142	274	297	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	2004	363	9406					381	391		10.1016/S0140-6736(04)15440-8	http://dx.doi.org/10.1016/S0140-6736(04)15440-8			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768TQ	15070571				2022-12-28	WOS:000188590900024
J	Mason, L; Moore, RA; Derry, S; Edwards, JE; McQuay, HJ				Mason, L; Moore, RA; Derry, S; Edwards, JE; McQuay, HJ			Systematic review of topical capsaicin for the treatment of chronic pain	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CLINICAL-TRIALS; DOUBLE-BLIND; NEUROPATHIC PAIN; METAANALYSIS; MANAGEMENT; CREAM	Objective To determine the efficacy and safety of topically applied capsaicin for chronic pain from neuropathic or musculoskeletal disorders. Data sources Cochrane Library, Medline, Embase, PubMed, an in-house database, and contact with manufacturers of topical capsaicin. Study selection Randomised controlled trials comparing topically applied capsaicin with placebo or in adults with chronic pain. another treatment Data extraction Primary outcome was dichotomous information for the number of patients with around at least 50% pain reduction. Outcomes were extracted at four weeks for musculoskeletal conditions and eight weeks for neuropathic conditions. Secondary outcomes were adverse events mid withdrawals due to adverse events. Data synthesis Six double blind placebo controlled trials ( 56 patients) were pooled for analysis of neuropathic conditions. The relative benefit from topical capsaicin 0.075% compared with placebo was 1.4 (95% confidence interval 1.2 to 1.7) and the number needed to treat was 5.7 (4.0 to 10.0). Three double blind placebo controlled trials (368 patients) were pooled for analysis of musculoskeletal conditions. The relative benefit from topical capsaicin 0.025% or plaster compared with placebo was 1.5 (1.1 to 2.0) and die number needed to treat was S. 1 (4.6 to 34). Around one third of patients experienced local adverse events with capsaicin, which would not have been the case with placebo. Conclusions Although topically applied capsaicin has moderate to poor efficacy in the treatment of chronic musculoskeletal or neuropathic pain, it may be useful as an adjunct or sole therapy for a small number of patients who are unresponsive to, or intolerant of, other treatments.	Univ Oxford, Oxford Radcliffe Hosp, Nuffield Dept Anaesthet, Oxford OX3 7LJ, England	University of Oxford	Moore, RA (corresponding author), Univ Oxford, Oxford Radcliffe Hosp, Nuffield Dept Anaesthet, S Parks Rd, Oxford OX3 7LJ, England.	andrew.moore@pru.ox.ac.uk						ALTMAN RD, 1994, SEMIN ARTHRITIS RHEU, V23, P248, DOI 10.1016/0049-0172(94)90048-5; BERNSTEIN JE, 1989, J AM ACAD DERMATOL, V21, P265, DOI 10.1016/S0190-9622(89)70171-7; BIESBROECK R, 1995, ADV THER, V12, P111; *BRIT MED ASS ROYA, 2003, BRIT NAT FORM; CHAD DA, 1990, PAIN, V42, P387, DOI 10.1016/0304-3959(90)91153-A; COOK D, 1992, ANN INTERN MED, V117, pA16; DEAL CL, 1991, CLIN THER, V13, P383; DONOFRIO P, 1991, ARCH INTERN MED, V151, P2225; Ellison N, 1997, J CLIN ONCOL, V15, P2974, DOI 10.1200/JCO.1997.15.8.2974; Jadad AR, 1996, PAIN, V66, P239, DOI 10.1016/0304-3959(96)03033-3; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kalso E, 2000, EUR J PAIN-LONDON, V4, P321, DOI 10.1053/eujp.2000.0191; Keitel WG, 2001, ARZNEIMITTELFORSCH, V51, P896; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LOW PA, 1995, PAIN, V62, P163, DOI 10.1016/0304-3959(94)00261-C; MASON L, 2004, BMJ-BRIT MED J, DOI DOI 10.1136/BMJ.38040.3607141.EE; McCleane G, 2000, BRIT J CLIN PHARMACO, V49, P574, DOI 10.1046/j.1365-2125.2000.00200.x; MOORE R, 2003, BANDOLIERS LITTLE BO, P238; Moore RA, 1998, BRIT MED J, V316, P333, DOI 10.1136/bmj.316.7128.333; MORRIS JA, 1995, STAT CONFIDENCE CONF, P50; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; Nolano M, 1999, PAIN, V81, P135, DOI 10.1016/S0304-3959(99)00007-X; Paice JA, 2000, J PAIN SYMPTOM MANAG, V19, P45, DOI 10.1016/S0885-3924(99)00139-6; RAINS C, 1995, DRUG AGING, V7, P317, DOI 10.2165/00002512-199507040-00007; REYNOLDS JEF, 1999, MARTINDALE EXTRA PHA; Schnitzer T J, 1995, J Clin Rheumatol, V1, P268; Schnitzer Thomas, 1994, Seminars in Arthritis and Rheumatism, V23, P34, DOI 10.1016/S0049-0172(10)80024-1; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Tramer MR, 1997, BMJ-BRIT MED J, V315, P635, DOI 10.1136/bmj.315.7109.635; WATSON CPN, 1993, CLIN THER, V15, P510; WATSON CPN, 1992, PAIN, V51, P375, DOI 10.1016/0304-3959(92)90223-X; Winocur E, 2000, J OROFAC PAIN, V14, P31; ZHANG WY, 1994, EUR J CLIN PHARMACOL, V46, P517	33	269	288	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 24	2004	328	7446					991	994		10.1136/bmj.38042.506748.EE	http://dx.doi.org/10.1136/bmj.38042.506748.EE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	816SR	15033881	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000221130100017
J	Murry, CE; Soonpaa, MH; Reinecke, H; Nakajima, H; Nakajima, HO; Rubart, M; Pasumarthi, KBS; Virag, JI; Bartelmez, SH; Poppa, V; Bradford, G; Dowell, JD; Williams, DA; Field, LJ				Murry, CE; Soonpaa, MH; Reinecke, H; Nakajima, H; Nakajima, HO; Rubart, M; Pasumarthi, KBS; Virag, JI; Bartelmez, SH; Poppa, V; Bradford, G; Dowell, JD; Williams, DA; Field, LJ			Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts	NATURE			English	Article							MARROW-DERIVED CELLS; BONE-MARROW; PROGENITOR CELLS; IN-VIVO; CARDIOMYOCYTES; TRANSPLANTATION; HEART; REGENERATION; MUSCLE; MICE	The mammalian heart has a very limited regenerative capacity and, hence, heals by scar formation(1). Recent reports suggest that haematopoietic stem cells can transdifferentiate into unexpected phenotypes such as skeletal muscle(2,3), hepatocytes(4), epithelial cells(5), neurons(6,7), endothelial cells(8) and cardiomyocytes(8,9), in response to tissue injury or placement in a new environment. Furthermore, transplanted human hearts contain myocytes derived from extra-cardiac progenitor cells(10-12), which may have originated from bone marrow(8,13-15). Although most studies suggest that transdifferentiation is extremely rare under physiological conditions, extensive regeneration of myocardial infarcts was reported recently after direct stem cell injection(9), prompting several clinical trials(16,17). Here, we used both cardiomyocyte-restricted and ubiquitously expressed reporter transgenes to track the fate of haematopoietic stem cells after 145 transplants into normal and injured adult mouse hearts. No transdifferentiation into cardiomyocytes was detectable when using these genetic techniques to follow cell fate, and stem-cell-engrafted hearts showed no overt increase in cardiomyocytes compared to sham-engrafted hearts. These results indicate that haematopoietic stem cells do not readily acquire a cardiac phenotype, and raise a cautionary note for clinical studies of infarct repair.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Indiana Univ, Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Indiana University System; Indiana University-Purdue University Indianapolis; University of Washington; University of Washington Seattle	Murry, CE (corresponding author), Univ Washington, Dept Pathol, Box 357470,Room D-514 HSB, Seattle, WA 98195 USA.	murry@u.washington.edu; ljfield@iupui.edu	Virag, Jitka/AAW-6690-2020; Virag, Jitka Amira Ismail/AAW-7427-2020	Virag, Jitka Amira Ismail/0000-0003-3321-9861; Pasumarthi, Kishore/0000-0001-9317-076X				Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Badorff C, 2003, CIRCULATION, V107, P1024, DOI 10.1161/01.CIR.0000051460.85800.BB; Bittner RE, 1999, ANAT EMBRYOL, V199, P391, DOI 10.1007/s004290050237; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Deb A, 2003, CIRCULATION, V107, P1247, DOI 10.1161/01.CIR.0000061910.39145.F0; Dowell JD, 2003, CARDIOVASC RES, V58, P336, DOI 10.1016/S0008-6363(03)00254-2; Ferrari G, 1998, SCIENCE, V281, P923; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kudo M, 2003, J MOL CELL CARDIOL, V35, P1113, DOI 10.1016/S0022-2828(03)00211-6; Kuramochi Y, 2003, PEDIATR RES, V54, P319, DOI 10.1203/01.PDR.0000078275.14079.77; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Mallory GK, 1939, AM HEART J, V18, P647; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Muller P, 2002, CIRCULATION, V106, P31, DOI 10.1161/01.CIR.0000022405.68464.CA; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Reinecke H, 2002, J MOL CELL CARDIOL, V34, P241, DOI 10.1006/jmcc.2001.1507; Reinecke Hans, 2003, Methods Mol Biol, V219, P97; Rubart M, 2003, CIRC RES, V92, P1217, DOI 10.1161/01.RES.0000075089.39335.8C; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; Soonpaa MH, 1997, AM J PHYSIOL-HEART C, V272, pH220, DOI 10.1152/ajpheart.1997.272.1.H220; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Stripecke R, 1999, GENE THER, V6, P1305, DOI 10.1038/sj.gt.3300951; Virag JI, 2003, AM J PATHOL, V163, P2433, DOI 10.1016/S0002-9440(10)63598-5	30	1642	1829	1	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 8	2004	428	6983					664	668		10.1038/nature02446	http://dx.doi.org/10.1038/nature02446			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810IE	15034593				2022-12-28	WOS:000220697200047
J	Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH				Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH		US Preventive Services Task Force	Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: Recommendation statement	ANNALS OF INTERNAL MEDICINE			English	Article							PREGNANT-WOMEN; CONSUMPTION; AUDIT; CAGE	This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on behavioral counseling interventions to reduce alcohol misuse in primary care patients and updates the 1996 recommendations on this topic. The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the systematic evidence review on this topic. The complete USPSTF recommendation statement (which includes a brief review of the supporting evidence), the accompanying journal article, and the complete systematic evidence review are avail able through the USPSTF Web site (www.preventiveservices.ahrq.gov). The journal article and the USPSTF recommendation statement are available in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs@ahrq.gov).	CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Merck & Co Inc, West Point, PA USA; Columbia Univ, New York, NY USA; Virginia Commonwealth Univ, Fairfax, VA USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Merck & Company; Columbia University; Virginia Commonwealth University	Berg, AO (corresponding author), CUNY Mt Sinai Sch Med, New York, NY 10029 USA.							American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Anderson JE, 2002, CHEST, V121, P932, DOI 10.1378/chest.121.3.932; Babor T., 2001, BRIEF INTERVENTION H; Chang G, 2001, ALCOHOL RES HEALTH, V25, P204; DiClemente C.C., 2002, MOTIVATIONAL INTERVI, V2nd ed., P201; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Fiellin DA, 2000, ARCH INTERN MED, V160, P1977, DOI 10.1001/archinte.160.13.1977; FLEMING MF, 2000, IDENTIFICATION RISK; Knight JR, 2003, ALCOHOL CLIN EXP RES, V27, P67, DOI 10.1097/01.ALC.0000046598.59317.3A; Mukamal KJ, 2003, NEW ENGL J MED, V348, P109, DOI 10.1056/NEJMoa022095; *NAT I HLTH NAT I, 1997, TRAIN PHYS TECHN ALC; *NAT I HLTH NAT I, 2000, NIH PUBL; *NIAAA, 1995, NIH PUBL; Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38; Reid MC, 1999, ARCH INTERN MED, V159, P1681, DOI 10.1001/archinte.159.15.1681; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Whaley SE, 2003, AM J HEALTH PROMOT, V17, P369, DOI 10.4278/0890-1171-17.6.369; Whitlock EP, 2002, AM J PREV MED, V22, P267, DOI 10.1016/S0749-3797(02)00415-4; World Health Organisation, 1993, ICD 10 CLASSIFICATIO	19	272	276	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 6	2004	140	7					554	556		10.7326/0003-4819-140-7-200404060-00016	http://dx.doi.org/10.7326/0003-4819-140-7-200404060-00016			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808OE	15068984				2022-12-28	WOS:000220577600008
J	Lilford, R; Mohammed, MA; Spiegelhalter, D; Thomson, R				Lilford, R; Mohammed, MA; Spiegelhalter, D; Thomson, R			Use and misuse of process and outcome data in managing performance of acute medical care: avoiding institutional stigma	LANCET			English	Article							ADJUSTED SURGICAL OUTCOMES; PROSPECTIVE PAYMENT SYSTEM; NEW-YORK-STATE; INTENSIVE-CARE; MORTALITY-RATES; MYOCARDIAL-INFARCTION; CLINICAL GOVERNANCE; QUALITY IMPROVEMENT; RISK ADJUSTMENT; CARDIAC-SURGERY	The history of monitoring the outcomes of health care by external agencies can be traced to ancient times. However, the danger, now as then, is that in the search for improvement, comparative measures of mortality and morbidity are often overinterpreted, resulting in judgments about the underlying quality of care. Such judgments can translate into performance management strategies in the form of capricious sanctions (such as star ratings) and unjustified rewards (such as special freedoms or financial allocations). The resulting risk of stigmatising an entire institution injects huge tensions into health-care organisations and can divert attention from genuine improvement towards superficial improvement or even gaming behaviour (ie, manipulating the system). These dangers apply particularly to measures of outcome and throughput. We argue that comparative outcome data (league tables) should not be used by external agents to make judgments about quality of hospital care. Although they might provide a reasonable measure of quality in some high-risk surgical situations, they have little validity in acute medical settings. Their use to support a system of reward and punishment is unfair and, unsurprisingly, often resisted by clinicians and managers. We argue further that although outcome data are useful for research and monitoring trends within an organisation, those who wish to improve care for patients and not penalise doctors and managers, should concentrate on direct measurement of adherence to clinical and managerial standards.	Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Publ Hlth & Epidemiol, Birmingham B15 2TT, W Midlands, England; Univ Newcastle, Sch Populat & Hlth Sci Epidemiol & Publ Hlth, Newcastle Upon Tyne, Tyne & Wear, England; Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England	University of Birmingham; University of Birmingham; Newcastle University - UK; MRC Biostatistics Unit; University of Cambridge	Lilford, R (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England.	R.J.Lilford@Bham.ac.uk						Aiken LH, 2002, JAMA-J AM MED ASSOC, V288, P1987, DOI 10.1001/jama.288.16.1987; [Anonymous], 2001, SUNDAY TIMES; ASH AS, 1997, RISK ADJUSTMENT MEAS, P427; Aylin P, 2001, LANCET, V358, P181, DOI 10.1016/S0140-6736(01)05404-6; Baker R, 2003, BRIT MED J, V326, P274, DOI 10.1136/bmj.326.7383.274; BATES DW, 1995, MED CARE, V33, P452, DOI 10.1097/00005650-199505000-00002; BEST WR, 1994, MED CARE, V32, P390, DOI 10.1097/00005650-199404000-00007; Blumberg M S, 1986, Med Care Rev, V43, P351, DOI 10.1177/107755878604300205; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Burack JH, 1999, ANN THORAC SURG, V68, P1195, DOI 10.1016/S0003-4975(99)00907-8; Carey J S, 1998, Bull Am Coll Surg, V83, P24; Carmel S, 2001, Curr Opin Crit Care, V7, P284, DOI 10.1097/00075198-200108000-00013; Carthey J, 2003, SAFETY SCI, V41, P409, DOI 10.1016/S0925-7535(01)00076-5; Chambler AFW, 1997, ANN ROY COLL SURG, V79, P174; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; Daley J, 2001, ANNU REV MED, V52, P275, DOI 10.1146/annurev.med.52.1.275; Daley J, 1997, J AM COLL SURGEONS, V185, P341, DOI 10.1016/S1072-7515(97)00091-4; DALEY J, 1997, RISK ADJUSTMENT MEAS, P331; DAVIES HTO, 1995, BRIT MED J, V311, P766, DOI 10.1136/bmj.311.7008.766; Deming EW., 1986, OUT CRISIS; *DEP HLTH, 2002, NAT SURV NHS PAT CAN; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; Dunn PM, 1998, BRIT MED J, V317, P1144; Ebrahim S, 2000, BRIT MED J, V320, P1155, DOI 10.1136/bmj.320.7243.1155; Edhouse JA, 1996, J ACCID EMERG MED, V13, P123; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; EPSTEIN AM, 1990, NEW ENGL J MED, V323, P266, DOI 10.1056/NEJM199007263230410; FEY CF, 2000, SERIES BUSINESS ADM, V2000; Freeman C, 2002, QUAL SAF HEALTH CARE, V11, P239, DOI 10.1136/qhc.11.3.239; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; Gibbs J, 2001, INT J QUAL HEALTH C, V13, P187, DOI 10.1093/intqhc/13.3.187; Glance LG, 2002, CRIT CARE MED, V30, P1976, DOI 10.1097/00003246-200209000-00005; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P385, DOI 10.2307/2983325; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; Gunning K, 1999, BRIT MED J, V319, P241, DOI 10.1136/bmj.319.7204.241; Gupta N, 2002, J INTENSIVE CARE MED, V17, P211, DOI 10.1177/088506602237105; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HARTZ AJ, 1994, AM J PUBLIC HEALTH, V84, P1609, DOI 10.2105/AJPH.84.10.1609; HAYWARD RA, 1993, MED CARE, V31, P394, DOI 10.1097/00005650-199305000-00002; HENDERSON J, 1992, J EPIDEMIOL COMMUN H, V46, P297, DOI 10.1136/jech.46.3.297; HUSELID MA, 1995, ACAD MANAGE J, V38, P635, DOI 10.2307/256741; Iezzoni LI, 1997, JAMA-J AM MED ASSOC, V278, P1600, DOI 10.1001/jama.278.19.1600; Iezzoni LI, 2012, RISK ADJUSTMENT MEAS, V4th; Inquiry. BRI Inquiry Panel, 2001, LEARN BRIST REP PUBL; Institute of Medicine, 2001, CROSSING QUALITY CHA; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; Julious SA, 2000, BRIT J SURG, V87, P8, DOI 10.1046/j.1365-2168.2000.01328.x; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; Kaska SC, 1998, SPINE, V23, P629, DOI 10.1097/00007632-199803010-00019; Khuri SF, 2002, ARCH SURG-CHICAGO, V137, P20, DOI 10.1001/archsurg.137.1.20; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; Koch MJ, 1996, STRATEGIC MANAGE J, V17, P335; Krumholz HM, 2002, JAMA-J AM MED ASSOC, V287, P1277, DOI 10.1001/jama.287.10.1277; KUHN EM, 1994, MED CARE, V32, P1098, DOI 10.1097/00005650-199411000-00003; Landrum MB, 2000, HLTH SERVICES OUTCOM, V1, P23, DOI [10.1023/A:1010093701870, DOI 10.1023/A:1010093701870]; LEHRER S, 1979, EXPLORERS BODY; Lilford R J, 2003, Health Serv Manage Res, V16, P147, DOI 10.1258/095148403322167906; Lilford RJ, 2003, QUAL SAF HEALTH CARE, V12, pII8, DOI 10.1136/qhc.12.suppl_2.ii8; Mant J, 2001, INT J QUAL HEALTH C, V13, P475, DOI 10.1093/intqhc/13.6.475; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; Marshall MN, 2000, JAMA-J AM MED ASSOC, V283, P1866, DOI 10.1001/jama.283.14.1866; Mason S, 2002, BRIT MED J, V324, P419, DOI 10.1136/bmj.324.7334.419; McKee M, 1995, Qual Health Care, V4, P5, DOI 10.1136/qshc.4.1.5; McNaughton H, 2003, STROKE, V34, P713, DOI 10.1161/01.STR.0000057580.23952.0D; McQuillan P, 1998, BMJ-BRIT MED J, V316, P1853; Meehan TP, 1997, JAMA-J AM MED ASSOC, V278, P2080, DOI 10.1001/jama.278.23.2080; Mohammed MA, 2001, LANCET, V357, P463, DOI 10.1016/S0140-6736(00)04019-8; MULLEY A, 1994, OUTCOMES CLIN PRACTI, P13; Neale G, 2001, J ROY SOC MED, V94, P322, DOI 10.1177/014107680109400702; Nelson EC, 1998, ANN INTERN MED, V128, P460, DOI 10.7326/0003-4819-128-6-199803150-00007; NORMAND SL, 1997, JAMA-J AM MED ASSOC, V92, P802; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; Pfeffer J., 1995, ACAD MANAGEMENT EXEC, V9, P55; Pronovost P J, 2001, Curr Opin Crit Care, V7, P297, DOI 10.1097/00075198-200108000-00014; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; Scally G, 1998, BRIT MED J, V317, P61, DOI 10.1136/bmj.317.7150.61; Shahian DM, 2001, ANN THORAC SURG, V72, P2155, DOI 10.1016/S0003-4975(01)03222-2; Sirio CA, 1999, CHEST, V115, P793, DOI 10.1378/chest.115.3.793; Spiegelhalter D, 2003, INT J QUAL HEALTH C, V15, P7, DOI 10.1093/intqhc/15.1.7; Spiegelhalter DJ, 1999, J ROY STAT SOC A STA, V162, P45, DOI 10.1111/1467-985X.00120; *STAT OFF, 2002, 1 STAT OFF; THOMAS JW, 1993, INQUIRY-J HEALTH CAR, V30, P6; Thomas JW, 1998, MED CARE RES REV, V55, P371, DOI 10.1177/107755879805500401; Thomson RG, 2000, QUAL HEALTH CARE, V9, P201, DOI 10.1136/qhc.9.4.201; Treasure Tom, 2002, Health Care Manag Sci, V5, P243, DOI 10.1023/A:1020373921395; Vaughan-Sarrazin MS, 2002, JAMA-J AM MED ASSOC, V288, P1859, DOI 10.1001/jama.288.15.1859; WEST MA, 2002, INT J HUMAN RES MANA, V13, P1310; Wilson B, 2002, INT J QUAL HEALTH C, V14, P175, DOI 10.1093/oxfordjournals.intqhc.a002609; Young M P, 2000, Eff Clin Pract, V3, P284	90	336	342	1	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	2004	363	9415					1147	1154		10.1016/S0140-6736(04)15901-1	http://dx.doi.org/10.1016/S0140-6736(04)15901-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	808VB	15064036				2022-12-28	WOS:000220595500025
J	Cummins, JM; Rago, C; Kohli, M; Kinzler, KW; Lengauer, C; Vogelstein, B				Cummins, JM; Rago, C; Kohli, M; Kinzler, KW; Lengauer, C; Vogelstein, B			Disruption of HAUSP gene stabilizes p53	NATURE			English	Editorial Material							EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; RESCUE		Johns Hopkins Univ, Inst Med, Howard Hughes Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Inst Med, Program Mol & Cellular Biol, Baltimore, MD 21231 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Cummins, JM (corresponding author), Johns Hopkins Univ, Inst Med, Howard Hughes Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.	vogelbe@welch.jhu.edu						Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Haupt Ygal, 2002, Oncogene, V21, P8223, DOI 10.1038/sj.onc.1206137; Hirata R, 2002, NAT BIOTECHNOL, V20, P735, DOI 10.1038/nbt0702-735; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KOHLI M, 2004, NUCLEIC ACIDS RES, V32, P1; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; LUNA RMD, 1995, NATURE, V378, P203; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WOOD SA, 2002, SCI STKE, pPE34	12	229	235	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982								10.1038/nature02501	http://dx.doi.org/10.1038/nature02501			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15058298				2022-12-28	WOS:000220540100030
J	Paddison, PJ; Silva, JM; Conklin, DS; Schlabach, M; Li, MM; Aruleba, S; Balija, V; O'Shaughnessy, A; Gnoj, L; Scobie, K; Chang, K; Westbrook, T; Cleary, M; Sachidanandam, R; McCombie, WR; Elledge, SJ; Hannon, GJ				Paddison, PJ; Silva, JM; Conklin, DS; Schlabach, M; Li, MM; Aruleba, S; Balija, V; O'Shaughnessy, A; Gnoj, L; Scobie, K; Chang, K; Westbrook, T; Cleary, M; Sachidanandam, R; McCombie, WR; Elledge, SJ; Hannon, GJ			A resource for large-scale RNA-interference-based screens in mammals	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE GENOME; PROTEASOME; CELLS; EXPRESSION; SHRNAS; GENES	Gene silencing by RNA interference (RNAi) in mammalian cells using small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) has become a valuable genetic tool(1-10). Here, we report the construction and application of a shRNA expression library targeting 9,610 human and 5,563 mouse genes. This library is presently composed of about 28,000 sequence-verified shRNA expression cassettes contained within multi-functional vectors, which permit shRNA cassettes to be packaged in retroviruses, tracked in mixed cell populations by means of DNA 'bar codes', and shuttled to customized vectors by bacterial mating. In order to validate the library, we used a genetic screen designed to report defects in human proteasome function. Our results suggest that our large-scale RNAi library can be used in specific, genetic applications in mammals, and will become a valuable resource for gene analysis and discovery.	Watson Sch Biol Sci, Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Baylor Coll Med, Howard Hughes Med Inst, Dept Biochem, Houston, TX 77030 USA; Rosetta Inpharmat, Kirkland, WA 98034 USA	Cold Spring Harbor Laboratory; Baylor College of Medicine; Howard Hughes Medical Institute; Merck & Company	Hannon, GJ (corresponding author), Watson Sch Biol Sci, Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	selledge@genetics.med.harvard.edu; hannon@cshl.org	Hannon, Gregory/AAB-3568-2019; sachidanandam, ravi/Q-6916-2019	sachidanandam, ravi/0000-0001-9844-4459; Conklin, Douglas/0000-0003-4922-4307; McCombie, W. Richard/0000-0003-1899-0682				Birrell GW, 2001, P NATL ACAD SCI USA, V98, P12608, DOI 10.1073/pnas.231366398; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Coux O, 2003, BIOCHEM SOC T, V31, P465, DOI 10.1042/BST0310465; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2003, CURR OPIN MOL THER, V5, P217; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	19	559	626	2	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	2004	428	6981					427	431		10.1038/nature02370	http://dx.doi.org/10.1038/nature02370			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042091				2022-12-28	WOS:000220404300043
J	Lerman, C; Kaufmann, V; Rukstalis, M; Patterson, F; Perkins, K; Audrain-McGovern, J; Benowitz, N				Lerman, C; Kaufmann, V; Rukstalis, M; Patterson, F; Perkins, K; Audrain-McGovern, J; Benowitz, N			Individualizing nicotine replacement therapy for the treatment of tobacco dependence	ANNALS OF INTERNAL MEDICINE			English	Article							SMOKING-CESSATION; NASAL SPRAY; TRIAL; COTININE; SMOKERS; PATCH; PREDICTORS; DOPAMINE; PHARMACOTHERAPY; QUIT	Background: Despite the well-documented efficacy and different pharmacokinetic and pharmacodynamic properties of different forms of nicotine replacement therapy, empirical data are insufficient to guide practitioners in selecting a particular form of treatment for individual patients with tobacco dependence. Objective: To evaluate the comparative efficacy of transdermal nicotine and nicotine nasal spray and identify predictors of treatment outcome. Design: Randomized, open-label clinical trial with a 6-month follow-up period. Setting: 2 university-based smoking cessation research programs. Participants: 299 treatment-seeking smokers who were followed for 6 months after the target quit date. Intervention: Behavioral group counseling and 8 weeks of therapy with nicotine nasal spray or transdermal nicotine. Measurements: Demographic characteristics, smoking history, depression symptoms, and body mass index were measured at baseline. Smoking practices were biochemically verified at the end of treatment and at 6 months after the target quit date. Results: Abstinence rates for the transdermal nicotine and nicotine nasal spray groups were not significantly different at 6-month follow-up (15.0% vs. 12.2%, respectively; P > 0.2). Interactions in abstinence rates for subgroups of smokers were statistically significant (P < 0.05). Smokers who had low to moderate dependence levels, were not obese, and were white achieved higher abstinence rates with transdermal nicotine, whereas smokers who were highly dependent, obese, or members of minority groups achieved higher abstinence rates with nasal spray. Limitations: The subgroup findings need confirmation in additional large studies before they are routinely applied. Conclusions: Ethnicity, weight, and level of nicotine dependence may help identify smokers who have greater or lesser abstinence rates with either transdermal or nasal spray nicotine.	Univ Penn, Transdisciplinary Tobacco Use Res Ctr, Philadelphia, PA 19104 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco	Lerman, C (corresponding author), Univ Penn, Transdisciplinary Tobacco Use Res Ctr, 3535 Market St,Suite 4100, Philadelphia, PA 19104 USA.		Patterson, Freda/T-9389-2019; Perkins, Kenneth A/E-4085-2010; Lerman, Caryn/AHC-5180-2022	Patterson, Freda/0000-0001-6561-3092	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002277, R37DA002277, P30DA012393] Funding Source: NIH RePORTER; NCI NIH HHS [CA078703] Funding Source: Medline; NCRR NIH HHS [M01-RR0040] Funding Source: Medline; NIDA NIH HHS [DA12393, DA02277] Funding Source: Medline; PHS HHS [P5084718] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1991, JAMA, V266, P3133; Benowitz NL, 1996, ANNU REV PHARMACOL, V36, P597, DOI 10.1146/annurev.pa.36.040196.003121; Brown RA, 1998, PSYCHOL ADDICT BEHAV, V12, P101, DOI 10.1037/0893-164X.12.2.101; Caraballo RS, 1998, JAMA-J AM MED ASSOC, V280, P135, DOI 10.1001/jama.280.2.135; Clark PI, 1996, CHEST, V110, P1194, DOI 10.1378/chest.110.5.1194; Epstein LH, 2000, REFRAMING HEALTH BEHAVIOR CHANGE WITH BEHAVIORAL ECONOMICS, P293; Epstein LH, 2002, OBES RES, V10, P1232, DOI 10.1038/oby.2002.168; Fiore MC, 2000, JAMA-J AM MED ASSOC, V283, P3244; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; FIORE MC, 1994, CHEST, V105, P524, DOI 10.1378/chest.105.2.524; Gilpin EA, 2002, ANN EPIDEMIOL, V12, P141, DOI 10.1016/S1047-2797(01)00266-6; Hajek P, 1999, ARCH INTERN MED, V159, P2033, DOI 10.1001/archinte.159.17.2033; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; HENNINGFIELD JE, 1993, J CONSULT CLIN PSYCH, V61, P743, DOI 10.1037/0022-006X.61.5.743; HENNINGFIELD JE, 1995, NEW ENGL J MED, V333, P1196, DOI 10.1056/NEJM199511023331807; HJALMARSON A, 1994, ARCH INTERN MED, V154, P2567, DOI 10.1001/archinte.154.22.2567; HUGHES JR, 1993, J CONSULT CLIN PSYCH, V61, P751, DOI 10.1037/0022-006X.61.5.751; Hughes JR, 2003, NICOTINE TOB RES, V5, P13, DOI 10.1080/1462220031000070552; Hughes JR, 1999, JAMA-J AM MED ASSOC, V281, P72, DOI 10.1001/jama.281.1.72; HYMOWITZ N, 1995, PREV MED, V24, P503, DOI 10.1006/pmed.1995.1080; JACOB P, 1981, J CHROMATOGR, V222, P61, DOI 10.1016/S0378-4347(00)81033-6; JOHANSSON CJ, 1991, EUR J CLIN PHARMACOL, V41, P585, DOI 10.1007/BF00314989; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; Kiefe CI, 2001, AM J PUBLIC HEALTH, V91, P213, DOI 10.2105/AJPH.91.2.213; Lawson GM, 1998, J CLIN PHARMACOL, V38, P502, DOI 10.1002/j.1552-4604.1998.tb05787.x; Lerman C, 1999, HEALTH PSYCHOL, V18, P14, DOI 10.1037/0278-6133.18.1.14; NOBLE EP, 1994, MED HYPOTHESES, V42, P257, DOI 10.1016/0306-9877(94)90127-9; NORREGAARD J, 1993, PREV MED, V22, P261, DOI 10.1006/pmed.1993.1021; Paoletti P, 1996, EUR RESPIR J, V9, P643, DOI 10.1183/09031936.96.09040643; Patterson F, 2003, DRUG ALCOHOL DEPEN, V72, P123, DOI 10.1016/S0376-8716(03)00194-7; Perez-Stable EJ, 1998, JAMA-J AM MED ASSOC, V280, P152, DOI 10.1001/jama.280.2.152; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Piper M E, 2001, Nicotine Tob Res, V3, P291; PRATHER RD, 1993, J CLIN PHARMACOL, V33, P644, DOI 10.1002/j.1552-4604.1993.tb04718.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SALAMONE JD, 1994, BEHAV BRAIN RES, V61, P117, DOI 10.1016/0166-4328(94)90153-8; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; SRNT Subcommittee on Biochemical Verification, 2002, Nicotine Tob Res, V4, P149, DOI 10.1080/14622200210123581; STAPLETON JA, 1995, ADDICTION, V90, P31, DOI 10.1046/j.1360-0443.1995.901316.x; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; SUTHERLAND G, 1992, LANCET, V340, P324, DOI 10.1016/0140-6736(92)91403-U; Swan GE, 1997, ADDICTION, V92, P207, DOI 10.1046/j.1360-0443.1997.9222079.x; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; West R, 2001, PSYCHOPHARMACOLOGY, V153, P225, DOI 10.1007/s002130000577; Westman EC, 1997, ARCH INTERN MED, V157, P335, DOI 10.1001/archinte.157.3.335; Wetter DW, 1999, J CONSULT CLIN PSYCH, V67, P555, DOI 10.1037/0022-006X.67.4.555	46	82	85	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 16	2004	140	6					426	433		10.7326/0003-4819-140-6-200403160-00009	http://dx.doi.org/10.7326/0003-4819-140-6-200403160-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	803AU	15023708				2022-12-28	WOS:000220204800003
J	Wilson, JF				Wilson, JF			Risks from microbes on the rise: Reasons why and ways to prevent future epidemics	ANNALS OF INTERNAL MEDICINE			English	News Item												jenwilson@acponline.org	Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136					0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 16	2004	140	6					497	500		10.7326/0003-4819-140-6-200403160-00040	http://dx.doi.org/10.7326/0003-4819-140-6-200403160-00040			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803AU	15023731				2022-12-28	WOS:000220204800029
J	Oktay, K; Buyuk, E; Veeck, L; Zaninovic, N; Xu, KP; Takeuchi, T; Opsahl, M; Rosenwaks, Z				Oktay, K; Buyuk, E; Veeck, L; Zaninovic, N; Xu, KP; Takeuchi, T; Opsahl, M; Rosenwaks, Z			Embryo development after heterotopic transplantation of cryopreserved ovarian tissue	LANCET			English	Article							CORTICAL STRIPS; FERTILITY; QUALITY; SHEEP; IVF	Background Cancer treatments, including chemotherapy, radiotherapy, and radical surgery, can induce premature menopause and infertility in hundreds of thousands of women of reproductive age every year. One of the ways to possibly preserve fertility before these treatments is to cryopreserve ovarian tissue for later transplantation. We aimed to restore fertility by cryopreservation and transplantation of ovarian tissue. Methods Ovarian tissue was cryopreserved from a 30-year-old woman with breast cancer before chemotherapy-induced menopause, and this tissue was transplanted beneath the skin of her abdomen 6 years later. Findings Ovarian function returned in the patient 3 months after transplantation, as shown by follicle development and oestrogen production. The patient underwent eight oocyte retrievals percutaneously and 20 oocytes were retrieved. Of the eight oocytes suitable for in-vitro fertilisation, one fertilised normally and developed into a four-cell embryo, Interpretation Fertility and ovarian endocrine function can be preserved in women by long-term ovarian tissue banking.	Cornell Univ, Joan & Sanford I Weill Med Coll, Ctr Reprod Med & Infertil, New York, NY 10021 USA; Genet & IVF Inst, Fairfax, VA 22031 USA	Cornell University	Oktay, K (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Ctr Reprod Med & Infertil, 505 E 70th St,HT-340, New York, NY 10021 USA.	kuo9001@med.cornell.edu	Buyuk, Erkan/E-9611-2012	Opsahl, Michael/0000-0002-8754-7943				Baird DT, 1999, ENDOCRINOLOGY, V140, P462, DOI 10.1210/en.140.1.462; Chian RC, 2004, REPROD BIOMED ONLINE, V8, P148, DOI 10.1016/S1472-6483(10)60511-1; CLAMAN P, 1987, J IN VITRO FERTIL EM, V4, P218, DOI 10.1007/BF01533759; FADDY MJ, 1995, HUM REPROD, V10, P770, DOI 10.1093/oxfordjournals.humrep.a136036; GOSDEN RG, 1994, HUM REPROD, V9, P597, DOI 10.1093/oxfordjournals.humrep.a138556; Gunasena KT, 1997, HUM REPROD, V12, P101, DOI 10.1093/humrep/12.1.101; LEWIN A, 1994, J ASSIST REPROD GEN, V11, P500, DOI 10.1007/BF02216029; MUNNE S, 1993, HUM REPROD, V8, P2185, DOI 10.1093/oxfordjournals.humrep.a138001; Oktay K, 1998, HUM REPROD, V13, P1133, DOI 10.1093/humrep/13.5.1133; Oktay K, 2000, NEW ENGL J MED, V342, P1919, DOI 10.1056/NEJM200006223422516; Oktay K, 2001, JAMA-J AM MED ASSOC, V286, P1490, DOI 10.1001/jama.286.12.1490; Oktay K, 2003, HUM REPROD, V18, P90, DOI 10.1093/humrep/deg045; Oktay K, 2003, FERTIL STERIL, V80, P193, DOI 10.1016/S0015-0282(03)00568-5; Oktay K, 2001, HUM REPROD UPDATE, V7, P526, DOI 10.1093/humupd/7.6.526; OKTAY K, 2003, COLOR ATLAS HUMAN AS, P229; OKTAY K, 2001, TXB ASSISTED REPROD, P279; SCOTT RT, 1989, J IN VITRO FERTIL EM, V6, P73, DOI 10.1007/BF01130729; VEECK LL, 1985, ANN NY ACAD SCI, V442, P357, DOI 10.1111/j.1749-6632.1985.tb37540.x; Veeck LL., 1999, ATLAS HUMAN GAMETES, V40; Veeck LL, 1990, HDB LAB DIAGNOSIS TR, P353; Zhu JJ, 1997, J ASSIST REPROD GEN, V14, P245, DOI 10.1007/BF02765824	21	404	432	1	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	2004	363	9412					837	840		10.1016/S0140-6736(04)15728-0	http://dx.doi.org/10.1016/S0140-6736(04)15728-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15031026				2022-12-28	WOS:000220231500007
J	Singer, JB; Hill, AE; Burrage, L; Olszens, KR; Song, JH; Justice, M; O'Brien, WE; Conti, DV; Witte, JS; Lander, ES; Nadeau, JH				Singer, JB; Hill, AE; Burrage, L; Olszens, KR; Song, JH; Justice, M; O'Brien, WE; Conti, DV; Witte, JS; Lander, ES; Nadeau, JH			Genetic dissection of complex traits with chromosome substitution strains of mice	SCIENCE			English	Article							LABORATORY MICE; SUSCEPTIBILITY; BEHAVIOR; OBESITY; MODELS; LOCUS	Chromosome substitution strains (CSSs) have been proposed as a simple and powerful way to identify quantitative trait loci (QTLs) affecting developmental, physiological, and behavioral processes. Here, we report the construction of a complete CSS panel for a vertebrate species. The CSS panel consists of 22 mouse strains, each of which carries a single chromosome substituted from a donor strain (A/J) onto a common host background (C57BL/6J). A survey of 53 traits revealed evidence for 150 QTLs affecting serum levels of sterols and amino acids, diet-induced obesity, and anxiety. These results demonstrate that CSSs greatly facilitate the detection and identification of genes that control the wide diversity of naturally occurring phenotypic variation in the A/J and C57BL/6J inbred strains.	Broad Inst, Cambridge, MA 02142 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Computat Genom & Syst Biol, Cleveland, OH 44106 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Hosp Cleveland, Ctr Human Genet, Cleveland, OH 44106 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Case Western Reserve University; Case Western Reserve University; Baylor College of Medicine; Case Western Reserve University; Massachusetts Institute of Technology (MIT); University Hospitals of Cleveland	Lander, ES (corresponding author), Broad Inst, Cambridge, MA 02142 USA.	lander@broad.mit.edu; jhn4@cwru.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR012305] Funding Source: NIH RePORTER; NCRR NIH HHS [RR12305] Funding Source: Medline; NICHD NIH HHS [HD07518] Funding Source: Medline; NIGMS NIH HHS [GM07250] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBURNER M, 1997, GENETICS BIOL DROSOP; Belknap JK, 2003, MAMM GENOME, V14, P723, DOI 10.1007/s00335-003-2264-1; Brockmann GA, 2002, TRENDS GENET, V18, P367, DOI 10.1016/S0168-9525(02)02703-8; Cowley AW, 2001, HYPERTENSION, V37, P456, DOI 10.1161/01.HYP.37.2.456; Crawley Jacqueline N., 2007, WHATS WRONG MY MOUSE; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Festing MFW, 1979, INBRED STRAINS BIOME; FLINT J, 1995, SCIENCE, V269, P1432, DOI 10.1126/science.7660127; Gershenfeld HK, 1997, BEHAV GENET, V27, P201, DOI 10.1023/A:1025653812535; Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1989, GENETICS, V121, P185; Matin A, 1999, NAT GENET, V23, P237, DOI 10.1038/13874; Nadeau JH, 2000, NAT GENET, V24, P221, DOI 10.1038/73427; Roman RJ, 2002, COLD SPRING HARB SYM, V67, P309, DOI 10.1101/sqb.2002.67.309; Santos J, 2002, ONCOGENE, V21, P6680, DOI 10.1038/sj.onc.1205846; SCRIVER CR, 2001, METABOLIC MOL BASIS, V2; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; Turri MG, 2001, GENETICS, V158, P1217; Youngren KK, 2003, HUM MOL GENET, V12, P389, DOI 10.1093/hmg/ddg036; Zhang SM, 2003, OBES RES, V11, P828, DOI 10.1038/oby.2003.114	22	267	282	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	2004	304	5669					445	448		10.1126/science.1093139	http://dx.doi.org/10.1126/science.1093139			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	812NE	15031436				2022-12-28	WOS:000220845400050
J	Hardy, SE; Gill, TM				Hardy, SE; Gill, TM			Recovery from disability among community-dwelling older persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the American-Geriatrics-Society	MAY 14-18, 2003	BALTIMORE, MD	Amer Geriatr Soc			PHYSICAL PERFORMANCE; FUNCTIONAL DEPENDENCE; RESTRICTED ACTIVITY; RISK-FACTORS; PEOPLE; POPULATION; DECLINE; UNDERESTIMATION; IMPAIRMENTS; IMPACT	Context Previous studies have found that a sizeable minority of newly disabled older persons recover independent function; however, long intervals between assessments have led to difficulty in determining the true incidence and duration of disability, and therefore in accurately characterizing the probability and course of recovery. Objectives To determine the rate of and time to recovery of independent function in community-dwelling older persons who become newly disabled in their activities of daily living (ADLs), to determine the duration of recovery, and to compare the likelihood of recovery among pertinent subgroups of older persons. Design, Setting, and Participants Prospective cohort study, with monthly assessments of ADL function, for 754 initially nondisabled, community-dwelling persons aged 70 years or older, performed in a small urban area from March 1998 to May 2003. Main Outcome Measures Demographic features, chronic conditions, cognitive function, and physical frailty were determined during comprehensive assessments at 18-month intervals. Disability, defined as needing personal assistance with 1 or more key ADLs (bathing, dressing, walking, and transferring), was assessed during monthly telephone interviews. Results A total of 420 participants (56%) experienced disability during a median follow-up of 51 months. Of these participants, 399 (81%) recovered (ie, regained independence in all 4 ADLs) within 12 months of their initial disability episode, and a majority (57%) of these maintained independence for at least 6 months. Among participants who experienced 3 or more consecutive months of disability, a majority (60%) recovered, but only a third of these maintained independence for at least 6 months. Persons who were cognitively impaired, physically frail, or severely disabled (ie, in 3-4 ADLs) at onset were less likely to recover than those who were cognitively intact, non-frail, or mildly disabled, respectively. Nonetheless, a majority of participants within each subgroup recovered. Conclusions Newly disabled older persons recover independent ADL function at rates far exceeding those that have been previously reported. Recovery from disability, however, is often short-lasting, suggesting that additional efforts are warranted to maintain independence in this high-risk group.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA	Yale University	Hardy, SE (corresponding author), 20 York St,Tompkins Bsmt 15, New Haven, CT 06504 USA.	susan.hardy@yale.edu	Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368	NATIONAL INSTITUTE ON AGING [R01AG001934, K23AG000759, K24AG021507, R01AG017560] Funding Source: NIH RePORTER; NIA NIH HHS [K23AG00759, K24AG021507, R01AG17560, T32AG1934] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 2000, SAS STAT US GUID VER; Beckett LA, 1996, AM J EPIDEMIOL, V143, P766; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; Buchner D M, 1992, Clin Geriatr Med, V8, P1; de Leon CFM, 1999, J GERONTOL B-PSYCHOL, V54, pS162, DOI 10.1093/geronb/54B.3.S162; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR; Ferroni MA, 1996, EUR J CLIN PHARMACOL, V51, P23, DOI 10.1007/s002280050155; Ferrucci L, 1997, JAMA-J AM MED ASSOC, V277, P728; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GILL TM, 1995, J GERONTOL A-BIOL, V50, pM235, DOI 10.1093/gerona/50A.5.M235; Gill TM, 2002, NEW ENGL J MED, V347, P1068, DOI 10.1056/NEJMoa020423; Gill TM, 2003, AM J EPIDEMIOL, V158, P1090, DOI 10.1093/aje/kwg237; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; Gill TM, 2003, ARCH INTERN MED, V163, P1317, DOI 10.1001/archinte.163.11.1317; Gill TM, 2003, J GERONTOL A-BIOL, V58, P70; Gill TM, 1996, J GERONTOL A-BIOL, V51, pM283, DOI 10.1093/gerona/51A.6.M283; Gill TM, 1997, J GEN INTERN MED, V12, P757, DOI 10.1046/j.1525-1497.1997.07161.x; Gill TM, 2002, J AM GERIATR SOC, V50, P1492, DOI 10.1046/j.1532-5415.2002.50403.x; Gill TM, 2001, ANN INTERN MED, V135, P313, DOI 10.7326/0003-4819-135-5-200109040-00007; Gill TM, 1999, J GERONTOL A-BIOL, V54, pM377, DOI 10.1093/gerona/54.7.M377; GILL TM, IN PRESS ARCH PHYS M; Guralnik JM, 2000, J GERONTOL A-BIOL, V55, pM221, DOI 10.1093/gerona/55.4.M221; Guralnik JM, 2002, J AM GERIATR SOC, V50, P1599, DOI 10.1046/j.1532-5415.2002.50421.x; Hansen K, 1999, J AM GERIATR SOC, V47, P360, DOI 10.1111/j.1532-5415.1999.tb03002.x; Hardy SE, 2002, J GEN INTERN MED, V17, P841, DOI 10.1046/j.1525-1497.2002.20105.x; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; Kempen GIJM, 1998, AGE AGEING, V27, P595, DOI 10.1093/ageing/27.5.595; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MAGAZINER J, 1990, J GERONTOL, V45, pM101, DOI 10.1093/geronj/45.3.M101; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; Rodgers W, 1997, J GERONTOL B-PSYCHOL, V52, P21, DOI 10.1093/geronb/52B.Special_Issue.21; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; Studenski S, 2003, J AM GERIATR SOC, V51, P314, DOI 10.1046/j.1532-5415.2003.51104.x; Szklo M, 1998, EPIDEMIOL REV, V20, P81, DOI 10.1093/oxfordjournals.epirev.a017974; *US BUR CENS, AM FACTF; VERBRUGGE LM, 1994, J HEALTH SOC BEHAV, V35, P97, DOI 10.2307/2137359; VERBRUGGE LM, 1989, MILBANK Q, V67, P450, DOI 10.2307/3350223	39	257	256	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2004	291	13					1596	1602		10.1001/jama.291.13.1596	http://dx.doi.org/10.1001/jama.291.13.1596			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	809PQ	15069047	Bronze			2022-12-28	WOS:000220649000024
J	Mason, C; Givler, A				Mason, C; Givler, A			Name brand medically necessary: Do not substitute	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												drgiv@aol.com							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2004	291	13					1541	1542		10.1001/jama.291.13.1541	http://dx.doi.org/10.1001/jama.291.13.1541			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809PQ	15069029				2022-12-28	WOS:000220649000001
J	McMichael, AJ; McKee, M; Shkolnikov, V; Valkonen, T				McMichael, AJ; McKee, M; Shkolnikov, V; Valkonen, T			Mortality trends and setbacks: global convergence or divergence?	LANCET			English	Article							SOCIOECONOMIC INEQUALITIES; LIFE EXPECTANCY; POVERTY; PATTERN; EQUITY; HEALTH	Health trends over much of the past century have been generally, and notably, positive throughout the world. In several regions, however, life expectancy has declined over the past 1-2 decades. This trend suggests that the expectation that emerged in the 1960s and 1970s of worldwide gains and convergence in population health status is not guaranteed by a general deterministic process. National populations can now be clearly grouped into those that have achieved rapid gains in life expectancy; those whose gains are slower or are perhaps plateauing; and those in which the trends have reversed. Over the past two centuries, outside times of war and famine, such reversals have been rare. Exploration of these varied population health trends elucidates better the close relation between population health and the processes of economic, social, and technological change. Such analysis has shown that the health status of human populations should be a guiding criterion in the debate on sustainable development.	Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia; London Sch Hyg & Trop Med, London WC1, England; Max Planck Inst Demog Res, Rostock, Germany; Univ Helsinki, Dept Sociol, FIN-00014 Helsinki, Finland	Australian National University; University of London; London School of Hygiene & Tropical Medicine; Max Planck Society; University of Helsinki	McMichael, AJ (corresponding author), Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia.	tony.mcmichael@anu.edu.au	McKee, Marc D/E-2187-2011; Shkolnikov, Vladimir/D-2986-2017; Mckee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; Shkolnikov, Vladimir/0000-0003-2259-5423; Mckee, Martin/0000-0002-0121-9683				Ali MM, 2003, POP STUD-J DEMOG, V57, P217, DOI 10.1080/0032472032000097119; Andreev EM, 2003, INT J EPIDEMIOL, V32, P437, DOI 10.1093/ije/dyg085; Butler C, 2000, LANCET, V356, P1445, DOI 10.1016/S0140-6736(05)74091-5; CASELLI G, 2002, GENUS, V9, P9; Chenet L, 1996, J EPIDEMIOL COMMUN H, V50, P404, DOI 10.1136/jech.50.4.404; Farmer P, 2003, LANCET, V361, P420, DOI 10.1016/S0140-6736(03)12380-X; *GOSK, 2002, DEM YB RUSS FED 2002, P105; Gwatkin D.R., 2002, OXFORD TXB PUBLIC HL, V3, P1581; Haines MR, 2000, DEV HLTH NUTR MORTAL; HATTERSLEY L, 1999, WORLD HLTH STAT Q, V2, P17; HOYERT DL, 2001, NATL VITAL STAT REP, V49, P3; Knudsen A. B., 1995, Parassitologia (Rome), V37, P91; Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6; Mackenbach JP, 2003, INT J EPIDEMIOL, V32, P830, DOI 10.1093/ije/dyg209; McMichael AJ, 2001, HUMAN FRONTIERS ENV, DOI [10.1017/CBO9781139106924, DOI 10.1017/CBO9781139106924]; NGOM P, 2002, POPULATION HLTH DYNA, P86; OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375; PRESTON SH, 1995, J AGING HEALTH, V7, P476, DOI 10.1177/089826439500700402; PRESTON SH, 1906, MORTALITY PATTERNS N; Schieber GJ, 1997, INNOVATIONS HLTH CAR, P266; Shkolnikov V, 1996, Popul, V8, P123; Shkolnikov V, 2001, LANCET, V357, P917, DOI 10.1016/S0140-6736(00)04212-4; Smil V, 1999, BMJ-BRIT MED J, V319, P1619, DOI 10.1136/bmj.319.7225.1619; Steckel R.H., 2001, POVERTY INEQUALITY H, P37; Telishevka M, 2001, DIABETIC MED, V18, P3, DOI 10.1046/j.1464-5491.2001.00437.x; Tuljapurkar S, 2000, NATURE, V405, P789, DOI 10.1038/35015561; *UN WORLD POP PROS, 2002, POP DAT; *UNAIDS, 2000, REP GLOB HIV AIDS EP; United Nations, 1981, WORLD POP PROSP ASS, P3; United Nations, 1977, WORLD POP PROSP ASS, P10; Valkonen T, 2001, TRENDS MORTALITY DIF, V36, P185; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494; Wagstaff A, 2000, B WORLD HEALTH ORGAN, V78, P19; Whitehead M, 2001, LANCET, V358, P833, DOI 10.1016/S0140-6736(01)05975-X; *WHO, 2003, WORLD HLTH REP RED R, P186; *WHO, 2002, WORLD HLTH REP 2002, P9; Wilson C, 2001, POPUL DEV REV, V27, P155, DOI 10.1111/j.1728-4457.2001.00155.x; *WORLD BANK, 2003, WORLD DEV IND 2003	39	134	138	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	2004	363	9415					1155	1159		10.1016/S0140-6736(04)15902-3	http://dx.doi.org/10.1016/S0140-6736(04)15902-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808VB	15064037				2022-12-28	WOS:000220595500026
J	Roberts, SE; Goldacre, MJ; Neil, HAW				Roberts, SE; Goldacre, MJ; Neil, HAW			Mortality in young people admitted to hospital for diabetes: database study	BRITISH MEDICAL JOURNAL			English	Article							MELLITUS; IDDM		Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England	University of Oxford	Roberts, SE (corresponding author), Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England.	stephen.roberts@uhcc.ox.ac.uk						KYVIK KO, 1994, DIABETES CARE, V17, P210, DOI 10.2337/diacare.17.3.210; Laing SP, 1999, DIABETIC MED, V16, P459, DOI 10.1046/j.1464-5491.1999.00075.x; MCNALLY PC, 1995, DIABETIC MED, V12, P961, DOI 10.1111/j.1464-5491.1995.tb00406.x; Nishimura R, 1996, DIABETES CARE, V19, P758, DOI 10.2337/diacare.19.7.758; Wibell L, 2001, J INTERN MED, V249, P263, DOI 10.1046/j.1365-2796.2001.00802.x	5	16	16	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 27	2004	328	7442					741	742		10.1136/bmj.328.7442.741	http://dx.doi.org/10.1136/bmj.328.7442.741			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809WH	15044290	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000220666300015
J	Aloy, P; Bottcher, B; Ceulemans, H; Leutwein, C; Mellwig, C; Fischer, S; Gavin, AC; Bork, P; Superti-Furga, G; Serrano, L; Russell, RB				Aloy, P; Bottcher, B; Ceulemans, H; Leutwein, C; Mellwig, C; Fischer, S; Gavin, AC; Bork, P; Superti-Furga, G; Serrano, L; Russell, RB			Structure-based assembly of protein complexes in yeast	SCIENCE			English	Article							RNA-POLYMERASE-II; CRYSTAL-STRUCTURE; CHAPERONIN; TRANSCRIPTION; ORGANIZATION; ARCHITECTURE; INITIATION; RESOLUTION; PHOSDUCIN; NETWORKS	Images of entire cells are preceding atomic structures of the separate molecular machines that they contain. The resulting gap in knowledge can be partly bridged by protein-protein interactions, bioinformatics, and electron microscopy. Here we use interactions of known three-dimensional structure to model a large set of yeast complexes, which we also screen by electron microscopy. For 54 of 102 complexes, we obtain at least partial models of interacting subunits. For 29, including the exosome, the chaperonin containing TCP-1, a 3'-messenger RNA degradation complex, and RNA polymerase II, the process suggests atomic details not easily seen by homology, involving the combination of two or more known structures. We also consider interactions between complexes (cross-talk) and use these to construct a structure-based network of molecular machines in the cell.	European Mol Biol Lab, Struct & Computat Biol Programme, D-69117 Heidelberg, Germany; Cellzome AG, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); GlaxoSmithKline; Cellzome GmbH	Russell, RB (corresponding author), European Mol Biol Lab, Struct & Computat Biol Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.	russell@embl.de	Bottcher, Bettina/E-9397-2010; Russell, Rob/AAH-9145-2019; Russell, Robert/GWU-6389-2022; Aloy, Patrick/AAB-3538-2019; Serrano, Luis/B-3355-2013; Superti-Furga, Giulio/AAE-5681-2019; Superti-Furga, Giulio/F-4755-2015; Bork, Peer/F-1813-2013	Bottcher, Bettina/0000-0002-7962-4849; Russell, Rob/0000-0002-1905-4717; Russell, Robert/0000-0002-7213-1398; Serrano, Luis/0000-0002-5276-1392; Superti-Furga, Giulio/0000-0002-0570-1768; Bork, Peer/0000-0002-2627-833X; Aloy, Patrick/0000-0002-3557-0236; Gavin, Anne-Claude/0000-0003-4917-2340; Ceulemans, Hugo/0000-0002-7059-4399				Aloy P, 2003, J MOL BIOL, V332, P989, DOI 10.1016/j.jmb.2003.07.006; Aloy P, 2002, TRENDS BIOCHEM SCI, V27, P633, DOI 10.1016/S0968-0004(02)02204-1; Aloy P, 2002, EMBO REP, V3, P628, DOI 10.1093/embo-reports/kvf135; Aloy P, 2002, P NATL ACAD SCI USA, V99, P5896, DOI 10.1073/pnas.092147999; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Brown JT, 2000, RNA, V6, P449, DOI 10.1017/S1355838200991787; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; CEULEMANS H, IN PRESS J MOL BIOL; Chamberlain JR, 1998, GENE DEV, V12, P1678, DOI 10.1101/gad.12.11.1678; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Douangamath A, 2002, MOL CELL, V10, P1007, DOI 10.1016/S1097-2765(02)00749-9; Gaudet R, 1999, MOL CELL, V3, P649, DOI 10.1016/S1097-2765(00)80358-5; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gavin AC, 2003, CURR OPIN CHEM BIOL, V7, P21, DOI 10.1016/S1367-5931(02)00007-8; Janin J, 2003, PROTEINS, V52, P2, DOI 10.1002/prot.10381; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; Lo Conte L, 2002, NUCLEIC ACIDS RES, V30, P264; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; McLaughlin JN, 2002, P NATL ACAD SCI USA, V99, P7962, DOI 10.1073/pnas.112075699; Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Poglitsch CL, 1999, CELL, V98, P791, DOI 10.1016/S0092-8674(00)81513-5; Sali A, 2003, NATURE, V422, P216, DOI 10.1038/nature01513; Symmons MF, 2000, STRUCTURE, V8, P1215, DOI 10.1016/S0969-2126(00)00521-9; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Tsai FTF, 2000, EMBO J, V19, P25, DOI 10.1093/emboj/19.1.25; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Valpuesta JM, 2002, FEBS LETT, V529, P11, DOI 10.1016/S0014-5793(02)03180-0; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4	31	300	313	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	2004	303	5666					2026	2029		10.1126/science.1092645	http://dx.doi.org/10.1126/science.1092645			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044803				2022-12-28	WOS:000220429800044
J	Ahn, KH; Lookman, T; Bishop, AR				Ahn, KH; Lookman, T; Bishop, AR			Strain-induced metal-insulator phase coexistence in perovskite manganites	NATURE			English	Article							TRANSITION; SEPARATION; MAGNETORESISTANCE; LA1-XCAXMNO3; DISORDER; PHYSICS; IMAGES	The coexistence of distinct metallic and insulating electronic phases within the same sample of a perovskite manganite(1-6), such as La1-x-yPryCaxMnO3, presents researchers with a tool for tuning the electronic properties in materials. In particular, colossal magnetoresistance(7) in these materials - the dramatic reduction of resistivity in a magnetic field - is closely related to the observed texture owing to nanometre- and micrometre-scale inhomogeneities(1) (-6,8). Despite accumulated data from various high-resolution probes, a theoretical understanding for the existence of such inhomogeneities has been lacking. Mechanisms invoked so far, usually based on electronic mechanisms and chemical disorder(9-11), have been inadequate to describe the multiscale, multiphase coexistence within a unified picture. Moreover, lattice distortions and long-range strains(12,13) are known to be important in the manganites(14). Here we show that the texturing can be due to the intrinsic complexity of a system with strong coupling between the electronic and elastic degrees of freedom. This leads to local energetically favourable configurations and provides a natural mechanism for the self-organized inhomogeneities over both nanometre and micrometre scales. The framework provides a physical understanding of various experimental results and a basis for engineering nanoscale patterns of metallic and insulating phases.	Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	Ahn, KH (corresponding author), Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA.	ahn@lanl.gov						Ahn KH, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.092101; AHN KH, 2003, ORGCONDMAT0309328; AHN KH, UNPUB PHYS REV B; Bishop AR, 2003, EUROPHYS LETT, V63, P289, DOI 10.1209/epl/i2003-00522-9; BURGY J, UNPUB PHYS REV LETT; BURGY J, 2003, ORGCONDMAT0308456; Chen CH, 1996, PHYS REV LETT, V76, P4042, DOI 10.1103/PhysRevLett.76.4042; Dagotto E, 2001, PHYS REP, V344, P1, DOI 10.1016/S0370-1573(00)00121-6; Fath M, 1999, SCIENCE, V285, P1540, DOI 10.1126/science.285.5433.1540; Ferrari V, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.227202; Fiebig M, 1998, SCIENCE, V280, P1925, DOI 10.1126/science.280.5371.1925; HWANG HY, 1995, PHYS REV LETT, V75, P914, DOI 10.1103/PhysRevLett.75.914; JIN S, 1994, SCIENCE, V264, P413, DOI 10.1126/science.264.5157.413; Kim KH, 2000, PHYS REV B, V62, P11945, DOI 10.1103/PhysRevB.62.R11945; Kiryukhin V, 1997, NATURE, V386, P813, DOI 10.1038/386813a0; Levy P, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.137001; Lookman T, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.024114; Lynn JW, 1997, J APPL PHYS, V81, P5488, DOI 10.1063/1.364576; Lynn JW, 1996, PHYS REV LETT, V76, P4046, DOI 10.1103/PhysRevLett.76.4046; Mathur N, 2003, PHYS TODAY, V56, P25, DOI 10.1063/1.1554133; Mathur ND, 2001, SOLID STATE COMMUN, V119, P271, DOI 10.1016/S0038-1098(01)00112-0; Millis AJ, 2003, SOLID STATE COMMUN, V126, P3, DOI 10.1016/S0038-1098(02)00668-3; Millis AJ, 1998, NATURE, V392, P147, DOI 10.1038/32348; Moreo A, 1999, SCIENCE, V283, P2034, DOI 10.1126/science.283.5410.2034; Podzorov V, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.140406; Renner C, 2002, NATURE, V416, P518, DOI 10.1038/416518a; RodriguezMartinez LM, 1996, PHYS REV B, V54, P15622, DOI 10.1103/PhysRevB.54.R15622; Salamon MB, 2001, REV MOD PHYS, V73, P583, DOI 10.1103/RevModPhys.73.583; SETO H, 1990, J PHYS SOC JPN, V59, P978, DOI 10.1143/JPSJ.59.978; Tokura Y, 1996, PHYS REV LETT, V76, P3184, DOI 10.1103/PhysRevLett.76.3184; Uehara M, 1999, NATURE, V399, P560, DOI 10.1038/21142; Zhang LW, 2002, SCIENCE, V298, P805, DOI 10.1126/science.1077346	32	513	523	1	197	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	2004	428	6981					401	404		10.1038/nature02364	http://dx.doi.org/10.1038/nature02364			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042083				2022-12-28	WOS:000220404300035
J	Wang, PH				Wang, PH			Growing pains in the pursuit of diabetes prevention	LANCET			English	Editorial Material							MELLITUS		Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Wang, PH (corresponding author), Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA.	phwang@uci.edu						Hirschhorn Joel N, 2003, Pediatr Diabetes, V4, P87, DOI 10.1034/j.1399-5448.2001.00013.x; Knip M, 2002, HORM RES, V57, P6, DOI 10.1159/000053305; Liu E, 2002, ENDOCRIN METAB CLIN, V31, P391, DOI 10.1016/S0889-8529(01)00017-2; Skyler JS, 2002, NEW ENGL J MED, V346, P1685	4	1	1	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	2004	363	9413					910	910		10.1016/S0140-6736(04)15818-2	http://dx.doi.org/10.1016/S0140-6736(04)15818-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043953				2022-12-28	WOS:000220308600002
J	King, M				King, M			A novel BRCA2-binding protein and breast and ovarian tumorigenesis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BRCA2; COMPLEX; REPAIR		Univ Washington, Dept Med Med Genet, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	King, M (corresponding author), Univ Washington, Dept Med Med Genet, Seattle, WA 98195 USA.			King, Mary-Claire/0000-0001-9426-1743				Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Wang Y, 2000, GENE DEV, V14, P927	4	12	12	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	2004	350	12					1252	1253		10.1056/NEJMcibr033528	http://dx.doi.org/10.1056/NEJMcibr033528			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803PG	15028830				2022-12-28	WOS:000220242400014
J	Morris, RJ; Lewis, OT; Godfray, HCJ				Morris, RJ; Lewis, OT; Godfray, HCJ			Experimental evidence for apparent competition in a tropical forest food web	NATURE			English	Article							ENEMY-FREE-SPACE; PREY; CONSEQUENCES; COMMUNITY	The herbivorous insects of tropical forests constitute some of the most diverse communities of living organisms(1). For this reason it has been difficult to discover the degree to which these communities are structured, and by what processes. Interspecific competition for resources does occur, but its contemporary importance is limited because most pairs of potentially competing insects feed on different host plants(2). An alternative way in which species can interact is through shared natural enemies, a process called apparent competition(3). Despite extensive theoretical discussion there are few field demonstrations of apparent competition, and none in hyper-diverse tropical communities. Here, we experimentally removed two species of herbivore from a community of leaf-mining insects in a tropical forest. We predicted that other species that share natural enemies with the two removed species would experience lower parasitism and have higher population densities in treatment compared with control sites. In both cases ( on removal of a dipteran and a coleopteran leaf-miner species) we found significantly lower parasitism, and in one case ( removal of the dipteran) we found significantly higher abundance a year after the manipulation. Our results suggest that apparent competition may be important in structuring tropical insect communities.	Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Ascot SL5 7PY, Berks, England; Univ Oxford, Dept Zool, Oxford OX1 3PS, England	Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Oxford	Morris, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Silwood Pk Campus, Ascot SL5 7PY, Berks, England.	r.j.morris@imperial.ac.uk	Lewis, Owen T/B-9531-2011	Lewis, Owen/0000-0001-7935-6111				ABRAMS P, 1983, ANNU REV ECOL SYST, V14, P359, DOI 10.1146/annurev.es.14.110183.002043; Abrams P., 1995, FOOD WEBS INTEGRATIO, P371; Abrams PA, 1996, ECOLOGY, V77, P610, DOI 10.2307/2265634; Bonsall MB, 2000, P ROY SOC B-BIOL SCI, V267, P2207, DOI 10.1098/rspb.2000.1270; Bonsall MB, 1999, RES POPUL ECOL, V41, P59, DOI 10.1007/PL00011983; Bonsall MB, 1997, NATURE, V388, P371, DOI 10.1038/41084; Henneman ML, 2001, SCIENCE, V293, P1314, DOI 10.1126/science.1060788; HESPENHEIDE HA, 1991, ANNU REV ENTOMOL, V36, P535, DOI 10.1146/annurev.en.36.010191.002535; HOLT RD, 1993, AM NAT, V142, P623, DOI 10.1086/285561; HOLT RD, 1977, THEOR POPUL BIOL, V12, P197, DOI 10.1016/0040-5809(77)90042-9; HOLT RD, 1994, ANNU REV ECOL SYST, V25, P495, DOI 10.1146/annurev.es.25.110194.002431; HOWARTH FG, 1991, ANNU REV ENTOMOL, V36, P485, DOI 10.1146/annurev.en.36.010191.002413; JANZEN DH, 1970, AM NAT, V104, P501, DOI 10.1086/282687; JEFFRIES MJ, 1984, BIOL J LINN SOC, V23, P269, DOI 10.1111/j.1095-8312.1984.tb00145.x; Lewis OT, 2002, J ANIM ECOL, V71, P855, DOI 10.1046/j.1365-2656.2002.00651.x; Memmott J., 1994, P300; MENGE BA, 1995, ECOL MONOGR, V65, P21, DOI 10.2307/2937158; Morris RJ, 2001, J ANIM ECOL, V70, P301, DOI 10.1046/j.1365-2656.2001.00495.x; Muller CB, 1997, J ANIM ECOL, V66, P57, DOI 10.2307/5964; Novotny V, 2002, NATURE, V416, P841, DOI 10.1038/416841a; Power ME, 1996, BIOSCIENCE, V46, P609, DOI 10.2307/1312990; SCHMITT RJ, 1987, ECOLOGY, V68, P1887, DOI 10.2307/1939880; SETTLE WH, 1990, ECOLOGY, V71, P1461, DOI 10.2307/1938283; Simberloff D., 1992, Selection criteria and ecological consequences of importing natural enemies., P103; STRAUSS SY, 1991, TRENDS ECOL EVOL, V6, P206, DOI 10.1016/0169-5347(91)90023-Q; Strong D., 1984, INSECTS PLANTS COMMU; TOMKINS DM, 2000, ECOL LETT, V3, P10; Turchin Peter, 2003, Monographs in Population Biology, V35, pi; WOOTTON JT, 1994, ANNU REV ECOL SYST, V25, P443, DOI 10.1146/annurev.es.25.110194.002303	29	209	218	3	145	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 18	2004	428	6980					310	313		10.1038/nature02394	http://dx.doi.org/10.1038/nature02394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15029194				2022-12-28	WOS:000220250200041
J	Wilczek, F				Wilczek, F			From 'not wrong' to (maybe) right - How ignoring glaring problems can sometimes lead to fruitful theories.	NATURE			English	Editorial Material									MIT, Dept Phys, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Wilczek, F (corresponding author), MIT, Dept Phys, 77 Massachusetts Ave, Cambridge, MA 02139 USA.								0	2	2	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 18	2004	428	6980					261	261		10.1038/428261a	http://dx.doi.org/10.1038/428261a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15029174	Green Submitted			2022-12-28	WOS:000220250200021
J	Lee, JH; Paull, TT				Lee, JH; Paull, TT			Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex	SCIENCE			English	Article							NIJMEGEN-BREAKAGE-SYNDROME; DNA-DAMAGE RESPONSE; TELANGIECTASIA-LIKE DISORDER; S-PHASE CHECKPOINT; ATAXIA-TELANGIECTASIA; DEPENDENT PHOSPHORYLATION; IONIZING-RADIATION; HISTONE H2AX; NBS1; REPAIR	The complex containing the Mre11, Rad50, and Nbs1 proteins (MRN) is essential for the cellular response to DNA double-strand breaks, integrating DNA repair with the activation of checkpoint signaling through the protein kinase ATM ( ataxia telangiectasia mutated). We demonstrate that MRN stimulates the kinase activity of ATM in vitro toward its substrates p53, Chk2, and histone H2AX. MRN makes multiple contacts with ATM and appears to stimulate ATM activity by facilitating the stable binding of substrates. Phosphorylation of Nbs1 is critical for MRN stimulation of ATM activity toward Chk2, but not p53. Kinase-deficient ATM inhibits wild-type ATM phosphorylation of Chk2, consistent with the dominant-negative effect of kinase-deficient ATM in vivo.	Univ Texas, Inst Mol & Cellular Biol, Dept Mol Genet & Microbiol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Paull, TT (corresponding author), Univ Texas, Inst Mol & Cellular Biol, Dept Mol Genet & Microbiol, 1 Univ Stn,A4800, Austin, TX 78712 USA.	tpaull@icrnb.utexas.edu	Lee, Jihoon/AAK-3497-2021	Lee, Jihoon/0000-0001-7387-935X; Paull, Tanya/0000-0002-2991-651X	NCI NIH HHS [CA94008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Lee J.-S., UNPUB; Lee JH, 2003, J BIOL CHEM, V278, P45171, DOI 10.1074/jbc.M308705200; Lee JH, 2003, MOL CANCER RES, V1, P674; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Spring K, 2002, NAT GENET, V32, P185, DOI 10.1038/ng958; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	29	570	589	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					93	96		10.1126/science.1091496	http://dx.doi.org/10.1126/science.1091496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15064416				2022-12-28	WOS:000220567900044
J	Floyd, SK; Bowman, JL				Floyd, SK; Bowman, JL			Gene regulation: Ancient microRNA target sequences in plants	NATURE			English	Editorial Material							ARABIDOPSIS; EXPRESSION		Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA	University of California System; University of California Davis	Floyd, SK (corresponding author), Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA.	jlbowman@ucdavis.edu		Bowman, John/0000-0001-7347-3691				Aukerman MJ, 2003, PLANT CELL, V15, P2730, DOI 10.1105/tpc.016238; Baima S, 1995, DEVELOPMENT, V121, P4171; Emery JF, 2003, CURR BIOL, V13, P1768, DOI 10.1016/j.cub.2003.09.035; Lang A, 2002, MOVEMENT DISORD, V17, P1, DOI 10.1002/mds.10108; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; McConnell JR, 1998, DEVELOPMENT, V125, P2935; McConnell JR, 2001, NATURE, V411, P709, DOI 10.1038/35079635; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; TALBERT PB, 1995, DEVELOPMENT, V121, P2723; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	12	313	349	3	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					485	486		10.1038/428485a	http://dx.doi.org/10.1038/428485a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15057819				2022-12-28	WOS:000220540100028
J	Derdeyn, CA; Decker, JM; Bibollet-Ruche, F; Mokili, JL; Muldoon, M; Denham, SA; Heil, ML; Kasolo, F; Musonda, R; Hahn, BH; Shaw, GM; Korber, BT; Allen, S; Hunter, E				Derdeyn, CA; Decker, JM; Bibollet-Ruche, F; Mokili, JL; Muldoon, M; Denham, SA; Heil, ML; Kasolo, F; Musonda, R; Hahn, BH; Shaw, GM; Korber, BT; Allen, S; Hunter, E			Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; FUSION INHIBITOR T-20; DISCORDANT COUPLES; CD4 INDEPENDENCE; INFECTION; GP120; VARIANTS; ANTIBODIES; EMERGENCE; ESCAPE	Heterosexual transmission accounts for the majority of human immunodeficiency virus-1 (HIV-1) infections worldwide, yet the viral properties that determine transmission fitness or outgrowth have not been elucidated. Here we show, for eight heterosexual transmission pairs, that recipient viruses were monophyletic, encoding compact, glycan-restricted envelope glycoproteins. These viruses were also uniquely sensitive to neutralization by antibody from the transmitting partner. Thus, the exposure of neutralizing epitopes, which are lost in chronic infection because of immune escape, appears to be favored in the newly infected host. This reveals characteristics of the envelope glycoprotein that influence HIV-1 transmission and may have implications for vaccine design.	Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Howard Hughes Med Inst, Birmingham, AL 35294 USA; Los Alamos Natl Lab, HIV Sequence Database, Los Alamos, NM 87544 USA; Univ Manchester, Inst Sci & Technol, Inst Math, Manchester M60 1QD, Lancs, England; Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol & Int Hlth, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Birmingham Ctr AIDS Res, Birmingham, AL 35294 USA; Univ Teaching Hosp, Dept Pathol & Microbiol, Lusaka, Zambia; Trop Dis Res Ctr, Ndola, Zambia; Santa Fe Inst, Santa Fe, NM 87501 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham; United States Department of Energy (DOE); Los Alamos National Laboratory; University of Manchester; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Zambia; The Santa Fe Institute	Hunter, E (corresponding author), Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA.	ehunter@uab.edu	Muldoon, Mark/T-9192-2019; Muldoon, Mark R/C-7505-2009	Korber, Bette/0000-0002-2026-5757; Hahn, Beatrice/0000-0002-9400-9887; Muldoon, Mark/0000-0002-5004-7195	NIAID NIH HHS [U01-AI-41530, AI-51231, AI-40951] Funding Source: Medline; PHS HHS [N01-85338] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041530, R01AI051231, R01AI040951, R37AI051231] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; Allen S, 2003, AIDS, V17, P733, DOI 10.1097/00002030-200303280-00012; ARENDRUP M, 1992, J ACQ IMMUN DEF SYND, V5, P303; Bradney AP, 1999, J INFECT DIS, V179, P1264, DOI 10.1086/314711; Chackerian B, 1997, J VIROL, V71, P7719, DOI 10.1128/JVI.71.10.7719-7727.1997; Derdeyn CA, 2001, J VIROL, V75, P8605, DOI 10.1128/JVI.75.18.8605-8614.2001; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; DERDEYN CA, UNPUB; Edwards TG, 2001, J VIROL, V75, P5230, DOI 10.1128/JVI.75.11.5230-5239.2001; Fideli OS, 2001, AIDS RES HUM RETROV, V17, P901, DOI 10.1089/088922201750290023; Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441; Johnson WE, 2002, J VIROL, V76, P2075, DOI 10.1128/JVI.76.5.2075-2086.2002; Kolchinsky P, 2001, J VIROL, V75, P2041, DOI 10.1128/JVI.75.5.2041-2050.2001; Kolchinsky P, 2001, J VIROL, V75, P3435, DOI 10.1128/JVI.75.7.3435-3443.2001; KUIKEN CL, 2002, HIV SEQUENCE COMPEND; Kwong PD, 2000, STRUCTURE, V8, P1329, DOI 10.1016/S0969-2126(00)00547-5; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; KWONG PD, COMMUNICATION; Learn GH, 2002, J VIROL, V76, P11953, DOI 10.1128/JVI.76.23.11953-11959.2002; Long EM, 2000, NAT MED, V6, P71; Ly A, 2000, J VIROL, V74, P6769, DOI 10.1128/JVI.74.15.6769-6776.2000; McKenna SL, 1997, AIDS, V11, pS103; Piot P, 2001, NATURE, V410, P968, DOI 10.1038/35073639; Puffer BA, 2002, J VIROL, V76, P2595, DOI 10.1128/JVI.76.6.2595-2605.2002; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Trask SA, 2002, J VIROL, V76, P397, DOI 10.1128/JVI.76.1.397-405.2002; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996	34	488	508	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	2004	303	5666					2019	2022		10.1126/science.1093137	http://dx.doi.org/10.1126/science.1093137			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	806JI	15044802				2022-12-28	WOS:000220429800042
J	Hallman, M				Hallman, M			Lung surfactant, respiratory failure, and genes	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PROTEINS		Bioctr Oulu, Oulu, Finland; Univ Oulu, Dept Pediat, SF-90100 Oulu, Finland	University of Oulu; University of Oulu	Hallman, M (corresponding author), Bioctr Oulu, Oulu, Finland.		Hallman, Niilo/AHD-9810-2022					Haataja R, 2002, ANN MED, V34, P324, DOI 10.1080/078538902320772089; Shulenin S, 2004, NEW ENGL J MED, V350, P1296, DOI 10.1056/NEJMoa032178; Whitsett JA, 2002, NEW ENGL J MED, V347, P2141, DOI 10.1056/NEJMra022387	3	17	19	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2004	350	13					1278	1280		10.1056/NEJMp048036	http://dx.doi.org/10.1056/NEJMp048036			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VN	15044636				2022-12-28	WOS:000220393900003
J	Haines, TP; Bennell, KL; Osborne, RH; Hill, KD				Haines, TP; Bennell, KL; Osborne, RH; Hill, KD			Effectiveness of targeted falls prevention programme in subacute hospital setting: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							REHABILITATION; FRAILTY	Objective To assess the effectiveness of a targeted, multiple intervention falls prevention programme in reducing falls and injuries related to falls in a subacute hospital. Design Randomised controlled trial of a targeted multiple intervention programme implemented in addition to usual care compared with usual care alone. Setting Three subacute wards in a metropolitan hospital specialising in rehabilitation and care of elderly patients. Participants 626 men and women aged 38 to 99 years (average 80 years) were recruited from consecutive admissions to subacute hospital wards. Intervention Falls risk alert card with information brochure, exercise programme, education programme, and hip protectors. Main outcome measures Incidence rate of falls, injuries related to falls, and proportion of participants who experienced one or more falls during their stay in hospital. Results Participants in the intervention group (n = 310) experienced 30% fewer falls than participants in the control group (n = 316). This difference was significant (Peto log rank test P = 0.045) and was most obvious after 45 days of observation. In the intervention group there was a trend for a reduction in the proportion of participants who experienced falls (relative risk 0.78, 95% confidence interval 0.56 to 1.06) and 28% fewer falls resulted in injury (log rank test P = 0.20). Conclusions A targeted multiple intervention falls prevention programme reduces the incidence of falls in the subacute hospital setting.	Natl Ageing Res Inst, Parkville, Vic, Australia; Univ Melbourne, Sch Physiotherapy, Parkville, Vic 3052, Australia; Royal Melbourne Hosp, Ctr Rheumat Dis, Parkville, Vic 3050, Australia; Melbourne Extended Care & Rehabil Serv, Parkville, Vic, Australia	National Ageing Research Institute; University of Melbourne; Royal Melbourne Hospital	Hill, KD (corresponding author), Natl Ageing Res Inst, Parkville, Vic, Australia.	k.hill@nari.unimelb.edu.au	Haines, Terrence/E-9372-2015; Hill, Keith D/L-6398-2017; Osborne, Richard H/A-9447-2010; Bennell, Kim/C-7022-2014	Haines, Terrence/0000-0003-3150-6154; Hill, Keith D/0000-0002-2191-0308; Osborne, Richard H/0000-0002-9081-2699; Bennell, Kim/0000-0003-4982-5639				Altman D, 1993, PRACTICAL STAT MED R; Brandis S, 1999, J Qual Clin Pract, V19, P215, DOI 10.1046/j.1440-1762.1999.00337.x; Donald IP, 2000, CLIN REHABIL, V14, P178, DOI 10.1191/026921500677888641; Fleiss J. L., 1981, STAT METHODS RATES P, V2; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI 10.1002/14651858.CD007146.pub3; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Grenier-Sennelier C, 2002, INT J QUAL HEALTH C, V14, P419, DOI 10.1093/intqhc/14.5.419; Liddle J., 1995, CLIN REHABIL, V9, P110, DOI DOI 10.1177/026921559500900204; MAYO NE, 1994, ARCH PHYS MED REHAB, V75, P1302; Mion L C, 1989, Rehabil Nurs, V14, P17; NELSON W, 1972, TECHNOMETRICS, V14, P945, DOI 10.2307/1267144; Oliver D, 2000, J AM GERIATR SOC, V48, P1679, DOI 10.1111/j.1532-5415.2000.tb03883.x; PEPE MS, 1993, J AM STAT ASSOC, V88, P811, DOI 10.2307/2290770; Perell KL, 2001, J GERONTOL A-BIOL, V56, pM761, DOI 10.1093/gerona/56.12.M761; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; RAPPORT LJ, 1993, ARCH PHYS MED REHAB, V74, P621, DOI 10.1016/0003-9993(93)90160-C; TIDEIKSAAR R, 1993, MT SINAI J MED, V60, P522; *VICT DEP HUM SERV, 2002, VICT ADM EP DAT; VLAHOV D, 1990, ARCH PHYS MED REHAB, V71, P8; WOLF SL, 1993, J AM GERIATR SOC, V41, P329, DOI 10.1111/j.1532-5415.1993.tb06713.x; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x	22	196	198	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 20	2004	328	7441					676	+		10.1136/bmj.328.7441.676	http://dx.doi.org/10.1136/bmj.328.7441.676			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VB	15031238	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000220392700018
J	Liljegren, SJ; Roeder, AHK; Kempin, SA; Gremski, K; Ostergaard, L; Guimil, S; Reyes, DK; Yanofsky, MF				Liljegren, SJ; Roeder, AHK; Kempin, SA; Gremski, K; Ostergaard, L; Guimil, S; Reyes, DK; Yanofsky, MF			Control of fruit patterning in Arabidopsis by INDEHISCENT	CELL			English	Article							LOOP-HELIX PROTEIN; BHLH-PAS PROTEIN; BRASSICA-NAPUS L; MADS-BOX GENES; CNS MIDLINE; DNA-BINDING; TRANSCRIPTION; ENCODES; DEHISCENCE; IDENTITY	The Arabidopsis seedpod opens through a spring-loaded mechanism known as pod shatter, which is essential for dispersal of the seeds. Here, we identify INDEHISCIENT (IND), an atypical bHLH protein, that is necessary for fruit opening and is involved in patterning each of the three fruit cell types required for seed dispersal. Previous studies suggested that FRUITFULL (FUL), a member of the MADS-domain transcription factor family, is required for fruit growth since ful mutant fruit fail to undergo the dramatic enlargement that normally occurs after fertilization. Here we show, however, that FUL is not directly required for fruit elongation and instead is required to prevent ectopic activity of IND. Our molecular and genetic studies suggest a model for the regulatory interactions among the genes that control fruit development and the mechanism that results in the expression of IND in a narrow stripe of cells.	Univ Calif San Diego, Div Biol Sci, Sect Cell & Dev Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Yanofsky, MF (corresponding author), Univ Calif San Diego, Div Biol Sci, Sect Cell & Dev Biol, 9500 Gilman Dr,Dept 0116, La Jolla, CA 92093 USA.	marty@ucsd.edu	Roeder, Adrienne/ABF-5334-2021; Ostergaard, Lars/AAA-3020-2020	Ostergaard, Lars/0000-0003-2459-0511; Roeder, Adrienne/0000-0001-6685-2984; Ostergaard, Lars/0000-0002-7619-605X				Alvarez J, 1999, DEVELOPMENT, V126, P2377; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; Buck MJ, 2003, J MOL EVOL, V56, P742, DOI 10.1007/s00239-002-2449-3; CAL M, 1990, CELL, V61, P437; Child RD, 1998, J EXP BOT, V49, P829, DOI 10.1093/jexbot/49.322.829; Eshed Y, 1999, CELL, V99, P199, DOI 10.1016/S0092-8674(00)81651-7; Ferrandiz C, 2000, SCIENCE, V289, P436, DOI 10.1126/science.289.5478.436; Ferrandiz C, 2000, DEVELOPMENT, V127, P725; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; Flanagan CA, 1996, PLANT J, V10, P343, DOI 10.1046/j.1365-313X.1996.10020343.x; Gu Q, 1998, DEVELOPMENT, V125, P1509; Heisler MGB, 2001, DEVELOPMENT, V128, P1089; Kempin SA, 1997, NATURE, V389, P802, DOI 10.1038/39770; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Ledent V, 2001, GENOME RES, V11, P754, DOI 10.1101/gr.177001; Liljegren SJ, 2000, NATURE, V404, P766, DOI 10.1038/35008089; MacLeod J., 1981, Oilseed rape book., P107; MEAKIN PJ, 1990, J EXP BOT, V41, P995, DOI 10.1093/jxb/41.8.995; MEAKIN PJ, 1990, J EXP BOT, V41, P1003, DOI 10.1093/jxb/41.8.1003; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; PEARSONWHITE SH, 1991, NUCLEIC ACIDS RES, V19, P1148, DOI 10.1093/nar/19.5.1148; Rajani S, 2001, CURR BIOL, V11, P1914, DOI 10.1016/S0960-9822(01)00593-0; Roeder AHK, 2003, CURR BIOL, V13, P1630, DOI 10.1016/j.cub.2003.08.027; SAVIDGE B, 1995, PLANT CELL, V7, P721, DOI 10.1105/tpc.7.6.721; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; Spence J, 1996, J MICROSC-OXFORD, V181, P195, DOI 10.1046/j.1365-2818.1996.111391.x; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Toledo-Ortiz G, 2003, PLANT CELL, V15, P1749, DOI 10.1105/tpc.013839; Tsugeki R, 1996, PLANT J, V10, P479, DOI 10.1046/j.1365-313X.1996.10030479.x; WHARTON KA, 1994, J CELL BIOCHEM, P55; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	36	280	308	2	62	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 19	2004	116	6					843	853		10.1016/S0092-8674(04)00217-X	http://dx.doi.org/10.1016/S0092-8674(04)00217-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YS	15035986	Bronze			2022-12-28	WOS:000221499900010
J	Xu, Q; Wang, YS; Dabdoub, A; Smallwood, PM; Williams, J; Woods, C; Kelley, MW; Jiang, L; Tasman, W; Zhang, K; Nathans, J				Xu, Q; Wang, YS; Dabdoub, A; Smallwood, PM; Williams, J; Woods, C; Kelley, MW; Jiang, L; Tasman, W; Zhang, K; Nathans, J			Vascular development in the retina and inner ear: Control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair	CELL			English	Article							FAMILIAL EXUDATIVE VITREORETINOPATHY; SIGNALING PATHWAY; ANGIOGENESIS; PROTEIN; LOCALIZATION; BINDING; MEMBER; LRP5	Incomplete retinal vascularization occurs in both Norrie disease and familial exudative vitreoretinopathy (FEVR). Norrin, the protein product of the Norrie disease gene, is a secreted protein of unknown biochemical function. One form of FEVR is caused by defects in Frizzled-4 (Fz4), a presumptive Writ receptor. We show here that Norrin and Fz4 function as a ligand-receptor pair based on (1) the similarity in vascular phenotypes caused by Norrin and Fz4 mutations in humans and mice, (2) the specificity and high affinity of Norrin-Fz4 binding, (3) the high efficiency with which Norrin induces Fz4- and Lrp-dependent activation of the classical Wnt pathway, and (4) the signaling defects displayed by disease-associated variants of Norrin and Fz4. These data define a Norrin-Fz4 signaling system that plays a central role in vascular development in the eye and ear, and they indicate that ligands unrelated to Writs can act through Fz receptors.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Neurosci, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Ophthalmol, Baltimore, MD 21218 USA; NIDCD, Sect Dev Neurosci, NIH, Rockville, MD 20850 USA; Univ Utah, Program Human Mol Biol & Gneet, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84112 USA; Wills Eye Hosp & Res Inst, Dept Ophthalmol, Philadelphia, PA 19107 USA	Howard Hughes Medical Institute; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Utah System of Higher Education; University of Utah; Jefferson University	Nathans, J (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21218 USA.	jnathans@jhmi.edu	Jiang, Li/C-9537-2012; Zhang, Kang/Y-2740-2019	Zhang, Kang/0000-0002-4549-1697; Nathans, Jeremy/0000-0001-8106-5460; Dabdoub, Alain/0000-0002-4259-2425	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000059, Z01DC000059] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BERGER W, 2001, METABOLIC MOL BASES, P5977; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; CANNY CLB, 1976, ARCH OPHTHALMOL-CHIC, V94, P1114; CONNOLLY SE, 1988, MICROVASC RES, V36, P275, DOI 10.1016/0026-2862(88)90028-3; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; Flanagan JG, 2000, METHOD ENZYMOL, V327, P198, DOI 10.1016/S0076-6879(00)27277-7; Fruttiger M, 2002, INVEST OPHTH VIS SCI, V43, P522; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Hartzer MK, 1999, BRAIN RES BULL, V49, P355, DOI 10.1016/S0361-9230(99)00071-4; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Ito M, 1999, ANAT EMBRYOL, V200, P403, DOI 10.1007/s004290050289; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kondo H, 2003, BRIT J OPHTHALMOL, V87, P1291, DOI 10.1136/bjo.87.10.1291; LANG R, 1994, DEVELOPMENT, V120, P3395; Lee P, 2002, P NATL ACAD SCI USA, V99, P10470, DOI 10.1073/pnas.162366299; Liu H, 2003, DEV DYNAM, V227, P323, DOI 10.1002/dvdy.10315; Lyuksyutova AI, 2003, SCIENCE, V302, P1984, DOI 10.1126/science.1089610; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; Park M, 2002, NAT CELL BIOL, V4, P20, DOI 10.1038/ncb716; Pendergast SD, 1998, OPHTHALMOLOGY, V105, P1015, DOI 10.1016/S0161-6420(98)96002-X; Perez-Vilar J, 1997, J BIOL CHEM, V272, P33410, DOI 10.1074/jbc.272.52.33410; Ramulu P, 2001, J BIOL CHEM, V276, P25127, DOI 10.1074/jbc.M011712200; Rehm HL, 2002, J NEUROSCI, V22, P4286, DOI 10.1523/JNEUROSCI.22-11-04286.2002; Richter M, 1998, INVEST OPHTH VIS SCI, V39, P2450; Robitaille J, 2002, NAT GENET, V32, P326, DOI 10.1038/ng957; Rusch A, 2001, J NEUROSCI, V21, P9792, DOI 10.1523/JNEUROSCI.21-24-09792.2001; Shima DT, 2000, CURR OPIN GENET DEV, V10, P536, DOI 10.1016/S0959-437X(00)00124-6; Soucy E, 1998, NEURON, V21, P481, DOI 10.1016/S0896-6273(00)80560-7; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Stone J, 1997, PROG RETIN EYE RES, V16, P157, DOI 10.1016/S1350-9462(96)00019-5; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang YS, 2002, J NEUROSCI, V22, P8563; Wang YS, 2001, J NEUROSCI, V21, P4761, DOI 10.1523/JNEUROSCI.21-13-04761.2001; Wu CH, 2002, J BIOL CHEM, V277, P41762, DOI 10.1074/jbc.M207850200; Yoshikawa S, 2003, NATURE, V422, P583, DOI 10.1038/nature01522; Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6	39	626	674	2	42	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 19	2004	116	6					883	895		10.1016/S0092-8674(04)00216-8	http://dx.doi.org/10.1016/S0092-8674(04)00216-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YS	15035989	Bronze			2022-12-28	WOS:000221499900013
J	Kazazian, HH				Kazazian, HH			Mobile elements: Drivers of genome evolution	SCIENCE			English	Review							TRANSPOSABLE ELEMENTS; RETROTRANSPOSABLE ELEMENTS; L1 RETROTRANSPOSITION; REVERSE TRANSCRIPTION; CATALYTIC SUBUNIT; ALU REPEATS; RNA; TRANSPOSITION; INTEGRATION; GENE	Mobile elements within genomes have driven genome evolution in diverse ways. Particularly in plants and mammals, retrotransposons have accumulated to constitute a large fraction of the genome and have shaped both genes and the entire genome. Although the host can often control their numbers, massive expansions of retrotransposons have been tolerated during evolution. Now mobile elements are becoming useful tools for learning more about genome evolution and gene function.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania	Kazazian, HH (corresponding author), Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA.	kazazian@mail.med.upenn.edu						Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Arkhipova IR, 2003, NAT GENET, V33, P123, DOI 10.1038/ng1074; Bailey JA, 2003, AM J HUM GENET, V73, P823, DOI 10.1086/378594; Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; Belfort Marlene, 2002, P761; Bestor TH, 2003, TRENDS GENET, V19, P185, DOI 10.1016/S0168-9525(03)00049-0; Boeke JD, 1997, NAT GENET, V16, P6, DOI 10.1038/ng0597-6; Boeke JD., 2002, MOBILE DNA-UK, P631, DOI [10.1128/9781555817954.ch26, DOI 10.1128/9781555817954.CH26]; BOMAR JM, 2003, NAT GENET, V15, P270; Bowen NJ, 2003, GENOME RES, V13, P1984, DOI 10.1101/gr.1191603; Brooks MB, 2003, MAMM GENOME, V14, P788, DOI 10.1007/s00335-003-2290-z; Brosius J, 1995, VIRUS GENES, V11, P163, DOI 10.1007/BF01728656; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; BUCHETON A, 2002, MOBILE DNA, V2, P796; Buzdin A, 2003, NUCLEIC ACIDS RES, V31, P4385, DOI 10.1093/nar/gkg496; CAPPELLO J, 1985, CELL, V43, P105, DOI 10.1016/0092-8674(85)90016-9; Carlson CM, 2003, GENETICS, V165, P243; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; Cost GJ, 2002, EMBO J, V21, P5899, DOI 10.1093/emboj/cdf592; Craig N. L., 2002, MOBILE DNA, P3; Craig NL, 2002, MOBILE DNA 2; Curcio MJ, 2003, NAT REV MOL CELL BIO, V4, P865, DOI 10.1038/nrm1241; CURCIO MJ, 1991, P NATL ACAD SCI USA, V88, P936, DOI 10.1073/pnas.88.3.936; Devine SE, 1996, GENE DEV, V10, P620, DOI 10.1101/gad.10.5.620; Eickbush TH, 2002, CURR OPIN GENET DEV, V12, P669, DOI 10.1016/S0959-437X(02)00359-3; EMANUEL BS, NATURE REV GENET, V2, P791; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; EWANNIEUX M, 2003, NAT GENET, V35, P15; Fan H, 1998, MOL CELL BIOL, V18, P3201, DOI 10.1128/MCB.18.6.3201; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Garfinkel DJ, 2003, GENETICS, V165, P83; Garvey SM, 2002, GENOMICS, V79, P146, DOI 10.1006/geno.2002.6685; GARZA D, 1991, GENETICS, V128, P303; Gilbert N, 2002, CELL, V110, P315, DOI 10.1016/S0092-8674(02)00828-0; Goodier JL, 2001, GENOME RES, V11, P1677, DOI 10.1101/gr.198301; Goodwin TJD, 2001, CURR GENET, V39, P83, DOI 10.1007/s002940000181; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hagan CR, 2003, NAT GENET, V35, P219, DOI 10.1038/ng1259; Horie K, 2003, MOL CELL BIOL, V23, P9189, DOI 10.1128/MCB.23.24.9189-9207.2003; JAKUBCZAK JL, 1990, J MOL BIOL, V212, P37, DOI 10.1016/0022-2836(90)90303-4; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; Jiang YW, 2002, GENE DEV, V16, P467, DOI 10.1101/gad.923502; Jurka J, 1997, P NATL ACAD SCI USA, V94, P1872, DOI 10.1073/pnas.94.5.1872; Kajikawa M, 2002, CELL, V111, P433, DOI 10.1016/S0092-8674(02)01041-3; Kumar A, 2001, NAT REV GENET, V2, P302, DOI 10.1038/35066084; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li WH, 2001, NATURE, V409, P847, DOI 10.1038/35057039; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Lutz SM, 2003, AM J HUM GENET, V73, P1431, DOI 10.1086/379744; Lyon MF, 1998, CYTOGENET CELL GENET, V80, P133, DOI 10.1159/000014969; Malik HS, 1999, MOL BIOL EVOL, V16, P793, DOI 10.1093/oxfordjournals.molbev.a026164; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mizuuchi Kiyoshi, 2002, P12; Montini E, 2002, MOL THER, V6, P759, DOI 10.1006/mthe.2002.0812; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Morrish TA, 2002, NAT GENET, V31, P159, DOI 10.1038/ng898; Nigumann P, 2002, GENOMICS, V79, P628, DOI 10.1006/geno.2002.6758; Ohshima K, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-11-r74; Ostertag EM, 2003, AM J HUM GENET, V73, P1444, DOI 10.1086/380207; Ostertag EM, 2002, NAT GENET, V32, P655, DOI 10.1038/ng1022; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Ostertag EM, 2001, GENOME RES, V11, P2059, DOI 10.1101/gr.205701; Ovchinnikov I, 2001, GENOME RES, V11, P2050, DOI 10.1101/gr.194701; Pardue ML, 2003, ANNU REV GENET, V37, P485, DOI 10.1146/annurev.genet.38.072902.093115; Pasyukova EG, 1998, GENET RES, V72, P1, DOI 10.1017/S0016672398003358; Perepelitsa-Belancio V, 2003, NAT GENET, V35, P363, DOI 10.1038/ng1269; Prak ETL, 2003, P NATL ACAD SCI USA, V100, P1832, DOI 10.1073/pnas.0337627100; SanMiguel P, 1996, SCIENCE, V274, P765, DOI 10.1126/science.274.5288.765; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; SERGOLD GD, COMMUNICATION; Shevchenko Y, 2002, NUCLEIC ACIDS RES, V30, P2469, DOI 10.1093/nar/30.11.2469; Sijen T, 2003, NATURE, V426, P310, DOI 10.1038/nature02107; Simmen MW, 1999, SCIENCE, V283, P1164, DOI 10.1126/science.283.5405.1164; Spradling AC, 1999, GENETICS, V153, P135; Symer DE, 2002, CELL, V110, P327, DOI 10.1016/S0092-8674(02)00839-5; Takahashi H, 1997, NUCLEIC ACIDS RES, V25, P1578, DOI 10.1093/nar/25.8.1578; Volff JN, 2003, TRENDS GENET, V19, P674, DOI 10.1016/j.tig.2003.10.006; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WEI W, 2001, MOL CELL BIOL, V21; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568; Zhu YX, 2003, P NATL ACAD SCI USA, V100, P5891, DOI 10.1073/pnas.1036705100	84	1307	1361	9	274	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1626	1632		10.1126/science.1089670	http://dx.doi.org/10.1126/science.1089670			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016989				2022-12-28	WOS:000220151400032
J	Yan, LL; Loukoianov, A; Blechl, A; Tranquilli, G; Ramakrishna, W; SanMiguel, P; Bennetzen, JL; Echenique, V; Dubcovsky, J				Yan, LL; Loukoianov, A; Blechl, A; Tranquilli, G; Ramakrishna, W; SanMiguel, P; Bennetzen, JL; Echenique, V; Dubcovsky, J			The wheat VRN2 gene is a flowering repressor down-regulated by vernalization	SCIENCE			English	Article							ARABIDOPSIS; TIME; PROTEIN; ENCODES; BARLEY	Plants with a winter growth habit flower earlier when exposed for several weeks to cold temperatures, a process called vernalization. We report here the positional cloning of the wheat vernalization gene VRN2, a dominant repressor of flowering that is down-regulated by vernalization. Loss of function of VRN2, whether by natural mutations or deletions, resulted in spring lines, which do not require vernalization to flower. Reduction of the RNA level of VRN2 by RNA interference accelerated the flowering time of transgenic winter-wheat plants by more than a month.	Univ Calif Davis, Dept Agron & Range Sci, Davis, CA 95616 USA; ARS, USDA, Albany, CA 94710 USA; Michigan Technol Univ, Dept Biol Sci, Houghton, MI 49931 USA; Purdue Univ, Purdue Univ Genom Core, W Lafayette, IN 47907 USA; Univ Georgia, Dept Genet, Athens, GA 30602 USA	University of California System; University of California Davis; United States Department of Agriculture (USDA); Michigan Technological University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University System of Georgia; University of Georgia	Dubcovsky, J (corresponding author), Univ Calif Davis, Dept Agron & Range Sci, Davis, CA 95616 USA.	jdubcovsky@ucdavis.edu	Echenique, Viviana/GRX-7389-2022; Ramakrishna, Wusirika/M-6646-2017; SanMiguel, Phillip J/I-2196-2015; Wusirika, Ramakrishna/O-9116-2019; Dubcovsky, Jorge/A-4969-2008; Dubcovsky, Jorge/T-5214-2019	Ramakrishna, Wusirika/0000-0002-8571-5827; SanMiguel, Phillip J/0000-0002-3742-9527; Dubcovsky, Jorge/0000-0002-7571-4345; Echenique, Viviana/0000-0003-3755-9062	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		CHEN CL, 2002, THESIS U CALIFORNIA; Clayton W.D., 1986, GENERA GRAMINUM GRAS; Dubcovsky J, 1998, THEOR APPL GENET, V97, P968, DOI 10.1007/s001220050978; Gazzani S, 2003, PLANT PHYSIOL, V132, P1107, DOI 10.1104/pp.103.021212; Gendall AR, 2001, CELL, V107, P525, DOI 10.1016/S0092-8674(01)00573-6; Griffiths S, 2003, PLANT PHYSIOL, V131, P1855, DOI 10.1104/pp.102.016188; Johanson U, 2000, SCIENCE, V290, P344, DOI 10.1126/science.290.5490.344; Kurup S, 2000, PLANT J, V21, P143, DOI 10.1046/j.1365-313x.2000.00663.x; LAURIE DA, 1995, GENOME, V38, P575, DOI 10.1139/g95-074; Levy YY, 2002, SCIENCE, V297, P243, DOI 10.1126/science.1072147; Lijavetzky D, 1999, GENOME, V42, P1176, DOI 10.1139/gen-42-6-1176; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Robson F, 2001, PLANT J, V28, P619, DOI 10.1046/j.1365-313x.2001.01163.x; Sheldon CC, 1999, PLANT CELL, V11, P445, DOI 10.1105/tpc.11.3.445; Sung SB, 2004, NATURE, V427, P159, DOI 10.1038/nature02195; TAKAHASHI R, 1971, P 2 INT BARL GEN S W, P388; TAKAHASHI R, 1983, CATALOGUE BARLEY GER; Tranquilli G, 2000, J HERED, V91, P304, DOI 10.1093/jhered/91.4.304; Yan L, 2003, P NATL ACAD SCI USA, V100, P6263, DOI 10.1073/pnas.0937399100; YAN L, UNPUB	21	735	829	6	192	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1640	1644		10.1126/science.1094305	http://dx.doi.org/10.1126/science.1094305			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016992	Green Accepted			2022-12-28	WOS:000220151400035
J	Sharp, D				Sharp, D			Highs and lows of cannabis	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							[Anonymous], 1963, LANCET, V2, P989; Arseneault L, 2002, BRIT MED J, V325, P1212, DOI 10.1136/bmj.325.7374.1212; Baker D, 2003, LANCET NEUROL, V2, P291, DOI 10.1016/S1474-4422(03)00381-8; BOGGAN S, 2004, TIMES LONDON    0107, P4; BOOTH M, 2003, CANNABIS HIST, P354; Buggy DJ, 2003, PAIN, V106, P169, DOI 10.1016/S0304-3959(03)00331-2; Degenhardt L, 2003, DRUG ALCOHOL DEPEN, V71, P37, DOI 10.1016/S0376-8716(03)00064-4; Degenhardt Louisa, 2002, Curr Psychiatry Rep, V4, P191, DOI 10.1007/s11920-002-0026-5; DYER G, 2003, FINANCIAL TIMES 1017, P15; *FED BUR INV, 2003, UN CRIM REP 2002; Hall W, 1998, LANCET, V352, P1611, DOI 10.1016/S0140-6736(98)05021-1; Iversen L, 2003, BRAIN, V126, P1252, DOI 10.1093/brain/awg143; Pertwee RG, 2002, PROSTAG LEUKOTR ESS, V66, P101, DOI 10.1054/plef.2001.0341; Zajicek J, 2003, LANCET, V362, P1517, DOI 10.1016/S0140-6736(03)14738-1	14	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	2004	363	9406					344	344		10.1016/S0140-6736(04)15474-3	http://dx.doi.org/10.1016/S0140-6736(04)15474-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768TQ	15070561				2022-12-28	WOS:000188590900006
J	Hasan, RK; Wulfkuhle, JD; Liotta, LA; Petricoin, EF				Hasan, RK; Wulfkuhle, JD; Liotta, LA; Petricoin, EF			Molecular technologies for personalized cancer management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHASE PROTEIN MICROARRAYS; BREAST-CANCER; OVARIAN-CANCER; CHEMOTHERAPY; SURVIVAL; PROGRESSION; MUTATIONS; DNA		Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; NCI, Bethesda, MD 20892 USA; US FDA, Bethesda, MD 20014 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)	Hasan, RK (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.							*AM CANC SOC, 2003, CANC FACTS FIG; Baak JPA, 2003, EUR J CANCER, V39, P1199, DOI 10.1016/S0959-8049(03)00265-X; Cheng L, 1999, CANCER, V85, P2455, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2455::AID-CNCR22>3.3.CO;2-3; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Haber D, 2002, NEW ENGL J MED, V346, P1660, DOI 10.1056/NEJMed020044; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; LU ZH, 1993, CANCER RES, V53, P5433; Mariadason JM, 2003, HEMATOL ONCOL CLIN N, V17, P377, DOI 10.1016/S0889-8588(03)00006-6; McLeod HL, 2000, LEUKEMIA, V14, P567, DOI 10.1038/sj.leu.2401723; Ntzani EE, 2003, LANCET, V362, P1439, DOI 10.1016/S0140-6736(03)14686-7; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Shirota Y, 2001, J CLIN ONCOL, V19, P4298, DOI 10.1200/JCO.2001.19.23.4298; Sotiriou C, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr433; Templin MF, 2002, TRENDS BIOTECHNOL, V20, P160, DOI 10.1016/S0167-7799(01)01910-2; Traverso G, 2002, NEW ENGL J MED, V346, P311, DOI 10.1056/NEJMoa012294; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Workman P, 2001, Expert Opin Pharmacother, V2, P911; Wulfkuhle JD, 2003, PROTEOMICS, V3, P2085, DOI 10.1002/pmic.200300591; Wulfkuhle JD, 2003, NAT REV CANCER, V3, P267, DOI 10.1038/nrc1043	20	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2004	291	13					1644	1645		10.1001/jama.291.13.1644	http://dx.doi.org/10.1001/jama.291.13.1644			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809PQ	15069056				2022-12-28	WOS:000220649000033
J	Azzalin, CM; Lingner, J				Azzalin, CM; Lingner, J			Telomere wedding ends in divorce	SCIENCE			English	Editorial Material							TANKYRASE; REPAIR; CELLS; TRF1		Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Azzalin, CM (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.	joachim.lingner@isrec.unil.ch	azzalin, claus M/K-3898-2015	azzalin, claus M/0000-0002-9396-1980; Lingner, Joachim/0000-0002-2853-5803				AMON A, 2004, MIAM NAT BIOT WINT S; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Chang W, 2003, GENE DEV, V17, P1328, DOI 10.1101/gad.1077103; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Griffith J, 1998, J MOL BIOL, V278, P79, DOI 10.1006/jmbi.1998.1686; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Miller KM, 2003, MOL CELL, V11, P303, DOI 10.1016/S1097-2765(03)00041-8; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Sjogren C, 2001, CURR BIOL, V11, P991, DOI 10.1016/S0960-9822(01)00271-8; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0	13	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					60	62		10.1126/science.1096809	http://dx.doi.org/10.1126/science.1096809			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15064409				2022-12-28	WOS:000220567900033
J	Korobkova, E; Emonet, T; Vilar, JMG; Shimizu, TS; Cluzel, P				Korobkova, E; Emonet, T; Vilar, JMG; Shimizu, TS; Cluzel, P			From molecular noise to behavioural variability in a single bacterium	NATURE			English	Article							ESCHERICHIA-COLI; CHEMOTAXIS; ADAPTATION; METHYLATION; ROBUSTNESS; PROTEINS; MODEL; MOTOR; CELLS	The chemotaxis network that governs the motion of Escherichia coli has long been studied to gain a general understanding of signal transduction. Although this pathway is composed of just a few components, it exhibits some essential characteristics of biological complexity, such as adaptation and response to environmental signals(1). In studying intracellular networks, most experiments and mathematical models(2-5) have assumed that network properties can be inferred from population measurements. However, this approach masks underlying temporal fluctuations of intracellular signalling events. We have inferred fundamental properties of the chemotaxis network from a noise analysis of behavioural variations in individual bacteria. Here we show that certain properties established by population measurements, such as adapted states, are not conserved at the single-cell level: for timescales ranging from seconds to several minutes, the behaviour of non-stimulated cells exhibit temporal variations much larger than the expected statistical fluctuations. We find that the signalling network itself causes this noise and identify the molecular events that produce it. Small changes in the concentration of one key network component suppress temporal behavioural variability, suggesting that such variability is a selected property of this adaptive system.	Univ Chicago, Inst Biophys Dynam, Chicago, IL 60637 USA; Univ Chicago, James Franck Inst, Chicago, IL 60637 USA; Rockefeller Univ, New York, NY 10021 USA; Keio Univ, Inst Adv Biosci, Lab Bioinformat, Fujisawa, Kanagawa 2528520, Japan	University of Chicago; University of Chicago; Rockefeller University; Keio University	Cluzel, P (corresponding author), Univ Chicago, Inst Biophys Dynam, 5640 S Ellis Ave, Chicago, IL 60637 USA.	cluzel@uchicago.edu	Vilar, Jose MG/A-9069-2013; Emonet, Thierry/AAI-3740-2020	Vilar, Jose MG/0000-0003-4037-0746; 				Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; Alon U, 1998, EMBO J, V17, P4238, DOI 10.1093/emboj/17.15.4238; ASAKURA S, 1984, J MOL BIOL, V176, P349, DOI 10.1016/0022-2836(84)90494-7; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BLOCK SM, 1983, J BACTERIOL, V154, P312, DOI 10.1128/JB.154.1.312-323.1983; Bourret RB, 2002, J BIOL CHEM, V277, P9625, DOI 10.1074/jbc.R100066200; Cluzel P, 2000, SCIENCE, V287, P1652, DOI 10.1126/science.287.5458.1652; Detwiler PB, 2000, BIOPHYS J, V79, P2801, DOI 10.1016/S0006-3495(00)76519-2; Elf J, 2003, BIOPHYS J, V84, P154, DOI 10.1016/S0006-3495(03)74839-5; FAHRNER KA, 1995, THESIS HARVARD U; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; ISHIHARA A, 1983, J BACTERIOL, V155, P228, DOI 10.1128/JB.155.1.228-237.1983; KATZ B, 1972, J PHYSIOL-LONDON, V224, P665, DOI 10.1113/jphysiol.1972.sp009918; KHAN S, 1980, J MOL BIOL, V138, P563, DOI 10.1016/S0022-2836(80)80018-0; LARSEN SH, 1974, NATURE, V249, P74, DOI 10.1038/249074a0; Levit MN, 2002, J BIOL CHEM, V277, P36760, DOI 10.1074/jbc.M204325200; Morton-Firth CJ, 1999, J MOL BIOL, V286, P1059, DOI 10.1006/jmbi.1999.2535; Morton-Firth CJ, 1998, J THEOR BIOL, V192, P117, DOI 10.1006/jtbi.1997.0651; Rao CV, 2002, NATURE, V420, P231, DOI 10.1038/nature01258; SAMUEL ADT, 1995, P NATL ACAD SCI USA, V92, P3502, DOI 10.1073/pnas.92.8.3502; Spiro PA, 1997, P NATL ACAD SCI USA, V94, P7263, DOI 10.1073/pnas.94.14.7263; SPUDICH JL, 1976, NATURE, V262, P467, DOI 10.1038/262467a0; Viswanathan GM, 1999, NATURE, V401, P911, DOI 10.1038/44831; Yi TM, 2000, P NATL ACAD SCI USA, V97, P4649, DOI 10.1073/pnas.97.9.4649	24	343	354	1	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					574	578		10.1038/nature02404	http://dx.doi.org/10.1038/nature02404			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15058306				2022-12-28	WOS:000220540100045
J	Schneider, H; Schuettpelz, E; Pryer, KM; Cranfill, R; Magallon, S; Lupia, R				Schneider, H; Schuettpelz, E; Pryer, KM; Cranfill, R; Magallon, S; Lupia, R			Ferns diversified in the shadow of angiosperms	NATURE			English	Article							DIVERGENCE TIMES; EVOLUTION; SEQUENCES; ABUNDANCE; PLANTS; LIGHT; RATES; RBCL	The rise of angiosperms during the Cretaceous period is often portrayed as coincident with a dramatic drop in the diversity and abundance of many seed-free vascular plant lineages, including ferns(1-5). This has led to the widespread belief that ferns, once a principal component of terrestrial ecosystems(6), succumbed to the ecological predominance of angiosperms and are mostly evolutionary holdovers from the late Palaeozoic/early Mesozoic era. The first appearance of many modern fern genera in the early Tertiary fossil record implies another evolutionary scenario; that is, that the majority of living ferns resulted from a more recent diversification(7-10). But a full understanding of trends in fern diversification and evolution using only palaeobotanical evidence is hindered by the poor taxonomic resolution of the fern fossil record in the Cretaceous(11). Here we report divergence time estimates for ferns and angiosperms based on molecular data, with constraints from a reassessment of the fossil record. We show that polypod ferns (>80% of living fern species) diversified in the Cretaceous, after angiosperms, suggesting perhaps an ecological opportunistic response to the diversification of angiosperms, as angiosperms came to dominate terrestrial ecosystems.	Duke Univ, Dept Biol, Durham, NC 27708 USA; Univ Gottingen, Albert von Haller Inst Pflanzenwissensch, Abt Systemat Bot, D-37073 Gottingen, Germany; Univ Calif Berkeley, Univ Herbarium, Berkeley, CA 94720 USA; Univ Nacl Autonoma Mexico, Inst Biol, Dept Bot, Mexico City 04510, DF, Mexico; Univ Oklahoma, Sam Noble Oklahoma Museum Nat Hist, Norman, OK 73072 USA; Univ Oklahoma, Sch Geol & Geophys, Norman, OK 73072 USA	Duke University; University of Gottingen; University of California System; University of California Berkeley; Universidad Nacional Autonoma de Mexico; University of Oklahoma System; University of Oklahoma - Norman; University of Oklahoma System; University of Oklahoma - Norman	Pryer, KM (corresponding author), Duke Univ, Dept Biol, Durham, NC 27708 USA.	pryer@duke.edu	Pryer, Kathleen M./ABF-4908-2020; Pryer, Kathleen/X-4635-2019; Schuettpelz, Eric/A-4881-2008; Schneider, Harald/B-6681-2008	Pryer, Kathleen M./0000-0002-9776-6736; Schneider, Harald/0000-0002-4548-7268; Schuettpelz, Eric/0000-0003-3891-9904; Magallon, Susana/0000-0002-6838-7497				Benton MJ, 2003, SCIENCE, V300, P1698, DOI 10.1126/science.1077795; Collinson M. E., 1996, PTERIDOLOGY PERSPECT, P349; Crane P. R., 1987, ORIGINS ANGIOSPERMS, P107; CRANE PR, 1995, NATURE, V374, P27, DOI 10.1038/374027a0; Deng SH, 2002, REV PALAEOBOT PALYNO, V119, P93, DOI 10.1016/S0034-6667(01)00131-2; Dilcher DL, 2001, TAXON, V50, P697, DOI 10.2307/1223702; Friis EM, 2001, NATURE, V410, P357, DOI 10.1038/35066557; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Kawai H, 2003, NATURE, V421, P287, DOI 10.1038/nature01310; LIDGARD S, 1990, PALEOBIOLOGY, V16, P77, DOI 10.1017/S009483730000974X; Lovis JD, 1977, ADV BOT RES, V4, P229, DOI DOI 10.1016/S0065-2296(08)60371-7; Lupia R, 1999, PALEOBIOLOGY, V25, P305, DOI 10.1017/S009483730002131X; Magallon S, 2001, EVOLUTION, V55, P1762, DOI 10.1111/j.0014-3820.2001.tb00826.x; Nagalingum NS, 2002, REV PALAEOBOT PALYNO, V119, P69, DOI 10.1016/S0034-6667(01)00130-0; NIKLAS KJ, 1983, NATURE, V303, P614, DOI 10.1038/303614a0; PAGEL M, 2002, BIOL EVOLUTION STAT, P148; Pryer KM, 2001, NATURE, V409, P618, DOI 10.1038/35054555; Qiu YL, 1999, NATURE, V402, P404, DOI 10.1038/46536; Rothwell G. W., 1996, PTERIDOLOGY PERSPECT, P395; Sanderson MJ, 2002, MOL BIOL EVOL, V19, P101, DOI 10.1093/oxfordjournals.molbev.a003974; Sandler HM, 2002, CANCER J, V8, P301, DOI 10.1097/00130404-200207000-00005; Schneider H, 2001, REV PALAEOBOT PALYNO, V115, P33, DOI 10.1016/S0034-6667(01)00048-3; Skog JE, 2001, BRITTONIA, V53, P236, DOI 10.1007/BF02812701; SMITH A R, 1972, Biotropica, V4, P4, DOI 10.2307/2989639; Smith H, 2000, NATURE, V407, P585, DOI 10.1038/35036500; Soltis DE, 2000, BOT J LINN SOC, V133, P381, DOI [10.1111/j.1095-8339.2000.tb01588.x, 10.1006/bojl.2000.0380]; Soltis PS, 1999, NATURE, V402, P402, DOI 10.1038/46528; Soltis PS, 2002, P NATL ACAD SCI USA, V99, P4430, DOI 10.1073/pnas.032087199; Wikstrom N, 2001, P ROY SOC B-BIOL SCI, V268, P2211, DOI 10.1098/rspb.2001.1782; Wikstrom N, 2001, MOL PHYLOGENET EVOL, V19, P177, DOI 10.1006/mpev.2001.0936	30	547	611	5	143	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					553	557		10.1038/nature02361	http://dx.doi.org/10.1038/nature02361			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15058303				2022-12-28	WOS:000220540100040
J	McNamara, PS; Flanagan, BF; Baldwin, LM; Newland, P; Hart, CA; Smyth, RL				McNamara, PS; Flanagan, BF; Baldwin, LM; Newland, P; Hart, CA; Smyth, RL			Interleukin 9 production in the lungs of infants with severe respiratory syncytial virus bronchlolitis	LANCET			English	Article							TRANSGENIC MICE; BRONCHOALVEOLAR LAVAGE; CHEMOKINE EXPRESSION; AIRWAY INFLAMMATION; EPITHELIAL-CELLS; BRONCHIAL LAVAGE; BRONCHIOLITIS; DISEASE; IL-9; INFECTION	Background Respiratory syncytial virus (RSV) bronchiolitis is the most prevalent acute wheezing disorder in infants and is associated with recurrent wheeze and asthma in childhood. Interleukin 9, a type 2 cytokine has been proposed as a key cytokine in susceptibility to asthma. We aimed to investigate whether interleukin 9 was produced in the lungs of infants with severe RSV disease and if found, from which cells it originated. Methods We did 150 non-bronchoscopic bronchoalveolar lavages during the course of ventilation in 24 term infants and 21 preterm infants ventilated for RSV bronchiolitis. We also did 10 bronchoalveolar lavages on the day of intubation in 10 control infants ventilated for non-respiratory causes. We measured pulmonary interleukin 9 mRNA and protein in samples from all groups. We used immunostaining to identify the cells that produce interleukin 9. Findings Interleukin 9 mRNA expression, which persisted over the course of ventilation, was noted in all infants with bronchiolitis. Three of the control group also showed interleukin 9 mRNA expression. Median interleukin 9 protein concentration on day 1 (1.9 mug,/L [range 0.1-36.2]) was significantly greater in term infants with bronchiolitis than either preterm infants (0.4 mug/L [0.1-2.9]; p<0.05) or the control group (0.7, mu g/L [0.4-2.5]; p<0.05). There was a trend for interleukin 9 protein concentrations in term, but not preterm infants to decrease over time. Immunostained cell smears showed that most interleukin 9 expression in bronchoalveolar lavage was by neutrophils. Interpretation In term infants with RSV bronchiolitis, we noted large amounts of interleukin 9 mRNA and interleukin 9 protein. Neutrophils seem to be the main source of this type 2 cytokine. Interleukin 9 production by neutrophils may contribute to the pathogenesis of RSV disease. These findings may be relevant to other disease processes in the lung where neutrophils are the predominant inflammatory cell type.	Univ Liverpool, Dept Child Hlth, Inst Child Hlth, Liverpool L69 3BX, Merseyside, England; Alder Hey Childrens Hosp, Dept Biochem, Liverpool L12 2AP, Merseyside, England; Univ Liverpool, Dept Med Microbiol, Liverpool L69 3BX, Merseyside, England; Univ Liverpool, Dept Immunol, Liverpool L69 3BX, Merseyside, England; Univ Liverpool, Dept Clin Engn, Liverpool L69 3BX, Merseyside, England	University of Liverpool; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool	Smyth, RL (corresponding author), Alder Hey Childrens Hosp, Dept Child Hlth, Eaton Rd, Liverpool L12 2AP, Merseyside, England.	r.l.smyth@liv.ac.uk		McNamara, Paul/0000-0002-7055-6034				Abdelilah SG, 2001, J IMMUNOL, V166, P2768, DOI 10.4049/jimmunol.166.4.2768; Bhathena PR, 2000, LUNG, V178, P149, DOI 10.1007/s004080000018; Cheng G, 2002, AM J RESP CRIT CARE, V166, P409, DOI 10.1164/rccm.2105079; de Blic J, 2000, EUR RESPIR J, V15, P217; Dong Q, 1999, EUR J IMMUNOL, V29, P2130, DOI 10.1002/(SICI)1521-4141(199907)29:07<2130::AID-IMMU2130>3.0.CO;2-S; EVERARD ML, 1994, ARCH DIS CHILD, V71, P428, DOI 10.1136/adc.71.5.428; Garofalo RP, 2001, J INFECT DIS, V184, P393, DOI 10.1086/322788; Gavin R, 1996, NEW ZEAL MED J, V109, P137; Graham BS, 2000, IMMUNOPHARMACOLOGY, V48, P237, DOI 10.1016/S0162-3109(00)00233-2; Grigg J, 1999, EUR RESPIR J, V14, P1198, DOI 10.1183/09031936.99.14511989; Hall CB, 1998, TXB PEDIAT INFECT DI, P2084; Harrison AM, 1999, AM J RESP CRIT CARE, V159, P1918, DOI 10.1164/ajrccm.159.6.9805083; Hornsleth A, 2001, J CLIN VIROL, V21, P163, DOI 10.1016/S1386-6532(01)00159-7; Hussell T, 2001, EUR J IMMUNOL, V31, P2566, DOI 10.1002/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L; Kim WD, 1997, EUR RESPIR J, V10, P1914, DOI 10.1183/09031936.97.10081914; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; McNamara PS, 2003, ARCH DIS CHILD, V88, P922, DOI 10.1136/adc.88.10.922; McNamara PS, 2002, BRIT MED BULL, V61, P13, DOI 10.1093/bmb/61.1.13; NAVAS L, 1992, J PEDIATR-US, V121, P348, DOI 10.1016/S0022-3476(05)90000-0; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; Shimbara A, 2000, J ALLERGY CLIN IMMUN, V105, P108, DOI 10.1016/S0091-6749(00)90185-4; Smith PK, 2001, J PAEDIATR CHILD H, V37, P146, DOI 10.1046/j.1440-1754.2001.00618.x; Smyth RL, 2002, PEDIATR PULM, V33, P339, DOI 10.1002/ppul.10080; Soussi-Gounni A, 2001, J ALLERGY CLIN IMMUN, V107, P575, DOI 10.1067/mai.2001.114238; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Tonnel AB, 2001, INT ARCH ALLERGY IMM, V124, P267, DOI 10.1159/000053729; Whittaker L, 2002, AM J RESP CELL MOL, V27, P593, DOI 10.1165/rcmb.4838	29	81	84	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	2004	363	9414					1031	1037		10.1016/S0140-6736(04)15838-8	http://dx.doi.org/10.1016/S0140-6736(04)15838-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15051283				2022-12-28	WOS:000220497300009
J	Reynolds, SJ; Shepherd, ME; Risbud, AR; Gangakhedkar, RR; Brookmeyer, RS; Divekar, AD; Mehendale, SM; Bollinger, RC				Reynolds, SJ; Shepherd, ME; Risbud, AR; Gangakhedkar, RR; Brookmeyer, RS; Divekar, AD; Mehendale, SM; Bollinger, RC			Male circumcision and risk of HIV-1 and other sexually transmitted infections in India	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; COHORT	Circumcised men have a lower risk of HIV-1 infection than uncircumcised men. Laboratory findings suggest that the foreskin is enriched with HIV-1 target cells. However, some data suggest that circumcision could simply be a marker for low-risk behaviours. In a prospective study of 2298 HIV-uninfected men attending sexually transmitted infection clinics in India, we noted that circumcision was strongly protective against HIV-1 infection (adjusted relative risk 0.15; 95% Cl 0.04-0.62; p=0.0089); however, we noted no protective effect against herpes simplex virus type 2, syphilis, or gonorrhoea. The specificity of this relation suggests a biological rather than behavioural explanation for the protective effect of male circumcision against HIV-1.	Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA; Natl AIDS Res Inst, Pune, Maharashtra, India	Johns Hopkins University; Indian Council of Medical Research (ICMR); ICMR - National AIDS Research Institute (NARI)	Bollinger, RC (corresponding author), Johns Hopkins Univ, Sch Med, Div Infect Dis, Ross 1150,720 Rutland Ave, Baltimore, MD 21205 USA.	rcb@jhmi.edu		Reynolds, Steven/0000-0002-5403-2759; Bollinger, Robert/0000-0002-6798-6834	FIC NIH HHS [TW000010] Funding Source: Medline; NIAID NIH HHS [R21-AI3387901, N01-AI35173, R01-AI41369] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI035173, R01AI041369, R21AI033879] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Gray RH, 2000, AIDS, V14, P2371, DOI 10.1097/00002030-200010200-00019; Lavreys L, 1999, J INFECT DIS, V180, P330, DOI 10.1086/314884; MEHENDALE SM, 1995, J INFECT DIS, V172, P1486, DOI 10.1093/infdis/172.6.1486; Patterson BK, 2002, AM J PATHOL, V161, P867, DOI 10.1016/S0002-9440(10)64247-2; Weiss HA, 2000, AIDS, V14, P2361, DOI 10.1097/00002030-200010200-00018	5	126	127	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	2004	363	9414					1039	1040		10.1016/S0140-6736(04)15840-6	http://dx.doi.org/10.1016/S0140-6736(04)15840-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15051285				2022-12-28	WOS:000220497300011
J	Norman, M				Norman, M			Have cuprates earned their stripes?	SCIENCE			English	Editorial Material							BI2SR2CACU2O8+DELTA; SUPERCONDUCTIVITY; STATES		Argonne Natl Lab, Div Mat Sci, Argonne, IL 60439 USA	United States Department of Energy (DOE); Argonne National Laboratory	Norman, M (corresponding author), Argonne Natl Lab, Div Mat Sci, 9700 S Cass Ave, Argonne, IL 60439 USA.	norman@anl.gov	Norman, Michael R/C-3644-2013	Norman, Michael R/0000-0002-9459-078X				Cho A, 2002, SCIENCE, V297, P499, DOI 10.1126/science.297.5581.499; Hoffman JE, 2002, SCIENCE, V295, P466, DOI 10.1126/science.1066974; Hoffman JE, 2002, SCIENCE, V297, P1148, DOI 10.1126/science.1072640; Howald C, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.014533; Lang KM, 2002, NATURE, V415, P412, DOI 10.1038/415412a; McElroy K, 2003, NATURE, V422, P592, DOI 10.1038/nature01496; MCELROY K, UNPUB; Norman MR, 1998, NATURE, V392, P157, DOI 10.1038/32366; Pan SH, 2001, NATURE, V413, P282, DOI 10.1038/35095012; Vershinin M, 2004, SCIENCE, V303, P1995, DOI 10.1126/science.1093384	11	8	8	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	2004	303	5666					1985	1986		10.1126/science.1096341	http://dx.doi.org/10.1126/science.1096341			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044795				2022-12-28	WOS:000220429800030
J	Cacciuto, A; Auer, S; Frenkel, D				Cacciuto, A; Auer, S; Frenkel, D			Onset of heterogeneous crystal nucleation in colloidal suspensions	NATURE			English	Article							MIXTURES	The addition of small 'seed' particles to a supersaturated solution can greatly increase the rate at which crystals nucleate. This process is understood, at least qualitatively, when the seed has the same structure as the crystal that it spawns(1,2). However, the microscopic mechanism of seeding by a 'foreign' substance is not well understood. Here we report numerical simulations of colloidal crystallization seeded by foreign objects. We perform Monte Carlo simulations to study how smooth spherical seeds of various sizes affect crystallization in a suspension of hard colloidal particles. We compute the free-energy barrier associated with crystal nucleation(3,4). A low barrier implies that nucleation is easy. We find that to be effective crystallization promoters, the seed particles need to exceed a well-defined minimum size. Just above this size, seed particles act as crystallization 'catalysts' as newly formed crystallites detach from the seed. In contrast, larger seed particles remain covered by the crystallites that they spawn. This phenomenon should be experimentally observable and can have important consequences for the control of the resulting crystal size distribution.	FOM, Inst Atom & Mol Phys, NL-1098 SJ Amsterdam, Netherlands	AMOLF	Cacciuto, A (corresponding author), FOM, Inst Atom & Mol Phys, Kruislaan 407, NL-1098 SJ Amsterdam, Netherlands.	cacciuto@amolf.nl	Frenkel, Daan/G-2580-2014; Auer, Stefan/F-8395-2011	Frenkel, Daan/0000-0002-6362-2021; 				Auer S, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.015703; Auer S, 2001, NATURE, V413, P711, DOI 10.1038/35099513; AUER S, 2004, ANN REV PHYS CHEM, V55; Dinsmore AD, 1997, EUROPHYS LETT, V40, P337, DOI 10.1209/epl/i1997-00468-4; Ehrenreich H., 1991, SOLID STATE PHYS, V45; EULER I, 1953, OPERA OMNIA SERIES 1, V26; Gasser U, 2001, SCIENCE, V292, P258, DOI 10.1126/science.1058457; Hilton P, 1996, AM MATH MON, V103, P121, DOI 10.2307/2975104; KAPLAN PD, 1994, PHYS REV LETT, V72, P582, DOI 10.1103/PhysRevLett.72.582; KOSE A, 1976, J COLLOID INTERF SCI, V55, P487, DOI 10.1016/0021-9797(76)90059-X; Ostwald W., 1897, Z PHYS CHEM, V22, P289, DOI [DOI 10.1515/ZPCH-1897-2233, 10.1515/zpch-1897-2233]; tenWolde PR, 1996, J CHEM PHYS, V104, P9932, DOI 10.1063/1.471721	12	330	334	8	162	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 25	2004	428	6981					404	406		10.1038/nature02397	http://dx.doi.org/10.1038/nature02397			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042084	Green Published			2022-12-28	WOS:000220404300036
J	Gratson, GM; Xu, MJ; Lewis, JA				Gratson, GM; Xu, MJ; Lewis, JA			Microperiodic structures - Direct writing of three-dimensional webs	NATURE			English	Editorial Material									Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL 61801 USA; Univ Illinois, Dept Mat Sci & Engn, Urbana, IL 61801 USA; Univ Illinois, Dept Chem & Biomol Engn, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Lewis, JA (corresponding author), Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL 61801 USA.	jalewis@uiuc.edu						Caruso F, 1998, SCIENCE, V282, P1111, DOI 10.1126/science.282.5391.1111; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chrisey DB, 2000, SCIENCE, V289, P879, DOI 10.1126/science.289.5481.879; Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232; Griffith LG, 2002, SCIENCE, V295, P1009, DOI 10.1126/science.1069210; Lee YJ, 2003, ADV MATER, V15, P563, DOI 10.1002/adma.200304588; Lin SY, 1998, NATURE, V394, P251, DOI 10.1038/28343; Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661; SITTINGHOUS H, 2000, SCIENCE, V290, P2123; Therriault D, 2003, NAT MATER, V2, P265, DOI 10.1038/nmat863; Zezin A.B., 1982, RUSS CHEM REV+, V51, P833, DOI [10.1070/RC1982v051n09ABEH002921, DOI 10.1070/RC1982V051N09ABEH002921, 10.1070/RC1982V051N09ABEH002921]; Zintchenko A, 2003, LANGMUIR, V19, P2507, DOI 10.1021/la0265427	12	294	322	3	185	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 25	2004	428	6981					386	386		10.1038/428386a	http://dx.doi.org/10.1038/428386a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042080	Bronze			2022-12-28	WOS:000220404300030
J	Brown, MM				Brown, MM			Surprising post morterns	LANCET			English	Editorial Material									UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Brown, MM (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England.		Brown, Martin M/B-3288-2009	Brown, Martin M/0000-0002-3273-1356					0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 20	2004	363	9413					988	988		10.1016/S0140-6736(04)15795-4	http://dx.doi.org/10.1016/S0140-6736(04)15795-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043968				2022-12-28	WOS:000220308600026
J	McNutt, R; Abrams, R; Hasler, S				McNutt, R; Abrams, R; Hasler, S			Why blame systems for unsafe care?	LANCET			English	Editorial Material							ERRORS		Rush Univ, Med Ctr, Dept Med, Chicago, IL 60621 USA	Rush University	McNutt, R (corresponding author), Rush Univ, Med Ctr, Dept Med, Chicago, IL 60621 USA.	Robert_McNutt@rush.edu						Berwick DM, 2003, NEW ENGL J MED, V348, P2570, DOI 10.1056/NEJMe030044; Berwick DM, 2001, BMJ-BRIT MED J, V322, P247, DOI 10.1136/bmj.322.7281.247; Cleghorn GD, 1996, JOINT COMM J QUAL IM, V22, P206, DOI 10.1016/S1070-3241(16)30223-1; McNutt RA, 2002, JAMA-J AM MED ASSOC, V287, P1997, DOI 10.1001/jama.287.15.1997; Pande PS, 2000, 6 SIGMA WAY GE MOTOR; SCHRIEBER J, 2003, MANAGEMENT DIABETIC	6	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	2004	363	9413					913	914		10.1016/S0140-6736(04)15821-2	http://dx.doi.org/10.1016/S0140-6736(04)15821-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043956				2022-12-28	WOS:000220308600005
J	Pilkey, OH; Cooper, JAG				Pilkey, OH; Cooper, JAG			Society and sea level rise	SCIENCE			English	Editorial Material							COASTAL EROSION; MODELS		Duke Univ, Nicholas Sch Environm & Earth Sci, Durham, NC 27708 USA; Univ Ulster, Coastal Res Grp, Coleraine BT52 1SA, Londonderry, North Ireland	Duke University; Ulster University	Pilkey, OH (corresponding author), Duke Univ, Nicholas Sch Environm & Earth Sci, Durham, NC 27708 USA.	opilkey@duke.edu; jag.cooper@ulster.ac.uk	Cooper, Andrew/AAH-4251-2020	Cooper, Andrew/0000-0003-4972-8812				Bruun P., 1962, J WATERWAYS HARBORS, V88, P117, DOI [DOI 10.1061/JWHEAU.0000252, DOI 10.2112/SI65-356.1]; Day C, 2004, PHYS TODAY, V57, P24; DEANDA D, 1990, CHILD ADOLESCENT SOC, V7, P53, DOI DOI 10.1007/BF00757589; KOMAR PD, 1991, J COASTAL RES, V7, P895; Leatherman SP., 2001, INT GEOPHYS, V75, P181, DOI DOI 10.1016/S0074-6142(01)80011-5; List JH, 1997, MAR GEOL, V140, P347, DOI 10.1016/S0025-3227(97)00035-2; Pilkey O.H., 2000, EOS T AM GEOPHYS UNI, V81, P436, DOI [10.1029/00EO00327, DOI 10.1029/00EO00327]; PILKEY OH, 1987, SEPM SPEC PUB, V19, P59; Sallenger A., 2000, EOS T AM GEOPHYS UN, V81, P436, DOI DOI 10.1029/E0081I038P00436-02; Thieler ER, 2000, J COASTAL RES, V16, P48	10	95	97	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	2004	303	5665					1781	1782		10.1126/science.1093515	http://dx.doi.org/10.1126/science.1093515			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031484				2022-12-28	WOS:000220281600032
J	Phillips, CO; Wright, SM; Kern, DE; Singa, RM; Shepperd, S; Rubin, HR				Phillips, CO; Wright, SM; Kern, DE; Singa, RM; Shepperd, S; Rubin, HR			Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MANAGEMENT TELEPHONE INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; HOME-BASED INTERVENTION; HOSPITAL READMISSIONS; MEDICARE BENEFICIARIES; ELDERLY PATIENTS; CLINICAL-TRIALS; CARE; MULTIDISCIPLINARY; QUALITY	Context Comprehensive discharge planning plus postdischarge support may reduce readmission rates for older patients with congestive heart failure(CHF). Objective To evaluate the effect of comprehensive discharge planning plus postdischarge support on the rate of readmission in patients with CHF, all-cause mortality, length of stay (LOS), quality of life (QOL), and medical costs. DataSources We searched MEDLINE (1966 to October 2003), the Cochrane Clinical Trials Register (all years), Social Science Citation Index (1992 to October 2003), and other databases for studies that described such an intervention and evaluated its effect in patients with CHF. Where possible we also contacted lead investigators and experts in the field. Study Selection We selected English-language publications of randomized clinical trials that described interventions to modify hospital discharge for older patients with CHF (mean age 55 years), delineated clearly defined inpatient and outpatient components, compared efficacy with usual care, and reported readmission as the primary outcome. Data Extraction Two authors independently reviewed each report, assigned quality scores, and extracted data for primary and secondary outcomes in an unblinded standardized manner. Data Synthesis Eighteen studies representing data from 8 countries randomized 3304 older inpatients with CHF to comprehensive discharge planning plus postdischarge support or usual care. During a pooled mean observation period of 8 months (range, 3-12 months), fewer intervention patients were readmitted compared with controls (555/ 1590 vs 741/1714, number needed to treat = 12; relative risk [RR], 0.75; 95% confidence interval [CI], 0.64-0.88). Analysis of studies reporting secondary outcomes found a trend toward lower all-cause mortality for patients assigned to an intervention compared with usual care (RR, 0.87 95 % Cl, 0.73-1.03; n = 14 studies), similar initial LOS (mean [SE]: 8.4 [2.5] vs 8.5 [2.2] days, P=.60; n=10), greater percentage improvement in QOL scores compared with baseline scores (25.7% [95% Cl, 11.0%-40.4%] vs 13.5% [95% Cl, 5.1%-22.0%]; n=6, P=.01), and similaror lower charges for medical care per patient per month for the initial hospital stay, administering the intervention, outpatient care, and readmission (-$359 [95 % Cl, -$763 to $45]; n =4, P=. 10 for non-US trials and -$536 [95% Cl, -$956 to -$115]; n=4, P=.03, for US trials). Conclusion Comprehensive discharge planning plus postdischarge support for older patients with CHF significantly reduced readmission rates and may improve health outcomes such as survival and QOL without increasing costs.	Univ Oxford, Inst Hlth Sci, Oxford, England; Johns Hopkins Univ, Dept Med, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Johns Hopkins Bayview Med Ctr, Div Gen Internal Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA	University of Oxford; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Phillips, CO (corresponding author), Brigham & Womens Hosp, 75 Francis St,Tower 5-509A, Boston, MA 02115 USA.	chr_phi@yahoo.com		Shepperd, Sasha/0000-0001-6384-8322	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [T32PE010025] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL073347] Funding Source: NIH RePORTER; NHLBI NIH HHS [K24 HL073347] Funding Source: Medline; BHP HRSA HHS [2-T32-PE10025] Funding Source: Medline	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BHP HRSA HHS		*AM MED ASS, 1996, PHYS CURR PROC TERM; ANDERSON GF, 1984, NEW ENGL J MED, V311, P1349, DOI 10.1056/NEJM198411223112105; ASHTON CM, 1995, ANN INTERN MED, V122, P415, DOI 10.7326/0003-4819-122-6-199503150-00003; Berlin JA, 1997, LANCET, V350, P185, DOI 10.1016/S0140-6736(05)62352-5; Blue L, 2001, BRIT MED J, V323, P715, DOI 10.1136/bmj.323.7315.715; Capomolla S, 2002, J AM COLL CARDIOL, V40, P1259, DOI 10.1016/S0735-1097(02)02140-X; Cline CMJ, 1998, HEART, V80, P442, DOI 10.1136/hrt.80.5.442; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DESHARNAIS S, 1991, EVAL HEALTH PROF, V14, P228, DOI 10.1177/016327879101400206; FISHER ES, 1994, NEW ENGL J MED, V331, P989, DOI 10.1056/NEJM199410133311506; Funk M, 1996, J Cardiovasc Nurs, V10, P1; GHALI JK, 1990, ARCH INTERN MED, V150, P769, DOI 10.1001/archinte.150.4.769; Grancelli H, 2003, J CARD FAIL, V9, P172, DOI 10.1054/jcaf.2003.33; Harrison MB, 2002, MED CARE, V40, P271, DOI 10.1097/00005650-200204000-00003; *HLTH CAR FIN REV, 1997, MED MED STAT SUPPL 1; Hunt SA, 2002, J HEART LUNG TRANSPL, V21, P189, DOI 10.1016/S1053-2498(01)00776-8; Jaarsma T, 1999, EUR HEART J, V20, P673, DOI 10.1053/euhj.1998.1341; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; KONSTAM M, 1994, AHCPR PUBLICATION; Krumholz HM, 1997, ARCH INTERN MED, V157, P99, DOI 10.1001/archinte.157.1.99; Krumholz HM, 2002, J AM COLL CARDIOL, V39, P83, DOI 10.1016/S0735-1097(01)01699-0; Laramee AS, 2003, ARCH INTERN MED, V163, P809, DOI 10.1001/archinte.163.7.809; LOEB JM, 1993, JAMA-J AM MED ASSOC, V269, P1282; Macaskill P, 2001, STAT MED, V20, P641, DOI 10.1002/sim.698; MAMON J, 1992, HEALTH SERV RES, V27, P155; Marcantonio ER, 1999, AM J MED, V107, P13, DOI 10.1016/S0002-9343(99)00159-X; McAlister FA, 2001, AM J MED, V110, P378, DOI 10.1016/S0002-9343(00)00743-9; McDonald K, 2002, J CARD FAIL, V8, P142, DOI 10.1054/jcaf.2002.124340; Moher D, 2000, J CLIN EPIDEMIOL, V53, P964, DOI 10.1016/S0895-4356(00)00188-8; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; NOETHER M, 1988, PUBLICATION HCFA; Oddone E Z, 1999, Eff Clin Pract, V2, P201; Parker S G, 2002, Health Technol Assess, V6, P1; Parkes J, 2000, COCHRANE DB SYST REV, V4; Payne SMC, 2002, HEALTH SERV RES, V37, P683, DOI 10.1111/1475-6773.00044; Peterson GM, 2002, ARCH INTERN MED, V162, P2142, DOI 10.1001/archinte.162.18.2142-a; Philbin EF, 1999, J GEN INTERN MED, V14, P130, DOI 10.1046/j.1525-1497.1999.00291.x; Rainville EC, 1999, AM J HEALTH-SYST PH, V56, P1339, DOI 10.1093/ajhp/56.13.1339; RICH MW, 1993, J GEN INTERN MED, V8, P585, DOI 10.1007/BF02599709; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Riegel B, 2002, ARCH INTERN MED, V162, P705, DOI 10.1001/archinte.162.6.705; Serxner S, 1998, CONGESTIVE HEART FAI, V4, P23; Stewart S, 1999, LANCET, V354, P1077, DOI 10.1016/S0140-6736(99)03428-5; Stewart S, 1998, ARCH INTERN MED, V158, P1067, DOI 10.1001/archinte.158.10.1067; THOMAS JW, 1991, MED CARE, V29, P377, DOI 10.1097/00005650-199104000-00006; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; Wolinsky FD, 1997, J AM GERIATR SOC, V45, P558, DOI 10.1111/j.1532-5415.1997.tb03087.x	48	591	604	2	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	2004	291	11					1358	1367		10.1001/jama.291.11.1358	http://dx.doi.org/10.1001/jama.291.11.1358			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	802PF	15026403				2022-12-28	WOS:000220174700030
J	Chou, R; Clark, EC; Helfand, M				Chou, R; Clark, EC; Helfand, M			Screening for hepatitis C virus infection: A review of the evidence for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							QUALITY-OF-LIFE; HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE-CHAIN-REACTION; PERCUTANEOUS LIVER-BIOPSY; INJECTION-DRUG USERS; NORMAL AMINOTRANSFERASE LEVELS; SEXUALLY-TRANSMITTED-DISEASES; RECOMBINANT IMMUNOBLOT ASSAY; LINKED-IMMUNOSORBENT-ASSAY; CHRONIC ACTIVE HEPATITIS	Background: Hepatitis C virus (HCV) is the most common bloodborne pathogen in the United States and is an important cause of patient morbidity and mortality, but it is unclear whether screening to identify asymptomatic infected persons is appropriate. Purpose: To synthesize the evidence on risks and benefits of screening for HCV infection. Data Sources: MEDLINE (through February 2003), Cochrane Clinical Trials Registry (2002, Issue 2), reference lists, and experts. Study Selection: Controlled studies of screening and antiviral therapy and observational studies on other interventions, risk factors, accuracy of antibody testing, work-up, harms of biopsy, and long-term outcomes. Data Extraction: Using preset criteria, the authors assessed the quality of included studies and abstracted information about settings, patients, interventions, and outcomes. Data Synthesis: There are no published trials of screening for HCV infection. Approximately 2% of U.S. adults have HCV anti-bodies, with the majority having chronic infection. Risk factor assessment could identify adults at substantially higher risk. Antiviral treatment can result in a sustained virologic response rate of 54% to 56%, but no trials have been done specifically in asymptomatic patients likely to be identified by screening. Data are insufficient to determine whether treatment improves long-term outcomes. There are no data to estimate the benefit from counseling or immunizations. Although risks of biopsy and treatment appear minimal or self-limited, data on other adverse effects of screening, such as labeling or anxiety, are sparse. Conclusions: Antiviral treatment can successfully eradicate HCV, but data on long-term outcomes in populations likely to be identified by screening are lacking. Although the yield from targeted screening, particularly in intravenous drug users, would be substantially higher than in the general population, data are inadequate to accurately weigh the overall benefits and risks of screening in otherwise healthy asymptomatic adults.	Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Vet Affairs Med Ctr, Portland, OR 97201 USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Chou, R (corresponding author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA.		Hug, Balthasar L./G-1568-2010; Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Chou, Roger/0000-0001-9889-8610	PHS HHS [290-97-0018] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adinolfi LE, 2001, HEPATOLOGY, V33, P1358, DOI 10.1053/jhep.2001.24432; AKAHANE Y, 1994, ANN INTERN MED, V120, P748, DOI 10.7326/0003-4819-120-9-199405010-00005; Alberti A, 2002, ANN INTERN MED, V137, P961, DOI 10.7326/0003-4819-137-12-200212170-00009; ALBERTI A, 1992, LANCET, V340, P697, DOI 10.1016/0140-6736(92)92234-7; Alter Miriam J, 2003, MMWR Recomm Rep, V52, P1; Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; Alter MJ, 2002, HEPATOLOGY, V36, pS93, DOI 10.1053/jhep.2002.36389; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1999, J Hepatol, V30, P956; [Anonymous], 1997, HEPATOLOGY, V26, pS2; Austin GE, 2000, AM J MED SCI, V319, P353, DOI 10.1097/00000441-200006000-00002; Bacon BR, 2002, HEPATOLOGY, V36, pS179, DOI 10.1053/jhep.2002.36386; Balasekaran R, 1999, AM J GASTROENTEROL, V94, P1341, DOI 10.1111/j.1572-0241.1999.01084.x; Barrett S, 2001, GUT, V49, P423, DOI 10.1136/gut.49.3.423; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; BELL J, 1990, MED J AUSTRALIA, V153, P274, DOI 10.5694/j.1326-5377.1990.tb136900.x; Bellentani S, 1999, GUT, V44, P874, DOI 10.1136/gut.44.6.874; Bernardinello E, 1999, HEPATO-GASTROENTEROL, V46, P3216; Bernstein D, 2002, HEPATOLOGY, V35, P704, DOI 10.1053/jhep.2002.31311; Bonkovsky HL, 1999, HEPATOLOGY, V29, P264, DOI 10.1002/hep.510290124; BOOTH JC, 2001, GUT               S1, V48, P11; BOOTH JCL, 1995, GUT, V37, P449, DOI 10.1136/gut.37.4.449; Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706; BROWN D, 1992, J MED VIROL, V38, P167, DOI 10.1002/jmv.1890380303; Busch MP, 2000, TRANSFUSION, V40, P585, DOI 10.1046/j.1537-2995.2000.40050585.x; Cadranel JF, 2000, HEPATOLOGY, V32, P477, DOI 10.1053/jhep.2000.16602; CALDWELL SH, 1991, AM J GASTROENTEROL, V86, P1219; Carithers RL, 2000, SEMIN LIVER DIS, V20, P159; Caturelli E, 1996, AM J GASTROENTEROL, V91, P1318; Cawthorne CH, 2002, AM J GASTROENTEROL, V97, P149, DOI 10.1111/j.1572-0241.2002.05439.x; Chander G, 2002, HEPATOLOGY, V36, pS135, DOI 10.1053/jhep.2002.37146; Cheung RC, 2000, AM J GASTROENTEROL, V95, P740, DOI 10.1111/j.1572-0241.2000.01854.x; CHOU R, 2003, SCREENING HEPATITIS; Colin C, 2001, J VIRAL HEPATITIS, V8, P87, DOI 10.1046/j.1365-2893.2001.00280.x; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; Conte D, 2000, HEPATOLOGY, V31, P751, DOI 10.1002/hep.510310328; Coughlan BM, 2001, GASTROENTEROLOGY, V120, pA568; COUROUCE AM, 1995, VOX SANG, V69, P213, DOI 10.1111/j.1423-0410.1995.tb02597.x; Courouce Anne-Marie, 1994, V61, P36; Culver DH, 2000, TRANSFUSION, V40, P1176, DOI 10.1046/j.1537-2995.2000.40101176.x; DAMEN M, 1995, TRANSFUSION, V35, P745, DOI 10.1046/j.1537-2995.1995.35996029158.x; DAVIS GL, 1994, CLIN THER, V16, P334; Degos F, 1999, J HEPATOL, V31, P113, DOI 10.1016/S0168-8278(99)80386-9; Dore GJ, 1997, BRIT MED J, V315, P333; Dow BC, 1996, J MED VIROL, V49, P132, DOI 10.1002/(SICI)1096-9071(199606)49:2&lt;132::AID-JMV10&gt;3.0.CO;2-G; Dubois F, 1997, HEPATOLOGY, V25, P1490, DOI 10.1002/hep.510250630; Falck-Ytter Y, 2002, ANN INTERN MED, V136, P288, DOI 10.7326/0003-4819-136-4-200202190-00008; Farrell RJ, 1999, J HEPATOL, V30, P580, DOI 10.1016/S0168-8278(99)80187-1; Feldman JG, 2000, SEX TRANSM DIS, V27, P338, DOI 10.1097/00007435-200007000-00007; Flamm SL, 1998, AM J GASTROENTEROL, V93, P597, DOI 10.1111/j.1572-0241.1998.171_b.x; Foster GR, 1998, HEPATOLOGY, V27, P209, DOI 10.1002/hep.510270132; Freeman AJ, 2001, HEPATOLOGY, V34, P809, DOI 10.1053/jhep.2001.27831; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; FROEHLICH F, 1993, DIGEST DIS SCI, V38, P1480, DOI 10.1007/BF01308607; Furusyo N, 2000, DIGEST DIS SCI, V45, P2221, DOI 10.1023/A:1026696721059; Galmiche JP, 1998, GUT, V42, P318, DOI 10.1136/gut.42.3.318; GARCIATSAO G, 1993, ANN INTERN MED, V118, P150, DOI 10.7326/0003-4819-118-2-199301150-00013; GEBO K, 2002, AGENCY HEALTHCARE RE; Gebo KA, 2002, HEPATOLOGY, V36, pS161, DOI 10.1053/jhep.2002.36989; Gibb DM, 2000, LANCET, V356, P904, DOI 10.1016/S0140-6736(00)02681-7; GILMORE IT, 1995, GUT, V36, P437, DOI 10.1136/gut.36.3.437; Glue P, 2000, HEPATOLOGY, V32, P647, DOI 10.1053/jhep.2000.16661; Gordon Fredric D., 1999, American Journal of Medicine, V107, p36S; GORDON SC, 1993, HEPATOLOGY, V18, P1338, DOI 10.1002/hep.1840180609; Gordon SC, 1998, HEPATOLOGY, V28, P562, DOI 10.1002/hep.510280238; Gore SM, 1999, QJM-MON J ASSOC PHYS, V92, P25, DOI 10.1093/qjmed/92.1.25; Gretch DR, 1997, HEPATOLOGY, V26, pS43, DOI 10.1002/hep.510260708; Gunn RA, 2001, SEX TRANSM DIS, V28, P166, DOI 10.1097/00007435-200103000-00008; Haley RW, 2001, MEDICINE, V80, P134, DOI 10.1097/00005792-200103000-00006; Harris DR, 2001, ANN INTERN MED, V134, P120, DOI 10.7326/0003-4819-134-2-200101160-00012; Harris HE, 2002, BMJ-BRIT MED J, V324, P450, DOI 10.1136/bmj.324.7335.450; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hasle G, 1998, LANCET, V351, P1888, DOI 10.1016/S0140-6736(05)78838-3; Heathcote EJ, 2000, NEW ENGL J MED, V343, P1673, DOI 10.1056/NEJM200012073432302; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; Huber KR, 1996, HEPATOLOGY, V24, P471, DOI 10.1053/jhep.1996.v24.pm0008781309; Icardi G, 2001, J CLIN MICROBIOL, V39, P3110, DOI 10.1128/JCM.39.9.3110-3114.2001; Ikeda K, 1999, HEPATOLOGY, V29, P1124, DOI 10.1002/hep.510290439; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; JANES CH, 1993, ANN INTERN MED, V118, P96, DOI 10.7326/0003-4819-118-2-199301150-00003; Jonas M M, 2001, Clin Liver Dis, V5, P1063, DOI 10.1016/S1089-3261(05)70209-9; KALDOR JM, 1992, MED J AUSTRALIA, V157, P227, DOI 10.5694/j.1326-5377.1992.tb137123.x; KAO JH, 1992, J INFECT DIS, V166, P900, DOI 10.1093/infdis/166.4.900; Kaur S, 1996, HEPATOLOGY, V24, P979; Keeffe EB, 1998, HEPATOLOGY, V27, P881, DOI 10.1002/hep.510270336; Kenny-Walsh E, 1999, NEW ENGL J MED, V340, P1228, DOI 10.1056/NEJM199904223401602; Kjaergard LL, 2001, BMJ-BRIT MED J, V323, P1151, DOI 10.1136/bmj.323.7322.1151; Kliem V, 1996, TRANSPLANTATION, V62, P1417, DOI 10.1097/00007890-199611270-00007; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Koff RS, 2001, J CLIN GASTROENTEROL, V33, P20, DOI 10.1097/00004836-200107000-00006; Koff RS, 1999, HEPATOLOGY, V29, P277, DOI 10.1002/hep.510290127; Kumar RM, 1998, OBSTET GYNECOL, V91, P426, DOI 10.1016/S0029-7844(97)00684-4; Lapane KL, 1998, AM J GASTROENTEROL, V93, P591, DOI 10.1111/j.1572-0241.1998.170_b.x; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; Lavanchy D, 1996, J CLIN LAB ANAL, V10, P269, DOI 10.1002/(SICI)1098-2825(1996)10:5<269::AID-JCLA7>3.0.CO;2-3; Lesens O, 1999, J INFECT DIS, V179, P1254, DOI 10.1086/314720; Lindor KD, 1996, HEPATOLOGY, V23, P1079; Lindsay KL, 2001, HEPATOLOGY, V34, P395, DOI 10.1053/jhep.2001.26371; Long GS, 1996, CLEV CLIN J MED, V63, P264; Magriples U, 1998, AM J PERINAT, V15, P395, DOI 10.1055/s-2007-993964; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; McCormick SE, 1996, AM J GASTROENTEROL, V91, P1516; MCGILL DB, 1990, GASTROENTEROLOGY, V99, P1396, DOI 10.1016/0016-5085(90)91167-5; McHutchison JG, 2001, J HEPATOL, V34, P140, DOI 10.1016/S0168-8278(00)00026-X; Mele A, 1998, NEW ENGL J MED, V338, P1771; Montalto G, 1997, DIGEST DIS SCI, V42, P1703, DOI 10.1023/A:1018813532098; Muir AJ, 2002, J CLIN GASTROENTEROL, V34, P268, DOI 10.1097/00004836-200203000-00015; Murphy EL, 1996, JAMA-J AM MED ASSOC, V275, P995, DOI 10.1001/jama.275.13.995; Nalpas B, 2001, J HEPATOL, V35, P312, DOI 10.1016/S0168-8278(01)00114-3; NEAL KR, 1994, EPIDEMIOL INFECT, V112, P595, DOI 10.1017/S0950268800051293; Nishiguchi S, 2001, LANCET, V357, P196, DOI 10.1016/S0140-6736(00)03595-9; Ompad DC, 2002, CLIN INFECT DIS, V35, P783, DOI 10.1086/342063; OSMOND DH, 1993, JAMA-J AM MED ASSOC, V269, P361, DOI 10.1001/jama.269.3.361; Pasha T, 1998, HEPATOLOGY, V27, P1220, DOI 10.1002/hep.510270506; Patrick DM, 2001, CAN MED ASSOC J, V165, P889; Pawlotsky JM, 1997, HEPATOLOGY, V26, P1; Pawlotsky JM, 1996, J CLIN MICROBIOL, V34, P80, DOI 10.1128/JCM.34.1.80-83.1996; Pawlotsky JM, 2002, HEPATOLOGY, V36, pS65, DOI 10.1053/jhep.2002.36815; Pessione F, 1998, HEPATOLOGY, V27, P1717, DOI 10.1002/hep.510270635; Peters MG, 2002, HEPATOLOGY, V36, pS220, DOI 10.1053/jhep.2002.36811; POYNARD T, 1991, HEPATOLOGY, V13, P896, DOI 10.1016/0270-9139(91)90260-3; Poynard T, 2001, J HEPATOL, V34, P730, DOI 10.1016/S0168-8278(00)00097-0; Poynard T, 1996, HEPATOLOGY, V24, P778; Prati D, 1996, GASTROENTEROLOGY, V110, P178, DOI 10.1053/gast.1996.v110.pm8536854; Prefontaine R, 1994, Can J Infect Dis, V5, P153; PRIETO M, 1995, HEPATOLOGY, V22, P413, DOI 10.1016/0270-9139(95)90559-6; Prince AM, 1997, TRANSFUSION, V37, P211, DOI 10.1046/j.1537-2995.1997.37297203526.x; Puoti C, 2000, DIGEST LIVER DIS, V32, P634, DOI 10.1016/S1590-8658(00)80850-6; Puoti C, 1999, LIVER, V19, P104, DOI 10.1111/j.1478-3231.1999.tb00018.x; Reddy KR, 2001, HEPATOLOGY, V33, P433, DOI 10.1053/jhep.2001.21747; Reichard O, 1998, SCAND J INFECT DIS, V30, P441, DOI 10.1080/00365549850161395; Rodger AJ, 1999, HEPATOLOGY, V30, P1299, DOI 10.1002/hep.510300504; Rosman AS, 1996, AM J GASTROENTEROL, V91, P498; Rostaing L, 1996, TRANSPLANT P, V28, P2836; RoudotThoraval F, 1997, HEPATOLOGY, V26, P485, DOI 10.1002/hep.510260233; Roy E, 2001, CAN MED ASSOC J, V165, P557; Saadeh S, 2001, HEPATOLOGY, V33, P196, DOI 10.1053/jhep.2001.20534; SAITO M, 1992, CLIN CHEM, V38, P2434; SAKUGAWA H, 1995, J MED VIROL, V46, P334, DOI 10.1002/jmv.1890460408; Salleras L, 1997, J MED VIROL, V52, P164, DOI 10.1002/(SICI)1096-9071(199706)52:2&lt;164::AID-JMV8&gt;3.0.CO;2-1; SanchezQuijano A, 1995, EUR J CLIN MICROBIOL, V14, P949, DOI 10.1007/BF01691375; Schiff ER, 1999, SEMIN LIVER DIS, V19, P3; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SEEFF LB, 1994, ANN INTERN MED, V120, P807, DOI 10.7326/0003-4819-120-9-199405010-00014; Seeff LB, 2002, HEPATOLOGY, V36, pS35, DOI 10.1053/jhep.2002.36806; Seeff LB, 2000, ANN INTERN MED, V132, P105, DOI 10.7326/0003-4819-132-2-200001180-00003; SHAKIL AO, 1995, ANN INTERN MED, V123, P330, DOI 10.7326/0003-4819-123-5-199509010-00002; Shepherd J, 2000, Health Technol Assess, V4, P1; SHEV S, 1995, SEX TRANSM DIS, V22, P210, DOI 10.1097/00007435-199507000-00002; Silverman AL, 2000, AM J GASTROENTEROL, V95, P1312, DOI 10.1111/j.1572-0241.2000.02031.x; Singer ME, 2001, AM J MED, V111, P614, DOI 10.1016/S0002-9343(01)00951-2; Soto B, 1997, J HEPATOL, V26, P1, DOI 10.1016/S0168-8278(97)80001-3; STARY A, 1992, SEX TRANSM DIS, V19, P252, DOI 10.1097/00007435-199209000-00003; Strader DB, 2002, HEPATOLOGY, V36, pS226, DOI 10.1053/jhep.2002.36991; Stuyver L, 1996, KIDNEY INT, V49, P889, DOI 10.1038/ki.1996.122; Tajiri H, 2001, PEDIATR INFECT DIS J, V20, P10, DOI 10.1097/00006454-200101000-00003; Terrault NA, 2002, HEPATOLOGY, V36, pS99, DOI 10.1053/jhep.2002.36797; Thomas DL, 1996, J INFECT DIS, V174, P690, DOI 10.1093/infdis/174.4.690; THOMAS DL, 1995, J INFECT DIS, V171, P768, DOI 10.1093/infdis/171.4.768; UYTTENDAELE S, 1994, VOX SANG, V66, P122, DOI 10.1111/j.1423-0410.1994.tb00293.x; VAUTIER G, 1994, BRIT MED J, V309, P1455, DOI 10.1136/bmj.309.6967.1455; Vento S, 1998, NEW ENGL J MED, V338, P286, DOI 10.1056/NEJM199801293380503; Villano SA, 1997, J CLIN MICROBIOL, V35, P3274, DOI 10.1128/JCM.35.12.3274-3277.1997; WEINSTOCK HS, 1993, JAMA-J AM MED ASSOC, V269, P392; Widell A, 2002, TRANSFUSION MED, V12, P107, DOI 10.1046/j.1365-3148.2002.00359.x; Wiese M, 2000, HEPATOLOGY, V32, P91, DOI 10.1053/jhep.2000.8169; Wiley TE, 2002, AM J GASTROENTEROL, V97, P700, DOI 10.1111/j.1572-0241.2002.05555.x; Wiley TE, 1998, HEPATOLOGY, V28, P805, DOI 10.1002/hep.510280330; WOLFF C, 1994, TRANSFUSION, V34, P361, DOI 10.1046/j.1537-2995.1994.34494233591.x; Yawn BP, 2002, J FAM PRACTICE, V51, P135; Yokosuka O, 1999, J HEPATOL, V31, P394, DOI 10.1016/S0168-8278(99)80028-2; ZAAIJER HL, 1993, LANCET, V341, P722, DOI 10.1016/0140-6736(93)90488-3; ZANETTI AR, 1995, LANCET, V345, P289, DOI 10.1016/S0140-6736(95)90277-5; Zarski JP, 1998, J HEPATOL, V28, P27, DOI 10.1016/S0168-8278(98)80198-0; Zarski JP, 1999, J HEPATOL, V31, P136, DOI 10.1016/S0168-8278(99)80390-0; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301; Zylberberg H, 1999, GUT, V45, P112, DOI 10.1136/gut.45.1.112; 2002, NIH CONS DEV C STAT	181	99	102	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 16	2004	140	6					465	479		10.7326/0003-4819-140-6-200403160-00014	http://dx.doi.org/10.7326/0003-4819-140-6-200403160-00014			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803AU	15023713				2022-12-28	WOS:000220204800008
J	Moore, JH; Ritchie, MD				Moore, JH; Ritchie, MD			The challenges of whole-genome approaches to common diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTIFACTOR-DIMENSIONALITY REDUCTION; GENE-GENE INTERACTIONS; NEURAL-NETWORK ARCHITECTURE; ENVIRONMENT; BREAST; CANCER		Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA	Vanderbilt University	Moore, JH (corresponding author), Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.		Moore, Jason H./AAV-9645-2021	Moore, Jason H./0000-0002-5015-1099	NHLBI NIH HHS [HL65962, HL65234] Funding Source: Medline; NIA NIH HHS [AG20135, AG19085] Funding Source: Medline; NIGMS NIH HHS [GM31304] Funding Source: Medline; NLM NIH HHS [LM007450] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065234, U19HL065962, U01HL065962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019085, R01AG020135] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007450] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Bellman R., 1961, ADAPTIVE CONTROL PRO; EASTON DF, 1995, AM J HUM GENET, V56, P265; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Hahn LW, 2003, BIOINFORMATICS, V19, P376, DOI 10.1093/bioinformatics/btf869; HAHN LW, 2004, IN SILICO BIOL, V4, P16; Hastie T., 2009, ELEMENTS STAT LEARNI, DOI 10.1007/978-0-387-84858-7_7; Jansen RC, 2003, NAT REV GENET, V4, P145, DOI 10.1038/nrg996; Lucek PR, 1997, GENET EPIDEMIOL, V14, P1101, DOI 10.1002/(SICI)1098-2272(1997)14:6<1101::AID-GEPI90>3.0.CO;2-K; Marinov M, 2001, HUM HERED, V51, P169, DOI 10.1159/000053338; Moore JH, 2003, HUM HERED, V56, P73, DOI 10.1159/000073735; Moore JH, 2002, ANN MED, V34, P88, DOI 10.1080/07853890252953473; Moore JH, 2003, BIOSYSTEMS, V72, P177, DOI 10.1016/S0303-2647(03)00142-4; North BV, 2003, ANN HUM GENET, V67, P348, DOI 10.1046/j.1469-1809.2003.00030.x; Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276; Ritchie MD, 2003, GENET EPIDEMIOL, V24, P150, DOI 10.1002/gepi.10218; Ritchie MD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-28; Sing CF, 2003, ARTERIOSCL THROM VAS, V23, P1190, DOI 10.1161/01.ATV.0000075081.51227.86; Strohman R, 2002, SCIENCE, V296, P701, DOI 10.1126/science.1070534; Williams SM, 2004, BIOESSAYS, V26, P170, DOI 10.1002/bies.10401; Wu C. H., 2000, NEURAL NETWORKS GENO	20	97	107	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2004	291	13					1642	1643		10.1001/jama.291.13.1642	http://dx.doi.org/10.1001/jama.291.13.1642			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809PQ	15069055				2022-12-28	WOS:000220649000032
J	Pronovost, PJ; Nolan, T; Zeger, S; Miller, M; Rubin, H				Pronovost, PJ; Nolan, T; Zeger, S; Miller, M; Rubin, H			How can clinicians measure safety and quality in acute care?	LANCET			English	Article							HEALTH-CARE; CAROTID-ENDARTERECTOMY; INTENSIVE-CARE; TRIAL; PANCREATICODUODENECTOMY; CHOLECYSTECTOMY; MORTALITY; REPAIR	The demand for high quality care is increasing and warranted. Evidence suggests that the quality of care in hospitals can be improved. The greatest opportunity to improve outcomes for patients over the next quarter century will probably come not from discovering new treatments but from learning how to deliver existing effective therapies. To improve, caregivers need to know what to do, how they are doing, and be able to improve the processes of care. The ability to monitor performance, though challenging in healthcare, is essential to improving quality of care. We present a practical method to assess and learn from routine practice. Methods to evaluate performance from industrial engineering can be broadly applied to efforts to improve the quality of healthcare. One method that may help to provide caregivers frequent feedback is time series data-le, results are graphically correlated with time. Broad use of these tools might lead to the necessary improvements in quality of care.	Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biostat, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Hlth Policy & Management, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Inst Healthcare Improvement, Baltimore, MD USA; Bloomberg Sch Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Pronovost, PJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care Med, Meyer 297A, Baltimore, MD 21287 USA.	ppronovo@jhmi.edu		Zeger, Scott/0000-0001-8907-1603	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS011902] Funding Source: NIH RePORTER; AHRQ HHS [U18HS11902-01] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AAAS, 2003, AAAS AN R D FY 2004; Angus DC, 2000, CRIT CARE MED, V28, P150, DOI 10.1097/00003246-200001000-00025; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Berwick DM, 1996, BRIT MED J, V312, P619, DOI 10.1136/bmj.312.7031.619; Bion JF, 2004, LANCET, V363, P970, DOI 10.1016/S0140-6736(04)15793-0; Blumenthal D, 1996, NEW ENGL J MED, V335, P1328, DOI 10.1056/NEJM199610243351721; Brennan T., 1996, NEW RULES REGULATION; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Buist MD, 1999, MED J AUSTRALIA, V171, P22, DOI 10.5694/j.1326-5377.1999.tb123492.x; Buist MD, 2002, BRIT MED J, V324, P387, DOI 10.1136/bmj.324.7334.387; CHASSIN M, 1998, JAMA-J AM MED ASSOC, V280, P1005; CLEVELAND WS, 1993, VISUALIZIING DATA; Deming WE, 1976, REP STAT APPL, V23, P25; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; Doty JR, 2002, J GASTROINTEST SURG, V6, P776, DOI 10.1016/S1091-255X(02)00039-2; Elting LS, 1999, BRIT MED J, V318, P1527, DOI 10.1136/bmj.318.7197.1527; GOTT VL, 1986, NEW ENGL J MED, V314, P1070, DOI 10.1056/NEJM198604243141702; Gott VL, 1999, NEW ENGL J MED, V340, P1307, DOI 10.1056/NEJM199904293401702; Gray Bradford H., AHCPR CHANGING POLIT; Institute of Medicine, 2001, CROSSING QUALITY CHA; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; Juran J.M., 1988, JURANS QUALITY CONTR, V4; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, VVolume 600; Langley Gj., 1996, IMPROVEMENT GUIDE PR; Layde PM, 2002, JAMA-J AM MED ASSOC, V287, P1993, DOI 10.1001/jama.287.15.1993; Leape LL, 2002, NEW ENGL J MED, V347, P1633, DOI 10.1056/NEJMNEJMhpr011493; Lenfant C, 2003, NEW ENGL J MED, V349, P868, DOI 10.1056/NEJMsa035507; Lillemoe K D, 2000, J Hepatobiliary Pancreat Surg, V7, P115, DOI 10.1007/s005340050164; LOHR K, 1999, NEW ENGL J MED, V322, P1161; Lundberg GD, 1997, JAMA-J AM MED ASSOC, V278, P1615, DOI 10.1001/jama.278.19.1615; Martinez EA, 2003, CRIT CARE MED, V31, P2302, DOI 10.1097/01.CCM.0000084857.87446.DD; McGlynn E A, 1998, Jt Comm J Qual Improv, V24, P470; McGlynn EA, 1998, AM J PREV MED, V14, P14, DOI 10.1016/S0749-3797(97)00032-9; McGlynn EA, 2003, MED CARE, V41, pI39; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; MCGLYNN EA, 2002, MED CARE S, V41, P8; MCNUTT R, 2001, JAMA-J AM MED ASSOC, V287, P1997; Melton GB, 2002, ANN SURG, V235, P888, DOI 10.1097/00000658-200206000-00018; Nelson E C, 1998, Front Health Serv Manage, V15, P3; Nelson Eugene C, 2003, Jt Comm J Qual Saf, V29, P5; Ovretveit J, 2002, QUAL SAF HEALTH CARE, V11, P345, DOI 10.1136/qhc.11.4.345; *PC, QUAL 1 BTTER HLTH CA; Plsek P E, 1999, Pediatrics, V103, P203; Plsek P E, 1994, Qual Manag Health Care, V3, P78; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; Pronovost PJ, 2001, EFFECTIVE CLIN PRACT, V4, P100; Rubin HR, 2001, INT J QUAL HEALTH C, V13, P489, DOI 10.1093/intqhc/13.6.489; Rubin HR, 2001, INT J QUAL HEALTH C, V13, P469, DOI 10.1093/intqhc/13.6.469; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; SHEWHART W, 1945, STAT METHOD VIEWPOIN; Tu JV, 1998, NEW ENGL J MED, V339, P1441, DOI 10.1056/NEJM199811123392006; TUFTE RE, 1983, VISUAL DISPLAY QUANT; Vincent C, 1998, BRIT MED J, V316, P1154, DOI 10.1136/bmj.316.7138.1154; Vincent C, 2003, NEW ENGL J MED, V348, P1051, DOI 10.1056/NEJMhpr020760; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; Wennberg DE, 1998, JAMA-J AM MED ASSOC, V279, P1278, DOI 10.1001/jama.279.16.1278; WHEELER DJ, 1992, SOME DIFFERENCES THE; Yeo CJ, 2002, ANN SURG, V236, P355, DOI 10.1097/00000658-200209000-00012	60	131	133	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	2004	363	9414					1061	1067		10.1016/S0140-6736(04)15843-1	http://dx.doi.org/10.1016/S0140-6736(04)15843-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15051287				2022-12-28	WOS:000220497300022
J	Turchyn, AV; Schrag, DP				Turchyn, AV; Schrag, DP			Oxygen isotope constraints on the sulfur cycle over the past 10 million years	SCIENCE			English	Article							DEEP-SEA SEDIMENTS; SULFATE REDUCTION; GEOCHEMICAL CYCLES; CARBON; WATER; DISPROPORTIONATION; FRACTIONATION; OXIDATION; OCEAN; IRON	Oxygen isotopes in marine sulfate (delta(18)O(SO4)) measured in marine barite show variability over the past 10 million years, including a 5 per mil decrease during the Plio-Pleistocene, with near-constant values during the Miocene that are slightly enriched over the modern ocean. A numerical model suggests that sea level fluctuations during Plio-Pleistocene glacial cycles affected the sulfur cycle by reducing the area of continental shelves and increasing the oxidative weathering of pyrite. The data also require that sulfate concentrations were 10 to 20% lower in the late Miocene than today.	Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA	Harvard University	Turchyn, AV (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, 20 Oxford St, Cambridge, MA 02138 USA.	avan@fas.harvard.edu		Turchyn, Alexandra/0000-0002-9298-2173				Alt JC, 2003, GEOCHIM COSMOCHIM AC, V67, P641, DOI 10.1016/S0016-7037(02)01142-0; Bottcher ME, 2001, GEOCHIM COSMOCHIM AC, V65, P1601, DOI 10.1016/S0016-7037(00)00628-1; Bottcher ME, 2001, GEOCHIM COSMOCHIM AC, V65, P1573, DOI 10.1016/S0016-7037(00)00622-0; Canfield DE, 1999, AM J SCI, V299, P697, DOI 10.2475/ajs.299.7-9.697; Canfield DE, 2000, SCIENCE, V288, P658, DOI 10.1126/science.288.5466.658; CANFIELD DE, 1991, AM J SCI, V291, P177, DOI 10.2475/ajs.291.2.177; CANFIELD DE, 1996, NATURE, V382, P697; CLAYPOOL GE, 1980, CHEM GEOL, V28, P199, DOI 10.1016/0009-2541(80)90047-9; Cook P.G., 2000, ENV TRACERS SUBSURFA, P195, DOI 10.1007/978-1-4615-4557-6_7; D'Hondt S, 2002, SCIENCE, V295, P2067, DOI 10.1126/science.1064878; Derry LA, 1996, PALEOCEANOGRAPHY, V11, P267, DOI 10.1029/95PA03839; FRITZ P, 1989, CHEM GEOL, V79, P99, DOI 10.1016/0168-9622(89)90012-2; Habicht KS, 2002, SCIENCE, V298, P2372, DOI 10.1126/science.1078265; HOLSER WT, 1979, CHEM GEOL, V25, P1, DOI 10.1016/0009-2541(79)90079-2; JORGENSEN BB, 1982, NATURE, V296, P643, DOI 10.1038/296643a0; Kasten S., 2000, MARINE GEOCHEMISTRY, P263, DOI [10.1007/978-3-662-04242-7-8, DOI 10.1007/978-3-662-04242-7_8, DOI 10.1007/978-3-662-04242-7-8]; KUKASABE M, 1968, GEOCHIM COSMOCHIM AC, V41, P1033; LIN S, 1991, AM J SCI, V291, P55, DOI 10.2475/ajs.291.1.55; LLOYD RM, 1968, J GEOPHYS RES, V73, P6099, DOI 10.1029/JB073i018p06099; LONGINELLI A, 1967, SCIENCE, V156, P56, DOI 10.1126/science.156.3771.56; MCDUFF RE, 1982, EARTH PLANET SC LETT, V57, P117, DOI 10.1016/0012-821X(82)90178-9; MEYBECK M, 1979, REV GEOL DYN GEOGR, V21, P215; Niewohner C, 1998, GEOCHIM COSMOCHIM AC, V62, P455, DOI 10.1016/S0016-7037(98)00055-6; Paytan A, 1998, SCIENCE, V282, P1459, DOI 10.1126/science.282.5393.1459; PAYTAN A, 1993, NATURE, V366, P445, DOI 10.1038/366445a0; Petsch ST, 1998, AM J SCI, V298, P246, DOI 10.2475/ajs.298.3.246; Schrag DP, 1996, SCIENCE, V272, P1930, DOI 10.1126/science.272.5270.1930; Strauss H, 1999, CHEM GEOL, V161, P89, DOI 10.1016/S0009-2541(99)00082-0; THAMDRUP B, 1994, GEOCHIM COSMOCHIM AC, V58, P5115, DOI 10.1016/0016-7037(94)90298-4; VANSTEMPVOORT DR, 1994, ENV GEOCHEMISTRY SUL, P446; VONDAMM KL, 1995, SEAFLOOR HYDROTHERMA, P173; WALKER JCG, 1986, MAR GEOL, V70, P159, DOI 10.1016/0025-3227(86)90093-9; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412	33	93	96	0	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	2004	303	5666					2004	2007		10.1126/science.1092296	http://dx.doi.org/10.1126/science.1092296			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044800				2022-12-28	WOS:000220429800038
J	Warrell, MJ; Warrell, DA				Warrell, MJ; Warrell, DA			Rabies and other lyssavirus diseases	LANCET			English	Review							EUROPEAN BAT LYSSAVIRUS; POSTEXPOSURE PROPHYLAXIS; VIRUS-INFECTION; NEUTRALIZING ANTIBODY; MONOCLONAL-ANTIBODIES; EPTESICUS-SEROTINUS; LENTIVIRAL VECTORS; RAPID DIAGNOSIS; DAUBENTONS BAT; UNITED-STATES	The full scale of the global burden of human rabies is unknown, owing to inadequate surveillance of this fatal disease. However, the terror of hydrophobia, a cardinal symptom of rabies encephalitis, is suffered by tens of thousands of people each year. The recent discovery of enzootic European bat lyssavirus infection in the UK is indicative of our expanding awareness of the. Lyssavirus genus. The main mammalian vector species vary geographically, so the health problems created by the lyssaviruses and their management differ throughout the world. The methods by which these neurotropic viruses hijack neurophysiological mechanisms while evading immune surveillance is beginning to be unravelled by, for example, studies of molecular motor transport systems. Meanwhile, enormous challenges remain in the control of animal rabies and the provision of accessible, appropriate human prophylaxis worldwide.	John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England	University of Oxford	Warrell, MJ (corresponding author), John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.	mary.warrell@ndm.ox.ac.uk						AGHOMO HO, 1990, VET MICROBIOL, V22, P17, DOI 10.1016/0378-1135(90)90120-K; AGHOMO HO, 1990, J WILDLIFE DIS, V26, P258, DOI 10.7589/0090-3558-26.2.258; ALVAREZ L, 1994, PEDIATR INFECT DIS J, V13, P1154, DOI 10.1097/00006454-199412000-00020; Amengual B, 1997, J GEN VIROL, V78, P2319, DOI 10.1099/0022-1317-78-9-2319; ANDERSON LJ, 1984, ANN INTERN MED, V100, P728, DOI 10.7326/0003-4819-100-5-728; [Anonymous], 1977, Morbidity and Mortality Weekly Report, V26, P183; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; Arguin PM, 2002, EMERG INFECT DIS, V8, P258, DOI 10.3201/eid0803.010330; Ayele W, 2001, ETHIOPIAN MED J, V39, P313; Badrane H, 2001, J VIROL, V75, P3268, DOI 10.1128/JVI.75.7.3268-3276.2001; Bahri F, 1996, PRESSE MED, V25, P491; Baloul L, 2003, BIOCHIMIE, V85, P777, DOI 10.1016/S0300-9084(03)00137-8; BALTAZARD M, 1955, Bull World Health Organ, V13, P747; Bell J. F., 1975, The natural history of rabies,, P331; BISSERU B, 1972, RABIES, P34; BOUZAMONDO E, 1993, NEUROREPORT, V4, P555, DOI 10.1097/00001756-199305000-00023; Briggs DJ, 2000, VACCINE, V19, P1055, DOI 10.1016/S0264-410X(00)00342-X; Charlton KM, 1997, ACTA NEUROPATHOL, V94, P73, DOI 10.1007/s004010050674; CHUTIVONGSE S, 1990, LANCET, V335, P896, DOI 10.1016/0140-6736(90)90488-Q; Constantine DG, 2003, EMERG INFECT DIS, V9, P17; CORNWALL JW, 1923, BRIT MED J, V2, P298; Crick J., 1981, Virus diseases of food animals. Volume II, P469; Desmaris N, 2001, MOL THER, V4, P149, DOI 10.1006/mthe.2001.0431; DIETZSCHOLD B, 1983, P NATL ACAD SCI-BIOL, V80, P70, DOI 10.1073/pnas.80.1.70; DIETZSCHOLD B, 1987, J INFECT DIS, V156, P815, DOI 10.1093/infdis/156.5.815; Dietzschold B, 2000, J HUMAN VIROL, V3, P50; Dietzschold B, 2001, CURR TOP MICROBIOL, V253, P145; DIETZSCHOLD B, 1992, P NATL ACAD SCI USA, V89, P7252, DOI 10.1073/pnas.89.15.7252; Durrheim DN, 2002, TROP MED INT HEALTH, V7, P459, DOI 10.1046/j.1365-3156.2002.00868.x; Dutta J K, 2001, J Assoc Physicians India, V49, P589; East ML, 2001, P NATL ACAD SCI USA, V98, P15026, DOI 10.1073/pnas.261411898; Echevarria JE, 2001, J CLIN MICROBIOL, V39, P3678, DOI 10.1128/JCM.39.10.3678-3683.2001; Ertl HCJ, 2003, EXPERT OPIN BIOL TH, V3, P639, DOI 10.1517/14712598.3.4.639; Etessami R, 2000, J GEN VIROL, V81, P2147, DOI 10.1099/0022-1317-81-9-2147; EVERARD COR, 1981, T ROY SOC TROP MED H, V75, P654, DOI 10.1016/0035-9203(81)90143-7; FAMILUSI J B, 1972, African Journal of Medical Sciences, V3, P93; FAMILUSI JB, 1972, AM J TROP MED HYG, V21, P959, DOI 10.4269/ajtmh.1972.21.959; Fekadu M, 1972, Ethiop Med J, V10, P79; FEKADU M, 1988, VACCINE, V6, P533, DOI 10.1016/0264-410X(88)90107-7; Galelli A, 2000, J NEUROVIROL, V6, P359, DOI 10.3109/13550280009018300; Gaudin Y, 2000, J CELL BIOL, V150, P601, DOI 10.1083/jcb.150.3.601; Gibbons RV, 2002, ANN EMERG MED, V39, P528, DOI 10.1067/mem.2002.121521; Gosztonyi G, 2001, CURR TOP MICROBIOL, V253, P121; GOSZTONYI G, 1993, LAB INVEST, V68, P285; GOSZTONYI G, 1979, P 4 MUN S MICR MECH, P323; Graf W, 2002, EUR J NEUROSCI, V15, P1557, DOI 10.1046/j.1460-9568.2002.01994.x; GRAUBALLE PC, 1987, LANCET, V1, P379; Hanlon CA, 2001, VACCINE, V19, P3834, DOI 10.1016/S0264-410X(01)00135-9; Hanna JN, 2000, MED J AUSTRALIA, V172, P597, DOI 10.5694/j.1326-5377.2000.tb124126.x; HATTWICK MA, 1972, ANN INTERN MED, V76, P931, DOI 10.7326/0003-4819-76-6-931; Hemachudha T, 1999, CLIN INFECT DIS, V28, P143, DOI 10.1086/517179; HERZOG M, 1991, CLIN EXP IMMUNOL, V85, P224, DOI 10.1111/j.1365-2249.1991.tb05709.x; Hooper DC, 1998, J VIROL, V72, P3711, DOI 10.1128/JVI.72.5.3711-3719.1998; Hooper DC, 2002, CURR TOP MICROBIOL, V265, P163; Hooper PT, 1997, B I PASTEUR, V95, P209, DOI 10.1016/S0020-2452(97)83529-5; Irwin DJ, 1999, J NEUROVIROL, V5, P485, DOI 10.3109/13550289909045377; Iwata M, 2000, EUR J PHARMACOL, V404, P79, DOI 10.1016/S0014-2999(00)00621-X; Jackson AC, 1999, LAB INVEST, V79, P945; Jackson AC, 2003, CLIN INFECT DIS, V36, P60, DOI 10.1086/344905; JACKSON AC, 2002, RABIES, P245; Jacob Y, 2000, J VIROL, V74, P10217, DOI 10.1128/JVI.74.21.10217-10222.2000; Johnson N, 2003, VET REC, V152, P383, DOI 10.1136/vr.152.13.383; Kamoltham T, 2003, B WORLD HEALTH ORGAN, V81, P375; Kaplan C, 1986, RABIES FACTS; KAPLAN MM, 1962, B WORLD HEALTH ORGAN, V26, P765; Khawplod P, 2002, CLIN INFECT DIS, V35, P1562, DOI 10.1086/344954; KING AA, 1993, J COMP PATHOL, V108, P1, DOI 10.1016/S0021-9975(08)80224-1; Kuwert E., 1981, CELL CULTURE RABIES, P160; Kuzmin IV, 2003, VIRUS RES, V97, P65, DOI 10.1016/S0168-1702(03)00217-X; LABEL LS, 1982, ARCH NEUROL-CHICAGO, V39, P426, DOI 10.1001/archneur.1982.00510190044014; LAFON M, 1986, LANCET, V2, P515; LAFON M, 1988, VACCINE, V6, P362, DOI 10.1016/0264-410X(88)90184-3; Lalli G, 2002, J CELL BIOL, V156, P233, DOI 10.1083/jcb.200106142; Langevin C, 2002, J BIOL CHEM, V277, P37655, DOI 10.1074/jbc.M201374200; LENTZ TL, 1982, SCIENCE, V215, P182, DOI 10.1126/science.7053569; Lewis P, 2000, MUSCLE NERVE, V23, P720, DOI 10.1002/(SICI)1097-4598(200005)23:5<720::AID-MUS9>3.0.CO;2-5; LOCKHART BP, 1992, ANTIMICROB AGENTS CH, V36, P1750, DOI 10.1128/AAC.36.8.1750; Lord R.D., 1975, Bulletin of the Pan American Health Organization, V9, P189; Madhusudana S. N., 2002, International Journal of Infectious Diseases, V6, P85, DOI 10.1016/S1201-9712(02)90144-X; Madhusudana SN, 2001, NATL MED J INDIA, V14, P145; Mazarakis ND, 2001, HUM MOL GENET, V10, P2109, DOI 10.1093/hmg/10.19.2109; McColl KA, 2002, AUST VET J, V80, P636, DOI 10.1111/j.1751-0813.2002.tb10973.x; McLean R.G., 1975, P53; MEBATSION T, 1992, J VET MED B, V39, P233, DOI 10.1111/j.1439-0450.1992.tb01162.x; Mebatsion T, 2001, J VIROL, V75, P11496, DOI 10.1128/JVI.75.23.11496-11502.2001; Meslin FX, 1997, RABIES CONTROL IN ASIA, P15; Messenger SL, 2002, CLIN INFECT DIS, V35, P738, DOI 10.1086/342387; Miranda-Saksena M, 2000, J VIROL, V74, P1827, DOI 10.1128/JVI.74.4.1827-1839.2000; MONTANOHIROSE JA, 1993, VACCINE, V11, P1259, DOI 10.1016/0264-410X(93)90052-Y; MORENO JA, 1980, AM J TROP MED HYG, V29, P254, DOI 10.4269/ajtmh.1980.29.254; Morimoto K, 1999, J VIROL, V73, P510, DOI 10.1128/JVI.73.1.510-518.1999; MURPHY FA, 1977, ARCH VIROL, V54, P279, DOI 10.1007/BF01314774; Nathwani D, 2003, CLIN INFECT DIS, V37, P598, DOI 10.1086/376641; Noah DL, 1998, ANN INTERN MED, V128, P922, DOI 10.7326/0003-4819-128-11-199806010-00012; OGUNKOYA AB, 1990, T ROY SOC TROP MED H, V84, P842, DOI 10.1016/0035-9203(90)90103-L; Parviz S, 1998, CLIN INFECT DIS, V27, P751, DOI 10.1086/514931; Pawan J. L., 1936, Annals of Tropical Medicine and Parasitology, V30, P401; PEREZJORDA JL, 1995, J WILDLIFE DIS, V31, P372, DOI 10.7589/0090-3558-31.3.372; PERRIN P, 1991, VACCINE, V9, P549, DOI 10.1016/0264-410X(91)90241-W; PORRAS C, 1976, ANN INTERN MED, V85, P44, DOI 10.7326/0003-4819-85-1-44; Prosniak M, 2003, J INFECT DIS, V188, P53, DOI 10.1086/375247; Prosniak M, 2003, P NATL ACAD SCI USA, V100, P6765, DOI 10.1073/pnas.0430999100; Prosniak M, 2001, P NATL ACAD SCI USA, V98, P2758, DOI 10.1073/pnas.051630298; QUIAMBO BP, 2003, 14 INT C RAB AM, P51; Raux H, 2000, J VIROL, V74, P10212, DOI 10.1128/JVI.74.21.10212-10216.2000; ROINE RO, 1988, BRAIN, V111, P1505, DOI 10.1093/brain/111.6.1505; ROSATTE R C, 1984, Journal of Wildlife Diseases, V20, P171; Rupprecht CE, 2001, NEW ENGL J MED, V345, P582, DOI 10.1056/NEJMoa010560; SALISBURY D, 1996, IMMUNISATION INFECT; Samaratunga H, 1998, NEUROPATH APPL NEURO, V24, P331, DOI 10.1046/j.1365-2990.1998.00129.x; SELIMOV MA, 1989, ACTA VIROL, V33, P542; SERIE C, 1960, ANN I PASTEUR PARIS, V98, P688; Serra-Cobo J, 2002, EMERG INFECT DIS, V8, P413, DOI 10.3201/eid0804.010263; SIKES RK, 1962, AM J VET RES, V23, P1041; Strady A, 1998, J INFECT DIS, V177, P1290, DOI 10.1086/515267; Thisyakorn U, 2000, CLIN INFECT DIS, V30, P218, DOI 10.1086/313610; Thoulouze MI, 1998, J VIROL, V72, P7181, DOI 10.1128/JVI.72.9.7181-7190.1998; TRIMARCHI CV, 1977, J WILDLIFE DIS, V13, P366, DOI 10.7589/0090-3558-13.4.366; TRIMARCHI CV, 2002, RABIES, P307; TSIANG H, 1993, ADV VIRUS RES, V42, P375, DOI 10.1016/S0065-3527(08)60090-1; Tuffereau C, 2001, J GEN VIROL, V82, P2861, DOI 10.1099/0022-1317-82-12-2861; Veeraraghavan N., 1969, STUDIES SALIVARY EXC, P68; VEERARGHAVAN N, 1971, ANN REPORT DIRECTOR; *VET HOOFD VOLKSG, 1989, TIJDSCHR DIERGENEESK, V114, P913; Wacharapluesadee S, 2001, LANCET, V358, P892, DOI 10.1016/S0140-6736(01)06041-X; Wandeler A.I., 1993, Revue Scientifique et Technique Office International des Epizooties, V12, P51; WARRELL MJ, 1988, CLIN EXP IMMUNOL, V71, P229; Warrell MJ, 2003, VACCINE, V21, P706, DOI 10.1016/S0264-410X(02)00585-6; WARRELL MJ, 1985, LANCET, V1, P1059; Warrell MJ, 2003, MANSONS TROPICAL DIS, P807; WARRELL MJ, 1995, HDB INFECT DIS EXOTI, P343; WARRELL MJ, 2001, PRACT NEUROL, V1, P14; Whitby JE, 2000, VET REC, V147, P385, DOI 10.1136/vr.147.14.385; *WHO, 1999, WHOCDSCSRAPH996; *WHO, 2000, WHOCDSCSRAPH20005; WINKLER WG, 1973, JAMA-J AM MED ASSOC, V226, P1219, DOI 10.1001/jama.226.10.1219; Wong LF, 2004, MOL THER, V9, P101, DOI 10.1016/j.ymthe.2003.09.017; World Health Organization, WHOEMCZOO966; Xuyen DK, 2001, RABIES CONTROL IN ASIA, P255; [No title captured]	141	185	210	2	55	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	2004	363	9413					959	969		10.1016/S0140-6736(04)15792-9	http://dx.doi.org/10.1016/S0140-6736(04)15792-9			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043965				2022-12-28	WOS:000220308600023
J	Holmes, EC				Holmes, EC			1918 and all that	SCIENCE			English	Editorial Material							SPANISH INFLUENZA-VIRUS		Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Holmes, EC (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	edward.holmes@zoo.ox.ac.uk	Holmes, Edward/GVR-9499-2022; Holmes, Edward/Y-2789-2019	Holmes, Edward/0000-0001-9596-3552				Fanning TG, 2002, J VIROL, V76, P7860, DOI 10.1128/JVI.76.15.7860-7862.2002; Gamblin SJ, 2004, SCIENCE, V303, P1838, DOI 10.1126/science.1093155; Oxford JS, 2001, PHILOS T ROY SOC B, V356, P1857, DOI 10.1098/rstb.2001.1012; Reid AH, 2003, EMERG INFECT DIS, V9, P1249; Stevens J, 2004, SCIENCE, V303, P1866, DOI 10.1126/science.1093373; Taubenberger JK, 1997, SCIENCE, V275, P1793, DOI 10.1126/science.275.5307.1793; Taubenberger JK, 2001, PHILOS T ROY SOC B, V356, P1829, DOI 10.1098/rstb.2001.1020; Webster RG, 1999, P NATL ACAD SCI USA, V96, P1164, DOI 10.1073/pnas.96.4.1164	8	9	14	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	2004	303	5665					1787	1788		10.1126/science.1096550	http://dx.doi.org/10.1126/science.1096550			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031487				2022-12-28	WOS:000220281600035
J	Mundy, NI; Badcock, NS; Hart, T; Scribner, K; Janssen, K; Nadeau, NJ				Mundy, NI; Badcock, NS; Hart, T; Scribner, K; Janssen, K; Nadeau, NJ			Conserved genetic basis of a quantitative plumage trait involved in mate choice	SCIENCE			English	Article							GOOSE ANSER-CAERULESCENS; ADAPTIVE MELANISM; POCKET MICE; POLYMORPHISM; PIGMENTATION; MUTATIONS	A key question in evolutionary genetics is whether shared genetic mechanisms underlie the independent evolution of similar phenotypes across phylogenetically divergent lineages. Here we show that in two classic examples of melanic plumage polymorphisms in birds, lesser snow geese (Anser c. caerulescens) and arctic skuas (Stercorarius parasiticus), melanism is perfectly associated with variation in the melanocortin-1 receptor (MC1R) gene. In both species, the degree of melanism correlates with the number of copies of variant MC1R alleles. Phylogenetic reconstructions of variant MC1R alleles in geese and skuas show that melanism is a derived trait that evolved in the Pleistocene.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Tromso, Dept Mol Biotechnol, N-9037 Tromso, Norway; Michigan State Univ, Dept Zool, E Lansing, MI 48824 USA; Michigan State Univ, Dept Fisheries & Wildlife, E Lansing, MI 48824 USA; Univ Oxford, Dept Biol Anthropol, Oxford OX2 6QS, England	University of Cambridge; UiT The Arctic University of Tromso; Michigan State University; Michigan State University; University of Oxford	Mundy, NI (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	nim21@cam.ac.uk	Nadeau, Nicola J./E-1149-2011	Nadeau, Nicola J./0000-0002-9319-921X				AVISE JC, 1992, EVOLUTION, V46, P1084, DOI 10.1111/j.1558-5646.1992.tb00621.x; Bennett DC, 2003, PIGM CELL RES, V16, P333, DOI 10.1034/j.1600-0749.2003.00067.x; Clement M, 2000, MOL ECOL, V9, P1657, DOI 10.1046/j.1365-294x.2000.01020.x; Cohen BL, 1997, P ROY SOC B-BIOL SCI, V264, P181, DOI 10.1098/rspb.1997.0026; COOKE F, 1988, AUK, V105, P467, DOI 10.1093/auk/105.3.467; COOKE F, 1968, EVOLUTION, V22, P289, DOI 10.1111/j.1558-5646.1968.tb05897.x; COOKE F, 1976, BEHAV GENET, V6, P127, DOI 10.1007/BF01067143; Eizirik E, 2003, CURR BIOL, V13, P448, DOI 10.1016/S0960-9822(03)00128-3; Griffiths RC, 1999, ANN APPL PROBAB, V9, P567; Hoekstra HE, 2003, MOL ECOL, V12, P1185, DOI 10.1046/j.1365-294X.2003.01788.x; Jackson IJ, 1997, HUM MOL GENET, V6, P1613, DOI 10.1093/hmg/6.10.1613; King M. K., 2003, EUR J BIOCHEM, V270, P1441; MacDougall-Shackleton EA, 2003, MOL BIOL EVOL, V20, P1675, DOI 10.1093/molbev/msg186; Nachman MW, 2003, P NATL ACAD SCI USA, V100, P5268, DOI 10.1073/pnas.0431157100; O'Donald P., 1987, P433; Phillips RA, 1998, J ZOOL, V245, P245, DOI 10.1017/S0952836998007018; Quinn TW, 1992, MOL ECOL, V1, P105, DOI 10.1111/j.1365-294X.1992.tb00162.x; RATTRAY B, 1984, ZOOL J LINN SOC-LOND, V80, P437, DOI 10.1111/j.1096-3642.1984.tb02554.x; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROCKWELL RF, 1985, EVOLUTION, V39, P178, DOI 10.1111/j.1558-5646.1985.tb04090.x; Takeuchi S, 1996, BBA-GENE STRUCT EXPR, V1308, P164, DOI 10.1016/0167-4781(96)00100-5; TEMPLETON AR, 1992, GENETICS, V132, P619; Theron E, 2001, CURR BIOL, V11, P550, DOI 10.1016/S0960-9822(01)00158-0	23	211	221	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	2004	303	5665					1870	1873		10.1126/science.1093834	http://dx.doi.org/10.1126/science.1093834			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031505				2022-12-28	WOS:000220281600056
J	Azam, F; Worden, AZ				Azam, F; Worden, AZ			Microbes, molecules, and marine ecosystems	SCIENCE			English	Editorial Material							DIVERSITY; BACTERIA; CORAL; VIRUSES; GENOME		Univ Calif San Diego, Scripps Inst Oceanog, Div Marine Biol Res, La Jolla, CA 92093 USA; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Div Marine Biol & Fisheries, Miami, FL 33149 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Miami	Azam, F (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Div Marine Biol Res, La Jolla, CA 92093 USA.	fazam@ucsd.edu; aworden@rsmas.miami.edu	Worden, Alexandra Z./AAD-6567-2019; Azam, Farooq/A-2306-2012	Worden, Alexandra/0000-0002-9888-9324	PHS HHS [R01 A146600] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Azam F, 1998, SCIENCE, V280, P694, DOI 10.1126/science.280.5364.694; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Bidle KD, 1999, NATURE, V397, P508, DOI 10.1038/17351; Bidle KD, 2002, SCIENCE, V298, P1980, DOI 10.1126/science.1076076; Breitbart M, 2002, P NATL ACAD SCI USA, V99, P14250, DOI 10.1073/pnas.202488399; Capone DG, 1997, SCIENCE, V276, P1221, DOI 10.1126/science.276.5316.1221; Culley AI, 2003, NATURE, V424, P1054, DOI 10.1038/nature01886; de la Torre JR, 2003, P NATL ACAD SCI USA, V100, P12830, DOI 10.1073/pnas.2133554100; Dufresne A, 2003, P NATL ACAD SCI USA, V100, P10020, DOI 10.1073/pnas.1733211100; Frias-Lopez J, 2002, APPL ENVIRON MICROB, V68, P2214, DOI 10.1128/AEM.68.5.2214-2228.2002; Fuhrman JA, 2003, BIOL BULL-US, V204, P192, DOI 10.2307/1543557; Fuhrman JA, 1999, NATURE, V399, P541, DOI 10.1038/21119; Gonzalez JM, 2003, INT J SYST EVOL MICR, V53, P1261, DOI 10.1099/ijs.0.02491-0; HOBBIE JE, 1977, APPL ENVIRON MICROB, V33, P1225, DOI 10.1128/AEM.33.5.1225-1228.1977; Kolber ZS, 2001, SCIENCE, V292, P2492, DOI 10.1126/science.1059707; Moran MA, 2003, GEOMICROBIOL J, V20, P375, DOI 10.1080/01490450303901; Morris RM, 2002, NATURE, V420, P806, DOI 10.1038/nature01240; PANEIK B, 2003, NATURE, V424, P1037; Patterson KL, 2002, P NATL ACAD SCI USA, V99, P8725, DOI 10.1073/pnas.092260099; *PEW FDN OC COMM, 2003, PEW FDN OC COMM REP; Rocap G, 2003, NATURE, V424, P1042, DOI 10.1038/nature01947; Rohwer F, 2002, MAR ECOL PROG SER, V243, P1, DOI 10.3354/meps243001; SEIJE N, 2004, NATURE, V427, P445; Sullivan MB, 2003, NATURE, V424, P1047, DOI 10.1038/nature01929; Thingstad TF, 1997, AQUAT MICROB ECOL, V13, P19, DOI 10.3354/ame013019; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Zehr JP, 2001, NATURE, V412, P635, DOI 10.1038/35088063	27	118	130	2	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1622	1624		10.1126/science.1093892	http://dx.doi.org/10.1126/science.1093892			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016987				2022-12-28	WOS:000220151400030
J	Hensch, TK; Stryker, MP				Hensch, TK; Stryker, MP			Columnar architecture sculpted by GABA circuits in developing cat visual cortex	SCIENCE			English	Article							OCULAR DOMINANCE COLUMNS; GAMMA-AMINOBUTYRIC-ACID; STRIATE CORTEX; CELLS; ORIENTATION; VARIABILITY; CONDUCTANCE; SUBTYPES; PATTERN	The mammalian visual cortex is organized into columns. Here, we examine cortical influences upon developing visual afferents in the cat by altering intrinsic gamma-aminobutyric acid (GABA)-mediated inhibition with benzodiazepines. Local enhancement by agonist (diazepam) infusion did not perturb visual responsiveness, but did widen column spacing. An inverse agonist (DMCM) produced the opposite effect. Thus, intracortical inhibitory circuits shape the geometry of incoming thalamic arbors, suggesting that cortical columnar architecture depends on neuronal activity.	RIKEN, Brain Sci Inst, Lab Neuronal Circuit Dev, Wako, Saitama 3510198, Japan; Univ Calif San Francisco, Dept Physiol, WM Keck Fdn Ctr Integrat Neurosci, San Francisco, CA 94143 USA	RIKEN; University of California System; University of California San Francisco	Hensch, TK (corresponding author), RIKEN, Brain Sci Inst, Lab Neuronal Circuit Dev, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	hensch@postman.riken	Hensch, Takao/L-4182-2019	Stryker, Michael/0000-0003-1546-5831	NEI NIH HHS [R37 EY002874-24S1, R37 EY002874] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY002874] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adams DL, 2003, NAT NEUROSCI, V6, P113, DOI 10.1038/nn1004; Adams DL, 2002, SCIENCE, V298, P572, DOI 10.1126/science.1074887; ANTONINI A, 1993, J NEUROSCI, V13, P3549; Buzas P, 2001, J COMP NEUROL, V437, P259, DOI 10.1002/cne.1282; CAPOGNA M, 1994, NEUROPHARMACOLOGY, V33, P875, DOI 10.1016/0028-3908(94)90185-6; Crair MC, 2001, J COMP NEUROL, V430, P235, DOI 10.1002/1096-9861(20010205)430:2<235::AID-CNE1028>3.0.CO;2-P; Crowley JC, 2002, CURR OPIN NEUROBIOL, V12, P104, DOI 10.1016/S0959-4388(02)00297-0; DAW N, 1995, VISUAL DEV; Eghbali M, 1997, NATURE, V388, P71, DOI 10.1038/40404; Fagiolini M, 2004, SCIENCE, V303, P1681, DOI 10.1126/science.1091032; Fagiolini M, 2000, NATURE, V404, P183, DOI 10.1038/35004582; Galarreta M, 2001, SCIENCE, V292, P2295, DOI 10.1126/science.1061395; Hata Y, 1999, NEURON, V22, P375, DOI 10.1016/S0896-6273(00)81097-1; HATA Y, 1994, SCIENCE, V265, P1732, DOI 10.1126/science.8085163; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; Horton JC, 1996, J NEUROSCI, V16, P7228; Kaschube M, 2003, EUR J NEUROSCI, V18, P3251, DOI 10.1111/j.1460-9568.2003.02979.x; Kaschube M, 2002, J NEUROSCI, V22, P7206; Klausberger T, 2002, J NEUROSCI, V22, P2513, DOI 10.1523/JNEUROSCI.22-07-02513.2002; LOWEL S, 1994, J NEUROSCI, V14, P7451; LOWEL S, 1987, EXP BRAIN RES, V68, P661; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; ROE AW, 1995, SOC NEUR ABSTR, V121; SHAW C, 1987, DEV BRAIN RES, V37, P67, DOI 10.1016/0165-3806(87)90229-X; SHIROKAWA T, 1992, BRAIN RES, V589, P157, DOI 10.1016/0006-8993(92)91177-G; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SILLITO AM, 1980, EXP BRAIN RES, V41, P1; SOMERS DC, 1995, J NEUROSCI, V15, P5448; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; WILLSHAW DJ, 1976, PROC R SOC SER B-BIO, V194, P431, DOI 10.1098/rspb.1976.0087	30	131	137	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1678	1681		10.1126/science.1091031	http://dx.doi.org/10.1126/science.1091031			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15017001	Green Accepted			2022-12-28	WOS:000220151400046
J	Berrington de Gonzalez, A; Darby, S				Berrington de Gonzalez, A; Darby, S			Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries	LANCET			English	Article							RADIATION; CT	Background Diagnostic X-rays are the largest man-made source of radiation exposure to the general population, contributing about 14% of the total annual exposure worldwide from all sources. Although diagnostic X-rays provide great benefits, that their use involves some small risk of developing cancer is generally accepted. Our aim was to estimate the extent of this risk on the basis of the annual number of diagnostic X-rays undertaken in the UK and in 14 other developed countries. Methods We combined data on the frequency of diagnostic X-ray use, estimated radiation doses from X-rays to individual body organs, and risk models, based mainly on the Japanese atomic bomb survivors, with population-based cancer incidence rates and mortality rates for all causes of death, using life table methods. Findings Our results indicate that in the UK about 0.6% of the cumulative risk of cancer to age 75 years could be attributable to diagnostic X-rays. This percentage is equivalent to about 700 cases of cancer per year. In 13 other developed countries, estimates of the attributable risk ranged from 0.6% to 1.8%, whereas in Japan, which had the highest estimated annual exposure frequency in the world, it was more than 3%. Interpretation We provide detailed estimates of the cancer risk from diagnostic X-rays. The calculations involved a number of assumptions and so are inevitably subject to considerable uncertainty. The possibility that we have overestimated the risks cannot be ruled out, but that we have underestimated them substantially seems unlikely.	Univ Oxford, Radcliffe Infirm, Canc Res UK Epidemiol Unit, Oxford OX2 6HE, England; Univ Oxford, Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England; Univ Oxford, Radcliffe Infirm, Epidemiol Studies Unit, Oxford OX2 6HE, England	Cancer Research UK; Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Berrington de Gonzalez, A (corresponding author), Univ Oxford, Radcliffe Infirm, Canc Res UK Epidemiol Unit, Gibson Bldg, Oxford OX2 6HE, England.	amy.berrington@cancer.org.uk	de gonzalez, amy berrington/L-7017-2017	de gonzalez, amy berrington/0000-0002-7332-8387				Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; *DEP HLTH, 2003, STAT B BREAST SCREEN; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Golding SJ, 2002, BRIT J RADIOL, V75, P1, DOI 10.1259/bjr.75.889.750001; Hart D., 2002, DOSES PATIENTS MED X; Hart D, 2002, RAD EXPOSURE UK POPU; International Agency for Research on Cancer, 2002, BREAST CANC SCREEN; Kaul A, 1997, EUR RADIOL, V7, P1127, DOI 10.1007/s003300050267; KENDALL GM, 1980, FREQUENCY SURVEY RAD; Khursheed A, 2002, BRIT J RADIOL, V75, P819, DOI 10.1259/bjr.75.898.750819; Maitino AJ, 2003, RADIOLOGY, V227, P113, DOI 10.1148/radiol.2272020617; Mooney R, 1998, BRIT J RADIOL, V71, P852, DOI 10.1259/bjr.71.848.9828798; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; Pierce DA, 2003, RADIAT RES, V159, P511, DOI 10.1667/0033-7587(2003)159[0511:JEORAS]2.0.CO;2; Preston DL, 2002, RADIAT RES, V158, P220, DOI 10.1667/0033-7587(2002)158[0220:REOBCR]2.0.CO;2; PRESTON DL, 1994, RADIAT RES, V137, pS68, DOI 10.2307/3578893; RANNIKO S, 1997, PATIENT POPULATION D; Ron E, 2003, HEALTH PHYS, V85, P47, DOI 10.1097/00004032-200307000-00011; Royal College of Radiologists, 2003, MAK BEST US DEP CLIN, V5th; Shiralkar S, 2003, BRIT MED J, V327, P371, DOI 10.1136/bmj.327.7411.371; SHRIMPTON PC, 1991, SURVEY CT PRACTICE U; SHRIMPTON PC, 1991, SURVEY CT PRACTICE U, V2; TANNER RJ, 2000, FREQUENCY MED DENT E; THOMAS D, 1992, HEALTH PHYS, V63, P259, DOI 10.1097/00004032-199209000-00001; United Nations Scientific Committee on the Effect of Atomic Radiation, 1993, SOURC EFF ION RAD; United Nations Scientific Committee on the Effects of Atomic Radiation, 2000, SOURC EFF ION RAD; Upton AC, 2003, HEALTH PHYS, V85, P15, DOI 10.1097/00004032-200307000-00005; *WHO, STAT INF SYST; YOUNG KC, 2002, BRIT J RADIOL, V73, P278	30	1099	1121	2	50	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	2004	363	9406					345	351		10.1016/S0140-6736(04)15433-0	http://dx.doi.org/10.1016/S0140-6736(04)15433-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768TQ	15070562				2022-12-28	WOS:000188590900007
J	Minn, AH; Kayton, M; Lorang, D; Hoffmann, SC; Harlan, DM; Libutti, SK; Shalev, A				Minn, AH; Kayton, M; Lorang, D; Hoffmann, SC; Harlan, DM; Libutti, SK; Shalev, A			Insulinomas and expression of an insulin splice variant	LANCET			English	Article							HUMAN PANCREATIC-ISLETS; TRANSLATIONAL CONTROL; PROINSULIN BIOSYNTHESIS; BETA-CELL; GLUCOSE; GENE; INITIATION; MUTATIONS	Background Insulinomas are beta-cell tumours characterised by uncontrolled insulin secretion even in the presence of hypoglycaemia. However, the mechanisms allowing such excessive insulin secretion are not known. Insulin secretion can occur only when the beta-cell insulin stores have been replenished by insulin biosynthesis, which is mainly controlled by translation. Such specific translational regulation often involves the 5' untranslated region. We have identified an insulin splice variant in isolated human pancreatic islets of non-diabetic donors that retains 26 bp of intron 1 and thereby changes the 5' untranslated region, but leaves the coding region unchanged. This splice variant has increased translation efficiency in vitro and in vivo compared with native insulin mRNA. However, splice variant expression is less than 1% of native insulin mRNA in normal islets. Methods To test whether this splice variant is involved in insulin production by human insulinomas, we extracted RNA from nine laser-captured surgical insulinoma samples and from isolated islets of nine donors who did not have diabetes. We then determined the ratio of splice variant to native insulin mRNA by quantitative real-time RT-PCR. Findings The mean ratio of the splice variant to native insulin mRNA was increased more than 50-fold in insulinomas compared with normal islets, and this difference was present in all nine human insulinomas. Overexpression of the splice variant therefore seems to be a general characteristic of insulinomas and is estimated to contribute about 90% to insulin synthesis by these tumours. Interpretation Overexpression of the insulin splice variant with increased translation efficiency in insulinomas might explain how these tumours maintain high levels of insulin synthesis and secretion leading to hyperinsulinaemia-the hallmark of this disease.	Univ Wisconsin, Dept Med, Endocrinol Sect, Madison, WI 53792 USA; NCI, NIH, DHHS, Bethesda, MD 20892 USA; NIDDKD, NIH, DHHS, Bethesda, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Shalev, A (corresponding author), Univ Wisconsin, Dept Med, Endocrinol Sect, H4-526 Clin Sci Ctr,600 Highland Ave, Madison, WI 53792 USA.	as7@medicine.wisc.edu			NATIONAL CANCER INSTITUTE [Z01SC010368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK062000] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Creutzfeldt W, 1976, Horm Metab Res, VSuppl 6, P7; FLATT PR, 1990, BIOCHEM SOC T, V18, P124, DOI 10.1042/bst0180124; Goodge KA, 2000, SEMIN CELL DEV BIOL, V11, P235, DOI 10.1006/scdb.2000.0172; GORDEN P, 1995, J CLIN ENDOCR METAB, V80, P2884, DOI 10.1210/jc.80.10.2884; Hirshberg B, 2000, J CLIN ENDOCR METAB, V85, P3222, DOI 10.1210/jc.85.9.3222; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; Kozak M, 2000, GENOMICS, V70, P396, DOI 10.1006/geno.2000.6412; Lan H, 2003, DIABETES, V52, P688, DOI 10.2337/diabetes.52.3.688; Lou H, 2001, ENDOCR REV, V22, P205, DOI 10.1210/er.22.2.205; Pannett AAJ, 2001, J CLIN ENDOCR METAB, V86, P4371, DOI 10.1210/jc.86.9.4371; Pavelic K, 1996, ANTICANCER RES, V16, P1707; Pelengaris S, 2001, ENDOCR-RELAT CANCER, V8, P307, DOI 10.1677/erc.0.0080307; Philips AV, 2000, CELL MOL LIFE SCI, V57, P235, DOI 10.1007/PL00000687; Rhodes Christopher J., 1996, P27; RICORDI C, 1989, DIABETES, V38, P140, DOI 10.2337/diab.38.1.S140; SERVICE FJ, 1991, MAYO CLIN PROC, V66, P711, DOI 10.1016/S0025-6196(12)62083-7; Shalev A, 2002, ENDOCRINOLOGY, V143, P2541, DOI 10.1210/en.143.7.2541; Shalev A, 2002, ENDOCRINOLOGY, V143, P3695, DOI 10.1210/en.2002-220564; Skelly RH, 1996, DIABETES, V45, P37, DOI 10.2337/diabetes.45.1.37; VESSEY SJR, 1994, CLIN SCI, V87, P493, DOI 10.1042/cs0870493; VISCHER U, 1987, BIOCHEM J, V241, P249, DOI 10.1042/bj2410249; Wang E, 2000, NAT BIOTECHNOL, V18, P457, DOI 10.1038/74546; Wang XQ, 2001, J BIOL CHEM, V276, P1311, DOI 10.1074/jbc.M005191200; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; Wilder RM, 1927, J AMER MED ASSOC, V89, P348, DOI 10.1001/jama.1927.02690050014007; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2	29	19	22	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	2004	363	9406					363	367		10.1016/S0140-6736(04)15438-X	http://dx.doi.org/10.1016/S0140-6736(04)15438-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768TQ	15070567				2022-12-28	WOS:000188590900012
J	Tomlinson, JM; Wright, D				Tomlinson, JM; Wright, D			Impact of erectile dysfunction and its subsequent treatment with sildenafil: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EPIDEMIOLOGY; IMPOTENCE; LIFE	Objectives To determine the effects of erectile dysfunction and to explore the impact of treatment with sildenafil (Viagra). Design An exploratory qualitative study with semistructured interviews. Setting Men's health clinic in NHS hospital. Participants 40 men who had had erectile dysfunction and had attended the clinic during the year before interview. Main outcome measures Impact of erectile dysfunction on men, their expectations of sildenafil, and impact of treatment on men and their relationships. Issues explored with exploratory qualitative approach. Results Erectile dysfunction caused serious distress to all those men who experienced it, with marked effects on their self esteem and their relationships. Sildenafil, when it worked, caused a great improvement in wellbeing. The expectations raised by media hyperbole with the launch of sildenafil had an adverse effect on the morale of those who found it did not work. When, according to the patient, treatment did not work, the distress was severe and for many confirmed their lack of self worth. Conclusions Further study is needed to explore the feelings of men affected by erectile dysfunction and their perception of treatment. Health professionals should be aware of the extreme distress erectile dysfunction can cause.	Royal Hampshire Cty Hosp, Winchester SO22 5DG, Hants, England; Univ Southampton, Macmillan Res Unit, Southampton SO17 1BJ, Hants, England	University of Southampton	Tomlinson, JM (corresponding author), Clays Farm, E Worldham GU34 3AD, Alton, England.	john@jptomlinson.com						Althof SE, 2002, UROLOGY, V59, P803, DOI 10.1016/S0090-4295(02)01606-0; Braun M, 2000, INT J IMPOT RES, V12, P305, DOI 10.1038/sj.ijir.3900622; BRITTEN N, 1995, BRIT MED J, V311, P251, DOI 10.1136/bmj.311.6999.251; COOPER AJ, 1986, BRIT J HOSP MED, V36, P186; Dunn KM, 2002, J SEX MARITAL THER, V28, P399, DOI 10.1080/00926230290001529; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; FuglMeyer AR, 1997, INT J IMPOT RES, V9, P141, DOI 10.1038/sj.ijir.3900269; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; HAMMERSLEY M, 1989, ETHNOGRAPHY PRINCIPL, P205; Hoddinott P, 1997, FAM PRACT, V14, P307, DOI 10.1093/fampra/14.4.307; *IMP ASS, 1997, SURV 1997; Kaye JA, 2003, BRIT MED J, V326, P424, DOI 10.1136/bmj.326.7386.424; LEE RM, 1993, DOING RES SENSITIVE, P97; MASTERS WH, 1976, AM J PSYCHIAT, V133, P5; McKinlay JB, 2000, INT J IMPOT RES, V12, pS6, DOI 10.1038/sj.ijir.3900567; Melman A, 1999, J UROLOGY, V161, P5, DOI 10.1016/S0022-5347(01)62045-7; Murphy E, 1998, HEALTH TECHNOL ASSES, V2, P112; RILEY AJ, 1994, J SEX HLTH       SUM, pS3; Strauss AL, 2003, QUALITATIVE ANAL SOC, DOI [10.1017/CBO9780511557842, DOI 10.1017/CBO9780511557842]; 1998, SUNDAY TIMES MA 0906, P44; 1998, GAY TIMES        SEP, P18; 1998, INDEPENDENT SUN 0426, P26; 1998, NEWSWEEK        0622	23	96	99	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 1	2004	328	7447					1037	1039		10.1136/bmj.38044.662176.EE	http://dx.doi.org/10.1136/bmj.38044.662176.EE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817JT	15051618	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000221174500013
J	Arroll, B; Goodyear-Smith, F				Arroll, B; Goodyear-Smith, F			Corticosteroid injections for osteoarthritis of the knee: meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTRAARTICULAR CORTICOSTEROIDS; DOUBLE-BLIND; TRIALS; MANAGEMENT; EFFICACY; STEROIDS; QUALITY; THERAPY; LAVAGE	Objectives To determine the efficacy of intra-articular corticosteroid injections for osteoarthritis of the knee and to identify numbers needed to treat. Data sources Cochrane controlled trials register, Medline (1966 to 2003), Embase (1980 to 2003), hand searches, and contact with authors. Inclusion criteria Randomised controlled trial in which the efficacy of intra-articular corticosteroid injections for osteoarthritis of the knee could be ascertained. Results In high quality studies, the pooled relative risk for improvement in symptoms of osteoarthritis of the knee at 16-24 weeks after intra-articular corticosteroid injections was 2.09 (95% confidence interval 1.2 to 3.7) and the number needed to treat was 4.4. The pooled relative risk for improvement up to two weeks after injections was 1.66 (1.37 to 2.0). In the statistically significant studies the numbers needed to treat to get one improvement was 1.3 to 3.5 patients. Conclusion Evidence supports short term (up to two weeks) improvement in symptoms of osteoarthritis of the knee after intra-articular corticosteroid injection. Significant improvement was also shown in the only methodologically sound studies addressing longer term response (16-24 weeks). A dose equivalent to 50 mg of prednisone may be needed to show benefit at 16-24 weeks.	Univ Auckland, Sch Populat Hlth, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand	University of Auckland	Arroll, B (corresponding author), Univ Auckland, Sch Populat Hlth, Dept Gen Practice & Primary Hlth Care, Private Bag 92019, Auckland 1, New Zealand.	b.arroll@auckland.ac.nz	Bannuru, Raveendhara/G-2601-2011; Goodyear-Smith, Felicity/K-2538-2017	Bannuru, Raveendhara/0000-0002-8069-5783; Goodyear-Smith, Felicity/0000-0002-6657-9401				Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; Ayral X, 2001, BEST PRACT RES CL RH, V15, P609, DOI 10.1053/berh.2001.0177; Cederlof S, 1966, Acta Chir Scand, V132, P532; DIEPPE PA, 1980, RHEUMATOL REHABIL, V19, P212, DOI 10.1093/rheumatology/19.4.212; FRIEDMAN DM, 1980, J RHEUMATOL, V7, P850; GAFFNEY K, 1995, ANN RHEUM DIS, V54, P379, DOI 10.1136/ard.54.5.379; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jones A, 1996, ANN RHEUM DIS, V55, P829, DOI 10.1136/ard.55.11.829; Lane NE, 1998, ENDOCRIN METAB CLIN, V27, P465, DOI 10.1016/S0889-8529(05)70017-7; Liang MH, 2002, MED CARE, V40, P45; MAZIERES B, 1991, J RHEUMATOL, V18, P134; MILLER JH, 1958, J BONE JOINT SURG BR, V40, P636, DOI 10.1302/0301-620X.40B4.636; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Peat G, 2001, ANN RHEUM DIS, V60, P91, DOI 10.1136/ard.60.2.91; Pendleton A, 2000, ANN RHEUM DIS, V59, P936, DOI 10.1136/ard.59.12.936; Ravaud P, 1999, ARTHRITIS RHEUM-US, V42, P475, DOI 10.1002/1529-0131(199904)42:3<475::AID-ANR12>3.0.CO;2-S; Raynauld JP, 2003, ARTHRITIS RHEUM, V48, P370, DOI 10.1002/art.10777; Smith MD, 2003, RHEUMATOLOGY, V42, P1477, DOI 10.1093/rheumatology/keg398; Wang JJ, 1998, ANESTH ANALG, V87, P1113, DOI 10.1097/00000539-199811000-00024; WRIGHT V, 1960, ANN RHEUM DIS, V19, P257, DOI 10.1136/ard.19.3.257	21	204	209	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 10	2004	328	7444					869	870A		10.1136/bmj.38039.573970.7C	http://dx.doi.org/10.1136/bmj.38039.573970.7C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	812XE	15039276	Green Published, Green Submitted			2022-12-28	WOS:000220871400017
J	Ciechanowski, P; Wagner, E; Schmaling, K; Schwartz, S; Williams, B; Diehr, P; Kulzer, J; Gray, S; Collier, C; LoGerfo, J				Ciechanowski, P; Wagner, E; Schmaling, K; Schwartz, S; Williams, B; Diehr, P; Kulzer, J; Gray, S; Collier, C; LoGerfo, J			Community-integrated home-based depression treatment in older adults - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LATE-LIFE DEPRESSION; PROBLEM-SOLVING TREATMENT; PRIMARY-CARE PATIENTS; MINOR DEPRESSION; MYOCARDIAL-INFARCTION; REGRESSION-ANALYSIS; COMPUTER-PROGRAM; MAJOR DEPRESSION; ELDERLY-PATIENTS; PHYSICAL HEALTH	Context Older adults with social isolation, medical comorbidity, and physical impairment are more likely to be depressed but may be less able to seek appropriate care for depression compared with older adults without these characteristics. Objective To determine the effectiveness of a home-based program of detecting and managing minor depression or dysthymia among older adults. Design and Setting Randomized controlled trial with recruitment through community senior service agencies in metropolitan Seattle, Wash, from January 2000 to May 2003. Patients One hundred thirty-eight patients aged 60 years or older with minor depression (51.4%) or dysthymia (48.6%). Patients had a mean of 4.6 (SD, 2.1) chronic medical conditions; 42% of the sample belonged to a racial/ethnic minority, 72% lived alone, 58% had an annual income of less than $10000, and 69% received a form of home assistance. Interventions Patients were randomly assigned to the Program to Encourage Active, Rewarding Lives for Seniors (PEARLS) intervention (n=72) or usual care (n=66). The PEARLS intervention consisted of problem-solving treatment, social and physical activation, and potential recommendations to patients' physicians regarding antidepressant medications. Main Outcome Measures Assessments of depression and quality of life at 12 months compared with baseline. Results At 12 months, compared with the usual care group, patients receiving the PEARLS intervention were more likely to have at least a 50% reduction in depressive symptoms (43% vs 15%; odds ratio [OR], 5.21; 95% confidence interval [CI], 2.01-13.49), to achieve complete remission from depression (36% vs 12%; OR, 4.96; 95% CI, 1.79-13.72), and to have greater health-related quality-of-life improvements in functional well-being (P=.001) and emotional well-being (P=.048). Conclusions The PEARLS program, a community-integrated, home-based treatment for depression, significantly reduced depressive symptoms and improved health status in chronically medically ill older adults with minor depression and dysthymia.	Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Hlth Promot Res Ctr, Seattle, WA 98195 USA; Univ Washington, Sch Pharm, Seattle, WA 98195 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, WA MacColl Inst Healthcare Innovat, Seattle, WA 98101 USA; Univ Texas, El Paso, TX 79968 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative; University of Texas System; University of Texas El Paso	Ciechanowski, P (corresponding author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Box 356560,1959 NE Pacific, Seattle, WA 98195 USA.	pavelcie@u.washington.edu	Schmaling, Karen B/F-5217-2011	Schmaling, Karen B/0000-0003-2085-134X	ODCDC CDC HHS [U48/CCU009654] Funding Source: Medline	ODCDC CDC HHS		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Banerjee S, 1996, BRIT MED J, V313, P1058; BANERJEE S, 1993, INT J GERIATR PSYCH, V8, P125, DOI 10.1002/gps.930080204; Beekman ATF, 1997, PSYCHOL MED, V27, P1397, DOI 10.1017/S0033291797005734; Blazer DG, 2002, DEPRESSION LATE LIFE; BROWN JB, 1992, MED CARE, V30, P400, DOI 10.1097/00005650-199205000-00003; BRUCE ML, 1994, SOC PSYCH PSYCH EPID, V29, P165; Callahan CM, 2001, MED CARE, V39, P772, DOI 10.1097/00005650-200108000-00004; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Ciechanowski PS, 2000, ARCH INTERN MED, V160, P3278, DOI 10.1001/archinte.160.21.3278; Costa P.T., 1985, NEO PERSONALITY INVE; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; Eaton WW, 1996, DIABETES CARE, V19, P1097, DOI 10.2337/diacare.19.10.1097; Engels JM, 2003, J CLIN EPIDEMIOL, V56, P968, DOI 10.1016/S0895-4356(03)00170-7; Ferketich AK, 2000, ARCH INTERN MED, V160, P1261, DOI 10.1001/archinte.160.9.1261; First M.B., 2014, STRUCTURED CLIN INTE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; Geerlings SW, 2000, PSYCHOL MED, V30, P369, DOI 10.1017/S0033291799001890; GIBBONS RD, 1993, ARCH GEN PSYCHIAT, V50, P739; GIL KM, 1992, J CONSULT CLIN PSYCH, V60, P267, DOI 10.1037/0022-006X.60.2.267; GLASS RM, 1978, ARCH GEN PSYCHIAT, V35, P1189; GOLDBERG DP, 1976, BRIT J PSYCHIAT, V129, P61, DOI 10.1192/bjp.129.1.61; HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233, DOI 10.1093/oxfordjournals.aje.a115129; Hedeker D, 1996, COMPUT METH PROG BIO, V49, P229, DOI 10.1016/0169-2607(96)01723-3; Hedeker D, 1996, COMPUT METH PROG BIO, V49, P157, DOI 10.1016/0169-2607(96)01720-8; Hegel M, 1999, PROBLEM SOLVING TREA; Hegel M. T., 2000, FAMILIES SYSTEMS HLT, V18, P423, DOI DOI 10.1037/H0091866; Katon W, 2002, J PSYCHOSOM RES, V53, P859, DOI 10.1016/S0022-3999(02)00313-6; KATON W, 1994, J AFFECT DISORDERS, V31, P81, DOI 10.1016/0165-0327(94)90111-2; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Katon WJ, 2003, ARCH GEN PSYCHIAT, V60, P897, DOI 10.1001/archpsyc.60.9.897; Kawakami N, 1999, DIABETES CARE, V22, P1071, DOI 10.2337/diacare.22.7.1071; Koenig HG, 1996, AM J GERIAT PSYCHIAT, V4, pS14; Krishnan KRR, 1998, AM HEART J, V136, P491, DOI 10.1016/S0002-8703(98)70225-X; Lebowitz BD, 1996, AM J GERIAT PSYCHIAT, V4, pS3; Lewinsohn P., 1986, CONTROL YOUR DEPRESS; MEYERS BS, 1997, NAT I MENT HLTH C IM; MULROW CD, 1995, ANN INTERN MED, V122, P913, DOI 10.7326/0003-4819-122-12-199506150-00004; Mynors-Wallis L, 2002, PSYCHOL MED, V32, P1315, DOI 10.1017/S0033291702006025; Mynors-Wallis LM, 2000, BMJ-BRIT MED J, V320, P26, DOI 10.1136/bmj.320.7226.26; Oldehinkel AJ, 2001, AM J GERIAT PSYCHIAT, V9, P241, DOI 10.1176/appi.ajgp.9.3.241; Ormel J, 1997, PSYCHOL MED, V27, P1065, DOI 10.1017/S0033291797005321; OXMAN TE, 1990, PSYCHOSOMATICS, V31, P174, DOI 10.1016/S0033-3182(90)72191-3; Penninx BWJH, 1998, JAMA-J AM MED ASSOC, V279, P1720, DOI 10.1001/jama.279.21.1720; Pratt LA, 1996, CIRCULATION, V94, P3123, DOI 10.1161/01.CIR.94.12.3123; Prince MJ, 1998, PSYCHOL MED, V28, P337, DOI 10.1017/S0033291797006478; ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P993, DOI 10.1001/jama.265.8.993; Schoevers RA, 2000, J AFFECT DISORDERS, V59, P127, DOI 10.1016/S0165-0327(99)00124-X; Simon GE, 2001, AM J PSYCHIAT, V158, P1638, DOI 10.1176/appi.ajp.158.10.1638; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Stewart AL, 2001, MED SCI SPORT EXER, V33, P1126, DOI 10.1097/00005768-200107000-00010; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; Unutzer J, 1997, JAMA-J AM MED ASSOC, V277, P1618, DOI 10.1001/jama.277.20.1618; Unutzer J, 1999, MILBANK Q, V77, P225, DOI 10.1111/1468-0009.00132; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; VONKORFF M, 1992, HDB PAIN ASSESSMENT, P391; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; Webster Kimberly, 2003, Health Qual Life Outcomes, V1, P79, DOI 10.1186/1477-7525-1-79; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; Williams JW, 2000, JAMA-J AM MED ASSOC, V284, P1519, DOI 10.1001/jama.284.12.1519	62	283	287	0	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2004	291	13					1569	1577		10.1001/jama.291.13.1569	http://dx.doi.org/10.1001/jama.291.13.1569			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	809PQ	15069044				2022-12-28	WOS:000220649000021
J	Nelson, HD				Nelson, HD			Postmenopausal estrogen for treatment of hot flashes - Clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HORMONE REPLACEMENT THERAPY; PLUS PROGESTIN; BREAST-CANCER; ESTROGEN/PROGESTIN REPLACEMENT; DOUBLE-BLIND; MEDROXYPROGESTERONE ACETATE; CLIMACTERIC SYMPTOMS; MENOPAUSAL SYMPTOMS; DISEASE OUTCOMES; WOMEN	Use of postmenopausal estrogen has changed since the release of the first results from the Women's Health Initiative in 2002. Professional organizations, the US Food and Drug Administration, and the US Preventive Services Task Force have issued new recommendations against use of estrogen and progestin or progesterone for prevention of chronic conditions. This article applies the current state of evidence for postmenopausal estrogen use to management decisions in 2 clinical scenarios: initiating therapy in a peri-menopausal woman with hot flashes and discontinuing estrogen use in a long-term user.	Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Oregon Evidence Based Practice Ctr, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Nelson, HD (corresponding author), Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Oregon Evidence Based Practice Ctr, Mail Code BICC 504,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	nelsonh@ohsu.edu						Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; BacchiModena A, 1997, MATURITAS, V27, P285, DOI 10.1016/S0378-5122(97)00039-X; Barry MJ, 2002, ANN INTERN MED, V136, P127, DOI 10.7326/0003-4819-136-2-200201150-00010; Bech P, 1998, PSYCHOTHER PSYCHOSOM, V67, P259, DOI 10.1159/000012289; Berg AO, 2002, ANN INTERN MED, V137, P526, DOI 10.7326/0003-4819-137-6-200209170-00014; Blumel J E, 1994, Rev Chil Obstet Ginecol, V59, P354; CAMPBELL S, 1976, MANAGEMENT MENOPAUSE; Cauley JA, 2003, JAMA-J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Connelly MT, 1999, ANN INTERN MED, V131, P265, DOI 10.7326/0003-4819-131-4-199908170-00005; Coope J, 1981, J R Coll Gen Pract, V31, P134; de Vrijer B, 2000, MATURITAS, V34, P47, DOI 10.1016/S0378-5122(99)00085-7; DITKOFF EC, 1991, OBSTET GYNECOL, V78, P991; Good W R, 1999, Climacteric, V2, P29, DOI 10.3109/13697139909025560; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Grady D, 2002, JAMA-J AM MED ASSOC, V287, P2130, DOI 10.1001/jama.287.16.2130; Greendale GA, 1998, OBSTET GYNECOL, V92, P982, DOI 10.1016/S0029-7844(98)00305-6; GRODSTEIN F, 1994, OBSTET GYNECOL, V83, P5; Harris PF, 2002, J PAIN SYMPTOM MANAG, V23, P501, DOI 10.1016/S0885-3924(02)00395-0; HATCHER RA, 1998, CONTRACEPTIVE TECHNO; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Humphrey LL, 2002, ANN INTERN MED, V137, P273, DOI 10.7326/0003-4819-137-4-200208200-00012; JENSEN PB, 1987, MATURITAS, V9, P207, DOI 10.1016/0378-5122(87)90003-X; Kam IW, 2002, MENOPAUSE, V9, P72, DOI 10.1097/00042192-200201000-00011; Khoo S K, 1998, Climacteric, V1, P55, DOI 10.3109/13697139809080682; Kronenberg F, 2002, ANN INTERN MED, V137, P805, DOI 10.7326/0003-4819-137-10-200211190-00009; KRONENBERG F, 1990, ANN NY ACAD SCI, V592, P52; Lindsay R, 2002, JAMA-J AM MED ASSOC, V287, P2668, DOI 10.1001/jama.287.20.2668; LIVINGSTON WW, 1994, J GEN INTERN MED, V9, P385, DOI 10.1007/BF02629518; Loprinzi CL, 2000, LANCET, V356, P2059, DOI 10.1016/S0140-6736(00)03403-6; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; MacLennan A, 2001, Climacteric, V4, P58, DOI 10.1080/713605036; Maclennan A H, 2004, Cochrane Database Syst Rev, pCD002978, DOI 10.1002/14651858.CD002978.pub2; Mansfield P K, 1997, Health Care Women Int, V18, P55; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; MARSLEW U, 1992, OBSTET GYNECOL, V79, P202; Miller J, 2002, ANN INTERN MED, V136, P680, DOI 10.7326/0003-4819-136-9-200205070-00011; Nelson HD, 2004, JAMA-J AM MED ASSOC, V291, P1610, DOI 10.1001/jama.291.13.1610; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Nelson HD, 2002, ANN INTERN MED, V137, P529, DOI 10.7326/0003-4819-137-6-200209170-00015; Pandya KJ, 2000, ANN INTERN MED, V132, P788, DOI 10.7326/0003-4819-132-10-200005160-00004; Polo-Kantola P, 1998, AM J OBSTET GYNECOL, V178, P1002, DOI 10.1016/S0002-9378(98)70539-3; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; ROTHERT M, 1994, EXP GERONTOL, V29, P463, DOI 10.1016/0531-5565(94)90026-4; Rymer J, 2003, BRIT MED J, V326, P322, DOI 10.1136/bmj.326.7384.322; Saure A, 2000, MATURITAS, V34, P133, DOI 10.1016/S0378-5122(99)00103-6; Simon JA, 2001, ANN INTERN MED, V135, P493, DOI 10.7326/0003-4819-135-7-200110020-00008; Soares CD, 2001, ARCH GEN PSYCHIAT, V58, P529; Speroff L, 2001, CLIN GUIDE CONTRACEP; Stearns V, 2000, ANN ONCOL, V11, P17, DOI 10.1023/A:1008382706068; Stephenson J, 2003, JAMA-J AM MED ASSOC, V289, P537, DOI 10.1001/jama.289.5.537; Tice JA, 2003, JAMA-J AM MED ASSOC, V290, P207, DOI 10.1001/jama.290.2.207; UTIAN WH, 1994, MENOPAUSE, V1, P39; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Wells G, 2002, ENDOCR REV, V23, P529, DOI 10.1210/er.2001-5002; Whitney SN, 2004, ANN INTERN MED, V140, P54, DOI 10.7326/0003-4819-140-1-200401060-00012; *WYETH PHARM, 2004, WEB SIT; 2000, CONSUM REP, V65, P17; 2004, WOMENS HLTH INITATIV	63	25	27	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2004	291	13					1621	1625		10.1001/jama.291.13.1621	http://dx.doi.org/10.1001/jama.291.13.1621			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809PQ	15069050				2022-12-28	WOS:000220649000027
J	Taylor, RW; Zimmerman, JL; Dellinger, RP; Straube, RC; Criner, GJ; Davis, K; Kelly, KM; Smith, TC; Small, RJ				Taylor, RW; Zimmerman, JL; Dellinger, RP; Straube, RC; Criner, GJ; Davis, K; Kelly, KM; Smith, TC; Small, RJ		Inhaled Nitric Oxide ARDS Study Gr	Low-dose inhaled nitric oxide in patients with acute lung injury - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS-SYNDROME; HYPOXIC PULMONARY VASOCONSTRICTION; INHALATION; ARDS; VENTILATION; FAILURE; THERAPY; TRANSPLANTATION; REVERSES; TERM	Context Inhaled nitric oxide has been shown to improve oxygenation in acute lung injury. Objective To evaluate the clinical efficacy of low-dose (5-ppm) inhaled nitric oxide in patients with acute lung injury. Design and Setting Multicenter, randomized, placebo-controlled study, with blinding of patients, caregivers, data collectors, assessors of outcomes, and data analysts (triple blind), conducted in the intensive care units of 46 hospitals in the United States. Patients were enrolled between March 1996 and September 1999. Patients Patients (n=385) with moderately severe acute lung injury, a modification of the American-European Consensus Conference definition of acute respiratory distress syndrome (ARDS) using a ratio of PaO2 to FiO(2) of less than or equal to250, were enrolled if the onset was within 72 hours of randomization, sepsis was not the cause of the lung injury, and the patient had no significant nonpulmonary organ system dysfunction at randomization. Interventions Patients were randomly assigned to placebo (nitrogen gas) or inhaled nitric oxide at 5 ppm until 28 days, discontinuation of assisted breathing, or death. Main Outcome Measures The primary end point was days alive and off assisted breathing. Secondary outcomes included mortality, days alive and meeting oxygenation criteria for extubation, and days patients were alive following a successful unassisted ventilation test. Results An intent-to-treat analysis revealed that inhaled nitric oxide at 5 ppm did not increase the number of days patients were alive and off assisted breathing (mean [SD], 10.6 [9.8] days in the placebo group and 10.7 [9.7] days in the inhaled nitric oxide group; P=.97; difference, -0.1 day [95% confidence interval, -2.0 to 1.9 days]). This lack of effect on clinical outcomes was seen despite a statistically significant increase in PaO2 that resolved by 48 hours. Mortality was similar between groups (20% placebo vs 23% nitric oxide; P=.54). Days patients were alive following a successful 2-hour unassisted ventilation trial were a mean (SD) of 11.9 (9.9) for placebo and 11.4 (9.8) for nitric oxide patients (P=.54). Days alive and meeting criteria for extubation were also similar: 17.0 placebo vs 16.7 nitric oxide (P=.89). Conclusion Inhaled nitric oxide at a dose of 5 ppm in patients with acute lung injury not due to sepsis and without evidence of nonpulmonary organ system dysfunction results in short-term oxygenation improvements but has no substantial impact on the duration of ventilatory support or mortality.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Cooper Univ Hosp, Camden, NJ 08103 USA; St Louis Univ, St Johns Mercy Med Ctr, St Louis, MO 63103 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Ben Taub Gen Hosp, Houston, TX 77030 USA; INO Therapeut Inc, Clinton, NJ USA; Temple Univ Hosp & Med Sch, Temple Lung Ctr, Philadelphia, PA 19140 USA; Univ Cincinnati, Med Ctr, Dept Surg, Cincinnati, OH 45267 USA; Ortho Biotech, Dept Clin Res, Bridgewater, MA USA; Albany Med Coll, Dept Pulm Med, Albany, NY 12208 USA	Cooper University Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center; Saint Johns Mercy Medical Center; Saint Louis University; Baylor College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University System of Ohio; University of Cincinnati; Albany Medical College	Dellinger, RP (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Cooper Univ Hosp, 1 Cooper Plaza,393 Dorrance, Camden, NJ 08103 USA.	Dellinger-Phil@cooperhealth.edu						BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Clark RH, 2000, NEW ENGL J MED, V342, P469, DOI 10.1056/NEJM200002173420704; Cornfield DN, 2003, J HEART LUNG TRANSPL, V22, P903, DOI 10.1016/S1053-2498(02)00809-4; Dellinger RP, 1998, CRIT CARE MED, V26, P15, DOI 10.1097/00003246-199801000-00011; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; FROSTELL CG, 1993, ANESTHESIOLOGY, V78, P427, DOI 10.1097/00000542-199303000-00005; Gallart L, 1998, AM J RESP CRIT CARE, V158, P1770, DOI 10.1164/ajrccm.158.6.9804066; Gerlach H, 2003, AM J RESP CRIT CARE, V167, P1008, DOI 10.1164/rccm.2108121; Gust R, 1999, AM J RESP CRIT CARE, V159, P563, DOI 10.1164/ajrccm.159.2.9806133; Jean D, 2002, CRIT CARE MED, V30, P442, DOI 10.1097/00003246-200202000-00029; Krafft P, 1996, CHEST, V109, P486, DOI 10.1378/chest.109.2.486; Kroncke KD, 1997, NITRIC OXIDE-BIOL CH, V1, P107, DOI 10.1006/niox.1997.0118; Lundin S, 1996, INTENS CARE MED, V22, P728, DOI 10.1007/s001340050159; Lundin S, 1999, INTENS CARE MED, V25, P911, DOI 10.1007/s001340050982; Meade MO, 2003, AM J RESP CRIT CARE, V167, P1483, DOI 10.1164/rccm.2203034; Michael JR, 1998, AM J RESP CRIT CARE, V157, P1372, DOI 10.1164/ajrccm.157.5.96-10089; Papazian L, 1998, AM J RESP CRIT CARE, V157, P580, DOI 10.1164/ajrccm.157.2.9705046; PAYEN D, 1999, INTENS CARE MED S, V25, pS166; PUTENSEN C, 1994, AM J RESP CRIT CARE, V150, P330, DOI 10.1164/ajrccm.150.2.8049811; PUYBASSET L, 1994, ANESTHESIOLOGY, V80, P1254, DOI 10.1097/00000542-199406000-00013; PUYBASSET L, 1995, AM J RESP CRIT CARE, V152, P318, DOI 10.1164/ajrccm.152.1.7599840; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; ROSSAINT R, 1995, CHEST, V107, P1107, DOI 10.1378/chest.107.4.1107; ROVIRA I, 1994, J APPL PHYSIOL, V76, P345, DOI 10.1152/jappl.1994.76.1.345; Sokol J, 2003, ANESTH ANALG, V97, P989, DOI [10.1213/01.ANE.0000078819.48523.26, 10.1213/01.ANE.0000078819.45523.26]; Stork E, 1997, NEW ENGL J MED, V336, P597; Troncy E, 1998, AM J RESP CRIT CARE, V157, P1483, DOI 10.1164/ajrccm.157.5.9707090; Zhu GF, 1998, AM J RESP CRIT CARE, V158, P437, DOI 10.1164/ajrccm.158.2.9711107	30	316	336	1	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2004	291	13					1603	1609		10.1001/jama.291.13.1603	http://dx.doi.org/10.1001/jama.291.13.1603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809PQ	15069048	Bronze			2022-12-28	WOS:000220649000025
J	Sharp, D				Sharp, D			Elementary, my dear Mendeleev	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							LEHRER T, ELEMENTS; Oganessian YT, 2004, PHYS REV C, V69, DOI 10.1103/PhysRevC.69.021601; SCHEWE PP, 2004, PHYS NEWS UPDAT 0202	3	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	2004	363	9415					1092	1092		10.1016/S0140-6736(04)15933-3	http://dx.doi.org/10.1016/S0140-6736(04)15933-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808VB	15064025				2022-12-28	WOS:000220595500006
J	Lee, YS; Nakahara, K; Pham, JW; Kim, K; He, ZY; Sontheimer, EJ; Carthew, RW				Lee, YS; Nakahara, K; Pham, JW; Kim, K; He, ZY; Sontheimer, EJ; Carthew, RW			Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways	CELL			English	Article							NEGATIVE POSTTRANSCRIPTIONAL REGULATION; UTR SEQUENCE MOTIF; RNA-INTERFERENCE; C-ELEGANS; CAENORHABDITIS-ELEGANS; GENE-EXPRESSION; DSRNA-BINDING; MICRORNA; INITIATION; MATURATION	The RNase III enzyme Dicer processes RNA into siRNAs and miRNAs, which direct a RNA-induced silencing complex (RISC) to cleave mRNA or block its translation (RNAi). We have characterized mutations in the Drosophila dicer-1 and dicer-2 genes. Mutation in dicer-1 blocks processing of miRNA precursors, whereas dicer-2 mutants are defective for processing siRNA precursors. It has been recently found that Drosophila Dicer-1 and Dicer-2 are also components of siRNA-dependent RISC (siRISC). We find that Dicer-1 and Dicer-2 are required for siRNA-directed mRNA cleavage, though the RNase III activity of Dicer-2 is not required. Dicer-1 and Dicer-2 facilitate distinct steps in the assembly of siRISC. However, Dicer-1 but not Dicer-2 is essential for miRISC-directed translation repression. Thus, siRISCs and miRISCs are different with respect to Dicers in Drosophila.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Carthew, RW (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2205 Tech Dr, Evanston, IL 60208 USA.	r-carthew@northwestern.edu	Nakahara, Kenji/F-5780-2012; He, Zhengying/A-5635-2014	Nakahara, Kenji/0000-0002-9541-3208; Sontheimer, Erik/0000-0002-0881-0310	NIGMS NIH HHS [R01 GM077581, R01 GM068743] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077581, R01GM068743] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahante JE, 2003, DEV CELL, V4, P625, DOI 10.1016/S1534-5807(03)00127-8; Berger J, 2001, NAT GENET, V29, P475, DOI 10.1038/ng773; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Blaszczyk J, 2001, STRUCTURE, V9, P1225, DOI 10.1016/S0969-2126(01)00685-2; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Chou TB, 1996, GENETICS, V144, P1673; Dasgupta S, 1998, MOL MICROBIOL, V28, P629, DOI 10.1046/j.1365-2958.1998.00828.x; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Kennerdell JR, 2002, GENE DEV, V16, P1884, DOI 10.1101/gad.990802; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Lai EC, 1997, DEVELOPMENT, V124, P4847; Lai EC, 1998, DEVELOPMENT, V125, P4077; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lee YS, 2003, METHODS, V30, P322, DOI 10.1016/S1046-2023(03)00051-3; Lin SY, 2003, DEV CELL, V4, P639, DOI 10.1016/S1534-5807(03)00124-2; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Myers JW, 2003, NAT BIOTECHNOL, V21, P324, DOI 10.1038/nbt792; Newsome TP, 2000, DEVELOPMENT, V127, P851; Nicholson Allen W., 2003, P149; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Palatnik JF, 2003, NATURE, V425, P257, DOI 10.1038/nature01958; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Stowers RS, 1999, GENETICS, V152, P1631; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Xu CY, 2000, CELL, V103, P87, DOI 10.1016/S0092-8674(00)00107-0; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100	45	946	1029	2	139	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	2004	117	1					69	81		10.1016/S0092-8674(04)00261-2	http://dx.doi.org/10.1016/S0092-8674(04)00261-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YV	15066283	Bronze			2022-12-28	WOS:000221500300009
J	Chung, WH; Hung, SI; Hong, HS; Hsih, MS; Yang, LC; Ho, HC; Wu, JY; Chen, YT				Chung, WH; Hung, SI; Hong, HS; Hsih, MS; Yang, LC; Ho, HC; Wu, JY; Chen, YT			A marker for Stevens-Johnson syndrome	NATURE			English	Editorial Material							TOXIC EPIDERMAL NECROLYSIS; RISK		Chang Gung Mem Hosp, Dept Dermatol, Taipei 10591, Taiwan; Chang Gung Mem Hosp, Dept Neurol, Taipei 10591, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; China Med Univ Hosp, Dept Med Res, Taichung, Taiwan; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Academia Sinica - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Duke University	Chung, WH (corresponding author), Chang Gung Mem Hosp, Dept Dermatol, 199 Tung Hwa N Rd, Taipei 10591, Taiwan.	chen0010@ibms.sinica.edu.tw	Hung, Shuen-Iu/ABB-2139-2021; Wu, Jer-Yuarn/S-7010-2018; Hung, Shuen-Iu/HHS-9012-2022	Hung, Shuen-Iu/0000-0001-6531-5538; 				Erlich HA, 2001, IMMUNITY, V14, P347, DOI 10.1016/S1074-7613(01)00115-7; GEER L, 1998, HLA 1998, P327; Goldstein DB, 2003, NAT REV GENET, V4, P937, DOI 10.1038/nrg1229; Kamaliah MD, 1998, INT J DERMATOL, V37, P520, DOI 10.1046/j.1365-4362.1998.00490.x; KHON AKM, 1996, BURNS, V22, P275; ROUJEAU JC, 1986, TISSUE ANTIGENS, V28, P251; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; ROUJEAU JC, 1994, J INVEST DERMATOL, V102, P28; Rzany B, 1999, LANCET, V353, P2190, DOI 10.1016/S0140-6736(98)05418-X; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; Svensson CK, 2001, PHARMACOL REV, V53, P357	11	1171	1275	2	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					486	486		10.1038/428486a	http://dx.doi.org/10.1038/428486a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15057820	Bronze			2022-12-28	WOS:000220540100029
J	Coutinho, A				Coutinho, A			Pills and promises - a personal account from Uganda	LANCET			English	Editorial Material											Coutinho, A (corresponding author), POB 10443, Kampala, Uganda.	coutinhoa@tasouganda.org							0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	2004	363	9414					1073	1073		10.1016/S0140-6736(04)15848-0	http://dx.doi.org/10.1016/S0140-6736(04)15848-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15065566				2022-12-28	WOS:000220497300027
J	Urbach, DR; Baxter, NN				Urbach, DR; Baxter, NN			Does it matter what a hospital is "high volume" for? Specificity of hospital volume-outcome associations for surgical procedures: analysis of administrative data	BRITISH MEDICAL JOURNAL			English	Article							OPERATIVE MORTALITY; PANCREATIC RESECTION; SELECTION BIAS; HEALTH-CARE; PERFECT; SURGERY; CANCER; MODEL; RISK	Objective To determine whether the improved outcome of a Surgical procedure in high volume hospitals is specific to the volume of the same procedure. Design and setting Analysis of secondary data in Ontario, Canada. Participants Patients having an oesophagectomy, colorectal resection for cancer, pancreaticoduodenectomy, major lung resection for cancer, or repair of an unruptured abdominal aortic aneurysm between 1994 and 1999. Main outcome measures Odds ratio for death within 30 days of surgery in relation to the hospital volume of the same surgical procedure and the hospital volume of the other four procedures. Estimates were adjusted for age, sex, and comorbidity and accounted for hospital level clustering. Results With the exception of colorectal resection, 30 day mortality seemed to be inversely related not only to the hospital volume of the same procedure but also to the hospital volume of most of the other procedures. In some cases the effect of the volume of a different procedure was stronger than the effect of the volume of the same procedure. For example, the association of mortality from pancreaticoduodenectomy with hospital volume of lung resection (odds ratio for death in hospitals with a high volume of lung resection compared with low volume 0.36, 95% confidence interval 0.23 to 0.57) was much stronger than the association of mortality from pancreaticoduodenectomy with hospital volume of pancreaticoduodenectomy (0.76, 0.44 to 1.32). Conclusion ne inverse association between high volume of procedure and risk of operative death is not specific to the volume of the procedure being studied.	Univ Toronto, Dept Surg, Toronto, ON M5G 2C4, Canada; Univ Minnesota, Ctr Canc, Dept Surg, MMC 806, Minneapolis, MN 55455 USA	University of Toronto; University of Minnesota System; University of Minnesota Twin Cities	Urbach, DR (corresponding author), Univ Toronto, Dept Surg, 200 Elizabeth St,9EN-236A, Toronto, ON M5G 2C4, Canada.	david.urbach@uhn.on.ca	Baxter, Nancy N/E-7020-2015	Baxter, Nancy N/0000-0003-4793-4620				BALLARD DJ, 1994, HEALTH SERV RES, V28, P771; Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; Birkmeyer JD, 2000, JAMA-J AM MED ASSOC, V283, P1191, DOI 10.1001/jama.283.9.1191; Birkmeyer JD, 1999, SURGERY, V125, P250, DOI 10.1067/msy.1999.95211; Birkmeyer JD, 2000, J AM COLL SURGEONS, V190, P341, DOI 10.1016/S1072-7515(99)00270-7; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Burton P, 1998, STAT MED, V17, P1261, DOI 10.1002/(SICI)1097-0258(19980615)17:11<1261::AID-SIM846>3.0.CO;2-Z; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; DONABEDIAN A, 1985, METHODS FINDINGS QUA; Epstein AM, 2002, NEW ENGL J MED, V346, P1161, DOI 10.1056/NEJM200204113461512; FLOOD AB, 1984, MED CARE, V22, P115, DOI 10.1097/00005650-198402000-00003; FLOOD AB, 1984, MED CARE, V22, P98, DOI 10.1097/00005650-198402000-00002; Glasgow RE, 1996, WESTERN J MED, V165, P294; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; Iezzoni LI, 1997, ANN INTERN MED, V127, P666, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00048; IRON K, 1995, ICES WORKING PAPER S, V42; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; LUFT HS, 1987, HEALTH SERV RES, V22, P157; MELTON LJ, 1985, MAYO CLIN PROC, V60, P880, DOI 10.1016/S0025-6196(12)64794-6; SIMONOVIC M, 1999, CMAJ, V160, P643; Simunovic M, 1999, CAN MED ASSOC J, V160, P643; Urbach DR, 2003, CAN MED ASSOC J, V168, P1409; Urbach DR, 2000, SURGERY, V127, P238, DOI 10.1016/S0039-6060(00)99902-1; Urbach DR, 2002, J CLIN EPIDEMIOL, V55, P381, DOI 10.1016/S0895-4356(01)00508-X; 1985, METHODS FINDINGS QUA	26	95	95	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 27	2004	328	7442					737	740B		10.1136/bmj.38030.642963.AE	http://dx.doi.org/10.1136/bmj.38030.642963.AE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809WH	15020356	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000220666300014
J	Fuchs, E; Tumbar, T; Guasch, G				Fuchs, E; Tumbar, T; Guasch, G			Socializing with the neighbors: Stem cells and their niche	CELL			English	Review							HAIR FOLLICLE MORPHOGENESIS; ADHERENS JUNCTIONS; SELF-RENEWAL; BETA-CATENIN; DROSOPHILA; SKIN; DIFFERENTIATION; DIVISION; PROTEIN; MOUSE	The potential of stem cells in regenerative medicine relies upon removing them from their natural habitat, propagating them in culture, and placing them into a foreign tissue environment. To do so, it is essential to understand how stem cells interact with their microenvironment, the so-called stem cell niche, to establish and maintain their properties. In this review, we examine adult stem cell niches and their impact on stem cell biology.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Fuchs, E (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA.	fuchslb@rockefeller.edu	Fuchs, Elaine/G-1565-2016; Tumbar, Tudorita/A-1916-2014	Tumbar, Tudorita/0000-0002-2273-1889; Guasch, Geraldine/0000-0001-7362-9318	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050452] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR050452-04] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; Baksa K, 2002, DEV BIOL, V243, P166, DOI 10.1006/dbio.2001.0539; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Chen DH, 2003, CURR BIOL, V13, P1786, DOI 10.1016/j.cub.2003.09.033; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Clarke RB, 2003, CELL PROLIFERAT, V36, P45, DOI 10.1046/j.1365-2184.36.s.1.5.x; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Hackney JA, 2002, P NATL ACAD SCI USA, V99, P13061, DOI 10.1073/pnas.192124499; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jamora C, 2003, NATURE, V422, P317, DOI 10.1038/nature01458; Kai TS, 2003, P NATL ACAD SCI USA, V100, P4633, DOI 10.1073/pnas.0830856100; Kiger AA, 2001, SCIENCE, V294, P2542, DOI 10.1126/science.1066707; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611; Lu BW, 2001, NATURE, V409, P522, DOI 10.1038/35054077; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; McGregor JR, 2002, DEVELOPMENT, V129, P705; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Niemann C, 2002, DEVELOPMENT, V129, P95; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Petritsch C, 2003, DEV CELL, V4, P273, DOI 10.1016/S1534-5807(03)00020-0; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Shivdasani AA, 2003, CURR BIOL, V13, P2065, DOI 10.1016/j.cub.2003.10.063; Song XQ, 2003, DEVELOPMENT, V130, P3259, DOI 10.1242/dev.00524; Song XQ, 2002, SCIENCE, V296, P1855, DOI 10.1126/science.1069871; Stappenbeck TS, 2003, P NATL ACAD SCI USA, V100, P1004, DOI 10.1073/pnas.242735899; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wagers AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092-8674(04)00208-9; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Whetton AD, 1999, TRENDS CELL BIOL, V9, P233, DOI 10.1016/S0962-8924(99)01559-7; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhao GQ, 1996, GENE DEV, V10, P1657, DOI 10.1101/gad.10.13.1657; Zhao SM, 2002, EMBO J, V21, P2159, DOI 10.1093/emboj/21.9.2159; Zhong WM, 2003, NEURON, V37, P11, DOI 10.1016/S0896-6273(02)01178-9	48	1315	1440	4	207	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 19	2004	116	6					769	778		10.1016/S0092-8674(04)00255-7	http://dx.doi.org/10.1016/S0092-8674(04)00255-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YS	15035980	Bronze			2022-12-28	WOS:000221499900004
J	Bone, HG; Hosking, D; Devogelaer, J; Tucci, JR; Emkey, RD; Tonino, RP; Rodriguez-Portales, JA; Downs, RW; Gupta, J; Santora, AC; Liberman, UA				Bone, HG; Hosking, D; Devogelaer, J; Tucci, JR; Emkey, RD; Tonino, RP; Rodriguez-Portales, JA; Downs, RW; Gupta, J; Santora, AC; Liberman, UA		Alendronate Phase II Osteoporosis	Ten years' experience with alendronate for osteoporosis in postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; HORMONE REPLACEMENT THERAPY; FRACTURE RISK; AMINOBISPHOSPHONATE ALENDRONATE; VERTEBRAL FRACTURES; RANDOMIZED-TRIAL; ORAL ALENDRONATE; HIP FRACTURE; ESTROGEN; DISCONTINUATION	Background: Antiresorptive agents are widely used to treat osteoporosis. We report the results of a multinational randomized, double-blind study, in which postmenopausal women with osteoporosis were treated with alendronate for up to 10 years. Methods: The initial three-year phase of the study compared three daily doses of alendronate with placebo. Women in the original placebo group received alendronate in years 4 and 5 and then were discharged. Women in the original active-treatment groups continued to receive alendronate during the initial extension (years 4 and 5). In two further extensions (years 6 and 7, and 8 through 10), women who had received 5 mg or 10 mg of alendronate daily continued on the same treatment. Women in the discontinuation group received 20 mg of alendronate daily for two years and 5 mg daily in years 3, 4, and 5, followed by five years of placebo. Randomized group assignments and blinding were maintained throughout the 10 years. We report results for the 247 women who participated in all four phases of the study. Results: Treatment with 10 mg of alendronate daily for 10 years produced mean increases in bone mineral density of 13.7 percent at the lumbar spine (95 percent confidence interval, 12.0 to 15.5 percent), 10.3 percent at the trochanter (95 percent confidence interval, 8.1 to 12.4 percent), 5.4 percent at the femoral neck (95 percent confidence interval, 3.5 to 7.4 percent), and 6.7 percent at the total proximal femur (95 percent confidence interval, 4.4 to 9.1 percent) as compared with base-line values; smaller gains occurred in the group given 5 mg daily. The discontinuation of alendronate resulted in a gradual loss of effect, as measured by bone density and biochemical markers of bone remodeling. Safety data, including fractures and stature, did not suggest that prolonged treatment resulted in any loss of benefit. Conclusions: The therapeutic effects of alendronate were sustained, and the drug was well tolerated over a 10-year period. The discontinuation of alendronate resulted in the gradual loss of its effects.	Michigan Bone & Mineral Clin, Detroit, MI 48236 USA; City Hosp Nottingham, Med Res Ctr, Nottingham, England; Catholic Univ Louvain, St Luc Univ Hosp, B-1200 Brussels, Belgium; Roger Williams Gen Hosp, Dept Med, Providence, RI 02908 USA; Radiant Res Reading, Wyomissing, PA USA; Good Hlth Associates Adult Med, S Burlington, VT USA; Catholic Univ Chile, Escuela Med, Dept Endocrinol, Santiago, Chile; Virginia Commonwealth Univ, Richmond, VA USA; Merck Res Labs, Rahway, NJ USA; Tel Aviv Univ, Sackler Fac Med, Felsenstein Med Res Ctr, IL-49100 Petah Tiqwa, Israel	Nottingham University Hospital NHS Trust; Nottingham City Hospital; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Roger Williams Medical Center; Pontificia Universidad Catolica de Chile; Virginia Commonwealth University; Merck & Company; Tel Aviv University; Sackler Faculty of Medicine	Bone, HG (corresponding author), Michigan Bone & Mineral Clin, 22201 Moross Rd,Suite 260, Detroit, MI 48236 USA.							Ascott-Evans BH, 2003, ARCH INTERN MED, V163, P789, DOI 10.1001/archinte.163.7.789; BALENA R, 1993, J CLIN INVEST, V92, P2577, DOI 10.1172/JCI116872; Balena R, 1996, J PHARMACOL EXP THER, V276, P277; Bell NH, 2002, J CLIN ENDOCR METAB, V87, P2792, DOI 10.1210/jc.87.6.2792; Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118; Black DM, 2001, J CLIN ENDOCR METAB, V86, P938; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Boivin G, 2002, CONNECT TISSUE RES, V43, P535, DOI 10.1080/03008200290000934; Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756-3282(00)00376-8; Bone HG, 2000, J CLIN ENDOCR METAB, V85, P720, DOI 10.1210/jc.85.2.720; Bone HG, 1997, J CLIN ENDOCR METAB, V82, P265, DOI 10.1210/jc.82.1.265; Chapurlat RD, 2000, BONE, V27, P283, DOI 10.1016/S8756-3282(00)00325-2; Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668; CHRISTIANSEN C, 1981, LANCET, V1, P459; Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001-2002; Cummings SR, 2002, JAMA-J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; CUMMINGS SR, 2002, JAMA-J AM MED ASSOC, V288, P2825; Devogelaer JP, 1996, BONE, V19, P78; *FDA CTR DRUG EV R, 2002, END MET DRUGS ADV CO; Gallagher JC, 2002, J CLIN ENDOCR METAB, V87, P4914, DOI 10.1210/jc.2002-020727; Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307; Genant HK, 1996, J BONE MINER RES, V11, P984; Greenspan SL, 2002, ANN INTERN MED, V137, P875, DOI 10.7326/0003-4819-137-11-200212030-00008; Haynes RB, 2002, JAMA-J AM MED ASSOC, V288, P2880, DOI 10.1001/jama.288.22.2880; Heaney RP, 1997, J BONE MINER RES, V12, P1143, DOI 10.1359/jbmr.1997.12.8.1143; Hernandez CJ, 2001, BONE, V29, P511, DOI 10.1016/S8756-3282(01)00613-5; Hochberg MC, 1999, ARTHRITIS RHEUM-US, V42, P1246, DOI 10.1002/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U; Hochberg MC, 2002, J CLIN ENDOCR METAB, V87, P1586, DOI 10.1210/jc.87.4.1586; Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801; Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785; LAFAGE MH, 1995, J CLIN INVEST, V95, P2127, DOI 10.1172/JCI117901; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756-3282(95)00445-9; LINDSAY R, 1978, LANCET, V1, P1325; Michaelsson K, 1998, BMJ-BRIT MED J, V316, P1858; Neele SJM, 2002, BONE, V30, P599, DOI 10.1016/S8756-3282(01)00706-2; Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902; PECK WA, 1993, AM J MED, V94, P646; Pols HAP, 1999, OSTEOPOROSIS INT, V9, P461, DOI 10.1007/PL00004171; REID IR, 1991, J CLIN ENDOCR METAB, V72, P1372, DOI 10.1210/jcem-72-6-1372; Rodan GA, 1997, BONE, V20, P1, DOI 10.1016/S8756-3282(96)00318-3; Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502; Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109; Tonino RP, 2001, J CLIN ENDOCR METAB, V86, P1835, DOI 10.1210/jcem.86.4.7436-2; Tucci JR, 1996, AM J MED, V101, P488, DOI 10.1016/S0002-9343(96)00282-3; Wasnich RD, 2000, J CLIN ENDOCR METAB, V85, P231, DOI 10.1210/jc.85.1.231; YU W, 1995, CALCIFIED TISSUE INT, V57, P169, DOI 10.1007/BF00310253	48	939	1028	2	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 18	2004	350	12					1189	1199		10.1056/NEJMoa030897	http://dx.doi.org/10.1056/NEJMoa030897			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803PG	15028823	Green Published			2022-12-28	WOS:000220242400006
J	Groopman, J				Groopman, J			God at the bedside	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Groopman, J (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.								0	7	7	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	2004	350	12					1176	1178		10.1056/NEJMp038206	http://dx.doi.org/10.1056/NEJMp038206			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803PG	15028822				2022-12-28	WOS:000220242400004
J	King, CY; Diaz-Avalos, R				King, CY; Diaz-Avalos, R			Protein-only transmission of three yeast prion strains	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PROPAGATION; HYPOTHESIS; PSI(+); IDENTIFICATION; REPLICATION; INHERITANCE; DETERMINANT; INDUCTION; REGION	Key questions regarding the molecular nature of prions are how different prion strains can be propagated by the same protein and whether they are only protein(1-3). Here we demonstrate the protein-only nature of prion strains in a yeast model, the [ PSI] genetic element that enhances the read-through of nonsense mutations in the yeast Saccharomyces cerevisiae(4,5). Infectious fibrous aggregates containing a Sup35 prion-determining amino-terminal fragment labelled with green fluorescent protein were purified from yeast harbouring distinctive prion strains. Using the infectious aggregates as 'seeds', elongated fibres were generated in vitro from the bacterially expressed labelled prion protein. De novo generation of strain-specific [ PSI] infectivity was demonstrated by introducing sheared fibres into uninfected yeast hosts. The cross-sectional morphology of the elongated fibres generated in vitro was indistinguishable from that of the short yeast seeds, as visualized by electron microscopy. Electron diffraction of the long fibres showed the 4.7 Angstrom spacing characteristic of the cross-beta structure of amyloids. The fact that the amyloid fibres nucleated in vitro propagate the strain-specific infectivity of the yeast seeds implies that the heritable inforletters mation of distinct prion strains must be encoded by different, self-propagating cross-beta folding patterns of the same prion protein.	Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA	State University System of Florida; Florida State University	King, CY (corresponding author), Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA.	chihyen@sb.fsu.edu	King, Chih-Yen/ABG-2110-2021					Baxa U, 2003, J BIOL CHEM, V278, P43717, DOI 10.1074/jbc.M306004200; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; Derkatch IL, 1996, GENETICS, V144, P1375; DICKINSON AG, 1975, NATURE, V253, P556, DOI 10.1038/253556a0; DICKINSON AG, 1988, CIBA F SYMP, V135, P63; HARASHIMA S, 1984, MOL CELL BIOL, V4, P771, DOI 10.1128/MCB.4.4.771; King CY, 2001, J MOL BIOL, V307, P1247, DOI 10.1006/jmbi.2001.4542; Kushnirov VV, 1998, CELL, V94, P13, DOI 10.1016/S0092-8674(00)81216-7; Liebman SW, 2002, P NATL ACAD SCI USA, V99, P9098, DOI 10.1073/pnas.152318899; Liu JJ, 2002, P NATL ACAD SCI USA, V99, P16446, DOI 10.1073/pnas.252652099; Maddelein ML, 1999, MOL CELL BIOL, V19, P4516; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; ROSE MD, 1986, MOL CELL BIOL, V6, P3490, DOI 10.1128/MCB.6.10.3490; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Skerra A, 2000, METHOD ENZYMOL, V326, P271; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TERAVANESYAN MD, 1994, GENETICS, V137, P671; Tuite MF, 2003, NAT REV MOL CELL BIO, V4, P878, DOI 10.1038/nrm1247; Uptain SM, 2001, EMBO J, V20, P6236, DOI 10.1093/emboj/20.22.6236; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4884, DOI 10.1073/pnas.85.13.4884	27	394	400	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	2004	428	6980					319	323		10.1038/nature02391	http://dx.doi.org/10.1038/nature02391			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15029195				2022-12-28	WOS:000220250200044
J	Liu, ZF; Yan, HC; Wang, KB; Kuang, TY; Zhang, JP; Gui, LL; An, XM; Chang, WR				Liu, ZF; Yan, HC; Wang, KB; Kuang, TY; Zhang, JP; Gui, LL; An, XM; Chang, WR			Crystal structure of spinach major light-harvesting complex at 2.72 angstrom resolution	NATURE			English	Article							CAROTENOID-BINDING-SITES; 3-DIMENSIONAL STRUCTURE; XANTHOPHYLL CYCLE; ENERGY-TRANSFER; PROTEIN; LHCII; PHOTOPROTECTION; FLUORESCENCE; PROGRAM; PLANTS	The major light-harvesting complex of photosystem II (LHC-II) serves as the principal solar energy collector in the photosynthesis of green plants and presumably also functions in photoprotection under high-light conditions. Here we report the first X-ray structure of LHC-II in icosahedral proteoliposome assembly at atomic detail. One asymmetric unit of a large R32 unit cell contains ten LHC-II monomers. The 14 chlorophylls (Chl) in each monomer can be unambiguously distinguished as eight Chla and six Chlb molecules. Assignment of the orientation of the transition dipole moment of each chlorophyll has been achieved. All Chlb are located around the interface between adjacent monomers, and together with Chla they are the basis for efficient light harvesting. Four carotenoid-binding sites per monomer have been observed. The xanthophyll-cycle carotenoid at the monomer - monomer interface may be involved in the non-radiative dissipation of excessive energy, one of the photoprotective strategies that have evolved in plants.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Inst Bot, Lab Photosynth & Environm Mol Physiol, Beijing 100093, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Botany, CAS	Chang, WR (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd,Chaoyang Dist, Beijing 100101, Peoples R China.	wrchang@sun5.ibp.ac.cn	Yan, Hanchi/E-3639-2010	Yan, Hanchi/0000-0003-1055-5459; liu, zhen feng/0000-0001-5502-9474				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; Bassi R, 1997, PHYSIOL PLANTARUM, V100, P769, DOI 10.1034/j.1399-3054.1997.1000404.x; BEDDARD GS, 1976, CHEM PHYS LETT, V43, P27, DOI 10.1016/0009-2614(76)80749-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Croce R, 1999, FEBS LETT, V456, P1, DOI 10.1016/S0014-5793(99)00907-2; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Croce R, 2001, BIOPHYS J, V80, P901, DOI 10.1016/S0006-3495(01)76069-9; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; Elrad D, 2002, PLANT CELL, V14, P1801, DOI 10.1105/tpc.002154; FRANK HA, 1994, PHOTOSYNTH RES, V41, P389, DOI 10.1007/BF02183041; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Gilmore AM, 1997, PHYSIOL PLANTARUM, V99, P197, DOI 10.1034/j.1399-3054.1997.990127.x; Gradinaru CC, 1998, BIOPHYS J, V75, P3064, DOI 10.1016/S0006-3495(98)77747-1; Gradinaru CC, 2000, J PHYS CHEM B, V104, P9330, DOI 10.1021/jp001752i; Hieber AD, 2000, BBA-PROTEIN STRUCT M, V1482, P84, DOI 10.1016/S0167-4838(00)00141-2; Hobe S, 2000, EUR J BIOCHEM, V267, P616, DOI 10.1046/j.1432-1327.2000.01060.x; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jones TA, 1992, MOL REPLACEMENT, P92; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lou Shi-Qing, 1995, Acta Botanica Sinica, V37, P192; Ma YZ, 2003, P NATL ACAD SCI USA, V100, P4377, DOI 10.1073/pnas.0736959100; MASON JG, 1989, NUCLEIC ACIDS RES, V17, P5387, DOI 10.1093/nar/17.13.5387; McLuskey K, 2001, BIOCHEMISTRY-US, V40, P8783, DOI 10.1021/bi010309a; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MICHEL H, 1983, TRENDS BIOCHEM SCI, V8, P56, DOI 10.1016/0968-0004(83)90390-0; Moya I, 2001, BIOCHEMISTRY-US, V40, P12552, DOI 10.1021/bi010342x; Nilsson A, 1997, J BIOL CHEM, V272, P18350, DOI 10.1074/jbc.272.29.18350; NUSSBERGER S, 1993, J MOL BIOL, V234, P347, DOI 10.1006/jmbi.1993.1591; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; PETER GF, 1991, J BIOL CHEM, V266, P16745; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; Remelli R, 1999, J BIOL CHEM, V274, P33510, DOI 10.1074/jbc.274.47.33510; Rossmann MG, 2001, NATO SCI SER I LIFE, V325, P95; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504	42	1333	1405	21	406	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	2004	428	6980					287	292		10.1038/nature02373	http://dx.doi.org/10.1038/nature02373			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15029188				2022-12-28	WOS:000220250200035
J	Strewler, GJ				Strewler, GJ			Decimal point - Osteoporosis therapy at the 10-year mark	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							POSTMENOPAUSAL OSTEOPOROSIS; ORAL ALENDRONATE; WOMEN		Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Strewler, GJ (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.							Devogelaer JP, 1996, BONE, V19, P78; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436; Tucci JR, 1996, AM J MED, V101, P488, DOI 10.1016/S0002-9343(96)00282-3	4	23	24	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	2004	350	12					1172	1174		10.1056/NEJMp048017	http://dx.doi.org/10.1056/NEJMp048017			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803PG	15028820				2022-12-28	WOS:000220242400002
J	Woolf, CJ				Woolf, CJ			Pain: Moving from symptom control toward mechanism-specific pharmacologic management	ANNALS OF INTERNAL MEDICINE			English	Review							RAT SENSORY NEURONS; NEUROPATHIC PAIN; NERVE INJURY; SPINAL-CORD; CENTRAL SENSITIZATION; MOLECULAR-MECHANISMS; MYELINATED AFFERENTS; SODIUM-CHANNELS; PROTEIN-KINASE; UP-REGULATION		Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plastic Res Grp, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Woolf, CJ (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plastic Res Grp, 149 13th St,Room 4309, Boston, MA 02129 USA.	cwoolf@partners.org	Woolf, Clifford/A-9784-2010					Amaya F, 2000, MOL CELL NEUROSCI, V15, P331, DOI 10.1006/mcne.1999.0828; Bennett RM, 2002, RHEUM DIS CLIN N AM, V28, P181, DOI 10.1016/S0889-857X(02)00002-9; Bolay H, 2002, NAT MED, V8, P136, DOI 10.1038/nm0202-136; Burstein R, 2000, BRAIN, V123, P1703, DOI 10.1093/brain/123.8.1703; CAMPBELL JN, 1988, PAIN, V32, P89, DOI 10.1016/0304-3959(88)90027-9; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Cheng HYM, 2002, CELL, V108, P31, DOI 10.1016/S0092-8674(01)00629-8; Gold MS, 1998, J NEUROSCI, V18, P10345; Hunt SP, 2001, NAT REV NEUROSCI, V2, P83, DOI 10.1038/35053509; Hwang JH, 1997, PAIN, V70, P15, DOI 10.1016/S0304-3959(96)03249-6; Ji RR, 2002, J NEUROSCI, V22, P478, DOI 10.1523/JNEUROSCI.22-02-00478.2002; Ji RR, 2003, TRENDS NEUROSCI, V26, P696, DOI 10.1016/j.tins.2003.09.017; Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X; Jin SX, 2003, J NEUROSCI, V23, P4017; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Koltzenburg M, 2001, CURR OPIN NEUROL, V14, P641, DOI 10.1097/00019052-200110000-00014; Levine JD, 1999, TXB PAIN, P59; Liu CN, 2002, J NEUROPHYSIOL, V87, P2009, DOI 10.1152/jn.00705.2001; Luo ZD, 2001, J NEUROSCI, V21, P1868, DOI 10.1523/JNEUROSCI.21-06-01868.2001; Mannion RJ, 1999, P NATL ACAD SCI USA, V96, P9385, DOI 10.1073/pnas.96.16.9385; Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; McCleskey EW, 1999, ANNU REV PHYSIOL, V61, P835, DOI 10.1146/annurev.physiol.61.1.835; Miranda C, 2002, J BIOL CHEM, V277, P6455, DOI 10.1074/jbc.M110016200; Mogil JS, 2000, ANNU REV NEUROSCI, V23, P777, DOI 10.1146/annurev.neuro.23.1.777; Moore KA, 2002, J NEUROSCI, V22, P6724, DOI 10.1523/jneurosci.22-15-06724.2002; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Porreca F, 2002, TRENDS NEUROSCI, V25, P319, DOI 10.1016/S0166-2236(02)02157-4; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Rowbotham MC, 1996, BRAIN, V119, P347, DOI 10.1093/brain/119.2.347; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Sarkar S, 2000, LANCET, V356, P1154, DOI 10.1016/S0140-6736(00)02758-6; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; Shu XQ, 1999, NEUROSCI LETT, V274, P159, DOI 10.1016/S0304-3940(99)00701-6; Sindrup SH, 1999, PAIN, V83, P389, DOI 10.1016/S0304-3959(99)00154-2; South SM, 2003, J NEUROSCI, V23, P5031; Stubhaug A, 1997, ACTA ANAESTH SCAND, V41, P1124, DOI 10.1111/j.1399-6576.1997.tb04854.x; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Waldmann R, 2001, ADV EXP MED BIOL, V502, P293; WALKER K, 1995, NEUROCHEM INT, V26, P1, DOI 10.1016/0197-0186(94)00114-A; Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3; Waxman SG, 1999, BRAIN RES BULL, V50, P309, DOI 10.1016/S0361-9230(99)00158-6; WOOLF CJ, 1992, NATURE, V355, P75, DOI 10.1038/355075a0; Woolf CJ, 2001, ANESTHESIOLOGY, V95, P241, DOI 10.1097/00000542-200107000-00034; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765	45	536	569	0	41	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 16	2004	140	6					441	451		10.7326/0003-4819-140-8-200404200-00010	http://dx.doi.org/10.7326/0003-4819-140-8-200404200-00010			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803AU	15023710				2022-12-28	WOS:000220204800005
J	Derluyn, I; Broekaert, E; Schuyten, G; De Temmerman, E				Derluyn, I; Broekaert, E; Schuyten, G; De Temmerman, E			Post-traumatic stress in former Ugandan child soldiers	LANCET			English	Article								Worldwide, 300 000 children are currently used as child soldiers in armed conflicts. We interviewed 301 former child soldiers who had been abducted by the northern Ugandan rebellion movement Lord's Resistance Army. All the children were abducted at a young age (mean 12.9 years) and for a long time (mean 744 days). Almost all the children experienced several traumatic events (mean six events); 233 (77%) saw someone being killed, and 118 (39%) had to kill someone themselves. 71 children also filled in the impact of event scale-revised to assess their post-trauma stress reactions. 69 (97%) reported post-traumatic stress reactions of clinical importance. The death of a parent, especially of the mother, led to an important increase in score for avoidance symptoms (mother alive 1.6.4, mother not alive 21.6; p=0.04), with a high increase for girls (from 15.1 to 25.8), but almost no change for boys (from 17.7 to 17.4; p=0.02). Our findings shed light on the nature of severe trauma experienced by this group of children, and show a high rate of post-traumatic stress reactions.	State Univ Ghent, Dept Orthopedag, B-9000 Ghent, Belgium; State Univ Ghent, Dept Data Anal, B-9000 Ghent, Belgium; Sponsoring Children Uganda, Nevele, Belgium	Ghent University; Ghent University	Derluyn, I (corresponding author), State Univ Ghent, Dept Orthopedag, Henri Dunantlaan 2, B-9000 Ghent, Belgium.	Ilse.Derluyn@UGent.be	Singh, Sonal/A-4614-2008	Singh, Sonal/0000-0003-0912-941X; Derluyn, Ilse/0000-0001-5450-1239				Asukai N, 2002, J NERV MENT DIS, V190, P175, DOI 10.1097/00005053-200203000-00006; BRACKEN PJ, 1995, SOC SCI MED, V40, P1073, DOI 10.1016/0277-9536(94)00181-R; Dyregrov A, 2002, J TRAUMA STRESS, V15, P59, DOI 10.1023/A:1014335312219; Machel G., 2001, IMPACT WAR CHILDREN; Weiss DSMC, 1997, ASSESSING PSYCHOL TR	5	196	197	0	28	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 13	2004	363	9412					861	863		10.1016/S0140-6736(04)15734-6	http://dx.doi.org/10.1016/S0140-6736(04)15734-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15031032				2022-12-28	WOS:000220231500013
J	Hodgson, H				Hodgson, H			A statement by The Royal Free and University College Medical School and The Royal Free Hampstead NHS Trust	LANCET			English	Editorial Material									UCL Royal Free & Univ Coll, Sch Med, London NW3 2PF, England	University of London; University College London; UCL Medical School	Hodgson, H (corresponding author), UCL Royal Free & Univ Coll, Sch Med, London NW3 2PF, England.	h.hodgson@rfc.ucl.ac.uk							0	5	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 6	2004	363	9411					824	824		10.1016/S0140-6736(04)15711-5	http://dx.doi.org/10.1016/S0140-6736(04)15711-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15022651				2022-12-28	WOS:000220092000027
J	Horton, R				Horton, R			A statement by the editors of The Lancet	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Horton, R (corresponding author), The Lancet, 32 Jamestown Rd, London NW1 7BY, England.	richard.horton@lancet.com						[Anonymous], 1998, LANCET; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0	2	54	55	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	2004	363	9411					820	821		10.1016/S0140-6736(04)15699-7	http://dx.doi.org/10.1016/S0140-6736(04)15699-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15022645				2022-12-28	WOS:000220092000023
J	Gandon, Y; Olivie, D; Guyader, D; Aube, C; Oberti, F; Sebille, V; Deugnier, Y				Gandon, Y; Olivie, D; Guyader, D; Aube, C; Oberti, F; Sebille, V; Deugnier, Y			Non-invasive assessment of hepatic iron stores by MRI	LANCET			English	Article							NEEDLE-BIOPSY SPECIMENS; LIVER-IRON; GENETIC HEMOCHROMATOSIS; OVERLOAD; QUANTIFICATION; DIAGNOSIS; FIBROSIS; DISEASE	Background MRI has been proposed for non-invasive detection and quantification of liver iron content, but has not been validated as a reproducible and sensitive method, especially in patients with mild iron overload. We aimed to assess the accuracy of a simple, rapid, and easy to implement MRI procedure to detect and quantify hepatic iron stores. Methods Of 191 patients recruited, 17 were excluded and 174 studied, 139 in a study group and 35 in a validation group. All patients underwent both percutaneous liver biopsy with biochemical assessment of hepatic iron concentration (B-HIC) and MRI of the liver with various gradient-recalled-echo (GRE) sequences obtained with a 1.5 T magnet. Correlation between liver to muscle (L/M) signal intensity ratio and liver iron concentration was calculated. An algorithm to calculate magnetic resonance hepatic iron concentration (MR-HIC) was developed with data from the study group and then applied to the validation group. Findings A highly T2-weighted GRE sequence was most sensitive, with 89% sensitivity and 80% specificity in the validation group, with an L/M ratio below 0.88. This threshold allowed us to detect all clinically relevant liver iron overload greater than 60 mumol/g (normal value <36 &mu;mol/g). With other sequences, an L/M ratio less than I was highly specific (>87%) for raised hepatic iron concentration. With respect to B-HIC range analysed (3-375 mumol/g), mean difference and 95% CI between B-HIC and MR-HIC were quite similar for study and validation groups (0.8 mumol/g [-6.3 to 7.9] and -2.1 mumol/g [-12.9 to 8.9], respectively). Interpretation MRI is a rapid, non-invasive, and cost effective technique that could limit use of liver biopsy to assess liver iron content. Our MR-HIC algorithm is designed to be used on various magnetic resonance machines.	CHU Pontchaillou, Federat Imagerie Med, Rennes, France; CHU Pontchaillou, Serv Malad Foie, Rennes, France; CHU Pontchaillou, Ctr Invest Clin, Rennes, France; CHU Angers, Dept Radiol, Angers, France; CHU Angers, Serv Gastroenterol, Angers, France	CHU Rennes; CHU Rennes; CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers	Gandon, Y (corresponding author), Hop Pontchaillou, Federat Imagerie Med, F-35033 Rennes, France.	yves.gandon@chu-rennes.fr	Sebille, Veronique/I-3309-2015	Sebille, Veronique/0000-0002-0780-7742; Guyader, Dominique/0000-0001-8912-6950				ALUSTIZA J, 2000, P RAD SOC N AM NOV 2, P217; BARRY M, 1971, LANCET, V1, P100; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bonkovsky HL, 1999, RADIOLOGY, V212, P227, DOI 10.1148/radiology.212.1.r99jl35227; Bonkovsky HL, 1997, HEPATOLOGY, V25, P759, DOI 10.1002/hep.510250345; BRISSOT P, 1999, OXFORD TXB CLIN HEPA, P1379; BRITTENHAM GM, 1982, NEW ENGL J MED, V307, P1671, DOI 10.1056/NEJM198212303072703; de Valk B, 1999, ARCH INTERN MED, V159, P1542, DOI 10.1001/archinte.159.14.1542; Deugnier Y, 2000, B ACAD NAT MED PARIS, V184, P365; Deugnier Yves, 1998, Journal of Hepatology, V28, P21, DOI 10.1016/S0168-8278(98)80371-1; Ernst O, 1997, AM J ROENTGENOL, V168, P1205, DOI 10.2214/ajr.168.5.9129412; Fenzi A, 2003, J MAGN RESON IMAGING, V17, P589, DOI 10.1002/jmri.10306; GANDON Y, 1994, RADIOLOGY, V193, P533, DOI 10.1148/radiology.193.2.7972774; GANDON Y, 1998, P RAD SOC N AM NOV 2, P209; GOMORI JM, 1991, RADIOLOGY, V179, P367, DOI 10.1148/radiology.179.2.2014276; GUYADER D, 1989, GASTROENTEROLOGY, V97, P737, DOI 10.1016/0016-5085(89)90646-X; GUYADER D, 1992, J HEPATOL, V15, P304, DOI 10.1016/0168-8278(92)90060-3; Guyader D, 1998, GASTROENTEROLOGY, V115, P929, DOI 10.1016/S0016-5085(98)70265-3; HERNANDEZ RJ, 1988, J COMPUT ASSIST TOMO, V12, P91, DOI 10.1097/00004728-198801000-00017; Jensen JH, 2002, MAGNET RESON MED, V47, P1131, DOI 10.1002/mrm.10170; KALTWASSER JP, 1990, BRIT J HAEMATOL, V74, P360, DOI 10.1111/j.1365-2141.1990.tb02596.x; Kreeftenberg HG, 2000, NETH J MED, V56, P133, DOI 10.1016/S0300-2977(00)00003-6; Mendler MH, 1999, GASTROENTEROLOGY, V117, P1155, DOI 10.1016/S0016-5085(99)70401-4; Outwater EK, 1998, RADIOGRAPHICS, V18, P1465, DOI 10.1148/radiographics.18.6.9821195; Pawlotsky Y, 1999, ARTHRITIS RHEUM, V42, P799; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; ROCCHI E, 1993, HEPATOLOGY, V17, P997, DOI 10.1016/0270-9139(93)90113-2; Siegelman E S, 1997, Magn Reson Imaging Clin N Am, V5, P347; STARK DD, 1991, RADIOLOGY, V179, P333, DOI 10.1148/radiology.179.2.2014271; Villeneuve JP, 1996, J HEPATOL, V25, P172, DOI 10.1016/S0168-8278(96)80070-5	30	474	493	1	22	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	2004	363	9406					357	362		10.1016/S0140-6736(04)15436-6	http://dx.doi.org/10.1016/S0140-6736(04)15436-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768TQ	15070565				2022-12-28	WOS:000188590900010
J	Emerson, PM; Lindsay, SW; Alexander, N; Bah, M; Dibba, SM; Faal, HB; Lowe, K; McAdam, KPWJ; Ratcliffe, AA; Walraven, GEL; Bailey, RL				Emerson, PM; Lindsay, SW; Alexander, N; Bah, M; Dibba, SM; Faal, HB; Lowe, K; McAdam, KPWJ; Ratcliffe, AA; Walraven, GEL; Bailey, RL			Role of flies and provision of latrines in trachoma control: cluster-randomised controlled trial	LANCET			English	Article							GLOBAL ELIMINATION; BLINDNESS; TANZANIA; VECTOR; RISK	Background Eye-seeking flies have received much attention as possible trachoma vectors, but this remains unproved. We aimed to assess the role of eye-seeking flies as vectors of trachoma and to test provision of simple pit latrines, without additional health education, as a sustainable method of fly control. Methods In a community-based, cluster-randomised controlled trial, we recruited seven sets of three village clusters and randomly assigned them to either an intervention group that received regular insecticide spraying or provision of pit latrines (without additional health education) to each household, or to a control group with no intervention. Our primary outcomes were fly-eye contact and prevalence of active trachoma. Frequency of child fly-eye contact was monitored fortnightly. Whole communities were screened for clinical signs of trachoma at baseline and after 6 months. Analysis was per protocol. Findings Of 7080 people recruited, 6087 (86%) were screened at follow-up. Baseline community prevalence of active trachoma was 6%. The number of Musca sorbens flies caught from children's eyes was reduced by 88% (95% CI 64-100; p < 0.0001) by insecticide spraying and by 30% (7-52; p = 0.04) by latrine provision by comparison with controls. Analysis of age-standardised trachoma prevalence rates at the cluster level (n = 14) showed that spraying was associated with a mean reduction in trachoma prevalence of 56% (19-93; p = 0.01) and 30% with latrines (-81 to 22; p = 0.210) by comparison with the mean rate change in the controls. Interpretation Fly control with insecticide is effective at reducing the number of flies caught from children's eyes and is associated with substantially lower trachoma prevalence compared with controls. Such a finding is consistent with flies being important vectors of trachoma. Since latrine provision without health education was associated with a significant reduction in fly-eye contact by M sorbens, studies of their effect when combined with other trachoma control measures are warranted.	Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England; MRC Labs, Banjul, Gambia; Minist Hlth, Natl Eye Care Programme, Banjul, Gambia; London Sch Hyg & Trop Med, London WC1, England	Durham University; MRC Laboratory Molecular Biology; University of London; London School of Hygiene & Tropical Medicine	Emerson, PM (corresponding author), Univ Durham, Sch Biol & Biomed Sci, South Rd, Durham DH1 3LE, England.	p.m.emerson@durham.ac.uk		Emerson, Paul/0000-0002-6478-8816; Lindsay, Steve/0000-0002-3461-9050				Bailey R, 2001, B WORLD HEALTH ORGAN, V79, P233; Bennett S, 2002, INT J EPIDEMIOL, V31, P839, DOI 10.1093/ije/31.4.839; COURTRIGHT P, 1991, BRIT J OPHTHALMOL, V75, P322, DOI 10.1136/bjo.75.6.322; Dawson CR, 2002, LANCET, V359, P184, DOI 10.1016/S0140-6736(02)07463-9; Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930; Emerson PM, 2000, T ROY SOC TROP MED H, V94, P28, DOI 10.1016/S0035-9203(00)90427-9; Emerson PM, 2002, OPHTHALMIC EPIDEMIOL, V9, P105, DOI 10.1076/opep.9.2.105.1522; Emerson PM, 2001, MED VET ENTOMOL, V15, P314, DOI 10.1046/j.0269-283x.2001.00318.x; Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2; EMERSON PM, 2000, TROP MED INT HEALTH, V5, P250; Gaynor Bruce D., 2002, International Ophthalmology Clinics, V42, P85; HAFEZ MAHMOUD, 1958, BULL SOC ENT EGYPTE, V42, P83; HAFEZ MAHMOUD, 1958, BULL SOC ENT EGYPTE, V42, P275; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451; Mabey D, 1999, BRIT J OPHTHALMOL, V83, P1261, DOI 10.1136/bjo.83.11.1261; Mabey D, 2001, BRIT MED J, V323, P218, DOI 10.1136/bmj.323.7306.218; Mabey D. C. W., 1992, Reviews in Medical Microbiology, V3, P112; Munoz B, 1997, EPIDEMIOL REV, V19, P205, DOI 10.1093/oxfordjournals.epirev.a017953; PROST A, 1989, B WORLD HEALTH ORGAN, V67, P9; Pruss A, 2000, B WORLD HEALTH ORGAN, V78, P258; Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5; Schemann JF, 2003, T ROY SOC TROP MED H, V97, P63, DOI 10.1016/S0035-9203(03)90025-3; Schemann JF, 2002, INT J EPIDEMIOL, V31, P194, DOI 10.1093/ije/31.1.194; Taylor H, 1999, NAT MED, V5, P492, DOI 10.1038/8376; TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821, DOI 10.1001/archopht.1989.01070020903037; Taylor HR, 2002, CLIN EXP OPHTHALMOL, V30, P65; THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1; *WHO, 2001, 5 M WHO ALL GLOB EL; World Health Organization, 1997, 1 M WHO ALL GLOB EL	32	161	162	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	2004	363	9415					1093	1098		10.1016/S0140-6736(04)15891-1	http://dx.doi.org/10.1016/S0140-6736(04)15891-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808VB	15064026				2022-12-28	WOS:000220595500007
J	Nason, G				Nason, G			Multiple myeloma	LANCET			English	Editorial Material												gerson_nason@yahoo.co.uk							0	0	0	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 13	2004	363	9412					888	888		10.1016/S0140-6736(04)15737-1	http://dx.doi.org/10.1016/S0140-6736(04)15737-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15031035				2022-12-28	WOS:000220231500024
J	Sirohi, B; Powles, R				Sirohi, B; Powles, R			Multiple myeloma	LANCET			English	Review							STEM-CELL TRANSPLANTATION; HIGH-DOSE THERAPY; ALLOGENEIC BONE-MARROW; OVERCOMES DRUG-RESISTANCE; PREVIOUSLY UNTREATED PATIENTS; EVENT-FREE SURVIVAL; RANDOMIZED-TRIAL; AUTOLOGOUS TRANSPLANTATION; MONOCLONAL GAMMOPATHY; PHASE-I	Multiple myeloma is a malignant disease of plasma cells that manifests as one or more of lytic bone lesions, monoclonal protein in the blood or urine, and disease in the bone marrow. Treatment for myeloma has changed beyond recognition in the past decade, and now includes state of the art supportive treatment and infusional chemotherapy courses, followed for younger patients by high-dose melphalan and an autologous transplant. Patients younger than 70 years can now expect a doubling of median survival to 5 years, a 20% chance of surviving longer than 10 years, and a 50% chance of attaining complete morphological and biochemical remission. Bisphosphonate control of bone disease is essential. Exploitation of the understanding of the biology of myeloma has led to the development of biological treatments, such as thalidomide, CC-5013, and bortezomib, which target the myeloma cell and the bone-marrow microenvironment, which plays a crucial part in the disease's pathogenesis. These treatments will hold the key to future success.	Inst Canc Res, Sutton SM2 5PT, Surrey, England; Royal Marsden NHS Trust, Sutton SM2 5PT, Surrey, England	University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Powles, R (corresponding author), Parkside Oncol Clin, 49 Parkside, London SW19 5NB, England.	myeloma@clara.co.uk						Alegre A, 1998, BONE MARROW TRANSPL, V21, P133, DOI 10.1038/sj.bmt.1701062; ALEXANIAN R, 1969, J AMER MED ASSOC, V208, P1680, DOI 10.1001/jama.208.9.1680; ALEXANIAN R, 1992, BLOOD, V80, P887; Anderson KC, 2001, SEMIN HEMATOL, V38, P6, DOI 10.1053/shem.2001.21065; [Anonymous], 1998, J Clin Oncol, V16, P3832; Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Attal M, 2003, NEW ENGL J MED, V349, P2495, DOI 10.1056/NEJMoa032290; Attal M, 2001, SEMIN HEMATOL, V38, P226, DOI 10.1053/shem.2001.26005; Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; Badros A, 2001, BRIT J HAEMATOL, V114, P822, DOI 10.1046/j.1365-2141.2001.03033.x; Badros A, 2001, BRIT J HAEMATOL, V114, P600, DOI 10.1046/j.1365-2141.2001.02976.x; Badros A, 2001, BLOOD, V97, P2574, DOI 10.1182/blood.V97.9.2574; Barlogie B, 1997, BLOOD, V89, P789, DOI 10.1182/blood.V89.3.789; Barlogie B, 1999, BLOOD, V93, P55, DOI 10.1182/blood.V93.1.55.401k04_55_65; Barlogie B, 2001, BLOOD, V98, P492, DOI 10.1182/blood.V98.2.492; BATAILLE R, 1995, BRIT J HAEMATOL, V90, P721, DOI 10.1111/j.1365-2141.1995.tb05609.x; Bensinger WI, 2001, SEMIN HEMATOL, V38, P243, DOI 10.1053/shem.2001.26008; Berenson JR, 2002, BLOOD, V99, P3163, DOI 10.1182/blood.V99.9.3163; Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802; Bjorkstrand B, 1996, BLOOD, V88, P4711, DOI 10.1182/blood.V88.12.4711.bloodjournal88124711; Blade J, 2003, BLOOD, V102, p42A; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; Body JJ, 2003, CANCER-AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138; Bukowski RM, 2002, CANCER, V95, P389, DOI 10.1002/cncr.10663; Casassus P, 2001, BRIT J HAEMATOL, V113, P1020; Cavenagh JD, 2003, BRIT J HAEMATOL, V120, P18, DOI 10.1046/j.1365-2141.2003.03902.x; Cavo M, 1998, BONE MARROW TRANSPL, V22, P27, DOI 10.1038/sj.bmt.1701280; Cavo M, 2002, BLOOD, V100, p179A; Chauhan D, 2002, BLOOD, V100, P2187, DOI 10.1182/blood-2002-02-0376; Chesi M, 1996, BLOOD, V88, P674, DOI 10.1182/blood.V88.2.674.bloodjournal882674; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340; Clark AD, 2002, BRIT J HAEMATOL, V117, P605, DOI 10.1046/j.1365-2141.2002.03519.x; Claudio JO, 2002, BLOOD, V100, P2175, DOI 10.1182/blood-2002-01-0008; Davies FE, 2001, BRIT J HAEMATOL, V112, P814, DOI 10.1046/j.1365-2141.2001.02530.x; Derenne S, 1999, J BONE MINER RES, V14, P2048, DOI 10.1359/jbmr.1999.14.12.2048; Desikan KR, 1998, J CLIN ONCOL, V16, P1547, DOI 10.1200/JCO.1998.16.4.1547; Desikan R, 2000, BLOOD, V95, P4008; DIMOPOULOS MA, 1991, ANN INTERN MED, V115, P931, DOI 10.7326/0003-4819-115-12-931; Dudeney S, 2002, J CLIN ONCOL, V20, P2382, DOI 10.1200/JCO.2002.09.097; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; Facon T, 2001, BLOOD, V97, P1566, DOI 10.1182/blood.V97.6.1566; Fermand JP, 1998, BLOOD, V92, P3131, DOI 10.1182/blood.V92.9.3131.421k30_3131_3136; FERMAND JP, 1993, BLOOD, V82, P2005; Fermand JP, 2001, BLOOD, V98, p815A; Fermand JP, 1999, BLOOD, V94, p396A; Fonseca R, 2003, BLOOD, V101, P4569, DOI 10.1182/blood-2002-10-3017; Gahrton G, 2001, BRIT J HAEMATOL, V113, P209, DOI 10.1046/j.1365-2141.2001.02726.x; GAHRTON G, 1995, J CLIN ONCOL, V13, P1312, DOI 10.1200/JCO.1995.13.6.1312; GALTON DAG, 1968, BRIT J HAEMATOL, V15, P319; GREIPP PR, 1993, BLOOD, V81, P3382; GREIPP RP, 1982, BLOOD, V62, P161; Gupta D, 2002, EXP HEMATOL, V30, P711, DOI 10.1016/S0301-472X(02)00839-1; Hagmar L, 2001, SCAND J WORK ENV HEA, V27, P1; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Han JH, 2001, BLOOD, V97, P3349, DOI 10.1182/blood.V97.11.3349; Hayashi T, 2003, BRIT J HAEMATOL, V120, P10, DOI 10.1046/j.1365-2141.2003.03929.x; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Hideshima T, 2001, SEMIN ONCOL, V28, P607, DOI 10.1053/sonc.2001.28608; Hussein Mohamad A, 2003, Cancer Control, V10, P370; Katzmann JA, 1998, AM J CLIN PATHOL, V110, P503; KING RW, 1996, SCIENCE, V274; KOSMO MA, 1987, SEMIN HEMATOL, V24, P202; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Kulkarni S, 1999, BONE MARROW TRANSPL, V23, P675, DOI 10.1038/sj.bmt.1701634; Kyle R, 1997, MANUAL CLIN LAB IMMU, P156; KYLE RA, 1993, MAYO CLIN PROC, V68, P26, DOI 10.1016/S0025-6196(12)60015-9; KYLE RA, 1985, NEOPLASTIC DIS BLOOD, P385; Lacy MQ, 2003, BLOOD, V102, p453A; Lahuerta JJ, 2000, BRIT J HAEMATOL, V109, P438, DOI 10.1046/j.1365-2141.2000.02012.x; Liu Q, 2003, BLOOD, V101, P4078, DOI 10.1182/blood-2002-10-3231; LONGO DL, 2001, HARRISONS PRINCIPLES, V1, P727; Ludwig H, 1998, EUR J CANCER, V34, P12, DOI 10.1016/S0959-8049(97)10046-6; Maloney DG, 2003, BLOOD, V102, P3447, DOI 10.1182/blood-2002-09-2955; MARIT G, 1995, BONE MARROW TRANSPL, V15, P963; Marit G, 1997, BLOOD, V90, P996; Massaia M, 1999, BLOOD, V94, P673, DOI 10.1182/blood.V94.2.673.414k30_673_683; MCELWAIN TJ, 1983, LANCET, V2, P822; Mehta J, 1998, BONE MARROW TRANSPL, V22, P835, DOI 10.1038/sj.bmt.1701459; Mehta J, 1997, BLOOD, V90, P2259; MELLSTEDT H, 1979, LANCET, V1, P245; Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mitsiades CS, 2003, BLOOD, V102, p189A; Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; Moreau P, 2000, BRIT J HAEMATOL, V109, P661, DOI 10.1046/j.1365-2141.2000.02093.x; Moreau P, 2002, BLOOD, V99, P731, DOI 10.1182/blood.V99.3.731; Mundy GR, 1998, EUR J CANCER, V34, P246, DOI 10.1016/S0959-8049(97)10133-2; Munshi NC, 2001, SEMIN ONCOL, V28, P565, DOI 10.1053/sonc.2001.28954; Ochiai N, 2003, BLOOD, V102, P3349, DOI 10.1182/blood-2003-03-0851; Oyajobi BO, 2003, CANCER-AM CANCER SOC, V97, P813, DOI 10.1002/cncr.11133; Oyajobi BO, 2001, CANCER RES, V61, P2572; Palumbo A, 2003, BLOOD, V102, p984A; Pasqualetti P, 1997, BIOMED PHARMACOTHER, V51, P74, DOI 10.1016/S0753-3322(97)87730-X; Powles R, 1997, BONE MARROW TRANSPL, V20, P435, DOI 10.1038/sj.bmt.1700917; Powles R, 2001, BLOOD, V98, p165A; Powles R, 2000, BLOOD, V96, p515A; Qiang YW, 2002, BLOOD, V99, P4138, DOI 10.1182/blood.V99.11.4138; Raje N, 1997, BRIT J HAEMATOL, V97, P153, DOI 10.1046/j.1365-2141.1997.d01-2122.x; Raje N, 1997, BRIT J CANCER, V75, P1684, DOI 10.1038/bjc.1997.286; Rajkumar SV, 2002, J CLIN ONCOL, V20, P4319, DOI 10.1200/JCO.2002.02.116; Rao PH, 1998, BLOOD, V92, P1743; REECE DE, 1995, BONE MARROW TRANSPL, V15, P117; Reichardt VL, 1999, BLOOD, V93, P2411, DOI 10.1182/blood.V93.7.2411.407a24_2411_2419; RICCARDI A, 1991, EUR J CANCER, V27, P1401, DOI 10.1016/0277-5379(91)90020-E; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Richardson PG, 2003, BLOOD, V102, p235A; Richardson PG, 2002, BLOOD, V100, P3063, DOI 10.1182/blood-2002-03-0996; Roboz GJ, 2002, BLOOD, V100, p337A; Rosenthal MA, 2002, ANN ONCOL, V13, P770, DOI 10.1093/annonc/mdf117; SAMSON D, 1989, LANCET, V2, P882; SAWYER JR, 1995, CANCER GENET CYTOGEN, V82, P41, DOI 10.1016/0165-4608(94)00284-I; Schwarzenbach H, 2002, MED ONCOL, V19, P87, DOI 10.1385/MO:19:2:87; Segeren CM, 2003, BLOOD, V101, P2144, DOI 10.1182/blood-2002-03-0889; SEIDEN MV, 1995, LEUKEMIA LYMPHOMA, V17, P87, DOI 10.3109/10428199509051707; SELBY PJ, 1987, BRIT J HAEMATOL, V66, P55, DOI 10.1111/j.1365-2141.1987.tb06890.x; Shaughnessy J, 2000, BLOOD, V96, P1505, DOI 10.1182/blood.V96.4.1505.h8001505_1505_1511; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; Shipman CM, 2000, BLOOD, V96, p360A; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Sirohi B, 1999, BRIT J HAEMATOL, V107, P656, DOI 10.1046/j.1365-2141.1999.01744.x; Sirohi B, 2001, SEMIN HEMATOL, V38, P209, DOI 10.1053/shem.2001.26013; SIROHI B, 2002, P AN M AM SOC CLIN, V21, pA269; Smadja NV, 2001, BLOOD, V98, P2229, DOI 10.1182/blood.V98.7.2229; Sordillo EM, 2003, CANCER-AM CANCER SOC, V97, P802, DOI 10.1002/cncr.11134; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Spets H, 2002, EUR J HAEMATOL, V69, P76, DOI 10.1034/j.1600-0609.2002.01549.x; Streetly M, 2003, BLOOD, V102, p236A; Tabernero D, 1996, AM J PATHOL, V149, P153; Tarte K, 2002, BLOOD, V100, P1113, DOI 10.1182/blood.V100.4.1113.h81602001113_1113_1122; Teoh G, 1997, HEMATOL ONCOL CLIN N, V11, P27, DOI 10.1016/S0889-8588(05)70413-5; Tricot G, 2002, BRIT J HAEMATOL, V116, P211, DOI 10.1046/j.1365-2141.2002.03231.x; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Vesole DH, 1996, BLOOD, V88, P838; Weber D, 2003, J CLIN ONCOL, V21, P16, DOI 10.1200/JCO.2003.03.139; WEIDEN PL, 1981, NEW ENGL J MED, V304, P1529, DOI 10.1056/NEJM198106183042507; Zangari M, 2002, BLOOD, V100, P1168, DOI 10.1182/blood-2002-01-0335; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745; 2001, SEMIN HEMATOL, V38, P219	142	184	197	1	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	2004	363	9412					875	887		10.1016/S0140-6736(04)15736-X	http://dx.doi.org/10.1016/S0140-6736(04)15736-X			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15031034				2022-12-28	WOS:000220231500023
J	Walker-Smith, J				Walker-Smith, J			A statement by Professor John Walker-Smith	LANCET			English	Editorial Material									UCL, Wellcome Trust Ctr Hist Med, London NW1 1AD, England	University of London; University College London	Walker-Smith, J (corresponding author), UCL, Wellcome Trust Ctr Hist Med, London NW1 1AD, England.	johnwalker_smith@hotmail.com							0	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	2004	363	9411					822	823		10.1016/S0140-6736(04)15709-7	http://dx.doi.org/10.1016/S0140-6736(04)15709-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15022649				2022-12-28	WOS:000220092000025
J	Martin, DR				Martin, DR			Liver-iron assay by MRI	LANCET			English	Editorial Material									Emory Univ, Dept Radiol, Atlanta, GA 30322 USA	Emory University	Martin, DR (corresponding author), Emory Univ, Dept Radiol, Atlanta, GA 30322 USA.	dmartin@hsc.wvu.edu						Akanuma N, 2003, SEIZURE-EUR J EPILEP, V12, P346, DOI 10.1016/S1059-1311(02)00323-0; BATTOCLETTI JH, 1984, CRIT REV BIOMED ENG, V11, P313; Chenevert Thomas L, 2002, Mol Imaging, V1, P336, DOI 10.1162/153535002321093945; Chung JJ, 2001, MAGN RESON IMAGING, V19, P789, DOI 10.1016/S0730-725X(01)00411-8; Dreizen P, 2004, LANCET, V363, P78, DOI 10.1016/S0140-6736(03)15182-3; Frush DP, 2003, PEDIATRICS, V112, P951, DOI 10.1542/peds.112.4.951; Jaaskelainen J, 2003, ACT NEUR S, V88, P57; LAUTERBUR PC, 1973, NATURE, V242, P190, DOI 10.1038/242190a0; Martin-Trillo M, 2002, CURR OPIN BIOTECH, V13, P151, DOI 10.1016/S0958-1669(02)00305-1; Moore MM, 2003, IEEE T NEUR SYS REH, V11, P162, DOI 10.1109/TNSRE.2003.814433; Pomerantz Stuart, 2002, Magn Reson Imaging Clin N Am, V10, P105, DOI 10.1016/S1064-9689(03)00052-7; Rehemtulla A, 2002, MOL IMAGING, V1, P43, DOI 10.1162/153535002753395707	12	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	2004	363	9406					341	342		10.1016/S0140-6736(04)15471-8	http://dx.doi.org/10.1016/S0140-6736(04)15471-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768TQ	15070558				2022-12-28	WOS:000188590900003
J	Hill, SE; Blakely, TA; Kawachi, I; Woodward, A				Hill, SE; Blakely, TA; Kawachi, I; Woodward, A			Mortality among "never smokers" living with smokers: two cohort studies, 1981-4 and 1996-9	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PASSIVE SMOKING		Wellington Sch Med & Hlth Sci, Dept Publ Hlth, Wellington, New Zealand; Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA	University of Otago; Harvard University; Harvard T.H. Chan School of Public Health	Blakely, TA (corresponding author), Wellington Sch Med & Hlth Sci, Dept Publ Hlth, POB 7343, Wellington, New Zealand.	tblakely@wnmeds.ac.nz		Woodward, Alistair/0000-0001-5425-6018; Hill, Sarah/0000-0003-3555-433X				Blakely T, 2000, AUST NZ J PUBL HEAL, V24, P92, DOI 10.1111/j.1467-842X.2000.tb00732.x; HOLE DJ, 1989, BRIT MED J, V299, P423, DOI 10.1136/bmj.299.6696.423; HUMBLE C, 1990, AM J PUBLIC HEALTH, V80, P599, DOI 10.2105/AJPH.80.5.599; SANDLER DP, 1989, AM J PUBLIC HEALTH, V79, P163, DOI 10.2105/AJPH.79.2.163; SVENDSEN KH, 1987, AM J EPIDEMIOL, V126, P783, DOI 10.1093/oxfordjournals.aje.a114715	5	33	33	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 24	2004	328	7446					988	989		10.1136/bmj.38070.503009.EE	http://dx.doi.org/10.1136/bmj.38070.503009.EE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	816SR	15066889	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000221130100015
J	Kim, HC; Nam, CM; Jee, SH; Han, KH; Oh, DK; Suh, I				Kim, HC; Nam, CM; Jee, SH; Han, KH; Oh, DK; Suh, I			Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIALS; EPIDERMAL NERVE-FIBERS; CHRONIC HEPATITIS-C; TOPICAL CAPSAICIN; ALANINE AMINOTRANSFERASE; DOUBLE-BLIND; NEUROPATHIC PAIN; ALT LEVELS; QUALITY; VALUES	Objective To examine the relation between the normal nano-e of serum aminotransferase 0 concentration and mortality from liver disease. Design Prospective cohort study. Setting Korea Medical Insurance Corporation study with eight years' follow up. Participants 94 533 men and 47 522 women aged 35-59 years. Main outcome measure Mortality from liver diseases according, to death certificate. Results There was a positive association between the aminotransferase concentration, even within normal range (35-40 IU/I), and mortality from liver disease. Compared with the concentration < 20 IU/I, the adjusted relative risks for an aspartate aminotransferase concentration of 20-29 IU/I and 30-39 IU/I were 2.5 (95% confidence interval 2.0 to 3.0) and 8.0 (6.6 to 9.8) in men and 3.3 (1.7 to 6.4) and 18.2 (8.1 to 40.4) in women, respectively, The corresponding risks for alanine aminotransferase were 2.9 (2.4 to 3.5) and 9.5 (7.9 to 11.5) in men and 3.8 (1.9 to 7.7) and 6.6 (1.5 to 25.6) in women, respectively According to receiver operating characteristic curves the best cut-off values for the prediction of liver disease in men were 31 IU/I for aspartate aminotransferase and 30 IU/I for alanine aminotransferase. Conclusion People with slightly increased aminotransferase activity, but still within the normal range, should be closely observed and further investigated for liver diseases.	Yonsei Univ, Coll Med, Dept Prevent Med & Publ Hlth, Seoul 120752, South Korea; Yonsei Univ, Grad Sch Hlth Sci & Management, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University; Yonsei University Health System	Suh, I (corresponding author), Yonsei Univ, Coll Med, Dept Prevent Med & Publ Hlth, 134 Shinchon Dong, Seoul 120752, South Korea.	isuh@yumc.yonsei.ac.kr	Kim, Hyeon Chang/F-8796-2019	Kim, Hyeon Chang/0000-0001-7867-1240; Suh, Il/0000-0002-9689-7849; Jee, Sun Ha/0000-0001-9519-3068; Nam, Chung Mo/0000-0003-0985-0928				AHN YO, 1999, JAMA KOREA S E ASIA, P382; Altman Roy D., 1994, Seminars in Arthritis and Rheumatism, V23, P25, DOI 10.1016/S0049-0172(10)80023-X; BERNSTEIN JE, 1989, J AM ACAD DERMATOL, V21, P265, DOI 10.1016/S0190-9622(89)70171-7; BIESBROECK R, 1995, ADV THER, V12, P111; *BRIT MED ASS ROYA, 2003, BRIT NAT FORM; CHAD DA, 1990, PAIN, V42, P387, DOI 10.1016/0304-3959(90)91153-A; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Chun BY, 1992, KOREAN J EPIDEMIOL, V14, P54; COOK D, 1992, ANN INTERN MED, V117, pA16; DEAL CL, 1991, CLIN THER, V13, P383; *DEP HLTH, 2003, PRESCR COST AN ENGL; DONOFRIO P, 1991, ARCH INTERN MED, V151, P2225; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; Ellison N, 1997, J CLIN ONCOL, V15, P2974, DOI 10.1200/JCO.1997.15.8.2974; Espinosa M, 2000, CLIN NEPHROL, V54, P151; Gholson CF, 1997, AM J GASTROENTEROL, V92, P1788; Gotzsche PC, 2001, ANN RHEUM DIS, V60, P349, DOI 10.1136/ard.60.4.349; Guzzaloni G, 2000, INT J OBESITY, V24, P772, DOI 10.1038/sj.ijo.0801224; HULTCRANTZ R, 1986, SCAND J GASTROENTERO, V21, P109, DOI 10.3109/00365528609034632; Hung KY, 1997, NEPHROL DIAL TRANSPL, V12, P180, DOI 10.1093/ndt/12.1.180; Jadad AR, 1996, PAIN, V66, P239, DOI 10.1016/0304-3959(96)03033-3; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jamal MM, 1999, HEPATOLOGY, V30, P1307, DOI 10.1002/hep.510300526; JENSEN DM, 1987, ARCH INTERN MED, V147, P1734, DOI 10.1001/archinte.147.10.1734; Kalso E, 2000, EUR J PAIN-LONDON, V4, P321, DOI 10.1053/eujp.2000.0191; Kaplan MM, 2002, ANN INTERN MED, V137, P49, DOI 10.7326/0003-4819-137-1-200207020-00012; Keitel WG, 2001, ARZNEIMITTELFORSCH, V51, P896; KIRN YK, 1993, J CLIN PATHOL QUAL C, V15, P1; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LOW PA, 1995, PAIN, V62, P163, DOI 10.1016/0304-3959(94)00261-C; Mason L, 2004, BMJ-BRIT MED J, V328, P995, DOI 10.1136/bmj.38040.607141.EE; Mathiesen UL, 1999, SCAND J GASTROENTERO, V34, P85; McCleane G, 2000, BRIT J CLIN PHARMACO, V49, P574, DOI 10.1046/j.1365-2125.2000.00200.x; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; MOORE R, 2003, BANDOLIERS LITTLE BO, P238; Moore RA, 1998, BRIT MED J, V316, P333, DOI 10.1136/bmj.316.7128.333; Moore RA, 1998, PAIN, V78, P209, DOI 10.1016/S0304-3959(98)00140-7; MORRIS JA, 1995, STAT CONFIDENCE CONF, P50; *NAT STAT OFF, 2002, ANN REP CAUS DEATH S; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; Nolano M, 1999, PAIN, V81, P135, DOI 10.1016/S0304-3959(99)00007-X; Paice JA, 2000, J PAIN SYMPTOM MANAG, V19, P45, DOI 10.1016/S0885-3924(99)00139-6; Persico M, 2000, GASTROENTEROLOGY, V118, P760, DOI 10.1016/S0016-5085(00)70145-4; Piton A, 1998, HEPATOLOGY, V27, P1213, DOI 10.1002/hep.510270505; Pradat P, 2002, HEPATOLOGY, V36, P973, DOI 10.1053/jhep.2002.35530; Prati D, 2002, ANN INTERN MED, V137, P1, DOI 10.7326/0003-4819-137-1-200207020-00006; Pratt DS, 2000, NEW ENGL J MED, V342, P1266, DOI 10.1056/NEJM200004273421707; RAINS C, 1995, DRUG AGING, V7, P317, DOI 10.2165/00002512-199507040-00007; REYNOLDS JEF, 1999, MARTINDALE EXTRA PHA; SALVAGGIO A, 1991, CLIN CHEM, V37, P720; Schnitzer T J, 1995, J Clin Rheumatol, V1, P268; Schnitzer Thomas, 1994, Seminars in Arthritis and Rheumatism, V23, P34, DOI 10.1016/S0049-0172(10)80024-1; SHERMAN KE, 1991, ARCH INTERN MED, V151, P260, DOI 10.1001/archinte.151.2.260; SIEST G, 1975, CLIN CHEM, V21, P1077; Simone DA, 1998, J NEUROSCI, V18, P8947; Smith LA, 2000, PAIN, V86, P119, DOI 10.1016/S0304-3959(00)00234-7; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Tramer MR, 1997, BMJ-BRIT MED J, V315, P635, DOI 10.1136/bmj.315.7109.635; Tsai JF, 1997, LIVER, V17, P24; WATSON CPN, 1993, CLIN THER, V15, P510; WATSON CPN, 1992, PAIN, V51, P375, DOI 10.1016/0304-3959(92)90223-X; Winocur E, 2000, J OROFAC PAIN, V14, P31; ZHANG WY, 1994, EUR J CLIN PHARMACOL, V46, P517	63	399	425	2	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 24	2004	328	7446					983	986C		10.1136/bmj.38050.593634.63	http://dx.doi.org/10.1136/bmj.38050.593634.63			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	816SR	15028636	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000221130100013
J	Padayatty, SJ; Sun, H; Wang, YH; Riordan, HD; Hewitt, SM; Katz, A; Wesley, RA; Levine, M				Padayatty, SJ; Sun, H; Wang, YH; Riordan, HD; Hewitt, SM; Katz, A; Wesley, RA; Levine, M			Vitamin C pharmacokinetics: Implications for oral and intravenous use	ANNALS OF INTERNAL MEDICINE			English	Article							RECOMMENDED DIETARY ALLOWANCE; ASCORBIC-ACID; DISEASE PREVENTION; ADVANCED CANCER; CYTOTOXICITY; VOLUNTEERS; TRIAL	Background: Vitamin C at high concentrations is toxic to cancer cells in vitro. Early clinical studies of vitamin C in patients with terminal cancer suggested clinical benefit, but 2 double-blind, placebo-controlled trials showed none. However, these studies used different routes of administration. Objective: To determine whether plasma vitamin C concentrations vary substantially with the route of administration. Design: Dose concentratior. studies and pharmacokinetic modeling. Setting: Academic medical center. Participants: 17 healthy hospitalized volunteers. Measurements: Vitamin C plasma and urine concentrations were measured after administration of oral and intravenous doses at a dose range of 0.015 to 1.25 g, and plasma concentrations were calculated for a dose range of 1 to 100 g. Results: Peak plasma vitamin C concentrations were higher after administration of intravenous doses than after administration of oral doses (P < 0.001), and the difference increased according to dose. Vitamin C at a dose of 1.25 g administered orally produced mean ( +/- SD) peak plasma concentrations of 134.8 +/- 20.6 mumol/L compared with 885 +/- 201.2 mumol/L for intravenous administration. For the maximum tolerated oral dose of 3 g every 4 hours, pharmacokinetic modeling predicted peak plasma vitamin C concentrations of 220 mumol/L and 13 400 mumol/L for a 50-g intravenous dose. Peak predicted urine concentrations of vitamin C from intravenous administration were 140-fold higher than those from maximum oral doses. Limitations: Patient data are not available to confirm pharmacokinetic modeling at high doses and in patients with cancer. Conclusions: oral vitamin C produces plasma concentrations that are tightly controlled. Only intravenous administration of vitamin C produces high plasma and urine concentrations that might have antitumor activity. Because efficacy of vitamin C treatment cannot be judged from clinical trials that use only oral dosing, the role of vitamin C in cancer treatment should be re-evaluated.	NIH, Mol & Clin Nutr Sect, Bethesda, MD 20892 USA; NCI, NIDDKD, Bethesda, MD 20892 USA; NIH, Clin Ctr, Bethesda, MD 20892 USA; Food & Drug Adm, Rockville, MD USA; Biocommun Res Inst, Wichita, KS USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); US Food & Drug Administration (FDA)	Levine, M (corresponding author), NIH, Mol & Clin Nutr Sect, Bldg 10,Room 4D52-MSC 1372, Bethesda, MD 20892 USA.		Padayatty, Sebastian J/A-8581-2012	Padayatty, Sebastian J/0000-0001-8758-3170; Hewitt, Stephen/0000-0001-8283-1788	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK054506] Funding Source: NIH RePORTER; NIDDK NIH HHS [Z01 DK 54506] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAMERON E, 1978, P NATL ACAD SCI USA, V75, P4538, DOI 10.1073/pnas.75.9.4538; CAMERON E, 1974, CHEM-BIOL INTERACT, V9, P285, DOI 10.1016/0009-2797(74)90019-2; CAMERON E, 1993, CANC VITAMIN C; Clement MV, 2001, ANTIOXID REDOX SIGN, V3, P157, DOI 10.1089/152308601750100687; CREAGAN ET, 1979, NEW ENGL J MED, V301, P687, DOI 10.1056/NEJM197909273011303; Fairfield KM, 2002, JAMA-J AM MED ASSOC, V287, P3116, DOI 10.1001/jama.287.23.3116; Grad JM, 2001, BLOOD, V98, P805, DOI 10.1182/blood.V98.3.805; Graumlich JF, 1997, PHARMACEUT RES, V14, P1133, DOI 10.1023/A:1012186203165; LEUNG PY, 1993, ANTICANCER RES, V13, P475; Levine M, 2001, P NATL ACAD SCI USA, V98, P9842, DOI 10.1073/pnas.171318198; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; McCORMICK W J, 1959, Arch Pediatr, V76, P166; MOERTEL CG, 1985, NEW ENGL J MED, V312, P137, DOI 10.1056/NEJM198501173120301; Padayatty SJ, 2003, J AM COLL NUTR, V22, P18, DOI 10.1080/07315724.2003.10719272; Padayatty SJ, 2001, CAN MED ASSOC J, V164, P353; RIORDAN NH, 1995, MED HYPOTHESES, V44, P207, DOI 10.1016/0306-9877(95)90137-X; Sakagami H, 2000, CELL MOL BIOL, V46, P129; WANG XY, 1992, FREE RADICAL BIO MED, V12, P121, DOI 10.1016/0891-5849(92)90005-2; WASHKO PW, 1992, ANAL BIOCHEM, V204, P1, DOI 10.1016/0003-2697(92)90131-P; WITTES RE, 1985, NEW ENGL J MED, V312, P178, DOI 10.1056/NEJM198501173120310	20	557	583	2	51	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 6	2004	140	7					533	537		10.7326/0003-4819-140-7-200404060-00010	http://dx.doi.org/10.7326/0003-4819-140-7-200404060-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808OE	15068981				2022-12-28	WOS:000220577600005
J	Mrusek, S; Kruger, M; Greiner, P; Kleinschmidt, M; Brandis, M; Ehl, S				Mrusek, S; Kruger, M; Greiner, P; Kleinschmidt, M; Brandis, M; Ehl, S			Henoch-Schonlein purpura	LANCET			English	Editorial Material									Univ Freiburg, Ctr Pediat & Adolescent Med, D-79104 Freiburg, Germany; Univ Freiburg, Inst Pathol, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg	Ehl, S (corresponding author), Univ Freiburg, Ctr Pediat & Adolescent Med, D-79104 Freiburg, Germany.	ehl@kikli.ukl.uni-freiburg-de	Ehl, Stephan/AAM-6006-2020; Leung, Alexander/AAL-7427-2021	Leung, Alexander/0000-0003-2254-6971; Ehl, Stephan/0000-0002-9265-2721				Brendel-Muller K, 2001, PEDIATR NEPHROL, V16, P1084, DOI 10.1007/s004670100033; Esaki M, 2002, GASTROINTEST ENDOSC, V56, P920, DOI 10.1067/mge.2002.129592; Fitzgerald JF, 2000, J PEDIATR GASTR NUTR, V30, P5, DOI 10.1097/00005176-200001000-00008; Gunasekaran TS, 2000, J PEDIATR GASTR NUTR, V30, P22, DOI 10.1097/00005176-200001000-00013	4	9	11	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	2004	363	9415					1116	1116		10.1016/S0140-6736(04)15895-9	http://dx.doi.org/10.1016/S0140-6736(04)15895-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808VB	15064030				2022-12-28	WOS:000220595500011
J	Borner, GV; Kleckner, N; Hunter, N				Borner, GV; Kleckner, N; Hunter, N			Crossover/noncrossover differentiation, synaptonemal complex formation, and regulatory surveillance at the leptotene/zygotene transition of meiosis	CELL			English	Article							MEIOTIC CHROMOSOME SYNAPSIS; DOUBLE-STRAND BREAK; SACCHAROMYCES-CEREVISIAE; GENE CONVERSION; CROSSING-OVER; RECIPROCAL RECOMBINATION; FUNCTIONAL INTERACTIONS; CROSSOVER INTERFERENCE; BUDDING YEAST; RECA HOMOLOGS	Yeast mutants lacking meiotic proteins Zip1, Zip2, Zip3, Mer3, and/or Msh5 (ZMMs) were analyzed for recombination, synaptonemal complex (SC), and meiotic progression. At 33degreesC, recombination-initiating double-strand breaks (DSBs) and noncrossover products (NCRs) form normally while formation of single-end invasion strand exchange intermediates (SEIs), double Holliday junctions, crossover products (CRs), and SC are coordinately defective. Thus, during wildtype meiosis, recombinational interactions are differentiated into CR and NCR types very early, prior to onset of stable strand exchange and independent of SC. By implication, crossover interference does not require SC formation. We suggest that SC formation may require interference. Subsequently, CR-designated DSBs undergo a tightly coupled, ZMM-promoted transition that yields SEI-containing recombination complexes embedded in patches of SC. zmm mutant phenotypes differ strikingly at 33degreesC and 23degreesC implicating higher temperature as a positive effector of recombination and identifying a checkpoint that monitors local CR-specific events, not SC formation, at late leptotene.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Univ Calif Davis, Microbiol Sect, Ctr Genet & Dev, Davis, CA 95616 USA	Harvard University; University of California System; University of California Davis	Kleckner, N (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	kleckner@fas.harvard.edu			NIGMS NIH HHS [GM44794] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal S, 2000, CELL, V102, P245, DOI 10.1016/S0092-8674(00)00029-5; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALBINI SM, 1987, CHROMOSOMA, V95, P324, DOI 10.1007/BF00293179; Allers T, 2001, CELL, V106, P47, DOI 10.1016/S0092-8674(01)00416-0; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Blat Y, 2002, CELL, V111, P791, DOI 10.1016/S0092-8674(02)01167-4; BYERS B, 1975, P NATL ACAD SCI USA, V72, P5056, DOI 10.1073/pnas.72.12.5056; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Chua PR, 1998, CELL, V93, P349, DOI 10.1016/S0092-8674(00)81164-2; Colaiacovo MP, 2003, DEV CELL, V5, P463, DOI 10.1016/S1534-5807(03)00232-6; Copenhaver GP, 2002, GENETICS, V160, P1631; Darlington C. D., 1937, RECENT ADV CYTOLOGY; de los Santos T, 2003, GENETICS, V164, P81; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; EGEL R, 1978, HEREDITY, V41, P233, DOI 10.1038/hdy.1978.92; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; Fung JC, 2004, CELL, V116, P795, DOI 10.1016/S0092-8674(04)00249-1; HENDERSON KA, 2004, IN PRESS P NATL ACAD; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; Hunt PA, 2002, SCIENCE, V296, P2181, DOI 10.1126/science.1071907; Hunter N, 2001, CELL, V106, P59, DOI 10.1016/S0092-8674(01)00430-5; Hunter N, 2003, MOL CELL, V12, P533, DOI 10.1016/S1097-2765(03)00361-7; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Jones G.H., 1984, Symposia of the Society for Experimental Biology, P293; Kee K, 2002, GENETICS, V160, P111; Keeney S, 2001, CURR TOP DEV BIOL, V52, P1, DOI 10.1016/S0070-2153(01)52008-6; Kelly KO, 2000, GENETICS, V156, P617; Lichten M, 2001, CURR BIOL, V11, pR253, DOI 10.1016/S0960-9822(01)00131-2; Lydall D, 1996, NATURE, V383, P840, DOI 10.1038/383840a0; MAGUIRE MP, 1966, GENETICS, V53, P1071; Moens PB, 2002, J CELL SCI, V115, P1611; MOENS PB, 1978, CAN J GENET CYTOL, V20, P567, DOI 10.1139/g78-066; Nakagawa T, 1999, EMBO J, V18, P5714, DOI 10.1093/emboj/18.20.5714; Novak JE, 2001, GENETICS, V158, P1013; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; ROCKMILL B, 1995, GENE DEV, V9, P2684, DOI 10.1101/gad.9.21.2684; Rockmill B, 2003, CURR BIOL, V13, P1954, DOI 10.1016/j.cub.2003.10.059; Roeder GS, 2000, TRENDS GENET, V16, P395, DOI 10.1016/S0168-9525(00)02080-1; Rose MD., 1990, METHODS YEAST GENETI; San-Segundo PA, 2000, MOL BIOL CELL, V11, P3601, DOI 10.1091/mbc.11.10.3601; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SODMORIA.UA, 1974, J REPROD FERTIL, V37, P263, DOI 10.1530/jrf.0.0370263; Storlazzi A, 1996, P NATL ACAD SCI USA, V93, P9043, DOI 10.1073/pnas.93.17.9043; STORLAZZI A, 1995, P NATL ACAD SCI USA, V92, P8512, DOI 10.1073/pnas.92.18.8512; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; Tarsounas M, 1999, J CELL BIOL, V147, P207, DOI 10.1083/jcb.147.2.207; Tesse S, 2003, P NATL ACAD SCI USA, V100, P12865, DOI 10.1073/pnas.2034282100; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Webber HA, 2004, J CELL BIOL, V164, P819, DOI 10.1083/jcb.200310077; ZICKLER D, 1977, CHROMOSOMA, V61, P289, DOI 10.1007/BF00288615; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603; Zickler D, 1998, ANNU REV GENET, V32, P619, DOI 10.1146/annurev.genet.32.1.619	57	487	504	1	51	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	2004	117	1					29	45		10.1016/S0092-8674(04)00292-2	http://dx.doi.org/10.1016/S0092-8674(04)00292-2			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YV	15066280	Bronze			2022-12-28	WOS:000221500300006
J	Bouret, SG; Draper, SJ; Simerly, RB				Bouret, SG; Draper, SJ; Simerly, RB			Trophic action of leptin on hypothalamic neurons that regulate feeding	SCIENCE			English	Article							BODY-WEIGHT; BRAIN-DEVELOPMENT; THYROID-HORMONE; NERVOUS-SYSTEM; ENERGY-BALANCE; OBESITY	In adult mammals, the adipocyte-derived hormone leptin acts on the brain to reduce food intake by regulating the activity of neurons in the arcuate nucleus of the hypothalamus (ARH). Here, we report that neural projection pathways from the ARH are permanently disrupted in leptin-deficient (Lep(ob)/Lep(ob)) mice and leptin treatment in adulthood does not reverse these neuroanatomical defects. However, treatment of Lep(ob)/Lep(ob) neonates with exogenous leptin rescues the development of ARH projections, and leptin promotes neurite outgrowth from ARH neurons in vitro. These results suggest that leptin plays a neurotrophic role during the development of the hypothalamus and that this activity is restricted to a neonatal critical period that precedes leptin's acute regulation of food intake in adults.	Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Beaverton, OR 97006 USA	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University	Simerly, RB (corresponding author), Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR 97006 USA.	simerlyr@ohsu.edu	Lee, shin/C-1393-2016; Bouret, Sebastien/AAG-7120-2021	Bouret, Sebastien/0000-0002-4174-9769	NCRR NIH HHS [RR00163] Funding Source: Medline; NIDDK NIH HHS [DK55819, DK65900] Funding Source: Medline; NINDS NIH HHS [NS37952] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065900, P01DK055819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037952] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahima RS, 2000, REGUL PEPTIDES, V92, P1, DOI 10.1016/S0167-0115(00)00142-7; Ahima RS, 2000, FRONT NEUROENDOCRIN, V21, P263, DOI 10.1006/frne.2000.0197; Ahima RS, 1999, ENDOCRINOLOGY, V140, P2755, DOI 10.1210/en.140.6.2755; Ahima RS, 1998, J CLIN INVEST, V101, P1020, DOI 10.1172/JCI1176; Bernal J, 2002, J ENDOCRINOL INVEST, V25, P268, DOI 10.1007/BF03344003; Bouret SG, 2004, J NEUROSCI, V24, P2797, DOI 10.1523/JNEUROSCI.5369-03.2004; Elias CF, 2000, J COMP NEUROL, V423, P261; Elmquist JK, 1997, ENDOCRINOLOGY, V138, P839, DOI 10.1210/en.138.2.839; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; MADEIRA MD, 1995, PROG NEUROBIOL, V45, P275, DOI 10.1016/0301-0082(94)00052-J; MCEWEN BS, 1986, PHYSIOL REV, V66, P1121, DOI 10.1152/physrev.1986.66.4.1121; Mistry AM, 1999, AM J PHYSIOL-REG I, V277, pR742, DOI 10.1152/ajpregu.1999.277.3.R742; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; QIU K, 2001, 31 ANN M SOC NEUR SA; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Simerly RB, 2002, ANNU REV NEUROSCI, V25, P507, DOI 10.1146/annurev.neuro.25.112701.142745; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Steppan CM, 1999, BIOCHEM BIOPH RES CO, V256, P600, DOI 10.1006/bbrc.1999.0382; Zigman JM, 2003, ENDOCRINOLOGY, V144, P3749, DOI 10.1210/en.2003-0241	22	911	937	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					108	110		10.1126/science.1095004	http://dx.doi.org/10.1126/science.1095004			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15064420				2022-12-28	WOS:000220567900048
J	Langer, R; Tirrell, DA				Langer, R; Tirrell, DA			Designing materials for biology and medicine	NATURE			English	Review							DRUG-DELIVERY; HYDROGELS; ARRAYS; CHIP; PHOTOPOLYMERIZATION; MICROARRAYS; PROTEINS; POLYMERS; LIBRARY; GELS	Biomaterials have played an enormous role In the success of medical devices and drug delivery systems. We discuss here new challenges and directions In biomaterials research. These include synthetic replacements for biological tissues, designing materials for specific medical applications, and materials for new applications such as diagnostics and array technologies.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	Massachusetts Institute of Technology (MIT); California Institute of Technology	Langer, R (corresponding author), MIT, Dept Chem Engn, Bldg E25-342, Cambridge, MA 02139 USA.	rlanger@mit.edu	Supreme, Jez WR/A-9015-2011					Affleck DG, 2001, GENE THER, V8, P349, DOI 10.1038/sj.gt.3301395; Alsberg E, 2002, P NATL ACAD SCI USA, V99, P12025, DOI 10.1073/pnas.192291499; Anderson DG, 2003, ANGEW CHEM INT EDIT, V42, P3153, DOI 10.1002/anie.200351244; Anseth KS, 1999, NAT BIOTECHNOL, V17, P156, DOI 10.1038/6152; Arenkov P, 2000, ANAL BIOCHEM, V278, P123, DOI 10.1006/abio.1999.4363; BARRERA DA, 1993, J AM CHEM SOC, V115, P11010, DOI 10.1021/ja00076a077; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; Belu AM, 2000, RAPID COMMUN MASS SP, V14, P564, DOI 10.1002/(SICI)1097-0231(20000415)14:7<564::AID-RCM910>3.0.CO;2-0; BORENSTEIN JT, 1999, BIOMED MICRODEVICES, V4, P671; Brocchini S, 1998, J BIOMED MATER RES, V42, P66, DOI 10.1002/(SICI)1097-4636(199810)42:1<66::AID-JBM9>3.0.CO;2-M; Cheek BJ, 2001, ANAL CHEM, V73, P5777, DOI 10.1021/ac0108616; Cook AD, 1997, J BIOMED MATER RES, V35, P513; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Elisseeff J, 1999, P NATL ACAD SCI USA, V96, P3104, DOI 10.1073/pnas.96.6.3104; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Grayson ACR, 2003, NAT MATER, V2, P767, DOI 10.1038/nmat998; GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245; Groves JT, 2002, ACCOUNTS CHEM RES, V35, P149, DOI 10.1021/ar950039m; Haab BB, 2001, GENOME BIOL, V2; Halstenberg S, 2002, BIOMACROMOLECULES, V3, P710, DOI 10.1021/bm015629o; Hartgerink JD, 2002, P NATL ACAD SCI USA, V99, P5133, DOI 10.1073/pnas.072699999; Heilshorn SC, 2003, BIOMATERIALS, V24, P4245, DOI 10.1016/S0142-9612(03)00294-1; Hodneland CD, 2002, P NATL ACAD SCI USA, V99, P5048, DOI 10.1073/pnas.072685299; Houseman BT, 2002, NAT BIOTECHNOL, V20, P270, DOI 10.1038/nbt0302-270; Houseman BT, 2002, CHEM BIOL, V9, P443, DOI 10.1016/S1074-5521(02)00124-2; Huang L, 2000, MACROMOLECULES, V33, P2989, DOI 10.1021/ma991858f; Kajiyama T, 2003, GENOME RES, V13, P467, DOI 10.1101/gr.790603; Kaushik S, 2001, ANESTH ANALG, V92, P502, DOI 10.1213/00000539-200102000-00041; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kwon I, 2003, J AM CHEM SOC, V125, P7512, DOI 10.1021/ja0350076; Lahann J, 2003, SCIENCE, V299, P371, DOI 10.1126/science.1078933; Langer R, 2003, SCI AM, V288, P50, DOI 10.1038/scientificamerican0403-50; Langer R, 2001, SCIENCE, V293, P58, DOI 10.1126/science.1063273; Langer R, 1998, NATURE, V392, P5; Lee J, 2001, MACROMOLECULES, V34, P5968, DOI 10.1021/ma0017844; Lendlein A, 2002, SCIENCE, V296, P1673, DOI 10.1126/science.1066102; Lendlein A, 2002, ANGEW CHEM INT EDIT, V41, P2034, DOI 10.1002/1521-3773(20020617)41:12<2034::AID-ANIE2034>3.0.CO;2-M; Liu RH, 2003, ANAL CHEM, V75, P1911, DOI 10.1021/ac026267t; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; Lynn DM, 2001, J AM CHEM SOC, V123, P8155, DOI 10.1021/ja016288p; MacBeath G, 2000, SCIENCE, V289, P1760; Mathiowitz E, 1997, NATURE, V386, P410, DOI 10.1038/386410a0; McGall G, 1996, P NATL ACAD SCI USA, V93, P13555, DOI 10.1073/pnas.93.24.13555; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; McMillan RA, 2000, MACROMOLECULES, V33, P4809, DOI 10.1021/ma9921091; Miyata T, 1999, NATURE, V399, P766, DOI 10.1038/21619; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Nagapudi K, 2002, MACROMOLECULES, V35, P1730, DOI 10.1021/ma011429t; PATHAK CP, 1992, J AM CHEM SOC, V114, P8311, DOI 10.1021/ja00047a065; PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835; Peppas NA, 1997, CURR OPIN COLLOID IN, V2, P531, DOI 10.1016/S1359-0294(97)80103-3; Pun SH, 2002, BIOCONJUGATE CHEM, V13, P630, DOI 10.1021/bc0155768; Ratner Buddy D., 1996, P1, DOI 10.1016/B978-012582460-6/50002-5; Santini JT, 1999, NATURE, V397, P335, DOI 10.1038/16898; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schwarz M, 2000, SENSOR ACTUAT A-PHYS, V83, P40, DOI 10.1016/S0924-4247(00)00290-9; Sosnowski RG, 1997, P NATL ACAD SCI USA, V94, P1119, DOI 10.1073/pnas.94.4.1119; Stangel K, 2001, IEEE J SOLID-ST CIRC, V36, P1094, DOI 10.1109/4.933466; Torres-Lugo M, 2002, BIOTECHNOL PROGR, V18, P612, DOI 10.1021/bp0101379; URRY DW, 1991, J BIOACT COMPAT POL, V6, P263, DOI 10.1177/088391159100600306; Vacanti JP, 1999, LANCET S1, V354, pSi32; van Hest JCM, 2001, CHEM COMMUN, P1897, DOI 10.1039/b105185g; Yurchenco P. D., 1994, EXTRACELLULAR MATRIX; Zhang SG, 2002, BIOTECHNOL ADV, V20, P321, DOI 10.1016/S0734-9750(02)00026-5; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191; Zhu H, 2003, CURR OPIN CHEM BIOL, V7, P55, DOI 10.1016/S1367-5931(02)00005-4	66	2513	2608	36	1972	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					487	492		10.1038/nature02388	http://dx.doi.org/10.1038/nature02388			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15057821				2022-12-28	WOS:000220540100031
J	Hemingway, J; Craig, A				Hemingway, J; Craig, A			New ways to control malaria	SCIENCE			English	Editorial Material							GENOME SEQUENCE; PLASMODIUM; TRANSMISSION; MOSQUITOS; PARASITE		Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England	Liverpool School of Tropical Medicine; University of Liverpool	Hemingway, J (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.	hemingway@liverpool.ac.uk		Hemingway, Janet/0000-0002-3200-7173; Craig, Alister/0000-0003-0914-6164				Abraham EG, 2004, J BIOL CHEM, V279, P5573, DOI 10.1074/jbc.M307582200; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Ito J, 2002, NATURE, V417, P452, DOI 10.1038/417452a; JACOBSLORENA M, COMMUNICATION; Osta MA, 2004, SCIENCE, V303, P2030, DOI 10.1126/science.1091789; Ranson H, 2002, SCIENCE, V298, P179, DOI 10.1126/science.1076781; Sattabongkot J, 2003, AM J TROP MED HYG, V69, P536, DOI 10.4269/ajtmh.2003.69.536; Srinivasan P, 2004, J BIOL CHEM, V279, P5581, DOI 10.1074/jbc.M307587200; Targett GAT, 1995, T ROY SOC TROP MED H, V89, P585, DOI 10.1016/0035-9203(95)90399-2; Tomas AM, 2001, EMBO J, V20, P3975, DOI 10.1093/emboj/20.15.3975	11	13	13	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	2004	303	5666					1984	1985		10.1126/science.1096548	http://dx.doi.org/10.1126/science.1096548			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044794				2022-12-28	WOS:000220429800029
J	Miller, L; Douglas, BC				Miller, L; Douglas, BC			Mass and volume contributions to twentieth-century global sea level rise	NATURE			English	Article								The rate of twentieth-century global sea level rise and its causes are the subjects of intense controversy(1-7). Most direct estimates from tide gauges give 1.5-2.0 mm yr(-1), whereas indirect estimates based on the two processes responsible for global sea level rise, namely mass and volume change, fall far below this range. Estimates of the volume increase due to ocean warming give a rate of about 0.5 mm yr(-1) ( ref. 8) and the rate due to mass increase, primarily from the melting of continental ice, is thought to be even smaller. Therefore, either the tide gauge estimates are too high, as has been suggested recently(6), or one ( or both) of the mass and volume estimates is too low. Here we present an analysis of sea level measurements at tide gauges combined with observations of temperature and salinity in the Pacific and Atlantic oceans close to the gauges. We find that gauge-determined rates of sea level rise, which encompass both mass and volume changes, are two to three times higher than the rates due to volume change derived from temperature and salinity data. Our analysis supports earlier studies that put the twentieth-century rate in the 1.5-2.0 mm yr(-1) range, but more importantly it suggests that mass increase plays a larger role than ocean warming in twentieth-century global sea level rise.	NOAA, Lab Satellite Altimetry, NESDIS, Silver Spring, MD 20910 USA; Florida Int Univ, Lab Coastal Res, Miami, FL 33199 USA	National Oceanic Atmospheric Admin (NOAA) - USA; State University System of Florida; Florida International University	Miller, L (corresponding author), NOAA, Lab Satellite Altimetry, NESDIS, Silver Spring, MD 20910 USA.	laury.miller@noaa.gov	Miller, Laury/B-8305-2011	Miller, Laury/0000-0003-3095-5804				[Anonymous], PERMANENT SERVICE ME; ANTONOV JI, 2002, J GEOPHYS RES, V107, DOI DOI 10.1029/200/JC000964; Cabanes C, 2001, SCIENCE, V294, P840, DOI 10.1126/science.1063556; Church J. A., 2001, CLIMATE CHANGE 2001, P11; Douglas BC, 2002, PHYS TODAY, V55, P35, DOI 10.1063/1.1472392; Ducet N, 2000, J GEOPHYS RES-OCEANS, V105, P19477, DOI 10.1029/2000JC900063; Joyce TM, 2000, J CLIMATE, V13, P2550, DOI 10.1175/1520-0442(2000)013<2550:TRBDVO>2.0.CO;2; Levitus S, 2000, SCIENCE, V287, P2225, DOI 10.1126/science.287.5461.2225; Meier MF, 2002, P NATL ACAD SCI USA, V99, P6524, DOI 10.1073/pnas.112214499; Munk W, 2002, P NATL ACAD SCI USA, V99, P6550, DOI 10.1073/pnas.092704599; Munk W, 2003, SCIENCE, V300, P2041, DOI 10.1126/science.1085534; NEREM RS, 2001, SEA LEVEL RISE HIST, P65; Peltier W.R., 2001, SEA LEVEL RISE HIST, P65, DOI DOI 10.1016/S0074-6142(01)80007-3; 1998, WORLD OCEAN ATLAS; [No title captured]	15	176	186	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	2004	428	6981					406	409		10.1038/nature02309	http://dx.doi.org/10.1038/nature02309			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042085	Green Published			2022-12-28	WOS:000220404300037
J	Bion, JF; Heffner, JE				Bion, JF; Heffner, JE			Challenges in the care of the acutely ill	LANCET			English	Review							PATIENT SAFETY EFFORTS; QUALITY-OF-CARE; ADVERSE EVENTS; INTENSIVE-CARE; MEDICAL ERRORS; HOSPITALIZED-PATIENTS; ATTITUDINAL SURVEY; EMERGENCY; ADMISSION; TEAMWORK	Health care providers, hospital administrators, and politicians face competing challenges to reduce clinical errors, control expenditure, increase access and throughput, and improve quality of care. The safe management of the acutely ill inpatient presents particular difficulties. In the first of five Lancet articles on this topic we discuss patients' safety in the acute hospital. We also present a framework in which responsibility for improvement and better integration of care can be considered at the level of patient, local environment, hospital, and health care system; and the other four papers in the series will examine in greater detail methods for measuring, monitoring, and improving inpatient safety.	Univ Birmingham, Queen Elizabeth Hosp, Dept Anaesthesia & Intens Care Med, Birmingham B15 2TH, W Midlands, England; Med Univ S Carolina, Ctr Clin Effectiveness & Patient Safety, Charleston, SC 29425 USA	University of Birmingham; Medical University of South Carolina	Bion, JF (corresponding author), Univ Birmingham, Queen Elizabeth Hosp, Dept Anaesthesia & Intens Care Med, Birmingham B15 2TH, W Midlands, England.	j.f.bion@bham.ac.uk		Bion, Julian/0000-0003-0344-5403				Adams J., 1995, RISK, V1st ed.; *AG HEALTHC RES QU, MED ERR SCOP PROBL; Andrews LB, 1997, LANCET, V349, P309, DOI 10.1016/S0140-6736(96)08268-2; [Anonymous], ORG EC COOPERATION D; BAKER GR, PATIENT SAF HEALTHCA; Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; Bellomo R, 2002, MED J AUSTRALIA, V176, P216, DOI 10.5694/j.1326-5377.2002.tb04376.x; BELLOMO R, 2003, MJA, V179, P1; BELTON KJ, 1995, BRIT J CLIN PHARMACO, V39, P223, DOI 10.1111/j.1365-2125.1995.tb04440.x; Blendon RJ, 2002, NEW ENGL J MED, V347, P1933, DOI 10.1056/NEJMsa022151; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Brennan TA, 2000, NEW ENGL J MED, V342, P1123, DOI 10.1056/NEJM200004133421510; Buchan J, 2002, BMJ-BRIT MED J, V324, P751, DOI 10.1136/bmj.324.7340.751; Buist MD, 1999, MED J AUSTRALIA, V171, P22, DOI 10.5694/j.1326-5377.1999.tb123492.x; Buist MD, 2002, BRIT MED J, V324, P387, DOI 10.1136/bmj.324.7334.387; Busse D K, 2000, Top Health Inf Manage, V20, P1; Camacho LAB, 1998, MED CARE, V36, P748, DOI 10.1097/00005650-199805000-00014; Chassin MR, 1998, MILBANK Q, V76, P565, DOI 10.1111/1468-0009.00106; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Classen DC, 2002, ACAD MED, V77, P963, DOI 10.1097/00001888-200210000-00007; Cohn JN, 2000, ARCH INTERN MED, V160, P2429, DOI 10.1001/archinte.160.16.2429; Cook RI, 2000, BRIT MED J, V320, P791, DOI 10.1136/bmj.320.7237.791; Darchy B, 1999, ARCH INTERN MED, V159, P71, DOI 10.1001/archinte.159.1.71; *DEP HLTH, SHAP FUT LONG TERM P; Department of Health, ORG MEM; Dexter PR, 2001, NEW ENGL J MED, V345, P965, DOI 10.1056/NEJMsa010181; DONCHIN Y, 1995, CRIT CARE MED, V23, P294, DOI 10.1097/00003246-199502000-00015; Druss BG, 2003, NEW ENGL J MED, V348, P130, DOI 10.1056/NEJMsa020993; Eland IA, 1999, BRIT J CLIN PHARMACO, V48, P623; ELIXHAUSER A, 2000, HOSP US 1997; Ely EW, 2001, CHEST, V120, p454S, DOI 10.1378/chest.120.6_suppl.454S; *EM MED SERV, WHO REP; Estrada CA, 2000, BRIT MED J, V321, P507; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Gaba DM, 2002, NEW ENGL J MED, V347, P1249, DOI 10.1056/NEJMsa020846; GIRAUD T, 1993, CRIT CARE MED, V21, P40, DOI 10.1097/00003246-199301000-00011; Goldfrad C, 2000, LANCET, V355, P1138, DOI 10.1016/S0140-6736(00)02062-6; Goldhill DR, 1999, ANAESTHESIA, V54, P853; GRIMSHAW JM, 2001, MED CARE S, V39, P112; Handler JA, 2000, ACAD EMERG MED, V7, P1183, DOI 10.1111/j.1553-2712.2000.tb00462.x; Hayward RA, 2001, JAMA-J AM MED ASSOC, V286, P415, DOI 10.1001/jama.286.4.415; HEINRICH H. W., 1941, Industrial Accident Prevention. A Scientific Approach.; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hofer TP, 2000, MED CARE, V38, P152, DOI 10.1097/00005650-200002000-00005; HOFER TP, 2000, WHAT IS ERROR; *JCAHO, 1996, COND ROOT CAUS AN RE; Kilbridge P, 2003, NEW ENGL J MED, V348, P881, DOI 10.1056/NEJMp030010; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Lagasse RS, 2002, ANESTHESIOLOGY, V97, P1609, DOI 10.1097/00000542-200212000-00038; Layde PM, 2002, JAMA-J AM MED ASSOC, V287, P1993, DOI 10.1001/jama.287.15.1993; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; Leape LL, 2000, JAMA-J AM MED ASSOC, V284, P95, DOI 10.1001/jama.284.1.95; Leape LL, 2002, NEW ENGL J MED, V347, P1633, DOI 10.1056/NEJMNEJMhpr011493; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LEE A, 1995, ANAESTH INTENS CARE, V23, P183, DOI 10.1177/0310057X9502300210; Lee TH, 2002, NEW ENGL J MED, V347, P1965, DOI 10.1056/NEJMe020149; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; Luck J, 2000, AM J MED, V108, P642, DOI 10.1016/S0002-9343(00)00363-6; McCaig LF, 2002, NATL HOSP AMBULATORY; McDonald CJ, 2000, JAMA-J AM MED ASSOC, V284, P93, DOI 10.1001/jama.284.1.93; McNutt RA, 2002, JAMA-J AM MED ASSOC, V287, P1997, DOI 10.1001/jama.287.15.1997; McQuillan P, 1998, BMJ-BRIT MED J, V316, P1853; Morey JC, 2002, HEALTH SERV RES, V37, P1553, DOI 10.1111/1475-6773.01104; MUCKART DJJ, 1994, S AFR J SURG, V32, P69; *NAT COORD GROUP P, REP CHIEF EX NHS EX; Neale G, 2001, J ROY SOC MED, V94, P322, DOI 10.1177/014107680109400702; ODEA J, 2003, INTENS CARE MED, V29, P1594; Pearson G, 1997, LANCET, V349, P1213, DOI 10.1016/S0140-6736(96)12396-5; Perkins GD, 1999, RESUSCITATION, V41, P19, DOI 10.1016/S0300-9572(99)00037-4; Philibert I, 2002, JAMA-J AM MED ASSOC, V288, P1112, DOI 10.1001/jama.288.9.1112; PIZZI L, MAKING HLTH CARE SAF; Pizzi L, CREW RESOURCE MANAGE; POOL R, 1997, ENG SOC SHAPES TECHN; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; Reason J, 2000, BMJ-BRIT MED J, V320, P768, DOI 10.1136/bmj.320.7237.768; Reason J., 1990, HUMAN ERROR; REASON JT, 1995, CLIN RISK MANAGEMENT, P31; Risser DT, 1999, ANN EMERG MED, V34, P373, DOI 10.1016/S0196-0644(99)70134-4; Rothschild JM, 2000, ARCH INTERN MED, V160, P2717, DOI 10.1001/archinte.160.18.2717; SCHEIN RMH, 1990, CHEST, V98, P1388, DOI 10.1378/chest.98.6.1388; Sexton JB, 2000, BMJ-BRIT MED J, V320, P745, DOI 10.1136/bmj.320.7237.745; Shaw C, 2001, REPORTING ADVERSE CL; Shojania K G, 2002, Evid Rep Technol Assess (Summ), P1; Shojania K G, 2001, Eff Clin Pract, V4, P82; SHOJANIA KG, 2001, MAKING CARE SAFER CR; Steinbrook R, 2002, NEW ENGL J MED, V347, P1296, DOI 10.1056/NEJMhpr022383; Stenhouse C., 2000, BRIT J ANAESTH, V84, p663P, DOI [10.1093/bja/84.5.663, DOI 10.1093/BJA/84.5.663]; Vincent C, 2000, BRIT MED J, V320, P777, DOI 10.1136/bmj.320.7237.777; Vincent C, 2003, NEW ENGL J MED, V348, P1051, DOI 10.1056/NEJMhpr020760; Vincent C, 2001, BRIT MED J, V322, P517, DOI 10.1136/bmj.322.7285.517; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; WEICK KE, 1987, CALIF MANAGE REV, V29, P112, DOI 10.2307/41165243; Wilson DG, 1998, EUR J PEDIATR, V157, P769, DOI 10.1007/s004310050932; Wilson RM, 1995, MED J AUSTRALIA, V163, P458, DOI 10.5694/j.1326-5377.1995.tb124691.x; Wolff AM, 2001, MED J AUSTRALIA, V174, P621, DOI 10.5694/j.1326-5377.2001.tb143469.x; WRIGHT D, 1991, LANCET, V338, P676, DOI 10.1016/0140-6736(91)91243-N; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089; GUIDANCE IMPLEMENTIN; LEAPFROG PATIENT SAF	100	82	85	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	2004	363	9413					970	977		10.1016/S0140-6736(04)15793-0	http://dx.doi.org/10.1016/S0140-6736(04)15793-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043966				2022-12-28	WOS:000220308600024
J	Schubert, SD; Suarez, MJ; Pegion, PJ; Koster, RD; Bacmeister, JT				Schubert, SD; Suarez, MJ; Pegion, PJ; Koster, RD; Bacmeister, JT			On the cause of the 1930s Dust Bowl	SCIENCE			English	Article							SEA-SURFACE TEMPERATURE; CENTRAL UNITED-STATES; DROUGHT; VARIABILITY; PRECIPITATION; ENSO	During the 1930s, the United States experienced one of the most devastating droughts of the past century. The drought affected almost two-thirds of the country and parts of Mexico and Canada and was infamous for the numerous dust storms that occurred in the southern Great Plains. In this study, we present model results that indicate that the drought was caused by anomalous tropical sea surface temperatures during that decade and that interactions between the atmosphere and the land surface increased its severity. We also contrast the 1930s drought with other North American droughts of the 20th century.	NASA, Goddard Space Flight Ctr, Earth Sci Directorate, Greenbelt, MD 20771 USA; Sci Applicat Int Corp, Beltsville, MD 20705 USA; Univ Maryland, Goddard Earth Sci & Technol Ctr, Baltimore, MD 21250 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Science Applications International Corporation (SAIC); National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University System of Maryland; University of Maryland Baltimore	Schubert, SD (corresponding author), NASA, Goddard Space Flight Ctr, Earth Sci Directorate, Greenbelt, MD 20771 USA.	schubert@gmao.gsfc.nasa.gov	Koster, Randal D/F-5881-2012; Pegion, Philip/E-5247-2012	Koster, Randal D/0000-0001-6418-6383; 				ATLAS R, 1993, J CLIMATE, V6, P2034, DOI 10.1175/1520-0442(1993)006<2034:TEOSAS>2.0.CO;2; BACMEISTER J, 2000, 104606 NASA GODD SPA, V17, pG2003; BARK DL, 1978, N AM DROUGHTS, P9; Barlow M, 2001, J CLIMATE, V14, P2105, DOI 10.1175/1520-0442(2001)014<2105:EPDVAU>2.0.CO;2; BORCHERT JR, 1971, ANN ASSOC AM GEOGR, V61, P1, DOI 10.1111/j.1467-8306.1971.tb00762.x; FOLLAND CK, 2002, CLIVAR EXCHANGES, V7, P37; Giannini A, 2003, SCIENCE, V302, P1027, DOI 10.1126/science.1089357; Hoerling M, 2003, SCIENCE, V299, P691, DOI 10.1126/science.1079053; Koster RD, 2000, J HYDROMETEOROL, V1, P26, DOI 10.1175/1525-7541(2000)001<0026:VAPOPA>2.0.CO;2; Mo KC, 1997, J CLIMATE, V10, P3028, DOI 10.1175/1520-0442(1997)010<3028:APAWSF>2.0.CO;2; Namias J., 1955, MON WEA REV, V83, P199, DOI [https://doi.org/10.1175/1520-0493(1955)0832.0.CO;2, DOI 10.1175/1520-0493(1955)083<0199:SMAOD>2.0.CO;2]; Rayner NA, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002670; ROSENBERG NJ, 1978, N AM DROUGHTS, P1; Schubert SD, 2004, J CLIMATE, V17, P485, DOI [10.1175/1520-0442(2004)017<0485:COLDIT>2.0.CO;2, 10.1175/1520-0442(2004)017&lt;0485:COLDIT&gt;2.0.CO;2]; Ting MF, 1997, J CLIMATE, V10, P1853, DOI 10.1175/1520-0442(1997)010<1853:SUSPVA>2.0.CO;2; TRENBERTH KE, 1988, SCIENCE, V242, P1640, DOI 10.1126/science.242.4886.1640; Vose R.S., 1992, ORNLCDIAC53NDP041, V3912, DOI [10.3334/CDIAC/, DOI 10.3334/CDIAC]; Woodhouse CA, 1998, B AM METEOROL SOC, V79, P2693, DOI 10.1175/1520-0477(1998)079<2693:YODVIT>2.0.CO;2; Worster D, 1979, DUST BOWL SO GREAT P; Zhang Y, 1997, J CLIMATE, V10, P1004, DOI 10.1175/1520-0442(1997)010<1004:ELIV>2.0.CO;2	20	415	428	6	132	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1855	1859		10.1126/science.1095048	http://dx.doi.org/10.1126/science.1095048			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031502				2022-12-28	WOS:000220281600052
J	Kovacs, A; Connors, M				Kovacs, A; Connors, M			HIV-1 and immune control: can we change the course of HIV-1?	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; STRUCTURED TREATMENT INTERRUPTIONS; T-CELL DIFFERENTIATION; ANTIRETROVIRAL THERAPY; INFECTION; LYMPHOCYTES; RESPONSES; EFFECTOR; SUBSETS		Univ So Calif, Keck Sch Med, Maternal Child & Adolescent Ctr Infect Dis & Viro, Los Angeles, CA 90033 USA; NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	University of Southern California; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kovacs, A (corresponding author), Univ So Calif, Keck Sch Med, Maternal Child & Adolescent Ctr Infect Dis & Viro, Los Angeles, CA 90033 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000855, Z01AI000855] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander TH, 2003, JAIDS-J ACQ IMM DEF, V34, P475, DOI 10.1097/00126334-200312150-00005; Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Daar ES, 1998, ANN INTERN MED, V128, P827, DOI 10.7326/0003-4819-128-10-199805150-00005; Dybul M, 2003, J INFECT DIS, V188, P388, DOI 10.1086/376535; Haigwood NL, 1996, IMMUNOL LETT, V51, P107, DOI 10.1016/0165-2478(96)02563-1; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Lawrence J, 2003, NEW ENGL J MED, V349, P837, DOI 10.1056/NEJMoa035103; Lori F, 2000, SCIENCE, V290, P1591, DOI 10.1126/science.290.5496.1591; McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658; Metzner KJ, 2003, J INFECT DIS, V188, P1433, DOI 10.1086/379215; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; van Lier RAW, 2003, NAT REV IMMUNOL, V3, P931, DOI 10.1038/nri1228; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889	18	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 13	2004	363	9412					833	834		10.1016/S0140-6736(04)15770-X	http://dx.doi.org/10.1016/S0140-6736(04)15770-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15031022				2022-12-28	WOS:000220231500003
J	Moosmann, B; Behl, C				Moosmann, B; Behl, C			Selenoprotein synthesis and side-effects of statins	LANCET			English	Article							TOTAL PARENTERAL-NUTRITION; CONGENITAL MUSCULAR-DYSTROPHY; COA REDUCTASE INHIBITORS; LIPID-LOWERING DRUGS; SELENIUM DEFICIENCY; RHABDOMYOLYSIS SECONDARY; PERIPHERAL NEUROPATHY; ALZHEIMERS-DISEASE; MUSCLE DISEASE; TRANSFER-RNA	Statins are possibly the most effective drugs for the prevention and treatment of hypercholesterolaemia and coronary heart disease. They are generally well tolerated, however, they do cause some unusual side-effects with potentially severe consequences, most prominently myopathy or rhabdomyolysis and polyneuropathy. We noted that the pattern of side-effects associated with statins resembles the pathology of selenium deficiency, and postulated that the mechanism lay in a well established, but often overlooked, biochemical pathway-the isopentenylation of selenocysteine-tRNA([Ser]Sec). A negative effect of statins on selenoprotein synthesis does seem to explain many of the enigmatic effects and side-effects of statins, in particular, statin-induced myopathy.	Univ Mainz, Dept Pathobiochem, Sch Med, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz	Behl, C (corresponding author), Univ Mainz, Dept Pathobiochem, Sch Med, D-55099 Mainz, Germany.	cbehl@uni-mainz.de		Behl, Christian/0000-0001-8453-2378				AMMERMAN CB, 1975, J DAIRY SCI, V58, P1561, DOI 10.3168/jds.S0022-0302(75)84752-7; Benko AL, 2000, P NATL ACAD SCI USA, V97, P61, DOI 10.1073/pnas.97.1.61; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; Cheng Y Y, 1990, Biomed Environ Sci, V3, P422; DIHANICH ME, 1987, MOL CELL BIOL, V7, P177, DOI 10.1128/MCB.7.1.177; ENDO A, 1976, FEBS LETT, V72, P323, DOI 10.1016/0014-5793(76)80996-9; ENGLAND JDF, 1995, AUST NZ J MED, V25, P374, DOI 10.1111/j.1445-5994.1995.tb01912.x; Ferreiro A, 2002, AM J HUM GENET, V71, P739, DOI 10.1086/342719; Ferreiro A, 2000, ANN NEUROL, V48, P745, DOI 10.1002/1531-8249(200011)48:5<745::AID-ANA8>3.0.CO;2-F; Flanigan KM, 2000, ANN NEUROL, V47, P152, DOI 10.1002/1531-8249(200002)47:2<152::AID-ANA4>3.3.CO;2-L; Gaist D, 2002, NEUROLOGY, V58, P1333, DOI 10.1212/WNL.58.9.1333; Gaist D, 2001, EPIDEMIOLOGY, V12, P565, DOI 10.1097/00001648-200109000-00017; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hill MD, 1999, BRAIN PATHOL, V9, P607, DOI 10.1111/j.1750-3639.1999.tb00607.x; Hodel C, 2002, TOXICOL LETT, V128, P159, DOI 10.1016/S0378-4274(02)00010-3; Huynh T, 2002, INTERN MED J, V32, P486, DOI 10.1046/j.1445-5994.2002.00264.x; Ishihara H, 1999, J NEUROL NEUROSUR PS, V67, P829, DOI 10.1136/jnnp.67.6.829; Jeppesen U, 1999, EUR J CLIN PHARMACOL, V54, P835, DOI 10.1007/s002280050562; KELLY DA, 1988, J PEDIATR GASTR NUTR, V7, P783, DOI 10.1097/00005176-198809000-00029; MANOUKIAN AA, 1990, CLIN CHEM, V36, P2145; Moghadaszadeh B, 2001, NAT GENET, V29, P17, DOI 10.1038/ng713; Moustafa ME, 2001, MOL CELL BIOL, V21, P3840, DOI 10.1128/MCB.21.11.3840-3852.2001; Omar MA, 2002, ANN PHARMACOTHER, V36, P288, DOI 10.1345/aph.1A289; Omar MA, 2001, ANN PHARMACOTHER, V35, P1096, DOI 10.1345/aph.10228; Osaki Y, 1998, MUSCLE NERVE, V21, P637, DOI 10.1002/(SICI)1097-4598(199805)21:5<637::AID-MUS10>3.0.CO;2-S; Pedersen TR, 1996, DRUG SAFETY, V14, P11, DOI 10.2165/00002018-199614010-00003; Peng TQ, 2000, J CLIN MICROBIOL, V38, P3538, DOI 10.1128/JCM.38.10.3538-3543.2000; Petit N, 2003, HUM MOL GENET, V12, P1045, DOI 10.1093/hmg/ddg115; PHAN T, 1995, J NEUROL NEUROSUR PS, V58, P625, DOI 10.1136/jnnp.58.5.625; Phillips PS, 2002, ANN INTERN MED, V137, P581, DOI 10.7326/0003-4819-137-7-200210010-00009; Simons M, 2002, ANN NEUROL, V52, P346, DOI 10.1002/ana.10292; Sinzinger H, 2002, J CARDIOVASC PHARM, V40, P163, DOI 10.1097/00005344-200208000-00001; Thompson PD, 2003, JAMA-J AM MED ASSOC, V289, P1681, DOI 10.1001/jama.289.13.1681; Thompson PD, 1997, METABOLISM, V46, P1206, DOI 10.1016/S0026-0495(97)90218-3; VANRIJ AM, 1979, AM J CLIN NUTR, V32, P2076, DOI 10.1093/ajcn/32.10.2076; Warner GJ, 2000, J BIOL CHEM, V275, P28110; WATSON RD, 1985, JPEN-PARENTER ENTER, V9, P58, DOI 10.1177/014860718500900158; Wolozin B, 2002, BIOCHEM SOC T, V30, P525, DOI 10.1042/bst0300525; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	39	168	180	1	28	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	2004	363	9412					892	894		10.1016/S0140-6736(04)15739-5	http://dx.doi.org/10.1016/S0140-6736(04)15739-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15031036				2022-12-28	WOS:000220231500026
J	Kraehenbuhl, JP; Corbet, M				Kraehenbuhl, JP; Corbet, M			Keeping the gut microflora at bay	SCIENCE			English	Editorial Material							TOLL-LIKE RECEPTORS; EPITHELIAL-CELLS; DENDRITIC CELLS; BACTERIA; RESPONSES		Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Kraehenbuhl, JP (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.	jean-pierre.kraehenbuhl@isrec.unil.ch						Cario E, 2002, CURR OPIN GASTROEN, V18, P696, DOI 10.1097/00001574-200211000-00011; Fagarasan S, 2001, NATURE, V413, P639, DOI 10.1038/35098100; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; Macpherson AJ, 2004, SCIENCE, V303, P1662, DOI 10.1126/science.1091334; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Neutra MR, 2001, NAT IMMUNOL, V2, P1004, DOI 10.1038/ni1101-1004; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Shibuya A, 2000, NAT IMMUNOL, V1, P441, DOI 10.1038/80886; Sierro F, 2001, P NATL ACAD SCI USA, V98, P13722, DOI 10.1073/pnas.241308598; VANNHIEU GT, 2000, CELL MICROBIOL, V2, P187, DOI DOI 10.1046/J.1462-5822.2000.00046.X	15	52	55	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1624	1625		10.1126/science.1096222	http://dx.doi.org/10.1126/science.1096222			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016988				2022-12-28	WOS:000220151400031
J	Bernstein, R; Futterer, S				Bernstein, R; Futterer, S			Venous unresponsiveness	LANCET			English	Editorial Material							THROMBOSIS		Northwestern Univ, Feinberg Sch Med, Ken & Ruth Davee Dept Neurol & Clin Neurol Sci, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Radiol, Div Neuroradiol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Bernstein, R (corresponding author), Northwestern Univ, Feinberg Sch Med, Ken & Ruth Davee Dept Neurol & Clin Neurol Sci, Chicago, IL 60611 USA.	r-bernstein@northwestern.edu						Bernstein R, 2001, NEUROLOGY, V56, P424; EINHAUPL KM, 1991, LANCET, V338, P597, DOI 10.1016/0140-6736(91)90607-Q; FERRO JM, 2001, STROKE SYNDROMES, P258; HALEY EC, 1989, ARCH NEUROL-CHICAGO, V46, P337, DOI 10.1001/archneur.1989.00520390103026; PLUM F, 1980, DIAGNOSIS STUPOR COM, P306	5	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	2004	363	9406					368	368		10.1016/S0140-6736(04)15439-1	http://dx.doi.org/10.1016/S0140-6736(04)15439-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768TQ	15070568				2022-12-28	WOS:000188590900013
J	Mason, L; Moore, RA; Edwards, JE; McQuay, HJ; Derry, S; Wiffen, PJ				Mason, L; Moore, RA; Edwards, JE; McQuay, HJ; Derry, S; Wiffen, PJ			Systematic review of topical rubefacients containing salicylates for the treatment of acute and chronic pain	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CLINICAL-TRIALS; BACK-PAIN; METAANALYSIS; ASPIRIN; QUALITY; GEL; OSTEOARTHRITIS; OINTMENT; SPRAINS; RELIEF	Objectives To determine the efficacy and safety of topical rubefacients containing salicylates in acute and chronic pain. Data sources Electronic databases and manufacturers of salicylates. Study selection Randomised double blind trials comparing topical runbefacients with placebo or another active treatment in adults with acute or chronic pain, and reporting dichotomous information, around a 50% reduction in pain, and analyses at one week for acute conditions and two weeks for chronic conditions. Data extraction Relative benefit and number needed to treat, analysis of adverse events, and withdrawals. Data synthesis three double blind placebo controlled trials had information on 182 patients with acute conditions. Topical salicylate was significantly better than placebo (relative benefit 3.6, 95% confidence interval 2.4 to 5.6; number needed to treat 2.1, 1.7 to 2.8). Six double blind placebo controlled trials had information on 429 patients with chronic conditions. Topical salicylate was significantly better than placebo (relative benefit 1.5, 1.3 to 1.9; number needed to treat 5.3, 3.6 to 10.2), but larger, more valid studies were without significant effect. Local adverse events and withdrawals were generally rare in trials that reported them. Conclusions Based on limited information, topically applied rubefacients containing salicylates may be efficacious in the treatment of acute pain. Trials of musculoskeletal and arthritic pain suggested moderate to poor efficacy Adverse events were rare in studies of acute pain and poorly reported in those of chronic pain. Efficacy estimates for rubefacients are unreliable owing to a lack of good clinical trials.	Univ Oxford, Oxford Radcliffe Hosp, Nuffield Dept Anaesthet, Cochrane Pain & Palliat Care Grp, Oxford OX3 7LJ, England	University of Oxford	Moore, RA (corresponding author), Univ Oxford, Oxford Radcliffe Hosp, Nuffield Dept Anaesthet, Cochrane Pain & Palliat Care Grp, S Parks Rd, Oxford OX3 7LJ, England.	andrew.moore@pru.ox.ac.uk	Wiffen, Philip/GNP-1768-2022					ABBE KA, 1987, ANN INTERN MED, V107, P224; ALGOZZINE GJ, 1982, JAMA-J AM MED ASSOC, V247, P1311, DOI 10.1001/jama.247.9.1311; Amann R, 2002, EUR J PHARMACOL, V447, P1, DOI 10.1016/S0014-2999(02)01828-9; BACH GL, 1979, FORTSCHR MED, V97, P1249; BARRACLOUGH K, 2003, BMJ-BRIT MED J, V326, P1095; *BRIT MED ASS ROYA, 2003, BRIT NAT FORM; Camus JP, 1975, RHEUMATOLOGIE, V27, P61; COOK D, 1992, ANN INTERN MED, V117, pA16; DIEBSCHLAG W, 1987, ARZNEIMITTEL-FORSCH, V37-2, P1076; Edwards JE, 1999, J PAIN SYMPTOM MANAG, V18, P427, DOI 10.1016/S0885-3924(99)00093-7; FRAHM E, 1993, BRIT J CLIN PRACT, V47, P321; GELLER O, 1980, MUNCHEN MED WOCHEN, V122, P1231; GINSBERG F, 1987, J INT MED RES, V15, P148, DOI 10.1177/030006058701500304; GOLDEN EL, 1978, CURR THER RES CLIN E, V24, P524; Gotzsche PC, 2001, ANN RHEUM DIS, V60, P349, DOI 10.1136/ard.60.4.349; Jadad AR, 1996, PAIN, V66, P239, DOI 10.1016/0304-3959(96)03033-3; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LESTER AA, 1981, PRACTITIONER, V225, P935; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Moore RA, 1998, BRIT MED J, V316, P333, DOI 10.1136/bmj.316.7128.333; Moore RA, 1998, PAIN, V78, P209, DOI 10.1016/S0304-3959(98)00140-7; Morris J, 1995, STAT CONFIDENCE CONF, P50; Morton I, 2002, ROYAL SOC MED MED; PO ALW, 1996, PHARM J          DEC; REYNOLDS JEF, 1999, MARTINDALE EXTRA PHA; ROTHHAAR J, 1982, MED WELT, V33, P1006; Rutner M, 1995, Fortschr Med, V113, P111; Shackel NA, 1997, MED J AUSTRALIA, V167, P134, DOI 10.5694/j.1326-5377.1997.tb138811.x; Smith LA, 2000, PAIN, V86, P119, DOI 10.1016/S0304-3959(00)00234-7; Stam C, 2001, Br Homeopath J, V90, P21, DOI 10.1038/sj.bhj.5800460; Tramer MR, 1997, BMJ-BRIT MED J, V315, P635, DOI 10.1136/bmj.315.7109.635; Vaile JH, 1998, DRUGS, V56, P783, DOI 10.2165/00003495-199856050-00004; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Wanet G, 1979, J Belge Med Phys Rehabil, V2, P119; Whitton T, 2000, KNEE, V7, P207, DOI 10.1016/S0968-0160(00)00071-5	36	62	65	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 24	2004	328	7446					995	997		10.1136/bmj.38040.607141.EE	http://dx.doi.org/10.1136/bmj.38040.607141.EE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	816SR	15033879	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000221130100018
J	Yudkin, P; Munafo, M; Hey, K; Roberts, S; Welch, S; Johnstone, E; Murphy, M; Griffiths, S; Walton, R				Yudkin, P; Munafo, M; Hey, K; Roberts, S; Welch, S; Johnstone, E; Murphy, M; Griffiths, S; Walton, R			Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							SMOKING; GENE		Univ Oxford, Dept Primary Hlth Care, Oxford OX3 7LF, England; Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Canc Res UK Gen Practice Res Grp, Oxford OX2 6HE, England	University of Oxford; Radcliffe Infirmary; University of Oxford	Yudkin, P (corresponding author), Univ Oxford, Dept Primary Hlth Care, Oxford OX3 7LF, England.	pat.yudkin@dphpc.ox.ac.uk	Munafo, Marcus/AAE-2306-2020	Munafo, Marcus/0000-0002-4049-993X; Walton, Robert/0000-0001-7700-1907				BURKE P, 1994, BRIT MED J, V308, P1476; Comings DE, 1996, PHARMACOGENETICS, V6, P73, DOI 10.1097/00008571-199602000-00006; Johnstone EC, 2004, PHARMACOGENETICS, V14, P83, DOI 10.1097/00008571-200402000-00002; NOBLE EP, 1994, MED HYPOTHESES, V42, P257, DOI 10.1016/0306-9877(94)90127-9; Perkins K A, 1999, Nicotine Tob Res, V1, P301, DOI 10.1080/14622299050011431	5	95	96	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 24	2004	328	7446					989	990		10.1136/bmj.38050.674826.AE	http://dx.doi.org/10.1136/bmj.38050.674826.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	816SR	15033882	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000221130100016
J	Berg, AO; Allan, JD; Calonge, N; Frame, P; Garcia, J; Harris, RP; Johnson, MS; Klein, JD; Loveland-Cherry, C; Moyer, VA; Orleans, CT; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH				Berg, AO; Allan, JD; Calonge, N; Frame, P; Garcia, J; Harris, RP; Johnson, MS; Klein, JD; Loveland-Cherry, C; Moyer, VA; Orleans, CT; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH		US Preventive Services Task Force	Screening for coronary heart disease: Recommendation statement	ANNALS OF INTERNAL MEDICINE			English	Article							ARTERY BYPASS-SURGERY; RESTING ELECTROCARDIOGRAM; AMERICAN-COLLEGE; ANGIOPLASTY; TRIAL; MEN	This statement summarizes the current U.S. Preventive Services Task Force (USPSTF) recommendations on screening for coronary heart disease and the supporting scientific evidence and updates the 1996 recommendations on this topic. The complete information on which this statement is based, including evidence tables and references, is available in the background article and the systematic evidence review, available through the USPSTF Web site (www.preventiveservices.ahrq.gov) and through the National Guideline Clearinghouse (www.guideline.gov). The article and the recommendation statement are also available in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs@ahrq.gov).	Agcy Healthcare Res & Qual, US Prevent Serv Task Force, Rockville, MD USA	Agency for Healthcare Research & Quality	Berg, AO (corresponding author), Agcy Healthcare Res & Qual, US Prevent Serv Task Force, Rockville, MD USA.							*AM AC FAM PHYS, 2003, CLIN CAR RES; *AM HEART ASS, 2003, CARD DIS COST; [Anonymous], 1996, J Am Coll Cardiol, V27, P957; Ashley EA, 2000, LANCET, V356, P1592, DOI 10.1016/S0140-6736(00)03138-X; Ashley EA, 2001, PROG CARDIOVASC DIS, V44, P55, DOI 10.1053/pcad.2001.24683; Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; COPLAN NL, 1990, AM HEART J, V119, P987, DOI 10.1016/S0002-8703(05)80352-7; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; FROELICHER VF, 1989, ISRAEL J MED SCI, V25, P495; Gibbons RJ, 2002, CIRCULATION, V106, P1883, DOI 10.1161/01.CIR.0000034670.06526.15; HAMPTON JR, 1993, LANCET, V341, P573; HOPKIRK JAC, 1984, J AM COLL CARDIOL, V3, P821, DOI 10.1016/S0735-1097(84)80259-4; KANNEL WB, 1987, AM HEART J, V113, P370, DOI 10.1016/0002-8703(87)90280-8; O'Rourke RA, 2000, CIRCULATION, V102, P126, DOI 10.1161/01.CIR.102.1.126; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; Pignone M, 2003, SCREENING ASYMPTOMAT; SOX HC, 1989, ANN INTERN MED, V111, P489, DOI 10.7326/0003-4819-111-6-489; *US DEP HHS, 2003, FAST STATS A Z DEATH; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; 1983, J AM COLL CARDIOL, V68, P939	21	99	101	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 6	2004	140	7					569	572		10.7326/0003-4819-140-7-200404060-00001	http://dx.doi.org/10.7326/0003-4819-140-7-200404060-00001			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808OE	15068986				2022-12-28	WOS:000220577600010
J	Blencowe, M				Blencowe, M			Nanomechanical quantum limits	SCIENCE			English	Editorial Material									Dartmouth Coll, Dept Phys & Astron, Wilder Lab 6127, Hanover, NH 03755 USA	Dartmouth College	Blencowe, M (corresponding author), Dartmouth Coll, Dept Phys & Astron, Wilder Lab 6127, Hanover, NH 03755 USA.	miles.p.blencowe@dartmouth.edu		Blencowe, Miles/0000-0003-0051-0492				Blencowe MP, 2000, APPL PHYS LETT, V77, P3845, DOI 10.1063/1.1331090; Devoret MH, 2000, NATURE, V406, P1039, DOI 10.1038/35023253; Hackermuller L, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.090408; Huang XMH, 2003, NATURE, V421, P496, DOI 10.1038/421496a; Knobel RG, 2003, NATURE, V424, P291, DOI 10.1038/nature01773; LaHaye MD, 2004, SCIENCE, V304, P74, DOI 10.1126/science.1094419; Leggett AJ, 2002, J PHYS-CONDENS MAT, V14, pR415, DOI 10.1088/0953-8984/14/15/201; WHITE JD, 1993, JPN J APPL PHYS 2, V32, pL1571, DOI 10.1143/JJAP.32.L1571; Wilson-Rae I, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.075507	9	27	29	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					56	57		10.1126/science.1095768	http://dx.doi.org/10.1126/science.1095768			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15060311				2022-12-28	WOS:000220567900030
J	Gibbs, RA; Weinstock, GM; Metzker, ML; Muzny, DM; Sodergren, EJ; Scherer, S; Scott, G; Steffen, D; Worley, KC; Burch, PE; Okwuonu, G; Hines, S; Lewis, L; DeRamo, C; Delgado, O; Dugan-Rocha, S; Miner, G; Morgan, M; Hawes, A; Gill, R; Holt, RA; Adams, MD; Amanatides, PG; Baden-Tillson, H; Barnstead, M; Chin, S; Evans, CA; Ferriera, S; Fosler, C; Glodek, A; Gu, ZP; Jennings, D; Kraft, CL; Nguyen, T; Pfannkoch, CM; Sitter, C; Sutton, GG; Venter, JC; Woodage, T; Smith, D; Lee, HM; Gustafson, E; Cahill, P; Kana, A; Doucette-Stamm, L; Weinstock, K; Fechtel, K; Weiss, RB; Dunn, DM; Green, ED; Blakesley, RW; Bouffard, GG; de Jong, J; Osoegawa, K; Zhu, BL; Marra, M; Schein, J; Bosdet, I; Fjell, C; Jones, S; Krzywinski, M; Mathewson, C; Siddiqui, A; Wye, N; McPherson, J; Zhao, SY; Fraser, CM; Shetty, J; Shatsman, S; Geer, K; Chen, YX; Abramzon, S; Nierman, WC; Gibbs, RA; Weinstock, GM; Havlak, PH; Chen, R; Durbin, KJ; Egan, A; Ren, YR; Song, XZ; Li, BS; Liu, Y; Qin, X; Cawley, S; Weinstock, GM; Worley, KC; Cooney, AJ; Gibbs, RA; D'Souza, LM; Martin, K; Wu, JQ; Gonzalez-Garay, ML; Jackson, AR; Kalafus, KJ; McLeod, MP; Milosavljevic, A; Virk, D; Volkov, A; Wheeler, DA; Zhang, ZD; Bailey, JA; Eichler, EE; Tuzun, E; Birney, E; Mongin, E; Ureta-Vidal, A; Woodwark, C; Zdobnov, E; Bork, P; Suyama, M; Torrents, D; Alexandersson, M; Trask, BJ; Young, JM; Smith, D; Huang, H; Fechtel, K; Wang, HJ; Xing, HM; Weinstock, K; Daniels, S; Gietzen, D; Schmidt, J; Stevens, K; Vitt, U; Wingrove, J; Camara, F; Schmidt, J; Stevens, K; Vitt, U; Wingrove, J; Camara, F; Alba, MM; Abril, JF; Guigo, R; Smit, A; Dubchak, I; Rubin, EM; Couronne, O; Poliakov, A; Hubner, N; Ganten, D; Goesele, C; Hummel, O; Kreitler, T; Lee, YA; Monti, J; Schulz, H; Zimdahl, H; Himmelbauer, H; Lehrach, H; Jacob, HJ; Bromberg, S; Gullings-Handley, J; Jensen-Seaman, MI; Kwitek, AE; Lazar, J; Pasko, D; Tonellato, PJ; Twigger, S; Ponting, P; Duarte, JM; Rice, S; Goodstadt, L; Beatson, SA; Emes, RD; Winter, EE; Webber, C; Brandt, P; Nyakatura, G; Adetobi, M; Chiaromonte, F; Elnitski, L; Eswara, P; Hardison, RC; Hou, MM; Kolbe, D; Makova, K; Miller, W; Nekrutenko, A; Riemer, C; Schwartz, S; Taylor, J; Yang, S; Zhang, Y; Lindpaintner, K; Andrews, TD; Caccamo, M; Clamp, M; Clarke, L; Curwen, V; Durbin, R; Eyras, E; Searle, SM; Cooper, GM; Batzoglou, S; Brudno, M; Sidow, A; Stone, EA; Venter, JC; Payseur, BA; Bourque, G; Lopez-Otin, C; Puente, XS; Chakrabarti, K; Chatterji, S; Dewey, C; Pachter, L; Bray, N; Yap, VB; Caspi, A; Tesler, G; Pevzner, PA; Haussler, D; Roskin, KM; Baertsch, R; Clawson, H; Furey, TS; Hinrichs, AS; Karolchik, D; Kent, WJ; Rosenbloom, KR; Trumbower, H; Weirauch, M; Cooper, DN; Stenson, PD; Ma, B; Brent, M; Arumugam, M; Shteynberg, D; Copley, RR; Taylor, MS; Riethman, H; Mudunuri, U; Peterson, J; Guyer, M; Felsenfeld, A; Old, S; Mockrin, S; Collins, F				Gibbs, RA; Weinstock, GM; Metzker, ML; Muzny, DM; Sodergren, EJ; Scherer, S; Scott, G; Steffen, D; Worley, KC; Burch, PE; Okwuonu, G; Hines, S; Lewis, L; DeRamo, C; Delgado, O; Dugan-Rocha, S; Miner, G; Morgan, M; Hawes, A; Gill, R; Holt, RA; Adams, MD; Amanatides, PG; Baden-Tillson, H; Barnstead, M; Chin, S; Evans, CA; Ferriera, S; Fosler, C; Glodek, A; Gu, ZP; Jennings, D; Kraft, CL; Nguyen, T; Pfannkoch, CM; Sitter, C; Sutton, GG; Venter, JC; Woodage, T; Smith, D; Lee, HM; Gustafson, E; Cahill, P; Kana, A; Doucette-Stamm, L; Weinstock, K; Fechtel, K; Weiss, RB; Dunn, DM; Green, ED; Blakesley, RW; Bouffard, GG; de Jong, J; Osoegawa, K; Zhu, BL; Marra, M; Schein, J; Bosdet, I; Fjell, C; Jones, S; Krzywinski, M; Mathewson, C; Siddiqui, A; Wye, N; McPherson, J; Zhao, SY; Fraser, CM; Shetty, J; Shatsman, S; Geer, K; Chen, YX; Abramzon, S; Nierman, WC; Gibbs, RA; Weinstock, GM; Havlak, PH; Chen, R; Durbin, KJ; Egan, A; Ren, YR; Song, XZ; Li, BS; Liu, Y; Qin, X; Cawley, S; Weinstock, GM; Worley, KC; Cooney, AJ; Gibbs, RA; D'Souza, LM; Martin, K; Wu, JQ; Gonzalez-Garay, ML; Jackson, AR; Kalafus, KJ; McLeod, MP; Milosavljevic, A; Virk, D; Volkov, A; Wheeler, DA; Zhang, ZD; Bailey, JA; Eichler, EE; Tuzun, E; Birney, E; Mongin, E; Ureta-Vidal, A; Woodwark, C; Zdobnov, E; Bork, P; Suyama, M; Torrents, D; Alexandersson, M; Trask, BJ; Young, JM; Smith, D; Huang, H; Fechtel, K; Wang, HJ; Xing, HM; Weinstock, K; Daniels, S; Gietzen, D; Schmidt, J; Stevens, K; Vitt, U; Wingrove, J; Camara, F; Schmidt, J; Stevens, K; Vitt, U; Wingrove, J; Camara, F; Alba, MM; Abril, JF; Guigo, R; Smit, A; Dubchak, I; Rubin, EM; Couronne, O; Poliakov, A; Hubner, N; Ganten, D; Goesele, C; Hummel, O; Kreitler, T; Lee, YA; Monti, J; Schulz, H; Zimdahl, H; Himmelbauer, H; Lehrach, H; Jacob, HJ; Bromberg, S; Gullings-Handley, J; Jensen-Seaman, MI; Kwitek, AE; Lazar, J; Pasko, D; Tonellato, PJ; Twigger, S; Ponting, P; Duarte, JM; Rice, S; Goodstadt, L; Beatson, SA; Emes, RD; Winter, EE; Webber, C; Brandt, P; Nyakatura, G; Adetobi, M; Chiaromonte, F; Elnitski, L; Eswara, P; Hardison, RC; Hou, MM; Kolbe, D; Makova, K; Miller, W; Nekrutenko, A; Riemer, C; Schwartz, S; Taylor, J; Yang, S; Zhang, Y; Lindpaintner, K; Andrews, TD; Caccamo, M; Clamp, M; Clarke, L; Curwen, V; Durbin, R; Eyras, E; Searle, SM; Cooper, GM; Batzoglou, S; Brudno, M; Sidow, A; Stone, EA; Venter, JC; Payseur, BA; Bourque, G; Lopez-Otin, C; Puente, XS; Chakrabarti, K; Chatterji, S; Dewey, C; Pachter, L; Bray, N; Yap, VB; Caspi, A; Tesler, G; Pevzner, PA; Haussler, D; Roskin, KM; Baertsch, R; Clawson, H; Furey, TS; Hinrichs, AS; Karolchik, D; Kent, WJ; Rosenbloom, KR; Trumbower, H; Weirauch, M; Cooper, DN; Stenson, PD; Ma, B; Brent, M; Arumugam, M; Shteynberg, D; Copley, RR; Taylor, MS; Riethman, H; Mudunuri, U; Peterson, J; Guyer, M; Felsenfeld, A; Old, S; Mockrin, S; Collins, F		Rat Genome Sequencing Project Cons	Genome sequence of the Brown Norway rat yields insights into mammalian evolution	NATURE			English	Review							ARTIFICIAL CHROMOSOME LIBRARY; RECENT SEGMENTAL DUPLICATIONS; MURINE ENDOGENOUS RETROVIRUS; EMBRYONIC EPSILON-GLOBIN; GENE PREDICTION; ANIMAL-MODEL; DNA-SEQUENCE; MULTIPLE ALIGNMENT; DRAFT SEQUENCE; ALU ELEMENTS	The laboratory rat (Rattus norvegicus) is an indispensable tool in experimental medicine and drug development, having made inestimable contributions to human health. We report here the genome sequence of the Brown Norway (BN) rat strain. The sequence represents a high-quality 'draft' covering over 90% of the genome. The BN rat sequence is the third complete mammalian genome to be deciphered, and three-way comparisons with the human and mouse genomes resolve details of mammalian evolution. This first comprehensive analysis includes genes and proteins and their relation to human disease, repeated sequences, comparative genome-wide studies of mammalian orthologous chromosomal regions and rearrangement breakpoints, reconstruction of ancestral karyotypes and the events leading to existing species, rates of variation, and lineage-specific and lineage-independent evolutionary events such as expansion of gene families, orthology relations and protein evolution.	Baylor Coll Med, Dept Mol & Human Genet, Human Genome Sequencing Ctr, Houston, TX 77030 USA; British Columbia Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 4E6, Canada; Celera, Rockville, MD 20850 USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Computat Gen, Cleveland, OH 44106 USA; DSM Pharmaceut Inc, Greenville, NC 27834 USA; Inst Biol Energy Alternat, Rockville, MD 20850 USA; Intronn Inc, Gaithersburg, MD 20878 USA; Ctr Advancement Gen TCAG, Rockville, MD 20850 USA; Avalon Pharmaceut, Germantown, MD 20876 USA; NIAID, Basic Immunol Branch, Div Allergy Immunol & Transplantat, NIH,DHHS, Bethesda, MD 20892 USA; DynPort Vaccine Co LLC, Frederick, MD 21702 USA; Genome Therapeut Corp, Waltham, MA 02453 USA; Agencourt Biosci Corp, Beverly, MA 01915 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; NHGRI, NIH, Intramural Sequencing Ctr, NISC, Bethesda, MD 20892 USA; NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; Childrens Hosp, Oakland Res Inst, BACPAC Resources, Oakland, CA 94609 USA; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Inst Gen Res, Rockville, MD 20850 USA; Affymetrix, Oakland, CA 94608 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; EBI, Hinxton CB10 1SD, Cambs, England; European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Fraunhofer Chalmers Res Ctr Ind Math, S-41288 Gothenburg, Sweden; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Incyte Corp, Palo Alto, CA 94304 USA; Univ Pompeu Fabra, Inst Municipal Invest Med, Grp Rec Informat Biomedia, Barcelona 08003, Spain; Ctr Regulacio Gen, Programa Bioinformat & Gen, Barcelona 08003, Spain; Inst Syst Biol, Computat Biol Grp, Seattle, WA 98103 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Gen Div, Berkeley, CA 94720 USA; US DOE, Joint Genome Inst, Walnut Creek, CA 94598 USA; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Med Coll Wisconsin, Human & Mol Genet Ctr, Bioinformat Res Ctr, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Bioinformat Res Ctr, Rat Genome Database, Milwaukee, WI 53226 USA; Univ Oxford, MRC, Funct Genet Unit, Dept Human Anat & Genet, Oxford OX1 3QX, England; MWG Biotech, D-85560 Ebersberg, Germany; Penn State Univ, Dept Biol, Huck Inst Life Sci, Ctr Comparat Gen & Bioinformat, University Pk, PA 16802 USA; Penn State Univ, Dept Stat, University Pk, PA 16802 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Dept Comp Sci & Engn, University Pk, PA 16802 USA; Penn State Univ, Dept Hlth Evaluat Sci, University Pk, PA 16802 USA; F Hoffmann La Roche Ltd, Roche Genet & Roche Ctr Med Gen, CH-4070 Basel, Switzerland; Sanger Inst, Hinxton CB10 1SA, Cambs, England; Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Dept Comp Sci, James H Clark Ctr S256, Stanford, CA 94305 USA; Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA; Univ Montreal, Ctr Rech Math, Montreal, PQ H3T 1J8, Canada; Univ Oviedo, Inst Univ Oncol, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Math, Berkeley, CA 94720 USA; Univ Calif Berkeley, Bioengn Grad Grp, Berkeley, CA 94720 USA; Univ Calif San Diego, Dept Math, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Comp Sci & Engn, La Jolla, CA 92093 USA; Univ Calif Santa Cruz, Baskin Sch Engn, Ctr Biomol Sci & Engn, Howard Hughes Med Inst, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Baskin Sch Engn, Ctr Biomol Sci & Engn, Genome Bioinformat Grp, Santa Cruz, CA 95064 USA; Cardiff Univ, Inst Med Genet, Cardiff CF14 4XN, S Glam, Wales; Univ Western Ontario, Dept Comp Sci, London, ON N6A 5B7, Canada; Washington Univ, Lab Computat Gen, St Louis, MO 63130 USA; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; NHGRI, US NIH, Bethesda, MD 20892 USA; NHLBI, US NIH, Bethesda, MD 20892 USA; Baylor Coll Med, Program Struct & Computat Biol & Mol Biophys, Houston, TX 77030 USA	Baylor College of Medicine; British Columbia Cancer Agency; Case Western Reserve University; Case Western Reserve University; DSM NV; J. Craig Venter Institute; J. Craig Venter Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; Washington University (WUSTL); Affymetrix; Baylor College of Medicine; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Chalmers University of Technology; Fraunhofer-Chalmers Research Centre for Industrial Mathematics; Fred Hutchinson Cancer Center; Incyte; Pompeu Fabra University; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Institute for Systems Biology (ISB); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Joint BioEnergy Institute - JBEI; Joint Genome Institute - JGI; Max Planck Society; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; University of Oxford; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Roche Holding; Wellcome Trust Sanger Institute; Stanford University; Stanford University; Stanford University; University of Arizona; Universite de Montreal; University of Oviedo; Instituto Universitario de Oncologia de Asturias; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; Cardiff University; Western University (University of Western Ontario); Washington University (WUSTL); University of Oxford; Wellcome Centre for Human Genetics; The Wistar Institute; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Baylor College of Medicine	Gibbs, RA (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Human Genome Sequencing Ctr, MS BCM226,1 Baylor Plaza, Houston, TX 77030 USA.	agibbs@bcm.tmc.edu	Ferreira, Francisco Câmara/G-9841-2015; Weinstock, George M/C-6314-2013; Driemeier, David/H-3461-2012; Weirauch, Matthew/M-5459-2019; Ferrando, Josep F Abril/B-3877-2014; Li, Bingshan/H-1944-2011; Elnitski, Laura/AAD-3595-2021; Arumugam, Manimozhiyan/AAJ-2394-2020; Jones, Steven J/C-3621-2009; Wheeler, David A/M-9740-2018; Hardison, Ross C/G-1142-2010; Couronne, Olivier Couronne/G-1244-2012; McPherson, John D/D-2633-2017; Guigo, Roderic/D-1303-2010; Tuzun, Eray/B-5949-2018; Andrews, Dan/ABG-4815-2020; Holt, Robert A/C-3303-2009; Duarte, Jose M/I-6178-2018; Clawson, Hiram/ABE-6101-2020; Schein, Jacquie E/G-3674-2015; Puente, Xosé S./ADB-0672-2022; Zdobnov, Evgeny/AAB-2745-2022; Marra, Marco A/B-5987-2008; Ponting, Chris/AAV-2621-2021; Cooper, David N/H-4384-2011; Eyras, Eduardo/ABG-7144-2020; Bork, Peer/F-1813-2013; Taylor, James/F-1026-2011; López-Otín, Carlos/AAB-2106-2020; Arumugam, Manimozhiyan/E-1211-2011; Eduardo, Eyras/L-1053-2014; Bourque, Guillaume/AFR-2927-2022; Durbin, Richard/AAE-7178-2019; Alba, Mar/B-4793-2009; Hinrichs, Angie S./H-9159-2019; Gasull, Martina/J-4076-2019; Zdobnov, Evgeny M/K-1133-2012; Brent, Michael/AAK-3702-2020; Ma, Bin/C-7550-2013; Beatson, Scott/B-6985-2013; Stone, Eric/Q-7840-2016; Emes, Richard D/C-5341-2008; Eyras, Eduardo/A-1560-2010; Taylor, Martin S/C-3825-2009; Tuzun, Eray/AAD-7282-2021; Cooper, Gregory/D-6914-2011; Torrents, David/G-5785-2015	Ferreira, Francisco Câmara/0000-0002-1971-5466; Weinstock, George M/0000-0002-2997-4592; Driemeier, David/0000-0003-3766-0654; Ferrando, Josep F Abril/0000-0001-7793-589X; Arumugam, Manimozhiyan/0000-0002-0886-9101; Jones, Steven J/0000-0003-3394-2208; Wheeler, David A/0000-0002-9056-6299; Hardison, Ross C/0000-0003-4084-7516; McPherson, John D/0000-0001-8049-9347; Guigo, Roderic/0000-0002-5738-4477; Tuzun, Eray/0000-0002-5550-7816; Holt, Robert A/0000-0002-7259-1247; Duarte, Jose M/0000-0002-9544-5621; Puente, Xosé S./0000-0001-9525-1483; Zdobnov, Evgeny/0000-0002-5178-1498; Marra, Marco A/0000-0001-7146-7175; Cooper, David N/0000-0002-8943-8484; Eyras, Eduardo/0000-0003-0793-6218; Bork, Peer/0000-0002-2627-833X; Taylor, James/0000-0001-5079-840X; López-Otín, Carlos/0000-0001-6964-1904; Arumugam, Manimozhiyan/0000-0002-0886-9101; Eduardo, Eyras/0000-0003-0793-6218; Bourque, Guillaume/0000-0002-3933-9656; Durbin, Richard/0000-0002-9130-1006; Alba, Mar/0000-0002-7963-7375; Hinrichs, Angie S./0000-0002-1697-1130; Brent, Michael/0000-0002-8689-0299; Beatson, Scott/0000-0002-1806-3283; Emes, Richard D/0000-0001-6855-5481; Taylor, Martin S/0000-0001-7656-330X; Tuzun, Eray/0000-0002-5550-7816; Cooper, Gregory/0000-0001-5509-9923; Twigger, Simon/0000-0001-5659-3632; Clarke, Laura/0000-0002-5989-6898; Nguyen, Dac-Trung/0000-0003-2591-9948; Axelson-Fisk, Marina/0000-0003-3068-9593; Fraser, Claire/0000-0003-1462-2428; Elnitski, Laura/0000-0003-1065-019X; Nekrutenko, Anton/0000-0002-5987-8032; Ponting, Chris/0000-0003-0202-7816; Delgado, Oliver/0000-0003-2547-5857; Andrews, Dan/0000-0003-3922-6376; Clawson, Hiram/0000-0002-0480-0545; Furey, Terry/0000-0001-5546-9672; Webber, Caleb/0000-0001-8063-7674; Birney, Ewan/0000-0001-8314-8497; Pachter, Lior/0000-0002-9164-6231; Stone, Eric/0000-0002-2725-4209; Torrents, David/0000-0002-6086-9037; Gonzalez-Garay, Manuel/0000-0003-3412-0353; Worley, Kim/0000-0002-0282-1000; Kwitek, Anne/0000-0003-1024-4116; Xing, Heming/0000-0002-2253-0163; Himmelbauer, Heinz/0000-0001-8897-2928; Fjell, Christopher/0000-0001-6304-2628; Suyama, Mikita/0000-0001-9526-3193	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064541] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000060, Z01HG000196, R01HG002939, U01HG002137] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG002939, U01 HG002137, U01 HG002137-02S2] Funding Source: Medline; NHLBI NIH HHS [R01 HL064541] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Adkins RM, 2001, MOL BIOL EVOL, V18, P777, DOI 10.1093/oxfordjournals.molbev.a003860; Alba MM, 1999, MOL BIOL EVOL, V16, P1641, DOI 10.1093/oxfordjournals.molbev.a026077; Alba MM, 2004, GENOME RES, V14, P549, DOI 10.1101/gr.1925704; Alexandersson M, 2003, GENOME RES, V13, P496, DOI 10.1101/gr.424203; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Alves A, 2003, SURGERY, V133, P669, DOI 10.1067/msy.2003.152; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Bailey JA, 2001, GENOME RES, V11, P1005, DOI 10.1101/gr.GR-1871R; Barnett SA, 2002, STORY RATS THEIR IMP, P17; Batzoglou S, 2002, GENOME RES, V12, P177, DOI 10.1101/gr.208902; Bayona-Bafaluy MP, 2003, NUCLEIC ACIDS RES, V31, P5349, DOI 10.1093/nar/gkg739; Benit L, 1997, J VIROL, V71, P5652; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Birdsell JA, 2002, MOL BIOL EVOL, V19, P1181, DOI 10.1093/oxfordjournals.molbev.a004176; Birney E, 2000, GENOME RES, V10, P547, DOI 10.1101/gr.10.4.547; Blanchette M, 2004, GENOME RES, V14, P708, DOI 10.1101/gr.1933104; Boffelli D, 2003, SCIENCE, V299, P1391, DOI 10.1126/science.1081331; Bourque G, 2004, GENOME RES, V14, P507, DOI 10.1101/gr.1975204; Bourque G, 2002, GENOME RES, V12, P26; Bray N, 2004, GENOME RES, V14, P693, DOI 10.1101/gr.1960404; Brudno M, 2003, GENOME RES, V13, P721, DOI 10.1101/gr.926603; Brudno M, 2004, GENOME RES, V14, P685, DOI 10.1101/gr.2067704; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Burge CB, 1998, MOL CELL, V2, P773, DOI 10.1016/S1097-2765(00)80292-0; Cai L, 1997, GENOMICS, V39, P385, DOI 10.1006/geno.1996.4494; CANBY TY, 1977, NAT GEOGR        JUL, P60; Cantrell MA, 2001, GENETICS, V158, P769; Cavaggioni A, 2000, BBA-PROTEIN STRUCT M, V1482, P218, DOI 10.1016/S0167-4838(00)00149-7; Chakrabarti K, 2004, GENOME RES, V14, P716, DOI 10.1101/gr.1957004; CHANG BHJ, 1994, P NATL ACAD SCI USA, V91, P827, DOI 10.1073/pnas.91.2.827; CHANG BHJ, 1995, J MOL EVOL, V40, P70, DOI 10.1007/BF00166597; Chen R, 2004, GENOME RES, V14, P679, DOI 10.1101/gr.2171704; Cheung J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-8-r47; CHIAROMONTE F, IN PRESS COLD SPRING; CLARK AJ, 1984, EMBO J, V3, P2055, DOI 10.1002/j.1460-2075.1984.tb02091.x; CLERMONT Y, 1972, PHYSIOL REV, V52, P198, DOI 10.1152/physrev.1972.52.1.198; Cooper GM, 2004, GENOME RES, V14, P539, DOI 10.1101/gr.2034704; Cooper GM, 2003, GENOME RES, V13, P813, DOI 10.1101/gr.1064503; Costas J, 2003, J MOL EVOL, V56, P181, DOI 10.1007/s00239-002-2392-3; Crisci AR, 2002, ULTRASOUND MED BIOL, V28, P1335, DOI 10.1016/S0301-5629(02)00576-8; Danielson PB, 2002, CURR DRUG METAB, V3, P561, DOI 10.2174/1389200023337054; DARWIN C, 1859, ORIGIN SPECIES, P108; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Dermitzakis ET, 2003, SCIENCE, V302, P1033, DOI 10.1126/science.1087047; Dermitzakis ET, 2002, NATURE, V420, P578, DOI 10.1038/nature01251; Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223; Dewey C, 2004, GENOME RES, V14, P661, DOI 10.1101/gr.1939804; Duret L, 2000, MOL BIOL EVOL, V17, P68, DOI 10.1093/oxfordjournals.molbev.a026239; Eichler EE, 1998, GENOME RES, V8, P758, DOI 10.1101/gr.8.8.758; Eichler EE, 2001, GENOME RES, V11, P653, DOI 10.1101/gr.188901; Elnitski L, 2003, GENOME RES, V13, P64, DOI 10.1101/gr.817703; Emes RD, 2004, GENOME RES, V14, P591, DOI 10.1101/gr.1940604; Emes RD, 2003, HUM MOL GENET, V12, P701, DOI 10.1093/hmg/ddg078; Felsenfeld A, 1999, GENOME RES, V9, P1; Flicek P, 2003, GENOME RES, V13, P46, DOI 10.1101/gr.830003; Forte A, 2003, CARDIOVASC RES, V60, P654, DOI 10.1016/j.cardiores.2003.08.015; Fray MJ, 2003, J MED CHEM, V46, P3514, DOI 10.1021/jm0308038; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; GARCIAMEUNIER P, 1993, MAMM GENOME, V4, P695, DOI 10.1007/BF00357792; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Graves JAM, 2002, CYTOGENET GENOME RES, V99, P141, DOI 10.1159/000071585; GREEN H, 1994, P NATL ACAD SCI USA, V91, P4298, DOI 10.1073/pnas.91.10.4298; Green P, 2002, P NATL ACAD SCI USA, V99, P4143, DOI 10.1073/pnas.082095999; Greenhouse DD, 1990, GENETIC MONITORING I, P410; GUIGO R, 1992, J MOL BIOL, V226, P141, DOI 10.1016/0022-2836(92)90130-C; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; Gurates B, 2002, J CLIN ENDOCR METAB, V87, P4369, DOI 10.1210/jc.2002-020522; Guy J, 2003, GENOME RES, V13, P159, DOI 10.1101/gr.644503; Haldi ML, 1997, MAMM GENOME, V8, P284, DOI 10.1007/s003359900412; HARDISON R, 1993, NUCLEIC ACIDS RES, V21, P1265, DOI 10.1093/nar/21.5.1265; Hardison RC, 2003, GENOME RES, V13, P13, DOI 10.1101/gr.844103; Havlak P, 2004, GENOME RES, V14, P721, DOI 10.1101/gr.2264004; Hayward BE, 1997, GENETICS, V146, P641; HEDRICH HJ, 2000, HDB EXPT ANIMALS LAB, P3; Hillier LW, 2003, NATURE, V424, P157, DOI 10.1038/nature01782; Horvath JE, 2003, MOL BIOL EVOL, V20, P1463, DOI 10.1093/molbev/msg158; HUANG H, UNPUB GENOME BIOL; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; HUCKINS C, 1971, ANAT REC, V169, P533, DOI 10.1002/ar.1091690306; HUGHES AL, 1999, ADAPTIVE EVOLUTION G, P143; Hurst JL, 2001, NATURE, V414, P631, DOI 10.1038/414631a; Hurst LD, 2002, TRENDS GENET, V18, P486, DOI 10.1016/S0168-9525(02)02722-1; Hussar P, 2001, ANN CHIR GYNAECOL, V90, P271; Jaffe DB, 2003, GENOME RES, V13, P91, DOI 10.1101/gr.828403; Jensen-Seaman MI, 2004, GENOME RES, V14, P528, DOI 10.1101/gr.1970304; Jin XQ, 2003, ATHEROSCLEROSIS, V169, P225, DOI 10.1016/S0021-9150(03)00159-X; Kalafus KJ, 2004, GENOME RES, V14, P672, DOI 10.1101/gr.1963804; Kent WJ, 2003, P NATL ACAD SCI USA, V100, P11484, DOI 10.1073/pnas.1932072100; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Kirkness EF, 2003, SCIENCE, V301, P1898, DOI 10.1126/science.1086432; Kitagawa K, 2002, TRANSPLANT P, V34, P1030, DOI 10.1016/S0041-1345(02)02702-1; Kolbe D, 2004, GENOME RES, V14, P700, DOI 10.1101/gr.1976004; Komamura K, 2003, CARDIOVASC DRUG THER, V17, P303, DOI 10.1023/A:1027352703783; Korf I, 2001, Bioinformatics, V17 Suppl 1, pS140; Kostrubsky VE, 2003, TOXICOL SCI, V76, P220, DOI 10.1093/toxsci/kfg217; Krzywinski M, 2004, GENOME RES, V14, P766, DOI 10.1101/gr.2336604; Kuntz C, 2002, SURG ENDOSC, V16, P1175, DOI 10.1007/s00464-001-9159-6; Kwitek AE, 2004, GENOME RES, V14, P750, DOI 10.1101/gr.1968704; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; Li XM, 2003, GENOME RES, V13, P1916, DOI 10.1101/gr.1251803; Lindon JC, 2003, TOXICOL APPL PHARM, V187, P137, DOI 10.1016/S0041-008X(02)00079-0; Lindsey J. R., 1979, The laboratory rat. Volume I. Biology and diseases., P1; Liu MY, 2003, CANCER RES, V63, P2675; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Ma B, 2002, BIOINFORMATICS, V18, P440, DOI 10.1093/bioinformatics/18.3.440; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; Makova KD, 2004, GENOME RES, V14, P567, DOI 10.1101/gr.1971104; Malik AS, 2003, J NEUROTRAUM, V20, P463, DOI 10.1089/089771503765355531; Mara M, 1999, NAT GENET, V22, P265, DOI 10.1038/10327; Margulies EH, 2003, GENOME RES, V13, P2507, DOI 10.1101/gr.1602203; Marra MA, 1997, GENOME RES, V7, P1072, DOI 10.1101/gr.7.11.1072; Martin SL, 2001, MOL CELL BIOL, V21, P467, DOI 10.1128/MCB.21.2.467-475.2001; McBride MW, 2004, J PHYSIOL-LONDON, V554, P56, DOI 10.1113/jphysiol.2003.049361; McBride WJ, 1998, CRIT REV NEUROBIOL, V12, P339, DOI 10.1615/CritRevNeurobiol.v12.i4.40; McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157; Mendell JT, 2001, CELL, V107, P411, DOI 10.1016/S0092-8674(01)00583-9; MISRA S, 2002, GENOME BIOL, V3, P83, DOI [DOI 10.1186/GB-2002-3-12-RESEARCH0083, 10.1186/gb-2002-3-12-research0083]; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; Montoya-Burgos JI, 2003, TRENDS GENET, V19, P128, DOI 10.1016/S0168-9525(03)00021-0; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; Mural RJ, 2002, SCIENCE, V296, P1661, DOI 10.1126/science.1069193; Murphy William J., 2003, Human Genomics, V1, P30; Murphy WJ, 1999, GENOME RES, V9, P1223, DOI 10.1101/gr.9.12.1223; Murphy WJ, 2003, GENOME RES, V13, P1880, DOI 10.1101/gr.1022303; Myers EW, 2002, P NATL ACAD SCI USA, V99, P4145, DOI 10.1073/pnas.092136699; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; NADEAU JH, 1984, P NATL ACAD SCI-BIOL, V81, P814, DOI 10.1073/pnas.81.3.814; Nekrutenko A, 2003, TRENDS GENET, V19, P306, DOI 10.1016/S0168-9525(03)00114-8; Nekrutenko A, 2002, GENOME RES, V12, P198, DOI 10.1101/gr.200901; NEKRUTENKO A, IN PRESS GENOME RES; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; Ness SR, 2002, BIOINFORMATICS, V18, P484, DOI 10.1093/bioinformatics/18.3.484; *NIH, 2000, NETW LARG SCAL SEQ R; Oh B, 1997, DEVELOPMENT, V124, P493; Ohno S., 1970, P1; Osoegawa K, 2004, GENOME RES, V14, P780, DOI 10.1101/gr.2033904; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Ozkan O, 2002, ANN PLAS SURG, V49, P532, DOI 10.1097/01.SAP.0000015434.56344.A7; Parra G, 2003, GENOME RES, V13, P108, DOI 10.1101/gr.871403; Pennacchio LA, 2001, NAT REV GENET, V2, P100, DOI 10.1038/35052548; Petratos PB, 2003, PLAST RECONSTR SURG, V111, P1988, DOI 10.1097/01.PRS.0000056831.87062.4B; Pevzner P, 2003, P NATL ACAD SCI USA, V100, P7672, DOI 10.1073/pnas.1330369100; Pevzner P, 2003, GENOME RES, V13, P37, DOI 10.1101/gr.757503; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; Prak ETL, 2000, NAT REV GENET, V1, P134; Prince VE, 2002, NAT REV GENET, V3, P827, DOI 10.1038/nrg928; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Puente XS, 2004, GENOME RES, V14, P609, DOI 10.1101/gr.1946304; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; QUENTIN Y, 1994, NUCLEIC ACIDS RES, V22, P2222, DOI 10.1093/nar/22.12.2222; Ravingerova TA, 2003, MOL CELL BIOCHEM, V249, P167, DOI 10.1023/A:1024751109196; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; Riethman H, 2004, GENOME RES, V14, P18, DOI 10.1101/gr.1245004; Robinson R., 1965, GENETICS NORWAY RAT; ROSKIN KM, 2003, P 7 ANN INT C RES CO, P257, DOI DOI 10.1145/640075.640109; Rothenburg S, 2002, J MOL EVOL, V55, P251, DOI 10.1007/s00239-002-2322-4; Rouquier S, 2000, P NATL ACAD SCI USA, V97, P2870, DOI 10.1073/pnas.040580197; Roy-Engel AM, 2002, J MOL BIOL, V316, P1033, DOI 10.1006/jmbi.2001.5380; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Salem AH, 2003, P NATL ACAD SCI USA, V100, P12787, DOI 10.1073/pnas.2133766100; Salem AH, 2003, MOL BIOL EVOL, V20, P1349, DOI 10.1093/molbev/msg150; Sauve Y, 2002, NEUROSCIENCE, V114, P389, DOI 10.1016/S0306-4522(02)00271-3; Scarborough PE, 1999, DRUG METAB REV, V31, P205, DOI 10.1081/DMR-100101915; Schein Jacqueline, 2004, Methods Mol Biol, V255, P143; Schuler GD, 1997, GENOME RES, V7, P541, DOI 10.1101/gr.7.5.541; Schwartz S, 2003, NUCLEIC ACIDS RES, V31, P3518, DOI 10.1093/nar/gkg579; Schwartz S, 2003, GENOME RES, V13, P103, DOI 10.1101/gr.809403; SMIT AFA, 1993, NUCLEIC ACIDS RES, V21, P1863, DOI 10.1093/nar/21.8.1863; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; Smyth MD, 2002, EPILEPSY RES, V50, P251, DOI 10.1016/S0920-1211(02)00051-7; Soderlund C, 2000, GENOME RES, V10, P1772, DOI 10.1101/gr.GR-1375R; Soderlund C, 1997, COMPUT APPL BIOSCI, V13, P523; SOLOVYEV VV, 1995, INTELLIGENT SYSTEMS, V3, P367; Springer MS, 2003, P NATL ACAD SCI USA, V100, P1056, DOI 10.1073/pnas.0334222100; Stanyon R, 2003, GENOMICS, V82, P245, DOI 10.1016/S0888-7543(03)00109-5; Steen RG, 1999, GENOME RES, V9, pAP1; Stenson PD, 2003, HUM MUTAT, V21, P577, DOI 10.1002/humu.10212; Strassmann B I, 1992, Hum Nat, V3, P89, DOI 10.1007/BF02692249; Sundstrom H, 2003, GENETICS, V164, P259; TAGLE DA, 1988, J MOL BIOL, V203, P439, DOI 10.1016/0022-2836(88)90011-3; Tam RC, 2000, ANTIMICROB AGENTS CH, V44, P1276, DOI 10.1128/AAC.44.5.1276-1283.2000; Taylor JR, 2002, AM J PSYCHIAT, V159, P657, DOI 10.1176/appi.ajp.159.4.657; Taylor MS, 2004, GENOME RES, V14, P555, DOI 10.1101/gr.1977804; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858; Thomas JW, 2003, GENOME RES, V13, P55, DOI 10.1101/gr.791403; Torrents D, 2003, GENOME RES, V13, P2559, DOI 10.1101/gr.1455503; Trenite DGAKN, 2003, EPILEPTIC DISORD, V5, pS39; Trinklein ND, 2003, GENOME RES, V13, P308, DOI 10.1101/gr.794803; Tuzun E, 2004, GENOME RES, V14, P493, DOI 10.1101/gr.1907504; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Ventura M, 2001, GENOME RES, V11, P595, DOI 10.1101/gr.152101; Vitt U, 2004, GENOME RES, V14, P640, DOI 10.1101/gr.1932304; Wade CM, 2002, NATURE, V420, P574, DOI 10.1038/nature01252; Wang H, 2003, TRANSPLANTATION, V75, P1475, DOI 10.1097/01.TP.0000057245.59998.95; Watanabe TK, 1999, NAT GENET, V22, P27, DOI 10.1038/8737; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Waterston RH, 2003, P NATL ACAD SCI USA, V100, P3022, DOI 10.1073/pnas.0634129100; Waterston RH, 2002, P NATL ACAD SCI USA, V99, P3712, DOI 10.1073/pnas.042692499; Weiner AM, 2002, CURR OPIN CELL BIOL, V14, P343, DOI 10.1016/S0955-0674(02)00338-1; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; WOLFE KH, 1993, J MOL EVOL, V37, P441, DOI 10.1007/BF00178874; Woon PY, 1998, GENOMICS, V50, P306, DOI 10.1006/geno.1998.5319; Wu JQ, 2004, GENOME RES, V14, P665, DOI 10.1101/gr.1959604; Yang S, 2004, GENOME RES, V14, P517, DOI 10.1101/gr.1984404; Yang TD, 2002, ADV SPACE RES, V30, P751, DOI 10.1016/S0273-1177(02)00391-5; YANG ZH, 1994, MOL BIOL EVOL, V11, P316; Yap VB, 2004, GENOME RES, V14, P574, DOI 10.1101/gr.1967904; Young JM, 2002, HUM MOL GENET, V11, P535, DOI 10.1093/hmg/11.5.535; Youssef AF, 2003, REPROD TOXICOL, V17, P109, DOI 10.1016/S0890-6238(02)00099-0; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037; YUNIS JJ, 1982, SCIENCE, V215, P1525, DOI 10.1126/science.7063861; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800; Zhang ZD, 2004, GENOME RES, V14, P580, DOI 10.1101/gr.2160004; Zhang ZL, 2002, GENOME RES, V12, P1466, DOI 10.1101/gr.331902; Zimdahl H, 2004, SCIENCE, V303, P807, DOI 10.1126/science.1092427	225	1547	2522	4	213	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					493	521		10.1038/nature02426	http://dx.doi.org/10.1038/nature02426			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15057822	Bronze			2022-12-28	WOS:000220540100032
J	Jung, H; Green, HW; Dobrzhinetskaya, LF				Jung, H; Green, HW; Dobrzhinetskaya, LF			Intermediate-depth earthquake faulting by dehydration embrittlement with negative volume change	NATURE			English	Article							DEEP-FOCUS EARTHQUAKES; HIGH-PRESSURE; MANTLE; WATER; SERPENTINITE; STABILITY; FLUIDS; ZONES	Earthquakes are observed to occur in subduction zones to depths of approximately 680 km, even though unassisted brittle failure is inhibited at depths greater than about 50 km, owing to the high pressures and temperatures(1-3). It is thought that such earthquakes (particularly those at intermediate depths of 50-300 km) may instead be triggered by embrittlement accompanying dehydration of hydrous minerals, principally serpentine(1-3). A problem with failure by serpentine dehydration is that the volume change accompanying dehydration becomes negative at pressures of 2-4 GPa (60-120 km depth), above which brittle fracture mechanics predicts that the instability should be quenched(4,5). Here we show that dehydration of antigorite serpentinite under stress results in faults delineated by ultrafine-grained solid reaction products formed during dehydration. This phenomenon was observed under all conditions tested (pressures of 1-6 GPa; temperatures of 650-820degreesC), independent of the sign of the volume change of reaction. Although this result contradicts expectations from fracture mechanics, it can be explained by separation of fluid from solid residue before and during faulting, a hypothesis supported by our observations. These observations confirm that dehydration embrittlement is a viable mechanism for nucleating earthquakes independent of depth, as long as there are hydrous minerals breaking down under a differential stress.	Univ Calif Riverside, Inst Geophys & Planetary Phys, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Green, HW (corresponding author), Univ Calif Riverside, Inst Geophys & Planetary Phys, Riverside, CA 92521 USA.	hgreen@mail.ucr.edu						AGEE CB, 1988, J GEOPHYS RES-SOLID, V93, P3437, DOI 10.1029/JB093iB04p03437; AYDIN A, 1982, TECTONICS, V1, P91, DOI 10.1029/TC001i001p00091; Bromiley GD, 2003, AM MINERAL, V88, P99; Bureau H, 1999, EARTH PLANET SC LETT, V165, P187, DOI 10.1016/S0012-821X(98)00266-0; Burnley P. C., 1990, THESIS U CALIFORNIA; Christova C, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017701; Dobson DP, 2002, SCIENCE, V298, P1407, DOI 10.1126/science.1075390; FLETCHER RC, 1981, GEOLOGY, V9, P419, DOI 10.1130/0091-7613(1981)9<419:AMFPSS>2.0.CO;2; GREEN HW, 1990, NATURE, V348, P720, DOI 10.1038/348720a0; GREEN HW, 1995, ANNU REV EARTH PL SC, V23, P169, DOI 10.1146/annurev.ea.23.050195.001125; GREEN HW, 1989, EUR J MINERAL, V1, P213; HACKER BR, 2003, J GEOPHYS RES-SOL EA, V108, DOI DOI 10.1029/2001JB001129; Jiao WJ, 2000, J GEOPHYS RES-SOL EA, V105, P28125, DOI 10.1029/2000JB900314; KIRBY S, 1995, REV GEOPHYS, V33, P287, DOI 10.1029/95RG00353; MEADE C, 1991, SCIENCE, V252, P68, DOI 10.1126/science.252.5002.68; MURRELL SAF, 1976, TECTONOPHYSICS, V31, P207, DOI 10.1016/0040-1951(76)90120-7; Niu FL, 2003, NATURE, V426, P544, DOI 10.1038/nature02151; Omori S., 2002, B EARTHQ RES I TOKYO, V76, P455; Peacock SM, 2001, GEOLOGY, V29, P299, DOI 10.1130/0091-7613(2001)029<0299:ATLPOD>2.0.CO;2; RALEIGH CB, 1965, J GEOPHYS RES, V70, P3965, DOI 10.1029/JZ070i016p03965; RISPOLI R, 1981, TECTONOPHYSICS, V75, pT29, DOI 10.1016/0040-1951(81)90274-2; RUTTER EH, 1988, J GEOPHYS RES-SOLID, V93, P4907, DOI 10.1029/JB093iB05p04907; Seno T, 2001, EARTH PLANETS SPACE, V53, P861, DOI 10.1186/BF03351683; SILVER PG, 1995, SCIENCE, V268, P69, DOI 10.1126/science.268.5207.69; Stalder R, 2001, CONTRIB MINERAL PETR, V140, P670, DOI 10.1007/s004100000208; ULMER P, 1995, SCIENCE, V268, P858, DOI 10.1126/science.268.5212.858; Wong TF, 1997, J GEOPHYS RES-SOL EA, V102, P841, DOI 10.1029/96JB02484; ZHANG J, IN PRESS NATURE; Zhao DP, 2002, PHYS EARTH PLANET IN, V132, P249, DOI 10.1016/S0031-9201(02)00082-1	29	211	227	2	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					545	549		10.1038/nature02412	http://dx.doi.org/10.1038/nature02412			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15057828				2022-12-28	WOS:000220540100038
J	Tsuchida, T; Koga, R; Fukatsu, T				Tsuchida, T; Koga, R; Fukatsu, T			Host plant specialization governed by facultative symbiont	SCIENCE			English	Editorial Material							PEA APHID; POPULATIONS		Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Tsuchida, T (corresponding author), Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan.							Koga R, 2003, P ROY SOC B-BIOL SCI, V270, P2543, DOI 10.1098/rspb.2003.2537; Leonardo TE, 2003, P ROY SOC B-BIOL SCI, V270, pS209, DOI 10.1098/rsbl.2003.0064; Simon JC, 2003, P ROY SOC B-BIOL SCI, V270, P1703, DOI 10.1098/rspb.2003.2430; Tsuchida T, 2002, MOL ECOL, V11, P2123, DOI 10.1046/j.1365-294X.2002.01606.x; Via S, 2001, TRENDS ECOL EVOL, V16, P381, DOI 10.1016/S0169-5347(01)02188-7	5	413	451	4	159	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	2004	303	5666					1989	1989		10.1126/science.1094611	http://dx.doi.org/10.1126/science.1094611			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044797				2022-12-28	WOS:000220429800032
J	Poggio, T; Rifkin, R; Mukherjee, S; Niyogi, P				Poggio, T; Rifkin, R; Mukherjee, S; Niyogi, P			General conditions for predictivity in learning theory	NATURE			English	Article							BOUNDS	Developing theoretical foundations for learning is a key step towards understanding intelligence. 'Learning from examples' is a paradigm in which systems ( natural or artificial) learn a functional relationship from a training set of examples. Within this paradigm, a learning algorithm is a map from the space of training sets to the hypothesis space of possible functional solutions. A central question for the theory is to determine conditions under which a learning algorithm will generalize from its finite training set to novel examples. A milestone in learning theory(1-5) was a characterization of conditions on the hypothesis space that ensure generalization for the natural class of empirical risk minimization (ERM) learning algorithms that are based on minimizing the error on the training set. Here we provide conditions for generalization in terms of a precise stability property of the learning process: when the training set is perturbed by deleting one example, the learned hypothesis does not change much. This stability property stipulates conditions on the learning map rather than on the hypothesis space, subsumes the classical theory for ERM algorithms, and is applicable to more general algorithms. The surprising connection between stability and predictivity has implications for the foundations of learning theory and for the design of novel algorithms, and provides insights into problems as diverse as language learning and inverse problems in physics and engineering.	MIT, Brain Sci Dept, McGovern Inst Comp Sci, Artificial Intelligence Lab,Ctr Biol & Computat L, Cambridge, MA 02139 USA; Univ Chicago, Dept Comp Sci, Chicago, IL 60637 USA; Univ Chicago, Dept Stat, Chicago, IL 60637 USA; MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Canc Genom Grp, Cambridge, MA 02139 USA; Honda Res Inst USA Inc, Boston, MA 02111 USA	Massachusetts Institute of Technology (MIT); University of Chicago; University of Chicago; Massachusetts Institute of Technology (MIT); Whitehead Institute; Honda Motor Company	Poggio, T (corresponding author), MIT, Brain Sci Dept, McGovern Inst Comp Sci, Artificial Intelligence Lab,Ctr Biol & Computat L, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tp@ai.mit.edu		Mukherjee, Sayan/0000-0002-6715-3920				BOTTOU L, 1992, NEURAL COMPUT, V4, P888, DOI 10.1162/neco.1992.4.6.888; Bousquet O, 2002, J MACH LEARN RES, V2, P499, DOI 10.1162/153244302760200704; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Chomsky N., 1995, LECT GOVT BINDING; DONOHO DL, 1989, ANN STAT, V17, P58, DOI 10.1214/aos/1176347004; Dudley R. M., 1991, J THEORET PROBAB, V4, P485, DOI DOI 10.1007/BF01210321; Engl H. W., 1996, MATH APPL, DOI 10.1007/978-94-009-1740-8; Evgeniou T, 2000, ADV COMPUT MATH, V13, P1, DOI 10.1023/A:1018946025316; EVGENIOU T, IN PRESS MACHINE LEA; Fix E., 1951, DISCRIMINATORY ANAL; Freund Y, 1997, J COMPUT SYST SCI, V55, P119, DOI 10.1006/jcss.1997.1504; Hastie T., 2009, SPRINGER SERIES STAT, DOI 10.1007/978-0-387-84858-7; Kearns M, 1999, NEURAL COMPUT, V11, P1427, DOI 10.1162/089976699300016304; KUTIN S, 2002, P UNCERTAINTY AI; Mukherjee S., 2003, 223 CBCL MIT; POGGIO T, 1990, COLD SPRING HARB SYM, V55, P899; Poggio Tomaso, 2003, NOTICES AM MATH SOC, V50, P537; Pouget A, 1997, J COGNITIVE NEUROSCI, V9, P222, DOI 10.1162/jocn.1997.9.2.222; STONE CJ, 1986, ANN STAT, V14, P590, DOI 10.1214/aos/1176349940; Tikhonov A. N., 1977, SOLUTIONS ILL POSED; VALIANT LG, 1984, COMMUN ACM, V27, P1134, DOI 10.1145/1968.1972; Vapnik V., 1998, STAT LEARNING THEORY, V3, DOI DOI 10.1007/978-1-4419-1428-6_5864; Vapnik V., 1991, PATTERN RECOGNIT IMA, V1, P283; Wahba G., 1990, SERIES APPL MATH, V59; Zhou DX, 2002, J COMPLEXITY, V18, P739, DOI 10.1006/jcom.2002.0635	29	167	174	0	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 25	2004	428	6981					419	422		10.1038/nature02341	http://dx.doi.org/10.1038/nature02341			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042089				2022-12-28	WOS:000220404300041
J	Kuwabara, T; Hsieh, J; Nakashima, K; Taira, K; Gage, FH				Kuwabara, T; Hsieh, J; Nakashima, K; Taira, K; Gage, FH			A small modulatory dsRNA specifies the fate of adult neural stem cells	CELL			English	Article							SODIUM-CHANNEL GENE; TRANSCRIPTION FACTOR; HISTONE DEACETYLASE; TARGET GENES; IN-VIVO; EXPRESSION; REST; RNA; REPRESSION; DIFFERENTIATION	Discovering the molecular mechanisms that regulate neuron-specific gene expression remains a central challenge for CNS research. Here, we report that small, noncoding double-stranded [ds) RNAs play a critical role in mediating neuronal differentiation. The sequence defined by this dsRNA is NRSE/RE1, which is recognized by NRSF/REST, known primarily as a negative transcriptional regulator that restricts neuronal gene expression to neurons. The NRSE dsRNA can trigger gene expression of neuron-specific genes through interaction with NRSF/REST transcriptional machinery, resulting in the transition from neural stem cells with neuron-specific genes silenced by NRSF/REST into cells with neuronal identity that can express neuronal genes. The mechanism of action appears to be mediated through a dsRNA/protein interaction, rather than through siRNA or miRNA. The discovery of small modulatory dsRNAs (smRNAs) extends the important contribution of noncoding RNAs as key regulators of cell behavior at both transcriptional and posttranscriptional levels.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Natl Inst Adv Ind Sci & Technol, Gene Funct Res Ctr, Tsukuba, Ibaraki 3058562, Japan; Kumamoto Univ, Inst Mol Embryol & Genet, Dept Cell Fate Modulat, Kumamoto 8600811, Japan	Salk Institute; National Institute of Advanced Industrial Science & Technology (AIST); Kumamoto University	Gage, FH (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gage@salk.edu	Kuwabara, Tomoko/M-1639-2018	Kuwabara, Tomoko/0000-0002-7668-0896				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Dostie J, 2003, RNA, V9, P180, DOI 10.1261/rna.2141503; ECKSTEIN F, 1996, NUCL ACIDS MOL BIOL; Eddy SR, 2001, NAT REV GENET, V2, P919, DOI 10.1038/35103511; Finerty PJ, 1999, BIOCHEMISTRY-US, V38, P4001, DOI 10.1021/bi9825293; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Kallunki P, 1998, P NATL ACAD SCI USA, V95, P3233, DOI 10.1073/pnas.95.6.3233; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Koseki S, 1999, J VIROL, V73, P1868, DOI 10.1128/JVI.73.3.1868-1877.1999; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Myers SJ, 1998, J NEUROSCI, V18, P6723; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Palm K, 1998, J NEUROSCI, V18, P1280; Pasquinelli AE, 2002, TRENDS GENET, V18, P171, DOI 10.1016/S0168-9525(01)02624-5; Pfeifer A, 2001, P NATL ACAD SCI USA, V98, P11450, DOI 10.1073/pnas.201415498; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Shimojo M, 2001, J BIOL CHEM, V276, P13121, DOI 10.1074/jbc.M011193200; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Takizawa T, 2001, DEV CELL, V1, P749, DOI 10.1016/S1534-5807(01)00101-0; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; Timmusk T, 1999, J BIOL CHEM, V274, P1078; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Warashina M, 2000, CURR OPIN BIOTECH, V11, P354, DOI 10.1016/S0958-1669(00)00110-5	37	344	390	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 19	2004	116	6					779	793		10.1016/S0092-8674(04)00248-X	http://dx.doi.org/10.1016/S0092-8674(04)00248-X			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YS	15035981	Bronze, Green Submitted			2022-12-28	WOS:000221499900005
J	Turney, CSM; Kershaw, AP; Clemens, SC; Branch, N; Moss, PT; Fifield, LK				Turney, CSM; Kershaw, AP; Clemens, SC; Branch, N; Moss, PT; Fifield, LK			Millennial and orbital variations of El Nino/Southern Oscillation and high-latitude climate in the last glacial period	NATURE			English	Article							SOUTHERN-OSCILLATION; VARIABILITY; AUSTRALIA; PATTERNS; RECORD; OCEAN; ENSO; NINO	The El Nino/Southern Oscillation (ENSO) phenomenon is believed to have operated continuously over the last glacial interglacial cycle(1). ENSO variability has been suggested to be linked to millennial-scale oscillations in North Atlantic climate during that time(2,3), but the proposals disagree on whether increased frequency of El Nino events, the warm phase of ENSO, was linked to North Atlantic warm or cold periods. Here we present a high-resolution record of surface moisture, based on the degree of peat humification and the ratio of sedges to grass, from northern Queensland, Australia, covering the past 45,000 yr. We observe millennial-scale dry periods, indicating periods of frequent El Nino events ( summer precipitation declines in El Nino years in northeastern Australia). We find that these dry periods are correlated to the Dansgaard - Oeschger events - millennial-scale warm events in the North Atlantic climate record - although no direct atmospheric connection from the North Atlantic to our site can be invoked. Additionally, we find climatic cycles at a semiprecessional timescale (, 11,900 yr). We suggest that climate variations in the tropical Pacific Ocean on millennial as well as orbital timescales, which determined precipitation in northeastern Australia, also exerted an influence on North Atlantic climate through atmospheric and oceanic teleconnections.	Queens Univ Belfast, Sch Archaeol & Paleoecol, Belfast BT7 1NN, Antrim, North Ireland; Monash Univ, Sch Geog & Environm Sci, Clayton, Vic 3800, Australia; Brown Univ, Providence, RI 02912 USA; Univ London Royal Holloway & Bedford New Coll, Dept Geog, Egham TW20 0EX, Surrey, England; Univ Wisconsin, Dept Geog, Madison, WI 53706 USA; Australian Natl Univ, Res Sch Phys Sci & Engn, Dept Nucl Phys, Canberra, ACT 0200, Australia	Queens University Belfast; Monash University; Brown University; University of London; Royal Holloway University London; University of Wisconsin System; University of Wisconsin Madison; Australian National University	Turney, CSM (corresponding author), Univ Wollongong, Sch Earth & Environm Sci, Wollongong, NSW 2522, Australia.	cturney@uow.edu.au	Turney, Chris S M/P-8701-2018; Moss, Patrick/AFM-9408-2022	Turney, Chris S M/0000-0001-6733-0993; Fifield, Leslie/0000-0003-2866-4944; Moss, Patrick/0000-0003-1546-9242; Kershaw, Peter/0000-0002-9478-0567				Blackford JJ., 1993, INT PEAT J, V8, P7; BOND G, 1993, NATURE, V365, P143, DOI 10.1038/365143a0; Broecker WS, 2003, SCIENCE, V300, P1519, DOI 10.1126/science.1083797; Clement AC, 2001, J CLIMATE, V14, P2369, DOI 10.1175/1520-0442(2001)014<2369:AODTSF>2.0.CO;2; Dai A, 2000, GEOPHYS RES LETT, V27, P1283, DOI 10.1029/1999GL011140; Gagan MK, 2000, QUATERNARY SCI REV, V19, P45, DOI 10.1016/S0277-3791(99)00054-2; Godfred-Spenning CR, 2002, INT J CLIMATOL, V22, P509, DOI 10.1002/joc.710; GROUSSET FE, 1993, PALEOCEANOGRAPHY, V8, P175, DOI 10.1029/92PA02923; Hendy IL, 2003, QUATERNARY SCI REV, V22, P673, DOI 10.1016/S0277-3791(02)00186-5; Hoerling M, 2003, SCIENCE, V299, P691, DOI 10.1126/science.1079053; Jenkins G., 1968, SPECTRAL ANAL ITS AP; Johnson BJ, 1999, SCIENCE, V284, P1150, DOI 10.1126/science.284.5417.1150; KERSHAW AP, 1978, NATURE, V272, P159, DOI 10.1038/272159a0; Kukla GJ, 2002, QUATERNARY RES, V58, P27, DOI 10.1006/qres.2002.2327; Laj C, 2002, EARTH PLANET SC LETT, V200, P177, DOI 10.1016/S0012-821X(02)00618-0; MACAYEAL DR, 1993, EOS, V74, P359; MCGLONE MS, 1992, EL NINO HIST PALEOCL, P435; Moy CM, 2002, NATURE, V420, P162, DOI 10.1038/nature01194; NANSON GC, 1992, GEOLOGY, V20, P791, DOI 10.1130/0091-7613(1992)020<0791:WADOAO>2.3.CO;2; Rind D, 1998, J GEOPHYS RES-ATMOS, V103, P5943, DOI 10.1029/97JD03649; ROGNON P, 1977, PALAEOGEOGR PALAEOCL, V21, P285, DOI 10.1016/0031-0182(77)90040-2; SCHULZ M, 2002, GEOPHYS RES LETT, V29; Spero HJ, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000814; Stott L, 2002, SCIENCE, V297, P222, DOI 10.1126/science.1071627; Stuiver M, 2000, QUATERNARY RES, V53, P277, DOI 10.1006/qres.2000.2127; Tudhope AW, 2001, SCIENCE, V291, P1511, DOI 10.1126/science.1057969; Turney CSM, 2001, J QUATERNARY SCI, V16, P767, DOI 10.1002/jqs.643; Voelker AHL, 2000, RADIOCARBON, V42, P437, DOI 10.1017/S0033822200030368; Wang H, 2000, GEOLOGY, V28, P771, DOI 10.1130/0091-7613(2000)28<771:IEOPNO>2.0.CO;2; Wang YJ, 2001, SCIENCE, V294, P2345, DOI 10.1126/science.1064618	30	164	170	2	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	2004	428	6980					306	310		10.1038/nature02386	http://dx.doi.org/10.1038/nature02386			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15029193				2022-12-28	WOS:000220250200040
J	Wendel, HG; de Stanchina, E; Fridman, JS; Malina, A; Ray, S; Kogan, S; Cordon-Cardo, C; Pelletier, J; Lowe, SW				Wendel, HG; de Stanchina, E; Fridman, JS; Malina, A; Ray, S; Kogan, S; Cordon-Cardo, C; Pelletier, J; Lowe, SW			Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy	NATURE			English	Article							TRANSLATIONAL CONTROL; MTOR; PTEN; P53; PROTEIN; CHEMORESISTANCE; INHIBITION; APOPTOSIS; RAPAMYCIN; TUMORS	Evading apoptosis is considered to be a hallmark of cancer, because mutations in apoptotic regulators invariably accompany tumorigenesis(1). Many chemotherapeutic agents induce apoptosis, and so disruption of apoptosis during tumour evolution can promote drug resistance(2). For example, Akt is an apoptotic regulator that is activated in many cancers and may promote drug resistance in vitro(3). Nevertheless, how Akt disables apoptosis and its contribution to clinical drug resistance are unclear. Using a murine lymphoma model, we show that Akt promotes tumorigenesis and drug resistance by disrupting apoptosis, and that disruption of Akt signalling using the mTOR inhibitor rapamycin reverses chemoresistance in lymphomas expressing Akt, but not in those with other apoptotic defects. eIF4E, a translational regulator that acts downstream of Akt and mTOR, recapitulates Akt's action in tumorigenesis and drug resistance, but is unable to confer sensitivity to rapamycin and chemotherapy. These results establish Akt signalling through mTOR and eIF4E as an important mechanism of oncogenesis and drug resistance in vivo, and reveal how targeting apoptotic programmes can restore drug sensitivity in a genotype-dependent manner.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; McGill Univ, Montreal, PQ H3G 1Y6, Canada; Univ Calif San Francisco, San Francisco, CA 94143 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Cold Spring Harbor Laboratory; McGill University; University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center	Lowe, SW (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	lowe@cshl.edu	Clovis, Jeff/C-1020-2009	Malina, Abba/0000-0002-8511-9005; Kogan, Scott/0000-0002-2395-8479	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Grunwald V, 2002, CANCER RES, V62, P6141; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P637; Hosoi H, 1999, CANCER RES, V59, P886; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Min YH, 2003, LEUKEMIA, V17, P995, DOI 10.1038/sj.leu.2402874; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yang M, 2000, P NATL ACAD SCI USA, V97, P1206, DOI 10.1073/pnas.97.3.1206	30	814	848	0	80	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	2004	428	6980					332	337		10.1038/nature02369	http://dx.doi.org/10.1038/nature02369			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15029198				2022-12-28	WOS:000220250200047
J	Langhorne, P; Dennis, MS				Langhorne, P; Dennis, MS			Stroke units: the next 10 years	LANCET			English	Editorial Material							CARE; EXPERIENCE; SERVICES		Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland; Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh	Langhorne, P (corresponding author), Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland.	P.Langhorne@clinmed.gla.ac.uk						Asplund K, 2003, CEREBROVASC DIS, V15, P5, DOI 10.1159/000068203; Bereczki W, 2003, CEREBROVASC DIS, V15, P23, DOI 10.1159/000068208; Brainin M, 2003, CEREBROVASC DIS, V15, P29, DOI 10.1159/000068211; Busse O, 2003, CEREBROVASC DIS, V15, P8, DOI 10.1159/000068212; Czlonkowska A, 2003, CEREBROVASC DIS, V15, P14, DOI 10.1159/000068209; Hommel M, 2003, CEREBROVASC DIS, V15, P11, DOI 10.1159/000068206; Indredavik B, 2003, CEREBROVASC DIS, V15, P19, DOI 10.1159/000068213; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; Langhorne P, 2002, AGE AGEING, V31, P365, DOI 10.1093/ageing/31.5.365; Melo TP, 2003, CEREBROVASC DIS, V15, P21, DOI 10.1159/000068205; Sterzi R, 2003, CEREBROVASC DIS, V15, P16, DOI 10.1159/000068210; *STROK UN TRIAL CO, 2003, COCHR LIB; Sulter G, 2003, STROKE, V34, P101, DOI 10.1161/01.STR.0000048148.09143.6C; 2003, HLTH WHICH       AUG, P16	14	39	42	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	2004	363	9412					834	835		10.1016/S0140-6736(04)15771-1	http://dx.doi.org/10.1016/S0140-6736(04)15771-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15031023				2022-12-28	WOS:000220231500004
J	Keiser, J; Utzinger, J; Tanner, M; Singer, BH				Keiser, J; Utzinger, J; Tanner, M; Singer, BH			Representation of authors and editors from countries with different human development indexes in the leading literature on tropical medicine: Survey of current evidence	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To assess the current international representation of members of editorial and advisory boards and authors in the leading peer reviewed literature on tropical medicine. Design Systematic review. Main outcome measures Country affiliations, as classified by the human development index, of editorial and advisory board members of all tropical medicine journals referenced by the Institute of Scientific Information (ISI) as of late 2003 and of all contributing authors of full articles published in the six leading journals on tropical medicine in 2000-2. Results Sixteen (5.1%) of the 315 editorial and advisory board members from the 12 ISI referenced journals on tropical medicine are affiliated to countries with a low human development index and 223 (70.8%) to countries with a high index. Examination of the 2384 full articles published in 2000-2 in the six highest ranking tropical medicine journals showed that 48.1% of contributing authors are affiliated to countries with a high human development index, whereas the percentage of authors from countries with a low index was 13.7% Articles written exclusively by authors from low ranked countries accounted for 5.0%. Our data indicate that research collaborations between a country with a high human development index and one that has either a medium or a low index are common and account for 26.5% and 16.1% of all full articles, respectively. Conclusion Current collaborations should be transformed into research partnerships, with the goals of mutual learning and institutional capacity strengthening in the developing world.	Princeton Univ, Off Populat Res, Princeton, NJ 08544 USA; Swiss Trop Inst, CH-4002 Basel, Switzerland	Princeton University; University of Basel; Swiss Tropical & Public Health Institute	Keiser, J (corresponding author), Princeton Univ, Off Populat Res, Princeton, NJ 08544 USA.	jennifer.keiser@unibas.ch						Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Harris E, 2000, BRIT MED J, V321, P817, DOI 10.1136/bmj.321.7264.817; Horton R, 2003, LANCET, V361, P712, DOI 10.1016/S0140-6736(03)12665-7; Mendis S, 2003, LANCET, V361, P2246, DOI 10.1016/S0140-6736(03)13753-1; Patel V, 2001, BRIT J PSYCHIAT, V178, P406, DOI 10.1192/bjp.178.5.406; Saxena S, 2003, LANCET, V361, P609, DOI 10.1016/S0140-6736(03)12528-7; Sitthi-amorn C, 2000, BRIT MED J, V321, P813, DOI 10.1136/bmj.321.7264.813; Smith R, 2002, STAT MED, V21, P2869, DOI 10.1002/sim.1291; YACH D, 1992, INT J EPIDEMIOL, V21, P557, DOI 10.1093/ije/21.3.557	9	77	78	2	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	2004	328	7450					1229	1232		10.1136/bmj.38069.518137.F6	http://dx.doi.org/10.1136/bmj.38069.518137.F6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824HL	15059851	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000221677200018
J	Gea-Banacloche, J; Johnson, RT; Bagic, A; Butman, JA; Murray, PR; Agrawal, AG				Gea-Banacloche, J; Johnson, RT; Bagic, A; Butman, JA; Murray, PR; Agrawal, AG			West Nile Virus: Pathogenesis and therapeutic options	ANNALS OF INTERNAL MEDICINE			English	Article							ST-LOUIS ENCEPHALITIS; NEW-YORK-CITY; JAPANESE ENCEPHALITIS; RAPID DETECTION; INFECTION; IMMUNOGLOBULIN; ANTIBODY; FEVER; MIDAZOLAM; EPIDEMIC	West Nile virus, a member of the family Flaviviridae, has spread throughout the United States. With more than 9000 cases and 200 deaths in 2003, West Nile virus has become the most common cause of viral encephalitis in several states. West Nile virus encephalitis is a zoonosis. The life cycle of the virus includes mainly birds as hosts and mosquitoes as vectors. Humans are accidental hosts, insufficient to support the life cycle of the virus because of low-grade, transient viremia. However, human-to-human transmission through blood, organ transplantation, and lactation has been documented. The frequency of severe neurologic disease in the current epidemic suggests a more neurovirulent strain of virus than the one classically associated with West Nile fever. Several neurologic manifestations have been described, but the most characteristic presentation is encephalitis with weakness. Magnetic resonance imaging scans may be normal initially, but a characteristic pattern of involvement of deep gray matter nuclei can be recognized. Although results of polymerase chain reaction may be positive in the cerebrospinal fluid early in the course of the disease, diagnosis is based on serologic tests. Possible cross-reactivity with other members of the genus flavivirus mandates caution when serologic testing results are interpreted. Thus far, no therapeutic intervention has shown consistent clinical efficacy in West Nile virus disease. Several approaches, including interferon-alpha2b and immunoglobulin with high titer against West Nile virus, offer promise based on animal models and limited clinical experience. New drugs with in vitro activity are being investigated, and a vaccine is being developed.	NCI, Expt Transplantat & Immunol Branch, Bethesda, MD 20892 USA; Natl Inst Neurol Disorders & Stroke, NCI, NIH, Bethesda, MD USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute of Neurological Disorders & Stroke (NINDS); Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Gea-Banacloche, J (corresponding author), NCI, Expt Transplantat & Immunol Branch, 10 Ctr Dr,Room 12S227, Bethesda, MD 20892 USA.	banacloj@mail.nih.gov	Bagic, Anto I/Q-1406-2015; Butman, John/J-2780-2013; Butman, John A/A-2694-2008	Bagic, Anto I/0000-0002-6284-8336; Butman, John/0000-0002-1547-9195; 				Anderson JF, 2002, EMERG INFECT DIS, V8, P107, DOI 10.3201/eid0801.010252; Bassin S, 2002, CRIT CARE, V6, P137, DOI 10.1186/cc1472; Ben-Nathan D, 2003, J INFECT DIS, V188, P5, DOI 10.1086/376870; Briese T, 2000, LANCET, V355, P1614, DOI 10.1016/S0140-6736(00)02220-0; Brooks TJG, 1999, ANTIVIR RES, V41, P57, DOI 10.1016/S0166-3542(98)00063-1; CAMENGA DL, 1974, J INFECT DIS, V130, P634, DOI 10.1093/infdis/130.6.634; Campbell GL, 2002, LANCET INFECT DIS, V2, P519, DOI 10.1016/S1473-3099(02)00368-7; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P877; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P845; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P825; Cerna F, 1999, AM J NEURORADIOL, V20, P1281; Chowers MY, 2001, EMERG INFECT DIS, V7, P675; Claassen J, 2002, EPILEPSIA, V43, P146, DOI 10.1046/j.1528-1157.2002.28501.x; DEMAEREL P, 1992, NEURORADIOLOGY, V34, P490, DOI 10.1007/BF00598957; Diamond MS, 2003, J VIROL, V77, P2578, DOI 10.1128/JVI.77.4.2578-2586.2003; DWYER JM, 1988, PEDIATR INFECT DIS J, V7, pS30; Engle MJ, 2003, J VIROL, V77, P12941, DOI 10.1128/JVI.77.24.12941-12949.2003; ERLENDSSON K, 1985, NEW ENGL J MED, V312, P351, DOI 10.1056/NEJM198502073120605; FAGAN KJ, 1990, NEUROLOGY, V40, P1689, DOI 10.1212/WNL.40.11.1689; GEORGES AJ, 1987, ANN INST PASTEUR VIR, V138, P237, DOI 10.1016/S0769-2617(87)80007-2; Hamdan A, 2002, Transpl Infect Dis, V4, P160, DOI 10.1034/j.1399-3062.2002.01014.x; Hanley DF, 1998, CLIN THER, V20, P1093, DOI 10.1016/S0149-2918(98)80106-9; Hayes CG, 2001, ANN NY ACAD SCI, V951, P25; Huang CC, 1999, NEW ENGL J MED, V341, P936, DOI 10.1056/NEJM199909233411302; Hubalek Z, 1999, EMERG INFECT DIS, V5, P643, DOI 10.3201/eid0505.990505; Hunt AR, 2002, J CLIN MICROBIOL, V40, P2023, DOI 10.1128/JCM.40.6.2023-2030.2002; IKEDA A, 2002, CURRENT PRACTICE CLI, P348; Iwamoto M, 2003, NEW ENGL J MED, V348, P2196, DOI 10.1056/NEJMoa022987; Johnson R.T., 1998, VIRAL INFECT NERVOUS; JOHNSON RT, 1985, ANN NEUROL, V18, P567, DOI 10.1002/ana.410180510; Jordan I, 2000, J INFECT DIS, V182, P1214, DOI 10.1086/315847; Komar N, 2003, EMERG INFECT DIS, V9, P311, DOI 10.3201/eid0903.020628; KONDOH H, 1987, EUR J PEDIATR, V146, P610, DOI 10.1007/BF02467368; Koraka P, 2002, MICROBES INFECT, V4, P1209, DOI 10.1016/S1286-4579(02)01647-7; Kumar S, 1997, NEURORADIOLOGY, V39, P180, DOI 10.1007/s002340050388; Lanciotti RS, 2001, J CLIN MICROBIOL, V39, P4506, DOI 10.1128/JCM.39.12.4506-4513.2001; Lanciotti RS, 2000, J CLIN MICROBIOL, V38, P4066, DOI 10.1128/JCM.38.11.4066-4071.2000; LINCOLN AF, 1952, JAMA-J AM MED ASSOC, V150, P268, DOI 10.1001/jama.1952.03680040010003; MAIZTEGUI JI, 1979, LANCET, V2, P1216; MARBERG K, 1956, AM J HYG, V64, P259, DOI 10.1093/oxfordjournals.aje.a119838; Martin DA, 2002, CLIN DIAGN LAB IMMUN, V9, P544, DOI 10.1128/CDLI.9.3.544-549.2002; MELNICK JL, 1951, P SOC EXP BIOL MED, V77, P661, DOI 10.3181/00379727-77-18884; Monath Thomas P., 2002, P1097; Monath Thomas P., 2001, Current Drug Targets - Infectious Disorders, V1, P37, DOI 10.2174/1568005013343254; Morrey JD, 2002, ANTIVIR RES, V55, P107, DOI 10.1016/S0166-3542(02)00013-X; Mostashari F, 2001, LANCET, V358, P261, DOI 10.1016/S0140-6736(01)05480-0; Naidech A, 1999, CLIN INFECT DIS, V29, P1334, DOI 10.1086/313482; Nash D, 2001, NEW ENGL J MED, V344, P1807, DOI 10.1056/NEJM200106143442401; Pealer LN, 2003, NEW ENGL J MED, V349, P1236, DOI 10.1056/NEJMoa030969; Petersen LR, 2002, ANN INTERN MED, V137, P173, DOI 10.7326/0003-4819-137-3-200208060-00009; Platonov AE, 2001, EMERG INFECT DIS, V7, P128, DOI 10.3201/eid0701.010118; Prasad A, 2001, EPILEPSIA, V42, P380, DOI 10.1046/j.1528-1157.2001.27500.x; PRUZANSKI W., 1962, WORLD NEUROL, V3, P524; Roehrig JT, 2003, EMERG INFECT DIS, V9, P376, DOI 10.3201/eid0903.020531; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Schellinger PD, 2000, NEUROLOGY, V55, P299, DOI 10.1212/WNL.55.2.299; SHARP JCM, 1973, LANCET, V1, P656; Shi PY, 2001, J CLIN MICROBIOL, V39, P1264, DOI 10.1128/JCM.39.4.1264-1271.2001; Shimoni Z, 2001, EMERG INFECT DIS, V7, P759; SMITHBURN K. C, 1940, AMER JOUR TROP MED, V20, P471; Solomon T, 1998, LANCET, V351, P1094, DOI 10.1016/S0140-6736(97)07509-0; Solomon T, 2003, LANCET, V361, P821, DOI 10.1016/S0140-6736(03)12709-2; SOUTHAM CM, 1954, AM J TROP MED HYG, V3, P19, DOI 10.4269/ajtmh.1954.3.19; Tardei G, 2000, J CLIN MICROBIOL, V38, P2232; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Tsai TF, 1998, LANCET, V352, P767, DOI 10.1016/S0140-6736(98)03538-7; Tyler KL, 2001, NEW ENGL J MED, V344, P1858, DOI 10.1056/NEJM200106143442409; WIJDICKS E, 2000, NEUROLOGIC CATASTROP; WORK TH, 1955, AM J TROP MED HYG, V4, P872, DOI 10.4269/ajtmh.1955.4.872; ZIMMERMAN HM, 1946, AM J PATHOL, V22, P965	70	75	80	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 6	2004	140	7					545	553		10.7326/0003-4819-140-7-200404060-00015	http://dx.doi.org/10.7326/0003-4819-140-7-200404060-00015			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808OE	15068983				2022-12-28	WOS:000220577600007
J	Turner, BJ; Weiner, M; Yang, CY; TenHave, T				Turner, BJ; Weiner, M; Yang, CY; TenHave, T			Predicting adherence to colonoscopy or flexible sigmoidoscopy on the basis of physician appointment-keeping behavior	ANNALS OF INTERNAL MEDICINE			English	Article							INCOME MINORITY WOMEN; CANCER; RISK; FAILURE; ABILITY	Background: Poor patient attendance to scheduled flexible sigmoidoscopy or colonoscopy may contribute to deficient colorectal cancer screening. Objective: To examine the association of physician appoint ment-keeping behavior with attendance to scheduled endoscopic studies of the colon. Design: Retrospective cohort. Setting: 23 sites performing endoscopic procedures in a health care system. Patients: 11 803 patients scheduled for a first colon study with 3 or more scheduled physician visits from June 1999 through November 2001. Measurement: 2 outcomes from health system computerized records: 1) attendance at the first scheduled colon study and 2) among nonattendees, attendance at the study rescheduled within 6 months. Physician visit adherence was defined as the proportion of physician visits kept, grouped by quartile. Adjusted associations were examined in conditional logistic regression. Results: 11803 patients, 62% attended the first d=colon study. Of the 4496 nonattendees, 2739 (61%) rescheduled and, of these, 64% kept that appointment. Compared with the highest quartile of physician visit adherence (> 85%), the adjusted odds ratio of attending the first colon study decreased as physician visit adherence decreased: Adjusted odds ratios were 0.94 (95% Cl, 0.89 to 1.00) for 76% to 85% adherence, 0.87 (Cl, 0.81 to 0.92) for 66% to 75% adherence, and 0.79 (Cl, 0.73 to 0.85) for adherence of 65% or less. Among nonattendees who rescheduled, the lowest quartile of physician visit adherence (less than or equal to 65%) was the only statistically significant predictor of attending the rescheduled study (adjusted odds ratio, 0.87 [Cl, 0.78 to 0.98]). Limitations: The adherence measure applies only to patients with at least 3 scheduled visits. Persons having a colon study outside of the system could have been misclassified. Conclusion: Physician appointment- keeping behavior predicted attendance to colorectal endoscopic studies in this cohort and may help identify persons who need interventions to promote adherence.										Bastani R, 2001, J PSYCHOSOC ONCOL, V19, P65, DOI 10.1300/J077v19n03_06; Blackman D, 2003, MMWR-MORBID MORTAL W, V52, P193; Breen N, 2001, J NATL CANCER I, V93, P1704, DOI 10.1093/jnci/93.22.1704; Cardin VA, 2001, PUBLIC HEALTH REP, V116, P608, DOI 10.1093/phr/116.6.608; Feierabend RH, 1996, J FAM PRACTICE, V42, P482; Frew E, 2001, J Health Serv Res Policy, V6, P85, DOI 10.1258/1355819011927279; Harewood GC, 2002, AM J GASTROENTEROL, V97, P3186, DOI 10.1111/j.1572-0241.2002.07129.x; Heflin MT, 2002, J AM GERIATR SOC, V50, P1651, DOI 10.1046/j.1532-5415.2002.50456.x; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; MARGOLIS KL, 1993, J GEN INTERN MED, V8, P602, DOI 10.1007/BF02599713; McCaffery K, 2001, SOC SCI MED, V53, P679, DOI 10.1016/S0277-9536(00)00375-0; McMahon LF, 1999, MED CARE, V37, P712, DOI 10.1097/00005650-199907000-00011; Miller SM, 1997, JNCI-J NATL CANCER I, V89, P703, DOI 10.1093/jnci/89.10.703; MUSHLIN AI, 1977, ARCH INTERN MED, V137, P318, DOI 10.1001/archinte.137.3.318; Neal RD, 2001, BRIT J GEN PRACT, V51, P830; Richards RJ, 2002, DIGEST DIS SCI, V47, P2715, DOI 10.1023/A:1021001121026; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Slattery ML, 2000, CANCER CAUSE CONTROL, V11, P555, DOI 10.1023/A:1008924115604; Strzelczyk Jadwiga Jodi, 2002, Ethnicity and Disease, V12, P77; Weitzman ER, 2001, PREV MED, V32, P502, DOI 10.1006/pmed.2001.0838; Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044; 2001, CAN MED ASS J, V165, P206	22	43	44	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 6	2004	140	7					528	532		10.7326/0003-4819-140-7-200404060-00013	http://dx.doi.org/10.7326/0003-4819-140-7-200404060-00013			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808OE	15068980				2022-12-28	WOS:000220577600004
J	Everall, I; Grant, I				Everall, I; Grant, I			Proteomic pointers in HIV neurocognitive disorder	LANCET			English	Editorial Material									Kings Coll London, Inst Psychiat, Sect Expt Neuropathol & Psychiat, London SE5 8AF, England; Univ Calif San Diego, HIV Neurobehav Res Ctr, La Jolla, CA 92093 USA	University of London; King's College London; University of California System; University of California San Diego	Everall, I (corresponding author), Kings Coll London, Inst Psychiat, Sect Expt Neuropathol & Psychiat, London SE5 8AF, England.	i.everall@iop.kcl.ac.uk		Everall, Ian/0000-0003-3957-3861				Cherner M, 2002, NEUROLOGY, V59, P1563, DOI 10.1212/01.WNL.0000034175.11956.79; Everall IP, 1999, BRAIN PATHOL, V9, P209; GRANT I, 2002, ENCY HUMAN BRAIN, V2, P475; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Liu ZJ, 2000, J MOL MODEL, V6, P1, DOI 10.1007/PL00010720; Luo X, 2003, NEUROLOGY, V60, P1931, DOI 10.1212/01.WNL.0000064396.54554.26; Masliah E, 1997, ANN NEUROL, V42, P963, DOI 10.1002/ana.410420618	7	3	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	2004	363	9415					1091	1092		10.1016/S0140-6736(04)15932-1	http://dx.doi.org/10.1016/S0140-6736(04)15932-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808VB	15064024				2022-12-28	WOS:000220595500005
J	Gertsch, JH; Basnyat, B; Johnson, EW; Onopa, J; Holck, PS				Gertsch, JH; Basnyat, B; Johnson, EW; Onopa, J; Holck, PS		Prevention High Altitude Illness T	Randomised, controlled trial of ginkgo biloba and acetazolamide for prevention of acute mountain sickness: the prevention of high altitude illness trial (PHAIT)	BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND; PROPHYLAXIS; EFFICACY	Objective To evaluate the efficacy of ginkgo biloba, acetazolamide, and their combination as prophylaxis against acute mountain sickness. Design Prospective, double blind, randomised, placebo controlled trial. Setting Approach to Mount Everest base camp in the Nepal Himalayas. at 4280 m or 4358 m and study end point at 4928 m during October and November 2002.. Participants 614 healthy western trekkers (487 completed the trial) assigned to receive ginkgo, acetazolamide, combined acetazolamide and ginkgo, or placebo, initially taking at least three or four doses before continued ascent. Main outcome measures Incidence measured by Lake Louise acute mountain sickness score greater than or equal to 3 with. headache and one other symptom. Secondary outcome measures included blood oxygen content, severity of syndrome (Lake Louise scores greater than or equal to 5), incidence of headache, and severity of headache. Results Ginkgo was not significantly different from placebo for any outcome; however participants in the acetazolamide group showed significant levels of protection. The incidence of acute mountain sickness was 34% for placebo, 12% for acetazolamide (odds ratio 3.76,95% confidence interval 1.91 to 7.39, number needed to treat 4),35% for ginkgo (0.95, 0.56 to 1.62), and 14% for combined ginkgo and acetazolamide (3.04, 1.62 to 5.69). The proportion of patients with increased severity of acute mountain sickness was 18% for placebo, 3% for acetazolamide (6.46, 2.15 to 19.40, number needed to treat 7), 18% for ginkgo (1, 0.52 to 1.90), and 7% for combined ginkgo and acetazolamide (2.95, 1.30 to 6.70). Conclusions When compared with placebo, ginkgo is not effective at preventing acute mountain sickness. Acetazolamide 250 mg twice daily afforded robust protection against symptoms of acute mountain sickness.	Maricopa Cty Gen Hosp, Dept Internal Med, Phoenix, AZ 85008 USA; Himalayan Rescue Associat, Kathmandu, Nepal; Univ Washington, Sch Med, Seattle, WA 98195 USA; Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA	Maricopa County General Hospital; University of Washington; University of Washington Seattle; University of Hawaii System	Gertsch, JH (corresponding author), Maricopa Cty Gen Hosp, Dept Internal Med, 2601 E Roosevelt Ave Number O-D-10, Phoenix, AZ 85008 USA.	jeffgertsch@hotmail.com						Bailey DM, 2001, HIGH ALT MED BIOL, V2, P21, DOI 10.1089/152702901750067882; BARTSCH P, 1993, HYPOXIA AND MOLECULAR MEDICINE, P265; Basnyat B, 2003, HIGH ALT MED BIOL, V4, P45, DOI 10.1089/152702903321488979; BASNYAT B, 2001, CONNS CURRENT THERAP, P1166; Chen X, 1997, CLIN EXP PHARMACOL P, V24, P958, DOI 10.1111/j.1440-1681.1997.tb02727.x; Chow T. K., 2002, Medicine and Science in Sports and Exercise, V34, pS246, DOI 10.1097/00005768-200205001-01377; Dumont L, 2000, BRIT MED J, V321, P267, DOI 10.1136/bmj.321.7256.267; GERTSCH JH, 2002, HIGH ALT MED BIOL, V2, P110; HACKETT PH, 1976, LANCET, V2, P1149; Hackett PH, 2001, NEW ENGL J MED, V345, P107, DOI 10.1056/NEJM200107123450206; Leadbetter G, 2001, HIGH ALT MED BIOL, V2, P110; LEADBETTER GW, 2003, HIGH ALT MED BIOL, V3, P455; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Maggiorini M, 1998, AVIAT SPACE ENVIR MD, V69, P1186; MORAGA F, 2003, HIGH ALT MED BIOL, V3, P453; MURDOCH DR, 1995, AVIAT SPACE ENVIR MD, V66, P148; ROACH RC, 1993, HYPOXIA AND MOLECULAR MEDICINE, P272; Roncin JP, 1996, AVIAT SPACE ENVIR MD, V67, P445	18	88	91	1	18	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 3	2004	328	7443					797	799		10.1136/bmj.38043.501690.7C	http://dx.doi.org/10.1136/bmj.38043.501690.7C			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	811CG	15070635	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000220749400018
J	Turnbull, DA; Wilkinson, C; Gerard, K; Shanahan, M; Ryan, P; Griffith, EC; Kruzins, G; Stamp, GE				Turnbull, DA; Wilkinson, C; Gerard, K; Shanahan, M; Ryan, P; Griffith, EC; Kruzins, G; Stamp, GE			Clinical, psychosocial, and economic effects of antenatal day care for three medical complications of pregnancy: a randomised controlled trial of 395 women	LANCET			English	Article							HYPERTENSION; MANAGEMENT; HOSPITALIZATIONS; SAMPLE; SIZE	Background Day care is increasingly being used for complications of pregnancy, but there is little published evidence on its efficacy. We assessed the clinical, psychosocial, and economic effects of day care for three pregnancy complications in a randomised trial of day care versus standard care on an antenatal ward. Methods 395 women were randomly assigned day (263) or ward (132) care in a ratio of two to one, stratified for major diagnostic categories (non-proteinuric hypertension, proteinuric hypertension, and preterm premature rupture of membranes). The research hypothesis was that for these disorders, as an alternative to admission, antenatal day care will reduce specified interventions and investigations, result in no differences in clinical outcome, lead to greater satisfaction and psychological wellbeing, and be more cost-effective. Data were collected through case-note review, self-report questionnaires (response rates 81.0% or higher) and via the hospital's financial system. Analysis was by intention to treat. Findings All participants were included in the analyses. There were no differences between the groups in antenatal tests or investigations or intrapartum interventions. The total duration of antenatal care episodes was shorter in the day-care group than in the ward group (median 17 [IQR 5-9] vs 57 [35-123] h; p = 0.001). Overall stay was also significantly shorter in the day-care group (mean 7.22 [SE 0.31] vs 8.53 [0.44]; p = 0.014). The median number of care episodes was three (range one to 14) in the day-care group and two (one to nine) in the ward group (p = 0.01). There were no statistically or clinically significant differences in maternal or perinatal outcomes. The day-care group reported greater satisfaction, with no evidence of unintended psychosocial sequelae. There was no significant difference in either average cost per patient or average cost per day of care. Interpretation Since clinical outcomes and costs are similar, adoption by maternity services of a policy providing specified women with the choice between admission and day-unit care seems appropriate.	Womens & Childrens Hosp, Dept Gen Practice, Adelaide, SA, Australia; Womens & Childrens Hosp, Dept Psychol, Adelaide, SA, Australia; Womens & Childrens Hosp, Dept Publ Hlth, Adelaide, SA, Australia; Womens & Childrens Hosp, Dept Obstet, Adelaide, SA, Australia; Univ Southampton, Southampton Gen Hosp, Hlth Care Res Unit, Southampton, Hants, England; Univ Technol Sydney, Ctr Hlth Econ Res & Evaluat, Sydney, NSW 2007, Australia; Univ Technol Sydney, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2007, Australia; Univ S Australia, Ctr Res Nursing & Hlth Care, Adelaide, SA 5001, Australia	Womens & Childrens Hospital Australia; Womens & Childrens Hospital Australia; Womens & Childrens Hospital Australia; Womens & Childrens Hospital Australia; University of Southampton; University of Technology Sydney; University of Technology Sydney; University of South Australia	Turnbull, DA (corresponding author), Univ Adelaide, Dept Gen Practice, North Terrace, Adelaide, SA 5005, Australia.	deborah.turnbull@adelaide.edu.au	Wilkinson, Chris/I-7649-2015	Wilkinson, Chris/0000-0003-1438-0422; Shanahan, Marian/0000-0001-9873-3576				Adelson PL, 1999, MED J AUSTRALIA, V170, P211, DOI 10.5694/j.1326-5377.1999.tb140319.x; BOYCE P, 1993, AUST NZ J PSYCHIAT, V27, P472, DOI 10.3109/00048679309075805; Briggs A, 2000, BRIT MED J, V321, P1362, DOI 10.1136/bmj.321.7273.1362; BROWN MA, 1993, MED J AUSTRALIA, V158, P700; Brown MA, 2000, AUST NZ J OBSTET GYN, V40, P139, DOI 10.1111/j.1479-828X.2000.tb01137.x; *COMM DEP HLTH AG, 2001, ARDRG40 COMM DEP HLT; FRANKS AL, 1992, AM J OBSTET GYNECOL, V166, P1339, DOI 10.1016/0002-9378(92)91601-6; KRONER C, 2001, COCHRANE LIB; Murray D, 1990, J REPROD INFANT PSYC, V8, P99, DOI DOI 10.1080/02646839008403615; *NSW HLTH FUND SYS, 200102 NSW HLTH FUND; *ROYAL COLL OBST G, 1996, R COLL OBSTET GYNAEC, V10, P1; RUSSELL IT, 1977, LANCET, V1, P844; *S AUSTR GOV, WORKPL SERV ERIC EMP; Scott CL, 1997, OBSTET GYNECOL, V90, P225, DOI 10.1016/S0029-7844(97)00230-5; Snowdon C, 1999, CONTROL CLIN TRIALS, V20, P149, DOI 10.1016/S0197-2456(98)00049-X; Torgerson DJ, 2000, BRIT MED J, V321, P697, DOI 10.1136/bmj.321.7262.697; Torrance GW, 1987, METHODS EC EVALUATIO; TUFFNELL DJ, 1992, LANCET, V339, P224, DOI 10.1016/0140-6736(92)90017-W; Turnbull D, 1996, LANCET, V348, P213; TWADDLE S, 1992, BRIT J OBSTET GYNAEC, V99, P459, DOI 10.1111/j.1471-0528.1992.tb13781.x; WALKER JJ, 1993, BRIT J HOSP MED, V50, P225; *WOM CHILDR HOSP, 1996, CLIN INF SERV OBST D; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203	23	30	31	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	2004	363	9415					1104	1109		10.1016/S0140-6736(04)15893-5	http://dx.doi.org/10.1016/S0140-6736(04)15893-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	808VB	15064028				2022-12-28	WOS:000220595500009
J	Bergeron, DE; Castleman, AW; Morisato, T; Khanna, SN				Bergeron, DE; Castleman, AW; Morisato, T; Khanna, SN			Formation of Al13I-: Evidence for the superhalogen character of Al-13	SCIENCE			English	Article							ALUMINUM CLUSTER ANIONS; ELECTRONIC-STRUCTURE; BUILDING-BLOCKS; REACTIVITY; COMPLEXES	Al-13(-) is a cluster known for the pronounced stability that arises from coincident closures of its geometric and electronic shells. We present experimental evidence for a very stable cluster corresponding to Al13I-. Ab initio calculations show that the cluster features a structurally unperturbed Al-13(-) core and a region of high charge density on the aluminum vertex opposite from the iodine atom. This ionically bound magic cluster can be understood by considering that Al-13 has an electronic structure reminiscent of a halogen atom. Comparisons to polyhalides provide a sound explanation for our chemical observations.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA; Penn State Univ, Dept Phys, University Pk, PA 16802 USA; Virginia Commonwealth Univ, Dept Phys, Richmond, VA 23284 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Virginia Commonwealth University	Castleman, AW (corresponding author), Penn State Univ, Dept Chem, University Pk, PA 16802 USA.	awc@psu.edu	Bergeron, Denis E/I-4332-2013	Bergeron, Denis E/0000-0003-1150-7950				ASHMAN C, 2000, CLUSTER NANOSTRUCTUR, P383; Bergeron DE, 2003, CHEM PHYS LETT, V371, P189, DOI 10.1016/S0009-2614(03)00242-2; Bergeron DE, 2003, INT J MASS SPECTROM, V230, P71, DOI 10.1016/j.ijms.2003.05.001; BERGERON DE, UNPUB; Burkart S, 1999, CHEM PHYS LETT, V301, P546, DOI 10.1016/S0009-2614(98)01428-6; CASTLEMAN AW, 1987, J CHEM PHYS, V86, P3829, DOI 10.1063/1.451941; CHA CY, 1994, J CHEM PHYS, V100, P995, DOI 10.1063/1.466582; Cooper BT, 1998, CHEM PHYS LETT, V284, P401, DOI 10.1016/S0009-2614(97)01432-2; EKARDT W, 1984, PHYS REV B, V29, P1558, DOI 10.1103/PhysRevB.29.1558; Endo A, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.113310; GUTSEV GL, 1987, USP KHIM+, V56, P889; GUTSEV GL, 1989, J STRUCT CHEM+, V30, P733; HARMS AC, 1990, J AM CHEM SOC, V112, P5673, DOI 10.1021/ja00170a060; JACKSON K, 1990, PHYS REV B, V42, P3276, DOI 10.1103/PhysRevB.42.3276; KHANNA SN, 1994, CHEM PHYS LETT, V219, P479, DOI 10.1016/0009-2614(94)00097-2; KHANNA SN, 1995, PHYS REV B, V51, P13705, DOI 10.1103/PhysRevB.51.13705; Khanna SN, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.125105; KHANNA SN, 1994, CHEM PHYS LETT, V218, P383, DOI 10.1016/0009-2614(93)E1490-8; KNIGHT WD, 1984, PHYS REV LETT, V52, P2141, DOI 10.1103/PhysRevLett.52.2141; KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133; Leskiw BD, 2000, CHEM PHYS LETT, V316, P31, DOI 10.1016/S0009-2614(99)01295-6; Leskiw BD, 2001, J CHEM PHYS, V114, P1165, DOI 10.1063/1.1333017; LEUCHTNER RE, 1991, J CHEM PHYS, V94, P1093, DOI 10.1063/1.460716; LEUCHTNER RE, 1989, J CHEM PHYS, V91, P2753, DOI 10.1063/1.456988; LI X, 2000, PHYS REV B, V65, P3404; Mananes A, 2003, J CHEM PHYS, V119, P5128, DOI 10.1063/1.1597673; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; Porezag D, 1999, PHYS REV A, V60, P2840, DOI 10.1103/PhysRevA.60.2840; Rao BK, 1999, J CHEM PHYS, V111, P1890, DOI 10.1063/1.479458; Rao BK, 1999, J CLUST SCI, V10, P477, DOI 10.1023/A:1021948806958; Thomas OC, 2001, J CHEM PHYS, V114, P9895, DOI 10.1063/1.1365110	31	453	461	5	172	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					84	87		10.1126/science.1093902	http://dx.doi.org/10.1126/science.1093902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15066775				2022-12-28	WOS:000220567900041
J	Mazina, OM; Mazin, AV; Nakagawa, T; Kolodner, RD; Kowalczykowski, SC				Mazina, OM; Mazin, AV; Nakagawa, T; Kolodner, RD; Kowalczykowski, SC			Saccharomyces cerevisiae MER3 helicase stimulates 3 '-5 ' Heteroduplex extension by Rad51: Implications for crossover control in meiotic recombination	CELL			English	Article							DNA STRAND EXCHANGE; REPLICATION PROTEIN-A; COLI RECA PROTEIN; CROSSING-OVER; NUCLEOPROTEIN FILAMENT; YEAST RAD51; COMPLEX-FORMATION; BRANCH MIGRATION; CHROMOSOME SYNAPSIS; MISMATCH CORRECTION	Crossover and noncrossover recombinants can form by two different pathways during meiotic recombination in Saccharomyces cerevisiae. The MER3 gene is known to affect selectively crossover, but not noncrossover, recombination. The Mer3 protein is a DNA helicase that unwinds duplex DNA in the 3' to 5' direction. To define the underlying molecular steps of meiotic recombination, we investigated the role of Mer3 helicase in DNA strand exchange promoted by Rad51 protein. We found that Mer3 helicase does not function as an initiator of DNA pairing events but, rather, it stimulates DNA heteroduplex extension in the 3' --> 5' direction relative to the incoming (or displaced) single-stranded DNA. Conversely, Mer3 helicase blocks DNA heteroduplex extension in the 5' --> 3' direction. Our results support the idea that Mer3 helicase stabilizes nascent joint molecules via DNA heteroduplex extension to permit capture of the second processed end of a double-stranded DNA break, a step which is required for crossover recombinant product formation.	Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular BIol, Ctr Genet & Dev, Davis, CA 95616 USA; Drexel Univ, Coll Med, Dept Biochem, Philadelphia, PA 19102 USA; Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California Davis; University of California System; University of California Davis; Drexel University; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu	Nakagawa, Takuro/A-1367-2017	Nakagawa, Takuro/0000-0003-3455-8224	NIGMS NIH HHS [GM26017, GM62653] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062653, R37GM026017, R01GM026017, R37GM062653] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal S, 2000, CELL, V102, P245, DOI 10.1016/S0092-8674(00)00029-5; Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Allers T, 2001, CELL, V106, P47, DOI 10.1016/S0092-8674(01)00416-0; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Borner GV, 2004, CELL, V117, P29, DOI 10.1016/S0092-8674(04)00292-2; Chua PR, 1998, CELL, V93, P349, DOI 10.1016/S0092-8674(00)81164-2; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; Eggler AL, 2002, J BIOL CHEM, V277, P39280, DOI 10.1074/jbc.M204328200; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; Hong ERL, 2001, J BIOL CHEM, V276, P41906, DOI 10.1074/jbc.M105563200; Hunter N, 2001, CELL, V106, P59, DOI 10.1016/S0092-8674(01)00430-5; Hunter N, 1997, GENE DEV, V11, P1573, DOI 10.1101/gad.11.12.1573; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; Khazanehdari KA, 2000, CHROMOSOMA, V109, P94, DOI 10.1007/s004120050416; Kirkpatrick DT, 2000, GENETICS, V156, P1549; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; LEBOWITZ J, 1985, THESIS J HOPKINS U B; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; Mazin AV, 2003, J BIOL CHEM, V278, P14029, DOI 10.1074/jbc.M212779200; Mirshad JK, 2003, BIOCHEMISTRY-US, V42, P5937, DOI 10.1021/bi027232q; Nakagawa T, 1997, GENES CELLS, V2, P65, DOI 10.1046/j.1365-2443.1997.d01-283.x; Nakagawa T, 1999, EMBO J, V18, P5714, DOI 10.1093/emboj/18.20.5714; Nakagawa T, 1999, P NATL ACAD SCI USA, V96, P14186, DOI 10.1073/pnas.96.25.14186; Nakagawa T, 2002, J BIOL CHEM, V277, P28019, DOI 10.1074/jbc.M204165200; Nakagawa T, 2002, MOL CELL BIOL, V22, P3281, DOI 10.1128/MCB.22.10.3281-3291.2002; Nakagawa T, 2001, J BIOL CHEM, V276, P31487, DOI 10.1074/jbc.M104003200; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; Namsaraev EA, 1998, P NATL ACAD SCI USA, V95, P10477, DOI 10.1073/pnas.95.18.10477; Namsaraev EA, 2000, J BIOL CHEM, V275, P3970, DOI 10.1074/jbc.275.6.3970; New JH, 2002, J BIOL CHEM, V277, P26171, DOI 10.1074/jbc.M203670200; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; Shinohara A, 1997, GENES CELLS, V2, P615, DOI 10.1046/j.1365-2443.1997.1480347.x; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Solinger JA, 2001, P NATL ACAD SCI USA, V98, P8447, DOI 10.1073/pnas.121009898; Solinger JA, 2001, J MOL BIOL, V307, P1207, DOI 10.1006/jmbi.2001.4555; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Tsubouchi H, 2000, MOL BIOL CELL, V11, P2221, DOI 10.1091/mbc.11.7.2221; Van Komen S, 2002, J BIOL CHEM, V277, P43578, DOI 10.1074/jbc.M205864200; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Zaitseva EM, 1999, J BIOL CHEM, V274, P2907, DOI 10.1074/jbc.274.5.2907	72	79	82	2	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	2004	117	1					47	56		10.1016/S0092-8674(04)00294-6	http://dx.doi.org/10.1016/S0092-8674(04)00294-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YV	15066281	Bronze			2022-12-28	WOS:000221500300007
J	Evans, JG				Evans, JG			It is not just the patient ...	LANCET			English	Editorial Material									Radcliffe Infirm, Div Clin Gerontol, Oxford OX2 6HE, England	Radcliffe Infirmary	Evans, JG (corresponding author), Radcliffe Infirm, Div Clin Gerontol, Oxford OX2 6HE, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	2004	363	9414					1070	1070		10.1016/S0140-6736(04)15845-5	http://dx.doi.org/10.1016/S0140-6736(04)15845-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15051289				2022-12-28	WOS:000220497300024
J	Jamrozik, K				Jamrozik, K			ABC of smoking cessation - Population strategies to prevent smoking	BRITISH MEDICAL JOURNAL			English	Review									Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England	Imperial College London	Jamrozik, K (corresponding author), Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia.							Fichtenberg CM, 2002, BMJ-BRIT MED J, V325, P188, DOI 10.1136/bmj.325.7357.188; Glantz S.A., 1996, CIGARETTE PAPERS; *ROYAL COLL PHYS, 2001, NIC ADD BRIT REP TOB; Wakefield M, 2002, AUST NZ J PUBL HEAL, V26, P375, DOI 10.1111/j.1467-842X.2002.tb00190.x	4	41	43	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 27	2004	328	7442					759	762		10.1136/bmj.328.7442.759	http://dx.doi.org/10.1136/bmj.328.7442.759			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	809WH	15044295	Green Published			2022-12-28	WOS:000220666300023
J	Shattock, R; Solomon, S				Shattock, R; Solomon, S			Microbicides - aids to safer sex	LANCET			English	Editorial Material							HIV-1 TRANSMISSION; INDIA; WOMEN		St George Hosp, Sch Med, London SW17 0RE, England; VHS Tharamani, YR Gaitonde Ctr AIDS Res & Educ, Madras, Tamil Nadu, India	St Georges University London	Shattock, R (corresponding author), St George Hosp, Sch Med, London SW17 0RE, England.	Shattock@sghms.ac.uk						Baeten JM, 2003, CURR HIV RES, V1, P69, DOI 10.2174/1570162033352110; HU Q, IN PRESS J EXP MED; Miller CJ, 2003, MICROBES INFECT, V5, P59, DOI 10.1016/S1286-4579(02)00056-4; Newmann S, 2000, INT J STD AIDS, V11, P250, DOI 10.1258/0956462001915796; Pope M, 2003, NAT MED, V9, P847, DOI 10.1038/nm0703-847; Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729; Solomon S, 2003, NAT IMMUNOL, V4, P719, DOI 10.1038/ni0803-719; Stone A, 2002, NAT REV DRUG DISCOV, V1, P977, DOI 10.1038/nrd959; UNAIDS, 2003, AIDS EP UPD; Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8; Watts C, 2001, AIDS, V15, pS43, DOI 10.1097/00002030-200102001-00064	11	37	37	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	2004	363	9414					1002	1003		10.1016/S0140-6736(04)15876-5	http://dx.doi.org/10.1016/S0140-6736(04)15876-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15051276				2022-12-28	WOS:000220497300002
J	Baluska, F; Volkmann, D; Barlow, PW				Baluska, F; Volkmann, D; Barlow, PW			Cell bodies in a cage	NATURE			English	Editorial Material									Univ Bonn, Inst Cellular & Mol Bot, D-53115 Bonn, Germany; Univ Bristol, Sch Biol Sci, Bristol BS8 1UG, Avon, England	University of Bonn; University of Bristol	Baluska, F (corresponding author), Univ Bonn, Inst Cellular & Mol Bot, Kirschallee 1, D-53115 Bonn, Germany.		Baluska, Frantisek/AAQ-1358-2021	Molodiuc, Veaceslav/0000-0002-3014-4203				Baluska F, 2001, TRENDS PLANT SCI, V6, P104, DOI 10.1016/S1360-1385(00)01862-8; Mazzarello P, 1999, NAT CELL BIOL, V1, pE13, DOI 10.1038/8964; Oparka KJ, 2004, TRENDS PLANT SCI, V9, P33, DOI 10.1016/j.tplants.2003.11.001; Richmond ML, 2002, NAT REV MOL CELL BIO, V3, P61, DOI 10.1038/nrm701; Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133	5	52	54	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	2004	428	6981					371	371		10.1038/428371a	http://dx.doi.org/10.1038/428371a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042068				2022-12-28	WOS:000220404300020
J	Elazary, AS; Lador, N; Shauer, A; Meir, K; Pollak, A; Wolf, DG; Raz, I; Leitersdorf, E; Mevorach, D				Elazary, AS; Lador, N; Shauer, A; Meir, K; Pollak, A; Wolf, DG; Raz, I; Leitersdorf, E; Mevorach, D			Tongue necrosis and pericarditis	LANCET			English	Editorial Material							SYSTEMIC LUPUS-ERYTHEMATOSUS; INFARCTION		Hadassah Hebrew Univ Hosp, Dept Med B, IL-91120 Jerusalem, Israel; Hadassah Hebrew Univ Hosp, Oral Surg Clin, IL-91120 Jerusalem, Israel; Hadassah Hebrew Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel; Hadassah Hebrew Univ Hosp, Dept Infect Dis, IL-91120 Jerusalem, Israel; Hadassah Hebrew Univ Hosp, Dept Cardiol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	Mevorach, D (corresponding author), Hadassah Hebrew Univ Hosp, Dept Med B, IL-91120 Jerusalem, Israel.	mevorachd@hadassah.org.il						Baratti-Mayer D, 2003, LANCET INFECT DIS, V3, P419, DOI 10.1016/S1473-3099(03)00670-4; Hellmann DB, 2002, JAMA-J AM MED ASSOC, V287, P2996, DOI 10.1001/jama.287.22.2996; Iliopoulos AG, 1996, SEMIN ARTHRITIS RHEU, V25, P318, DOI 10.1016/S0049-0172(96)80018-7; KORN S, 1988, J RHEUMATOL, V15, P1281; Orita Y, 2000, ORAL SURG ORAL MED O, V89, P316, DOI 10.1016/S1079-2104(00)70095-3	5	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	2004	363	9413					948	948		10.1016/S0140-6736(04)15790-5	http://dx.doi.org/10.1016/S0140-6736(04)15790-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043963				2022-12-28	WOS:000220308600012
J	Peeters, M				Peeters, M			Cross-species transmissions of simian retroviruses in Africa and risk for human health	LANCET			English	Editorial Material							VIRUS TYPE-I; EPIDEMIOLOGY; INFECTION; HIV-1; ORIGINS		Inst Rech Dev, UMR 145, F-34392 Montpellier, France	Institut de Recherche pour le Developpement (IRD)	Peeters, M (corresponding author), Inst Rech Dev, UMR 145, F-34392 Montpellier, France.	martine.peeters@mpl.ird.fr						COURGNAUD V, IN PRESS J VIROL; DELAPORTE E, 1989, J ACQ IMMUN DEF SYND, V2, P410; Gessain A, 2000, B SOC PATHOL EXOT, V93, P163; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789; LEVINE PH, 1988, YALE J BIOL MED, V61, P215; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; Meiering CD, 2001, CLIN MICROBIOL REV, V14, P165, DOI 10.1128/CMR.14.1.165-176.2001; NGOLE EM, 2003, 2 IAS C HIV PATH TRE, P1210; Peeters M, 2002, EMERG INFECT DIS, V8, P451, DOI 10.3201/eid0805.010522; Switzer WM, 2004, J VIROL, V78, P2780, DOI 10.1128/JVI.78.6.2780-2789.2004; Touze E, 1996, J ACQ IMMUN DEF SYND, V13, pS38, DOI 10.1097/00042560-199600001-00008; UNAIDS, 2003, AIDS EP UPD; van der Loeff MFS, 1999, AIDS, V13, pS69; Vandamme AM, 1998, TRENDS MICROBIOL, V6, P477, DOI 10.1016/S0966-842X(98)01406-1	16	8	9	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	2004	363	9413					911	912		10.1016/S0140-6736(04)15819-4	http://dx.doi.org/10.1016/S0140-6736(04)15819-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043954				2022-12-28	WOS:000220308600003
J	Garkavtsev, I; Kozin, SV; Chernova, O; Xu, L; Winkler, F; Brown, E; Barnett, GH; Jain, RK				Garkavtsev, I; Kozin, SV; Chernova, O; Xu, L; Winkler, F; Brown, E; Barnett, GH; Jain, RK			The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis	NATURE			English	Article							INTERLEUKIN-8 EXPRESSION; P53 EXPRESSION; P33(ING1); FIBROBLASTS; INHIBITOR; CANCER; GENE	Gliomas are the most common primary tumours of the central nervous system, with nearly 15,000 diagnosed annually in the United States and a lethality approaching 80% within the first year of glioblastoma diagnosis(1). The marked induction of angiogenesis in glioblastomas suggests that it is a necessary part of malignant progression(2); however, the precise molecular mechanisms underlying the regulation of brain tumour growth and angiogenesis remain unresolved. Here we report that a candidate tumour suppressor gene, ING4, is involved in regulating brain tumour growth and angiogenesis. Expression of ING4 is significantly reduced in gliomas as compared with normal human brain tissue, and the extent of reduction correlates with the progression from lower to higher grades of tumours. In mice, xenografts of human glioblastoma U87MG, which has decreased expression of ING4, grow significantly faster and have higher vascular volume fractions than control tumours. We show that ING4 physically interacts with p65 ( RelA) subunit of nuclear factor NF-kappaB, and that ING4 regulates brain tumour angiogenesis through transcriptional repression of NF-kappaB-responsive genes. These results indicate that ING4 has an important role in brain tumour pathogenesis.	Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Radiat Oncol, Edwin L Steele Lab Tumour Biol, Boston, MA 02114 USA; Cleveland Clin Fdn, Brain Tumour Inst, Cleveland, OH 44195 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Cleveland Clinic Foundation	Garkavtsev, I (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Radiat Oncol, Edwin L Steele Lab Tumour Biol, Boston, MA 02114 USA.	igorg@steele.mgh.harvard.edu	Xu, Lei/GRR-9174-2022; Jain, Rakesh K/I-1384-2017	Jain, Rakesh K/0000-0001-7571-3548; Winkler, Frank/0000-0003-4892-6104	NCI NIH HHS [P01 CA080124] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA080124] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brat DJ, 2002, ADV ANAT PATHOL, V9, P24, DOI 10.1097/00125480-200201000-00004; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen B, 2003, INT J ONCOL, V22, P927; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Desbaillets I, 1999, ONCOGENE, V18, P1447, DOI 10.1038/sj.onc.1202424; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gunduz M, 2000, CANCER RES, V60, P3143; Jain RK, 2002, NAT REV CANCER, V2, P266, DOI 10.1038/nrc778; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Leung KM, 2002, CANCER RES, V62, P4890; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Nourani A, 2001, MOL CELL BIOL, V21, P7629, DOI 10.1128/MCB.21.22.7629-7640.2001; Oki E, 1999, CANCER LETT, V147, P157, DOI 10.1016/S0304-3835(99)00288-8; PLATE KH, 1995, GLIA, V15, P339, DOI 10.1002/glia.440150313; Shiseki M, 2003, CANCER RES, V63, P2373; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Xu L, 1999, CANCER RES, V59, P5822	25	295	343	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	2004	428	6980					328	332		10.1038/nature02329	http://dx.doi.org/10.1038/nature02329			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15029197				2022-12-28	WOS:000220250200046
J	Heukelbach, J; Feldmeier, H				Heukelbach, J; Feldmeier, H			Ectoparasites - the underestimated realm	LANCET			English	Review							HEAD LICE; PEDICULUS-CAPITIS; SCABIES; PREVALENCE; IVERMECTIN; RESISTANCE; EFFICACY	Context Ectoparasitoses (infestations with parasites that live on or in the skin) can cause considerable morbidity. Whereas. pediculosis and scabies are ubiquitous, cutaneous larva;, migrans and tungiasis (sand-flea disease) occur mainly in hot! climates. The prevalence of ectoparasitoses in the general population is usually low, but can be high in vulnerable groups. Scientific knowledge on how to deal best with parasitic skin diseases in different settings is scanty, and evidence-based measures for control are not available. For head lice and scabies the situation is daunting, because resistance of Pediculus humanus capitis and Sarcoptes scabiei to insecticides is spreading and unpredictable. Starting point J Hunter and S Barker reported different, patterns of resistance in schoolchildren in Brisbane, Australia: full resistance to malathion, permethrin, and pyrethrum in two schools, whereas head lice were susceptible to malathion and, to a lesser extent, to pyrethrums in three other schools (Parasitol Res 2003; 90: 476-78). K Yoon and colleagues found different resistance patterns in the USA and Ecuador (Arch Dermatol 2003; 1.39: 994-1000). Head lice from Florida were less susceptible to permethrin than those from Texas, and parasites from Ecuador were susceptible to both insecticides tested. Where next? The occurrence of resistant pediculosis and scabies is expected to increase numerically and geographically. Clinicoepidemiological studies are urgently needed to identify the factors which govern the emergence and spread 1 of strains of P humanus capitis and S scabiei that are resistant to insecticide or acaricide. Oral treatment with ivermectin could substitute for topically applied compounds, particularly in resource-poor communities where polyparasitism is common. A better understanding of local epidemiology is required to develop control measures. This knowledge has to be applied in combination with environmental sanitation, health education, and culturally acceptable interventions that are affordable by the underprivileged.	Charite Univ Med Berlin, Inst Int Hlth, D-12203 Berlin, Germany; Fed Univ Ceara State, Mandacaru Fdn, Fortaleza, Ceara, Brazil; Fed Univ Ceara State, Dept Community Med, Fortaleza, Ceara, Brazil	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Universidade Federal do Ceara; Universidade Federal do Ceara	Feldmeier, H (corresponding author), Charite Univ Med Berlin, Inst Int Hlth, Campus Benjamin Franklin, D-12203 Berlin, Germany.	Feldmeier.fuberlin@t-online.de		Heukelbach, Jorg/0000-0002-7845-5510				Bockarie MJ, 2000, ACTA TROP, V75, P127, DOI 10.1016/S0001-706X(99)00087-X; BURGESS I, 1994, ADV PARASIT, V33, P235, DOI 10.1016/S0065-308X(08)60414-5; Burgess Ian F., 1995, Advances in Parasitology, V36, P271, DOI 10.1016/S0065-308X(08)60493-5; Burkhart CG, 1998, J AM ACAD DERMATOL, V38, P979, DOI 10.1016/S0190-9622(98)70163-X; CAUMES E, 1995, CLIN INFECT DIS, V20, P542, DOI 10.1093/clinids/20.3.542; CHARLES V, 1992, TROP GEOGR MED, V44, P178; del Giudice Pascal, 2003, J Drugs Dermatol, V2, P13; Downs AMR, 2002, BRIT J DERMATOL, V146, P88, DOI 10.1046/j.1365-2133.2002.04473.x; Downs AMR, 1999, PARASITOL TODAY, V15, P1, DOI 10.1016/S0169-4758(98)01361-1; Elgart GW, 2003, DERMATOL CLIN, V21, P277, DOI 10.1016/S0733-8635(02)00095-5; Elston DM, 2003, ARCH DERMATOL, V139, P1061, DOI 10.1001/archderm.139.8.1061; Estrada Benjamin, 2003, Semin Pediatr Infect Dis, V14, P20, DOI 10.1053/spid.2003.127213; Feldmeier H, 2003, EMERG INFECT DIS, V9, P949; Heukelbach J, 2003, TROP MED INT HEALTH, V8, P368, DOI 10.1046/j.1365-3156.2003.01038.x; HEUKELBACH J, IN PRESS INT J DERMA; HEUKELBACH J, IN PRESS MED VET ENT; Hunter JA, 2003, PARASITOL RES, V90, P476, DOI 10.1007/s00436-003-0881-y; Leppard B, 2000, BRIT J DERMATOL, V143, P520, DOI 10.1111/j.1365-2133.2000.03704.x; McCage CM, 2002, PHYTOMEDICINE, V9, P743, DOI 10.1078/094471102321621377; Meinking TL, 2002, J PEDIATR-US, V141, P665, DOI 10.1067/mpd.2002.129031; Muehlen M, 2003, PARASITOL RES, V90, P449, DOI 10.1007/s00436-003-0877-7; Mumcuoglu KY, 2002, ISRAEL MED ASSOC J, V4, P790; Orion E, 2002, CLIN DERMATOL, V20, P618, DOI 10.1016/S0738-081X(02)00281-X; Picollo MI, 2000, J MED ENTOMOL, V37, P721, DOI 10.1603/0022-2585-37.5.721; Schwalfenberg S, 2004, ANN TROP MED PARASIT, V98, P89, DOI 10.1179/000349804225003091; Yoon KS, 2003, ARCH DERMATOL, V139, P994, DOI 10.1001/archderm.139.8.994	26	69	77	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	2004	363	9412					889	891		10.1016/S0140-6736(04)15738-3	http://dx.doi.org/10.1016/S0140-6736(04)15738-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15032237				2022-12-28	WOS:000220231500025
J	Sollner, C; Rauch, GJ; Siemens, J; Geisler, R; Schuster, SC; Muller, U; Nicolson, T				Sollner, C; Rauch, GJ; Siemens, J; Geisler, R; Schuster, SC; Muller, U; Nicolson, T		Tubingen 2000 Screen Consortium	Mutations in cadherin 23 affect tip links in zebrafish sensory hair cells	NATURE			English	Article							CALCIUM CHELATION; MYOSIN VIIA; SURFACE; CDH23; WALTZER; ANTIGEN; GENE; STEREOCILIA; HARMONIN; BUNDLES	Hair cells have highly organized bundles of apical projections, or stereocilia, that are deflected by sound and movement. Displacement of stereocilia stretches linkages at the tips of stereocilia that are thought to gate mechanosensory channels(1). To identify the molecular machinery that mediates mechanotransduction in hair cells, zebrafish mutants were identified with defects in balance and hearing(2). In sputnik mutants, stereociliary bundles are splayed to various degrees, with individuals displaying reduced or absent mechanotransduction(3,4). Here we show that the defects in sputnik mutants are caused by mutations in cadherin 23 (cdh23). Mutations in Cdh23 also cause deafness and vestibular defects in mice and humans(5-9), and the protein is present in hair bundles(10,11). We show that zebrafish Cdh23 protein is concentrated near the tips of hair bundles, and that tip links are absent in homozygous sputnik(tc317e) larvae. Moreover, tip links are absent in larvae carrying weak alleles of cdh23 that affect mechanotransduction but not hair bundle integrity. We conclude that Cdh23 is an essential tip link component required for hair-cell mechanotransduction.	Max Planck Inst Entwicklungsbiol, Genet Abt, D-72076 Tubingen, Germany; Max Planck Inst Entwicklungsbiol, AG Gen & Signal Transduct, D-72076 Tubingen, Germany; Scripps Res Inst, La Jolla, CA 92037 USA; Oregon Hearing Res Ctr, Portland, OR 97239 USA; Vollum Inst, Portland, OR 97239 USA; Artemis Pharmaceut GmbH, D-72076 Tubingen, Germany	Max Planck Society; Max Planck Society; Scripps Research Institute	Nicolson, T (corresponding author), Max Planck Inst Entwicklungsbiol, Genet Abt, Spemannstr 35, D-72076 Tubingen, Germany.	nicolson@ohsu.edu	Geisler, Robert/K-6201-2013	Geisler, Robert/0000-0002-3909-8311; Siemens, Jan/0000-0001-9051-9217; Maderspacher, Florian/0000-0003-4324-8455; Dahm, Ralf/0000-0001-5203-8578				ASSAD JA, 1991, NEURON, V7, P985, DOI 10.1016/0896-6273(91)90343-X; Baumgartner W, 2000, P NATL ACAD SCI USA, V97, P4005, DOI 10.1073/pnas.070052697; Boeda B, 2002, EMBO J, V21, P6689, DOI 10.1093/emboj/cdf689; Bolz H, 2001, NAT GENET, V27, P108, DOI 10.1038/83667; Bork JM, 2001, AM J HUM GENET, V68, P26, DOI 10.1086/316954; Di Palma F, 2001, NAT GENET, V27, P103, DOI 10.1038/83660; Ernest S, 2000, HUM MOL GENET, V9, P2189, DOI 10.1093/hmg/9.14.2189; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Goodyear R, 1999, J NEUROSCI, V19, P3761; GOODYEAR R, 1992, J COMP NEUROL, V325, P243, DOI 10.1002/cne.903250208; Goodyear RJ, 2003, J NEUROSCI, V23, P9208; Goodyear RJ, 2003, J NEUROSCI, V23, P4878; Granato M, 1996, DEVELOPMENT, V123, P399; HOWARD J, 1988, NEURON, V1, P189, DOI 10.1016/0896-6273(88)90139-0; Kachar B, 2000, P NATL ACAD SCI USA, V97, P13336, DOI 10.1073/pnas.97.24.13336; Katori Y, 1996, J ELECTRON MICROSC, V45, P207, DOI 10.1093/oxfordjournals.jmicro.a023434; Leckband D, 2000, CURR OPIN CELL BIOL, V12, P587, DOI 10.1016/S0955-0674(00)00136-8; NEUGEBAUER DC, 1987, CELL TISSUE RES, V249, P199, DOI 10.1007/BF00215434; Nicolson T, 1998, NEURON, V20, P271, DOI 10.1016/S0896-6273(00)80455-9; PICKLES JO, 1992, TRENDS NEUROSCI, V15, P254, DOI 10.1016/0166-2236(92)90066-H; PICKLES JO, 1989, HEARING RES, V41, P31, DOI 10.1016/0378-5955(89)90176-7; Riley BB, 1997, DEV BIOL, V191, P191, DOI 10.1006/dbio.1997.8736; Seiler C, 1999, J NEUROBIOL, V41, P424, DOI 10.1002/(SICI)1097-4695(19991115)41:3<424::AID-NEU10>3.0.CO;2-G; Sidi S, 2003, SCIENCE, V301, P96, DOI 10.1126/science.1084370; Siemens J, 2002, P NATL ACAD SCI USA, V99, P14946, DOI 10.1073/pnas.232579599; SIEMENS J, 2004, NATURE          0331, DOI DOI 10.1038/NATURE02483; Sivasankar S, 2001, BIOPHYS J, V80, P1758, DOI 10.1016/S0006-3495(01)76146-2; Steel KP, 2001, NAT GENET, V27, P143, DOI 10.1038/84758; Wada T, 2001, BIOCHEM BIOPH RES CO, V283, P113, DOI 10.1006/bbrc.2001.4724; WESTERFIELD M, 1995, ZEBRAFISH BOOK; Wilson SM, 2001, GENOMICS, V74, P228, DOI 10.1006/geno.2001.6554	31	247	254	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 29	2004	428	6986					955	959		10.1038/nature02484	http://dx.doi.org/10.1038/nature02484			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	816AO	15057246				2022-12-28	WOS:000221083000044
J	Hagoort, P; Hald, L; Bastiaansen, M; Petersson, KM				Hagoort, P; Hald, L; Bastiaansen, M; Petersson, KM			Integration of word meaning and world knowledge in language comprehension	SCIENCE			English	Article							SENTENCES; POTENTIALS; HUMANS; N400	Although the sentences that we hear or read have meaning, this does not necessarily mean that they are also true. Relatively little is known about the critical brain structures for, and the relative time course of, establishing the meaning and truth of linguistic expressions. We present electroencephalogram data that show the rapid parallel integration of both semantic and world knowledge during the interpretation of a sentence. Data from functional magnetic resonance imaging revealed that the left inferior prefrontal cortex is involved in the integration of both meaning and world knowledge. Finally, oscillatory brain responses indicate that the brain keeps a record of what makes a sentence hard to interpret.	Univ Nijmegen, FC Donders Ctr Cognit Neuroimaging, Nijmegen, Netherlands; Univ Nijmegen, Nijmegen Inst Cognit & Informat, Nijmegen, Netherlands; Max Planck Inst Psycholinguist, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Max Planck Society	Hagoort, P (corresponding author), Univ Nijmegen, FC Donders Ctr Cognit Neuroimaging, Nijmegen, Netherlands.	peter.hagoort@fcdonders.kun.nl	Bastiaansen, Marcel C.M./D-2507-2010; Hald, Lea A/J-3405-2012; GNC, GNC/B-5716-2013; Petersson, Karl Magnus/E-8188-2012; Petersson, Karl Magnus/HDO-0143-2022; Hagoort, Peter/B-7417-2012	Hald, Lea A/0000-0001-7641-8049; Petersson, Karl Magnus/0000-0002-8245-0392; Petersson, Karl Magnus/0000-0002-8245-0392; Bastiaansen, Marcel/0000-0003-2865-7859				Bastiaansen M, 2003, CORTEX, V39, P967, DOI 10.1016/S0010-9452(08)70873-6; BROWN C, 1993, J COGNITIVE NEUROSCI, V5, P34, DOI 10.1162/jocn.1993.5.1.34; Chomsky N., 1975, REFLECTIONS LANGUAGE; Clark H.H., 1996, USING LANGUAGE; Clifton C., 1999, ARCHITECTURES MECH L, P213; FORSTER KI, 1989, SENTENCE PROCESSING, P27; Frege G., 1892, Z PHILOS PHILOS KRIT, V100, P25; Gold BT, 2002, NEURON, V35, P803, DOI 10.1016/S0896-6273(02)00800-0; HALGREN E, 1994, J PHYSIOL-PARIS, V88, P1, DOI 10.1016/0928-4257(94)90092-2; Halgren E, 2002, NEUROIMAGE, V17, P1101, DOI 10.1006/nimg.2002.1268; JACKENDOFF R, 2003, FDN LANGUAGE BRAIN G; Jensen O, 2002, EUR J NEUROSCI, V15, P1395, DOI 10.1046/j.1460-9568.2002.01975.x; Katz J.J., 1972, SEMANTIC THEORY; KUTAS M, 1980, SCIENCE, V207, P203, DOI 10.1126/science.7350657; Marslen-Wilson WD., 1988, LANG COGN PROCESS, V3, P1; Miltner WHR, 1999, NATURE, V397, P434, DOI 10.1038/17126; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; Seuren Pieter A. M, 1985, DISCOURSE SEMANTICS; Seuren PieterA.M., 1998, W LINGUISTICS HIST I; Sperber Dan, 1986, RELEVANCE; Tallon-Baudry C, 1999, TRENDS COGN SCI, V3, P151, DOI 10.1016/S1364-6613(99)01299-1; TANENHAUS MK, 1995, SCIENCE, V268, P1632, DOI 10.1126/science.7777863; van Berkum JJA, 1999, J COGNITIVE NEUROSCI, V11, P657, DOI 10.1162/089892999563724; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; ZOLA-MORGAN S, 1990, P434	25	767	786	11	145	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	2004	304	5669					438	441		10.1126/science.1095455	http://dx.doi.org/10.1126/science.1095455			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	812NE	15031438	Green Published			2022-12-28	WOS:000220845400048
J	Abbasi, K; Khan, KS				Abbasi, K; Khan, KS			India versus Pakistan and the power of a six: an analysis of cricket results	BRITISH MEDICAL JOURNAL			English	Article									Birmingham Womens Hlth Care NHS Trust, Educ Resource Ctr, Birmingham, W Midlands, England			kabbasi@bmj.com	Khan, Khalid S/AAT-8824-2020	Khan, Khalid S/0000-0001-5084-7312				Shafqat S, 2004, BRIT MED J, V328, P843, DOI 10.1136/bmj.328.7443.843; Witte DR, 2000, BMJ-BRIT MED J, V321, P1552, DOI 10.1136/bmj.321.7276.1552	2	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 3	2004	328	7443					800	800		10.1136/bmj.328.7443.800	http://dx.doi.org/10.1136/bmj.328.7443.800			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	811CG	15070636	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000220749400019
J	Casserly, I; Topol, E				Casserly, I; Topol, E			Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins	LANCET			English	Review							AMYLOID-BETA-PEPTIDE; ENDOTHELIAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; LIVER-X-RECEPTORS; ANGIOTENSIN-CONVERTING ENZYME; RANDOMIZED CONTROLLED-TRIAL; A REDUCTASE INHIBITORS; NITRIC-OXIDE SYNTHASE; E-DEFICIENT MICE; APOLIPOPROTEIN-E	Late-onset sporadic Alzheimer's disease is a heterogeneous disorder. In elderly patients, increasing evidence suggests a link between this neurodegenerative disease, and vascular risk factors and atherosclerosis. The nature of this link remains speculative. Some investigators have suggested that the disease arises as a secondary event related to atherosclerosis of extracranial or intracranial vessels. A toxic effect of vascular factors on the microvasculature of susceptible brain regions has also been argued. An alternative explanation is that atherosclerosis and Alzheimer's disease are independent but convergent disease processes. This hypothesis is lent support by observations of shared epidemiology, pathophysiological elements, and response to treatment in both disorders. It provides a potential framework for an improved understanding of the pathogenesis of Alzheimer's disease, especially in elderly patients with vascular risk factors, and offers some promise toward the search for preventive and therapeutic treatments.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Topol, E (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	topole@ccf.org		Topol, Eric/0000-0002-1478-4729				Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Amin-Hanjani S, 2001, STROKE, V32, P980, DOI 10.1161/01.STR.32.4.980; BARNES JM, 1990, J CARDIOVASC PHARM, V16, P234, DOI 10.1097/00005344-199008000-00009; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; Brasier AR, 2002, ARTERIOSCL THROM VAS, V22, P1257, DOI 10.1161/01.ATV.0000021412.56621.A2; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; Bucciarelli LG, 2002, CELL MOL LIFE SCI, V59, P1117, DOI 10.1007/s00018-002-8491-x; Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; CHEN M, 1995, BIOCHEM BIOPH RES CO, V213, P96, DOI 10.1006/bbrc.1995.2103; Collen MF, 2002, METHOD INFORM MED, V41, P224; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Cummings JL, 2002, JAMA-J AM MED ASSOC, V287, P2335, DOI 10.1001/jama.287.18.2335; Cyrus T, 2002, CIRCULATION, V106, P1282, DOI 10.1161/01.CIR.0000027816.54430.96; de la Torre JC, 2002, STROKE, V33, P1152, DOI 10.1161/01.STR.0000014421.15948.67; De Meyer GRY, 2002, CIRC RES, V90, P1197, DOI 10.1161/01.RES.0000020017.84398.61; Etminan M, 2003, BMJ-BRIT MED J, V327, P128, DOI 10.1136/bmj.327.7407.128; Farkas E, 2000, ACTA NEUROPATHOL, V100, P395, DOI 10.1007/s004010000195; Farkas E, 2001, PROG NEUROBIOL, V64, P575, DOI 10.1016/S0301-0082(00)00068-X; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Frears ER, 1999, NEUROREPORT, V10, P1699, DOI 10.1097/00001756-199906030-00014; Freeman MW, 2003, NAT MED, V9, P168, DOI 10.1038/nm0203-168; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Grammas P, 1999, AM J PATHOL, V154, P337, DOI 10.1016/S0002-9440(10)65280-7; GREEN R, 2002, WORLD ALZH C STOCKH; Gustafson D, 2003, ARCH INTERN MED, V163, P1524, DOI 10.1001/archinte.163.13.1524; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hirawa N, 1999, HYPERTENSION, V34, P496, DOI 10.1161/01.HYP.34.3.496; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Hu JG, 2001, J BIOL CHEM, V276, P47863, DOI 10.1074/jbc.M104068200; Huang ZH, 2002, J LIPID RES, V43, P375; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; KALARIA RN, 1992, CEREBROVAS BRAIN MET, V4, P226; Kalmijn S, 2000, ARTERIOSCL THROM VAS, V20, P2255, DOI 10.1161/01.ATV.20.10.2255; Kivipelto M, 2001, BMJ-BRIT MED J, V322, P1447, DOI 10.1136/bmj.322.7300.1447; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Kusunoki J, 2001, CIRCULATION, V103, P2604; LEHTIMAKI T, 1990, J LIPID RES, V31, P487; MACGREGOR DP, 1995, BRAIN RES, V675, P231, DOI 10.1016/0006-8993(95)00076-3; Maron DJ, 2000, CIRCULATION, V101, P207, DOI 10.1161/01.CIR.101.2.207; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; Michikawa M, 2000, J NEUROCHEM, V74, P1008, DOI 10.1046/j.1471-4159.2000.0741008.x; Minino Arialdi M, 2002, Natl Vital Stat Rep, V50, P1; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; Notkola IL, 1998, NEUROEPIDEMIOLOGY, V17, P14, DOI 10.1159/000026149; OHM TG, 1995, NEUROSCIENCE, V64, P209, DOI 10.1016/0306-4522(95)90397-P; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Papassotiropoulos A, 2003, ARCH NEUROL-CHICAGO, V60, P29, DOI 10.1001/archneur.60.1.29; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Pratico D, 2001, P NATL ACAD SCI USA, V98, P3358, DOI 10.1073/pnas.061607398; PRINCE M, 1994, NEUROLOGY, V44, P97; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Rhodin J, 2001, MICROCIRCULATION, V8, P207, DOI 10.1038/sj.mn.7800086; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ritchie K, 2002, LANCET, V360, P1759, DOI 10.1016/S0140-6736(02)11667-9; Rockwood K, 2002, ARCH NEUROL-CHICAGO, V59, P223, DOI 10.1001/archneur.59.2.223; Rodriguez A, 2002, ATHEROSCLEROSIS, V161, P45, DOI 10.1016/S0021-9150(01)00620-7; Roher AE, 2003, ARTERIOSCL THROM VAS, V23, P2055, DOI 10.1161/01.ATV.0000095973.42032.44; Santiago-Garcia J, 2001, J BIOL CHEM, V276, P30655, DOI 10.1074/jbc.M102879200; Savaskan E, 2001, NEUROBIOL AGING, V22, P541, DOI 10.1016/S0197-4580(00)00259-1; Schleicher ED, 1997, J CLIN INVEST, V99, P457, DOI 10.1172/JCI119180; Schmidt R, 2002, ANN NEUROL, V52, P168, DOI 10.1002/ana.10265; Schuster GU, 2002, CIRCULATION, V106, P1147, DOI 10.1161/01.CIR.0000026802.79202.96; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Sheehy N, 2001, EXPERT OPIN INV DRUG, V10, P1847, DOI 10.1517/13543784.10.10.1847; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Skovronsky DM, 2001, J BIOL CHEM, V276, P17036, DOI 10.1074/jbc.M006285200; SPARKS DL, 1990, NEUROBIOL AGING, V11, P601, DOI 10.1016/0197-4580(90)90024-T; Steinberg D, 2002, NAT MED, V8, P1211, DOI 10.1038/nm1102-1211; STEINBERG D, 1989, CIRCULATION, V80, P1070, DOI 10.1161/01.CIR.80.4.1070; Sueishi K, 1997, ANN NY ACAD SCI, V811, P311, DOI 10.1111/j.1749-6632.1997.tb52011.x; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Tedgui A, 2002, CIRC RES, V90, P1145, DOI 10.1161/01.RES.0000023048.87638.92; Tuzcu EM, 2001, CIRCULATION, V103, P2705; Vagnucci AH, 2003, LANCET, V361, P605, DOI 10.1016/S0140-6736(03)12521-4; Vasse M, 1999, ARTERIOSCL THROM VAS, V19, P1835, DOI 10.1161/01.ATV.19.8.1835; Vaughan CJ, 1999, STROKE, V30, P1969, DOI 10.1161/01.STR.30.9.1969; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; Wang L, 2002, P NATL ACAD SCI USA, V99, P13878, DOI 10.1073/pnas.172510899; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wilson PWF, 1996, ARTERIOSCL THROM VAS, V16, P1250, DOI 10.1161/01.ATV.16.10.1250; Witztum JL, 1998, CURR OPIN LIPIDOL, V9, P441, DOI 10.1097/00041433-199810000-00008; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wyss-Coray T, 2002, P NATL ACAD SCI USA, V99, P10837, DOI 10.1073/pnas.162350199; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X; Yasojima K, 2000, BRAIN RES, V887, P80, DOI 10.1016/S0006-8993(00)02970-X; Yermakova AV, 1999, J NEUROPATH EXP NEUR, V58, P1135, DOI 10.1097/00005072-199911000-00003; ZHANG Y, 1993, AM J PATHOL, V143, P164	103	397	414	1	32	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	2004	363	9415					1139	1146		10.1016/S0140-6736(04)15900-X	http://dx.doi.org/10.1016/S0140-6736(04)15900-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808VB	15064035				2022-12-28	WOS:000220595500024
J	Kim, WJ; Singh, T				Kim, WJ; Singh, T			Trends and dynamics of youth suicides in developing countries	LANCET			English	Editorial Material							RISK-FACTORS; INDIA; ADOLESCENTS; CHILDREN; CHINA; RATES		Med Coll Ohio, Toledo, OH 43614 USA		Kim, WJ (corresponding author), Med Coll Ohio, Toledo, OH 43614 USA.	wjkim@mco.edu						Bolz Waltraud, 2002, Crisis, V23, P167, DOI 10.1027//0227-5910.23.4.167; Ganju V, 2000, INT J LAW PSYCHIAT, V23, P393, DOI 10.1016/S0160-2527(00)00044-3; Gould MS, 2003, J AM ACAD CHILD PSY, V42, P386, DOI 10.1097/01.CHI.0000046821.95464.CF; Joseph A, 2003, BRIT MED J, V326, P1121, DOI 10.1136/bmj.326.7399.1121; Kim WJ, 2003, ACAD PSYCHIATR, V27, P277, DOI 10.1176/appi.ap.27.4.277; Levi F, 2003, ACTA PSYCHIAT SCAND, V108, P341, DOI 10.1034/j.1600-0447.2003.00147.x; McClure GMG, 2001, BRIT J PSYCHIAT, V178, P469, DOI 10.1192/bjp.178.5.469; MURTHY RS, 2000, INT HDB SUICIDE ATTE, P631; Phillips MR, 2002, LANCET, V360, P1728, DOI 10.1016/S0140-6736(02)11681-3; Phillips MR, 2002, LANCET, V359, P835, DOI 10.1016/S0140-6736(02)07954-0; Shaffer D, 2001, J AM ACAD CHILD PSY, V40, p24S, DOI 10.1097/00004583-200107001-00003; Vijayakumar L, 1999, ACTA PSYCHIAT SCAND, V99, P407, DOI 10.1111/j.1600-0447.1999.tb00985.x	12	12	13	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	2004	363	9415					1090	1091		10.1016/S0140-6736(04)15931-X	http://dx.doi.org/10.1016/S0140-6736(04)15931-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808VB	15064023				2022-12-28	WOS:000220595500004
J	Sargent, W				Sargent, W			J. Beverley Oke (1928-2004) - Obituary	NATURE			English	Biographical-Item									CALTECH, Dept Astron, Pasadena, CA 91125 USA	California Institute of Technology	Sargent, W (corresponding author), CALTECH, Dept Astron, Pasadena, CA 91125 USA.	wws@astro.caltech.edu						OKE JB, PUBLICATION LIST	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					483	483		10.1038/428483a	http://dx.doi.org/10.1038/428483a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15057817	Bronze			2022-12-28	WOS:000220540100027
J	Holmes, W				Holmes, W			3 by 5, but at what cost?	LANCET			English	Editorial Material									Macfarlane Burnet Inst Med Res & Publ Hlth, Ctr Int Hlth, Melbourne, Vic 3004, Australia	Burnet Institute	Holmes, W (corresponding author), Macfarlane Burnet Inst Med Res & Publ Hlth, Ctr Int Hlth, Melbourne, Vic 3004, Australia.	holmes@burnet.edu.au						*AS PAC NETW PEOPL, DOC AIDS REL DISCR A; FREEDMAN LP, BACKGROUND PAPER TAS; Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6; Ogden J, 2003, SOC SCI MED, V57, P179, DOI 10.1016/S0277-9536(02)00373-8	4	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	2004	363	9414					1072	1073		10.1016/S0140-6736(04)15847-9	http://dx.doi.org/10.1016/S0140-6736(04)15847-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15065565				2022-12-28	WOS:000220497300026
J	Fishman, JA; Dey, BR; Hasserjian, RP; Amrein, P; Harris, NL; Weinstein, H				Fishman, JA; Dey, BR; Hasserjian, RP; Amrein, P; Harris, NL; Weinstein, H			A man with acute myeloid leukemia and fever after chemotherapy - Acute myeloid leukemia with multilineage dysplasia after a myelodysplastic syndrome.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							GRANULOCYTOPENIC CANCER-PATIENTS; NEUTROPENIC PATIENTS; ANTIBIOTIC-THERAPY		Massachusetts Gen Hosp, Div Infect Dis, Transplant Infect Dis & Compromised Host Program, Boston, MA 02114 USA; Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Div Hematol Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Fishman, JA (corresponding author), Massachusetts Gen Hosp, Div Infect Dis, Transplant Infect Dis & Compromised Host Program, Boston, MA 02114 USA.							Barton TD, 1996, CLIN INFECT DIS, V22, P1064, DOI 10.1093/clinids/22.6.1064; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; BRUNNING R, 2001, WHO CLASSIFICATION T, V3, P88; CALANDRA T, 1991, J INFECT DIS, V163, P951; CALANDRA T, 1991, J INFECT DIS, V164, P832; DONOWITZ GR, 1991, ARCH INTERN MED, V151, P701, DOI 10.1001/archinte.151.4.701; Hughes WT, 2002, CLIN INFECT DIS, V34, P730, DOI 10.1086/339215; KLASTERSKY J, 1988, EUR J CANCER CLIN ON, V24, pS35; Kocak U, 2002, SUPPORT CARE CANCER, V10, P58, DOI 10.1007/s005200100277; PIZZO PA, 1982, AM J MED, V72, P101, DOI 10.1016/0002-9343(82)90594-0; SCHIMPFF SC, 1986, AM J MED, V80, P13; Viscoli C, 1998, J ANTIMICROB CHEMOTH, V41, P65, DOI 10.1093/jac/41.suppl_4.65	12	0	0	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2004	350	13					1339	1347		10.1056/NEJMcpc030039	http://dx.doi.org/10.1056/NEJMcpc030039			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VN	15044646				2022-12-28	WOS:000220393900014
J	Hubbard, SR				Hubbard, SR			Oncogenic mutations in B-Raf: Some losses yield gains	CELL			English	Editorial Material							KINASE-ACTIVITY; HUMAN CANCER	A study by Wan et al. in this issue of Cell demonstrates that the majority of oncogenic mutations in the B-Raf protein kinase result in increased catalytic activity, through disruption of the autoinhibited state of the kinase domain. Surprisingly, several mutations lead to impaired B-Raf kinase activity, yet these mutants are nevertheless capable of stimulating downstream signaling through transactivation of C-Raf.	NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	New York University; New York University	Hubbard, SR (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, 550 1St Ave, New York, NY 10016 USA.			Hubbard, Stevan/0000-0002-2707-9383				BOS JL, 1989, CANCER RES, V49, P4682; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Papa FR, 2003, SCIENCE, V302, P1533, DOI 10.1126/science.1090031; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6	9	17	21	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 19	2004	116	6					764	766		10.1016/S0092-8674(04)00256-9	http://dx.doi.org/10.1016/S0092-8674(04)00256-9			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YS	15035978	Bronze			2022-12-28	WOS:000221499900002
J	MacCoss, M; Baillie, TA				MacCoss, M; Baillie, TA			Organic chemistry in drug discovery	SCIENCE			English	Article							ANTAGONIST; RECEPTOR; POTENT	The role played by organic chemistry in the pharmaceutical industry continues to be one of the main drivers in the drug discovery process. However, the precise nature of that role is undergoing a visible change, not only because of the new synthetic methods and technologies now available to the synthetic and medicinal chemist, but also in several key areas, particularly in drug metabolism and chemical toxicology, as chemists deal with the ever more rapid turnaround of testing data that influences their day-to-day decisions.	Merck Res Labs, Dept Basic Chem, Rahway, NJ 07065 USA; Merck Res Labs, Dept Drug Metab, W Point, PA 19486 USA	Merck & Company; Merck & Company	MacCoss, M (corresponding author), Merck Res Labs, Dept Basic Chem, 126 E Lincoln Ave, Rahway, NJ 07065 USA.	malcolm_maccoss@merck.com						DEPALMA A, 2003, DRUG DISCOV DEV, V6, P51; DEPALMA A, 2002, DRUG DISCOV DEV, V5, P50; Evans DC, 2004, CHEM RES TOXICOL, V17, P3, DOI 10.1021/tx034170b; Hale JJ, 1998, J MED CHEM, V41, P4607, DOI 10.1021/jm980299k; KOPPAL T, 2003, DRUG DISCOV DEV, V6, P59; KOPPAL T, 2003, DRUG DISCOV DEV, V6, P22; Korfmacher WA, 2001, RAPID COMMUN MASS SP, V15, P335, DOI 10.1002/rcm.235; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; McCoy M, 2003, CHEM ENG NEWS, V81, P15; Netzer R, 2001, DRUG DISCOV TODAY, V6, P78, DOI 10.1016/S1359-6446(00)01602-0; Rouhi AM, 2003, CHEM ENG NEWS, V81, P75; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; Uetrecht J, 2003, DRUG DISCOV TODAY, V8, P832, DOI 10.1016/S1359-6446(03)02816-2; 2003, DRUG DISCOV DEV, V6, P30	14	98	101	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	2004	303	5665					1810	1813		10.1126/science.1096800	http://dx.doi.org/10.1126/science.1096800			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031494				2022-12-28	WOS:000220281600042
J	Noble, MEM; Endicott, JA; Johnson, LN				Noble, MEM; Endicott, JA; Johnson, LN			Protein kinase inhibitors: Insights into drug design from structure	SCIENCE			English	Review							CYCLIN-DEPENDENT KINASE; GROWTH-FACTOR RECEPTOR; ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; P38 MAP KINASE; CELL-CYCLE; BCR-ABL; ANGIOGENESIS INHIBITORS; GLYCOGEN-PHOSPHORYLASE; CLINICAL DEVELOPMENT	Protein kinases are targets for treatment of a number of diseases. This review focuses on kinase inhibitors that are in the clinic or in clinical trials and for which structural information is available. Structures have informed drug design and have illuminated the mechanism of inhibition. We review progress with the receptor tyrosine kinases (growth factor receptors EGFR, VEGFR, and FGFR) and nonreceptor tyrosine kinases (Bcr-Abl), where advances have been made with cancer therapeutic agents such as Herceptin and Gleevec. Among the serine-threonine kinases, p38, Rho-kinase, cyclin-dependent kinases, and Chk1 have been targeted with productive results for inflammation and cancer. Structures have provided insights into targeting the inactive or active form of the kinase, for targeting the global constellation of residues at the ATP site or less conserved additional pockets or single residues, and into targeting noncatalytic domains.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford 3X2 3QU, England	University of Oxford	Johnson, LN (corresponding author), Univ Oxford, Dept Biochem, Lab Mol Biophys, Rex Richards Bldg, Oxford 3X2 3QU, England.	louise@biop.ox.ac.uk		Noble, Martin/0000-0002-3595-9807; Endicott, Jane/0000-0003-4868-0116				[Anonymous], 1992, CHIN DRUGS PLANT ORI; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Barker AJ, 2001, BIOORG MED CHEM LETT, V11, P1911, DOI 10.1016/S0960-894X(01)00344-4; Baselga J, 2002, ONCOLOGY-BASEL, V63, P6, DOI 10.1159/000066198; Blanke C D, 2001, Curr Treat Options Oncol, V2, P485, DOI 10.1007/s11864-001-0070-0; Breitenlechner C, 2003, STRUCTURE, V11, P1595, DOI 10.1016/j.str.2003.11.002; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Corbin AS, 2003, BLOOD, V101, P4611, DOI 10.1182/blood-2002-12-3659; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; Davies TG, 2002, NAT STRUCT BIOL, V9, P745, DOI 10.1038/nsb842; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; DEMOLINER E, UNPUB; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Engh RA, 2002, PHARMACOL THERAPEUT, V93, P99, DOI 10.1016/S0163-7258(02)00180-8; Fabbro D, 2002, PHARMACOL THERAPEUT, V93, P79, DOI 10.1016/S0163-7258(02)00179-1; Fischer PM, 2002, PROGR CELL CYCLE RES, V5, P235; FITZGERALD CE, 2000, NAT STRUCT BIOL, V10, P764; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Giles FJ, 2002, ONCOLOGY-NY, V16, P23; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Harper JW, 2001, CHEM REV, V101, P2511, DOI 10.1021/cr0001030; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Hidalgo M, 2001, J CLIN ONCOL, V19, P3267, DOI 10.1200/JCO.2001.19.13.3267; Holton S, 2003, STRUCTURE, V11, P1329, DOI 10.1016/j.str.2003.09.020; Johnson LN, 2002, PHARMACOL THERAPEUT, V93, P113, DOI 10.1016/S0163-7258(02)00181-X; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kaiser A, 2001, ARCH BIOCHEM BIOPHYS, V386, P179, DOI 10.1006/abbi.2000.2220; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; KAUR G, 1992, J NATL CANCER I, V84, P1736, DOI 10.1093/jnci/84.22.1736; Kim KS, 2002, J MED CHEM, V45, P3905, DOI 10.1021/jm0201520; Komander D, 2003, BIOCHEM J, V375, P255, DOI 10.1042/BJ20031119; Kontopidis G, 2003, STRUCTURE, V11, P1537, DOI 10.1016/j.str.2003.11.006; Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Levitzki A, 2003, ACCOUNTS CHEM RES, V36, P462, DOI 10.1021/ar0201207; MANLEY PW, 2003, BIOCH BIOPHYS ACTA; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; McKenna WG, 2003, GENE CHROMOSOME CANC, V38, P330, DOI 10.1002/gcc.10296; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Nagar B, 2002, CANCER RES, V62, P4236; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Oikonomakos NG, 2000, J BIOL CHEM, V275, P34566, DOI 10.1074/jbc.M004485200; Ono-Saito N, 1999, PHARMACOL THERAPEUT, V82, P123, DOI 10.1016/S0163-7258(98)00070-9; Pargellis C, 2002, NAT STRUCT BIOL, V9, P268, DOI 10.1038/nsb770; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PRATT DJ, IN PRESS CURR OPIN D; Sausville EA, 2003, ANNU REV PHARMACOL, V43, P199, DOI 10.1146/annurev.pharmtox.43.100901.135813; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schiering N, 2003, P NATL ACAD SCI USA, V100, P12654, DOI 10.1073/pnas.1734128100; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; SHAPIRO G, 2003, P AN M AM SOC CLIN, V22, P199; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; Shewchuk L, 2000, J MED CHEM, V43, P133, DOI 10.1021/jm990401t; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sridhar SS, 2003, LUNG CANCER, V42, pS81, DOI 10.1016/S0169-5002(03)00308-8; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wissner A, 2002, BIOORG MED CHEM LETT, V12, P2893, DOI 10.1016/S0960-894X(02)00598-X; Xiao ZJ, 2002, LEUKEMIA LYMPHOMA, V43, P1763, DOI 10.1080/1042819021000006295; Young TA, 2003, NAT STRUCT BIOL, V10, P168, DOI 10.1038/nsb897; Zhai SP, 2002, ANN PHARMACOTHER, V36, P905; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200	71	1022	1096	3	272	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1800	1805		10.1126/science.1095920	http://dx.doi.org/10.1126/science.1095920			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031492				2022-12-28	WOS:000220281600040
J	Donnadieu, Y; Godderis, Y; Ramstein, G; Nedelec, A; Meert, J				Donnadieu, Y; Godderis, Y; Ramstein, G; Nedelec, A; Meert, J			A 'snowball Earth' climate triggered by continental break-up through changes in runoff	NATURE			English	Article							GLACIAL DEPOSITS; LOW-LATITUDE; CONSTRAINTS; SIMULATION; REVERSALS; EROSION; IMPACT; MODEL; RATES; MA	Geological and palaeomagnetic studies indicate that ice sheets may have reached the Equator at the end of the Proterozoic eon, 800 to 550 million years ago(1,2), leading to the suggestion of a fully ice-covered 'snowball Earth' (3,4). Climate model simulations indicate that such a snowball state for the Earth depends on anomalously low atmospheric carbon dioxide concentrations(5,6), in addition to the Sun being 6 per cent fainter than it is today. However, the mechanisms producing such low carbon dioxide concentrations remain controversial(7,8). Here we assess the effect of the palaeogeographic changes preceding the Sturtian glacial period, 750 million years ago, on the long-term evolution of atmospheric carbon dioxide levels using the coupled climate(9) geochemical(10) model GEOCLIM. In our simulation, the continental break-up of Rodinia leads to an increase in runoff and hence consumption of carbon dioxide through continental weathering that decreases atmospheric carbon dioxide concentrations by 1,320 p. p. m. This indicates that tectonic changes could have triggered a progressive transition from a 'greenhouse' to an 'icehouse' climate during the Neoproterozoic era. When we combine these results with the concomitant weathering effect of the voluminous basaltic traps erupted throughout the break-up of Rodinia(11), our simulation results in a snowball glaciation.	CEA, CNRS, Lab Sci Climat & Environm, F-91191 Gif Sur Yvette, France; Univ Toulouse 3, CNRS, UMR 5563, Lab Mecan & Transferts Geol,IRD, F-31400 Toulouse, France; Univ Florida, Dept Geol Sci, Gainesville, FL 32611 USA	UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut de Recherche pour le Developpement (IRD); State University System of Florida; University of Florida	Donnadieu, Y (corresponding author), CEA, CNRS, Lab Sci Climat & Environm, F-91191 Gif Sur Yvette, France.	tiphe@lsce.saclay.cea.fr	Ramstein, Gilles/L-3328-2014; Meert, Joseph G/D-9633-2014; Donnadieu, Yannick/G-7546-2016	Ramstein, Gilles/0000-0002-1522-917X; Meert, Joseph G/0000-0003-0297-3239; Donnadieu, Yannick/0000-0002-7315-2684; NEDELEC, Anne/0000-0003-4038-4224				Barfod GH, 2002, EARTH PLANET SC LETT, V201, P203, DOI 10.1016/S0012-821X(02)00687-8; Berner RA, 1997, SCIENCE, V276, P544, DOI 10.1126/science.276.5312.544; Dessert C, 2001, EARTH PLANET SC LETT, V188, P459, DOI 10.1016/S0012-821X(01)00317-X; Donnadieu Y, 2003, EARTH PLANET SC LETT, V208, P101, DOI 10.1016/S0012-821X(02)01152-4; DONNADIEU Y, IN PRESS CLIM DYN; DONNADIEU Y, IN PRESS MULTIDISCIP; Evans DAD, 2000, AM J SCI, V300, P347, DOI 10.2475/ajs.300.5.347; GAFFIN S, 1987, AM J SCI, V287, P596, DOI 10.2475/ajs.287.6.596; Gaillardet J, 1999, CHEM GEOL, V159, P3, DOI 10.1016/S0009-2541(99)00031-5; Ganopolski A, 1998, NATURE, V391, P351, DOI 10.1038/34839; Godderis Y, 2004, PALAEOGEOGR PALAEOCL, V202, P309, DOI 10.1016/S0031-0182(03)00641-2; Godderis Y, 2003, EARTH PLANET SC LETT, V211, P1, DOI 10.1016/S0012-821X(03)00197-3; Hoffman PF, 2002, TERRA NOVA, V14, P129, DOI 10.1046/j.1365-3121.2002.00408.x; Hyde WT, 2000, NATURE, V405, P425, DOI 10.1038/35013005; Kirschvink J. L., 1992, PROTEROZOIC BIOSPHER, P51; Knoll AH, 2000, PRECAMBRIAN RES, V100, P3, DOI 10.1016/S0301-9268(99)00067-4; Li ZX, 2003, PRECAMBRIAN RES, V122, P85, DOI 10.1016/S0301-9268(02)00208-5; Meert JG, 2003, TECTONOPHYSICS, V375, P261, DOI 10.1016/S0040-1951(03)00342-1; Meert JG, 2003, TECTONOPHYSICS, V362, P1, DOI 10.1016/S0040-1951(02)00629-7; Millot R, 2002, EARTH PLANET SC LETT, V196, P83, DOI 10.1016/S0012-821X(01)00599-4; Oliva P, 2003, CHEM GEOL, V202, P225, DOI 10.1016/j.chemgeo.2002.08.001; Petoukhov V, 2000, CLIM DYNAM, V16, P1, DOI 10.1007/PL00007919; Pisarevsky SA, 2000, GEOPHYS J INT, V140, P598, DOI 10.1046/j.1365-246X.2000.t01-1-00056.x; Poulsen CJ, 2001, GEOPHYS RES LETT, V28, P1575, DOI 10.1029/2000GL012058; RICE AHN, 2003, GEOPH RES ABSTR, V5, P11425; Rowley DB, 2002, GEOL SOC AM BULL, V114, P927, DOI 10.1130/0016-7606(2002)114<0927:ROPCAD>2.0.CO;2; Schrag DP, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000219; Sohl LE, 1999, GEOL SOC AM BULL, V111, P1120, DOI 10.1130/0016-7606(1999)111<1120:PPRIMC>2.3.CO;2; Trindade RIF, 2003, TERRA NOVA, V15, P441, DOI 10.1046/j.1365-3121.2003.00510.x; WALKER JCG, 1981, J GEOPHYS RES-OCEANS, V86, P9776, DOI 10.1029/JC086iC10p09776	30	209	218	4	102	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	2004	428	6980					303	306		10.1038/nature02408	http://dx.doi.org/10.1038/nature02408			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15029192				2022-12-28	WOS:000220250200039
J	Murabito, JM; Nam, BH; D'Agostino, RB; Lloyd-Jones, DM; O'Donnell, CJ; Wilson, PWF				Murabito, JM; Nam, BH; D'Agostino, RB; Lloyd-Jones, DM; O'Donnell, CJ; Wilson, PWF			Accuracy of offspring reports of parental cardiovascular disease history: The Framingham offspring study	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; FAMILY-HISTORY; MYOCARDIAL-INFARCTION; ARTERY DISEASE; RISK-FACTORS; CHOLESTEROL; STROKE	Background: Family history is used to infer the risk for heart disease; however, little is known about the accuracy of family history reports. Objective: To examine the accuracy of offspring reports of parental cardiovascular disease. Design: Validation study. Setting: Framingham Heart Study. Participants: Offspring participants of the multigenerational Framingham Heart Study with both parents in the original cohort. Measurements: 791 men and 837 women (mean age, 57 years) completed a family history questionnaire from 1995 to 1998. Offspring reports were compared with confirmed medical evidence of parental status, and positive and negative predictive values and likelihood ratios were calculated. Results: Positive reports of high blood pressure, diabetes, and high cholesterol levels in fathers were accurate: Positive predictive values were 83% (95% CI, 80% to 86%), 76% (CI, 70% to 82%), and 78% (CI, 73% to 83%), respectively. Corresponding positive predictive values for reports in mothers were 91% (Cl, 89% to 93%), 79% (CI, 73% to 85%), and 88% (CI, 84% to 92%), respectively. Positive predictive values for reports of paternal heart attack occurring before 55 years of age and for stroke occurring before 65 years of age were 28% (CI, 22% to 34%) and 43% (CI, 33% to 53%), respectively, whereas the positive likelihood ratios were 8.6 (CI, 6.8 to 10.9) and 11.2 (CI, 9.2 to 13.6), respectively. Negative predictive values for parental history reports were greater than 90%, except for high blood pressure and high cholesterol level (negative predictive values, 33% to 55%, and negative likelihood ratios, 0.47 to 0.88). Limitations: This study does not determine whether more accurate measures of family history would meaningfully improve estimation of cardiovascular risk. Conclusions: Negative parental history reports were reliable, except for hypertension and high cholesterol levels. Although reports of parental premature heart attack and stroke had high likelihood ratios, their predictive values were low because the prevalence of these conditions was low in parents. If patients were more aware of their parents' medical illnesses, they might be able to estimate their risk for disease more accurately and perhaps motivate themselves to follow a healthy lifestye.	Framingham Heart Dis Epidemiol Study, NHLBI, Framingham, MA 01702 USA; Boston Univ, Massachusetts Gen Hosp, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; NHLBI, Bethesda, MD 20892 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Murabito, JM (corresponding author), Framingham Heart Dis Epidemiol Study, NHLBI, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.	Joanne@fram.nhlbi.nih.gov	Lloyd-Jones, Donald M/C-5899-2009; Wilson, Peter W.F./J-2455-2016	Lloyd-Jones, Donald/0000-0003-0847-6110; Murabito, Joanne/0000-0002-0192-7516	NHLBI NIH HHS [N01-HC-25195] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		American Diabetes Association, 1998, DIABETES CARE S1, V12, pS20, DOI DOI 10.2337/DIACARE.21.1.S20; Bensen JT, 1999, GENET EPIDEMIOL, V17, P141, DOI 10.1002/(SICI)1098-2272(1999)17:2<141::AID-GEPI4>3.0.CO;2-Q; CASTELLI WP, 1983, CIRCULATION, V67, P730, DOI 10.1161/01.CIR.67.4.730; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; COLDITZ GA, 1991, AM J CARDIOL, V67, P933, DOI 10.1016/0002-9149(91)90163-F; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; Gavin JR, 1999, DIABETES CARE, V22, pS5; HUNT SC, 1986, J CHRON DIS, V39, P809, DOI 10.1016/0021-9681(86)90083-4; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KEE F, 1993, BRIT MED J, V307, P1528, DOI 10.1136/bmj.307.6918.1528; KHAW KT, 1986, CIRCULATION, V74, P239, DOI 10.1161/01.CIR.74.2.239; KIELY DK, 1993, STROKE, V24, P1366, DOI 10.1161/01.STR.24.9.1366; Leander K, 2001, EPIDEMIOLOGY, V12, P215, DOI 10.1097/00001648-200103000-00014; Liao DP, 1997, STROKE, V28, P1908, DOI 10.1161/01.STR.28.10.1908; Lloyd-Jones DM, 1998, ANN INTERN MED, V129, P1020, DOI 10.7326/0003-4819-129-12-199812150-00005; Lloyd-Jones DM, 2003, CIRCULATION, V108, P725; MYERS RH, 1990, AM HEART J, V120, P963, DOI 10.1016/0002-8703(90)90216-K; RADICE M, 1986, AM J EPIDEMIOL, V124, P332, DOI 10.1093/oxfordjournals.aje.a114392; Reese S, 2001, JAMA-J AM MED ASSOC, V286, P1706; RONCAGLIONI MC, 1992, CIRCULATION, V85, P2065, DOI 10.1161/01.CIR.85.6.2065; *SAS I INC, 1999, SAS US GUID VERS 8, V1; *SAS I INC, 1999, SAS US GUID VERS 8, V3; SAS Institute, 1999, SAS US GUID VERS 8, V2; Sesso HD, 2001, CIRCULATION, V104, P393, DOI 10.1161/hc2901.093115; Silberberg JS, 1998, AM J EPIDEMIOL, V147, P1123; Tozawa M, 2001, HYPERTENS RES, V24, P93, DOI 10.1291/hypres.24.93; Watt G, 2000, J EPIDEMIOL COMMUN H, V54, P859, DOI 10.1136/jech.54.11.859; Weissler AM, 1999, MAYO CLIN PROC, V74, P1061, DOI 10.4065/74.11.1061; 1997, ARCH INTERN MED, V157, P2413	30	139	141	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 16	2004	140	6					434	440		10.7326/0003-4819-140-6-200403160-00010	http://dx.doi.org/10.7326/0003-4819-140-6-200403160-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803AU	15023709				2022-12-28	WOS:000220204800004
J	Bower, GC; Falcke, H; Herrnstein, RM; Zhao, JH; Goss, WM; Backer, DC				Bower, GC; Falcke, H; Herrnstein, RM; Zhao, JH; Goss, WM; Backer, DC			Detection of the intrinsic size of Sagittarius A* through closure amplitude imaging	SCIENCE			English	Article							SUPERMASSIVE BLACK-HOLE; SCATTER-BROADENED IMAGE; GALACTIC-CENTER; PROPER MOTION; RADIO; ELECTRONS; SPECTRUM; MODEL; POLARIZATION; VARIABILITY	We have detected the intrinsic size of Sagittarius A*, the Galactic center radio source associated with a supermassive black hole, showing that the short-wavelength radio emission arises from very near the event horizon of the black hole. Radio observations with the Very Long Baseline Array show that the source has a size of 24 +/- 2 Schwarzschild radii at 7-millimeter wavelength. In one of eight 7-millimeter epochs, we also detected an increase in the intrinsic size of 60(-17)(+25)%. These observations place a lower limit to the mass density of Sagittarius A* of 1.4 x 10(4) solar masses per cubic astronomical unit.	Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Univ Calif Berkeley, Radio Astron Lab, Berkeley, CA 94720 USA; ASTRON, Radio Observ Westerbork, NL-7990 AA Dwingeloo, Netherlands; Univ Nijmegen, Dept Astron, NL-6500 GL Nijmegen, Netherlands; Max Planck Inst Radioastron, D-53121 Bonn, Germany; Columbia Univ, Dept Astron, New York, NY 10027 USA; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Natl Radio Astron Observ, Array Operat Ctr, Socorro, NM 87801 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Radboud University Nijmegen; Max Planck Society; Columbia University; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; National Radio Astronomy Observatory (NRAO)	Bower, GC (corresponding author), Univ Calif Berkeley, Dept Astron, 601 Campbell Hall, Berkeley, CA 94720 USA.	gbower@astro.berkeley.edu	Bower, Geoffrey/ABC-8386-2020; Falcke, Heino D. E./H-5262-2012	Bower, Geoffrey/0000-0003-4056-9982; Falcke, Heino D. E./0000-0002-2526-6724				Backer DC, 1999, ASTROPHYS J, V524, P805, DOI 10.1086/307857; Baganoff FK, 2001, NATURE, V413, P45, DOI 10.1038/35092510; Beckert T, 1997, ASTRON ASTROPHYS, V328, P95; BLANDFORD RD, 1979, ASTROPHYS J, V232, P34, DOI 10.1086/157262; Bower GC, 2003, ASTROPHYS J, V588, P331, DOI 10.1086/373989; Bower GC, 2002, ASTROPHYS J, V571, P843, DOI 10.1086/340064; Bower GC, 2001, ASTROPHYS J, V558, P127, DOI 10.1086/322441; Broderick A, 2003, MON NOT R ASTRON SOC, V342, P1280, DOI 10.1046/j.1365-8711.2003.06618.x; Desai KM, 2001, ASTROPHYS J SUPPL S, V133, P395, DOI 10.1086/320349; Doeleman SS, 2001, ASTRON J, V121, P2610, DOI 10.1086/320376; Falcke H, 2000, ASTRON ASTROPHYS, V362, P113; Falcke H, 1998, ASTROPHYS J, V499, P731, DOI 10.1086/305687; Falcke H, 2000, ASTROPHYS J, V528, pL13, DOI 10.1086/312423; Genzel R, 2003, NATURE, V425, P934, DOI 10.1038/nature02065; Ghez AM, 2004, ASTROPHYS J, V601, pL159, DOI 10.1086/382024; Ghez AM, 2003, ASTROPHYS J, V586, pL127, DOI 10.1086/374804; Goss WM, 2003, ASTRON NACHR, V324, P497, DOI 10.1002/asna.200385047; Greisen EW, 2003, ASTROPHYS SPACE SC L, V285, P109; HERRNSTEIN R, IN PRESS ASTRON J; Lazio TJW, 1998, ASTROPHYS J, V505, P715, DOI 10.1086/306174; Lo KY, 1998, ASTROPHYS J, V508, pL61, DOI 10.1086/311726; Maoz E, 1998, ASTROPHYS J, V494, pL181, DOI 10.1086/311194; MELIA F, 1994, ASTROPHYS J, V426, P577, DOI 10.1086/174094; Melia F, 2001, ANNU REV ASTRON ASTR, V39, P309, DOI 10.1146/annurev.astro.39.1.309; NARAYAN R, 1989, MON NOT R ASTRON SOC, V238, P963, DOI 10.1093/mnras/238.3.963; Narayan R, 1998, ASTROPHYS J, V492, P554, DOI 10.1086/305070; Nord ME, 2004, ASTROPHYS J, V601, pL51, DOI 10.1086/381885; REID M, 2003, ASTRON NACHR, V324, pS1; Reid MJ, 1999, ASTROPHYS J, V524, P816, DOI 10.1086/307855; ROGERS AEE, 1995, ASTRON J, V109, P1391, DOI 10.1086/117371; Schodel R, 2003, ASTROPHYS J, V596, P1015, DOI 10.1086/378122; Thompson A. R., 2001, INTERFEROMETRY SYNTH; Trotter AS, 1998, ASTROPHYS J, V493, P666, DOI 10.1086/305142; WILKINSON PN, 1994, MON NOT R ASTRON SOC, V269, P67, DOI 10.1093/mnras/269.1.67; Yuan F, 2003, ASTROPHYS J, V598, P301, DOI 10.1086/378716; YUSEFZADEH F, 1994, ASTROPHYS J, V434, pL63, DOI 10.1086/187575; Zhao JH, 2003, ASTROPHYS J, V586, pL29, DOI 10.1086/374581	37	165	169	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 30	2004	304	5671					704	708		10.1126/science.1094023	http://dx.doi.org/10.1126/science.1094023			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	816JD	15060284	Green Submitted			2022-12-28	WOS:000221105300036
J	Lu, L; Shen, YF; Chen, XH; Qian, LH; Lu, K				Lu, L; Shen, YF; Chen, XH; Qian, LH; Lu, K			Ultrahigh strength and high electrical conductivity in copper	SCIENCE			English	Article							NANOCRYSTALLINE COPPER; RESISTIVITY; DUCTILITY; BEHAVIOR; NICKEL; CU	Methods used to strengthen metals generally also cause a pronounced decrease in electrical conductivity, so that a tradeoff must be made between conductivity and mechanical strength. We synthesized pure copper samples with a high density of nanoscale growth twins. They showed a tensile strength about 10 times higher than that of conventional coarse-grained copper, while retaining an electrical conductivity comparable to that of pure copper. The ultrahigh strength originates from the effective blockage of dislocation motion by numerous coherent twin boundaries that possess an extremely low electrical resistivity, which is not the case for other types of grain boundaries.	Chinese Acad Sci, Inst Met Res, Shenyang Natl Lab Mat Sci, Shenyang 110016, Peoples R China	Chinese Academy of Sciences; Institute of Metal Research, CAS	Lu, K (corresponding author), Chinese Acad Sci, Inst Met Res, Shenyang Natl Lab Mat Sci, Shenyang 110016, Peoples R China.	lu@imr.ac.cn	Shen, Yongfeng/ABI-4583-2020; Lu, Lei/E-3864-2012	Shen, Y.F./0000-0001-5366-3906				ANDERWS PV, 1969, PHILOS MAG, V19, P887; Brandes E.A., 1998, SMITHELLS METALS REF; BRENNER SS, 1956, J APPL PHYS, V27, P1484, DOI 10.1063/1.1722294; Callister DW., 2000, MAT SCI ENG INTRO, V5; CHRISTIAN JW, 1995, PROG MATER SCI, V39, P1, DOI 10.1016/0079-6425(94)00007-7; DAHLGREN SD, 1977, THIN SOLID FILMS, V40, P345, DOI 10.1016/0040-6090(77)90136-5; Koch CC, 1999, MRS BULL, V24, P54, DOI 10.1557/S0883769400051551; MANNAN KM, 1975, J PHYS F MET PHYS, V5, P1687, DOI 10.1088/0305-4608/5/9/009; Meyers M.A., 1999, MECH BEHAV MAT; Nakamichi I, 1996, MATER SCI FORUM, V207-, P47, DOI 10.4028/www.scientific.net/MSF.207-209.47; Natter H, 1998, J MATER RES, V13, P1186, DOI 10.1557/JMR.1998.0169; PRY RH, 1954, ACTA METALL MATER, V2, P318, DOI 10.1016/0001-6160(54)90174-1; Rasmussen AA, 2001, ELECTROCHIM ACTA, V47, P67, DOI 10.1016/S0013-4686(01)00583-7; Sanders PG, 1997, ACTA MATER, V45, P4019, DOI 10.1016/S1359-6454(97)00092-X; Sutton A. P., 1995, INTERFACES CRYSTALLI; Wang YM, 2002, NATURE, V419, P912, DOI 10.1038/nature01133; YOSHINAGA H, 1966, PHYS STATUS SOLIDI, V18, P625, DOI 10.1002/pssb.19660180215; Youngdahl CJ, 2001, SCRIPTA MATER, V44, P1475, DOI 10.1016/S1359-6462(01)00712-6	18	2340	2450	112	1800	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	2004	304	5669					422	426		10.1126/science.1092905	http://dx.doi.org/10.1126/science.1092905			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	812NE	15031435				2022-12-28	WOS:000220845400043
J	Oliver, D; Lien, CC; Soom, M; Baukrowitz, T; Jonas, P; Fakler, B				Oliver, D; Lien, CC; Soom, M; Baukrowitz, T; Jonas, P; Fakler, B			Functional conversion between A-type and delayed rectifier K+ channels by membrane lipids	SCIENCE			English	Article							ARACHIDONIC-ACID; POTASSIUM CHANNELS; ACTION-POTENTIALS; INACTIVATION; TRANSIENT; ION; PHOSPHORYLATION; SENSITIVITY; INHIBITION; MODULATION	Voltage-gated potassium (Kv) channels control action potential repolarization, interspike membrane potential, and action potential frequency in excitable cells. It is thought that the combinatorial association between distinct alpha and beta subunits determines whether Kv channels function as non-inactivating delayed rectifiers or as rapidly inactivating A-type channels. We show that membrane lipids can convert A-type channels into delayed rectifiers and vice versa. Phosphoinositides remove N-type inactivation from A-type channels by immobilizing the inactivation domains. Conversely, arachidonic acid and its amide anandamide endow delayed rectifiers with rapid voltage-dependent inactivation. The bidirectional control of Kv channel gating by lipids may provide a mechanism for the dynamic regulation of electrical signaling in the nervous system.	Univ Freiburg, Inst Physiol, D-79104 Freiburg, Germany; Univ Jena, Inst Physiol 2, D-07744 Jena, Germany	University of Freiburg; Friedrich Schiller University of Jena	Jonas, P (corresponding author), Univ Freiburg, Inst Physiol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	peter.jonas@physiologie.uni-freiburg.de; bernd.fakler@physiologie.uni-freiburg.de	Lien, Cheng-Chang/AAO-6249-2020; Oliver, Dominik/F-5845-2013	Lien, Cheng-Chang/0000-0002-6692-9942; Oliver, Dominik/0000-0002-8368-0923; Baukrowitz, Thomas/0000-0003-4562-0505; Jonas, Peter/0000-0001-5001-4804				Antz C, 1999, NAT STRUCT BIOL, V6, P146; Antz C, 1997, NATURE, V385, P272, DOI 10.1038/385272a0; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; CHANDY KG, 1995, HDB RECEPTORS CHANNE, V2; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Colbert CM, 1999, J NEUROSCI, V19, P8163; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P31, DOI 10.1113/jphysiol.1971.sp009366; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003; Geiger JRP, 2000, NEURON, V28, P927, DOI 10.1016/S0896-6273(00)00164-1; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; HONORE E, 1994, P NATL ACAD SCI USA, V91, P1937, DOI 10.1073/pnas.91.5.1937; Hwang TC, 2003, BIOCHEMISTRY-US, V42, P13646, DOI 10.1021/bi034887y; Jerng HH, 1999, J GEN PHYSIOL, V113, P641, DOI 10.1085/jgp.113.5.641; Keros S, 1997, J NEUROSCI, V17, P3476; Krauter T, 2001, MOL PHARMACOL, V59, P1086, DOI 10.1124/mol.59.5.1086; Lien CC, 2003, J NEUROSCI, V23, P2058; Lien CC, 2002, J PHYSIOL-LONDON, V538, P405, DOI 10.1113/jphysiol.2001.013066; Linden DJ, 1999, NEURON, V22, P661, DOI 10.1016/S0896-6273(00)80726-6; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OLIVER D, UNPUB; Pongs O, 1999, ANN NY ACAD SCI, V868, P344, DOI 10.1111/j.1749-6632.1999.tb11296.x; Roeper J, 1998, NATURE, V391, P390, DOI 10.1038/34916; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Suh BC, 2002, NEURON, V35, P507, DOI 10.1016/S0896-6273(02)00790-0; Valiyaveetil FI, 2002, BIOCHEMISTRY-US, V41, P10771, DOI 10.1021/bi026215y; Villarroel A, 1996, J NEUROSCI, V16, P1016; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Wu L, 2002, NATURE, V419, P947, DOI 10.1038/nature01118; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; Zhou YF, 2003, J MOL BIOL, V333, P965, DOI 10.1016/j.jmb.2003.09.022	41	268	278	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	2004	304	5668					265	270		10.1126/science.1094113	http://dx.doi.org/10.1126/science.1094113			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810QS	15031437				2022-12-28	WOS:000220719400039
J	Bibring, JP; Langevin, Y; Poulet, F; Gendrin, A; Gondet, B; Berthe, M; Soufflot, A; Drossart, P; Combes, M; Bellucci, G; Moroz, V; Mangold, N; Schmitt, B				Bibring, JP; Langevin, Y; Poulet, F; Gendrin, A; Gondet, B; Berthe, M; Soufflot, A; Drossart, P; Combes, M; Bellucci, G; Moroz, V; Mangold, N; Schmitt, B		OMEGA Team	Perennial water ice identified in the south polar cap of Mars	NATURE			English	Article							SURFACE; TOPOGRAPHY	The inventory of water and carbon dioxide reservoirs on Mars are important clues for understanding the geological, climatic and potentially exobiological evolution of the planet(1). From the early mapping observation of the permanent ice caps on the martian poles(2,3), the northern cap was believed to be mainly composed of water ice, whereas the southern cap was thought to be constituted of carbon dioxide ice. However, recent missions ( NASA missions Mars Global Surveyor and Odyssey) have revealed surface structures(4), altimetry profiles(5), underlying buried hydrogen(6), and temperatures of the south polar regions that are thermodynamically consistent with a mixture of surface water ice and carbon dioxide(7). Here we present the first direct identification and mapping of both carbon dioxide and water ice in the martian high southern latitudes, at a resolution of 2 km, during the local summer, when the extent of the polar ice is at its minimum. We observe that this south polar cap contains perennial water ice in extended areas: as a small admixture to carbon dioxide in the bright regions; associated with dust, without carbon dioxide, at the edges of this bright cap; and, unexpectedly, in large areas tens of kilometres away from the bright cap.	Inst Astrophys Spatiale, F-91405 Orsay, France; Observ Paris, LESIA, F-92195 Meudon, France; INAF, IFSI, Rome, Italy; IKI, Moscow, Russia; OrsayTerre, F-91405 Orsay, France; Lab Planetol Grenoble, F-38400 Grenoble, France	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Istituto Nazionale Astrofisica (INAF); Russian Academy of Sciences; Space Research Institute of the Russian Academy of Sciences; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Bibring, JP (corresponding author), Inst Astrophys Spatiale, Orsay Campus, F-91405 Orsay, France.	bibring@ias.u-psud.fr	Bellucci, Giancarlo/ABA-9201-2020; Drossart, Pierre/H-8670-2013; Schmitt, Bernard/A-1064-2009; Fouchet, Thierry/C-6374-2017	Bellucci, Giancarlo/0000-0003-0867-8679; Schmitt, Bernard/0000-0002-1230-6627; Forni, Olivier/0000-0001-6772-9689; Altieri, Francesca/0000-0002-6338-8300; Capaccioni, Fabrizio/0000-0003-1631-4314; Fouchet, Thierry/0000-0001-9040-8285; Ignatiev, Nikolay/0000-0002-6358-7094; Cerroni, Priscilla/0000-0003-0239-2741; Erard, Stephane/0000-0002-9099-8366				BIBRING JP, IN PRESS ESA; Boynton WV, 2002, SCIENCE, V297, P81, DOI 10.1126/science.1073722; Byrne S, 2003, SCIENCE, V299, P1051, DOI 10.1126/science.1080148; Clifford SM, 2000, ICARUS, V144, P210, DOI 10.1006/icar.1999.6290; HERKENHOFF KE, 2001, USGS GEOLOGIC INVE I, V2686; Kieffer H. H., 1992, MARS, P1180; KIEFFER HH, 1979, J GEOPHYS RES, V84, P8263, DOI 10.1029/JB084iB14p08263; Nye JF, 2000, ICARUS, V144, P449, DOI 10.1006/icar.1999.6306; PAIGE DA, 1990, J GEOPHYS RES-SOLID, V95, P1319, DOI 10.1029/JB095iB02p01319; Poulet F, 2002, ICARUS, V160, P313, DOI 10.1006/icar.2002.6970; Schenk PM, 2000, J GEOPHYS RES-PLANET, V105, P24529, DOI 10.1029/1999JE001054; Smith DE, 1999, SCIENCE, V284, P1495, DOI 10.1126/science.284.5419.1495; Thomas PC, 2000, NATURE, V404, P161, DOI 10.1038/35004528; Titus TN, 2003, SCIENCE, V299, P1048, DOI 10.1126/science.1080497; 2003, ESA B, V115, P10	15	236	246	2	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 8	2004	428	6983					627	630		10.1038/nature02461	http://dx.doi.org/10.1038/nature02461			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810IE	15024393				2022-12-28	WOS:000220697200036
J	Awasthi, S; Kabra, SK; Kulkarni, M; Murali, N; Niswade, AK; Pillai, RM; Singhi, S; Chande, CA; Das, B; Jain, A; Kamath, J; Mathur, M; Raje, K; Roy, P; Lalitha, MK; Agarwal, G; Jayseelan, L; Qazi, S; Agarwal, G; Awasthi, S; Kabra, SK; Kaul, A; Singhi, S; Walter, SD; Pande, JN; Wakhlu, I				Awasthi, S; Kabra, SK; Kulkarni, M; Murali, N; Niswade, AK; Pillai, RM; Singhi, S; Chande, CA; Das, B; Jain, A; Kamath, J; Mathur, M; Raje, K; Roy, P; Lalitha, MK; Agarwal, G; Jayseelan, L; Qazi, S; Agarwal, G; Awasthi, S; Kabra, SK; Kaul, A; Singhi, S; Walter, SD; Pande, JN; Wakhlu, I		ISCAP Study Grp	Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANTIMICROBIAL RESISTANCE; STREPTOCOCCUS-PNEUMONIAE; CARRIAGE; THERAPY; COTRIMOXAZOLE	Objective To assess the efficacy of three days versus five days of treatment with oral amoxicillin for curing non-severe pneumonia in children.. Design Randomised, double blind, placebo controlled multicentre trial. Setting Outpatient departments of seven referral hospitals in India. Participants 2188 children aged 2-59 months, 1095 given three days of treatment and 1093 given five days. Intervention Oral amoxicillin 31-54 mg/kg/day in three divided doses. Main outcome measures Treatment failure: defined as development of chest indrawing, convulsions, drowsiness, or inability to drink at any time; respiratory rate above age specific cut-off points on day 3 or later; or oxygen saturation by pulse oximetry < 90% on day 3. Results The clinical cure rates with three days and five days of treatment were 89.5% and 89.9%, respectively (absolute difference 0.4 (95% confidence interval - 2.1 to 3.0)). Adherence to treatment regimen was 94% and 85% for three day and five day treatments, respectively. Loss to follow up was 5.4% by day 5. There were no deaths, 41 hospitalisations, and 36 minor adverse reactions. There were 225 (10.3%) clinical failures and 106 (5.3%) relapses, and rates were similar in both treatments. At enrolment, 513 (23.4%) children tested positive for respiratory syncytial virus, and Streptococcus pneumoniae and Haemophilus influenzae were isolated from the nasopharynx in 878 (40.4%) and 496 (22.8%) children, respectively. Clinical failure was associated with isolation of respiratory syncytial virus (adjusted odds ratio 1.95 (95% confidence interval 1.0 to 3.8)), excess respiratory rate of > 10 breaths/minute (2.89 (1.83 to 4.55)), and non-adherence with treatment at day 5 (11.57 (7.4 to 18.0)). Conclusions Treatment with oral amoxicillin for three days was as effective as for five days in children with non-severe pneumonia.	King Georges Med Univ, Dept Paediat & Clin Epidemiol, Lucknow 226003, Uttar Pradesh, India; All India Inst Med Sci, New Delhi, India; Lok Manya Tilak Med Coll & Hosp, Bombay, Maharashtra, India; Christian Med Coll & Hosp, Vellore, Tamil Nadu, India; Govt Med Coll, Nagpur, Maharashtra, India; Govt Med Coll, Trivandrum, Kerala, India; Postgrad Inst Med Sci, Chandigarh, India; Univ Lucknow, Lucknow 226007, Uttar Pradesh, India; WHO, Dept Child & Adolescent Hlth & Denv, CH-1211 Geneva, Switzerland	King George's Medical University; All India Institute of Medical Sciences (AIIMS) New Delhi; Christian Medical College & Hospital (CMCH) Vellore; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Lucknow University; World Health Organization	Awasthi, S (corresponding author), King Georges Med Univ, Dept Paediat & Clin Epidemiol, Lucknow 226003, Uttar Pradesh, India.	sawasthi@sancharnet.in	Agarwal, Girdhar/AAD-9909-2020; Walter, Stephen/AAB-5548-2022	Agarwal, Girdhar/0000-0003-4902-4436; Walter, Stephen/0000-0003-4157-8928				[Anonymous], 1981, B WORLD HEALTH ORGAN, V59, P707; [Anonymous], 1999, WORLD HLTH REPORT 19; Arason VA, 1996, BMJ-BRIT MED J, V313, P387; de Francisco A, 1998, ANN TROP PAEDIATR, V18, P17, DOI 10.1080/02724936.1998.11747920; Hazir T, 2002, LANCET, V360, P835; KOK T, 1991, ARCH PATHOL LAB MED, V115, P451; MASTRO TD, 1993, PEDIATR INFECT DIS J, V12, P824, DOI 10.1097/00006454-199310000-00006; MATHERS CD, 2001, GLOBAL BURDEN DIS 20; McCormick AW, 2003, NAT MED, V9, P424, DOI 10.1038/nm839; Michael M, 2003, COCHRANE DB SYST REV, V1, DOI [10.1002/14651858.CD003966, DOI 10.1002/14651858.CD003966]; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Parkin PC, 2002, ARCH DIS CHILD, V87, P221, DOI 10.1136/adc.87.3.221; Peltola H, 2001, Int J Infect Dis, V5, P3, DOI 10.1016/S1201-9712(01)90041-4; Pichichero ME, 1997, PEDIATR INFECT DIS J, V16, P680, DOI 10.1097/00006454-199707000-00011; RASMUSSEN Z, 1997, INT J TUBERC LUNG D, V1, P119; Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0; Schrag SJ, 2001, JAMA-J AM MED ASSOC, V286, P49, DOI 10.1001/jama.286.1.49; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; Straus WL, 1998, LANCET, V352, P270, DOI 10.1016/S0140-6736(97)10294-X; Thomas K, 1999, LANCET, V353, P1216, DOI 10.1016/S0140-6736(98)07228-6; Varon E, 2000, CLIN INFECT DIS, V31, P477, DOI 10.1086/313981; Weber MW, 1998, TROP MED INT HEALTH, V3, P268, DOI 10.1046/j.1365-3156.1998.00213.x	22	103	109	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	2004	328	7443					791	794						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	811CG	15070633				2022-12-28	WOS:000220749400016
J	Connor, JTH				Connor, JTH			Beyond the ivory tower: The Victorian revolution in surgery	SCIENCE			English	Editorial Material									Armed Forces Inst Pathol, Natl Museum Hlth & Med, Washington, DC 20306 USA	United States Department of Defense	Connor, JTH (corresponding author), Armed Forces Inst Pathol, Natl Museum Hlth & Med, Washington, DC 20306 USA.	connorj@afip.osd.mil						Basalla G., 1988, EVOLUTION TECHNOLOGY; Burney I, 2000, BODIES EVIDENCE MED; Connor J T, 1999, Clio Med, V55, P29; Connor J.T.H., 2000, DOING GOOD LIFE TORO; CONNOR JTH, 1994, J HIST MED ALL SCI, V49, P207, DOI 10.1093/jhmas/49.2.207; CONNOR JTH, 1987, ONTARIO HIST, V79, P92; GARRETT RW, 1901, COMMUNICATION; Pickstone J. V., 2000, WAYS KNOWING NEW HIS; Youngson A. J, 1979, SCI REVOLUTION VICTO; [No title captured]	10	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 2	2004	304	5667					54	55						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15060310				2022-12-28	WOS:000220567900029
J	Moreno, E; Basler, K				Moreno, E; Basler, K			dMyc transforms cells into super-competitors	CELL			English	Article							LONG-RANGE ACTION; DEVELOPING DROSOPHILA EYE; C-MYC; MORPHOGEN GRADIENT; ENDOCYTIC PATHWAY; TYROSINE KINASE; CELLULAR GROWTH; APOPTOSIS; CANCER; GENES	Overexpression of myc protooncogenes has been implicated in the genesis of many human tumors. Myc proteins seem to regulate diverse biological processes, but their role in tumorigenesis remains enigmatic. Here we use Drosophila imaginal discs to mimic situations in which cells with unequal levels of Myc protein are apposed and show that this invariably elicits a win/lose situation reminiscent of cell competition; cells with lower levels of dMyc are eliminated by apoptosis whereas cells with higher levels of dMyc over-proliferate. We find that this competitive behavior correlates with, and can be corrected by, the activation of the BMP/Dpp survival signaling pathway. Hence the heritable increase in dMyc levels causes cells to behave as "super-competitors" and reveals a novel mode of clonal expansion that causes, but also relies on, the killing of surrounding cells.	Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	University of Zurich	Basler, K (corresponding author), Univ Zurich, Inst Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	basler@molbio.unizh.ch	Moreno, Eduardo/D-7262-2011	Basler, Konrad/0000-0003-3534-1529; moreno, eduardo/0000-0001-5040-452X				Abrams JM, 2002, CELL, V110, P403, DOI 10.1016/S0092-8674(02)00904-2; Adachi-Yamada T, 2002, DEV BIOL, V251, P74, DOI 10.1006/dbio.2002.0821; Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904; Baker NE, 2001, CELL, V104, P699, DOI 10.1016/S0092-8674(02)06076-2; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bourbon HM, 2002, MECH DEVELOP, V110, P71, DOI 10.1016/S0925-4773(01)00566-4; Braakhuis BJM, 2003, CANCER RES, V63, P1727; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burke R, 1996, DEVELOPMENT, V122, P2261; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Entchev EV, 2000, CELL, V103, P981, DOI 10.1016/S0092-8674(00)00200-2; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; Gibson MC, 2002, DEV CELL, V3, P451, DOI 10.1016/S1534-5807(02)00264-2; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Guo QM, 2000, CANCER RES, V60, P5922; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Lambertsson A, 1998, ADV GENET, V38, P69, DOI 10.1016/S0065-2660(08)60142-X; Lawrence P., 1992, MAKING FLY GENETICS; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Martin-Castellanos C, 2002, DEVELOPMENT, V129, P1003; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; Milan M, 2002, EMBO REP, V3, P724, DOI 10.1093/embo-reports/kvf151; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; Moreno E, 2002, NATURE, V416, P755, DOI 10.1038/416755a; Muller B, 2003, CELL, V113, P221, DOI 10.1016/S0092-8674(03)00241-1; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Pai LM, 1996, J BIOL CHEM, V271, P32411, DOI 10.1074/jbc.271.50.32411; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Prober DA, 2000, CELL, V100, P435, DOI 10.1016/S0092-8674(00)80679-0; Queenan AM, 1997, DEVELOPMENT, V124, P3871; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rosenblatt J, 2001, CURR BIOL, V11, P1847, DOI 10.1016/S0960-9822(01)00587-5; RUBERTE E, 1995, CELL, V80, P890; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SIMPSON P, 1979, DEV BIOL, V69, P182, DOI 10.1016/0012-1606(79)90284-7; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Yu SY, 2002, DEVELOPMENT, V129, P3269; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; ZECCA M, 1995, DEVELOPMENT, V121, P2265; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	61	421	429	0	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 2	2004	117	1					117	129		10.1016/S0092-8674(04)00262-4	http://dx.doi.org/10.1016/S0092-8674(04)00262-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YV	15066287	Bronze, Green Accepted			2022-12-28	WOS:000221500300013
J	Yamanouchi, M; Chiba, D; Matsukura, F; Ohno, H				Yamanouchi, M; Chiba, D; Matsukura, F; Ohno, H			Current-induced domain-wall switching in a ferromagnetic semiconductor structure	NATURE			English	Article							ELECTRIC-CURRENT; MOTION; FILMS; FORCE	Magnetic information storage relies on external magnetic fields to encode logical bits through magnetization reversal. But because the magnetic fields needed to operate ultradense storage devices are too high to generate, magnetization reversal by electrical currents is attracting much interest as a promising alternative encoding method. Indeed, spin-polarized currents can reverse the magnetization direction of nanometre- sized metallic structures through torque(1-4); however, the high current densities of 10(7)-10(8) A cm(-2) that are at present required exceed the threshold values tolerated by the metal interconnects of integrated circuits(5,6). Encoding magnetic information in metallic systems has also been achieved by manipulating the domain walls at the boundary between regions with different magnetization directions(7-13), but the approach again requires high current densities of about 10(7) A cm(-2). Here we demonstrate that, in a ferromagnetic semiconductor structure, magnetization reversal through domain-wall switching can be induced in the absence of a magnetic field using current pulses with densities below 10(5) A cm(-2). The slow switching speed and low ferromagnetic transition temperature of our current system are impractical. But provided these problems can be addressed, magnetic reversal through electric pulses with reduced current densities could provide a route to magnetic information storage applications.	Tohoku Univ, Res Inst Elect Commun, Lab Nanoelect & Spintron, Aoba Ku, Sendai, Miyagi 9808577, Japan; Japan Sci & Technol Agcy, ERATO, Semicond Spintron Project, Tokyo, Japan	Tohoku University; Japan Science & Technology Agency (JST)	Ohno, H (corresponding author), Tohoku Univ, Res Inst Elect Commun, Lab Nanoelect & Spintron, Aoba Ku, Katahira 2-1-1, Sendai, Miyagi 9808577, Japan.	ohno@riec.tohoku.ac.jp	Yamanouchi, Michihiko/G-9635-2014; Chiba, Daichi/D-3438-2015; Ohno, Hideo/E-6453-2010	Chiba, Daichi/0000-0002-6631-5131; Ohno, Hideo/0000-0001-9688-8259				Albert FJ, 2000, APPL PHYS LETT, V77, P3809, DOI 10.1063/1.1330562; BERGER L, 1984, J APPL PHYS, V55, P1954, DOI 10.1063/1.333530; BERGER L, 1992, J APPL PHYS, V71, P2721, DOI 10.1063/1.351045; BERGER L, 1974, J PHYS CHEM SOLIDS, V35, P947, DOI 10.1016/S0022-3697(74)80104-6; Berger L, 1996, PHYS REV B, V54, P9353, DOI 10.1103/PhysRevB.54.9353; Chiba D, 2003, APPL PHYS LETT, V82, P3020, DOI 10.1063/1.1571666; Chiba D, 2003, SCIENCE, V301, P943, DOI 10.1126/science.1086608; Dietl T, 2000, SCIENCE, V287, P1019, DOI 10.1126/science.287.5455.1019; Dietl T, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.195205; Flatte ME, 2003, APPL PHYS LETT, V82, P4740, DOI 10.1063/1.1586996; FREITAS PP, 1985, J APPL PHYS, V57, P1266, DOI 10.1063/1.334524; Gan L, 2000, IEEE T MAGN, V36, P3047, DOI 10.1109/20.908674; Grollier J, 2003, APPL PHYS LETT, V83, P509, DOI 10.1063/1.1594841; Labaye Y, 2002, J APPL PHYS, V91, P5341, DOI 10.1063/1.1461065; MICHAEL NL, 2002, P ADV MET C 29 30 OC, P42; Ohno H, 1998, SCIENCE, V281, P951, DOI 10.1126/science.281.5379.951; Ohno H, 2000, NATURE, V408, P944, DOI 10.1038/35050040; Ohno Y, 1999, NATURE, V402, P790, DOI 10.1038/45509; Pearton SJ, 2003, J APPL PHYS, V93, P1, DOI 10.1063/1.1517164; Saito H, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.207202; SALHI E, 1994, J APPL PHYS, V76, P4787, DOI 10.1063/1.357250; SLONCZEWSKI JC, 1996, J MAGN MAGN MATER, V159, P1; SZE SM, 1988, VLSI TECHNOLOGY, P412; Tang HX, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.107201; Tatara G, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.086601; Tsoi M, 1998, PHYS REV LETT, V81, P493, DOI 10.1103/PhysRevLett.81.493; Tsoi M, 2003, APPL PHYS LETT, V83, P2617, DOI 10.1063/1.1578165; VERNIER N, 2003, DOMAIN WALL PROPAGAT	29	596	607	2	149	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					539	542		10.1038/nature02441	http://dx.doi.org/10.1038/nature02441			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15057826				2022-12-28	WOS:000220540100036
J	Berns, K; Hijmans, EM; Mullenders, J; Brummelkamp, TR; Velds, A; Heimerikx, M; Kerkhoven, RM; Madiredjo, M; Nijkamp, W; Weigelt, B; Agami, R; Ge, W; Cavet, G; Linsley, PS; Beijersbergen, RL; Bernards, R				Berns, K; Hijmans, EM; Mullenders, J; Brummelkamp, TR; Velds, A; Heimerikx, M; Kerkhoven, RM; Madiredjo, M; Nijkamp, W; Weigelt, B; Agami, R; Ge, W; Cavet, G; Linsley, PS; Beijersbergen, RL; Bernards, R			A large-scale RNAi screen in human cells identifies new components of the p53 pathway	NATURE			English	Article							MAMMALIAN-CELLS; TUMOR SUPPRESSION; GENE; EXPRESSION; INTERFERENCE; SENESCENCE; FIBROBLASTS; P19(ARF); ARREST; MDM2	RNA interference (RNAi) is a powerful new tool with which to perform loss-of-function genetic screens in lower organisms and can greatly facilitate the identification of components of cellular signalling pathways(1-3). In mammalian cells, such screens have been hampered by a lack of suitable tools that can be used on a large scale. We and others have recently developed expression vectors to direct the synthesis of short hairpin RNAs (shRNAs) that act as short interfering RNA (siRNA)-like molecules to stably suppress gene expression(4,5). Here we report the construction of a set of retroviral vectors encoding 23,742 distinct shRNAs, which target 7,914 different human genes for suppression. We use this RNAi library in human cells to identify one known and five new modulators of p53-dependent proliferation arrest. Suppression of these genes confers resistance to both p53-dependent and p19(ARF)-dependent proliferation arrest, and abolishes a DNA-damage-induced G1 cell-cycle arrest. Furthermore, we describe siRNA bar-code screens to rapidly identify individual siRNA vectors associated with a specific phenotype. These new tools will greatly facilitate large-scale loss-of-function genetic screens in mammalian cells.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Tumor Biol, NL-1066 CX Amsterdam, Netherlands; Rosetta Inpharmat Inc, Kirkland, WA 98034 USA	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Beijersbergen, RL (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.beijersbergen@nki.nl; r.bernards@nki.nl	Mullenders, Jasper/J-2398-2015; agami, reuven/GOG-8289-2022	Mullenders, Jasper/0000-0003-3737-6901; Beijersbergen, Roderick/0000-0003-0116-4130; Velds, Arno/0000-0003-4333-8872; Agami, Reuven/0000-0002-2848-2473; Hijmans, Marielle/0000-0003-4847-9412; Bernards, Rene/0000-0001-8677-3423				Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brummelkamp TR, 2002, J BIOL CHEM, V277, P6567, DOI 10.1074/jbc.M110492200; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brummelkamp TR, 2003, NAT REV CANCER, V3, P781, DOI 10.1038/nrc1191; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Dirac AMG, 2003, J BIOL CHEM, V278, P11731, DOI 10.1074/jbc.C300023200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Heetebrij RJ, 2003, CHEMBIOCHEM, V4, P573, DOI 10.1002/cbic.200200498; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; MIYASHITA T, 1995, CELL, V80, P293; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang AH, 1999, MOL CELL BIOL, V19, P7816	30	864	953	1	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	2004	428	6981					431	437		10.1038/nature02371	http://dx.doi.org/10.1038/nature02371			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042092	Green Published			2022-12-28	WOS:000220404300044
J	Proudman, C; Pinchbeck, G; Clegg, P; French, N				Proudman, C; Pinchbeck, G; Clegg, P; French, N			Equine welfare: Risk of horses falling in the Grand National	NATURE			English	Editorial Material							FATALITIES		Univ Liverpool, Fac Vet Sci, Epidemiol Grp, Wirral CH64 7TE, Merseyside, England	University of Liverpool	Proudman, C (corresponding author), Univ Liverpool, Fac Vet Sci, Epidemiol Grp, Wirral CH64 7TE, Merseyside, England.	c.j.proudman@liverpool.ac.uk	French, Nigel/F-5725-2011	French, Nigel/0000-0002-6334-0657; Proudman, Christopher/0000-0002-9634-8073				McKee S. L., 1995, Equine Veterinary Education, V7, P202, DOI 10.1111/j.2042-3292.1995.tb01225.x; TUNER M, 2002, BRIT J SPORT MED, V36, P430; Williams RB, 2001, EQUINE VET J, V33, P478, DOI 10.2746/042516401776254808	3	16	16	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 25	2004	428	6981					385	386		10.1038/428385a	http://dx.doi.org/10.1038/428385a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042079				2022-12-28	WOS:000220404300029
J	Lazzaro, BP; Sceurman, BK; Clark, AG				Lazzaro, BP; Sceurman, BK; Clark, AG			Genetic basis of natural variation in D-melanogaster antibacterial immunity	SCIENCE			English	Article							GENOTYPE-ENVIRONMENT INTERACTION; GENOME-WIDE ANALYSIS; EVOLUTION; EXPRESSION; PEPTIDE; RESISTANCE; PROTEINS; FAMILY	Many genes involved in Drosophila melanogaster innate immune processes have been identified, but whether naturally occurring polymorphism in these genes leads to variation in immune competence among wild flies has not been tested. We report here substantial variability among wild-derived D. melanogaster in the ability to suppress infection by a Gram-negative entomopathogen, Serratia marcescens. Variability in immune competence was significantly associated with nucleotide polymorphism in 16 innate immunity genes, corresponding primarily to pathogen recognition and intracellular signaling loci, and substantial epistasis was detected between intracellular signaling and antimicrobial peptide genes. Variation in these genes, therefore, seems to drive variability in immunocompetence among wild Drosophila.	Cornell Univ, Dept Entomol, Ithaca, NY 14853 USA; NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Cornell University	Lazzaro, BP (corresponding author), Cornell Univ, Dept Entomol, 4138 Comstock Hall, Ithaca, NY 14853 USA.	bl89@cornell.edu		Clark, Andrew/0000-0001-7159-8511	NIAID NIH HHS [AI46402] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046402] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASLING B, 1995, INSECT BIOCHEM MOLEC, V25, P511, DOI 10.1016/0965-1748(94)00091-C; Begun DJ, 2000, GENETICS, V154, P1231; De Gregorio E, 2001, P NATL ACAD SCI USA, V98, P12590, DOI 10.1073/pnas.221458698; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; DIMARCQ JL, 1994, EUR J BIOCHEM, V221, P201, DOI 10.1111/j.1432-1033.1994.tb18730.x; Fry JD, 1998, GENET RES, V71, P133, DOI 10.1017/S0016672398003176; Gurganus MC, 1998, GENETICS, V149, P1883; Hedengren M, 2000, BIOCHEM BIOPH RES CO, V279, P574, DOI 10.1006/bbrc.2000.3988; Hoffmann R, 2002, GENOME BIOL, V3; Irving P, 2001, P NATL ACAD SCI USA, V98, P15119, DOI 10.1073/pnas.261573998; Kraaijeveld AR, 1997, NATURE, V389, P278, DOI 10.1038/38483; Lazzaro BP, 2003, MOL BIOL EVOL, V20, P914, DOI 10.1093/molbev/msg109; Lazzaro BP, 2001, GENETICS, V159, P659; LEVASHINA EA, 1995, EUR J BIOCHEM, V233, P694, DOI 10.1111/j.1432-1033.1995.694_2.x; Lewis SE, 2002, GENOME BIOL, V3; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; McKean KA, 2001, P NATL ACAD SCI USA, V98, P7904, DOI 10.1073/pnas.131216398; Nuzhdin SV, 1997, P NATL ACAD SCI USA, V94, P9734, DOI 10.1073/pnas.94.18.9734; Ramet M, 2001, IMMUNITY, V15, P1027, DOI 10.1016/S1074-7613(01)00249-7; Schlenke TA, 2003, GENETICS, V164, P1471; Tzou P, 2002, P NATL ACAD SCI USA, V99, P2152, DOI 10.1073/pnas.042411999; Vieira C, 2000, GENETICS, V154, P213; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Williams MJ, 2001, ADV IMMUNOL, V79, P225, DOI 10.1016/S0065-2776(01)79005-0	24	186	190	2	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1873	1876		10.1126/science.1092447	http://dx.doi.org/10.1126/science.1092447			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031506				2022-12-28	WOS:000220281600057
J	Thomas, JA; Telfer, MG; Roy, DB; Preston, CD; Greenwood, JJD; Asher, J; Fox, R; Clarke, RT; Lawton, JH				Thomas, JA; Telfer, MG; Roy, DB; Preston, CD; Greenwood, JJD; Asher, J; Fox, R; Clarke, RT; Lawton, JH			Comparative losses of British butterflies, birds, and plants and the global extinction crisis	SCIENCE			English	Article							BIODIVERSITY; FUTURE; RATES	There is growing concern about increased population, regional, and global extinctions of species. A key question is whether extinction rates for one group of organisms are representative of other taxa. We present a comparison at the national scale of population and regional extinctions of birds, butterflies, and vascular plants from Britain in recent decades. Butterflies experienced the greatest net losses, disappearing on average from 13% of their previously occupied 10-kilometer squares. If insects elsewhere in the world are similarly sensitive, the known global extinction rates of vertebrate and plant species have an unrecorded parallel among the invertebrates, strengthening the hypothesis that the natural world is experiencing the sixth major extinction event in its history.	Winfrith Technol Ctr, Dorset Lab, NERC, Ctr Ecol & Hydrol, Dorchester DT2 8ZD, England; Univ London Imperial Coll Sci Technol & Med, Ctr Populat Biol, Ascot SL5 7PY, Berks, England; NERC, Swindon SN2 1EU, Wilts, England; Butterfly Conservat, Wareham BH20 5QP, Dorset, England; British Trust Ornithol, Thetford IP2 2PU, Norfolk, England; NERC, Ctr Ecol & Hydrol, Huntingdon PE28 2LS, Cambs, England	UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); British Trust for Ornithology; UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Thomas, JA (corresponding author), Winfrith Technol Ctr, Dorset Lab, NERC, Ctr Ecol & Hydrol, Dorchester DT2 8ZD, England.	jat@ceh.ac.uk	Roy, David/A-6619-2009; Fox, Richard/G-3873-2011; Clarke, Ralph T/B-3859-2009; Preston, Christopher/F-6952-2010	Roy, David/0000-0002-5147-0331; Fox, Richard/0000-0001-6992-3522				Asher J, 2001, MILLENNIUM ATLAS BUT; Balmford A, 2003, TRENDS ECOL EVOL, V18, P326, DOI 10.1016/S0169-5347(03)00067-3; BROWN KS, 1992, TROPICAL DEFORESTATI, P119; Ceballos G, 2002, SCIENCE, V296, P904, DOI 10.1126/science.1069349; COWLEY MJR, 1999, P R SOC LONDON B, V266, P158; DIAMOND JM, 1989, PHILOS T ROY SOC B, V325, P469, DOI 10.1098/rstb.1989.0100; Dobson AP, 1997, SCIENCE, V275, P550, DOI 10.1126/science.275.5299.550; EHRLICH PR, 1994, PHILOS T R SOC B, V344, P99, DOI 10.1098/rstb.1994.0057; ERHARDT A, 1991, CONSERVATION INSECTS, P213; Gaston KJ, 2000, J APPL ECOL, V37, P39, DOI 10.1046/j.1365-2664.2000.00485.x; Gibbons D. W., 1993, NEW ATLAS BREEDING B; Heath J., 1984, ATLAS BUTTERFLIES BR; Luck GW, 2003, TRENDS ECOL EVOL, V18, P331, DOI 10.1016/S0169-5347(03)00100-9; Malakoff D, 1997, SCIENCE, V277, P486, DOI 10.1126/science.277.5325.486; MASTER LL, 2000, PRECIOUS HERITAGE ST; May Robert M., 1998, Conservation Biology Series (Cambridge), V1, P287; May Robert M., 1995, P1; McKinney ML, 1999, CONSERV BIOL, V13, P1273, DOI 10.1046/j.1523-1739.1999.97393.x; Perring F.H., 1962, ATLAS BRIT FLORA; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; Preston C, 2002, NEW ATLAS BRIT IRISH; Regan HM, 2001, AM NAT, V157, P1, DOI 10.1086/317005; Sala OE, 2000, SCIENCE, V287, P1770, DOI 10.1126/science.287.5459.1770; Sharrock J.T.R., 1976, ATLAS BREEDING BIRDS; Shirt D, 1987, BRIT RED DATA BOOKS; Thomas CD, 1999, NATURE, V399, P213, DOI 10.1038/20335; THOMAS JA, 1994, PHILOS T ROY SOC B, V344, P47, DOI 10.1098/rstb.1994.0050; Warren MS, 2001, NATURE, V414, P65, DOI 10.1038/35102054	28	613	663	14	342	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1879	1881		10.1126/science.1095046	http://dx.doi.org/10.1126/science.1095046			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031508				2022-12-28	WOS:000220281600059
J	Wan, PTC; Garnett, MJ; Roe, SM; Lee, S; Niculescu-Duvaz, D; Good, VM; Jones, CM; Marshall, CJ; Springer, CJ; Barford, D; Marais, R				Wan, PTC; Garnett, MJ; Roe, SM; Lee, S; Niculescu-Duvaz, D; Good, VM; Jones, CM; Marshall, CJ; Springer, CJ; Barford, D; Marais, R		Cancer Genome Project	Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF	CELL			English	Article							KINASE DOMAIN; BIOLOGICAL-ACTIVITY; CRYSTAL-STRUCTURE; MAP KINASE; BRAF; INHIBITION; DISCOVERY; COMPLEX	Over 30 mutations of the B-RAF gene associated with human cancers have been identified, the majority of which are located within the kinase domain. Here we show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo. Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells. The structures of wild type and oncogenic (VB)-B-599E-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by association with the P loop. The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation. The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.	Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, London SW3 6JB, England; Inst Canc Res, Sect Struct Biol, London SW3 6JB, England; Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, London SW3 6JB, England; Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England; Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Cancer Research UK; University of London; Institute of Cancer Research - UK; Wellcome Trust Sanger Institute	Barford, D (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, 237 Fulham Rd, London SW3 6JB, England.	david.barford@icr.ac.uk; richard.marais@icr.ac.uk		Springer, Caroline/0000-0002-0650-4002; Roe, Mark/0000-0002-7371-9855; Marais, Richard/0000-0001-7484-4183				Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Bankston D, 2002, ORG PROCESS RES DEV, V6, P777, DOI 10.1021/op020205n; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Brose MS, 2002, CANCER RES, V62, P6997; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; *CCP4, 1991, ACTA CRYSTALLOGR D, V50, P760; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Cohen Y, 2003, INVEST OPHTH VIS SCI, V44, P2876, DOI 10.1167/iovs.02-1329; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DENT JA, 1989, DEVELOPMENT, V105, P61; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; GLOVER HR, 1995, ONCOGENE, V11, P1347; Grant BD, 1998, BIOCHEMISTRY-US, V37, P7708, DOI 10.1021/bi972987w; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Ikenoue T, 2003, CANCER RES, V63, P8132; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Jones CM, 1996, DEVELOPMENT, V122, P1545; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Lowinger TB, 2002, CURR PHARM DESIGN, V8, P2269, DOI 10.2174/1381612023393125; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; MacNicol MC, 2000, J BIOL CHEM, V275, P3803, DOI 10.1074/jbc.275.6.3803; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Morrison DK, 2001, J CELL SCI, V114, P1609; Nagar B, 2002, CANCER RES, V62, P4236; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Pargellis C, 2002, NAT STRUCT BIOL, V9, P268, DOI 10.1038/nsb770; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; REIDL B, 2000, Patent No. 200041698; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Weber CK, 2001, CANCER RES, V61, P3595; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yuen ST, 2002, CANCER RES, V62, P6451; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429	48	2095	2232	5	196	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 19	2004	116	6					855	867		10.1016/S0092-8674(04)00215-6	http://dx.doi.org/10.1016/S0092-8674(04)00215-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YS	15035987	Bronze			2022-12-28	WOS:000221499900011
J	Mitzi, DB; Kosbar, LL; Murray, CE; Copel, M; Afzali, A				Mitzi, DB; Kosbar, LL; Murray, CE; Copel, M; Afzali, A			High-mobility ultrathin semiconducting films prepared by spin coating	NATURE			English	Article							FIELD-EFFECT TRANSISTORS; THIN-FILMS; HIGH-PERFORMANCE; DEPOSITION; SNS2	The ability to deposit and tailor reliable semiconducting films ( with a particular recent emphasis on ultrathin systems) is indispensable for contemporary solid-state electronics(1-3\). The search for thin-film semiconductors that provide simultaneously high carrier mobility and convenient solution-based deposition is also an important research direction, with the resulting expectations of new technologies ( such as flexible or wearable computers, large-area high-resolution displays and electronic paper) and lower-cost device fabrication(4-11). Here we demonstrate a technique for spin coating ultrathin (similar to50 Angstrom), crystalline and continuous metal chalcogenide films, based on the low-temperature decomposition of highly soluble hydrazinium precursors. We fabricate thin-film field-effect transistors (TFTs) based on semiconducting SnS2-xSex films, which exhibit n-type transport, large current densities (> 10(5) A cm(-2)) and mobilities greater than 10 cm(2) V-1 s(-1) - an order of magnitude higher than previously reported values for spin-coated semiconductors. The spin-coating technique is expected to be applicable to a range of metal chalcogenides, particularly those based on main group metals, as well as for the fabrication of a variety of thin-film-based devices (for example, solar cells(12), thermoelectrics(13) and memory devices(14)).	IBM Corp, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA	International Business Machines (IBM)	Mitzi, DB (corresponding author), IBM Corp, Thomas J Watson Res Ctr, POB 218, Yorktown Hts, NY 10598 USA.	dmitzi@us.ibm.com	Murray, Conal/S-8454-2019; Mitzi, David B/B-6260-2012	Mitzi, David B/0000-0001-5189-4612; Copel, Matt/0000-0002-7729-2748; Murray, Conal/0000-0001-9901-4290				Afzali A, 2002, J AM CHEM SOC, V124, P8812, DOI 10.1021/ja0266621; BRITT J, 1993, APPL PHYS LETT, V62, P2851, DOI 10.1063/1.109629; Carey PG, 1999, J VAC SCI TECHNOL A, V17, P1946, DOI 10.1116/1.581708; Dimitrakopoulos CD, 2002, ADV MATER, V14, P99, DOI 10.1002/1521-4095(20020116)14:2<99::AID-ADMA99>3.0.CO;2-9; Dimitrakopoulos CD, 1999, SCIENCE, V283, P822, DOI 10.1126/science.283.5403.822; DOMINGO G, 1966, PHYS REV, V143, P536, DOI 10.1103/PhysRev.143.536; Duan XF, 2003, NATURE, V425, P274, DOI 10.1038/nature01996; EISENMANN B, 1993, Z KRISTALLOGR, V203, P299, DOI 10.1524/zkri.1993.203.Part-2.299; Forrest SR, 1997, CHEM REV, V97, P1793, DOI 10.1021/cr941014o; Gan FY, 2002, IEEE T ELECTRON DEV, V49, P15, DOI 10.1109/16.974742; Huitema HEA, 2002, ADV MATER, V14, P1201, DOI 10.1002/1521-4095(20020903)14:17<1201::AID-ADMA1201>3.0.CO;2-5; Kagan CR, 1999, SCIENCE, V286, P945, DOI 10.1126/science.286.5441.945; Katz HE, 2000, NATURE, V404, P478, DOI 10.1038/35006603; Kim Y, 2002, J APPL PHYS, V91, P715, DOI 10.1063/1.1424056; Kyratsi T, 2003, ADV MATER, V15, P1428, DOI 10.1002/adma.200304994; MCCANDLESS BE, 1995, SOL ENERG MAT SOL C, V36, P369, DOI 10.1016/0927-0248(94)00189-8; Mitzi DB, 2003, THIN-FILM TRANSISTORS, P475; Mitzi DB, 2001, CHEM MATER, V13, P3728, DOI 10.1021/cm010105g; Mushrush M, 2003, J AM CHEM SOC, V125, P9414, DOI 10.1021/ja035143a; PALOSZ B, 1990, ACTA CRYSTALLOGR B, V46, P449, DOI 10.1107/S0108768189012577; Ridley BA, 1999, SCIENCE, V286, P746, DOI 10.1126/science.286.5440.746; SHIBATA T, 1991, J PHYS CHEM SOLIDS, V52, P551, DOI 10.1016/0022-3697(91)90190-B; Sirringhaus H, 2000, SCIENCE, V290, P2123, DOI 10.1126/science.290.5499.2123; STREETMAN BG, 1980, SOLID STATE ELECT DE, P443; Trivedi VP, 2003, IEEE T ELECTRON DEV, V50, P2095, DOI 10.1109/TED.2003.816915; Van der Veen JF, 1985, SURF SCI REP, V5, P199, DOI 10.1016/0167-5729(85)90001-9; Welsh TWB, 1915, J AM CHEM SOC, V37, P816, DOI 10.1021/ja02169a010; Zaslavsky A, 2003, APPL PHYS LETT, V83, P1653, DOI 10.1063/1.1600832	28	419	466	7	450	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 18	2004	428	6980					299	303		10.1038/nature02389	http://dx.doi.org/10.1038/nature02389			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15029191				2022-12-28	WOS:000220250200038
J	Neoptolemos, JP; Stocken, DD; Friess, H; Bassi, C; Dunn, JA; Hickey, H; Beger, H; Fernandez-Cruz, L; Dervenis, C; Lacaine, F; Falconi, M; Pederzoli, P; Pap, A; Spooner, D; Kerr, DJ; Buchler, MW				Neoptolemos, JP; Stocken, DD; Friess, H; Bassi, C; Dunn, JA; Hickey, H; Beger, H; Fernandez-Cruz, L; Dervenis, C; Lacaine, F; Falconi, M; Pederzoli, P; Pap, A; Spooner, D; Kerr, DJ; Buchler, MW		European Study Grp Pancreatic Can	A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADJUVANT COMBINED RADIATION; CURATIVE RESECTION; DUCTAL ADENOCARCINOMA; PROGNOSTIC INDICATORS; CLINICAL-TRIALS; SURVIVAL; THERAPY; CARCINOMA; RECURRENCE; PATTERNS	Background: The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results of the European Study Group for Pancreatic Cancer 1 Trial and update the interim results. Methods: In a multicenter trial using a two-by-two factorial design, we randomly assigned 73 patients with resected pancreatic ductal adenocarcinoma to treatment with chemoradiotherapy alone (20 Gy over a two-week period plus fluorouracil), 75 patients to chemotherapy alone (fluorouracil), 72 patients to both chemoradiotherapy and chemotherapy, and 69 patients to observation. Results: The analysis was based on 237 deaths among the 289 patients (82 percent) and a median follow-up of 47 months (interquartile range, 33 to 62). The estimated five-year survival rate was 10 percent among patients assigned to receive chemoradiotherapy and 20 percent among patients who did not receive chemoradiotherapy (P=0.05). The five-year survival rate was 21 percent among patients who received chemotherapy and 8 percent among patients who did not receive chemotherapy (P=0.009). The benefit of chemotherapy persisted after adjustment for major prognostic factors. Conclusions: Adjuvant chemotherapy has a significant survival benefit in patients with resected pancreatic cancer, whereas adjuvant chemoradiotherapy has a deleterious effect on survival.	Univ Liverpool, Dept Surg, Liverpool L69 3BX, Merseyside, England; Univ Birmingham, Canc Res UK, Clin Trials Unit, Birmingham, W Midlands, England; Univ Heidelberg, Heidelberg, Germany; Univ Verona, Dept Surg, I-37100 Verona, Italy; Univ Hosp Surg, Ulm, Germany; Barcelona Univ Hosp, Barcelona, Spain; Agia Olga Hosp, Dept Surg, Athens, Greece; Hop Tenon, Serv Chirurg Digest & Gen, F-75970 Paris, France; Mav Hosp, Dept Gastroenterol, Budapest, Hungary; Queen Elizabeth Hosp, Dept Radiotherapy, Birmingham B15 2TH, W Midlands, England	University of Liverpool; Cancer Research UK; University of Birmingham; Ruprecht Karls University Heidelberg; University of Verona; Ulm University; General Hospital of N. Ionia Agia Olga; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Birmingham	Neoptolemos, JP (corresponding author), Univ Liverpool, Dept Surg, Liverpool L69 3BX, Merseyside, England.		Neoptolemos, John/HGU-7742-2022; Falconi, Massimo/K-2194-2016; Falconi, Massimo/B-7359-2011	Falconi, Massimo/0000-0001-9654-7243; SALVIA, Roberto/0000-0002-3514-8473; Dunn, Janet/0000-0001-7313-4446; Neoptolemos, John/0000-0002-6201-7399; Stocken, Deborah/0000-0001-8031-1738				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; BAKKEVOLD KE, 1993, EUR J CANCER, V29A, P698, DOI 10.1016/S0959-8049(05)80349-1; Birkmeyer JD, 1999, SURGERY, V126, P178, DOI 10.1016/S0039-6060(99)70152-2; BRAMHALL SR, 1995, BRIT J SURG, V82, P111, DOI 10.1002/bjs.1800820137; Chakravarthy A, 2000, INT J RADIAT ONCOL, V48, P1089, DOI 10.1016/S0360-3016(00)00755-0; COX DR, 1972, J R STAT SOC B, V34, P187; DOUGLASS HO, 1987, CANCER, V59, P2006; *EARL BREAST CANC, 1990, INTR METH SECT REPR, V1; FERNANDEZ E, 1994, INT J CANCER, V57, P786, DOI 10.1002/ijc.2910570605; FOO ML, 1993, INT J RADIAT ONCOL, V26, P483, DOI 10.1016/0360-3016(93)90967-Z; GEER RJ, 1993, AM J SURG, V165, P68, DOI 10.1016/S0002-9610(05)80406-4; GRIFFIN JF, 1990, CANCER, V66, P56, DOI 10.1002/1097-0142(19900701)66:1<56::AID-CNCR2820660112>3.0.CO;2-6; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; JOHNSTONE PA, 1993, INT J RADIAT ONCOL, V27, P831, DOI 10.1016/0360-3016(93)90456-6; Jones L, 1999, DIGEST SURG, V16, P297, DOI 10.1159/000018739; KALSER MH, 1986, ARCH SURG-CHICAGO, V121, P1045; KALSER MH, 1985, ARCH SURG-CHICAGO, V120, P899; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006; Lim JE, 2003, ANN SURG, V237, P74, DOI 10.1097/00000658-200301000-00011; Neoptolemos JP, 2003, ANN ONCOL, V14, P675, DOI 10.1093/annonc/mdg207; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Neoptolemos JP, 2001, ANN SURG, V234, P758, DOI 10.1097/00000658-200112000-00007; *NIH DIV CTR TREAT, 1998, CANC THER EV PROGR C; NITECKI SS, 1995, ANN SURG, V221, P59, DOI 10.1097/00000658-199501000-00007; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Qian W, 2000, STAT MED, V19, P2657; Sener SF, 1999, J AM COLL SURGEONS, V189, P1, DOI 10.1016/S1072-7515(99)00075-7; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; Sperti C, 1997, WORLD J SURG, V21, P195, DOI 10.1007/s002689900215; Takada T, 2002, CANCER, V95, P1685, DOI 10.1002/cncr.10831; WESTERDAHL J, 1993, HEPATO-GASTROENTEROL, V40, P384; WHITTINGTON R, 1991, INT J RADIAT ONCOL, V21, P1137, DOI 10.1016/0360-3016(91)90268-9; WILLETT CG, 1993, ANN SURG, V217, P144, DOI 10.1097/00000658-199302000-00008	35	1936	2013	1	105	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	2004	350	12					1200	1210		10.1056/NEJMoa032295	http://dx.doi.org/10.1056/NEJMoa032295			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803PG	15028824				2022-12-28	WOS:000220242400007
J	Hilgemann, DW				Hilgemann, DW			Oily barbarians breach ion channel gates	SCIENCE			English	Editorial Material							SODIUM-CALCIUM EXCHANGE; CAPSAICIN RECEPTOR; INACTIVATION; RESIDUES; PIP2		Univ Texas SW, Dept Physiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Hilgemann, DW (corresponding author), Univ Texas SW, Dept Physiol, Dallas, TX 75235 USA.	donald.hilgemann@utsouthwestern.edu						Ahern CA, 2004, J GEN PHYSIOL, V123, P205, DOI 10.1085/jgp.200308993; Camacho J, 2002, BIOCHEM BIOPH RES CO, V291, P1287, DOI 10.1006/bbrc.2002.6597; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; COLLINS A, 1993, PFLUG ARCH EUR J PHY, V423, P347, DOI 10.1007/BF00374927; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; Cukras CA, 2002, J GEN PHYSIOL, V119, P581, DOI 10.1085/jgp.20028562; Hardie RC, 2003, ANNU REV PHYSIOL, V65, P735, DOI 10.1146/annurev.physiol.65.092101.142505; He F, 2004, J BIOL CHEM, V279, P8986, DOI 10.1074/jbc.M311488200; He ZP, 2000, AM J PHYSIOL-CELL PH, V278, pC661, DOI 10.1152/ajpcell.2000.278.4.C661; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Hwang TC, 2003, BIOCHEMISTRY-US, V42, P13646, DOI 10.1021/bi034887y; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; Oliver D, 2004, SCIENCE, V304, P265, DOI 10.1126/science.1094113; PATTON DE, 1992, P NATL ACAD SCI USA, V89, P10905, DOI 10.1073/pnas.89.22.10905; Poveda JA, 2003, BIOCHEMISTRY-US, V42, P7124, DOI 10.1021/bi027183h; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Roeper J, 1998, NATURE, V391, P390, DOI 10.1038/34916; Rogalski SL, 2001, J BIOL CHEM, V276, P14855, DOI 10.1074/jbc.M010097200; Suh BC, 2002, NEURON, V35, P507, DOI 10.1016/S0896-6273(02)00790-0; Tabarean IV, 2002, BIOPHYS J, V82, P2982, DOI 10.1016/S0006-3495(02)75639-7; Womack KB, 2000, J NEUROSCI, V20, P2792	25	29	32	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	2004	304	5668					223	224		10.1126/science.1097439	http://dx.doi.org/10.1126/science.1097439			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810QS	15031439				2022-12-28	WOS:000220719400030
J	McIsaac, WJ; Kellner, JD; Aufricht, P; Vanjaka, A; Low, DE				McIsaac, WJ; Kellner, JD; Aufricht, P; Vanjaka, A; Low, DE			Empirical validation of guidelines for the management of pharyngitis in children and adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	42nd Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 26-30, 2002	SAN DIEGO, CA				HEMOLYTIC STREPTOCOCCAL PHARYNGITIS; UNNECESSARY ANTIBIOTIC USE; GROUP-A STREPTOCOCCI; SORE THROAT; COST-EFFECTIVENESS; GENERAL-PRACTICE; RHEUMATIC-FEVER; PENICILLIN-V; STREP THROAT; DIAGNOSIS	Context Recent guidelines for management of pharyngitis vary in their recommendations concerning empirical antibiotic treatment and the need for laboratory confirmation of group A streptococcus (GAS). Objective To assess the impact of guideline recommendations and alternative approaches on identification and treatment of GAS pharyngitis in children and adults. Design, Setting, and Participants Throat cultures and rapid antigen tests were performed on 787 children and adults aged 3 to 69 years with acute sore throat attending a family medicine clinic in Calgary, Alberta, from September 1999 to August 2002. Recommendations from 2 guidelines (those of the Infectious Diseases Society of America and of the American College of Physicians-American Society of Internal Medicine/American Academy of Family Physicians/US Centers for Disease Control and Prevention) were compared with rapid testing alone, a clinical prediction rule (ie, the modified Centor score), and a criterion standard of treatment for positive throat culture results only. Main Outcome Measures Sensitivity and specificity of each strategy for identifying GAS pharyngitis, total antibiotics recommended, and unnecessary antibiotic prescriptions. Results In children, sensitivity for streptococcal infection ranged from 85.8% (133/155; 95% confidence interval [CI], 79.3%-90.0%) for rapid testing to 100% for culturing all. In adults, sensitivity ranged from 76.7% (56/73; 95% CI, 65.4%-85.8%) for rapid testing without culture confirmation of negative results to 100% for culturing all. In children, specificity ranged from 90.3% (270/299; 95% CI, 86.4%-93.4%) for use of modified Centor score and throat culture to 100% for culturing all. In adults, specificity ranged from 43.8% (114/260; 95% CI, 37.7%-50.1%) for empirical treatment based on a modified Centor score of 3 or 4 to 100% for culturing all. Total antibiotic prescriptions were lowest with rapid testing (24.7% [194/787]; 95% CI, 21.7%-27.8%) and highest with empirical treatment of high-risk adults (45.7% [360/787]; 95% CI, 42.2%-49.3%), due to a high rate of unnecessary prescriptions in adults (43.8% [146/333]; 95% CI, 38.4%-49.4%). Conclusions Guideline recommendations for the selective use of throat cultures but antibiotic treatment based only on positive rapid test or throat culture results can reduce unnecessary use of antibiotics for treatment of pharyngitis. However, empirical treatment of adults having a Centor score of 3 or 4 is associated with a high rate of unnecessary antibiotic use. In children, strategies incorporating throat culture or throat culture confirmation of negative rapid antigen test results are highly sensitive and specific. Throat culture of all adults or those selected on the basis of a clinical prediction rule had the highest sensitivity and specificity.	Mt Sinai Hosp, Ray D Wolfe Dept Family Med, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Lab Med & Pathol, Toronto, ON, Canada; Alberta Childrens Prov Gen Hosp, Dept Pediat, Calgary, AB T2T 5C7, Canada; Univ Calgary, Calgary, AB, Canada; Foothills Prov Gen Hosp, Dept Family Med, Calgary, AB T2N 2T9, Canada; Abbott Labs, Montreal, PQ, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; Alberta Childrens Hospital; University of Calgary; University of Calgary; University of Calgary	McIsaac, WJ (corresponding author), Mt Sinai Hosp, Ray D Wolfe Dept Family Med, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	wmcisaac@mtsinai.on.ca	Low, Donald/B-1726-2012; Kellner, James Duncan/D-6358-2011	Kellner, James Duncan/0000-0002-9083-2980				Bisno AL, 2002, CLIN INFECT DIS, V35, P126, DOI 10.1086/342056; Bisno AL, 2002, CLIN INFECT DIS, V35, P113, DOI 10.1086/340949; Centor R M, 1981, Med Decis Making, V1, P239, DOI 10.1177/0272989X8100100304; Cooper RJ, 2001, ANN INTERN MED, V134, P509, DOI 10.7326/0003-4819-134-6-200103200-00019; Dagnelie CF, 1996, BRIT J GEN PRACT, V46, P589; DAJANI A, 1995, PEDIATRICS, V96, P758; Dale JC, 2002, ARCH PATHOL LAB MED, V126, P1467; Ebell MH, 2000, JAMA-J AM MED ASSOC, V284, P2912, DOI 10.1001/jama.284.22.2912; Ehrlich JE, 2002, PREV MED, V35, P250, DOI 10.1006/pmed.2002.1062; ELDAHER NT, 1991, PEDIATR INFECT DIS J, V10, P126, DOI 10.1097/00006454-199102000-00010; Gerber MA, 1997, JAMA-J AM MED ASSOC, V277, P899, DOI 10.1001/jama.277.11.899; HART WJ, 1976, CAN FAM PHYSICIAN, V22, P34; KLJAKOVIC M, 1993, NEW ZEAL MED J, V106, P381; LAUBSCHER B, 1995, J CLIN MICROBIOL, V33, P260, DOI 10.1128/JCM.33.1.260-261.1995; Linder JA, 2001, JAMA-J AM MED ASSOC, V286, P1181, DOI 10.1001/jama.286.10.1181; Mainous AG, 1996, PEDIATR INFECT DIS J, V15, P806, DOI 10.1097/00006454-199609000-00014; McCaig LF, 2002, JAMA-J AM MED ASSOC, V287, P3096, DOI 10.1001/jama.287.23.3096; McIsaac WJ, 2000, CAN MED ASSOC J, V163, P811; McIsaac WJ, 1998, CAN MED ASSOC J, V158, P75; McIsaac WJ, 2000, MED DECIS MAKING, V20, P33, DOI 10.1177/0272989X0002000104; Neuner JM, 2003, ANN INTERN MED, V139, P113, DOI 10.7326/0003-4819-139-2-200307150-00011; POSES RM, 1985, JAMA-J AM MED ASSOC, V254, P925, DOI 10.1001/jama.254.7.925; RANDOLPH MF, 1985, J PEDIATR-US, V106, P870, DOI 10.1016/S0022-3476(85)80228-6; SHANK JC, 1984, J FAM PRACTICE, V18, P857; Stollerman GH, 2001, CLIN INFECT DIS, V33, P806, DOI 10.1086/322665; Watson RL, 1999, PEDIATRICS, V104, P1251, DOI 10.1542/peds.104.6.1251; Webb KH, 2000, J FAM PRACTICE, V49, P34	27	214	239	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2004	291	13					1587	1595		10.1001/jama.291.13.1587	http://dx.doi.org/10.1001/jama.291.13.1587			9	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809PQ	15069046	Bronze			2022-12-28	WOS:000220649000023
J	Falkowski, PG; de Vargas, C				Falkowski, PG; de Vargas, C			Shotgun sequencing in the sea: A blast from the past?	SCIENCE			English	Editorial Material							GENETIC DIVERSITY; OCEAN; EVOLUTION; CYCLE		Rutgers State Univ, Environm Biophys & Mol Ecol Program, New Brunswick, NJ 08901 USA; Rutgers State Univ, Dept Geol Sci, New Brunswick, NJ 08901 USA; Rutgers State Univ, Inst Marine & Coastal Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Falkowski, PG (corresponding author), Rutgers State Univ, Environm Biophys & Mol Ecol Program, New Brunswick, NJ 08901 USA.	falko@imcs.rutgers.edu; vargas@imcs.rugers.edu						Anbar AD, 2002, SCIENCE, V297, P1137, DOI 10.1126/science.1069651; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Bekker A, 2004, NATURE, V427, P117, DOI 10.1038/nature02260; Falkowski P.G., 2013, AQUATIC PHOTOSYNTHES; Falkowski PG, 1997, NATURE, V387, P272, DOI 10.1038/387272a0; GIOVANNONI SJ, 1990, NATURE, V345, P60, DOI 10.1038/345060a0; Knoll AH., 2003, LIFE YOUNG PLANET; Kolber ZS, 2001, SCIENCE, V292, P2492, DOI 10.1126/science.1059707; Moon-van der Staay SY, 2001, NATURE, V409, P607, DOI 10.1038/35054541; Moreira D, 2002, TRENDS MICROBIOL, V10, P31, DOI 10.1016/S0966-842X(01)02257-0; Pochon X, 2001, MAR BIOL, V139, P1069; Veldhuis MJW, 1997, J PHYCOL, V33, P527, DOI 10.1111/j.0022-3646.1997.00527.x; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857	13	38	46	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					58	60		10.1126/science.1097146	http://dx.doi.org/10.1126/science.1097146			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15066774				2022-12-28	WOS:000220567900032
J	Pinto, S; Roseberry, AG; Liu, HY; Diano, S; Shanabrough, M; Cai, XL; Friedman, JM; Horvath, TL				Pinto, S; Roseberry, AG; Liu, HY; Diano, S; Shanabrough, M; Cai, XL; Friedman, JM; Horvath, TL			Rapid rewiring of arcuate nucleus feeding circuits by leptin	SCIENCE			English	Article							PROOPIOMELANOCORTIN MESSENGER-RNA; OBESE GENE-PRODUCT; NEUROPEPTIDE-Y; SYNAPTIC PLASTICITY; OB/OB MICE; NEURONS; HYPOTHALAMUS; RECEPTOR; RATS; COEXPRESSION	The fat-derived hormone leptin regulates energy balance in part by modulating the activity of neuropeptide Y and proopiomelanocortin neurons in the hypothalamic arcuate nucleus. To study the intrinsic activity of these neurons and their responses to leptin, we generated mice that express distinct green fluorescent proteins in these two neuronal types. Leptin-deficient (ob/ob) mice differed from wild-type mice in the numbers of excitatory and inhibitory synapses and postsynaptic currents onto neuropeptide Y and proopiomelanocortin neurons. When leptin was delivered systemically to ob/ob mice, the synaptic density rapidly normalized, an effect detectable within 6 hours, several hours before leptin's effect on food intake. These data suggest that leptin-mediated plasticity in the ob/ob hypothalamus may underlie some of the hormone's behavioral effects.	Rockefeller Univ, Genet Mol Lab, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Yale University; Yale University	Friedman, JM (corresponding author), Rockefeller Univ, Genet Mol Lab, 1230 York Ave, New York, NY 10021 USA.	friedj@mail.rockefeller.edu; tamas.horvath@yale.edu	Friedman, Jeffrey M/E-5784-2011	Roseberry, Aaron/0000-0003-0468-0333	NCRR NIH HHS [RR014451] Funding Source: Medline; NIDDK NIH HHS [F32DK61176, R01 DK061619, R01 DK041096, DK060711] Funding Source: Medline; NINDS NIH HHS [F32NS046921] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR014451] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060711, F32DK061176, R01DK061619, R01DK041096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS046921] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baskin DG, 1999, DIABETES, V48, P828, DOI 10.2337/diabetes.48.4.828; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; DECAVEL C, 1990, J COMP NEUROL, V302, P1019, DOI 10.1002/cne.903020423; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; GARCIASEGURA LM, 1986, BRAIN RES, V366, P131, DOI 10.1016/0006-8993(86)91287-4; Hahn TM, 1998, NAT NEUROSCI, V1, P271, DOI 10.1038/1082; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Horvath TL, 1999, J NEUROSCI, V19, P1072; Hung AJ, 2003, EXP GERONTOL, V38, P53, DOI 10.1016/S0531-5565(02)00183-3; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Lin S, 2000, BRAIN RES, V875, P89, DOI 10.1016/S0006-8993(00)02580-4; Mercer JG, 1996, J NEUROENDOCRINOL, V8, P733, DOI 10.1046/j.1365-2826.1996.05161.x; Mizuno TM, 1998, DIABETES, V47, P294, DOI 10.2337/diabetes.47.2.294; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Peters A., 1991, FINE STRUCTURE NERVO; Pinto S., UNPUB; Schwartz MW, 1997, DIABETES, V46, P2119, DOI 10.2337/diabetes.46.12.2119; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Stern JE, 1998, J NEUROSCI, V18, P841; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; VANDENPOL AN, 1990, SCIENCE, V250, P1276, DOI 10.1126/science.1978759; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071; ZARJEVSKI N, 1993, ENDOCRINOLOGY, V133, P1753, DOI 10.1210/en.133.4.1753; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	757	768	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					110	115		10.1126/science.1089459	http://dx.doi.org/10.1126/science.1089459			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15064421				2022-12-28	WOS:000220567900049
J	Ekimov, EA; Sidorov, VA; Bauer, ED; Mel'nik, NN; Curro, NJ; Thompson, JD; Stishov, SM				Ekimov, EA; Sidorov, VA; Bauer, ED; Mel'nik, NN; Curro, NJ; Thompson, JD; Stishov, SM			Superconductivity in diamond	NATURE			English	Article							ELECTRICAL-CONDUCTIVITY; CELL PARAMETER; TEMPERATURE; FABRICATION; DONORS	Diamond is an electrical insulator well known for its exceptional hardness. It also conducts heat even more effectively than copper, and can withstand very high electric fields(1). With these physical properties, diamond is attractive for electronic applications(2), particularly when charge carriers are introduced (by chemical doping) into the system. Boron has one less electron than carbon and, because of its small atomic radius, boron is relatively easily incorporated into diamond(3); as boron acts as a charge acceptor, the resulting diamond is effectively hole-doped. Here we report the discovery of superconductivity in boron-doped diamond synthesized at high pressure (nearly 100,000 atmospheres) and temperature (2,500-2,800 K). Electrical resistivity, magnetic susceptibility, specific heat and field-dependent resistance measurements show that boron-doped diamond is a bulk, type-II superconductor below the superconducting transition temperature T(c)approximate to4 K; superconductivity survives in a magnetic field up to H-c2(0)greater than or equal to3.5 T. The discovery of superconductivity in diamond-structured carbon suggests that Si and Ge, which also form in the diamond structure, may similarly exhibit superconductivity under the appropriate conditions.	Russian Acad Sci, Vereshchagin Inst High Pressure Phys, Troitsk 142190, Moscow Region, Russia; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Russian Acad Sci, PN Lebedev Phys Inst, Moscow 117924, Russia	Russian Academy of Sciences; Vereshchagin Institute of High Pressure Physics, Russian Academy of Sciences; United States Department of Energy (DOE); Los Alamos National Laboratory; Russian Academy of Sciences; Russian Academy of Science Lebedev Physical Institute	Sidorov, VA (corresponding author), Russian Acad Sci, Vereshchagin Inst High Pressure Phys, Troitsk 142190, Moscow Region, Russia.	sidorov@hppi.troitsk.ru	Curro, Nicholas/D-3413-2009; Melnik, Nikolay N/E-5666-2014; Ekimov, Evgeny/ABH-3480-2020; Bauer, Eric D/D-7212-2011; Ekimov, Evgeny/E-9606-2018; Stishov, Sergei M/J-9873-2018	Curro, Nicholas/0000-0001-7829-0237; Melnik, Nikolay N/0000-0002-7058-0333; Ekimov, Evgeny/0000-0001-7644-0078; Ekimov, Evgeny/0000-0001-7644-0078; 				BEAN CP, 1962, PHYS REV LETT, V8, P250, DOI 10.1103/PhysRevLett.8.250; Borst TH, 1996, PHYS STATUS SOLIDI A, V154, P423, DOI 10.1002/pssa.2211540130; Brunet F, 1997, J APPL PHYS, V81, P1120, DOI 10.1063/1.363856; Cohen M.L., 1969, SUPERCONDUCTIVITY, P615; COHEN ML, 1964, PHYS REV, V134, pA511, DOI 10.1103/PhysRev.134.A511; Eremets MI, 2001, SCIENCE, V293, P272, DOI 10.1126/science.1062286; Field E.J., 1992, PROPERTIES NATURAL S; Garrido JA, 2003, APPL PHYS LETT, V82, P988, DOI 10.1063/1.1545152; GEIS MW, 1995, APPL PHYS LETT, V67, P1328, DOI 10.1063/1.114529; Grosche FM, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.247002; GUREVICH VL, 1962, SOV PHYS-SOL STATE, V4, P131; Hulm J. K., 1970, PROGR LOW TEMP PHYS, V6, P205; Kalish R, 2001, DIAM RELAT MATER, V10, P1749, DOI 10.1016/S0925-9635(01)00426-5; KAWAJI H, 1995, PHYS REV LETT, V74, P1427, DOI 10.1103/PhysRevLett.74.1427; Khvostantsev L G, 1977, HIGH TEMP HIGH PRESS, V9, P637; KOHMOTO M, 1990, J PHYS SOC JPN, V59, P1541, DOI 10.1143/JPSJ.59.1541; May PW, 2000, PHILOS T ROY SOC A, V358, P473, DOI 10.1098/rsta.2000.0542; MCMILLAN WL, 1968, PHYS REV, V167, P331, DOI 10.1103/PhysRev.167.331; Nozieres P, 1999, EUR PHYS J B, V10, P649, DOI 10.1007/s100510050897; Teukam Z, 2003, NAT MATER, V2, P482, DOI 10.1038/nmat929; VISHNEVSKII AS, 1981, SOV PHYS SEMICOND+, V15, P659; VORONOV OA, 1993, INORG MATER+, V29, P707; WERNER M, 1994, APPL PHYS LETT, V64, P595, DOI 10.1063/1.111088; WERTHAME.NR, 1966, PHYS REV, V147, P295, DOI 10.1103/PhysRev.147.295; WILLIAMS AW, 1970, J PHYS PART C SOLID, V3, P1727, DOI 10.1088/0022-3719/3/8/011; Zhang RJ, 1996, DIAM RELAT MATER, V5, P1288, DOI 10.1016/0925-9635(96)00539-0	26	897	913	12	408	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					542	545		10.1038/nature02449	http://dx.doi.org/10.1038/nature02449			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15057827	Green Submitted			2022-12-28	WOS:000220540100037
J	Trivedi, OA; Arora, P; Sridharan, V; Tickoo, R; Mohanty, D; Gokhale, RS				Trivedi, OA; Arora, P; Sridharan, V; Tickoo, R; Mohanty, D; Gokhale, RS			Enzymic activation and transfer of fatty acids as acyl-adenylates in mycobacteria	NATURE			English	Article							CRYSTAL-STRUCTURE; TUBERCULOSIS; SYNTHASE; GENE; SYNTHETASE; BIOSYNTHESIS; SUPERFAMILY; SPECIFICITY; ADJACENT; COENZYME	The metabolic repertoire in nature is augmented by generating hybrid metabolites from a limited set of gene products(1-3). In mycobacteria, several unique complex lipids are produced by the combined action of fatty acid synthases and polyketide synthases (PKSs)(4-6), although it is not clear how the covalently sequestered biosynthetic intermediates are transferred from one enzymatic complex to another. Here we show that some of the 36 annotated fadD genes, located adjacent to the PKS genes in the Mycobacterium tuberculosis genome, constitute a new class of long-chain fatty acyl-AMP ligases (FAALs). These proteins activate long-chain fatty acids as acyl-adenylates, which are then transferred to the multifunctional PKSs for further chain extension. This mode of activation and transfer of fatty acids is contrary to the previously described universal mechanism involving the formation of acyl-coenzyme A thioesters. Similar mechanisms may operate in the biosynthesis of other lipid-containing metabolites and could have implications in engineering novel hybrid products.	Natl Inst Immunol, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Gokhale, RS (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India.	rsg@nii.res.in	Mohanty, Debasisa/A-1428-2009	MOHANTY, DEBASISA/0000-0002-3374-0588; arora, pooja/0000-0002-4037-7406; Shrivastava, Rashmi/0000-0002-2988-4693				Admiraal SJ, 2001, BIOCHEMISTRY-US, V40, P6116, DOI 10.1021/bi010080z; Azad AK, 1997, J BIOL CHEM, V272, P16741, DOI 10.1074/jbc.272.27.16741; Camacho LR, 2001, J BIOL CHEM, V276, P19845, DOI 10.1074/jbc.M100662200; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; de Laureto PP, 2003, J MOL BIOL, V334, P129, DOI 10.1016/j.jmb.2003.09.024; Dieckmann R, 1999, J MOL BIOL, V288, P129, DOI 10.1006/jmbi.1999.2671; Duitman EH, 1999, P NATL ACAD SCI USA, V96, P13294, DOI 10.1073/pnas.96.23.13294; Fitzmaurice AM, 1997, J BACTERIOL, V179, P2608, DOI 10.1128/jb.179.8.2608-2615.1997; Fitzmaurice AM, 1998, J BIOL CHEM, V273, P8033, DOI 10.1074/jbc.273.14.8033; Gokhale RS, 1999, SCIENCE, V284, P482, DOI 10.1126/science.284.5413.482; Gokhale RS, 2001, BIOTECHNOLOGY, P341; Gulick AM, 2003, BIOCHEMISTRY-US, V42, P2866, DOI 10.1021/bi0271603; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; KELLER U, 1984, BIOCHEMISTRY-US, V23, P1479, DOI 10.1021/bi00302a022; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; May JJ, 2002, P NATL ACAD SCI USA, V99, P12120, DOI 10.1073/pnas.182156699; Moore BS, 2002, NAT PROD REP, V19, P70, DOI 10.1039/b003939j; Rindi L, 2002, MICROBIOL-SGM, V148, P3873, DOI 10.1099/00221287-148-12-3873; Saxena P, 2003, J BIOL CHEM, V278, P44780, DOI 10.1074/jbc.M306714200; Sirakova TD, 2001, J BIOL CHEM, V276, P16833, DOI 10.1074/jbc.M011468200; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; Tosato V, 1997, MICROBIOL-UK, V143, P3443, DOI 10.1099/00221287-143-11-3443; Yadav G, 2003, NUCLEIC ACIDS RES, V31, P3654, DOI 10.1093/nar/gkg607; Yadav G, 2003, J MOL BIOL, V328, P335, DOI 10.1016/S0022-2836(03)00232-8	27	220	244	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	2004	428	6981					441	445		10.1038/nature02384	http://dx.doi.org/10.1038/nature02384			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042094				2022-12-28	WOS:000220404300046
J	Amowitz, LL; Kim, G; Reis, C; Asher, JL; Iacopino, V				Amowitz, LL; Kim, G; Reis, C; Asher, JL; Iacopino, V			Human rights abuses and concerns about women's health and human rights in southern Iraq	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AFGHANISTAN; PREVALENCE; RAPE; WAR	Context Although human rights abuses have been reported in Iraq, the full scope of these abuses has not been well documented. Objective To assess the prevalence of human rights abuses since 1991 in southern Iraq, along with attitudes about women's health and human rights and women's rights and roles in society, to inform reconstruction and humanitarian assistance efforts in Iraq. Design Cross-sectional, randomized survey of Iraqi men and women conducted in July 2003 using structured questionnaires. Setting Three major cities in 3 of the 9 governorates in southern Iraq. Participants A total of 1991 respondents representing 16520 household members. Main Outcome Measures Respondent demographics, information on human rights abuses that occurred among household members since 1991, women's health and human rights, opinions regarding women's rights and roles in society, and conditions for community health and development. Results Respondents were a mean age of 38 years and were mostly of Arab ethnicity (99.7% [1976/1982]) and Muslim Shi'a (96.7% [1906/1971]). Overall, 47% of those interviewed reported 1 or more of the following abuses among themselves and household members since 1991: torture, killings, disappearance, forced conscription, beating, gunshot wounds, kidnappings, being held hostage, and ear amputation, among others. Seventy percent of abuses (408/586) were reputed to have occurred in homes. Baath party regime-affiliated groups were identified most often (95% [449/475]) as the perpetrators of the abuses; 53% of the abuses occurred between 1991 and 1993, following the Shi' a uprising, and another 30% between 2000 and the first 6 months of 2003. While the majority of men and women expressed support for women's equal opportunities for education, freedom of expression, access to health care, equality in deciding marriage and the number and spacing of children, and participation in community development decisions, there was less support among both men and women for women's freedom of movement, association with people of their choosing, and rights to refuse sex. Half of women and men (54% and 50%, respectively) reported agreeing that a man has the right to beat his wife if she disobeys. Fifty-three percent of respondents reported that there were reasons to restrict educational opportunities for women at the present time and 50% reported that there were reasons to restrict work opportunities for women at the present time. Conclusions Nearly half of participating households in 3 southern cities in Iraq reported human rights abuses among household members between 1991 and 2003. The households surveyed supported a government that will protect and promote human rights, including the rights of women. However, currently, neither men nor women appear to support a full range of women's human rights.	Brigham & Womens Hosp, Div Womens Hlth, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Beth Israel Deaconess Med Ctr, Div Gen Internal Med, Boston, MA 02215 USA; Martus Project, Palo Alto, CA USA; Physicians Human Rights, Boston, MA 02116 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Amowitz, LL (corresponding author), Physicians Human Rights, 100 Boylston St,Suite 702, Boston, MA 02116 USA.	lamowitz@rics.bwh.harvard.edu	Lawry, Lynn/ABE-8391-2021; David, Maribel/E-2812-2012	Lawry, Lynn/0000-0001-8229-8768; Reis, Chen/0000-0003-4647-7149				Amowitz LL, 2003, J WOMEN HEALTH GEN-B, V12, P577, DOI 10.1089/154099903768248285; Amowitz LL, 2002, JAMA-J AM MED ASSOC, V288, P1284, DOI 10.1001/jama.288.10.1284; Amowitz LL, 2002, JAMA-J AM MED ASSOC, V287, P513, DOI 10.1001/jama.287.4.513; AMOWITZ LL, 2001, WOMENS HLTH HUMAN RI; Askin Kelly Dawn, 1997, WAR CRIMES WOMEN PRO; *ASS AFGH, BAS PREM PRINC COMM; *BBC NEWS, 2003, IR KILL FIELDS; *BBC NEWS, US TROOPS CHARG POW; Burt CDB, 2001, MEM COGNITION, V29, P127, DOI 10.3758/BF03195747; *CDCP, SUIC ID; *CIA, CIA WORLD FACTB IR; *COL U CTR STUD HU, 1994, 25 HUM RIGHTS DOC; *CRIM VICT RES TRE, 1992, RAP AM; *FREED PEAC TRUST, REP BAGHD; *GRAP CO INC, SAMPL SIZ CALC; GROSSMAN M, 1975, NATL BUREAU EC RES S, V40; HAYNER PB, 1994, HUM RIGHTS QUART, V16, P597, DOI 10.2307/762562; *HUM RIGHTS WATCH, CLIM FEAR SEX VIOL A; *HUM RIGHTS WATCH, 2003, MASS GRAV AL MAH TRU; Human Rights Watch, 1993, BACKGR HUM RIGHTS CO; Iacopino V, 1998, Health Hum Rights, V3, P98, DOI 10.2307/4065302; Iacopino Vincent, 1999, WAR CRIMES KOSOVO PO; *INT PLANN PAR FED, WHAT IS GEND BAS VIO; KOSS MP, 1993, J INTERPERS VIOLENCE, V8, P198, DOI 10.1177/088626093008002004; KUNARAC, 2T 96 23 IT 96 23 1; *MADRE, US APPOINTED COUNCIL; Mullan Cook-Deegan R., 1989, WINDS DEATH IRAQA US; NEIER A, 1998, WAR CRIMES BRUTALITY, P35; *NIH, SUIC SUIC BEH; Packer George, 2003, NEW YORKER      1124, P58; Patton M., 2015, QUALITATIVE RES EVAL, V4th; *PHYS HUM RIGHTS, NEW SURV 2000 IR HOU; Rasekh Z, 1998, JAMA-J AM MED ASSOC, V280, P449, DOI 10.1001/jama.280.5.449; RELDMAN J, 1989, AM J EPIDEMIOL, V129, P919; RENNISON C, INTIMATE PARTNER VIO; RUBENSTEIN LS, 2001, ENDLESS BRUTALITY WA, P1; *STATA CORP, 2000, STATA 7 0 INT WIND C; SWISS S, 1993, JAMA-J AM MED ASSOC, V270, P612, DOI 10.1001/jama.270.5.612; Thompson J, 1997, MEMORY, V5, P615, DOI 10.1080/741941482; UN Statistics Division, WORLDS WOM 2000 TREN; *WORLD BANK, IR GLANC; *WORLD GAZ, POP IR; World Health Organization, SUIC RAT; *WORLD MED ASS, 2000, DECL HELS ETH PRINC; ZALAQUETT J, 1995, TRANSITIONAL JUSTICE, V1, P3	45	43	44	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	2004	291	12					1471	1479		10.1001/jama.291.12.1471	http://dx.doi.org/10.1001/jama.291.12.1471			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	805UI	15039414	Bronze			2022-12-28	WOS:000220390800028
J	Goldzweig, CL; Rowe, S; Wenger, NS; MacLean, CH; Shekelle, PG				Goldzweig, CL; Rowe, S; Wenger, NS; MacLean, CH; Shekelle, PG			Preventing and managing visual disability in primary care - Clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							AGE-RELATED MACULOPATHY; SELF-RATED VISION; QUALITY-OF-LIFE; DIABETIC-RETINOPATHY; EYE DISEASE; MACULAR DEGENERATION; SMOKING-CESSATION; FUNCTIONAL STATUS; RISK-FACTORS; CATARACT	Clinicians in primary care settings are well positioned to participate in the prevention and management of visual disability. They can have a significant impact on their patients' visual health by screening for vision problems, aggressively controlling known risk factors for visual loss, ensuring adherence to ophthalmologic treatment and continuity of eye care, and by timely referral of specific patient populations to qualified eye care professionals (eg, ophthalmologists and optometrists). Using their knowledge about common ophthalmic medications, clinicians can detect adverse effects of these agents, including exacerbations of heart or lung disease. They can ensure that appropriate patients are screened for common serious eye diseases, such as glaucoma, and that patients with disabilities related to vision problems are assessed for treatable conditions, such as cataracts or refractive error. Finally, clinicians can direct patients with low vision from any cause to resources designed to help enhance patient function and emotional support.	Greater Los Angeles Vet Affairs Hlth Care Syst, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA; Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; RAND Hlth, Santa Monica, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Boston University; RAND Corporation	Goldzweig, CL (corresponding author), Vet Affairs W Los Angeles Healthcare Ctr, 111-G, Los Angeles, CA 90073 USA.	goldzweig@med.va.gov		Rowe, Susannah/0000-0002-2061-6828				Abrahamsson M, 1996, ACTA OPHTHALMOL SCAN, V74, P69; *AM AC OPHTH, 2000, COMPR MED EYE EV; *AM OPT ASS CONS P, COMPR AD EYE VIS EX; Anand R, 2000, OPHTHALMOLOGY, V107, P2224; Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477; Buonaccorso K M, 1999, J Healthc Qual, V21, P35; Buonaccorso KM, 1999, J HEALTHC Q, V21, P46; Cheng A. C. K., 2000, Hong Kong Medical Journal, V6, P195; Chew EY, 1996, ARCH OPHTHALMOL-CHIC, V114, P1079, DOI 10.1001/archopht.1996.01100140281004; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Christen WG, 2000, JAMA-J AM MED ASSOC, V284, P713, DOI 10.1001/jama.284.6.713; Eke T, 1999, EYE, V13, P647, DOI 10.1038/eye.1999.175; Elliott DB, 1997, BRIT J OPHTHALMOL, V81, P889, DOI 10.1136/bjo.81.10.889; Gasch AT, 2000, OPHTHALMOLOGY, V107, P303, DOI 10.1016/S0161-6420(99)00076-7; Gutierrez P, 1997, ARCH OPHTHALMOL-CHIC, V115, P777, DOI 10.1001/archopht.1997.01100150779014; Ivers RQ, 2000, CLIN EXP OPHTHALMOL, V28, P41, DOI 10.1046/j.1442-9071.2000.00236.x; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X; Klein R, 1998, AM J EPIDEMIOL, V147, P103; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P237, DOI 10.1001/archopht.1989.01070010243030; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023; Lee P, 1999, AM J OPHTHALMOL, V127, P447, DOI 10.1016/S0002-9394(98)00418-8; Lee PP, 1999, OPHTHALMOLOGY, V106, P401, DOI 10.1016/S0161-6420(99)90082-9; LEE PP, 1995, QUAL LIFE RES, V4, P319, DOI 10.1007/BF01593884; Lee PP, 1997, OPHTHALMOLOGY, V104, P390, DOI 10.1016/S0161-6420(97)30303-0; Livingston PM, 1998, BRIT J OPHTHALMOL, V82, P780, DOI 10.1136/bjo.82.7.780; Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5; MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004; MANGIONE CM, 1994, ARCH OPHTHALMOL-CHIC, V112, P1419, DOI 10.1001/archopht.1994.01090230033017; *NAT COMM QUAL ASS, DIAB QUAL IMPR PROJ; PasagianMacaulay A, 1997, DIABETES EDUCATOR, V23, P433, DOI 10.1177/014572179702300408; Philis-Tsimikas A, 2001, J Ambul Care Manage, V24, P39; Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041; Rowe S, 2004, JAMA-J AM MED ASSOC, V291, P1487, DOI 10.1001/jama.291.12.1487; Schoenfeld ER, 2001, OPHTHALMOLOGY, V108, P563, DOI 10.1016/S0161-6420(00)00600-X; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SMEETH L, 2003, COCHRANE DB SYST REV, V1; Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7; Stratton IM, 2001, DIABETOLOGIA, V44, P156, DOI 10.1007/s001250051594; Sudesh S, 1993, Qual Health Care, V2, P175, DOI 10.1136/qshc.2.3.175; TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369; TROBE J, 2001, PHYS GUIDE EYE CARE; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; *VET AFF DEP DEF C, 1999, MAN DIAB MELL; Walker EA, 1997, J DIABETES COMPLICAT, V11, P298, DOI 10.1016/S1056-8727(96)00121-3; *WALT KLUW HLTH IN, 2003, DRUG FACTS COMP; Weintraub JM, 2002, AM J EPIDEMIOL, V155, P72, DOI 10.1093/aje/155.1.72	47	19	20	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	2004	291	12					1497	1502		10.1001/jama.291.12.1497	http://dx.doi.org/10.1001/jama.291.12.1497			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805UI	15039417	Bronze			2022-12-28	WOS:000220390800031
J	Reis, C; Ahmed, AT; Amowitz, LL; Kushner, AL; Elahi, M; Iacopino, V				Reis, C; Ahmed, AT; Amowitz, LL; Kushner, AL; Elahi, M; Iacopino, V			Physician participation in human rights abuses in southern Iraq	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TORTURE; DOCTORS	Context Physicians are known to have participated in human rights abuses in Iraq during Saddam Hussein's Baathist regime, but the nature and extent of that participation are not well documented., Objectives To characterize the nature of physician participation inhuman rights abuses, identify structural factors that facilitated physician participation, and assess approaches for accountability and for prevention of future physician participation in abuses. Design, Setting, and Participants A self-administered survey in June and July, 2003, of a convenience sample of 98 physicians and semistructured interviews of hospital directors and physicians in 3 major hospitals with general surgical units in 2 cities in southern Iraq. Main Outcome Measure Respondent reports of peer and self-participation in. human rights abuses in Iraq since 1988. Results The majority of participants were male (88% [86/98]) and Shi'a Muslims (97% [95/98]). Respondents reported a mean of 6.8 years in practice. A total of 71% of respondents (65/91) reported that torture was a problem to an extreme extent in Iraq since 1988. The proportion of respondents indicating that, since 1988, their physician peers as a group were extremely or quite a bit involved in human rights abuses included 50% (42/83) for nontherapeutic amputation of ears as a form of punishment, 49% (39/ 79) for falsification of medical-legal reports of torture, and 32% (25/78) for falsification of death certificates. Fewer numbers of respondents (range, n=2 to 6) reported participation in abuses themselves. More than half (52% [48/92]) indicated that physicians did not willingly participate in these abuses; 93% (52/71) reported that the Iraqi paramilitary force Fedayeen Saddam was responsible for initiating physician complicity. Fear of harm to oneself or family members was a common explanation for complicity. Respondents reported that physicians who refused to participate in abuses faced consequences including loss of job, imprisonment, torture, and disappearance. Respondents reported on preventive measures that should be undertaken to prevent physician involvement in future abuses, including increasing human rights and ethics education of physicians (99% [79/80]), legal provisions to ensure effective monitoring (97% [73/75]), punitive sanctions for physicians who commit abuses (96% [77/80]), and ensuring the independence of physicians from state authorities (95% [76/80]). Conclusions Although not generalizable beyond the study participants, the findings of this study suggest that among those surveyed, physician participation in human rights abuses included falsification of medical-legal reports of alleged torture, physical mutilation as a form of punishment, and falsification of death certificates. As Iraq rebuilds, it is essential that the country address these violations and enact measures to prevent physicians from future complicity in human rights abuses.	Physicians Human Rights, Boston, MA 02116 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Survivors Int, San Francisco, CA USA; Brigham & Womens Hosp, Div Womens Hlth, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Trinity Coll, Hartford, CT 06106 USA	University of California System; University of California Berkeley; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Trinity College	Reis, C (corresponding author), Physicians Human Rights, 100 Boylston St,Suite 702, Boston, MA 02116 USA.	CReis@phrusa.org	Lawry, Lynn/ABE-8391-2021	Lawry, Lynn/0000-0001-8229-8768; Reis, Chen/0000-0003-4647-7149; Kushner, Adam/0000-0002-7797-4837				ALSHAWAF T, 1995, BRIT MED J, V310, P130, DOI 10.1136/bmj.310.6972.130b; *AM ASS ADV SCI, 1997, TRUTH REC EX HUM RIG; *AMN INT, 1996, IR STAT CRUELT BRAND; *AMN INT, 2001, SYST TORT EX PUN SUR; *AMN INT, 1984, TORT 80, P231; Amowitz LL, 2004, JAMA-J AM MED ASSOC, V291, P1471, DOI 10.1001/jama.291.12.1471; Bassiouni MC, 1996, LAW CONTEMP PROBL, V59, P63, DOI 10.2307/1192190; *BRIT MED ASS, 2001, MED PROF HUM RIGHTS; Brownlie Ian, 1998, PRINCIPLES PUBLIC IN; BUTT G, 1994, BRIT MED J, V309, P898, DOI 10.1136/bmj.309.6959.898; *CENTR INT AG, CIA FACTB IR MIL BRA; COURT C, 1994, BRIT MED J, V309, P760, DOI 10.1136/bmj.309.6957.760; Eitinger L, 1998, CARING FOR VICTIMS OF TORTURE, P3; GEIGER HJ, 1993, JAMA-J AM MED ASSOC, V270, P616; *GLOB SEC ORG, SADD MART FED SADD; Heisler M, 2003, JAMA-J AM MED ASSOC, V289, P2135, DOI 10.1001/jama.289.16.2135; Iacopino V, 1996, JAMA-J AM MED ASSOC, V276, P396, DOI 10.1001/jama.276.5.396; International Dual Loyalty Working Group, 2003, DUAL LOYALT HUM RIGH; KIMANI D, 2000, E AFRICAN       0515; Mann J., 1999, HLTH HUMAN RIGHTS RE, P7; Patton M., 2015, QUALITATIVE RES EVAL, V4th; Reich, 1990, ORIGINS TERRORISM PS, P161; Rubenstein L S, 1999, Minn Med, V82, P46; SCARRY E, 1985, BODY PAIN MAKING UNM, P27; *STAT CORP, 2002, STAT 7 0 INT WIND; *UN GEN ASS, 1983, PRINC MED ETH REL PR; *US GEN ASS, 2000, ARES54178 UN GEN ASS; Welsh J, 1998, LANCET, V352, P1852, DOI 10.1016/S0140-6736(98)10541-X; *WORLD GAZ, 2004, WORLD GAZ WEB SIT; *WORLD MED ASS, 2000, DECL HELS ETH PRINC; World Medical Association, 1983, DECL GEN; World Medical Association, 1975, DECL TOK; [No title captured]	33	26	26	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	2004	291	12					1480	1486		10.1001/jama.291.12.1480	http://dx.doi.org/10.1001/jama.291.12.1480			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805UI	15039415	Bronze			2022-12-28	WOS:000220390800029
J	van Zwanenberg, T				van Zwanenberg, T			Revalidation: the purpose needs to be clear	BRITISH MEDICAL JOURNAL			English	Article							GMCS PROPOSALS; APPRAISAL		Univ Newcastle Upon Tyne, Postgrad Inst Med & Dent, Newcastle Upon Tyne NE2 4AB, Tyne & Wear, England	Newcastle University - UK	van Zwanenberg, T (corresponding author), Univ Newcastle Upon Tyne, Postgrad Inst Med & Dent, Newcastle Upon Tyne NE2 4AB, Tyne & Wear, England.	t.d.van-zwanenberg@ncl.ac.uk						Conlon M, 2003, BRIT MED J, V327, P389, DOI 10.1136/bmj.327.7411.389; Dauphinee WD, 1999, BMJ-BRIT MED J, V319, P1188, DOI 10.1136/bmj.319.7218.1188; *DEP HLTH, 2001, ASS QUAL MED PRACT I; *DEP HLTH, 2000, MOD MED REG INT STRE; *DEP HLTH, 1998, 1 CLASS SERV QUAL NE; Department of Health, 1999, SUPP DOCT PROT PAT; Department of Health, 1997, NEW NHS MOD DEP; General Medical Council, 2001, GOOD MED PRACT; General Medical Council, 2000, REV DOCT ENS STAND S; General Medical Council, 2003, LIC PRACT REV; IRVINE D, 1993, BRIT J GEN PRACT, V43, P121; Newble D, 2001, BRIT MED J, V322, P358, DOI 10.1136/bmj.322.7282.358; Pringle M, 2003, BRIT J GEN PRACT, V53, P437; Roberts C, 2002, MED EDUC, V36, P899, DOI 10.1046/j.1365-2923.2002.01288.x; Taylor A.J.P., 1975, ENGLISH HIST 1914 19; VANZWANENBERG T, 2003, REBUILDING TRUST HEA; VANZWANENBERG TD, 2002, THESIS U NEWCASTLE; Wakeford R, 2000, BRIT MED J, V321, P1220, DOI 10.1136/bmj.321.7270.1220; Wakeford RE, 2003, BRIT MED J, V327, P161, DOI 10.1136/bmj.327.7407.161	19	11	11	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 20	2004	328	7441					684	686		10.1136/bmj.328.7441.684	http://dx.doi.org/10.1136/bmj.328.7441.684			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VB	15031240	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000220392700020
J	Wolfe, ND; Switzer, WM; Carr, JK; Bhullar, VB; Shanmugam, V; Tamoufe, U; Prosser, AT; Torimiro, JN; Wright, A; Mpoudi-Ngole, E; McCutchan, FE; Birx, DL; Folks, TM; Burke, DS; Heneine, W				Wolfe, ND; Switzer, WM; Carr, JK; Bhullar, VB; Shanmugam, V; Tamoufe, U; Prosser, AT; Torimiro, JN; Wright, A; Mpoudi-Ngole, E; McCutchan, FE; Birx, DL; Folks, TM; Burke, DS; Heneine, W			Naturally acquired simian retrovirus infections in central African hunters	LANCET			English	Article							FOAMY VIRUS-INFECTION; IMMUNODEFICIENCY VIRUS; NONHUMAN-PRIMATES; LABORATORY WORKER; IDENTIFICATION; TRANSMISSION; POPULATIONS; HEALTH; RISK	Background Hunting and butchering of wild non-human primates infected with simian immunodeficiency virus (SIV) is thought to have sparked the HIV pandemic. Although SIV and other primate retroviruses infect laboratory workers and zoo workers, zoonotic retrovirus transmission has not been documented in natural settings. We investigated zoonotic infection in individuals living in central Africa. Methods We obtained behavioural data, plasma samples, and peripheral blood lymphocytes from individuals living in rural villages in Cameroon. We did serological testing, PCR, and sequence analysis to obtain evidence of retrovirus infection. Findings Zoonotic infections with simian foamy virus (SFV), a retrovirus endemic in most Old World primates, were identified in people living in central African forests who reported direct contact with blood and body fluids of wild non-human primates. Ten (1%) of 1099 individuals had antibodies to SFV. Sequence analysis from these individuals revealed three geographically-independent human SFV infections, each of which was acquired from a distinct non-human primate lineage: De Brazza's guenon (Cercopithecus neglectus), mandrill (Mandrillus sphinx), and gorilla (Gorilla gorilla), two of which (De Brazza's guenon and mandrill) are naturally infected with SIV. Interpretation Our findings show that retroviruses are actively crossing into human populations, and demonstrate that people in central Africa are currently infected with SFV. Contact with non-human primates, such as happens during hunting and butchering, can play a part in the emergence of human retroviruses and the reduction of primate bushmeat hunting has the potential to decrease the frequency of. disease emergence.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Ctr Dis Control & Prevent, HIV & Retrovirol Branch, Div AIDS Sexually Transmitted Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, TB Lab Res, Natl Ctr HIV AIDS Sexually Transmitted Dis & TB P, Atlanta, GA USA; Henry M Jackson Fdn, Rockville, MD USA; Army Hlth Res Ctr, Yaounde, Cameroon; Walter Reed Army Inst Res, Rockville, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Wolfe, ND (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St E7132, Baltimore, MD 21205 USA.	nwolfe@jhsph.edu		/0000-0002-5704-8094				Ali M, 1996, AIDS RES HUM RETROV, V12, P1473, DOI 10.1089/aid.1996.12.1473; BEINIASZ PD, 1995, VIROLOGY, V207, P217; Brooks JI, 2002, LANCET, V360, P387, DOI 10.1016/S0140-6736(02)09597-1; Broussard SR, 1997, VIROLOGY, V237, P349, DOI 10.1006/viro.1997.8797; Groves C.P., 2001, PRIMATE TAXONOMY; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; Heneine W, 1998, NAT MED, V4, P403, DOI 10.1038/nm0498-403; Hu JJ, 2003, J VIROL, V77, P4867, DOI 10.1128/JVI.77.8.4867-4880.2003; Hussain AI, 2003, VIROLOGY, V309, P248, DOI 10.1016/S0042-6822(03)00070-9; KHABBAZ RF, 1994, NEW ENGL J MED, V330, P172, DOI 10.1056/NEJM199401203300304; KHABBAZ RF, 1992, LANCET, V340, P271, DOI 10.1016/0140-6736(92)92358-M; Lerche NW, 2001, J VIROL, V75, P1783, DOI 10.1128/JVI.75.4.1783-1789.2001; Meiering CD, 2001, CLIN MICROBIOL REV, V14, P165, DOI 10.1128/CMR.14.1.165-176.2001; Peeters M, 2002, EMERG INFECT DIS, V8, P451, DOI 10.3201/eid0805.010522; Sandstrom PA, 2000, LANCET, V355, P551, DOI 10.1016/S0140-6736(99)05292-7; SCHWEIZER M, 1995, AIDS RES HUM RETROV, V11, P161, DOI 10.1089/aid.1995.11.161; Schweizer M, 1997, J VIROL, V71, P4821, DOI 10.1128/JVI.71.6.4821-4824.1997; Sotir M, 1997, J MED PRIMATOL, V26, P233, DOI 10.1111/j.1600-0684.1997.tb00217.x; SWITZER WM, 1995, J VIROL, V69, P621, DOI 10.1128/JVI.69.2.621-632.1995; Switzer WM, 2001, TRANSPLANTATION, V71, P959, DOI 10.1097/00007890-200104150-00022; Walsh PD, 2003, NATURE, V422, P611, DOI 10.1038/nature01566; Wolfe ND, 1998, EMERG INFECT DIS, V4, P149, DOI 10.3201/eid0402.980202	22	280	294	3	80	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	2004	363	9413					932	937		10.1016/S0140-6736(04)15787-5	http://dx.doi.org/10.1016/S0140-6736(04)15787-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043960				2022-12-28	WOS:000220308600009
J	Winkler, WC; Nahvi, A; Roth, A; Collins, JA; Breaker, RR				Winkler, WC; Nahvi, A; Roth, A; Collins, JA; Breaker, RR			Control of gene expression by a natural metabolite-responsive ribozyme	NATURE			English	Article							MESSENGER-RNA STRUCTURE; INTRINSIC TRANSCRIPTION TERMINATION; ALLOSTERIC RIBOZYMES; MOLECULAR SWITCHES; MECHANISM; RIBOSWITCHES; SELECTION; BACTERIA; INTRONS	Most biological catalysts are made of protein; however, eight classes of natural ribozymes have been discovered that catalyse fundamental biochemical reactions. The central functions of ribozymes in modern organisms support the hypothesis that life passed through an 'RNA world' before the emergence of proteins and DNA. We have identified a new class of ribozymes that cleaves the messenger RNA of the glmS gene in Gram-positive bacteria. The ribozyme is activated by glucosamine-6-phosphate (GlcN6P), which is the metabolic product of the GlmS enzyme. Additional data indicate that the ribozyme serves as a metabolite-responsive genetic switch that represses the glmS gene in response to rising GlcN6P concentrations. These findings demonstrate that ribozyme switches may have functioned as metabolite sensors in primitive organisms, and further suggest that modern cells retain some of these ancient genetic control systems.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University; Yale University	Breaker, RR (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, POB 208103, New Haven, CT 06520 USA.	ronald.breaker@yale.edu	Breaker, Ronald/E-9679-2010	Breaker, Ronald/0000-0002-2165-536X				ABRASH HI, 1967, BIOCHEMISTRY-US, V6, P1303; BARRICK JE, UNPUB P NATL ACAD SC; Breaker RR, 1997, CHEM REV, V97, P371, DOI 10.1021/cr960008k; Breaker RR, 2002, CURR OPIN BIOTECH, V13, P31, DOI 10.1016/S0958-1669(02)00281-1; Breaker RR, 2003, RNA, V9, P949, DOI 10.1261/rna.5670703; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; Doherty EA, 2000, ANNU REV BIOCHEM, V69, P597, DOI 10.1146/annurev.biochem.69.1.597; Emilsson GM, 2003, RNA, V9, P907, DOI 10.1261/rna.5680603; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; Joyce GF, 2002, NATURE, V418, P214, DOI 10.1038/418214a; Koizumi M, 1999, NAT STRUCT BIOL, V6, P1062; Kubodera T, 2003, FEBS LETT, V555, P516, DOI 10.1016/S0014-5793(03)01335-8; Li YF, 1999, J AM CHEM SOC, V121, P5364, DOI 10.1021/ja990592p; Mandal M, 2004, NAT STRUCT MOL BIOL, V11, P29, DOI 10.1038/nsmb710; Mandal M, 2003, CELL, V113, P577, DOI 10.1016/S0092-8674(03)00391-X; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; Milewski S, 2002, BBA-PROTEIN STRUCT M, V1597, P173, DOI 10.1016/S0167-4838(02)00318-7; MILLER JH, 1992, SHORT COURSE BACTERI, V72; Mironov AS, 2002, CELL, V111, P747, DOI 10.1016/S0092-8674(02)01134-0; Nahvi A, 2002, CHEM BIOL, V9, P1043, DOI 10.1016/S1074-5521(02)00224-7; Osborne SE, 1997, CHEM REV, V97, P349, DOI 10.1021/cr960009c; PTASHNE M, 2002, GENES SIGNALS; SAVILLE BJ, 1990, CELL, V61, P685, DOI 10.1016/0092-8674(90)90480-3; Seetharaman S, 2001, NAT BIOTECHNOL, V19, P336, DOI 10.1038/86723; Silverman SK, 2003, RNA, V9, P377, DOI 10.1261/rna.2200903; Soukup GA, 1999, RNA, V5, P1308, DOI 10.1017/S1355838299990891; Soukup GA, 1999, P NATL ACAD SCI USA, V96, P3584, DOI 10.1073/pnas.96.7.3584; Soukup GA, 2001, RNA, V7, P524, DOI 10.1017/S1355838201002175; Soukup GA, 2000, CURR OPIN STRUC BIOL, V10, P318, DOI 10.1016/S0959-440X(00)00090-7; Sudarsan N, 2003, RNA, V9, P644, DOI 10.1261/rna.5090103; Sudarsan N, 2003, GENE DEV, V17, P2688, DOI 10.1101/gad.1140003; Tang J, 1997, CHEM BIOL, V4, P453, DOI 10.1016/S1074-5521(97)90197-6; Vitreschak AG, 2004, TRENDS GENET, V20, P44, DOI 10.1016/j.tig.2003.11.008; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145; Winkler WC, 2003, CHEMBIOCHEM, V4, P1024, DOI 10.1002/cbic.200300685; Winkler WC, 2002, P NATL ACAD SCI USA, V99, P15908, DOI 10.1073/pnas.212628899; Winkler WC, 2003, NAT STRUCT BIOL, V10, P701, DOI 10.1038/nsb967; Yarnell WS, 1999, SCIENCE, V284, P611, DOI 10.1126/science.284.5414.611	40	652	715	2	134	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	2004	428	6980					281	286		10.1038/nature02362	http://dx.doi.org/10.1038/nature02362			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15029187				2022-12-28	WOS:000220250200034
J	Michailov, GV; Sereda, MW; Brinkmann, BG; Fischer, TM; Haug, B; Birchmeier, C; Role, L; Lai, C; Schwab, MH; Nave, KA				Michailov, GV; Sereda, MW; Brinkmann, BG; Fischer, TM; Haug, B; Birchmeier, C; Role, L; Lai, C; Schwab, MH; Nave, KA			Axonal neuregulin-1 regulates myelin sheath thickness	SCIENCE			English	Article							SCHWANN-CELLS; GROWTH; NERVE; MAINTENANCE; EXPRESSION; RECEPTORS; ISOFORMS; NEURONS; CALIBER; SIZE	In the nervous system of vertebrates, myelination is essential for rapid and accurate impulse conduction. Myelin thickness depends on axon fiber size. We use mutant and transgenic mouse lines to show that axonal Neuregulin-1 (Nrg1) signals information about axon size to Schwann cells. Reduced Nrg1 expression causes hypomyelination and reduced nerve conduction velocity. Neuronal overexpression of Nrg1 induces hypermyelination and demonstrates that Nrg1 type III is the responsible isoform. We suggest a model by which myelin-forming Schwann cells integrate axonal Nrg1 signals as a biochemical measure of axon size.	Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany; Univ Gottingen, Dept Clin Neurophysiol, D-37075 Gottingen, Germany; Univ Gottingen, Dept Neurol, D-37075 Gottingen, Germany; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Columbia Univ, New York, NY 10032 USA; Hertie Inst Multiple Sclerosis Res, D-37075 Gottingen, Germany	Max Planck Society; University of Gottingen; University of Gottingen; Scripps Research Institute; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Columbia University	Nave, KA (corresponding author), Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany.	nave@em.mpg.de	Role, LW/Q-7371-2018; Nave, Klaus-Armin/C-8883-2011	Role, LW/0000-0001-5851-212X; 				Adlkofer K, 2000, GLIA, V29, P104, DOI 10.1002/(SICI)1098-1136(20000115)29:2<104::AID-GLIA2>3.0.CO;2-2; Balice-Gordon RJ, 1998, J CELL BIOL, V142, P1095, DOI 10.1083/jcb.142.4.1095; Bao JX, 2003, J CELL BIOL, V161, P1133, DOI 10.1083/jcb.200212085; Bermingham-McDonogh O, 1997, MOL CELL NEUROSCI, V10, P184, DOI 10.1006/mcne.1997.0654; BRINKMANN BG, UNPUB; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Caroni P, 1997, J NEUROSCI METH, V71, P3, DOI 10.1016/S0165-0270(96)00121-5; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Colognato H, 2002, NAT CELL BIOL, V4, P833, DOI 10.1038/ncb865; Cosgaya JM, 2002, SCIENCE, V298, P1245, DOI 10.1126/science.1076595; DEWEBSTER FH, 1971, NEUROSCI RES PROGRAM, V9, P470; Donaldson HH, 1905, J COMP NEUROL PSYCHO, V15, P1, DOI 10.1002/cne.920150102; Elder GA, 2001, J NEUROSCI RES, V65, P493, DOI 10.1002/jnr.1179; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; FRAHER JP, 1990, ACTA NEUROPATHOL, V79, P364, DOI 10.1007/BF00308712; FRIEDE RL, 1986, EXP NEUROL, V92, P234, DOI 10.1016/0014-4886(86)90137-8; FRIEDE RL, 1982, BRAIN RES, V235, P335, DOI 10.1016/0006-8993(82)91012-5; Garratt AN, 2000, J CELL BIOL, V148, P1035, DOI 10.1083/jcb.148.5.1035; Garratt AN, 2000, BIOESSAYS, V22, P987, DOI 10.1002/1521-1878(200011)22:11<987::AID-BIES5>3.0.CO;2-5; Gassmann M, 1997, CURR OPIN NEUROBIOL, V7, P87, DOI 10.1016/S0959-4388(97)80125-0; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; Maurel P, 2000, J NEUROSCI, V20, P4635, DOI 10.1523/JNEUROSCI.20-12-04635.2000; Meyer D, 1997, DEVELOPMENT, V124, P3575; MICHAILOV GV, UNPUB; ONEILL JH, 1984, ACTA NEUROPATHOL, V63, P313, DOI 10.1007/BF00687339; PANNESE E, 1987, ANAT EMBRYOL, V175, P423, DOI 10.1007/BF00309678; Rosenbaum C, 1997, EXP NEUROL, V148, P604, DOI 10.1006/exnr.1997.6696; SALZER J, COMMUNICATION; Sandrock AW, 1997, SCIENCE, V276, P599, DOI 10.1126/science.276.5312.599; Sereda M, 1996, NEURON, V16, P1049, DOI 10.1016/S0896-6273(00)80128-2; VOYVODIC JT, 1989, NATURE, V342, P430, DOI 10.1038/342430a0; WAXMAN SG, 1980, MUSCLE NERVE, V3, P141, DOI 10.1002/mus.880030207; Waxman SG, 1997, CURR BIOL, V7, pR406, DOI 10.1016/S0960-9822(06)00203-X; WILLIAMS PL, 1971, J ANAT, V109, P505; Wolpowitz D, 2000, NEURON, V25, P79, DOI 10.1016/S0896-6273(00)80873-9; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zanazzi G, 2001, J CELL BIOL, V152, P1289, DOI 10.1083/jcb.152.6.1289	38	697	718	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 30	2004	304	5671					700	703		10.1126/science.1095862	http://dx.doi.org/10.1126/science.1095862			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	816JD	15044753				2022-12-28	WOS:000221105300035
J	Kansagra, S; List, J				Kansagra, S; List, J			The clinical relevance of genomic variation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK; MEDICINE; GENE; PHARMACOGENETICS; POLYMORPHISMS; ASSOCIATION; DISEASE		Duke Univ, Sch Med, Durham, NC 27706 USA; Yale Univ, Sch Divin, New Haven, CT 06520 USA	Duke University; Yale University	Kansagra, S (corresponding author), Duke Univ, Sch Med, Durham, NC 27706 USA.			List, Justin/0000-0002-6934-6419				Aithal GP, 1999, LANCET, V353, P717, DOI 10.1016/S0140-6736(98)04474-2; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Garred P, 1999, J CLIN INVEST, V104, P431, DOI 10.1172/JCI6861; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Guttmacher AE, 2002, NEW ENGL J MED, V347, P1512, DOI 10.1056/NEJMra012240; Haga SB, 2003, NAT GENET, V34, P347, DOI 10.1038/ng0803-347; Phillips KA, 2001, JAMA-J AM MED ASSOC, V286, P2270, DOI 10.1001/jama.286.18.2270; Roses AD, 2000, NATURE, V405, P857, DOI 10.1038/35015728; Small KM, 2002, NEW ENGL J MED, V347, P1135, DOI 10.1056/NEJMoa020803; Splawski I, 2002, SCIENCE, V297, P1333, DOI 10.1126/science.1073569; Wolf CR, 2000, BRIT MED J, V320, P987, DOI 10.1136/bmj.320.7240.987	12	0	0	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2004	291	13					1641	1641		10.1001/jama.291.13.1641	http://dx.doi.org/10.1001/jama.291.13.1641			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809PQ	15069054				2022-12-28	WOS:000220649000031
J	Ghaffar, A; Reddy, KS; Singhi, M				Ghaffar, A; Reddy, KS; Singhi, M			Burden of non-communicable diseases in South Asia	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CORONARY-HEART-DISEASE; IMPAIRED FASTING GLYCEMIA; HIGH PREVALENCE; FETAL ORIGINS; RISK-FACTORS; POPULATION; INDIA; HYPERTENSION; ASTHMA		WHO, Global Forum Hlth Res, CH-1211 Geneva 27, Switzerland; All India Inst Med Sci, Dept Cardiol, New Delhi 110029, India; Initiat Cardiovasc Hlth Res Dev Countries, New Delhi 110016, India	World Health Organization; All India Institute of Medical Sciences (AIIMS) New Delhi	Ghaffar, A (corresponding author), WHO, Global Forum Hlth Res, CH-1211 Geneva 27, Switzerland.	ghaffara@who.int						AbuSayeed M, 1997, DIABETES CARE, V20, P551, DOI 10.2337/diacare.20.4.551; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; *DIAB ASS SRI LANK, 1999, INT DIAB FED SE AS R; Ferlay J, 2001, 5 IARC; Gupta R, 1996, Indian Heart J, V48, P241; Gupta Rajeev, 2002, Indian Heart J, V54, P59; *ICMR, 1994, COMM CONTR RHEUM FEV; *IDF, 2000, DIAB ATL 2000; Jafar TH, 2003, J HYPERTENS, V21, P905, DOI 10.1097/00004872-200305000-00014; Jindal S K, 2001, Indian J Chest Dis Allied Sci, V43, P139; Jose V Jacob, 2003, Indian Heart J, V55, P158; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; KRISHNASWAMI S, 1991, B WORLD HEALTH ORGAN, V69, P325; LALCHANDANI A, 2000, INDIAN HEART J, V52, P672; MCKEIGUE PM, 1993, CIRCULATION, V87, P152, DOI 10.1161/01.CIR.87.1.152; Melsom T, 2001, THORAX, V56, P477, DOI 10.1136/thorax.56.6.477; MENDIS S, 1994, INT J CARDIOL, V46, P135, DOI 10.1016/0167-5273(94)90034-5; Mishra V, 2003, ENVIRON HEALTH PERSP, V111, P71, DOI 10.1289/ehp.5559; Murray CJL, 1996, GLOBAL BURDEN DIS IN, V1; National Cancer Registry Programme, 2001, CONS REP POP BAS CAN; Nishtar S, 2002, LANCET, V360, P1015, DOI 10.1016/S0140-6736(02)11088-9; Ramachandran A, 2003, DIABETES RES CLIN PR, V60, P199, DOI 10.1016/S0168-8227(03)00060-3; Ramachandran A, 2001, DIABETOLOGIA, V44, P1094, DOI 10.1007/s001250100627; Reddy N Krishna, 2002, Indian Heart J, V54, P697; Sayeed MA, 2003, DIABETES CARE, V26, P1034, DOI 10.2337/diacare.26.4.1034; Singh DL, 2003, DIABETIC MED, V20, P170, DOI 10.1046/j.1464-5491.2003.00829_4.x; Singh RB, 1998, INT J CARDIOL, V66, P65, DOI 10.1016/S0167-5273(98)00141-7; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; WHO, 2004, LANCET, V363, P902; *WHO, 2002, NONC DIS SE AS REG P; *WHO, 2002, HLTH SIT SE AS REG 1; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; Yajnik CS, 2001, NUTR REV, V59, P1	33	264	266	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	2004	328	7443					807	810		10.1136/bmj.328.7443.807	http://dx.doi.org/10.1136/bmj.328.7443.807			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	811CG	15070638	Green Published			2022-12-28	WOS:000220749400021
J	Boyd, PW; Law, CS; Wong, CS; Nojiri, Y; Tsuda, A; Levasseur, M; Takeda, S; Rivkin, R; Harrison, PJ; Strzepek, R; Gower, J; McKay, RM; Abraham, E; Arychuk, M; Barwell-Clarke, J; Crawford, W; Crawford, D; Hale, M; Harada, K; Johnson, K; Kiyosawa, H; Kudo, I; Marchetti, A; Miller, W; Needoba, J; Nishioka, J; Ogawa, H; Page, J; Robert, M; Saito, H; Sastri, A; Sherry, N; Soutar, T; Sutherland, N; Taira, Y; Whitney, F; Wong, SKE; Yoshimura, T				Boyd, PW; Law, CS; Wong, CS; Nojiri, Y; Tsuda, A; Levasseur, M; Takeda, S; Rivkin, R; Harrison, PJ; Strzepek, R; Gower, J; McKay, RM; Abraham, E; Arychuk, M; Barwell-Clarke, J; Crawford, W; Crawford, D; Hale, M; Harada, K; Johnson, K; Kiyosawa, H; Kudo, I; Marchetti, A; Miller, W; Needoba, J; Nishioka, J; Ogawa, H; Page, J; Robert, M; Saito, H; Sastri, A; Sherry, N; Soutar, T; Sutherland, N; Taira, Y; Whitney, F; Wong, SKE; Yoshimura, T			The decline and fate of an iron-induced subarctic phytoplankton bloom	NATURE			English	Article							PACIFIC-OCEAN; NORTH PACIFIC; FERTILIZATION; SINKING; COPEPOD; FLUXES	Iron supply has a key role in stimulating phytoplankton blooms in high-nitrate low-chlorophyll oceanic waters(1-5). However, the fate of the carbon fixed by these blooms, and how efficiently it is exported into the ocean's interior, remains largely unknown(1-5). Here we report on the decline and fate of an iron-stimulated diatom bloom in the Gulf of Alaska. The bloom terminated on day 18, following the depletion of iron and then silicic acid, after which mixed-layer particulate organic carbon (POC) concentrations declined over six days. Increased particulate silica export via sinking diatoms was recorded in sediment traps at depths between 50 and 125 m from day 21, yet increased POC export was not evident until day 24. Only a small proportion of the mixed-layer POC was intercepted by the traps, with more than half of the mixed-layer POC deficit attributable to bacterial remineralization and mesozooplankton grazing. The depletion of silicic acid and the inefficient transfer of iron-increased POC below the permanent thermocline have major implications both for the biogeochemical interpretation of times of greater iron supply in the geological past(6,7), and also for proposed geo-engineering schemes to increase oceanic carbon sequestration(3,8).	Univ Otago, NIWA Ctr Chem & Phys Oceanog, Dept Chem, Dunedin 9003, New Zealand; Natl Inst Water & Atmospher Res, Wellington, New Zealand; Fisheries & Oceans Canada, Inst Ocean Sci, Sidney, BC V8L 4B2, Canada; Natl Inst Environm Studies, Tsukuba, Ibaraki 3058506, Japan; Univ Tokyo, Ocean Res Inst, Tokyo 1648639, Japan; Univ Laval, Dept Biol, Quebec City, PQ G1K 7P4, Canada; Univ Tokyo, Dept Aquat Biosci, Bunkyo Ku, Tokyo 1138657, Japan; Mem Univ Newfoundland, Ctr Ocean Sci, St John, NF A1C 5S7, Canada; Univ British Columbia, Vancouver, BC V6T 1Z4, Canada; Hong Kong Univ Sci & Technol, Hong Kong, Hong Kong, Peoples R China; Bowling Green State Univ, Dept Biol Sci, Bowling Green, OH 43403 USA; Natl Inst Adv Ind Sci & Technol, Chiyoda Ku, Tokyo 1008921, Japan; Marine Biol Res Inst Japan, Shinagawa Ku, Tokyo 1420042, Japan; Hokkaido Univ, Grad Sch Fisheries Sci, Hakodate, Hokkaido 0418611, Japan; Univ British Columbia, Dept Bot, Vancouver, BC V6T 1Z4, Canada; Dalhousie Univ, Dept Oceanog, Halifax, NS B3H 4J1, Canada; Cent Res Inst Elect Power Ind, Chiba 2701194, Japan; Univ Tokyo, Ocean Res Inst, Marine Biogeochem Lab, Nakano Ku, Tokyo 1648639, Japan; Tohoku Natl Fisheries Res Inst, Shiogama, Miyagi 9850001, Japan; Univ Victoria, Sch Earth & Ocean Sci, Victoria, BC V8W 3N5, Canada	University of Otago; National Institute of Water & Atmospheric Research (NIWA) - New Zealand; Fisheries & Oceans Canada; National Institute for Environmental Studies - Japan; University of Tokyo; Laval University; University of Tokyo; Memorial University Newfoundland; University of British Columbia; Hong Kong University of Science & Technology; University System of Ohio; Bowling Green State University; National Institute of Advanced Industrial Science & Technology (AIST); Hokkaido University; University of British Columbia; Dalhousie University; Central Research Institute of Electric Power Industry - Japan; University of Tokyo; Japan Fisheries Research & Education Agency (FRA); University of Victoria	Boyd, PW (corresponding author), Univ Otago, NIWA Ctr Chem & Phys Oceanog, Dept Chem, POB 56, Dunedin 9003, New Zealand.	p.boyd@niwa.co.nz	Abraham, Edward R/D-7422-2011; Strzepek, Robert/GQH-8703-2022; Crawford, David W./AAS-9927-2020; 毅, 芳村/M-1778-2017; Sastri, Akash/D-7798-2013; Nojiri, Yukihiro/D-1999-2010; Strzepek, Robert Francis/A-1216-2011; SAITO, HIROAKI/J-6948-2017; McKay, Robert Michael/P-3759-2017; Crawford, David W/B-5679-2012; Nishioka, Jun/F-5314-2011; Boyd, Philip W/J-7624-2014	Abraham, Edward R/0000-0003-4490-6704; Crawford, David W./0000-0003-2948-1007; 毅, 芳村/0000-0001-5700-2590; Sastri, Akash/0000-0001-8075-0917; Nojiri, Yukihiro/0000-0001-9885-9195; Strzepek, Robert Francis/0000-0002-6442-7121; SAITO, HIROAKI/0000-0002-5502-9076; McKay, Robert Michael/0000-0003-2723-5371; Crawford, David W/0000-0003-2948-1007; Nishioka, Jun/0000-0003-1723-9344; Boyd, Philip W/0000-0001-7850-1911; Takeda, Shigenobu/0000-0002-4997-1583; Law, Cliff/0000-0002-7669-2475; Marchetti, Adrian/0000-0003-4608-4775				Abraham ER, 2000, NATURE, V407, P727, DOI 10.1038/35037555; Bidle KD, 2002, SCIENCE, V298, P1980, DOI 10.1126/science.1076076; Bishop JKB, 1999, DEEP-SEA RES PT I, V46, P353, DOI 10.1016/S0967-0637(98)00069-7; Boyd PW, 2000, NATURE, V407, P695, DOI 10.1038/35037500; Buesseler KO, 2003, SCIENCE, V300, P67, DOI 10.1126/science.1082959; Buesseler KO, 1998, GLOBAL BIOGEOCHEM CY, V12, P297, DOI 10.1029/97GB03366; BUESSELER KO, 1994, GLOBAL BIOGEOCHEM CY, V8, P179, DOI 10.1029/94GB00207; Chisholm SW, 2001, SCIENCE, V294, P309, DOI 10.1126/science.1065349; Coale KH, 1996, NATURE, V383, P495, DOI 10.1038/383495a0; CULLEN JJ, 1991, LIMNOL OCEANOGR, V36, P1578, DOI 10.4319/lo.1991.36.8.1578; DAGG M, 1993, DEEP-SEA RES PT I, V40, P1431, DOI 10.1016/0967-0637(93)90121-I; Gervais F, 2002, LIMNOL OCEANOGR, V47, P1324, DOI 10.4319/lo.2002.47.5.1324; Harrison KG, 2000, PALEOCEANOGRAPHY, V15, P292, DOI 10.1029/1999PA000427; Honda MC, 2002, DEEP-SEA RES PT II, V49, P5595, DOI 10.1016/S0967-0645(02)00201-1; KOMAR PD, 1981, LIMNOL OCEANOGR, V26, P172, DOI 10.4319/lo.1981.26.1.0172; LaRoche J, 1996, NATURE, V382, P802; Law CS, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2002JC001604; Martin JH, 1990, PALEOCEANOGRAPHY, V5, P1, DOI 10.1029/PA005i001p00001; Matsumoto K, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001442; Nishioka J, 2001, MAR CHEM, V74, P157, DOI 10.1016/S0304-4203(01)00013-5; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Rivkin RB, 2001, SCIENCE, V291, P2398, DOI 10.1126/science.291.5512.2398; SIEGEL DA, 1990, J GEOPHYS RES-OCEANS, V95, P5305, DOI 10.1029/JC095iC04p05305; SMITH DC, 1992, NATURE, V359, P139, DOI 10.1038/359139a0; STRATHMANN RR, 1967, LIMNOL OCEANOGR, V12, P411, DOI 10.4319/lo.1967.12.3.0411; SUNDA WG, 1995, MAR CHEM, V50, P189, DOI 10.1016/0304-4203(95)00035-P; Tabata S, 1975, ATMOSPHERE, V13, P133, DOI [10.1080/00046973.1975.9648394, DOI 10.1080/00046973.1975.9648394]; TREGUER P, 1995, SCIENCE, V268, P375, DOI 10.1126/science.268.5209.375; Tsuda A, 2003, SCIENCE, V300, P958, DOI 10.1126/science.1082000; TSUDA A, 1994, MAR BIOL, V120, P203, DOI 10.1007/BF00349680	30	370	389	3	242	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					549	553		10.1038/nature02437	http://dx.doi.org/10.1038/nature02437			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15058302				2022-12-28	WOS:000220540100039
J	Minot, ED; Yaish, Y; Sazonova, V; McEuen, PL				Minot, ED; Yaish, Y; Sazonova, V; McEuen, PL			Determination of electron orbital magnetic moments in carbon nanotubes	NATURE			English	Article							SUSCEPTIBILITY	The remarkable transport properties of carbon nanotubes (CNTs) are determined by their unusual electronic structure(1). The electronic states of a carbon nanotube form one-dimensional electron and hole sub-bands, which, in general, are separated by an energy gap(2,3). States near the energy gap are predicted(4,5) to have an orbital magnetic moment, mu(orb), that is much larger than the Bohr magneton (the magnetic moment of an electron due to its spin). This large moment is due to the motion of electrons around the circumference of the nanotube, and is thought to play a role in the magnetic susceptibility of CNTs6-9 and the magnetoresistance observed in large multiwalled CNTs10-12. But the coupling between magnetic field and the electronic states of individual nanotubes remains to be quantified experimentally. Here we report electrical measurements of relatively small diameter (2-5 nm) individual CNTs in the presence of an axial magnetic field. We observe field-induced energy shifts of electronic states and the associated changes in sub-band structure, which enable us to confirm quantitatively the predicted values for mu(orb).	Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA	Cornell University	McEuen, PL (corresponding author), Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA.	mceuen@ccmr.cornell.edu						AJIKI H, 1993, J PHYS SOC JPN, V62, P1255, DOI 10.1143/JPSJ.62.1255; Bachtold A, 1999, NATURE, V397, P673, DOI 10.1038/17755; CHAUVET O, 1995, PHYS REV B, V52, pR6963, DOI 10.1103/PhysRevB.52.R6963; Cobden DH, 1998, PHYS REV LETT, V81, P681, DOI 10.1103/PhysRevLett.81.681; de Pablo PJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.036804; Fujiwara A, 1999, PHYS REV B, V60, P13492, DOI 10.1103/PhysRevB.60.13492; Kane CL, 1997, PHYS REV LETT, V78, P1932, DOI 10.1103/PhysRevLett.78.1932; Kong J, 1998, NATURE, V395, P878, DOI 10.1038/27632; Kwon YK, 1998, PHYS REV B, V58, P16001, DOI 10.1103/PhysRevB.58.R16001; Lee JO, 2000, SOLID STATE COMMUN, V115, P467, DOI 10.1016/S0038-1098(00)00222-2; Liang WJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.126801; LU JP, 1995, PHYS REV LETT, V74, P1123, DOI 10.1103/PhysRevLett.74.1123; Maiti A, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.126805; Minot ED, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.156401; Nygard J, 2000, NATURE, V408, P342, DOI 10.1038/35042545; Odom TW, 1998, NATURE, V391, P62, DOI 10.1038/34145; RAMIREZ AP, 1994, SCIENCE, V265, P84, DOI 10.1126/science.265.5168.84; Rosenblatt S, 2002, NANO LETT, V2, P869, DOI 10.1021/nl025639a; Sohn L.L., 2001, CARBON NANOTUBES; Sohn L.L., 1997, MESOSCOPIC ELECT TRA; Tans SJ, 1998, NATURE, V394, P761, DOI 10.1038/29494; Walters DA, 2001, CHEM PHYS LETT, V338, P14, DOI 10.1016/S0009-2614(01)00072-0; WANG XK, 1994, J MATER RES, V9, P1578, DOI 10.1557/JMR.1994.1578; Wildoer JWG, 1998, NATURE, V391, P59, DOI 10.1038/34139; Yaish Y, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.046401; Yang L, 2000, PHYS REV LETT, V85, P154, DOI 10.1103/PhysRevLett.85.154; Zhou CW, 2000, PHYS REV LETT, V84, P5604, DOI 10.1103/PhysRevLett.84.5604	27	220	224	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					536	539		10.1038/nature02425	http://dx.doi.org/10.1038/nature02425			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15057825	Green Submitted			2022-12-28	WOS:000220540100035
J	Yang, ZY; Kong, WP; Huang, Y; Roberts, A; Murphy, BR; Subbarao, K; Nabel, GJ				Yang, ZY; Kong, WP; Huang, Y; Roberts, A; Murphy, BR; Subbarao, K; Nabel, GJ			A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice	NATURE			English	Article							ACUTE RESPIRATORY SYNDROME; HONG-KONG; VIRUS; IDENTIFICATION; CHALLENGE; INFECTION; PROTEINS; GENOME; PIGS	Public health measures have successfully identified and contained outbreaks of the severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV)(1-5), but concerns remain over the possibility of future recurrences. Finding a vaccine for this virus therefore remains a high priority. Here, we show that a DNA vaccine encoding the spike (S) glycoprotein of the SARS-CoV induces T cell and neutralizing antibody responses, as well as protective immunity, in a mouse model. Alternative forms of S were analysed by DNA immunization. These expression vectors induced robust immune responses mediated by CD4 and CD8 cells, as well as significant antibody titres, measured by enzyme-linked immunosorbent assay. Moreover, antibody responses in mice vaccinated with an expression vector encoding a form of S that includes its transmembrane domain elicited neutralizing antibodies. Viral replication was reduced by more than six orders of magnitude in the lungs of mice vaccinated with these S plasmid DNA expression vectors, and protection was mediated by a humoral but not a T-cell-dependent immune mechanism. Gene-based vaccination for the SARS-CoV elicits effective immune responses that generate protective immunity in an animal model.	NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Nabel, GJ (corresponding author), NIAID, Vaccine Res Ctr, NIH, Bldg 40,Room 4502,MSC-3005,40 Convent Dr, Bethesda, MD 20892 USA.	gnabel@nih.gov		Subbarao, Kanta/0000-0003-1713-3056	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000934, Z01AI005056, Z01AI000934] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 2013, WHOCDSCSRGAR2003; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Epstein SL, 2000, INT IMMUNOL, V12, P91, DOI 10.1093/intimm/12.1.91; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927; Knipe D, 2001, FIELDS VIROLOGY, P1187; Kong WP, 2003, J VIROL, V77, P12764, DOI 10.1128/JVI.77.23.12764-12772.2003; Lai M.M.C., 2001, FIELDS VIROLOGY, P1163; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a; Park SK, 1998, AM J VET RES, V59, P1002; Perlman S, 1998, ADV EXP MED BIOL, V440, P503; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; SAIF LJ, 1993, VET MICROBIOL, V37, P285, DOI 10.1016/0378-1135(93)90030-B; Sestak K, 1999, VET IMMUNOL IMMUNOP, V70, P203, DOI 10.1016/S0165-2427(99)00074-4; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; YANG ZY, IN PRESS J VIROL	23	508	563	2	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					561	564		10.1038/nature02463	http://dx.doi.org/10.1038/nature02463			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15024391	Green Published, Bronze			2022-12-28	WOS:000220540100042
J	Beral, V; Bull, D; Doll, R; Peto, R; Reeves, G				Beral, V; Bull, D; Doll, R; Peto, R; Reeves, G		Collaborative Group on Hormonal Factors in Breast Cancer	Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 3.6 countries	LANCET			English	Article							ORAL-CONTRACEPTIVE USE; REQUIRING PROLONGED OBSERVATION; REPRODUCTIVE FACTORS; RISK-FACTORS; YOUNG-WOMEN; AGE; COHORT; BIAS; ASSOCIATION; ETIOLOGY	Background The Collaborative Group on Hormonal Factors in Breast Cancer has brought together the worldwide epidemiological evidence on the possible relation between breast cancer and previous spontaneous and induced abortions. Methods Data on individual women from 53 studies undertaken in 16 countries with liberal abortion laws were checked and analysed centrally. Relative risks of breast cancer-comparing the effects of having had a pregnancy that ended as an abortion with those of never having had that pregnancy-were calculated, stratified by study, age at diagnosis, parity, and age at first birth. Because the extent of under-reporting of past induced abortions might be influenced by whether or not women had been diagnosed with breast cancer, results of the studies-including a total of 44 000 women with breast cancer-that used prospective information on abortion (ie, information that had been recorded before the diagnosis of breast cancer) were considered separately from results of the studies-including 39 000 women with the disease-that used retrospective information (recorded after the diagnosis of breast cancer). Findings The overall relative risk of breast cancer, comparing women with a prospective record of having had one or more pregnancies that ended as a spontaneous abortion versus women with no such record, was 0.98 (95% Cl 0.92-1-04, p=0.5). The corresponding relative risk for induced abortion was 0.93 (0.89-0.96, p=0.0002). Among women with a prospective record of having had a spontaneous or an induced abortion, the risk of breast cancer did not differ significantly according to the number or timing of either type of abortion. Published results on induced abortion from the few studies with prospectively recorded information that were not available for inclusion here are consistent with these findings. Overall results for induced abortion differed substantially between studies with prospective and those with retrospective information on abortion (test for heterogeneity between relative risks: chi(1)(2),=33.1, p<0.0001). Interpretation Pregnancies that end as a spontaneous or induced abortion do not increase a woman's risk of developing breast cancer. Collectively, the studies of breast cancer with retrospective recording of induced abortion yielded misleading results, possibly because women who had developed breast cancer were, on average, more likely than other women to disclose previous induced abortions.	Radcliffe Infirm, Canc Res UK Epidemiol Unit, Collaborat Grp Hormonal Factors Breast Canc, Oxford OX2 6HE, England	Cancer Research UK; Radcliffe Infirmary	Beral, V (corresponding author), Radcliffe Infirm, Canc Res UK Epidemiol Unit, Collaborat Grp Hormonal Factors Breast Canc, Oxford OX2 6HE, England.			Olsson, Hakan/0000-0002-8794-9635				*ACOG COMM OP, 2003, INT J GYNECOL OBSTET, V83, P233; ADAMI HO, 1990, BRIT J CANCER, V62, P122, DOI 10.1038/bjc.1990.242; Bartholomew L L, 1998, Obstet Gynecol Surv, V53, P708, DOI 10.1097/00006254-199811000-00024; Becher H, 2003, INT J EPIDEMIOL, V32, P38, DOI 10.1093/ije/dyg003; Beral V, 2002, LANCET, V360, P187, DOI 10.1016/S0140-6736(02)09454-0; Brind J, 1996, J EPIDEMIOL COMMUN H, V50, P481, DOI 10.1136/jech.50.5.481; BRINTON LA, 1983, BRIT J CANCER, V47, P757, DOI 10.1038/bjc.1983.128; Burany B, 1979, Jugosl Ginekol Opstet, V19, P237; Calle EE, 1996, CONTRACEPTION, V54, pS1; CATES W, 1982, SCIENCE, V215, P1586, DOI 10.1126/science.7071579; CHILVERS C, 1989, LANCET, V1, P973; CLAVEL F, 1991, INT J EPIDEMIOL, V20, P32, DOI 10.1093/ije/20.1.32; Daling JR, 1996, AM J EPIDEMIOL, V144, P373, DOI 10.1093/oxfordjournals.aje.a008938; DALING JR, 1994, JNCI-J NATL CANCER I, V86, P1584, DOI 10.1093/jnci/86.21.1584; Davey GK, 2003, PUBLIC HEALTH NUTR, V6, P259, DOI 10.1079/PHN2002430; Davidson T, 2001, LANCET ONCOL, V2, P756, DOI 10.1016/S1470-2045(01)00591-5; DVOIRIN VV, 1978, METHODS RESULTS STUD, P53; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1; Enger SM, 1998, CANCER EPIDEM BIOMAR, V7, P365; Erlandsson G, 2003, INT J CANCER, V103, P676, DOI 10.1002/ijc.10877; EWERTZ M, 1988, BRIT J CANCER, V58, P99, DOI 10.1038/bjc.1988.172; Gammon MD, 1996, JAMA-J AM MED ASSOC, V275, P321, DOI 10.1001/jama.275.4.321; Goldacre MJ, 2001, J EPIDEMIOL COMMUN H, V55, P336, DOI 10.1136/jech.55.5.336; HARRIS BML, 1989, BMJ-BRIT MED J, V299, P1430, DOI 10.1136/bmj.299.6713.1430; Hartge P, 1997, NEW ENGL J MED, V336, P127, DOI 10.1056/NEJM199701093360209; Hirohata T, 1985, Natl Cancer Inst Monogr, V69, P187; HISLOP TG, 1986, INT J EPIDEMIOL, V15, P469, DOI 10.1093/ije/15.4.469; Hopper J L, 1999, J Natl Cancer Inst Monogr, P95; HOWE HL, 1989, INT J EPIDEMIOL, V18, P300, DOI 10.1093/ije/18.2.300; JONES EF, 1992, DEMOGRAPHY, V29, P113, DOI 10.2307/2061366; KAY CR, 1988, BRIT J CANCER, V58, P675, DOI 10.1038/bjc.1988.285; LAING AE, 1993, J NATL MED ASSOC, V85, P931; Lazovich D, 2000, EPIDEMIOLOGY, V11, P76, DOI 10.1097/00001648-200001000-00016; LE MG, 1984, HORMONES SEXUAL FACT; Levi F, 1996, EUR J CANCER, V32A, P2108, DOI 10.1016/S0959-8049(96)00229-8; LEVSHIN VF, 1986, SOV MEDITISINA, P15; LINDEFORSHARRIS BM, 1991, AM J EPIDEMIOL, V134, P1003, DOI 10.1093/oxfordjournals.aje.a116173; LIPWORTH L, 1995, INT J CANCER, V61, P181, DOI 10.1002/ijc.2910610207; LUBIN F, 1986, JNCI-J NATL CANCER I, V77, P605, DOI 10.1093/jnci/77.3.605; Mahue-Giangreco M, 2003, CANCER EPIDEM BIOMAR, V12, P209; Marcus PM, 1999, AM J PUBLIC HEALTH, V89, P1244, DOI 10.2105/AJPH.89.8.1244; McCredie M, 1998, INT J CANCER, V76, P182, DOI 10.1002/(SICI)1097-0215(19980413)76:2<182::AID-IJC3>3.0.CO;2-T; McCredie MRE, 1998, CANCER CAUSE CONTROL, V9, P189, DOI 10.1023/A:1008886328352; MCPHERSON K, 1987, BRIT J CANCER, V56, P653, DOI 10.1038/bjc.1987.261; Melbye M, 1997, NEW ENGL J MED, V336, P81, DOI 10.1056/NEJM199701093360201; Michels KB, 1996, EPIDEMIOLOGY, V7, P521, DOI 10.1097/00001648-199609000-00012; MORABIA A, 1993, PREV MED, V22, P178, DOI 10.1006/pmed.1993.1015; MOSESON M, 1993, INT J EPIDEMIOL, V22, P1000, DOI 10.1093/ije/22.6.1000; Newcomb PA, 2000, CANCER CAUSE CONTROL, V11, P777, DOI 10.1023/A:1008980804706; Newcomb RA, 1996, JAMA-J AM MED ASSOC, V275, P283, DOI 10.1001/jama.275.4.283; Nishiyama F., 1982, SHIKOKU ACTA MEDICA, V38, P333; Palmer JR, 1997, CANCER CAUSE CONTROL, V8, P841, DOI 10.1023/A:1018408211089; Paoletti X, 2003, INT J CANCER, V106, P270, DOI 10.1002/ijc.11203; PARAZZINI F, 1991, INT J CANCER, V48, P816, DOI 10.1002/ijc.2910480605; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PIKE MC, 1981, BRIT J CANCER, V43, P72, DOI 10.1038/bjc.1981.10; PRIMICZAKELJ M, 1995, INT J CANCER, V62, P414, DOI 10.1002/ijc.2910620410; RAVNIHAR B, 1988, NEOPLASMA, V35, P109; REMENNICK LI, 1990, J EPIDEMIOL COMMUN H, V44, P259, DOI 10.1136/jech.44.4.259; Rockhill B, 1998, J NATL CANCER I, V90, P1155, DOI 10.1093/jnci/90.15.1155; ROHAN TE, 1988, MED J AUSTRALIA, V149, P520, DOI 10.5694/j.1326-5377.1988.tb120759.x; Rookus MA, 1996, J NATL CANCER I, V88, P1759, DOI 10.1093/jnci/88.23.1759; ROSENBERG L, 1992, AM J EPIDEMIOL, V136, P1437, DOI 10.1093/oxfordjournals.aje.a116464; Rossing MA, 1996, AM J EPIDEMIOL, V144, P161, DOI 10.1093/oxfordjournals.aje.a008903; Sanderson M, 2001, INT J CANCER, V92, P899, DOI 10.1002/ijc.1263; Segi M, 1957, GANN               S, V48, P1; Tang MTC, 2000, EPIDEMIOLOGY, V11, P177, DOI 10.1097/00001648-200003000-00016; Tavani A, 1996, INT J CANCER, V65, P401, DOI 10.1002/(SICI)1097-0215(19960208)65:4<401::AID-IJC1>3.0.CO;2-0; THOMAS DB, 1993, INT J EPIDEMIOL, V22, P619, DOI 10.1093/ije/22.4.619; Thomas HV, 1997, J NATL CANCER I, V89, P396, DOI 10.1093/jnci/89.5.396; Thorp JM, 2003, OBSTET GYNECOL SURV, V58, P67, DOI 10.1097/00006254-200301000-00023; TIETZE C, 1983, INDUCED ABORTION WOR; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; VESSEY MP, 1989, BRIT J CANCER, V59, P613, DOI 10.1038/bjc.1989.124; WANG QS, 1992, CANCER EPIDEM BIOMAR, V1, P435; WATANABE H, 1968, NIPPON RINSHO, V26, P1853; Weed DL, 1996, J NATL CANCER I, V88, P1698, DOI 10.1093/jnci/88.23.1698; WEINSTEIN AL, 1991, EPIDEMIOLOGY, V2, P353, DOI 10.1097/00001648-199109000-00007; WILCOX AJ, 1984, AM J EPIDEMIOL, V120, P727, DOI 10.1093/oxfordjournals.aje.a113940; Wingo PA, 1997, CANCER CAUSE CONTROL, V8, P93, DOI 10.1023/A:1018443507512; WINGO PA, 1991, OBSTET GYNECOL, V78, P161; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360; Ye Z, 2002, BRIT J CANCER, V87, P977, DOI 10.1038/sj.bjc.6600603; YUAN JM, 1988, CANCER RES, V48, P1949	85	151	157	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	2004	363	9414					1007	1016						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15051280				2022-12-28	WOS:000220497300006
J	Piao, XH; Hill, RS; Bodell, A; Chang, BS; Basel-Vanagaite, L; Straussberg, R; Dobyns, WB; Qasrawi, B; Winter, RM; Innes, AM; Voit, T; Ross, ME; Michaud, JL; Descarle, JC; Barkovich, AJ; Walsh, CA				Piao, XH; Hill, RS; Bodell, A; Chang, BS; Basel-Vanagaite, L; Straussberg, R; Dobyns, WB; Qasrawi, B; Winter, RM; Innes, AM; Voit, T; Ross, ME; Michaud, JL; Descarle, JC; Barkovich, AJ; Walsh, CA			G protein-coupled receptor-dependent development of human frontal cortex	SCIENCE			English	Article							BILATERAL FRONTOPARIETAL POLYMICROGYRIA; CEREBRAL-CORTEX; PERISYLVIAN POLYMICROGYRIA; CORTICAL AREAS; NEOCORTEX; MIGRATION; EPILEPSY; IDENTITY; NEURONS; GENES	The mammalian cerebral cortex is characterized by complex patterns of anatomical and functional areas that differ markedly between species, but the molecular basis for this functional subdivision is largely unknown. Here, we show that mutations in GPR56, which encodes an orphan G protein - coupled receptor (GPCR) with a large extracellular domain, cause a human brain cortical malformation called bilateral frontoparietal polymicrogyria (BFPP). BFPP is characterized by disorganized cortical lamination that is most severe in frontal cortex. Our data suggest that GPCR signaling plays an essential role in regional development of human cerebral cortex.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Newborn Med,Dept Med, Boston, MA 02115 USA; Rabin Med Ctr, Dept Med Genet, IL-49100 Petah Tiqwa, Israel; Schneider Childrens Med Ctr, Dept Child Neurol, Neurogenet Clin, IL-49202 Petah Tiqwa, Israel; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Minist Social Affairs & Labor, Social Welf Inst, Kuwait 13006, Kuwait; Inst Child Hlth, Clin Genet Unit, London WC1N 1EH, England; Univ Calgary, Alberta Childrens Hosp, Dept Med Genet, Calgary, AB T2T 5C7, Canada; Univ Essen Gesamthsch, Dept Pediat, D-45122 Essen, Germany; Cornell Univ, Dept Neurol & Neurosci, New York, NY 10021 USA; Hop St Justine, Div Med Genet, Montreal, PQ H3T 1C5, Canada; Hop St Justine, Dept Med Imaging, Montreal, PQ H3T 1C5, Canada; Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Rabin Medical Center; University of Chicago; University of London; University College London; Alberta Childrens Hospital; University of Calgary; University of Duisburg Essen; Cornell University; Universite de Montreal; Universite de Montreal; University of California System; University of California San Francisco	Walsh, CA (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Howard Hughes Med Inst, Boston, MA 02115 USA.	cwalsh@bidmc.harvard.edu	Dobyns, William Brian/ABC-6525-2021; Dobyns, William/AAI-2768-2020; innes, allan micheil/A-9955-2017	Dobyns, William/0000-0002-7681-2844; Basel-Vanagaite, Vanagaite, Lina/0000-0002-9076-8157; Innes, Micheil/0000-0001-9881-5467; Piao, Xianhua/0000-0001-7540-6767; Walsh, Christopher/0000-0002-0156-2238	NICHD NIH HHS [HD07466] Funding Source: Medline; NINDS NIH HHS [R37 NS35129, K08 NS045762-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS035129, K08NS045762] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson SA, 1997, SCIENCE, V278, P474, DOI 10.1126/science.278.5337.474; Bishop KM, 2000, SCIENCE, V288, P344, DOI 10.1126/science.288.5464.344; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Chang BS, 2003, ANN NEUROL, V53, P596, DOI 10.1002/ana.10520; Donoghue MJ, 1999, CEREB CORTEX, V9, P586, DOI 10.1093/cercor/9.6.586; FERRER I, 1991, ANAT EMBRYOL, V184, P517, DOI 10.1007/BF01236058; Fredriksson R, 2003, BIOCHEM BIOPH RES CO, V301, P725, DOI 10.1016/S0006-291X(03)00026-3; Fukuchi-Shimogori T, 2001, SCIENCE, V294, P1071, DOI 10.1126/science.1064252; Guerreiro MM, 2000, ANN NEUROL, V48, P39, DOI 10.1002/1531-8249(200007)48:1<39::AID-ANA7>3.3.CO;2-O; Guerrini R, 1997, ANN NEUROL, V41, P65, DOI 10.1002/ana.410410112; Hevner RF, 2001, NEURON, V29, P353, DOI 10.1016/S0896-6273(01)00211-2; Krasnoperov V, 2002, J BIOL CHEM, V277, P46518, DOI 10.1074/jbc.M206415200; KUZNIECKY R, 1993, LANCET, V341, P608, DOI 10.1016/0140-6736(93)90363-L; Letinic K, 2002, NATURE, V417, P645, DOI 10.1038/nature00779; Liu M, 1999, GENOMICS, V55, P296, DOI 10.1006/geno.1998.5644; Liu Q, 2000, J NEUROSCI, V20, P7682; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; Mallamaci A, 2000, NAT NEUROSCI, V3, P679, DOI 10.1038/76630; OLEARY DDM, 1989, TRENDS NEUROSCI, V12, P400, DOI 10.1016/0166-2236(89)90080-5; Piao XH, 2002, AM J HUM GENET, V70, P1028, DOI 10.1086/339552; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Sztriha L, 2000, PEDIATR NEUROL, V22, P240, DOI 10.1016/S0887-8994(99)00142-3; Tan SS, 1998, NEURON, V21, P295, DOI 10.1016/S0896-6273(00)80539-5; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; Villard L, 2002, AM J HUM GENET, V70, P1003, DOI 10.1086/339433; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; Wichterle H, 1999, NAT NEUROSCI, V2, P461, DOI 10.1038/8131	30	400	406	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	2004	303	5666					2033	2036		10.1126/science.1092780	http://dx.doi.org/10.1126/science.1092780			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044805				2022-12-28	WOS:000220429800046
J	Bichet, DG; Fujiwara, TM				Bichet, DG; Fujiwara, TM			Reabsorption of sodium chloride - Lessons from the chloride channels	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Membrane Prot Study Grp, Montreal, PQ H3C 3J7, Canada; McGill Univ, Ctr Human Genet & Med, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; McGill University	Bichet, DG (corresponding author), Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada.			BICHET, DANIEL-G/0000-0003-2856-6850				BARTTER FC, 1962, AM J MED, V33, P811, DOI 10.1016/0002-9343(62)90214-0; Bichet DG, 2001, METABOLIC MOL BASES, VIII, P4181; Clapham DE, 2003, CELL, V115, P641, DOI 10.1016/S0092-8674(03)00980-2; Hubner CA, 2002, HUM MOL GENET, V11, P2435, DOI 10.1093/hmg/11.20.2435; Peters M, 2002, AM J MED, V112, P183, DOI 10.1016/S0002-9343(01)01086-5	5	17	17	1	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2004	350	13					1281	1283		10.1056/NEJMp048026	http://dx.doi.org/10.1056/NEJMp048026			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VN	15044637				2022-12-28	WOS:000220393900004
J	Chaudhuri, A; Behan, PO				Chaudhuri, A; Behan, PO			Fatigue in neurological disorders	LANCET			English	Review							PLACEBO-CONTROLLED TRIAL; MULTIPLE-SCLEROSIS; DOUBLE-BLIND; POSTEROVENTRAL PALLIDOTOMY; ORTHOSTATIC INTOLERANCE; BASAL GANGLIA; EXERCISE; PATHOPHYSIOLOGY; METABOLISM; DISEASE	Chronic fatigue is a typical symptom of neurological diseases, and is most disabling in multiple sclerosis, postpoliomyelitis, poststroke, and in chronic fatigue syndrome. Disorders of neuromuscular junction transmission and metabolic diseases cause muscle fatigability, which is characterised by failure to sustain the force of muscle contraction (peripheral fatigue). Fatigue is also seen in diseases that affect the central, peripheral, and autonomic nervous systems (central fatigue). Enhanced perception of effort and limited endurance of sustained physical and mental activities are the main characteristics of central fatigue. Metabolic and structural lesions that disrupt the usual process of activation in pathways interconnecting the basal ganglia, thalamus, limbic system, and higher cortical Centre are implicated in the pathophysiological process of central fatigue. A state of pre-existing relative hypocortisolaemia might sensitise the hypothalamic-pitultary-adrenal axis to development of persistent central fatigue after stress. The contributions of physiological, cognitive, and affective changes underlying fatigue are variable, and treatment is largely symptomatic and rehabilitative.	Univ Glasgow, Div Clin Neurosci, Glasgow G51 4TF, Lanark, Scotland	University of Glasgow	Chaudhuri, A (corresponding author), Univ Glasgow, Div Clin Neurosci, Glasgow G51 4TF, Lanark, Scotland.	ac54p@udcf.gla.ac.uk						Adams R. D., 1997, PRINCIPLES NEUROLOGY, P497; Alegret M, 2003, MOVEMENT DISORD, V18, P323, DOI 10.1002/mds.10329; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Bagert B, 2002, CNS DRUGS, V16, P445, DOI 10.2165/00023210-200216070-00002; BARRON JL, 1985, J CLIN ENDOCR METAB, V60, P803, DOI 10.1210/jcem-60-4-803; BIRK TJ, 1993, MED SCI SPORT EXER, V25, P466; Borowsky Beth, 2002, Nature Medicine, V8, P1039; Bradley LA, 1999, ARTHRITIS RHEUM, V60, P471; Branas P., 2000, HLTH TECHNOL ASSESS, V4, P1, DOI [DOI 10.3310/HTA4270, 10.3310/hta4270]; Bruno R.L., 1998, J CHRONIC FATIGUE SY, V4, P61; Bruno Richard L., 1998, American Journal of Medicine, V105, p66S, DOI 10.1016/S0002-9343(98)00161-2; BRUNO RL, 1995, ARCH PHYS MED REHAB, V76, P1093, DOI 10.1016/S0003-9993(95)80115-4; Bruno RL, 2000, AM J PHYS MED REHAB, V79, P4, DOI 10.1097/00002060-200001000-00003; Bruno RL, 1996, AM J PHYS MED REHAB, V75, P340, DOI 10.1097/00002060-199609000-00007; BRUNO RL, 1993, ARCH PHYS MED REHAB, V74, P1061, DOI 10.1016/0003-9993(93)90062-F; BRUNO RL, 1995, ANN NY ACAD SCI, V753, P257, DOI 10.1111/j.1749-6632.1995.tb27552.x; Bruno RL, 2000, AM J PHYS MED REHAB, V79, P343, DOI 10.1097/00002060-200007000-00005; Buchwald D, 2001, PSYCHOSOM MED, V63, P936, DOI 10.1097/00006842-200111000-00012; Buckley C, 2001, ANN NEUROL, V50, P73, DOI 10.1002/ana.1097; Chang L, 1998, ARCH NEUROL-CHICAGO, V55, P305, DOI 10.1001/archneur.55.3.305; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Chaudhuri A, 2003, NEUROREPORT, V14, P225, DOI 10.1097/00001756-200302100-00013; CHAUDHURI A, 1998, P R COLL PHYS EDINB, V28, P150; Chaudhuri A., 2000, J CHRONIC FATIGUE SY, V6, P51, DOI [10.1300/J092v06n03_05, DOI 10.1300/J092V06N03_05]; Comi G, 2001, J NEUROL, V248, P174, DOI 10.1007/s004150170222; Dalsgaard MK, 2003, EXP PHYSIOL, V88, P297, DOI 10.1113/eph8802469; DeLuca J, 1997, J NEUROL NEUROSUR PS, V62, P151, DOI 10.1136/jnnp.62.2.151; Denny-Brown D., 1962, BASAL GANGLIA THEIR; DINAN TG, 1993, IRISH J PSYCHOL MED, V10, P4, DOI 10.1017/S0790966700013173; DINSMORE S, 1995, ANN NY ACAD SCI, V753, P303, DOI 10.1111/j.1749-6632.1995.tb27556.x; Felix R, 2002, CELL MOL NEUROBIOL, V22, P103, DOI 10.1023/A:1019807719343; Filippi M, 2003, BRAIN, V126, P433, DOI 10.1093/brain/awg038; Filippi M, 2002, NEUROIMAGE, V15, P559, DOI 10.1006/nimg.2001.1011; FREAL JE, 1984, ARCH PHYS MED REHAB, V65, P135; FRIEDMAN J, 1993, NEUROLOGY, V43, P2016, DOI 10.1212/WNL.43.10.2016; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Ghika J, 1999, J NEUROSURG, V91, P313, DOI 10.3171/jns.1999.91.2.0313; GIESSER B, 1985, DRUGS, V29, P88, DOI 10.2165/00003495-198529010-00004; Giovannoni G, 2001, NEUROLOGY, V57, P676, DOI 10.1212/WNL.57.4.676; Glader EL, 2002, STROKE, V33, P1327, DOI 10.1161/01.STR.0000014248.28711.D6; Gonen O, 2000, NEUROLOGY, V54, P15, DOI 10.1212/WNL.54.1.15; Griebel G, 2002, P NATL ACAD SCI USA, V99, P6370, DOI 10.1073/pnas.092012099; HARBUZ MS, 1992, ENDOCRINOLOGY, V130, P1394, DOI 10.1210/en.130.3.1394; HARPER PS, 2001, MYOTONIC DYSTROPHY, P139; HILL J, 1987, CAN J NEUROL SCI, V14, P273; HITTEN JJ, 1993, J NEUROL NEUROSUR PS, V56, P874; HORROBIN D, 2002, MADNESS ADAM EVE SCH, P296; Isella V, 2002, MOVEMENT DISORD, V17, P366, DOI 10.1002/mds.10041; Jakobi JM, 2001, MUSCLE NERVE, V24, P1040, DOI 10.1002/mus.1108; KANDEL ER, 1995, ESSENTIALS NEURAL SC, P71; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; KRUPP LB, 1988, ARCH NEUROL-CHICAGO, V45, P435, DOI 10.1001/archneur.1988.00520280085020; KRUPP LB, 1989, ANN NEUROL, V26, P155; Krupp LB, 2000, NEUROLOGY, V55, P934, DOI 10.1212/WNL.55.7.934; Latash M, 1996, Mult Scler, V1, P236; Leocani L, 2001, NEUROIMAGE, V13, P1186, DOI 10.1006/nimg.2001.0759; LOW PA, 1995, NEUROLOGY, V45, pS19; Martin SD, 2001, ARCH GEN PSYCHIAT, V58, P641, DOI 10.1001/archpsyc.58.7.641; McComas AJ, 1997, BRAIN, V120, P1415, DOI 10.1093/brain/120.8.1415; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; Merkies ISJ, 1999, NEUROLOGY, V53, P1648, DOI 10.1212/WNL.53.8.1648; MURRAY TJ, 1985, CAN J NEUROL SCI, V12, P251, DOI 10.1017/S0317167100047107; NAUTA WJH, 1986, HDB CLIN NEUROLOGY, V49, P19; PEACH PE, 1991, ORTHOPEDICS, V14, P1199; Pearn J, 2001, J NEUROL NEUROSUR PS, V70, P4, DOI 10.1136/jnnp.70.1.4; Pelleymounter MA, 2002, J PHARMACOL EXP THER, V302, P145, DOI 10.1124/jpet.302.1.145; PINCUS JH, 2003, BEHAV NEUROL, P249; Puri BK, 2002, ACTA PSYCHIAT SCAND, V106, P224, DOI 10.1034/j.1600-0447.2002.01300.x; Rammohan KW, 2002, J NEUROL NEUROSUR PS, V72, P179, DOI 10.1136/jnnp.72.2.179; Roelcke U, 1997, NEUROLOGY, V48, P1566, DOI 10.1212/WNL.48.6.1566; SANDRONI P, 1992, ARCH NEUROL-CHICAGO, V49, P517, DOI 10.1001/archneur.1992.00530290105019; Scammell TE, 2003, ANN NEUROL, V53, P154, DOI 10.1002/ana.10444; Scott LV, 1999, FUNCT NEUROL, V14, P3; Shannon JR, 2000, NEW ENGL J MED, V342, P541, DOI 10.1056/NEJM200002243420803; Sharma OP, 1999, EUR RESPIR J, V13, P713, DOI 10.1034/j.1399-3003.1999.13d01.x; Sheean GL, 1997, BRAIN, V120, P299, DOI 10.1093/brain/120.2.299; SHEEAN GL, 1998, BRAIN, V121, P867; SMITH CUM, 2002, ELEMENTS MOL NEUROBI, P507; Staub F, 2001, CEREBROVASC DIS, V12, P75, DOI 10.1159/000047685; STEIN DP, 1995, ANN NY ACAD SCI, V753, P296, DOI 10.1111/j.1749-6632.1995.tb27555.x; STEINMAN L, 1993, SCI AM, V269, P106, DOI 10.1038/scientificamerican0993-106; Stewart JM, 1999, PEDIATRICS, V103, P116, DOI 10.1542/peds.103.1.116; Sutherland G, 2001, J SPORT MED PHYS FIT, V41, P421; Taivassalo T, 2002, ANN NEUROL, V51, P38, DOI 10.1002/ana.10027; Tam SL, 2002, MUSCLE NERVE, V25, P359, DOI 10.1002/mus.10057; Tiersky L A, 2001, Appl Neuropsychol, V8, P41, DOI 10.1207/S15324826AN0801_6; Tomoda A, 2000, BRAIN DEV-JPN, V22, P60, DOI 10.1016/S0387-7604(99)00111-4; Trojan DA, 1999, NEUROLOGY, V53, P1225, DOI 10.1212/WNL.53.6.1225; Van Zandvoort M, 2003, J INT NEUROPSYCH SOC, V9, P490, DOI 10.1017/S1355617703000146; Van Zandvoort MJE, 1998, J NEUROL NEUROSUR PS, V65, P697, DOI 10.1136/jnnp.65.5.697; WEINSHENKER BG, 1992, NEUROLOGY, V42, P1468, DOI 10.1212/WNL.42.8.1468; WHITING P, 2001, JAMA-J AM MED ASSOC, V284, P11360; Yehuda R, 2002, PSYCHIAT CLIN N AM, V25, P341, DOI 10.1016/S0193-953X(02)00002-3; Zifko UA, 2002, J NEUROL, V249, P983, DOI 10.1007/s00415-002-0765-6	94	785	811	4	124	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	2004	363	9413					978	988		10.1016/S0140-6736(04)15794-2	http://dx.doi.org/10.1016/S0140-6736(04)15794-2			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043967				2022-12-28	WOS:000220308600025
J	Gallione, CJ; Repetto, GM; Legius, E; Rustgi, AK; Schelley, SL; Tejpar, S; Mitchell, G; Drouin, E; Westermann, CJJ; Marchuk, DA				Gallione, CJ; Repetto, GM; Legius, E; Rustgi, AK; Schelley, SL; Tejpar, S; Mitchell, G; Drouin, E; Westermann, CJJ; Marchuk, DA			A combined syndrome of juvenile polyposis and hereditary haemorrhagic telanglectasia associated with mutations in MADH4 (SMAD4)	LANCET			English	Article							PULMONARY ARTERIOVENOUS-MALFORMATIONS; HYPERTROPHIC OSTEOARTHROPATHY; TELANGIECTASIA; GENE; PROTEIN; ENDOGLIN; PATHWAY; CELLS	Background Juvenile polyposis and hereditary haemorrhagic telangiectasia are autosomal dominant disorders with distinct and non-overlapping clinical features. The former, an inherited gastrointestinal malignancy predisposition, is caused by mutations in MADH4 (encoding SMAD4) or BMPR1A, and the latter is a vascular malformation disorder caused by mutations in ENG (endoglin) or ACVRL1 (ALK1). All four genes encode proteins involved in the transforming-growth-factor-beta signalling pathway. Although there are reports of patients and families with phenotypes of both disorders combined, the genetic aetiology of this association is unknown. Methods Blood samples were collected from seven unrelated families segregating both phenotypes. DNA from the proband of each family was sequenced for the ACVRL1, ENG, and MADH4 genes. Mutations were examined for familial cosegregation with phenotype and presence or absence in population controls. Findings No patient had mutations in the ENG or ACVRL1 genes; all had MADH4 mutations. Three cases of de-novo MADH4 mutations were found. In one, the mutation was passed on to a similarly affected child. Each mutation cosegregated with the syndromic phenotype in other affected family members. Interpretation Mutations in MADH4 can cause a syndrome consisting of both juvenile polyposis and hereditary haemorrhagic telangiectasia phenotypes. Since patients with these disorders are generally ascertained through distinct medical specialties, genetic testing is recommended for patients presenting with either phenotype to identify those at risk of this syndrome. Patients with juvenile polyposis who have an MADH4 mutation should be screened for the vascular lesions associated with hereditary haemorrhagic telangiectasia, especially occult arteriovenous malformations in visceral organs that may otherwise present suddenly with serious medical consequences.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Univ Desarrollo Clin Alemana, Fac Ciencias Salud, Santiago, Chile; Hosp Padre Hurtado, Santiago, Chile; Univ Hosp Gasthuisberg, Ctr Human Genet, B-3000 Louvain, Belgium; Univ Hosp Gasthuisberg, Dept Gastroenterol, B-3000 Louvain, Belgium; Univ Penn, Dept Genet, Div Gastroenterol, Philadelphia, PA 19104 USA; Abramson Family Canc Res Inst & Canc Ctr, Philadelphia, PA USA; Stanford Univ, Dept Pediat Genet, Stanford, CA 94305 USA; Hop St Justine, Div Genet, Montreal, PQ H3T 1C5, Canada; Hop St Justine, Div Gastroenterol, Montreal, PQ H3T 1C5, Canada; St Antonius Hosp, Dept Pulm Dis, Nieuwegein, Netherlands	Duke University; Clinica Alemana; Universidad de Chile; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; University of Pennsylvania; Stanford University; Universite de Montreal; Universite de Montreal; St. Antonius Hospital Utrecht	Marchuk, DA (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Box 3175, Durham, NC 27710 USA.	march004@mc.duke.edu	Legius, Eric/H-1735-2011; Repetto, Gabriela/C-7833-2012	Repetto, Gabriela/0000-0003-0120-5684; Marchuk, Douglas/0000-0002-3110-6671	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049171] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49171] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAERT AL, 1983, AM J ROENTGENOL, V141, P661, DOI 10.2214/ajr.141.4.661; Ballauff A, 1999, Z GASTROENTEROL, V37, P385; Begbie ME, 2003, POSTGRAD MED J, V79, P18, DOI 10.1136/pmj.79.927.18; Berg J, 2003, J MED GENET, V40, P585, DOI 10.1136/jmg.40.8.585; Burger B, 2002, AM J MED GENET, V110, P289, DOI 10.1002/ajmg.10411; Coffin CM, 1996, ARCH PATHOL LAB MED, V120, P1032; CONTE WJ, 1982, CLIN RES, V30, pA93; COX KL, 1980, GASTROENTEROLOGY, V78, P1566; Desai DC, 1998, J MED GENET, V35, P476, DOI 10.1136/jmg.35.6.476; ERKUL PE, 1994, PEDIATR RADIOL, V24, P145, DOI 10.1007/BF02020177; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Inoue S, 1999, AM J MED SCI, V317, P59, DOI 10.1097/00000441-199901000-00010; JASS JR, 1988, HISTOPATHOLOGY, V13, P619; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Marchuk DA, 2003, HUM MOL GENET, V12, pR97, DOI 10.1093/hmg/ddg103; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; PRIETO G, 1990, J PEDIATR GASTR NUTR, V11, P133, DOI 10.1097/00005176-199007000-00026; RADIN DR, 1994, ABDOM IMAGING, V19, P140, DOI 10.1007/BF00203488; Roth S, 1999, GENE CHROMOSOME CANC, V26, P54, DOI 10.1002/(SICI)1098-2264(199909)26:1<54::AID-GCC8>3.0.CO;2-D; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; SCHUMACHER B, 1994, Z GASTROENTEROL, V32, P105; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Shovlin CL, 2000, AM J MED GENET, V91, P66, DOI 10.1002/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P; SIMPSON EL, 1985, AM J ROENTGENOL, V144, P983, DOI 10.2214/ajr.144.5.983; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178	31	491	515	0	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	2004	363	9412					852	859		10.1016/S0140-6736(04)15732-2	http://dx.doi.org/10.1016/S0140-6736(04)15732-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15031030				2022-12-28	WOS:000220231500011
J	Woo, PCY; Lau, SKP; Tsoi, HW; Chan, KH; Wong, BHL; Che, XY; Tam, VKP; Tam, SCF; Cheng, VCC; Hung, IFN; Wong, SSY; Zheng, BJ; Guan, Y; Yuen, KY				Woo, PCY; Lau, SKP; Tsoi, HW; Chan, KH; Wong, BHL; Che, XY; Tam, VKP; Tam, SCF; Cheng, VCC; Hung, IFN; Wong, SSY; Zheng, BJ; Guan, Y; Yuen, KY			Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia	LANCET			English	Article							ACUTE RESPIRATORY SYNDROME; RECOMBINANT NUCLEOCAPSID PROTEIN; ANTIBODIES; ENCODES; IDENTIFICATION; SERODIAGNOSIS; MANNOPROTEIN; DIAGNOSIS; OUTBREAK; ELISA	Background Although the genome of severe acute respiratory syndrome coronavirus (SARS-CoV) has been sequenced and a possible animal reservoir identified, seroprevalence studies and mass screening for detection of subclinical and non-pneumonic infections are still lacking. Methods We cloned and purified the nucleocapsid protein and spike polypeptide of SARS-CoV and examined their immunogenicity with serum from patients with SARS-CoV pneumonia. An ELISA based on recombinant nucleocapsid protein for IgG detection was tested with serum from 149 healthy blood donors who donated 3 years previously and with serum positive for antibodies against SARS-CoV (by indirect immunofluorescence assay) from 106 patients with SARS-CoV pneumonia. The seroprevalence of SARS-CoV was studied with the ELISA in healthy blood donors who donated during the SARS outbreak in Hong Kong, non-pneumonic hospital inpatients, and symptom-free health-care workers. All positive samples were confirmed by two separate western-blot assays (with recombinant nucleocapsid protein and recombinant spike polypeptide). Findings Western-blot analysis showed that the nucleocapsid protein and spike polypeptide of SARS-CoV are highly immunogenic. The specificity of the IgG antibody test (ELISA with positive samples confirmed by the two western-blot assays) was 100%, and the sensitivity was 94.3%. Three of 400 healthy blood donors who donated during the SARS outbreak and one of 131 non-pneumonic paediatric inpatients were positive for IgG antibodies, confirmed by the two western-blot assays (total, 0.48% of our study population). Interpretation Our findings support the existence of subclinical or non-pneumonic SARS-CoV infections. Such infections are more common than SARS-CoV pneumonia in our locality.	Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; First Mil Med Univ, Zhujiang Hosp, Cent Lab, Guangzhou, Peoples R China; Queen Mary Hosp, Dept Clin Biochem, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; Southern Medical University - China; University of Hong Kong	Yuen, KY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.	kyyuen@hkucc.hku.hk	Lau, Susanna/C-4321-2009; Wong, Samson/C-4446-2009; Hung, Ivan FN/ABD-5916-2021; Tsoi, Hoi Wah/C-4428-2009; Yuen, Kwok Yung/C-4465-2009; Chan, Kwok Hung/ABD-5399-2021; Woo, Patrick Chiu Yat/C-4449-2009	Hung, Ivan FN/0000-0002-1556-2538; Guan, Yi/0000-0001-6057-9243; CHENG, Vincent Chi-Chung/0000-0003-1765-7706; Yuen, Kwok-yung/0000-0002-2083-1552; Woo, Patrick Chiu Yat/0000-0001-9401-1832				BRIESE T, 1995, J CLIN MICROBIOL, V33, P348, DOI 10.1128/JCM.33.2.348-351.1995; Cao L, 1998, INFECT IMMUN, V66, P966, DOI 10.1128/IAI.66.3.966-973.1998; Cao L, 1998, J CLIN MICROBIOL, V36, P3028, DOI 10.1128/JCM.36.10.3028-3031.1998; Chan CM, 2002, J CLIN MICROBIOL, V40, P2041, DOI 10.1128/JCM.40.6.2041-2045.2002; Chan PKS, 2003, EMERG INFECT DIS, V9, P1453, DOI 10.3201/eid0911.030421; Denac H, 1997, J VIROL METHODS, V65, P169, DOI 10.1016/S0166-0934(97)02186-1; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Ndifuna A, 1998, J VIROL METHODS, V70, P37, DOI 10.1016/S0166-0934(97)00170-5; Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; POHLKOPPE A, 1995, J VIROL METHODS, V55, P175, DOI 10.1016/0166-0934(95)00041-R; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Seah JN, 2000, VET MICROBIOL, V75, P11, DOI 10.1016/S0378-1135(00)00202-9; So LKY, 2003, LANCET, V361, P1615, DOI 10.1016/S0140-6736(03)13265-5; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; Wang CH, 2002, VET MICROBIOL, V85, P333, DOI 10.1016/S0378-1135(01)00525-9; Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997; Woo PCY, 2003, J CLIN MICROBIOL, V41, P845, DOI 10.1128/JCM.41.2.845-850.2003; Woo PCY, 2001, CLIN DIAGN LAB IMMUN, V8, P832, DOI 10.1128/CDLI.8.4.832-836.2001; Woo PCY, 2001, J MED MICROBIOL, V50, P330, DOI 10.1099/0022-1317-50-4-330; Yuen KY, 2001, J CLIN MICROBIOL, V39, P3830, DOI 10.1128/JCM.39.11.3830-3837.2001	27	108	115	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	2004	363	9412					841	845		10.1016/S0140-6736(04)15729-2	http://dx.doi.org/10.1016/S0140-6736(04)15729-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15031027	Green Published, Bronze			2022-12-28	WOS:000220231500008
J	Stierle, A; Renner, F; Streitel, R; Dosch, H; Drube, W; Cowie, BC				Stierle, A; Renner, F; Streitel, R; Dosch, H; Drube, W; Cowie, BC			X-ray diffraction study of the ultrathin Al2O3 layer on NiAl(110)	SCIENCE			English	Article							ORDERED ALUMINA FILM; OXIDE-FILMS	Ultrathin Al2O3 layers on alloys are used as templates for model catalysts, tunneling barriers in electronic devices, or corrosion-resistant layers. The complex atomic structure of well-ordered alumina overlayers on NiAl(110) was solved by surface x-ray diffraction. The oxide layer is composed of a double layer of strongly distorted hexagonal oxygen ions that hosts aluminum ions on both octahedral and tetrahedral sites with equal probability. The alumina overlayer exhibits a domain structure that can be related to characteristic growth defects and is generated during the growth of a hexagonally ordered overlayer (Al2O3) on a body-centered cubic (110) substrate (NiAl).	Max Planck Inst Met Res, D-70569 Stuttgart, Germany; DESY, D-22603 Hamburg, Germany; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Max Planck Society; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); European Synchrotron Radiation Facility (ESRF)	Stierle, A (corresponding author), Max Planck Inst Met Res, Heisenbergstr 3, D-70569 Stuttgart, Germany.	stierle@mf.mpg.de	Drube, Wolfgang/C-9310-2012; Renner, Frank U/G-1655-2014; Stierle, Andreas/Q-2679-2018	Renner, Frank U/0000-0003-0425-393X; Stierle, Andreas/0000-0002-0303-6282; Drube, Wolfgang/0000-0003-3938-7823				Baumer M, 1999, PROG SURF SCI, V61, P127, DOI 10.1016/S0079-6816(99)00012-X; BINNIG G, 1983, PHYS REV LETT, V50, P120, DOI 10.1103/PhysRevLett.50.120; Ceballos G, 2002, CHEM PHYS LETT, V359, P41, DOI 10.1016/S0009-2614(02)00578-X; Dellwig T, 2000, PHYS REV LETT, V85, P776, DOI 10.1103/PhysRevLett.85.776; Franchy R, 2000, SURF SCI REP, V38, P199; Frank M, 2001, SURF SCI, V492, P270, DOI 10.1016/S0039-6028(01)01475-3; Hansen KH, 2001, SURF SCI, V475, P96, DOI 10.1016/S0039-6028(00)01077-3; Hansen KH, 1999, PHYS REV LETT, V83, P4120, DOI 10.1103/PhysRevLett.83.4120; JAEGER RM, 1991, SURF SCI, V259, P235, DOI 10.1016/0039-6028(91)90555-7; Jennison DR, 2000, SURF SCI, V464, P108, DOI 10.1016/S0039-6028(00)00578-1; Jennison DR, 1999, PHYS REV B, V59, P15605, DOI 10.1103/PhysRevB.59.R15605; Kulawik M, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.256101; LIBUDA J, 1994, SURF SCI, V318, P61, DOI 10.1016/0039-6028(94)90341-7; MOODERA JS, 1998, PHYS REV LETT, V75, P3273; Nilius N, 2000, PHYS REV LETT, V84, P3994, DOI 10.1103/PhysRevLett.84.3994; Padture NP, 2002, SCIENCE, V296, P280, DOI 10.1126/science.1068609; Pang CL, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.201401; Qiu XH, 2003, SCIENCE, V299, P542, DOI 10.1126/science.1078675; ROBINSON IK, 1992, REP PROG PHYS, V55, P599, DOI 10.1088/0034-4885/55/5/002; Ruppi S, 2001, THIN SOLID FILMS, V388, P50, DOI 10.1016/S0040-6090(01)00814-8; Stierle A, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.165413; Yourdshahyan Y, 1999, J AM CERAM SOC, V82, P1365, DOI 10.1111/j.1151-2916.1999.tb01926.x	22	148	148	4	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1652	1656		10.1126/science.1094060	http://dx.doi.org/10.1126/science.1094060			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016996				2022-12-28	WOS:000220151400039
J	Wiegman, A; de Groot, E; Hutten, BA; Rodenburg, J; Gort, J; Bakker, HD; Sijbrands, EJG; Kastelein, JJP				Wiegman, A; de Groot, E; Hutten, BA; Rodenburg, J; Gort, J; Bakker, HD; Sijbrands, EJG; Kastelein, JJP			Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia	LANCET			English	Article								Patients with familial hypercholesterolaemia have severe coronary-artery disease early in adult life. Whether lipid-lowering treatment should be started in childhood remains to be established. We therefore assessed 201 children heterozygous for familial hypercholesterolaemia and 80 unaffected siblings (both age ranges 8-18 years) with B-mode ultrasound to measure carotid wall intima-media thickness. Mean combined carotid intima-media thickness of heterozygotes was significantly greater than that of unaffected siblings (0.494 mm [SD 0.051] vs 0.472 [SD 0.049], p=0.002). A significant deviation in intima-media thickness was noted from age 12 years in children with familial hypercholesterolaemia. Findings on multivariate analysis showed LDL cholesterol, age, and sex to be strong and independent predictors of intima-media thickness. Since raised LDL cholesterol concentrations can be lowered efficiently, clinical studies are needed to investigate long-term safety and effectiveness of statin treatment in children with familial hypercholesterolaemia.	Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Paediat, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Epidemiol & Biostat, NL-1100 DD Amsterdam, Netherlands; Univ Rotterdam, Erasmus Med Ctr, Dept Internal Med, Rotterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Erasmus University Rotterdam; Erasmus MC	Kastelein, JJP (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands.	e.vandongen@amc.uva.nl	Sijbrands, Eric/A-1065-2009; Kastelein, John/AAF-7950-2020	Sijbrands, Eric/0000-0001-8857-7389; Wiegman, Albert/0000-0001-6223-5671				MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; Neil HAW, 1999, ATHEROSCLEROSIS, V142, P105; Tonstad S, 1996, ARTERIOSCL THROM VAS, V16, P984, DOI 10.1161/01.ATV.16.8.984; Wiegman A, 2003, CIRCULATION, V107, P1473, DOI 10.1161/01.CIR.0000058166.99182.54	4	222	231	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	2004	363	9406					369	370		10.1016/S0140-6736(04)15467-6	http://dx.doi.org/10.1016/S0140-6736(04)15467-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768TQ	15070569				2022-12-28	WOS:000188590900014
J	Balsam, LB; Wagers, AJ; Christensen, JL; Kofidis, T; Weissman, IL; Robbins, RC				Balsam, LB; Wagers, AJ; Christensen, JL; Kofidis, T; Weissman, IL; Robbins, RC			Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium	NATURE			English	Article							FUSION; HEART; TRANSPLANTATION; CARDIOMYOCYTES; REGENERATION; INFARCTION; PHENOTYPE	Under conditions of tissue injury, myocardial replication and regeneration have been reported(1). A growing number of investigators have implicated adult bone marrow (BM) in this process, suggesting that marrow serves as a reservoir for cardiac precursor cells(2-6). It remains unclear which BM cell(s) can contribute to myocardium, and whether they do so by transdifferentiation or cell fusion. Here, we studied the ability of c-kit-enriched BM cells, Lin(-) c-kit(+) BM cells and c-kit(+) Thy1.1(lo) Lin(-) Sca-1(+) long-term reconstituting haematopoietic stem cells to regenerate myocardium in an infarct model. Cells were isolated from transgenic mice expressing green fluorescent protein (GFP) and injected directly into ischaemic myocardium of wild-type mice. Abundant GFP(+) cells were detected in the myocardium after 10 days, but by 30 days, few cells were detectable. These GFP(+) cells did not express cardiac tissue-specific markers, but rather, most of them expressed the haematopoietic marker CD45 and myeloid marker Gr-1. We also studied the role of circulating cells in the repair of ischaemic myocardium using GFP(+)-GFP(-) parabiotic mice. Again, we found no evidence of myocardial regeneration from blood-borne partner-derived cells. Our data suggest that even in the microenvironment of the injured heart, c-kit-enriched BM cells, Lin(-) c-kit(+) BM cells and c-kit(+) Thy1.1(lo) Lin(-) Sca-1(+) long-term reconstituting haematopoietic stem cells adopt only traditional haematopoietic fates.	Stanford Univ, Sch Med, Dept Cardiothorac Surg, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Robbins, RC (corresponding author), Stanford Univ, Sch Med, Dept Cardiothorac Surg, Stanford, CA 94305 USA.	robbins@stanford.edu	Kofidis, Theodoros/B-9283-2011; Kofidis, Theodoros/B-9283-2011	Kofidis, Theodoros/0000-0002-9623-6450; Kofidis, Theodoros/0000-0002-8938-819X				Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Deb A, 2003, CIRCULATION, V107, P1247, DOI 10.1161/01.CIR.0000061910.39145.F0; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140-6736(03)12110-1; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Tse HF, 2003, LANCET, V361, P47, DOI 10.1016/S0140-6736(03)12111-3; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081; Wright DE, 2001, BLOOD, V97, P2278, DOI 10.1182/blood.V97.8.2278; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	17	1336	1485	1	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 8	2004	428	6983					668	673		10.1038/nature02460	http://dx.doi.org/10.1038/nature02460			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810IE	15034594				2022-12-28	WOS:000220697200048
J	Sadana, R; D'Souza, C; Hyder, AA; Chowdhury, AMR				Sadana, R; D'Souza, C; Hyder, AA; Chowdhury, AMR			Importance of health research in South Asia	BMJ-BRITISH MEDICAL JOURNAL			English	Article								South Asian countries face similar health problems and would benefit from collaboration in health research.	WHO, Evidence & Informat Policy Cluster, Res Policy & Cooperat Dept, Hlth Res Syst Anal Initiat, CH-1211 Geneva 27, Switzerland; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Int Hlth Fac, Hlth Syst Programme, Baltimore, MD 21205 USA; Columbia Univ, Heilbrunn Dept Populat & Family Hlth, New York, NY 10032 USA	World Health Organization; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Columbia University	Sadana, R (corresponding author), WHO, Evidence & Informat Policy Cluster, Res Policy & Cooperat Dept, Hlth Res Syst Anal Initiat, CH-1211 Geneva 27, Switzerland.	sadanar@who.int	Hyder, Adnan/AAT-9503-2021	Hyder, Adnan/0000-0002-7292-577X				Agarwal SP, 2002, NATL MED J INDIA, V15, P213; Akhtar T, 2000, HLTH RES CAPACITY PA; *BANGL HLTH EQ WAT, 2002, BROCHURE; Beaglehole R., 2003, WORLD HLTH REPORT 20; Bhutta ZA, 2000, BRIT MED J, V321, P809, DOI 10.1136/bmj.321.7264.809; *FED BUR REP, PAKISTAN TIMES; *GFHR, 1999, 10 90 REP HLTH RES; *HLTH INN ACC RES, SCI PUBL; HOSSAIN M, 2000, ESSENTIAL NATL HLTH; Hyder AA, 2003, HEALTH POLICY PLANN, V18, P338, DOI 10.1093/heapol/czg040; Innvaer Simon, 2002, J Health Serv Res Policy, V7, P239, DOI 10.1258/135581902320432778; *INT ORG COMM, 2001, REP INT C HLTH RES D; Islam A, 2002, HEALTH POLICY, V60, P151, DOI 10.1016/S0168-8510(01)00211-1; *MIN COMM SCI TECH, 2003, REP REG DIR; PANG T, 2003, B WORLD HEALTH ORGAN, V81, P777; Pappas G, 2001, AM J PUBLIC HEALTH, V91, P93, DOI 10.2105/AJPH.91.1.93; PARAJE G, IN PRESS METHODOLOGI; PETERS DA, 2004, HLTH POL RES S AS BU; Peters DH, 2003, HEALTH POLICY PLANN, V18, P249, DOI 10.1093/heapol/czg031; Ray TK, 2002, NATL MED J INDIA, V15, P257; The Commission on Health Research for Development, 1990, HLTH RES ESS LINK EQ; *WHO, NAT LIB MED REG DAT; *WHO, 2003, HLTH RES SYST DEV WH; *WHO SE AS REG OFF, 2002, 27 SESS WHO SE AS AD; World Health Organization World Bank USAID, 2003, GUID PROD NAT HLTH A	25	58	58	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	2004	328	7443					826	830		10.1136/bmj.328.7443.826	http://dx.doi.org/10.1136/bmj.328.7443.826			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	811CG	15070643	Green Published			2022-12-28	WOS:000220749400026
J	Webby, RJ; Perez, DR; Coleman, JS; Guan, Y; Knight, JH; Govorkova, EA; McClain-Moss, LR; Peiris, JS; Rehg, JE; Tuomanen, EI; Webster, RG				Webby, RJ; Perez, DR; Coleman, JS; Guan, Y; Knight, JH; Govorkova, EA; McClain-Moss, LR; Peiris, JS; Rehg, JE; Tuomanen, EI; Webster, RG			Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines	LANCET			English	Article							A VIRUS; HONG-KONG; H5N1 VIRUS; GENERATION; PATHOGENICITY; HEMAGGLUTININ; RESCUE; SYSTEM; DNA	Background In response to the emergence of severe infection capable of rapid global spread, WHO will issue a pandemic alert. Such alerts are rare; however, on Feb 19, 2003, a pandemic alert was issued in response to human infections caused by an avian H5N1 influenza virus, A/Hong Kong/213/03. H5N1 had been noted once before in human beings in 1997 and killed a third (6/18) of infected people.(1,2) The 2003 variant seemed to have been transmitted directly from birds to human beings and caused fatal pneumonia in one of two infected individuals. Candidate vaccines were sought, but no avirulent viruses antigenically similar to the pathogen were available, and the isolate killed embryonated chicken eggs. Since traditional strategies of vaccine production were not viable, we sought to produce a candidate reference virus using reverse genetics. Methods We removed the polybasic aminoacids that are associated with high virulence from the haemagglutinin cleavage site of A/Hong Kong/213/03 using influenza reverse genetics techniques. A reference vaccine virus was then produced on an A/Puerto Rico/8/34 (PR8) backbone on WHO-approved Vero cells. We assessed this reference virus for pathogenicity in in-vivo and in-vitro assays. Findings A reference vaccine virus was produced in Good Manufacturing Practice (GMP)-grade facilities in less than 4 weeks from the time of virus isolation. This virus proved to be non-pathogenic in chickens and ferrets and was shown to be stable after multiple passages in embryonated chicken eggs. Interpretation The ability to produce a candidate reference virus in such a short period of time sets a new standard for rapid response to emerging infectious disease threats and clearly shows the usefulness of reverse genetics for influenza vaccine development. The same technologies and procedures are currently being used to create reference vaccine viruses against the 2004 H5N1 viruses circulating in Asia.	St Jude Childrens Res Hosp, Dept Infect Dis, Div Virol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Therapeut Prod & Qual, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; Univ Maryland, Dept Vet Med, College Pk, MD 20742 USA; Univ Hong Kong, Queen Mary Hosp, Dept Pathol & Microbiol, Hong Kong, Hong Kong, Peoples R China	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University System of Maryland; University of Maryland College Park; University of Hong Kong	Webby, RJ (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, Div Virol, MS 330,332 N Lauderdale St, Memphis, TN 38105 USA.	richard.webby@stjude.org	Webby, Richard J/N-5657-2018; Tuomanen, Elaine I/N-3081-2018; Perez, Daniel R./D-5044-2016; Rehg, Jerold E/N-8111-2018	Tuomanen, Elaine I/0000-0003-0349-8716; Perez, Daniel R./0000-0002-6569-5689; Govorkova, Elena/0000-0001-9067-5682; Guan, Yi/0000-0001-6057-9243	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA021765, CA21765] Funding Source: Medline; NIAID NIH HHS [N01AI95357, AI95357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOSCH FX, 1979, VIROLOGY, V95, P197, DOI 10.1016/0042-6822(79)90414-8; BOSCH FX, 1981, VIROLOGY, V113, P725, DOI 10.1016/0042-6822(81)90201-4; Brands R, 1999, Dev Biol Stand, V98, P93; deJong JC, 1997, NATURE, V389, P554, DOI 10.1038/39218; Fedson DS, 2003, CLIN INFECT DIS, V36, P1552, DOI 10.1086/375056; Fodor E, 1999, J VIROL, V73, P9679, DOI 10.1128/JVI.73.11.9679-9682.1999; Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P1356, DOI 10.1073/pnas.0308352100; Halperin SA, 2002, VACCINE, V20, P1240, DOI 10.1016/S0264-410X(01)00428-5; Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697; Hoffmann E, 2002, VACCINE, V20, P3165, DOI 10.1016/S0264-410X(02)00268-2; KAWAOKA Y, 1987, VIROLOGY, V158, P218, DOI 10.1016/0042-6822(87)90256-X; KILBOURN.ED, 1969, B WORLD HEALTH ORGAN, V41, P643; Kistner O, 1999, Dev Biol Stand, V98, P101; Li SQ, 1999, J INFECT DIS, V179, P1132, DOI 10.1086/314713; Liu M, 2003, VIROLOGY, V314, P580, DOI 10.1016/S0042-6822(03)00458-6; Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345; Ozaki H, 2004, J VIROL, V78, P1851, DOI 10.1128/JVI.78.4.1851-1857.2004; Schickli JH, 2001, PHILOS T ROY SOC B, V356, P1965, DOI 10.1098/rstb.2001.0979; Shortridge KF, 1998, VIROLOGY, V252, P331, DOI 10.1006/viro.1998.9488; Shortridge KF, 2000, VET MICROBIOL, V74, P141, DOI 10.1016/S0378-1135(00)00174-7; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; Subbarao K, 2003, VIROLOGY, V305, P192, DOI 10.1006/viro.2002.1742; Wood JM, 2001, PHILOS T R SOC B, V356, P1953, DOI 10.1098/rstb.2001.0981	23	199	273	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	2004	363	9415					1099	1103		10.1016/S0140-6736(04)15892-3	http://dx.doi.org/10.1016/S0140-6736(04)15892-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808VB	15064027	Green Published, Bronze			2022-12-28	WOS:000220595500008
J	Hogg, T; Mechold, U; Malke, H; Cashel, M; Hilgenfeld, R				Hogg, T; Mechold, U; Malke, H; Cashel, M; Hilgenfeld, R			Conformational antagonism between opposing active sites in a bifunctional Re1A/SpoT homolog modulates (p)ppGpp metabolism during the stringent response	CELL			English	Article							DNA-POLYMERASE-BETA; RELA/SPOT HOMOLOGS; STATIONARY-PHASE; MECHANISM; RELA; EXPRESSION; SEQUENCES; GENE	Enzymes of the Rel/Spo family enable bacteria to survive prolonged periods of nutrient limitation by producing an intracellular signaling alarmone, (p)ppGpp, which triggers the so-called stringent response. Both the synthesis of (p)ppGpp from ATP and GDP(GTP), and its hydrolysis to GDP(GTP) and pyrophosphate, are catalyzed by Rel/Spo proteins. The 2.1 Angstrom crystal structure of the bifunctional catalytic fragment of the Rel/Spo homolog from Streptococcus dysgalactiae subsp. equisimilis, Rel(Seq), reveals two conformations of the enzyme corresponding to known reciprocal activity states: (p)ppGpp-hydrolase-OFF/(p)ppGpp-synthetase-ON and hydrolase-ON/synthetase-OFF. The hydrolase and synthetase domains bear remarkable similarities to the catalytic domains of the cyclic phosphodiesterase and nucleotidyltransferase superfamilies, respectively. The active sites, separated by more than 30 Angstrom, contain bound nucleotides including an unusual (p)ppGpp derivative, GDP-2':3'-cyclic monophosphate. Reciprocal regulation of the antagonistic catalytic activities, suggested by the structure, is supported by mutagenesis experiments and appears to involve ligand-induced signal transmission between the two active sites.	Med Univ Lubeck, Inst Biochem, D-23538 Lubeck, Germany; Univ Jena, Inst Mol Biotechnol, D-07745 Jena, Germany; Univ Jena, Inst Mol Biol, D-07745 Jena, Germany; NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA	University of Lubeck; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Oklahoma System; University of Oklahoma Health Sciences Center	Hilgenfeld, R (corresponding author), Med Univ Lubeck, Inst Biochem, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	hilgenfeld@biochem.uni-luebeck.de	Hilgenfeld, Rolf/C-9675-2011; Mechold, Undine/GYV-3918-2022	Mechold, Undine/0000-0002-6019-0972	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000067] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000067] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P469, DOI 10.1016/S0968-0004(98)01293-6; Arndt JW, 2001, BIOCHEMISTRY-US, V40, P5368, DOI 10.1021/bi002176j; Avarbock D, 2000, BIOCHEMISTRY-US, V39, P11640, DOI 10.1021/bi001256k; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; Chatterji D, 2001, CURR OPIN MICROBIOL, V4, P160, DOI 10.1016/S1369-5274(00)00182-X; Dahl JL, 2003, P NATL ACAD SCI USA, V100, P10026, DOI 10.1073/pnas.1631248100; DeLano W.L, PYMOL MOL GRAPHICS S; Givens RM, 2004, J BIOL CHEM, V279, P7495, DOI 10.1074/jbc.M311573200; GOLDBETER A, 1987, J BIOL CHEM, V262, P4460; Hammer BK, 2002, MOL MICROBIOL, V44, P107, DOI 10.1046/j.1365-2958.2002.02884.x; Hendrickson W. A., 1970, Acta Crystallographica, Section B (Structural Crystallography and Crystal Chemistry), Vb26, P136, DOI 10.1107/S0567740870002078; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; Hou ZL, 1999, J BIOL CHEM, V274, P17505, DOI 10.1074/jbc.274.25.17505; Huai Q, 2003, STRUCTURE, V11, P865, DOI 10.1016/S0969-2126(03)00123-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KITAMURA K, 1988, J BIOL CHEM, V263, P16796; Kuhar I, 2001, MOL MICROBIOL, V41, P207, DOI 10.1046/j.1365-2958.2001.02508.x; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mechold U, 1997, J BACTERIOL, V179, P2658, DOI 10.1128/jb.179.8.2658-2667.1997; Mechold U, 2002, J BACTERIOL, V184, P2878, DOI 10.1128/JB.184.11.2878-2888.2002; Mildvan AS, 1999, ADV ENZYMOL RAMB, V73, P183, DOI 10.1002/9780470123195.ch6; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P585; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAO CC, 1980, J BIOL CHEM, V255, P1830; PAO CC, 1981, BIOCHIM BIOPHYS ACTA, V677, P358, DOI 10.1016/0304-4165(81)90247-6; Riboldi-Tunnicliffe A, 1999, J APPL CRYSTALLOGR, V32, P1003, DOI 10.1107/S0021889899008584; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Steiner K, 2000, MOL MICROBIOL, V38, P1004, DOI 10.1046/j.1365-2958.2000.02203.x; Sun JH, 2001, J BACTERIOL, V183, P3488, DOI 10.1128/JB.183.11.3488-3498.2001; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Van Delden C, 2001, J BACTERIOL, V183, P5376, DOI 10.1128/JB.183.18.5376-5384.2001; van der Biezen EA, 2000, P NATL ACAD SCI USA, V97, P3747, DOI 10.1073/pnas.060392397; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weiss MS, 1997, J APPL CRYSTALLOGR, V30, P203, DOI 10.1107/S0021889897003907; Wendrich TM, 2000, FEMS MICROBIOL LETT, V190, P195, DOI 10.1016/S0378-1097(00)00335-9; Wendrich TM, 2002, MOL CELL, V10, P779, DOI 10.1016/S1097-2765(02)00656-1; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822	43	231	239	4	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	2004	117	1					57	68		10.1016/S0092-8674(04)00260-0	http://dx.doi.org/10.1016/S0092-8674(04)00260-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YV	15066282	Bronze			2022-12-28	WOS:000221500300008
J	Kai, T; Spradling, A				Kai, T; Spradling, A			Differentiating germ cells can revert into functional stem cells in Drosophila melanogaster ovaries	NATURE			English	Article							MORPHOGENESIS; EXPRESSION; NICHES; SRC64	Many tissues including blood, skin, gut and germ cells are continuously maintained by tissue stem cells(1-2). Under certain conditions, however, other organs can undergo repair using stem-cell-like progenitors generated by cell de-differentiation(3). Cell fates have been broadened experimentally(4-7), but mechanisms allowing de-differentiation to a stem cell state are poorly known. Germline stem cells begin to differentiate by forming interconnected germ cell cysts (cystocytes), and under certain conditions male mouse cystocytes have been postulated to revert into functional progenitors(8,9). Here we report that four- and eight-cell Drosophila germline cystocytes generated either in second instar larval ovaries or in adults over-producing the BMP4-like stem cell signal Decapentaplegic efficiently convert into single stem-like cells. These de-differentiated cells can develop into functional germline stem cells and support normal fertility. Our results show that cystocytes represent a relatively abundant source of regenerative precursors that might help replenish germ cells after depletion by genotoxic chemicals, radiation or normal ageing. More generally, Drosophila cystocytes now provide a system for studying de-differentiation and its potential as a source of functional stem cells.	Carnegie Inst Washington, Dept Embryol, Howard Hughes Med Inst, Res Labs, Baltimore, MD 21210 USA	Carnegie Institution for Science; Howard Hughes Medical Institute	Spradling, A (corresponding author), Carnegie Inst Washington, Dept Embryol, Howard Hughes Med Inst, Res Labs, 115 W Univ Pkwy, Baltimore, MD 21210 USA.	spradling@ciwemb.edu		Kai, Toshie/0000-0001-8675-8469	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Brinster RL, 2002, SCIENCE, V296, P2174, DOI 10.1126/science.1071607; Chen DH, 2003, CURR BIOL, V13, P1786, DOI 10.1016/j.cub.2003.09.033; CLERMONT Y, 1968, AM J ANAT, V122, P237, DOI 10.1002/aja.1001220205; de Cuevas M, 1997, ANNU REV GENET, V31, P405, DOI 10.1146/annurev.genet.31.1.405; de Cuevas M, 1998, DEVELOPMENT, V125, P2781; De Rooij DG, 2000, J ANDROL, V21, P776; Dodson GS, 1998, DEVELOPMENT, V125, P2883; GODT D, 1995, DEVELOPMENT, V121, P173; Kai TS, 2003, P NATL ACAD SCI USA, V100, P4633, DOI 10.1073/pnas.0830856100; Kramerova IA, 1999, DEV DYNAM, V216, P349, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<349::AID-DVDY4>3.0.CO;2-X; Mikkola I, 2002, SCIENCE, V297, P110, DOI 10.1126/science.1067518; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Ohlstein B, 1997, DEVELOPMENT, V124, P3651; Pearson BJ, 2003, NATURE, V425, P624, DOI 10.1038/nature01910; Prohaska SS, 2002, SEMIN IMMUNOL, V14, P377, DOI 10.1016/S1044532302000726; ROBINSON DN, 1994, DEVELOPMENT, V120, P2015; Roulier EM, 1998, MOL CELL, V1, P819, DOI 10.1016/S1097-2765(00)80081-7; Song XQ, 2002, SCIENCE, V296, P1855, DOI 10.1126/science.1069871; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; STOCUM DL, 2000, CURR TOP MICROBIOL I, V280, P1; Tanimoto H, 2000, MOL CELL, V5, P59, DOI 10.1016/S1097-2765(00)80403-7; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Xie T, 1998, CELL, V94, P251, DOI 10.1016/S0092-8674(00)81424-5; Zhu CH, 2003, DEVELOPMENT, V130, P2579, DOI 10.1242/dev.00499	24	252	268	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					564	569		10.1038/nature02436	http://dx.doi.org/10.1038/nature02436			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15024390				2022-12-28	WOS:000220540100043
J	Vickers, AJ; Rees, RW; Zollman, CE; McCarney, R; Smith, C; Ellis, N; Fisher, P; Van Haselen, R				Vickers, AJ; Rees, RW; Zollman, CE; McCarney, R; Smith, C; Ellis, N; Fisher, P; Van Haselen, R			Acupuncture for chronic headache in primary care: large, pragmatic, randomised trial	BRITISH MEDICAL JOURNAL			English	Article							TENSION-TYPE HEADACHE; PROPHYLACTIC TREATMENT; NEEDLE ACUPUNCTURE; DOUBLE-BLIND; MIGRAINE; PLACEBO; FLUNARIZINE	Objectives To determine the effects of a policy of "use acupuncture" on headache, health status, days off sick, and use of resources in patients with chronic headache compared with a policy of "avoid acupuncture." Design Randomised, controlled trial. Setting General practices in England and Wales. Participants 401 patients with chronic headache, predominantly migraine. Interventions Patients were randomly allocated to receive up to 12 acupuncture treatments over three months or to a control intervention offering usual care. Main outcome measures Headache score, SF-36 health status, and use of medication were assessed at baseline, three, and 12 months. Use of resources was assessed every three months. Results Headache score at 12 months, the primary end point, was lower in the acupuncture group (16.2, SD 13.7, n = 161, 34% reduction from baseline) than in controls (22.3, SD 17.0, n = 140, 161% reduction from baseline). The adjusted difference between means is 4.6 (95% confidence interval 2.2 to 7.0; P = 0.0002). This result is robust to sensitivity analysis incorporating imputation for missing data. Patients in the acupuncture group experienced the equivalent of 22 fewer days of headache per year (8 to 38). SF-36 data favoured acupuncture, although differences reached significance only for physical role functioning, energy, and change in health. Compared with controls, patients randomised to acupuncture used 15% less medication (P = 0.02), made 25% fewer visits to general practitioners (P = 0.10), and took 15% fewer days off sick (P = 0.2). Conclusions Acupuncture leads to persisting, clinically relevant benefits for primary care patients with chronic headache, particularly migraine. Expansion of NHS acupuncture services should be considered.	Mem Sloan Kettering Canc Ctr, Biostat Serv, Integrat Med Serv, New York, NY 10021 USA; Inst Educ, Evidence Policy & Practice Informat & Coordinatin, Social Sci Res Unit, London WC1H 0NS, England; Montpelier Hlth Ctr, Bristol BS6 5PT, Avon, England; Univ London Imperial Coll Sci Technol & Med, Dept Psychol Med, London W2 1PD, England; Univ London Kings Coll, Weston Educ Ctr, London SE5 9RJ, England; Coventry Univ, Dept Hlth & Social Sci, Coventry CV1 5FB, W Midlands, England; Royal London Homeopath Hosp, London W1W 5PB, England	Memorial Sloan Kettering Cancer Center; University of London; University College London; UCL Institute of Education; Imperial College London; University of London; King's College London; Coventry University; University College London Hospitals NHS Foundation Trust	Vickers, AJ (corresponding author), Mem Sloan Kettering Canc Ctr, Biostat Serv, Integrat Med Serv, 1275 York Ave, New York, NY 10021 USA.	vickersa@mskcc.org		Vickers, Andrew/0000-0003-1525-6503; Rees, Rebecca/0000-0003-1413-1952				Allais G, 2002, HEADACHE, V42, P855, DOI 10.1046/j.1526-4610.2002.02203.x; Karakurum B, 2001, CEPHALALGIA, V21, P813, DOI 10.1046/j.1468-2982.2001.218238.x; Karst M, 2000, PAIN, V88, P199, DOI 10.1016/S0304-3959(00)00315-8; Karst M, 2001, CEPHALALGIA, V21, P637, DOI 10.1046/j.1468-2982.2001.00198.x; Kee W. G., 1998, AM J PAIN MANAGEMENT, V8, P83; LENHARD L, 1983, NEW ZEAL MED J, V96, P663; Melchart D, 2003, J INTERN MED, V253, P181, DOI 10.1046/j.1365-2796.2003.01081.x; MELCHART D, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001218; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Tfelt-Hansen P, 2000, CEPHALALGIA, V20, P765; Thomas KJ, 2001, BRIT J GEN PRACT, V51, P25; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; VINCENT CA, 1989, CLIN J PAIN, V5, P305, DOI 10.1097/00002508-198912000-00006; Wadlow G., 1996, COMPLEMENT THER MED, V4, P1, DOI [10.1016/S0965-2299(96)80048-3, DOI 10.1016/S0965-2299(96)80048-3]; Whittaker SJ, 1996, BT TECHNOL J, V14, P11	16	170	187	0	20	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 27	2004	328	7442					744	747		10.1136/bmj.38029.421863.EB	http://dx.doi.org/10.1136/bmj.38029.421863.EB			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809WH	15023828	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000220666300017
J	Osta, MA; Christophides, GK; Kafatos, FC				Osta, MA; Christophides, GK; Kafatos, FC			Effects of mosquito genes on Plasmodium development	SCIENCE			English	Article							ANOPHELES-GAMBIAE; MOLECULAR-INTERACTIONS; MALARIA INFECTION; RESPONSES; RECOGNITION; PATHOGENS; RECEPTORS; LECTINS	Malaria parasites must complete a complex developmental cycle in an Anopheles mosquito vector before transmission to a vertebrate host. Sexual development of the parasite in the midgut is initiated in the lumen immediately after the mosquito ingests infected blood, and the resulting ookinetes must traverse the surrounding epithelial layer before transforming into oocysts. The innate immune system of the mosquito is activated during midgut invasion, but to date, no evidence has been published identifying mosquito immune genes that affect parasite development. Here, we show by gene silencing that an Anopheles gambiae leucine rich-repeat protein acts as an antagonist and two C-type lectines act as protective agonists on the development of Plasmodium ookinetes to oocysts.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Kafatos, FC (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	dg-office@ernbl.de		Christophides, George/0000-0002-3323-1687				Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Blandin S, 2002, EMBO REP, V3, P852, DOI 10.1093/embo-reports/kvf180; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Dimopoulos G, 1998, EMBO J, V17, P6115, DOI 10.1093/emboj/17.21.6115; Dimopoulos G, 2002, P NATL ACAD SCI USA, V99, P8814, DOI 10.1073/pnas.092274999; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Girardin SE, 2002, TRENDS MICROBIOL, V10, P193, DOI 10.1016/S0966-842X(02)02334-X; Han YS, 2000, EMBO J, V19, P6030, DOI 10.1093/emboj/19.22.6030; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; KAFATOS F, UNPUB; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; LEVASHINA EA, UNPUB; Niare O, 2002, SCIENCE, V298, P213, DOI 10.1126/science.1073420; OSTA M, UNPUB; Richman AM, 1997, EMBO J, V16, P6114, DOI 10.1093/emboj/16.20.6114; Sinden RE, 2002, CELL MICROBIOL, V4, P713, DOI 10.1046/j.1462-5822.2002.00229.x; Vasselon T, 2002, INFECT IMMUN, V70, P1033, DOI 10.1128/IAI.70.3.1033-1041.2002; VERNICK KD, 1995, EXP PARASITOL, V80, P583, DOI 10.1006/expr.1995.1074; VLACHOU D, IN PRESS CELL MICROB; Yu XQ, 2003, DEV COMP IMMUNOL, V27, P189, DOI 10.1016/S0145-305X(02)00099-X	24	334	347	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	2004	303	5666					2030	2032		10.1126/science.1091789	http://dx.doi.org/10.1126/science.1091789			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044804				2022-12-28	WOS:000220429800045
J	Rothwell, PM; Eliasziw, M; Gutnikov, SA; Warlow, CP; Barnett, HJM				Rothwell, PM; Eliasziw, M; Gutnikov, SA; Warlow, CP; Barnett, HJM		Carotid Endarterectomy Trialists C	Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery	LANCET			English	Article							EXTRACRANIAL ARTERIAL-OCCLUSION; ISCHEMIC ATTACKS; STROKE; RISK; PREVENTION; PROGNOSIS; TRIALS; GUIDELINES; STATEMENT; JOINT	Background Carotid endarterectomy reduces the risk of stroke in patients with recently symptomatic stenosis. Benefit depends on the degree of stenosis, and we aimed to see whether it might also depend on other clinical and angiographic characteristics, and on the timing of surgery. Methods We analysed pooled data from the European Carotid Surgery Trial and North American Symptomatic Carotid Endarterectomy Trial. The risk of ipsilateral ischaemic stroke for patients on medical treatment, the perioperative risk of stroke and death, and the overall benefit from surgery were determined in relation to seven predefined and seven post hoc subgroups. Results 5893 patients with 33 000 patient-years of follow-up were analysed. Sex (p=0.003), age (p=0.03), and time from the last symptomatic event to randomisation (p=0.009) modified the effectiveness of surgery. Benefit from surgery was greatest in men, patients aged 75 years or older, and those randomised within 2 weeks after their last ischaemic event, and fell rapidly with increasing delay. For patients with 50% or higher stenosis, the number of patients needed to undergo surgery (ie, number needed to treat) to prevent one ipsilateral stroke in 5 years was nine for men versus 36 for women, five for age 75 years or older versus 18 for younger than 65 years, and five for those randomised within 2 weeks after their last ischaemic event, versus 125 for patients randomised after more than 12 weeks. These results were consistent across the individual trials. Interpretation: Benefit from endarterectomy depends not only on the degree of carotid stenosis, but also on several other clinical characteristics such as delay to surgery after the presenting event. Ideally, the procedure should be done within 2 weeks of the patient's last symptoms.	Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford OX2 6HE, England; Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland; John P Robarts Res Inst, London, ON N6A 5K8, Canada	Radcliffe Infirmary; University of Oxford; University of Calgary; University of Calgary; University of Edinburgh; Western University (University of Western Ontario)	Rothwell, PM (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford OX2 6HE, England.	peter.rothwell@clneuro.ox.ac.uk	BEJOT, Yannick/E-6088-2010; Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211	NINDS NIH HHS [R01-NS-24456] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024456] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alamowitch S, 2001, LANCET, V357, P1154, DOI 10.1016/S0140-6736(00)04332-4; BARNETT HJM, 1993, STROKE, V24, P1281, DOI 10.1161/01.STR.24.9.1281; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; Barnett HJM, 2002, CAN MED ASSOC J, V166, P1169; Benavente O, 2001, NEW ENGL J MED, V345, P1084, DOI 10.1056/NEJMoa002994; Biller J, 1998, CIRCULATION, V97, P501; BLAISDELL WF, 1969, J AMER MED ASSOC, V209, P1889, DOI 10.1001/jama.209.12.1889; Brandl R, 2001, VASA-J VASCULAR DIS, V30, P115, DOI 10.1024/0301-1526.30.2.115; CINA C, 1999, COCHRANE LIB; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; ELIASZIW M, 1994, STROKE, V25, P304, DOI 10.1161/01.STR.25.2.304; ELIASZIW M, 1994, STROKE, V25, P2445, DOI 10.1161/01.STR.25.12.2445; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; FIELDS WS, 1970, J AMER MED ASSOC, V211, P1993, DOI 10.1001/jama.211.12.1993; Golledge J, 1996, J VASC SURG, V24, P120, DOI 10.1016/S0741-5214(96)70152-0; Henderson RD, 2000, STROKE, V31, P128, DOI 10.1161/01.STR.31.1.128; HOWARD VJ, 1992, STROKE, V23, P583, DOI 10.1161/01.STR.23.4.583; Hsia DC, 1998, STROKE, V29, P346, DOI 10.1161/01.STR.29.2.346; *INT WORK PART STR, 2000, NAT CLIN GUID STROK; Kappelle IJ, 1999, STROKE, V30, P282, DOI 10.1161/01.STR.30.2.282; Masuhr F, 1998, STROKE, V29, P339, DOI 10.1161/01.STR.29.2.339; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; MOORE WS, 1995, STROKE, V26, P188, DOI 10.1161/01.STR.26.1.188; Morgenstern LB, 1997, NEUROLOGY, V48, P911, DOI 10.1212/WNL.48.4.911; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; PETO R, 1995, J CLIN EPIDEMIOL, V48, P23, DOI 10.1016/0895-4356(94)00150-O; Pritz MB, 1997, STROKE, V28, P2563, DOI 10.1161/01.STR.28.12.2563; ROB CG, 1969, SURGERY, V65, P862; Rothwell PM, 1997, BMJ-BRIT MED J, V315, P1571, DOI 10.1136/bmj.315.7122.1571; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; ROTHWELL PM, 1994, STROKE, V25, P2435, DOI 10.1161/01.STR.25.12.2435; Rothwell PM, 1999, LANCET, V353, P2105, DOI 10.1016/S0140-6736(98)11415-0; Rothwell PM, 2000, STROKE, V31, P615, DOI 10.1161/01.STR.31.3.615; Rothwell PM, 2003, STROKE, V34, P514, DOI 10.1161/01.STR.0000054671.71777.C7; SHAW DA, 1984, J NEUROL SCI, V64, P45, DOI 10.1016/0022-510X(84)90054-6; STILLER CA, 1994, BRIT J CANCER, V70, P352, DOI 10.1038/bjc.1994.306; Streifler JY, 2002, STROKE, V33, P1651, DOI 10.1161/01.STR.0000018010.38749.08; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Tu JV, 1998, NEW ENGL J MED, V339, P1441, DOI 10.1056/NEJM199811123392006; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; Wennberg DE, 1998, JAMA-J AM MED ASSOC, V279, P1278, DOI 10.1001/jama.279.16.1278	42	988	1042	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	2004	363	9413					915	924		10.1016/S0140-6736(04)15785-1	http://dx.doi.org/10.1016/S0140-6736(04)15785-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043958				2022-12-28	WOS:000220308600007
J	Spice, P				Spice, P			ABC of smoking cessation - Setting up a cessation service	BRITISH MEDICAL JOURNAL			English	Review									Nottingham Hlth Author, Nottingham, England									*DEP HLTH, 2000, NAT CANC PLAN; *DEP HLTH, 2000, NHS PLAN; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Department of Health, 1998, SMOK KILLS WHIT PAP; NHSBSA, 2018, NHS DENT SERV CLIN O; West R, 2000, THORAX, V55, P987, DOI 10.1136/thorax.55.12.987	6	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 20	2004	328	7441					699	701		10.1136/bmj.328.7441.699	http://dx.doi.org/10.1136/bmj.328.7441.699			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VB	15031245	Green Published			2022-12-28	WOS:000220392700027
J	Hawthorne, MF; Zink, JI; Skelton, JM; Bayer, MJ; Liu, C; Livshits, E; Baer, R; Neuhauser, D				Hawthorne, MF; Zink, JI; Skelton, JM; Bayer, MJ; Liu, C; Livshits, E; Baer, R; Neuhauser, D			Electrical or photocontrol of the rotary motion of a metallacarborane	SCIENCE			English	Article							MOLECULAR-STRUCTURE; ATP SYNTHASE; DERIVATIVES; RESONANCE; SPECTRA; CRYSTAL; STEPS	Rotary motion around a molecular axis has been controlled by simple electron transfer processes and by photoexcitation. The basis of the motion is intramolecular rotation of a carborane cage ligand ( 7,8-dicarbollide) around a nickel axle. The Ni(III) metallacarborane structure is a transoid sandwich with two pairs of carbon vertices reflected through a center of symmetry, but that of the Ni(IV) species is cisoid. The interconversion of the two provides the basis for controlled, rotational, oscillatory motion. The energies of the Ni(III) and Ni(IV) species are calculated as a function of the rotation angle.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Hebrew Univ Jerusalem, Dept Chem, Jerusalem, Israel	University of California System; University of California Los Angeles; Hebrew University of Jerusalem	Hawthorne, MF (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.	mfh@chem.ucla.edu	Baer, Roi/AAQ-6456-2020					ADLER RG, 1970, J AM CHEM SOC, V92, P6174, DOI 10.1021/ja00724a012; ANELLI PL, 1991, J AM CHEM SOC, V113, P5131, DOI 10.1021/ja00013a096; Asakawa M, 1997, J ORG CHEM, V62, P26, DOI 10.1021/jo961025c; Balzani V, 2000, ANGEW CHEM INT EDIT, V39, P3348, DOI 10.1002/1521-3773(20001002)39:19<3348::AID-ANIE3348>3.0.CO;2-X; Balzani V, 2000, J ORG CHEM, V65, P1924, DOI 10.1021/jo991781t; BEDARD TC, 1995, J AM CHEM SOC, V117, P10662, DOI 10.1021/ja00148a008; BOHN RK, 1966, J ORGANOMET CHEM, V5, P470, DOI 10.1016/S0022-328X(00)82382-7; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Chia SY, 2001, ANGEW CHEM INT EDIT, V40, P2447, DOI 10.1002/1521-3773(20010702)40:13<2447::AID-ANIE2447>3.0.CO;2-P; Cotton F.A., 1999, ADV INORG CHEM, P847; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FRISCH, 1998, GAUSSIAN 98 REVISION; HANSEN FV, 1973, ACTA CHEM SCAND, V27, P1210, DOI 10.3891/acta.chem.scand.27-1210; HAWTHORNE MF, 1968, J AM CHEM SOC, V90, P879, DOI 10.1021/ja01006a008; HAWTHORNE MF, 1972, SCIENCE, V178, P462, DOI 10.1126/science.178.4060.462; HELLER EJ, 1982, J PHYS CHEM-US, V86, P1822, DOI 10.1021/j100207a018; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Huheey J.E., 1993, INORGANIC CHEM; Kong J, 2000, J COMPUT CHEM, V21, P1532, DOI 10.1002/1096-987X(200012)21:16<1532::AID-JCC10>3.0.CO;2-W; Leigh DA, 2000, ANGEW CHEM INT EDIT, V39, P350, DOI 10.1002/(SICI)1521-3773(20000117)39:2<350::AID-ANIE350>3.3.CO;2-4; PRESTON DM, 1988, J AM CHEM SOC, V110, P5628, DOI 10.1021/ja00225a007; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; *SCHROD, 2000, JAG 4 1; SHIN KSK, 1989, INORG CHEM, V28, P4358, DOI 10.1021/ic00323a015; St Clair D., 1970, Journal of the American Chemical Society, V92, P1173, DOI 10.1021/ja00708a010; Vacek J, 2001, P NATL ACAD SCI USA, V98, P5481, DOI 10.1073/pnas.091100598; Warren L.F., 1970, J AM CHEM SOC, V92, P1157, DOI DOI 10.1021/JA00708A009; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; ZINK JI, 1991, ADV PHOTOCHEM, V16, P119, DOI DOI 10.1002/9780470133460.CH3	29	257	257	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	2004	303	5665					1849	1851		10.1126/science.1093846	http://dx.doi.org/10.1126/science.1093846			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031500				2022-12-28	WOS:000220281600050
J	Jorgensen, WL				Jorgensen, WL			The many roles of computation in drug discovery	SCIENCE			English	Review							HIV-1 REVERSE-TRANSCRIPTASE; FREE-ENERGY CALCULATIONS; BINDING AFFINITIES; MOLECULAR DOCKING; INHIBITORS; PREDICTION; VALIDATION; SOLUBILITY; ANALOGS; PERMEABILITY	An overview is given on the diverse uses of computational chemistry in drug discovery. Particular emphasis is placed on virtual screening, de novo design, evaluation of drug-likeness, and advanced methods for determining protein-ligand binding.	Yale Univ, Dept Chem, New Haven, CT 06520 USA	Yale University	Jorgensen, WL (corresponding author), Yale Univ, Dept Chem, 225 Prospect St, New Haven, CT 06520 USA.	william.jorgensen@yale.edu	/AAW-1187-2021					Ajay, 1999, J MED CHEM, V42, P4942, DOI 10.1021/jm990017w; AQVIST J, 1994, PROTEIN ENG, V7, P385, DOI 10.1093/protein/7.3.385; Bissantz C, 2000, J MED CHEM, V43, P4759, DOI 10.1021/jm001044l; Blake JF, 2003, ANNU REP MED CHEM, V38, P305, DOI 10.1016/S0065-7743(03)38031-5; Boehm HJ, 2000, J MED CHEM, V43, P2664, DOI 10.1021/jm000017s; BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P61, DOI 10.1007/bf00124387; Brandsdal BO, 2003, ADV PROTEIN CHEM, V66, P123; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARLSON HA, 1995, J PHYS CHEM-US, V99, P10667, DOI 10.1021/j100026a034; Cavalli A, 2002, J MED CHEM, V45, P3844, DOI 10.1021/jm0208875; Charifson PS, 1999, J MED CHEM, V42, P5100, DOI 10.1021/jm990352k; Colmenarejo G, 2001, J MED CHEM, V44, P4370, DOI 10.1021/jm010960b; De Clercq E, 2002, MED RES REV, V22, P531; Doman TN, 2002, J MED CHEM, V45, P2213, DOI 10.1021/jm010548w; Egan WJ, 2000, J MED CHEM, V43, P3867, DOI 10.1021/jm000292e; Ewing TJA, 1997, J COMPUT CHEM, V18, P1175, DOI 10.1002/(SICI)1096-987X(19970715)18:9<1175::AID-JCC6>3.0.CO;2-O; GILLET VJ, 1994, J CHEM INF COMP SCI, V34, P207, DOI 10.1021/ci00017a027; Gillet VJ, 1999, J CHEM INF COMP SCI, V39, P169, DOI 10.1021/ci980332b; Gohlke H, 2002, ANGEW CHEM INT EDIT, V41, P2645; HARDY LW, 2003, CURR DRUG DISCOV, P15; HERZBERG RP, 2000, CURR OPIN CHEM BIOL, V4, P445; Hester JB, 2001, J MED CHEM, V44, P1099, DOI 10.1021/jm0004289; Irvine JD, 1999, J PHARM SCI, V88, P28, DOI 10.1021/js9803205; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Jorgensen WL, 2002, ADV DRUG DELIVER REV, V54, P355, DOI 10.1016/S0169-409X(02)00008-X; KOLLMAN P, 1993, CHEM REV, V93, P2395, DOI 10.1021/cr00023a004; Lahana R, 1999, DRUG DISCOV TODAY, V4, P447, DOI 10.1016/S1359-6446(99)01393-8; Lamb ML, 1997, CURR OPIN CHEM BIOL, V1, P449, DOI 10.1016/S1367-5931(97)80038-5; LESNEY MS, 2004, TODAYS CHEM WORK, P27; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Lipinski CA, 2000, J PHARMACOL TOX MET, V44, P235, DOI 10.1016/S1056-8719(00)00107-6; Luco JM, 1999, J CHEM INF COMP SCI, V39, P396, DOI 10.1021/ci980411n; Maryanoff BE, 2004, J MED CHEM, V47, P769, DOI 10.1021/jm030493t; Massova I, 1999, J AM CHEM SOC, V121, P8133, DOI 10.1021/ja990935j; Mattos C, 2002, TRENDS BIOCHEM SCI, V27, P203, DOI 10.1016/S0968-0004(02)02067-4; Muegge I, 2003, MED RES REV, V23, P302, DOI 10.1002/med.10041; Ostrovsky D, 2003, J MED CHEM, V46, P5691, DOI 10.1021/jm030288d; Paiva AM, 2001, BBA-PROTEIN STRUCT M, V1545, P67, DOI 10.1016/S0167-4838(00)00262-4; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; Perez C, 2001, J MED CHEM, V44, P3768, DOI 10.1021/jm010141r; PLOUNTPRICE ML, 2001, BIOORG MED CHEM LETT, V11, P1541; Price MLP, 2000, J AM CHEM SOC, V122, P9455, DOI 10.1021/ja001018c; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; Regan J, 2002, J MED CHEM, V45, P2994, DOI 10.1021/jm020057r; Rizzo RC, 2002, J MED CHEM, V45, P2970, DOI 10.1021/jm010580q; Rizzo RC, 2000, J AM CHEM SOC, V122, P12898, DOI 10.1021/ja003113r; *SCHROD INC, 2003, GLID; *SCHROD INC, 2003, QIKPROP V 2 1; Shoichet BK, 2002, CURR OPIN CHEM BIOL, V6, P439, DOI 10.1016/S1367-5931(02)00339-3; Simonson T, 2002, ACCOUNTS CHEM RES, V35, P430, DOI 10.1021/ar010030m; Taskinen J, 2003, ADV DRUG DELIVER REV, V55, P1163, DOI 10.1016/S0169-409X(03)00117-0; Taylor RD, 2002, J COMPUT AID MOL DES, V16, P151, DOI 10.1023/A:1020155510718; TIRADORIVES J, 1990, J AM CHEM SOC, V112, P2773, DOI 10.1021/ja00163a046; TOMINAGA Y, IN PRESS J MED CHEM; Udier-Blagovic M, 2003, BIOORG MED CHEM LETT, V13, P3337, DOI 10.1016/S0960-894X(03)00681-4; Udier-Blagovic M, 2003, J AM CHEM SOC, V125, P6016, DOI 10.1021/ja034308c; Vinkers HM, 2003, J MED CHEM, V46, P2765, DOI 10.1021/jm030809x; Walters WP, 1998, DRUG DISCOV TODAY, V3, P160, DOI 10.1016/S1359-6446(97)01163-X; Walters WP, 2002, ADV DRUG DELIVER REV, V54, P255, DOI 10.1016/S0169-409X(02)00003-0; Wang DP, 2001, BIOORG MED CHEM LETT, V11, P2799, DOI 10.1016/S0960-894X(01)00510-8; Wang RX, 2003, J MED CHEM, V46, P2287, DOI 10.1021/jm0203783; Welling PG, 1997, PHARMACOKINETICS PRO; Wesolowski SS, 2002, BIOORG MED CHEM LETT, V12, P267, DOI 10.1016/S0960-894X(01)00825-3; Willett P, 1998, J CHEM INF COMP SCI, V38, P983, DOI 10.1021/ci9800211; Zhou RH, 2001, J PHYS CHEM B, V105, P10388, DOI 10.1021/jp011480z; [No title captured]	66	1075	1096	3	301	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1813	1818		10.1126/science.1096361	http://dx.doi.org/10.1126/science.1096361			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031495				2022-12-28	WOS:000220281600043
J	Walsh, CT				Walsh, CT			Polyketide and nonribosomal peptide antibiotics: Modularity and versatility	SCIENCE			English	Review							BIOSYNTHETIC GENE-CLUSTER; THIOESTERASE DOMAIN; VIBRIOBACTIN SYNTHETASE; ENGINEERED BIOSYNTHESIS; VANCOMYCIN; CYCLIZATION; GLYCOSYLTRANSFERASES; EPOTHILONE; BACKBONE; CLONING	Polyketide (PK) and nonribosomal peptides (NRP), constructed on multimodular enzymatic assembly lines, often attain the conformations that establish biological activity by cyclization constraints introduced by tailoring enzymes. The dedicated tailoring enzymes are encoded by genes clustered with the assembly line genes for coordinated regulation. NRP heterocyclizations to thiazoles and oxazoles can occur on the elongating framework of acyl-S enzyme intermediates, whereas tandem cyclic PK polyether formation of furans and pyrans can be initiated by post-assembly line epoxidases. Macrocyclizations of NRP, PK, and hybrid NRP-PK scaffolds occur in assembly line chain termination steps. Post-assembly line cascades of enzymatic oxidations also create cross-linked and cyclized architectures that generate the mature scaffolds of natural product antibiotics. The modularity of the natural product assembly lines and permissivity of tailoring enzymes offer prospects for reprogramming to create novel antibiotics with optimized properties.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Walsh, CT (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	christopher_walsh@hms.harvard.edu			NIAID NIH HHS [AI 42738] Funding Source: Medline; NIGMS NIH HHS [GM 49338, GM 20011] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020011, R37GM020011] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		August PR, 1998, CHEM BIOL, V5, P69, DOI 10.1016/S1074-5521(98)90141-7; Bischoff D, 2001, ANGEW CHEM INT EDIT, V40, P4688, DOI 10.1002/1521-3773(20011217)40:24<4688::AID-ANIE4688>3.0.CO;2-M; Boddy CN, 2003, J AM CHEM SOC, V125, P3428, DOI 10.1021/ja0298646; Bode HB, 2002, CHEMBIOCHEM, V3, P619, DOI 10.1002/1439-7633(20020703)3:7<619::AID-CBIC619>3.0.CO;2-9; Brautaset T, 2000, CHEM BIOL, V7, P395, DOI 10.1016/S1074-5521(00)00120-4; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; Chen HW, 2001, BIOCHEMISTRY-US, V40, P11651, DOI 10.1021/bi0115434; Chen HW, 2001, CHEM BIOL, V8, P301, DOI 10.1016/S1074-5521(01)00009-6; Cheng YQ, 2003, P NATL ACAD SCI USA, V100, P3149, DOI 10.1073/pnas.0537286100; Du LC, 2000, CHEM BIOL, V7, P623, DOI 10.1016/S1074-5521(00)00011-9; Hansen JL, 2002, MOL CELL, V10, P117, DOI 10.1016/S1097-2765(02)00570-1; Hillson NJ, 2003, BIOCHEMISTRY-US, V42, P766, DOI 10.1021/bi026903h; Hoffmeister D, 2003, J AM CHEM SOC, V125, P4678, DOI 10.1021/ja029645k; Hoffmeister D, 2000, CHEM BIOL, V7, P821, DOI 10.1016/S1074-5521(00)00029-6; Hojati Z, 2002, CHEM BIOL, V9, P1175, DOI 10.1016/S1074-5521(02)00252-1; Holtzel A, 2002, J ANTIBIOT, V55, P571; Hubbard BK, 2003, ANGEW CHEM INT EDIT, V42, P730, DOI 10.1002/anie.200390202; Hughes-Thomas ZA, 2003, ANGEW CHEM INT EDIT, V42, P4475, DOI 10.1002/anie.200351375; Hutchinson CR, 2003, P NATL ACAD SCI USA, V100, P3010, DOI 10.1073/pnas.0730689100; JANSEN R, 1994, LIEBIGS ANN CHEM, P759; Keating TA, 2001, CHEMBIOCHEM, V2, P99, DOI 10.1002/1439-7633(20010202)2:2<99::AID-CBIC99>3.0.CO;2-3; Keating TA, 2000, BIOCHEMISTRY-US, V39, P15522, DOI 10.1021/bi0016523; Khosla C, 2001, NATURE, V409, P247, DOI 10.1038/35051723; Kohli RM, 2002, NATURE, V418, P658, DOI 10.1038/nature00907; Kohli RM, 2003, J AM CHEM SOC, V125, P7160, DOI 10.1021/ja0352202; Kohli RM, 2003, CHEM COMMUN, P297, DOI 10.1039/b208333g; Kohli RM, 2001, BIOCHEMISTRY-US, V40, P7099, DOI 10.1021/bi010036j; Konz D, 1997, CHEM BIOL, V4, P927, DOI 10.1016/S1074-5521(97)90301-X; Kwon HJ, 2002, SCIENCE, V297, P1327, DOI 10.1126/science.1073175; Li AY, 2002, CHEM BIOL, V9, P1017, DOI 10.1016/S1074-5521(02)00223-5; Liu W, 2003, P NATL ACAD SCI USA, V100, P11959, DOI 10.1073/pnas.2034291100; Losey HC, 2001, BIOCHEMISTRY-US, V40, P4745, DOI 10.1021/bi010050w; Losey HC, 2002, CHEM BIOL, V9, P1305, DOI 10.1016/S1074-5521(02)00270-3; Mendez C, 2001, TRENDS BIOTECHNOL, V19, P449, DOI 10.1016/S0167-7799(01)01765-6; Miller DA, 2002, CHEM BIOL, V9, P333, DOI 10.1016/S1074-5521(02)00115-1; Mootz HD, 2002, CHEMBIOCHEM, V3, P490, DOI 10.1002/1439-7633(20020603)3:6<490::AID-CBIC490>3.0.CO;2-N; Mootz HD, 2002, J AM CHEM SOC, V124, P10980, DOI 10.1021/ja027276m; Nicolaou KC, 1999, ANGEW CHEM INT EDIT, V38, P2096, DOI 10.1002/(SICI)1521-3773(19990802)38:15<2096::AID-ANIE2096>3.0.CO;2-F; O'Connor SE, 2003, ANGEW CHEM INT EDIT, V42, P3917, DOI 10.1002/anie.200352077; Oliynyk M, 2003, MOL MICROBIOL, V49, P1179, DOI 10.1046/j.1365-2958.2003.03571.x; Omura S, 2001, P NATL ACAD SCI USA, V98, P12215, DOI 10.1073/pnas.211433198; Panda D, 1998, P NATL ACAD SCI USA, V95, P9313, DOI 10.1073/pnas.95.16.9313; Patel HM, 2001, BIOCHEMISTRY-US, V40, P9023, DOI 10.1021/bi010519n; Pfeifer BA, 2003, APPL ENVIRON MICROB, V69, P6698, DOI 10.1128/AEM.69.11.6698-6702.2003; Pfeifer BA, 2001, SCIENCE, V291, P1790, DOI 10.1126/science.1058092; PIEPER R, 1995, NATURE, V378, P263, DOI 10.1038/378263a0; Pojer F, 2002, MICROBIOL-SGM, V148, P3901, DOI 10.1099/00221287-148-12-3901; Pootoolal J, 2002, P NATL ACAD SCI USA, V99, P8962, DOI 10.1073/pnas.102285099; Rascher A, 2003, FEMS MICROBIOL LETT, V218, P223, DOI 10.1016/S0378-1097(02)01148-5; Recktenwald J, 2002, MICROBIOL-SGM, V148, P1105, DOI 10.1099/00221287-148-4-1105; Remsing LL, 2002, J AM CHEM SOC, V124, P1606, DOI 10.1021/ja0105156; Roy RS, 1999, NAT PROD REP, V16, P249, DOI 10.1039/a806930a; Schneider TL, 2003, BIOCHEMISTRY-US, V42, P9722, DOI 10.1021/bi034792w; Shen B, 2003, CURR OPIN CHEM BIOL, V7, P285, DOI 10.1016/S1367-5931(03)00020-6; Shin-ya K, 2001, J AM CHEM SOC, V123, P1262, DOI 10.1021/ja005780q; Sieber SA, 2004, ANGEW CHEM INT EDIT, V43, P493, DOI 10.1002/anie.200352787; Sieber SA, 2003, J BACTERIOL, V185, P7036, DOI 10.1128/JB.185.24.7036-7043.2003; Sosio M, 2004, MICROBIOL-SGM, V150, P95, DOI 10.1099/mic.0.26507-0; Sosio M, 2003, CHEM BIOL, V10, P541, DOI 10.1016/S1074-5521(03)00120-0; Sun YH, 2003, CHEM BIOL, V10, P431, DOI 10.1016/S1074-5521(03)00092-9; Tang Y, 2004, PLOS BIOL, V2, P227, DOI 10.1371/journal.pbio.0020031; Thomas MG, 2002, CHEM BIOL, V9, P171, DOI 10.1016/S1074-5521(02)00100-X; Trauger JW, 2001, BIOCHEMISTRY-US, V40, P7092, DOI 10.1021/bi010035r; Trauger JW, 2000, NATURE, V407, P215, DOI 10.1038/35025116; van Wageningen AMA, 1998, CHEM BIOL, V5, P155, DOI 10.1016/S1074-5521(98)90060-6; Walsh C, 2003, J MED CHEM, V46, P3425, DOI 10.1021/jm030257i; Walsh CT, 2001, CURR OPIN CHEM BIOL, V5, P525, DOI 10.1016/S1367-5931(00)00235-0; Weist S, 2002, ANGEW CHEM INT EDIT, V41, P3383, DOI 10.1002/1521-3773(20020916)41:18<3383::AID-ANIE3383>3.0.CO;2-R; Wilkinson B, 2000, CHEM BIOL, V7, P111, DOI 10.1016/S1074-5521(00)00076-4; Wu N, 2001, J AM CHEM SOC, V123, P6465, DOI 10.1021/ja010219t; Yoon YJ, 2002, CHEM BIOL, V9, P203, DOI 10.1016/S1074-5521(02)00095-9; Yu TW, 2002, P NATL ACAD SCI USA, V99, P7968, DOI 10.1073/pnas.092697199	72	451	477	7	173	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1805	1810		10.1126/science.1094318	http://dx.doi.org/10.1126/science.1094318			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031493				2022-12-28	WOS:000220281600041
J	Anderson, MR; Klink, K; Cohrssen, A				Anderson, MR; Klink, K; Cohrssen, A			Evaluation of vaginal complaints	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BACTERIAL VAGINOSIS; NONSPECIFIC VAGINITIS; GARDNERELLA-VAGINALIS; LABORATORY DIAGNOSIS; MENSTRUAL-CYCLE; RISK ASSESSMENT; GRAM STAIN; SYMPTOMS; WOMEN; INFECTIONS	Context Vaginal symptoms are one of the most common reasons for gynecological consultation. Clinicians have traditionally diagnosed vaginal candidiasis, bacterial vaginosis, and vaginal trichomoniasis using some combination of physical examination, pH, the wet mount, and the whiff test. Objectives To evaluate the role of the clinical examination and determine the positive and negative likelihood ratios (LRs) for the diagnosis of vaginal candidiasis, bacterial vaginosis, and vaginal trichomoniasis. Data Sources Using a structured literature review, we abstracted information on sensitivity and specificity for symptoms, signs, and office laboratory procedures, We chose published (1966 to April 2003) articles that appeared in the MEDLINE database and were indexed under the combined search terms of diagnosis with vaginitis, vaginal discharge, candidiasis, bacterial vaginosis, and trichomoniasis. Study Selection Included studies of symptomatic premenopausal women seen in primary care settings. Tests were evaluated only if they would provide diagnostic information during the office visit and were compared with an acceptable criterion standard. Data Extraction All 3 authors extracted the data and computed sensitivity and specificity from each article independently. The absence of standard definitions for symptoms and signs made it impossible to combine results across studies. Data Synthesis Symptoms alone do not allow clinicians to distinguish confidently between the causes of vaginitis. However, a patient's lack of itching makes candidiasis less likely (range of LRs, 0.18 [95% confidence interval {CI), 0.05-0.70] to 0.79 [95% Cl, 0.72-0.87]) and lack of perceived odor makes bacterial vaginosis unlikely (LR,0.07 [95% CI,0.01-0.51]). Similarly, physical examination signs are limited in their diagnostic power. The presence of inflammatory signs is associated with candidiasis (range of LRs, 2.1 [95% Cl, 1.5-2.8] to 8.4 [95% Cl, 2.3-31]). Presence of a "high cheese" odor on examination is predictive of bacterial vaginosis (LR, 3.2 (95% Cl, 2.1 4.7]) while lack of odor is associated with candidiasis (LR, 2.9 [95% Cl, 2.4-5.0]). Office laboratory tests, particularly microscopy of vaginal discharge, are the most useful way of diagnosing these 3 conditions. Conclusions The cause of vaginal complaints may be easily diagnosed when typical findings appear in microscopy. However, the poor performance of individual symptoms, signs, and office laboratory tests often makes it problematic to identify the cause of vaginal symptoms.	Beth Israel Med Ctr, Inst Urban Family Hlth, Dept Family Practice, New York, NY 10003 USA; Columbia Univ, Coll Phys & Surg, Ctr Family Med, New York, NY USA	Harvard University; Beth Israel Deaconess Medical Center; Columbia University	Anderson, MR (corresponding author), Montefiore Family Hlth Ctr, 360 E 193rd St, Bronx, NY 10458 USA.	andersonma@aol.com						ABBOTT J, 1995, ANN EMERG MED, V25, P587, DOI 10.1016/S0196-0644(95)70168-0; Allen-Davis JT, 2002, OBSTET GYNECOL, V99, P18, DOI 10.1016/S0029-7844(01)01670-2; *AM COLL OBST GYN, 1996, TECHN B AM COLL OBST, V226; AMSEL R, 1983, AM J MED, V74, P14, DOI 10.1016/0002-9343(83)91112-9; ANDERSON M, 2002, N AM PRIM CAR RES GR; *ASS PROF GYN OBST, 1996, DIAGN VAG; Bachmann GA, 2000, AM FAM PHYSICIAN, V61, P3090; BENNETT JR, 1989, ANN EMERG MED, V18, P564, DOI 10.1016/S0196-0644(89)80845-5; BERG AO, 1984, JAMA-J AM MED ASSOC, V251, P620, DOI 10.1001/jama.251.5.620; BERGMAN JJ, 1983, J FAM PRACTICE, V16, P509; BICKLEY LS, 1999, DIAGNOSTIC STRATEGIE, P255; BILLINGS EL, 1972, LANCET, V1, P282, DOI 10.1016/s0140-6736(72)90291-7; Blake DR, 1998, PEDIATRICS, V102, P939, DOI 10.1542/peds.102.4.939; BLEKER OP, 1989, EUR J OBSTET GYN R B, V31, P179, DOI 10.1016/0028-2243(89)90179-2; BORCHARDT KA, 1992, GENITOURIN MED, V68, P328; BRISELDEN AM, 1994, J CLIN MICROBIOL, V32, P148, DOI 10.1128/JCM.32.1.148-152.1994; Bro F, 1989, Scand J Prim Health Care, V7, P19, DOI 10.3109/02813438909103665; Burstein GR, 2003, PEDIATR REV, V24, P119, DOI 10.1542/pir.24-4-119; Carlson P, 2000, J CLIN MICROBIOL, V38, P1063, DOI 10.1128/JCM.38.3.1063-1065.2000; Chandeying V, 1998, SEX TRANSM INFECT, V74, P194, DOI 10.1136/sti.74.3.194; Chiu A, 1999, ALLERGY, V54, P184, DOI 10.1034/j.1398-9995.1999.00911.x; DOTY RL, 1975, SCIENCE, V190, P1316, DOI 10.1126/science.1239080; Eckert LO, 1998, OBSTET GYNECOL, V92, P757, DOI 10.1016/S0029-7844(98)00264-6; FULE RP, 1990, INDIAN J MED RES-A, V91, P360; GARDNER HL, 1955, AM J OBSTET GYNECOL, V69, P962, DOI 10.1016/0002-9378(55)90095-8; GWYTHER RE, 1986, J FAM PRACTICE, V23, P487; HOLST E, 1987, EUR J CLIN MICROBIOL, V6, P536, DOI 10.1007/BF02014242; Karasz A, 2003, SOC SCI MED, V56, P1013, DOI 10.1016/S0277-9536(02)00092-8; KENT HL, 1991, AM J OBSTET GYNECOL, V165, P1168, DOI 10.1016/S0002-9378(12)90722-X; KRIEGER JN, 1988, JAMA-J AM MED ASSOC, V259, P1223, DOI 10.1001/jama.259.8.1223; LIVENGOOD CH, 1990, AM J OBSTET GYNECOL, V163, P515, DOI 10.1016/0002-9378(90)91187-H; Ludman B G, 1999, J Obstet Gynecol Neonatal Nurs, V28, P359, DOI 10.1111/j.1552-6909.1999.tb02003.x; Mayaud P, 1998, SEX TRANSM INFECT, V74, pS77; MOGHISSI KS, 1972, AM J OBSTET GYNECOL, V114, P405, DOI 10.1016/0002-9378(72)90617-5; MOU S, 2003, CONNS CURRENT THERAP, P1149; Mulley AG, 2000, PRIMARY CARE MED OFF, P702, DOI 10.1001/jama.1995.03520430082051; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; ODOWD TC, 1987, J ROY COLL GEN PRACT, V37, P59; Priestley CJF, 1997, GENITOURIN MED, V73, P23; Ryan CA, 1998, SEX TRANSM INFECT, V74, pS59; Ryu JS, 1999, YONSEI MED J, V40, P56, DOI 10.3349/ymj.1999.40.1.56; SCHAAF VM, 1990, ARCH INTERN MED, V150, P1929, DOI 10.1001/archinte.150.9.1929; *SEATTL STD, EX VAG WET PREPS; Shaqra QMA, 2001, CYTOBIOS, V105, P35; Sobel JD, 1997, NEW ENGL J MED, V337, P1896, DOI 10.1056/NEJM199712253372607; SPIEGEL CA, 1983, J CLIN MICROBIOL, V18, P170, DOI 10.1128/JCM.18.1.170-177.1983; STUARTHARRIS C, 1983, J ANTIMICROB CHEMOTH, V12, P1; WATHNE B, 1994, ACTA OBSTET GYN SCAN, V73, P802, DOI 10.3109/00016349409072509; Wiesenfeld HC, 1999, AM J OBSTET GYNECOL, V181, P39, DOI 10.1016/S0002-9378(99)70433-3	49	186	205	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	2004	291	11					1368	1379		10.1001/jama.291.11.1368	http://dx.doi.org/10.1001/jama.291.11.1368			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	802PF	15026404				2022-12-28	WOS:000220174700031
J	Bobrie, G; Chatellier, G; Genes, N; Clerson, P; Vaur, L; Vaisse, L; Menard, J; Mallion, JM				Bobrie, G; Chatellier, G; Genes, N; Clerson, P; Vaur, L; Vaisse, L; Menard, J; Mallion, JM			Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WHITE-COAT HYPERTENSION; MILD HYPERTENSION; HOME; REPRODUCIBILITY; METAANALYSIS; FEASIBILITY; MORTALITY; VALUES; TRIALS; ADULTS	Context Blood pressure (BP) measurement in clinicians' offices with a mercury sphygmomanometer has numerous drawbacks. In contrast, the use of home BP measurement improves measurement precision and reproducibility. However, data about its prognostic value are lacking. Objective To assess the prognostic value of home vs off ice BP measurement by general practitioners in a European population of elderly patients being treated for hypertension. Design, Setting, and Participants Office and home BP and cardiac risk factors were measured at baseline in a cohort of 4939 treated hypertensive patients (mean age, 70 [SD, 6.5] years; 48.9% men) who were recruited and followed up by their usual general practitioners without specific recommendations about their management. The cohort was then followed up for a mean of 3.2 (SD, 0.5) years. The thresholds defining uncontrolled hypertension were at least 140/90 mm Hg for office BP and 135/85 mm Hg for home BP. Main Outcome Measures The primary end point was cardiovascular mortality. Secondary end points were total mortality and the combination of cardiovascular mortality, nonfatal myocardial infarction, nonfatal stroke, transient ischemic attack, hospitalization for angina or heart failure, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft surgery. Results At the end of follow-up, clinical status was known for 99.9% of patients. At least 1 cardiovascular event had occurred in 324 (incidence, 22.2/1000 patient-years). For BP self-measurement at home, each 10-mm Hg increase in systolic BP increased the risk of a cardiovascular event by 17.2% (95% confidence interval [CI], 11.0%-23.8%) and each 5-mm Hg increase in diastolic BP increased that risk by 11.7% (95% Cl, 5.7%-18.1%). Conversely, for the same increase in BP observed using office measurement, there was no significant increase in the risk of a cardiovascular event. In a multivariable model with patients having controlled hypertension (normal home and off ice BP) as the referent, the hazard ratio of cardiovascular events was 1.96 (95% Cl, 1.27-3.02) in patients with uncontrolled hypertension (high BP with both measurement methods), 2.06 (95% Cl, 1.22-3.47) in patients with normal office BID and elevated home BP, and 1.18 (95% Cl, 0.67-2.10) in patients with elevated office BP and normal home BP. Conclusions our findings suggest that home BP measurement has a better prognostic accuracy than office BP measurement. Blood pressure should systematically be measured at home in patients receiving treatment for hypertension.	Hop Europeen Georges Pompidou, Serv Hypertens Arterielle, F-75908 Paris 15, France; Hop Europeen Georges Pompidou, Serv Sante Publ & Informat Med, F-75908 Paris, France; Lab Aventis, Paris, France; Interphase Orgametrie, Wattrelos, France; Hop Enfants La Timone, Serv Med Interne, Marseille, France; CHU Grenoble, Serv Cardiol & Hyertens Arterielle, F-38043 Grenoble, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Sanofi-Aventis; Sanofi France; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Bobrie, G (corresponding author), Hop Europeen Georges Pompidou, Serv Hypertens, 20 Rue Leblanc, F-75908 Paris 15, France.	guillaume.bobrie@hop.egp.ap-hop-paris.fr						Bjorklund K, 2003, CIRCULATION, V107, P1297, DOI 10.1161/01.CIR.0000054622.45012.12; Bobrie G, 2001, ARCH INTERN MED, V161, P2205, DOI 10.1001/archinte.161.18.2205; Chalmers J, 1999, J HYPERTENS, V17, P151; Chatellier G, 1996, AM J HYPERTENS, V9, P644, DOI 10.1016/0895-7061(96)00018-0; CHATELLIER G, 1995, HYPERTENSION, V25, P294, DOI 10.1161/01.HYP.25.2.294; Clement DL, 2003, NEW ENGL J MED, V348, P2407, DOI 10.1056/NEJMoa022273; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DENOLLE T, 1995, ARCH MAL COEUR VAISS, V88, P1165; Khattar RS, 1998, CIRCULATION, V98, P1892, DOI 10.1161/01.CIR.98.18.1892; LARKIN KT, 1998, BLOOD PRESS MONIT, V3, P247; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Little P, 2002, BRIT MED J, V325, P258, DOI 10.1136/bmj.325.7358.258; Liu JE, 1999, ANN INTERN MED, V131, P564, DOI 10.7326/0003-4819-131-8-199910190-00003; Mancia G, 2002, J HYPERTENS, V20, P579, DOI 10.1097/00004872-200204000-00006; Mengden T, 1998, AM J HYPERTENS, V11, P1413, DOI 10.1016/S0895-7061(98)00241-6; O'Brien, 1996, Blood Press Monit, V1, P55; Ohkubo T, 1998, J HYPERTENS, V16, P971, DOI 10.1097/00004872-199816070-00010; Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8; PERLOFF D, 1989, J HYPERTENS       S3, V7, P3; Pickering T G, 1999, Blood Press Monit, V4, P333, DOI 10.1097/00126097-199905000-00006; Pickering TG, 2002, HYPERTENSION, V40, P795, DOI 10.1161/01.HYP.0000038733.08436.98; Selenta C, 2000, ARCH FAM MED, V9, P533, DOI 10.1001/archfami.9.6.533; Stergiou GS, 2002, J HYPERTENS, V20, P1987, DOI 10.1097/00004872-200210000-00018; Thijs L, 1998, ARCH INTERN MED, V158, P481, DOI 10.1001/archinte.158.5.481; Vaisse B, 2000, ARCH MAL COEUR VAISS, V93, P963; VERDECCHIA P, 1994, HYPERTENSION, V24, P793, DOI 10.1161/01.HYP.24.6.793; Wing LMH, 2002, J HYPERTENS, V20, P639, DOI 10.1097/00004872-200204000-00020	28	635	662	0	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	2004	291	11					1342	1349		10.1001/jama.291.11.1342	http://dx.doi.org/10.1001/jama.291.11.1342			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	802PF	15026401	Bronze			2022-12-28	WOS:000220174700028
J	Smitz, J				Smitz, J			Oocyte developmental competence after heterotopic transplantation of cryopreserved ovarian tissue	LANCET			English	Editorial Material							AUTOGRAFTS		Free Univ Brussels, Ctr Reprod Med, Follicle Biol Lab, B-1090 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Smitz, J (corresponding author), Free Univ Brussels, Ctr Reprod Med, Follicle Biol Lab, B-1090 Brussels, Belgium.	johan.smitz@az.vulb.ac.be		Smitz, Johan/0000-0002-5857-6542				Aubard Y, 1999, HUM REPROD, V14, P2149, DOI 10.1093/humrep/14.8.2149; Critchley Hilary O D, 2002, Hum Fertil (Camb), V5, P61, DOI 10.1080/1464727022000198942; Gook DA, 2001, HUM REPROD, V16, P417, DOI 10.1093/humrep/16.3.417; GOSDEN RG, 1994, HUM REPROD, V9, P597, DOI 10.1093/oxfordjournals.humrep.a138556; GOUGEON A, 1986, HUM REPROD, V1, P81, DOI 10.1093/oxfordjournals.humrep.a136365; Hubner K, 2003, SCIENCE, V300, P1251, DOI 10.1126/science.1083452; Larsen EC, 2003, J CLIN ENDOCR METAB, V88, P5307, DOI 10.1210/jc.2003-030352; MERTENS AC, 2000, CANCER, V95, P2431; Salle B, 2003, FERTIL STERIL, V80, P172, DOI 10.1016/S0015-0282(03)00554-5; Schnorr J, 2002, HUM REPROD, V17, P612, DOI 10.1093/humrep/17.3.612; SHAW JM, IN PRESS BIOL PATHOL; Smitz JEJ, 2002, REPRODUCTION, V123, P185, DOI 10.1530/rep.0.1230185	12	8	10	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	2004	363	9412					832	833		10.1016/S0140-6736(04)15769-3	http://dx.doi.org/10.1016/S0140-6736(04)15769-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15031021				2022-12-28	WOS:000220231500002
J	Seagroatt, V; Goldacre, M				Seagroatt, V; Goldacre, M			Hospital mortality league tables: influence of place of death	BRITISH MEDICAL JOURNAL			English	Article									Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England	University of Oxford	Seagroatt, V (corresponding author), Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England.	valerie.seagroatt@dphpc.ox.ac.uk						ELLIS R, 2002, MAIL SUNDAY     0310; Jacobson B, 2003, BRIT MED J, V326, P777, DOI 10.1136/bmj.326.7393.777; *STAT OFF, 2000, 33 STAT OFF; 2003, GOOD HOSP GUIDE	4	9	10	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 22	2004	328	7450					1235	1236		10.1136/bmj.38058.517118.47	http://dx.doi.org/10.1136/bmj.38058.517118.47			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	824HL	15051619	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000221677200021
J	Als-Nielsen, B; Gluud, LL; Gluud, C				Als-Nielsen, B; Gluud, LL; Gluud, C			Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED CLINICAL-TRIAL; DOUBLE-BLIND; CIRRHOTIC-PATIENTS; LACTULOSE; LACTITOL; NEOMYCIN; EFFICACY; PLACEBO; QUALITY; METAANALYSIS	Objective To assess the effects of non-absorbable disaccharides (lactulose and lactitol) in patients with hepatic encephalopathy. Data sources Cochrane Hepato-Biliary Group controlled trials register, Cochrane Library, Medline, and Embase until March 2003; reference lists of relevant articles; authors and pharmaceutical companies. Review methods Randomised trials that compared non-absorbable disaccharides with placebo, no intervention, or antibiotics for hepatic encephalopathy were included. The primary outcome measures were no improvement of hepatic encephalopathy and all cause mortality. Results 22 trials were included. Compared with placebo or no intervention, non-absorbable disaccharides seemed to reduce the risk of no improvement in patients with hepatic encephalopathy (relative risk 0.62, 95% confidence interval 0.46 to 0.84, six trials). However, high quality trials found no significant effect (0.92, 0.42 to 2.04, two trials). Compared with placebo or no intervention, non-absorbable disaccharides had no significant effect on mortality (0.41, 0.02 to 8.68, four trials). Non-absorbable disaccharides were inferior to antibiotics in reducing the risk of no improvement (1.24, 1.02 to 1.50, 10 trials) and lowering blood ammonia concentration (weighted mean difference 2.35 mumol/l, 0.06 mumol/l to 13.45 mumol/l, 10 trials). There was no significant difference in mortality (0.90, 0.48 to 1.67, five trials). Conclusions There is insufficient. evidence to support or refute the use of non-absorbable disaccharides for hepatic encephalopathy. Antibiotics were superior to non-absorbable disaccharides in improving hepatic encephalopathy, but it is unclear whether this difference is clinically important. Non-absorbable disaccharides should not serve as comparator in randomised trials on hepatic encephalopathy.	Univ Copenhagen Hosp, Dept 7102, HS Rigshosp,Ctr Clin Intervent Res, Cochrane Hepatobiliary Grp,Copenhagen Trial Unit, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Als-Nielsen, B (corresponding author), Univ Copenhagen Hosp, Dept 7102, HS Rigshosp,Ctr Clin Intervent Res, Cochrane Hepatobiliary Grp,Copenhagen Trial Unit, DK-2100 Copenhagen, Denmark.	bodil.a@ctu.rh.dk	Gluud, Christian/AAY-1027-2021; Gluud, Lise L/AAY-2120-2020; Gluud, Christian/HGB-3191-2022	Gluud, Christian/0000-0002-8861-0799; Gluud, Lise L/0000-0002-9462-4468; 				ALSNIELSEN B, 2001, COCHRANE LIB; Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; ATTERBURY CE, 1978, AM J DIG DIS, V23, P398, DOI 10.1007/BF01072921; BIRCHER J, 1966, LANCET, V1, P890; BLANC P, 1992, HEPATOLOGY, V15, P222, DOI 10.1002/hep.1840150209; BLANC P, 1994, GASTROEN CLIN BIOL, V18, P1063; Blanc P, 1993, GUT, V34, P46; Blei AT, 2001, AM J GASTROENTEROL, V96, P1968, DOI 10.1016/S0002-9270(01)02527-8; BUCCI L, 1993, CURR MED RES OPIN, V13, P109, DOI 10.1185/03007999309111539; CONN HO, 1977, GASTROENTEROLOGY, V72, P573; Conn HO, 1997, SCAND J GASTROENTERO, V32, P88, DOI 10.1080/00365521.1997.11720727; Conn HO, 1979, HEPATIC COMA SYNDROM, P323; CORAZZA GR, 1982, INT J CLIN PHARM RES, V2, P7; DAWSON AM, 1957, LANCET, V2, P1263; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dhiman RK, 2000, DIGEST DIS SCI, V45, P1549, DOI 10.1023/A:1005556826152; ELKINGTON SG, 1969, NEW ENGL J MED, V281, P408, DOI 10.1056/NEJM196908212810803; Fera G., 1993, EUR J CLIN RES, V4, P57; FESTI D, 1993, CURR THER RES CLIN E, V54, P598, DOI 10.1016/S0011-393X(05)80681-2; GAMMA C, 1993, DIGEST DIS SCI, V38, P916; GERMAIN L, 1973, ARCH FR MAL APP DIG, V62, P293; GITLIN N, 1996, HEPATOLOGY TXB LIVER, P605; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; Hunter P A, 2001, Drug News Perspect, V14, P309; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Kircheis G, 1997, HEPATOLOGY, V25, P1351, DOI 10.1002/hep.510250609; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; LI Z, 1999, XI YI JIE HE ZA ZHI, V9, P13; Liao C, 2000, HEPATOLOGY, V32, P721, DOI 10.1053/jhep.2000.17967; Loguercio C, 2003, Minerva Gastroenterol Dietol, V49, P53; Mas A, 2003, J HEPATOL, V38, P51, DOI 10.1016/S0168-8278(02)00350-1; Massa P., 1993, EUR J CLIN RES, V4, P7; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Morgan M, 1999, OXFORD TXB CLIN HEPA, P1923; MORGAN MY, 1987, J HEPATOL, V4, P236, DOI 10.1016/S0168-8278(87)80086-7; MORGAN MY, 1987, HEPATOLOGY, V7, P1278, DOI 10.1002/hep.1840070617; ORLANDI F, 1981, DIGEST DIS SCI, V26, P498, DOI 10.1007/BF01308097; Piaggio G, 2001, STAT MED, V20, P3571, DOI 10.1002/sim.1078; Pocock SJ., 1983, CLIN TRIALS PRACTICA; RODGERS JB, 1973, AM J GASTROENTEROL, V60, P459; RUSSO M, 1989, CURR THER RES CLIN E, V45, P133; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Shi H, 1997, CHIN J DIGESTION, V17, P221; SIMMONS F, 1970, GASTROENTEROLOGY, V59, P827; Stauch S, 1998, J HEPATOL, V28, P856, DOI 10.1016/S0168-8278(98)80237-7; STRAUSS E, 1992, HEPATO-GASTROENTEROL, V39, P542; URIBE M, 1987, HEPATOLOGY, V7, P639, DOI 10.1002/hep.1840070404; Watanabe A, 1997, HEPATOLOGY, V26, P1410; WEISSENBORN K, 1992, BAILLIERE CLIN GASTR, V6, P609, DOI 10.1016/0950-3528(92)90041-C; Weissenborn K, 2002, HEPATOLOGY, V35, P494, DOI 10.1053/jhep.2002.31552; 黎植昌, 1999, [中国药物化学杂志, Chinese Journal of Medicinal Chemistry], V9, P13; 1993, DIG DIS SCI, V38, P916	52	238	254	1	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 1	2004	328	7447					1046	1050		10.1136/bmj.38048.506134.EE	http://dx.doi.org/10.1136/bmj.38048.506134.EE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817JT	15054035	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000221174500016
J	Fikree, FF; Pasha, O				Fikree, FF; Pasha, O			Role of gender in health disparity: the South Asian context	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RHEUMATIC HEART-DISEASE; WOMENS AUTONOMY; INDIA; MORTALITY; IMMUNIZATION; COMMUNITY; CHILDREN; SEEKING; ANEMIA; GIRLS	South Asia's girls and women do not have the same life advantage as their Western counterparts. A human rights based approach may help to overcome gender related barriers and improve the wellbeing of men, women, and children.	Populat Council, Int Program Div, New York, NY 10017 USA; Emory Univ, Rollins Sch Publ Hlth, Womens & Childrens Ctr, Atlanta, GA 30322 USA	Population Council; Emory University; Rollins School Public Health	Fikree, FF (corresponding author), Populat Council, Int Program Div, 1 Dag Hammarskjold Plaza, New York, NY 10017 USA.	ffikree@popcouncil.org		Pasha, Omrana/0000-0003-4046-3918				ABBASI KA, 1998, PAK PAEDIAT J, V21, P121; AGARWAL AK, 1995, J ROY SOC HEALTH, V115, P303, DOI 10.1177/146642409511500509; Ahmed F, 2000, PUBLIC HEALTH NUTR, V3, P385, DOI 10.1017/S1368980000000446; Allahbadia GN, 2002, J ASSIST REPROD GEN, V19, P411, DOI 10.1023/A:1016859622724; Arnold F, 1998, POP STUD-J DEMOG, V52, P301, DOI 10.1080/0032472031000150486; BANTHIA JK, 2001, PROVISIONAL POPULATI; Barker G., 2000, WHAT BOYS LIT REV HL; Barua A, 2001, REPROD HEALTH MATTER, V9, P53, DOI 10.1016/S0968-8080(01)90008-4; Bentley ME, 2003, EUR J CLIN NUTR, V57, P52, DOI 10.1038/sj.ejcn.1601504; BHAT PNM, 2001, 24 INT UN SCI STUD P; BHATIA JC, 1993, STUD FAMILY PLANN, V24, P310, DOI 10.2307/2939224; BINDRA S, 2003, CABLE NEWS NETW 0707; Bloom SS, 2001, DEMOGRAPHY, V38, P67, DOI 10.1353/dem.2001.0001; Brockington I, 2001, INT CLIN PSYCHOPHARM, V16, pS7, DOI 10.1097/00004850-200103002-00003; Choudhury KK, 2000, J HEALTH POPUL NUTR, V18, P123; COALE AJ, 1991, POPUL DEV REV, V17, P517, DOI 10.2307/1971953; FIKREE FF, 2002, STATE WORLDS NEWBORN; FILMER D, 1867 WORLD BANK; George S.M., 1997, REPROD HEALTH MATTER, V5, P124, DOI [DOI 10.1016/S0968-8080(97)90093-8, 10.1016/S0968-8080(97)90093-8]; Hasan Imtiaz Jehan, 2000, JPMA (Journal of the Pakistan Medical Association), V50, P405; *INT I POP SCI OP, 2000, ORC MACRO NAT FAM HL; Jejeebhoy SJ, 2001, POPUL DEV REV, V27, P687, DOI 10.1111/j.1728-4457.2001.00687.x; Kabir ZN, 2003, ARCH GERONTOL GERIAT, V37, P77, DOI 10.1016/S0167-4943(03)00019-0; Khan AJ, 2000, B WORLD HEALTH ORGAN, V78, P956; Khan Murad M, 2002, Crisis, V23, P104, DOI 10.1027//0227-5910.23.3.104; Kumar V, 2003, BURNS, V29, P31, DOI 10.1016/S0305-4179(02)00235-8; Narayan D., 2000, VOICES POOR CAN ANYO, DOI DOI 10.1002/JID.793; Oberman M, 2003, INT J LAW PSYCHIAT, V26, P493, DOI 10.1016/S0160-2527(03)00083-9; Pande RP, 2003, SOC SCI MED, V57, P2075, DOI 10.1016/S0277-9536(03)00085-6; Pande RP, 2003, DEMOGRAPHY, V40, P395, DOI 10.1353/dem.2003.0029; Pandey A, 2002, J HEALTH POPUL NUTR, V20, P306; Prakash IJ, 1997, INDIAN J MED RES, V106, P396; RETHERFORD RD, 2003, NATL FAM HLTH SURVEY, P17; Rizvi SF, 2004, HEART, V90, P394, DOI 10.1136/hrt.2003.025981; Ronsmans C, 1999, LANCET, V354, P1448, DOI 10.1016/S0140-6736(99)03222-5; SEN A, 1992, BRIT MED J, V304, P587, DOI 10.1136/bmj.304.6827.587; Shaikh S, 2003, EUR J CLIN NUTR, V57, P389, DOI 10.1038/sj.ejcn.1601571; Sharma DC, 2003, LANCET, V362, P1553, DOI 10.1016/S0140-6736(03)14780-0; SINGH J, 2000, BBC             0711; SUGATHAN KS, 2001, NATL FAMILY HLTH SUR, P2; TIWARI BK, 1998, REG CONS NUTR STAT A; *UN FPA, 2003, STAT WORLDS POP MAK; *UNICEF UNAIDS WHO, 2002, YOUNG PEOPL HIV AIDS; Watts C, 2002, LANCET, V359, P1232, DOI 10.1016/S0140-6736(02)08221-1; WHO, 2003, GEND HLTH AG; *WHO, WORLD HLTH REP 2003; *WHO, GEND HIV AIDS; *WHO SE AS REG OFF, 2000, WOM SE AS HLTH PROF	48	128	128	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	2004	328	7443					823	826		10.1136/bmj.328.7443.823	http://dx.doi.org/10.1136/bmj.328.7443.823			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	811CG	15070642	Green Published			2022-12-28	WOS:000220749400025
J	Subramanian, SV; Nandy, S; Kelly, M; Gordon, D; Smith, GD				Subramanian, SV; Nandy, S; Kelly, M; Gordon, D; Smith, GD			Patterns and distribution of tobacco consumption in India: cross sectional multilevel evidence from the 1998-9 national family health survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SMOKELESS TOBACCO; ALCOHOL-DRINKING; SMOKING; CANCER; EPIDEMIOLOGY; PHARYNGEAL; ASIA; RISK; MEN	Objective To investigate the demographic, socioeconomic, and geographical distribution of tobacco consumption in India. Design Multilevel cross sectional analysis of the 1998-9 Indian national family health survey of 301984 individuals in 92 447 households in 3215 villages in 440 districts in 26 states. Setting Indian states. Participants 301984 adults (greater than or equal to 18 years). Main outcome measures Dichotomous variable for smoking and chewing tobacco for each respondent (1 if yes, 0 if no) as well as a combined measure of whether an individual smokes, chews tobacco, or both. Results Smoking and chewing tobacco are systematically associated with socioeconomic markers at the individual and household level: Individuals with no education are 2.69 times more likely to smoke and chew tobacco than those with postgraduate education. Households belonging to the lowest fifth of a standard of living index were 2:54 times more likely to consume tobacco than those in the highest fifth. Scheduled tribes (odds ratio 1.23, 95% confidence interval 1.18 to 1.29) and scheduled castes (1.19,1:16 to 1.23) were more likely to consume tobacco than other caste groups. The socioeconomic differences are more marked for smoking than for chewing tobacco. Socioeconomic markers and demographic characteristics of individuals and households do not account fully for the differences at the level of state, district, and village in smoking and chewing tobacco, with state accounting for the bulk of the variation in tobacco consumption. Conclusion The distribution of tobacco consumption is likely to maintain, and perhaps increase, the current considerable socioeconomic differentials in health in India. Interventions aimed at influencing change in tobacco consumption should consider the socioeconomic and geographical determinants of people's susceptibility to consume tobacco.	Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA; Univ Bristol, Sch Policy Studies, Bristol BS8 1TH, Avon, England; Univ London, Inst Educ, Social Sci Res Unit, London WC1E 7HU, England; Univ Bristol, Dept Social Med, Bristol BS8 1TH, Avon, England	Harvard University; Harvard T.H. Chan School of Public Health; University of Bristol; University of London; University College London; UCL Institute of Education; University of Bristol	Subramanian, SV (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, 677 Huntington Ave,KRESGE 7th Floor, Boston, MA 02115 USA.	svsubram@hsph.harvard.edu	Kelly-Irving, Michelle/G-3151-2010; Davey Smith, George/A-7407-2013; Kelly Irving, Michelle/AAA-5052-2022	Kelly-Irving, Michelle/0000-0001-5749-4791; Davey Smith, George/0000-0002-1407-8314; Kelly Irving, Michelle/0000-0001-5749-4791; Nandy, Shailen/0000-0003-1066-9181				Chaturvedi H. K., 1998, Southeast Asian Journal of Tropical Medicine and Public Health, V29, P66; Critchley JA, 2003, THORAX, V58, P435, DOI 10.1136/thorax.58.5.435; Gajalakshmi V, 2003, INT J CANCER, V107, P441, DOI 10.1002/ijc.11377; Gajalakshmi V, 2003, LANCET, V362, P507, DOI 10.1016/S0140-6736(03)14109-8; GIOVINO GA, 1995, EPIDEMIOL REV, V17, P48, DOI 10.1093/oxfordjournals.epirev.a036185; Goldstein H, 1995, MULTILEVEL STAT MODE, V2nd; Gupta P C, 1996, Tob Control, V5, P114, DOI 10.1136/tc.5.2.114; Gupta PC, 2003, RESPIROLOGY, V8, P419, DOI 10.1046/j.1440-1843.2003.00507.x; HIRAYAMA T, 1966, B WORLD HEALTH ORGAN, V34, P41; *IARC, 1985, TOB SMOK MON EV CARC; INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES (IIPS) & ORC MACRO, 2000, NAT FAM HLTH SURV 19; JENKS GF, 1971, ANN ASSOC AM GEOGR, V61, P217, DOI 10.1111/j.1467-8306.1971.tb00779.x; Jha P, 2002, AM J PUBLIC HEALTH, V92, P1002, DOI 10.2105/AJPH.92.6.1002; JOSEPH DT, 1992, CONTROL OF TOBACCO-RELATED CANCERS AND OTHER DISEASES, P345; Kumar S, 2000, LANCET, V356, P1089, DOI 10.1016/S0140-6736(05)74536-0; Moore SR, 2000, ORAL DIS, V6, P65; RASBASH J, 2000, USERS GUIDE MLWIN VE; Shimkhada R, 2003, B WORLD HEALTH ORGAN, V81, P48; SMITH GD, 2004, INEQUALITIES HLTH IN; Subramanian S. V., 2003, Neighborhoods and health, P65; World Health Organization, 1997, TOB HLTH GLOB STAT R; Znaor A, 2003, INT J CANCER, V105, P681, DOI 10.1002/ijc.11114	22	160	161	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	2004	328	7443					801	806		10.1136/bmj.328.7443.801	http://dx.doi.org/10.1136/bmj.328.7443.801			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	811CG	15070637	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000220749400020
J	Scott, JC				Scott, JC			Is there an immortal memory?	SCIENCE			English	Editorial Material									IBM Corp, Almaden Res Ctr, San Jose, CA 95120 USA	International Business Machines (IBM)	Scott, JC (corresponding author), IBM Corp, Almaden Res Ctr, 650 Harry Rd, San Jose, CA 95120 USA.	jcscott@almaden.ibm.com						Kornilovitch PE, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.245413; Krieger JH, 2001, SYNTHETIC MET, V122, P199, DOI 10.1016/S0379-6779(00)01354-0; Ma D, 2000, ADV MATER, V12, P1063, DOI 10.1002/1521-4095(200007)12:14<1063::AID-ADMA1063>3.0.CO;2-9; Ma LP, 2003, APPL PHYS LETT, V82, P1419, DOI 10.1063/1.1556555; Maimon J, 2001, AEROSP CONF PROC, P2289, DOI 10.1109/AERO.2001.931188; Mitkova M, 2002, J NON-CRYST SOLIDS, V299, P1023, DOI 10.1016/S0022-3093(01)01068-7; Moller S, 2003, NATURE, V426, P166, DOI 10.1038/nature02070; Parkin S, 2003, P IEEE, V91, P661, DOI 10.1109/JPROC.2003.811807; Reed MA, 2001, APPL PHYS LETT, V78, P3735, DOI 10.1063/1.1377042; Rossel C, 2001, J APPL PHYS, V90, P2892, DOI 10.1063/1.1389522; Taylor DM, 2001, J APPL PHYS, V90, P306, DOI 10.1063/1.1379564; Wachowiak A, 2002, SCIENCE, V298, P577, DOI 10.1126/science.1075302	12	181	226	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					62	63		10.1126/science.1095520	http://dx.doi.org/10.1126/science.1095520			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15064410				2022-12-28	WOS:000220567900034
J	Milpied, N; Deconinck, E; Gaillard, F; Delwail, V; Foussard, C; Berthou, C; Gressin, R; Lucas, V; Colombat, P; Harousseau, JL				Milpied, N; Deconinck, E; Gaillard, F; Delwail, V; Foussard, C; Berthou, C; Gressin, R; Lucas, V; Colombat, P; Harousseau, JL		Grp Ouest-Est Leucemies Autres Malad	Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW-TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; SURVIVAL BENEFIT; THERAPY; REMISSION; CHOP	BACKGROUND: The efficacy of first-line intensive chemotherapy plus transplantation of autologous hematopoietic stem cells in adults with disseminated aggressive lymphoma is unknown. METHODS: We compared high-dose therapy plus autologous stem-cell support with the standard regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in a randomized trial. The patients were 15 to 60 years of age, had untreated aggressive lymphoma, and were at low, low intermediate, or high intermediate risk of death (i.e., a maximum of two adverse prognostic factors) according to the age-adjusted International Prognostic Index. The primary outcome was event-free survival at five years. RESULTS: Of 207 consecutive patients, 197 underwent randomization; 99 were assigned to receive CHOP, and 98 to receive high-dose chemotherapy plus stem-cell transplantation. Overall, 78 percent of the patients completed the assigned treatment; the median follow-up was four years. The estimated event-free survival rate (+/-SD) at five years was significantly higher among patients who received high-dose therapy than among patients who received CHOP (55+/-5 percent vs. 37+/-5 percent, P=0.037). Among patients with a high intermediate risk of death, according to the age-adjusted International Prognostic Index, the five-year survival rate was significantly higher after high-dose therapy than after CHOP (74+/-6 percent vs. 44+/-7 percent, P=0.001). CONCLUSIONS: High-dose chemotherapy with autologous stem-cell support is superior to CHOP in adults with disseminated aggressive lymphoma.	Hop Jean Minjoz, F-25030 Besancon, France; Univ Hosp Nantes, Nantes, France; Hop Jean Bernard, Poitiers, France; Univ Hosp Angers, Angers, France; Univ Hosp Brest, Brest, France; Univ Hosp Grenoble, Grenoble, France; Ctr Hosp Dept Orleans, Orleans, France; Univ Hosp Tours, Tours, France	Universite de Franche-Comte; CHU Besancon; Nantes Universite; CHU de Nantes; CHU Poitiers; Universite de Poitiers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Brest; Universite de Bretagne Occidentale; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Centre Hospitalier Regional d'Orleans; CHU Tours	Milpied, N (corresponding author), CHU Nantes, Hematol Serv, F-44035 Nantes, France.	noel.milpied@chu-nantes.fr	DECONINCK, ERIC/AAF-3647-2021; Remy, GRESSIN/G-7303-2014	DECONINCK, ERIC/0000-0002-6006-8088; Remy, GRESSIN/0000-0002-9188-3501; Milpied, Noel/0000-0002-5177-014X				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Cortelazzo S, 1999, ANN ONCOL, V10, P427, DOI 10.1023/A:1008338607231; ELIAS L, 1978, CANCER, V42, P1705, DOI 10.1002/1097-0142(197810)42:4<1705::AID-CNCR2820420408>3.0.CO;2-P; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FREEDMAN AS, 1993, J CLIN ONCOL, V11, P931, DOI 10.1200/JCO.1993.11.5.931; Gianni AM, 1997, NEW ENGL J MED, V336, P1290, DOI 10.1056/NEJM199705013361804; Gisselbrecht C, 2002, J CLIN ONCOL, V20, P2472, DOI 10.1200/JCO.2002.02.125; GRAY RJ, 1990, BIOMETRICS, V46, P93, DOI 10.2307/2531633; Guglielmi C, 1998, J CLIN ONCOL, V16, P3264, DOI 10.1200/JCO.1998.16.10.3264; GULATI SC, 1988, J CLIN ONCOL, V6, P1303, DOI 10.1200/JCO.1988.6.8.1303; Haioun C, 1997, J CLIN ONCOL, V15, P1131, DOI 10.1200/JCO.1997.15.3.1131; Haioun C, 2000, J CLIN ONCOL, V18, P3025, DOI 10.1200/JCO.2000.18.16.3025; Kaiser U, 1999, BLOOD, V94, p611A; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kluin-Nelemans HC, 2001, JNCI-J NATL CANCER I, V93, P22, DOI 10.1093/jnci/93.1.22; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; NADEMANEE A, 1992, BLOOD, V80, P1130; NIE HH, 1979, SPSS STAT PACKAGE SO; Pettengell R, 1996, J CLIN ONCOL, V14, P586, DOI 10.1200/JCO.1996.14.2.586; PFREUNDSCHUH M, 2002, ANN ONCOL         S2, V13, P27; ROSENBERG SA, 1982, CANCER, V49, P2112; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Santini G, 1998, J CLIN ONCOL, V16, P2796, DOI 10.1200/JCO.1998.16.8.2796; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SIERRA J, 1993, BLOOD, V81, P1968	27	250	273	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2004	350	13					1287	1295		10.1056/NEJMoa031770	http://dx.doi.org/10.1056/NEJMoa031770			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VN	15044639	Bronze			2022-12-28	WOS:000220393900006
J	Bruce, D; Phillips, K; Reid, R; Snadden, D; Harden, R				Bruce, D; Phillips, K; Reid, R; Snadden, D; Harden, R			Revalidation for general practitioners: randomised comparison of two revalidation models	BRITISH MEDICAL JOURNAL			English	Article							EDUCATION; GUIDE; PORTFOLIOS	Objective To compare two models of revalidation for general practitioners. Design Randomised comparison of two revalidation models. Setting Primary care in Tayside, Scotland. Participants 66 Tayside general practitioners (principals and non-principals), 53 of whom completed the revalidation folders. Interventions Two revalidation models: a minimum criterion based model with revalidation as the primary purpose, and an educational outcome model with emphasis on combining revalidation with continuing professional development. Main outcome measures Feasibility and acceptability of each approach and effect on the doctor's continuing professional development. The ability to make a summative judgment on completed models and whether either model would allow patient groups to have confidence in the revalidation process. Results The criterion model was preferred by general practitioners. For both models doctors reported making changes to their practice and felt a positive effect on their continuing professional development. Summative assessment of the folders showed reasonable inter-rater reliability Conclusions The criterion model provides a practical and acceptable model for general practitioners to use when preparing for revalidation.	Tayside Ctr Gen Practice, NHS Educ Scotland, Dundee DD2 4AD, Scotland; Univ No British Columbia, No Med Program, Prince George, BC V2N 4Z9, Canada; Univ British Columbia, No Med Program, Prince George, BC V2N 4Z9, Canada; Univ Dundee, Ctr Med Educ, Dundee, Scotland	NHS Education for Scotland; University of Dundee; University of Northern British Columbia; University of British Columbia; University of Dundee	Bruce, D (corresponding author), Tayside Ctr Gen Practice, NHS Educ Scotland, Dundee DD2 4AD, Scotland.	d.bruce@tcgp.dundee.ac.uk	Snadden, David/ABF-1586-2020	Snadden, David/0000-0002-4818-1184				Ben David MF, 2001, MED TEACH, V23, P535; Bowling A, 2000, RES METHODS HLTH; Buckley G, 1999, BMJ-BRIT MED J, V319, P1145, DOI 10.1136/bmj.319.7218.1145; Chambers R, 1998, BRIT J GEN PRACT, V48, P1551; DAUPHINEE WD, 1994, CERTIFICATION RECERT, P201; *GEN MED COUNC, 1997, YOUR PROF PERF QUEST; General Medical Council, 2003, LIC PRACT REV; GROGAN S, 1995, BRIT J GEN PRACT, V45, P525; Harden RM, 1999, MED TEACH, V21, P546, DOI 10.1080/01421599978951; Pitts J, 1999, MED EDUC, V33, P515, DOI 10.1046/j.1365-2923.1999.00445.x; RAMSEY PG, 1993, JAMA-J AM MED ASSOC, V269, P1655, DOI 10.1001/jama.269.13.1655; *RCGP SCOTL BMA SC, 2003, REV FOLD DOCT WORK C; *ROYAL COLL GEN PR, 2000, METH REC REV GEN PRA; Royal College of General Practitioners, 2002, GOOD MED PRACT GEN P; Southgate L, 1999, BMJ-BRIT MED J, V319, P1180, DOI 10.1136/bmj.319.7218.1180; SPIEGAL N, 1992, BRIT MED J, V304, P231, DOI 10.1136/bmj.304.6821.231; TAYSIDE REVALIDATION	17	11	12	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 20	2004	328	7441					687	691		10.1136/bmj.328.7441.687	http://dx.doi.org/10.1136/bmj.328.7441.687			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VB	15031241	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000220392700024
J	Campbell, MK; Elbourne, DR; Altman, DG				Campbell, MK; Elbourne, DR; Altman, DG		CONSORT Grp	CONSORT statement: extension to cluster randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE; INTERVENTION TRIALS; SYSTEMATIC REVIEWS; QUALITY; PREVENTION; MANAGEMENT; DISEASE; DESIGN; IMPACT; RISK		Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland; London Sch Hyg & Trop Med, Med Stat Unit, London, England; Ctr Stat Med, Oxford, England	University of Aberdeen; University of London; London School of Hygiene & Tropical Medicine; University of Oxford	Campbell, MK (corresponding author), Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland.	m.k.campbell@abdn.ac.uk	Campbell, Marion/ABB-7063-2020	Campbell, Marion/0000-0001-5386-4097				Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; [Anonymous], 1997, Cardiovasc Res, V35, P2; Atienza AA, 2002, EPIDEMIOL REV, V24, P72, DOI 10.1093/epirev/24.1.72; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Butler C, 1996, FAM PRACT, V13, P402, DOI 10.1093/fampra/13.4.402; Campbell M, 2000, J Health Serv Res Policy, V5, P12; Chuang JH, 2000, J AM MED INFORM ASSN, P146; Connelly LB, 2003, CONTROL CLIN TRIALS, V24, P544, DOI 10.1016/S0197-2456(03)00093-X; Devereaux PJ, 2002, CONTROL CLIN TRIALS, V23, P380, DOI 10.1016/S0197-2456(02)00214-3; DIVINE GW, 1992, J GEN INTERN MED, V7, P623, DOI 10.1007/BF02599201; DONNER A, 1990, INT J EPIDEMIOL, V19, P795, DOI 10.1093/ije/19.4.795; Edwards SJL, 1999, BMJ-BRIT MED J, V318, P1407, DOI 10.1136/bmj.318.7195.1407; Egger M, 2001, JAMA-J AM MED ASSOC, V285, P1996, DOI 10.1001/jama.285.15.1996; Elbourne DR, 2001, STAT MED, V20, P489, DOI 10.1002/1097-0258(20010215)20:3<489::AID-SIM806>3.0.CO;2-S; Fayers PM, 2002, PALLIATIVE MED, V16, P69, DOI 10.1191/0269216302pm503xx; Feder G, 1999, BRIT MED J, V318, P1522, DOI 10.1136/bmj.318.7197.1522; Flottorp S, 2002, BMJ-BRIT MED J, V325, P367, DOI 10.1136/bmj.325.7360.367; Grimshaw J, 2000, FAM PRACT, V17, pS11, DOI 10.1093/fampra/17.suppl_1.S11; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; Hutton JL, 2001, STAT MED, V20, P473, DOI 10.1002/1097-0258(20010215)20:3<473::AID-SIM805>3.0.CO;2-D; Isaakidis P, 2003, AM J EPIDEMIOL, V158, P921, DOI 10.1093/aje/kwg232; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Kinmonth AL, 1998, BMJ-BRIT MED J, V317, P1202, DOI 10.1136/bmj.317.7167.1202; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Kroeger A, 2002, BMJ-BRIT MED J, V325, P810, DOI 10.1136/bmj.325.7368.810; MacLennan GS, 2003, CONTROL CLIN TRIALS, V24, p69S; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1992, DOI 10.1001/jama.285.15.1992; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Moher M, 2001, BMJ-BRIT MED J, V322, P1338, DOI 10.1136/bmj.322.7298.1338; Montgomery AA, 2000, BRIT MED J, V320, P686, DOI 10.1136/bmj.320.7236.686; Moore L, 2002, BRIT MED J, V325, P1383, DOI 10.1136/bmj.325.7377.1383; Puffer S, 2003, BMJ-BRIT MED J, V327, P785, DOI 10.1136/bmj.327.7418.785; Rooney BL, 1996, HEALTH EDUC QUART, V23, P48, DOI 10.1177/109019819602300104; SACKETT DL, 1979, NEW ENGL J MED, V301, P1410, DOI 10.1056/NEJM197912273012602; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SIMPSON JM, 1995, AM J PUBLIC HEALTH, V85, P1378, DOI 10.2105/AJPH.85.10.1378; Smeeth L, 2002, CONTROL CLIN TRIALS, V23, P409, DOI 10.1016/S0197-2456(02)00208-8; THOMAS RE, IN PRESS FAM PRACT; Ukoumunne OC, 1999, HLTH TECHNOLOGY ASSE, V3, piii, DOI DOI 10.3310/HTA3050; Wears RL, 2002, ACAD EMERG MED, V9, P330, DOI 10.1197/aemj.9.4.330; Wyatt JC, 1998, BMJ-BRIT MED J, V317, P1041	43	1314	1331	2	38	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 20	2004	328	7441					702	708		10.1136/bmj.328.7441.702	http://dx.doi.org/10.1136/bmj.328.7441.702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VB	15031246	Green Submitted, Green Published, Bronze, Green Accepted			2022-12-28	WOS:000220392700028
J	Gerberding, JL; Morgan, JG; Shepard, JO; Kradin, RL				Gerberding, JL; Morgan, JG; Shepard, JO; Kradin, RL			An 18-year-old man with respiratory symptoms and shock - Influenza A infection with rhabdomyolysis, severe; myoglobinuria; viral tracheobronchitis and pneumonia; virus-associated cardiac changes ("borderline myocarditis") and catecholamine-induced myonecrosis; pericardial effusion. Disseminated intravascular coagulation. Hepatic centrilobular necrosis. Cardiac hypertrophy of unknown cause.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACUTE-RENAL-FAILURE; MYOPERICARDITIS; DISEASE; CHILD		Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Massachusetts Gen Hosp, Cardiac Echo Lab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Centers for Disease Control & Prevention - USA; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University	Gerberding, JL (corresponding author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.							ADAMS CW, 1959, AM J CARDIOL, V4, P56, DOI 10.1016/0002-9149(59)90193-6; Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3; Baroldi G, 2001, INT J LEGAL MED, V115, P142, DOI 10.1007/s004140100229; BERLIN BS, 1974, JAMA-J AM MED ASSOC, V227, P1414; BERRY L, 1991, POSTGRAD MED J, V67, P389, DOI 10.1136/pgmj.67.786.389; Centers for Disease Control and Prevention (CDC) HIPAA Privacy Rule and Public Health, 2003, MMWR-MORBID MORTAL W, V52, P1; Craighead JE, 2000, PATHOLOGY PATHOGENES; Dell KM, 1997, PEDIATR NEPHROL, V11, P363, DOI 10.1007/s004670050299; DIBONA FJ, 1977, J PEDIATR-US, V91, P943, DOI 10.1016/S0022-3476(77)80896-2; DUFLOU J, 1995, AM HEART J, V130, P306, DOI 10.1016/0002-8703(95)90445-X; EDELEN JS, 1974, AM J EPIDEMIOL, V100, P79, DOI 10.1093/oxfordjournals.aje.a112019; Greaves K, 2003, ARCH INTERN MED, V163, P165, DOI 10.1001/archinte.163.2.165; Guarner J, 2000, AM J CLIN PATHOL, V114, P227, DOI 10.1309/HV74-N24T-2K2C-3E8Q; Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355; Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402; Kaiser L, 2003, ARCH INTERN MED, V163, P1667, DOI 10.1001/archinte.163.14.1667; KARJALAINEN J, 1980, ACTA MED SCAND, V207, P27; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; KELLY KJ, 1989, PEDIATRICS, V84, P312; KESSLER HA, 1980, JAMA-J AM MED ASSOC, V243, P461, DOI 10.1001/jama.243.5.461; Lucke B, 1919, ARCH INTERN MED, V24, P154, DOI 10.1001/archinte.1919.00090250027002; Nicholson KG, 2003, LANCET, V362, P1733, DOI 10.1016/S0140-6736(03)14854-4; ONITSUKA H, 2001, J CARDIOL, V37, P317; OSEASOHN R, 1959, NEW ENGL J MED, V260, P509, DOI 10.1056/NEJM195903122601101; PLOTKIN SA, 2004, VACCINES, P339; PROBY CM, 1986, Q J MED, V60, P887; Quach C, 2003, PEDIATRICS, V112, pE197, DOI 10.1542/peds.112.3.e197; Shui I., 2004, Morbidity and Mortality Weekly Report, V52, P1286; Singh U, 1996, CLIN INFECT DIS, V22, P642, DOI 10.1093/clinids/22.4.642; STEVENS KM, 1976, NEW ENGL J MED, V295, P1363, DOI 10.1056/NEJM197612092952407; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; TOLAN RW, 1993, CLIN INFECT DIS, V17, P43, DOI 10.1093/clinids/17.1.43; Warren JD, 2002, MUSCLE NERVE, V25, P332, DOI 10.1002/mus.10053; YELDANDI AV, 1994, HUM PATHOL, V25, P47, DOI 10.1016/0046-8177(94)90170-8; Yoshino M, 2000, INTERNAL MED, V39, P431, DOI 10.2169/internalmedicine.39.431; 2003, MMWR MORB MORTAL WKL, V52, P1254; 2004, MMWR MORB MORTAL WKL, V53, P97; 2004, MMWR MORB MORTAL WKL, V53, P63; 2003, MMWR MORB MORTAL WKL, V52, P526	39	15	16	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 18	2004	350	12					1236	1247		10.1056/NEJMcpc049006	http://dx.doi.org/10.1056/NEJMcpc049006			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803PG	15028828	Bronze			2022-12-28	WOS:000220242400012
J	Schnitzer, JJ; Briggs, SM				Schnitzer, JJ; Briggs, SM			Earthquake relief - The US medical response in Bam, Iran	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Int Med Surg Response Team, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Schnitzer, JJ (corresponding author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.							Briggs SM., 2003, ADV DISASTER MED RES; Leaning J., 1999, HUMANITARIAN CRISES	2	40	41	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	2004	350	12					1174	1176		10.1056/NEJMp048019	http://dx.doi.org/10.1056/NEJMp048019			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803PG	15028821				2022-12-28	WOS:000220242400003
J	Stephenson, AJ; Shariat, SF; Zelefsky, MJ; Kattan, MW; Butler, EB; Teh, BS; Klein, EA; Kupelian, PA; Roehrborn, CG; Pistenmaa, DA; Pacholke, HD; Liauw, SL; Katz, MS; Leibel, SA; Scardino, PT; Slawin, KM				Stephenson, AJ; Shariat, SF; Zelefsky, MJ; Kattan, MW; Butler, EB; Teh, BS; Klein, EA; Kupelian, PA; Roehrborn, CG; Pistenmaa, DA; Pacholke, HD; Liauw, SL; Katz, MS; Leibel, SA; Scardino, PT; Slawin, KM			Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITIVE SURGICAL MARGINS; ANTIGEN DOUBLING TIMES; RADIATION-THERAPY; LOCAL RECURRENCE; RETROPUBIC PROSTATECTOMY; BIOCHEMICAL FAILURE; PROGRESSION; BIOPSY; PSA; ELEVATION	Context Salvage radiotherapy may potentially cure patients with disease recurrence after radical prostatectomy, but previous evidence has suggested that it is ineffective in patients at the highest risk of metastatic disease progression. Objective To delineate patients who may benefit from salvage radiotherapy for prostate cancer recurrence by identifying variables associated with a durable response. Design, Setting, and Patients Retrospective review of a cohort of 501 patients at 5 US academic tertiary referral centers who received salvage radiotherapy between June 1987 and November 2002 for detectable and increasing prostate-specific antigen (PSA) levels after radical prostatectomy. Main Outcome Measure Disease progression after salvage radiotherapy, defined as a serum PSA value greater than or equal to0.1 ng/mL above the postradiotherapy PSA nadir confirmed by a second PSA measurement that was higher than the first by any amount, by,a continued increase in PSA level after treatment, or by the initiation of androgen deprivation therapy after treatment. Results Over a median follow-up of 45 months, 250 patients (50%) experienced disease progression after treatment, 49 (10%) developed distant metastases, 20 (4%) died from prostate cancer, and 21 (4%) died from other or unknown causes. The 4-year progression-free probability (PFP) was 45% (95% confidence interval [01, 40%-50%). By multivariable analysis, predictors of progression were Gleason score of 8 to 10 (hazard ratio [HRI, 2.6; 95% Cl, 1.7-4.1; P<.001), preradiotherapy PSA level greater than 2.0 ng/mL (HR, 2.3; 95% Cl, 1.7-3.2; P<.001), negative surgical margins (HR, 1.9; 95% Cl, 1.4-2.5; P<.001), PSA doubling time (PSADT) of 10 months or less (HR, 1.7; 95% Cl, 1.2-2.2; P=.001), and seminal vesicle invasion (HR, 1.4; 95% Cl, 1.1-1.9; P=.02). Patients with no adverse features had a 4-year PFP of 77% (95% Cl, 64%-91%). When treatment was given for early recurrence (PSA level <= 2.0 ng/mL), patients with Gleason scores of 4 to 7 and a rapid PSADT had a 4-year PFP of 64% (95% Cl, 51%-76%) and of 22% (95% Cl, 6%-38%) when the surgical margins were positive and negative, respectively. Patients with Gleason scores of 8 to 10, positive margins, and receiving early salvage radiotherapy had a 4-year PFP of 81% (95% Cl, 57%-100%) when the PSADT was longer than 10 months and of 37% (95% Cl, 16%-58%) when the PSADT was 10 months or less. Conclusions Gleason score, preradiotherapy PSA level, surgical margins, PSADT, and seminal vesicle invasion are prognostic variables for a durable response to salvage radiotherapy. Selected patients with high-grade disease and/or a rapid PSADT who were previously thought to be destined to develop progressive metastatic disease may achieve a durable response to salvage radiotherapy.	Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; Mem Sloan Kettering Canc Ctr, Dept Urol, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Radiat Oncol, Dallas, TX USA; Cleveland Clin, Dept Urol, Cleveland, OH 44106 USA; Cleveland Clin, Dept Radiat Oncol, Cleveland, OH 44106 USA; Univ Florida, Dept Radiat Oncol, Gainesville, FL USA; Methodist Hosp, Houston, TX 77030 USA	Baylor College of Medicine; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cleveland Clinic Foundation; Cleveland Clinic Foundation; State University System of Florida; University of Florida; The Methodist Hospital System; The Methodist Hospital - Houston	Slawin, KM (corresponding author), Baylor Coll Med, Scott Dept Urol, 6535 Fannin St,Suite 2100, Houston, TX 77030 USA.	kslawin@bcm.tmc.edu	Kupelian, Patrick/AAU-6311-2021; Katz, Matthew/AAA-8899-2019; Katz, Matthew/AAS-7308-2020; Kattan, Michael/AAF-9735-2021	Katz, Matthew/0000-0002-0239-9807; Kattan, Michael/0000-0002-3840-4161; Zelefsky, Michael/0000-0002-6090-6424; Liauw, Stanley/0000-0002-4701-2469	NATIONAL CANCER INSTITUTE [T32CA082088, P50CA092629] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA-82088, CA-92629] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amling CL, 2001, J UROLOGY, V165, P1146, DOI 10.1016/S0022-5347(05)66452-X; Anscher MS, 2000, INT J RADIAT ONCOL, V48, P369, DOI 10.1016/S0360-3016(00)00645-3; Cadeddu JA, 1998, J UROLOGY, V159, P173, DOI 10.1016/S0022-5347(01)64047-3; Chawla AK, 2002, UROLOGY, V59, P726, DOI 10.1016/S0090-4295(02)01540-6; Cher ML, 1998, J UROLOGY, V160, P1387, DOI 10.1016/S0022-5347(01)62545-X; Cox JD, 1999, J CLIN ONCOL, V17, P1155; D'Amico AV, 2002, J CLIN ONCOL, V20, P4567, DOI 10.1200/JCO.2002.03.061; Eastham JA, 2003, J UROLOGY, V170, P2292, DOI 10.1097/01.ju.0000091100.83725.51; Eulau SM, 1998, INT J RADIAT ONCOL, V41, P735, DOI 10.1016/S0360-3016(98)00127-8; Forman JD, 1996, UROLOGY, V47, P382, DOI 10.1016/S0090-4295(99)80457-9; Grossfeld GD, 1998, J UROLOGY, V160, P1398, DOI 10.1016/S0022-5347(01)62548-5; Han M, 2001, UROL CLIN N AM, V28, P555, DOI 10.1016/S0094-0143(05)70163-4; Holmberg L, 2002, NEW ENGL J MED, V347, P781, DOI 10.1056/NEJMoa012794; Hull GW, 2002, J UROLOGY, V167, P528, DOI 10.1016/S0022-5347(01)69079-7; Katz MS, 2003, J CLIN ONCOL, V21, P483, DOI 10.1200/JCO.2003.12.043; Koppie TM, 2001, J UROLOGY, V166, P111, DOI 10.1016/S0022-5347(05)66087-9; Leventis AK, 2001, RADIOLOGY, V219, P432, DOI 10.1148/radiology.219.2.r01ma20432; Leventis AK, 2001, J CLIN ONCOL, V19, P1030, DOI 10.1200/JCO.2001.19.4.1030; Liauw SL, 2003, UROLOGY, V61, P1204, DOI 10.1016/S0090-4295(03)00044-X; LIGHTNER DJ, 1990, J UROLOGY, V144, P921, DOI 10.1016/S0022-5347(17)39623-4; Moul JW, 2000, J UROLOGY, V163, P1632, DOI 10.1016/S0022-5347(05)67511-8; Ornstein DK, 1998, UROLOGY, V52, P1047, DOI 10.1016/S0090-4295(98)00403-8; PARTIN AW, 1994, UROLOGY, V43, P649, DOI 10.1016/0090-4295(94)90180-5; Patel A, 1997, J UROLOGY, V158, P1441, DOI 10.1016/S0022-5347(01)64238-1; Pisansky TM, 2000, J UROLOGY, V163, P845, DOI 10.1016/S0022-5347(05)67817-2; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; Pruthi RS, 1997, UROLOGY, V49, P737, DOI 10.1016/S0090-4295(97)00231-8; Ravery V, 1998, PROSTATE CANCER P D, V1, P321, DOI 10.1038/sj.pcan.4500261; Roberts SG, 2001, MAYO CLIN PROC, V76, P576; Rogers R, 1998, J UROLOGY, V160, P1748, DOI 10.1016/S0022-5347(01)62398-X; Shipley WU, 1999, JAMA-J AM MED ASSOC, V281, P1598, DOI 10.1001/jama.281.17.1598; Song DY, 2002, UROLOGY, V60, P281, DOI 10.1016/S0090-4295(02)01709-0; STEPHENSON AJ, 2003, P AM SOC LIN ONCOL, V22, pA1577; Thomas CT, 2003, J CLIN ONCOL, V21, P1715, DOI 10.1200/JCO.2003.05.138; Valicenti RK, 1998, UROLOGY, V52, P1034, DOI 10.1016/S0090-4295(98)00405-1; Wieder JA, 1998, J UROLOGY, V160, P299, DOI 10.1016/S0022-5347(01)62881-7; WU JJ, 1995, INT J RADIAT ONCOL, V32, P317, DOI 10.1016/0360-3016(95)00083-B; Zelefsky MJ, 2002, INT J RADIAT ONCOL, V53, P1111, DOI 10.1016/S0360-3016(02)02857-2; Zelefsky MJ, 1998, INT J RADIAT ONCOL, V41, P491, DOI 10.1016/S0360-3016(98)00091-1; ZINCKE H, 1994, J UROLOGY, V152, P1850, DOI 10.1016/S0022-5347(17)32399-6	40	528	543	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	2004	291	11					1325	1332		10.1001/jama.291.11.1325	http://dx.doi.org/10.1001/jama.291.11.1325			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	802PF	15026399	Bronze			2022-12-28	WOS:000220174700026
J	Mazor, KM; Simon, SR; Yood, RA; Martinson, BC; Gunter, MJ; Reed, GW; Gurwitz, JH				Mazor, KM; Simon, SR; Yood, RA; Martinson, BC; Gunter, MJ; Reed, GW; Gurwitz, JH			Health plan members' views about disclosure of medical errors	ANNALS OF INTERNAL MEDICINE			English	Article							PATIENT SAFETY; PHYSICIANS ATTITUDES; MALPRACTICE SUITS; RISK-MANAGEMENT; ADVERSE EVENTS; PATIENTS WANT; MISTAKES; DOCTORS; LEGAL; CARE	Background: various authorities and national organizations encourage disclosing medical errors, but there is little information on how patients respond to disclosure. Objective: To examine how the type of error, severity of adverse clinical outcome, and level of disclosure affect patients' responses to error and disclosure. Design: Mail questionnaire survey (8 versions were developed) varying 3 factors in a completely crossed, randomized, factorial design. Each questionnaire included a vignette describing 1) a medical error (failure to check for penicillin allergy or inadequate monitoring of antiepileptic medication); 2) an associated clinical outcome (life-threatening or less serious); and 3) a physician-patient dialogue, with either full disclosure (acceptance of responsibility and an apology) or nondisclosure (expression of regret without acceptance of responsibility or an apology). Setting: New England-based health plan. Participants: Random sample of 1500 adult members received the questionnaire, with a 66% response rate. Measurements: Likelihood of changing physicians, likelihood of seeking legal advice, ratings of patient satisfaction, trust and emotional reaction in response to a vignette and dialogue, and views on medical error and disclosure. Results: Full disclosure reduced the reported likelihood of changing physicians and increased patient satisfaction, trust, and positive emotional response. Full disclosure reduced the reported likelihood of seeking legal advice in only 1 error-and-outcome vignette. In the other vignettes, the percentage of patients indicating that they would seek legal advice was relatively high even with full disclosure. Almost all respondents (98.8%) wanted to be told of errors, most (83%) favored financial compensation if harm occurred, and few (12.7%) favored compensation if no harm occurred. Limitations: since the study was done in the context of a managed care plan in one geographic area, it could not assess whether the results are generalizable to other populations. In addition, it could not determine whether responses to the simulated situations used predict responses to real situations. Conclusions: Patients will probably respond more favorably to physicians who fully disclose medical errors than to physicians who are less forthright, but the specifics of the case and the severity of the clinical outcome also affect patients' responses. In some circumstances, the desire to seek legal advice may not diminish despite full disclosure.	Univ Massachusetts, Meyers Primary Care Inst, Sch Med, Worcester, MA 01605 USA; Fallon Fdn, Worcester, MA 01605 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Pilgrim Hlth Care, Boston, MA 02115 USA; HealthPartners Res Fdn, Minneapolis, MN USA; Lovelace Clin Fdn, Albuquerque, NM USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; HealthPartners Institute for Education & Research	Mazor, KM (corresponding author), Univ Massachusetts, Meyers Primary Care Inst, Sch Med, 630 Plantat St, Worcester, MA 01605 USA.		Martinson, Brian C/AAX-2860-2020	Martinson, Brian C/0000-0002-4255-5595	AHRQ HHS [U18HS10391-01, U18HS11843-01] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS011843, U18HS010391] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Allman J, 1998, HEALTH COMMUN, V10, P175, DOI 10.1207/s15327027hc1002_4; *AM BOARD INT MED, 1989, FIN REP PAT SAT QUES; *AM MED ASS COUNC, 2000, CODE MED ETH CURR OP; ANDERSON LA, 1990, PSYCHOL REP, V67, P1091, DOI 10.2466/pr0.1990.67.3f.1091; Baylis F, 1997, J CLIN ETHIC, V8, P336; BECKMAN HB, 1994, ARCH INTERN MED, V154, P1365, DOI 10.1001/archinte.154.12.1365; Blendon RJ, 2002, NEW ENGL J MED, V347, P1933, DOI 10.1056/NEJMsa022151; BRODSKY SL, 1991, INT J LAW PSYCHIAT, V14, P215, DOI 10.1016/0160-2527(91)90003-6; Finkelstein D, 1997, J CLIN ETHIC, V8, P330; Gallagher TH, 2003, JAMA-J AM MED ASSOC, V289, P1001, DOI 10.1001/jama.289.8.1001; Hebert PC, 2001, DRUG SAFETY, V24, P1095; Hebert PC, 2001, CAN MED ASSOC J, V164, P509; HICKSON GB, 1992, JAMA-J AM MED ASSOC, V267, P1359, DOI 10.1001/jama.267.10.1359; Hingorani M, 1999, BRIT MED J, V318, P640, DOI 10.1136/bmj.318.7184.640; Hobgood C, 2002, ACAD EMERG MED, V9, P1156, DOI 10.1111/j.1553-2712.2002.tb01570.x; HUYCKE LI, 1994, ANN INTERN MED, V120, P792, DOI 10.7326/0003-4819-120-9-199405010-00011; Ioannidis JPA, 2001, J GEN INTERN MED, V16, P325, DOI 10.1046/j.1525-1497.2001.00714.x; *JOINT COMM ACCR H, 2004, 2004 COMPR ASSR MAN; Kapp MB, 2001, J AM GERIATR SOC, V49, P1361, DOI 10.1046/j.1532-5415.2001.49267.x; Kapp MB, 1997, J GEN INTERN MED, V12, P787, DOI 10.1046/j.1525-1497.1997.07167.x; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, DOI 10.17226/9728; Kraman SS, 1999, ANN INTERN MED, V131, P963, DOI 10.7326/0003-4819-131-12-199912210-00010; Lamb RM, 2003, HEALTH AFFAIR, V22, P73, DOI 10.1377/hlthaff.22.2.73; Leape LL, 2002, JAMA-J AM MED ASSOC, V288, P501, DOI 10.1001/jama.288.4.501; Liang BA, 2002, QUAL SAF HEALTH CARE, V11, P64, DOI 10.1136/qhc.11.1.64; MAY ML, 1990, LAW SOC REV, V24, P105, DOI 10.2307/3053788; May T, 2001, KENNEDY INST ETHIC J, V11, P135, DOI 10.1353/ken.2001.0014; MIZRAHI T, 1984, SOC SCI MED, V19, P135, DOI 10.1016/0277-9536(84)90280-6; NOVACK DH, 1989, JAMA-J AM MED ASSOC, V261, P2980, DOI 10.1001/jama.261.20.2980; Ott M, 2001, J Healthc Risk Manag, V21, P27; PENCHANSKY R, 1994, MED CARE, V32, P813, DOI 10.1097/00005650-199408000-00005; Peterson L M, 1990, J Clin Ethics, V1, P207; Porto G G, 2001, J Healthc Risk Manag, V21, P67; Robinson AR, 2002, ARCH INTERN MED, V162, P2186, DOI 10.1001/archinte.162.19.2186; Rosner F, 2000, ARCH INTERN MED, V160, P2089, DOI 10.1001/archinte.160.14.2089; Shojania KG, 2002, JAMA-J AM MED ASSOC, V288, P508, DOI 10.1001/jama.288.4.508; Smith ML, 2000, CAMB Q HEALTHC ETHIC, V9, P38, DOI 10.1017/S0963180100901051; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; Sweet MP, 1997, J CLIN ETHIC, V8, P341; US Census Bureau, 2000, TABL DP 1 PROF GEN D; Vincent C, 2003, NEW ENGL J MED, V348, P1051, DOI 10.1056/NEJMhpr020760; VINCENT C, 1994, LANCET, V343, P1609, DOI 10.1016/S0140-6736(94)93062-7; Vincent C A, 1993, Qual Health Care, V2, P77, DOI 10.1136/qshc.2.2.77; Vincent JL, 1998, INTENS CARE MED, V24, P1251, DOI 10.1007/s001340050758; Volpp KGM, 2003, NEW ENGL J MED, V348, P851, DOI 10.1056/NEJMsb021667; Witman AB, 1996, ARCH INTERN MED, V156, P2565, DOI 10.1001/archinte.156.22.2565; Wu Albert, 2002, Jt Comm J Qual Improv, V28, P197; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089; Wu AW, 1997, J GEN INTERN MED, V12, P770, DOI 10.1046/j.1525-1497.1997.07163.x; 2002, LETS TALK DISCL ADVE; 2001, KENNEDY I ETHICS J, V11, P165	52	194	196	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 16	2004	140	6					409	418		10.7326/0003-4819-140-6-200403160-00006	http://dx.doi.org/10.7326/0003-4819-140-6-200403160-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	803AU	15023706				2022-12-28	WOS:000220204800001
J	Karoshi, MA				Karoshi, MA			Urine pregnancy test and intrauterine inseminations	LANCET			English	Editorial Material									N Middlesex Univ Hosp, Dept Obstet & Gynaecol, London N18 1QX, England		Karoshi, MA (corresponding author), N Middlesex Univ Hosp, Dept Obstet & Gynaecol, London N18 1QX, England.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	2004	363	9406					362	362		10.1016/S0140-6736(04)15437-8	http://dx.doi.org/10.1016/S0140-6736(04)15437-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768TQ	15070566				2022-12-28	WOS:000188590900011
J	You, LC; Cox, RS; Weiss, R; Arnold, FH				You, LC; Cox, RS; Weiss, R; Arnold, FH			Programmed population control by cell-cell communication and regulated killing	NATURE			English	Article							ESCHERICHIA-COLI; GENE-EXPRESSION; VIBRIO-FISCHERI; TOGGLE SWITCH; BACTERIA; NETWORKS; DEATH; CONSTRUCTION; EVOLUTION; ELEMENTS	De novo engineering of gene circuits inside cells is extremely difficult(1-9), and efforts to realize predictable and robust performance must deal with noise in gene expression and variation in phenotypes between cells(10-12). Here we demonstrate that by coupling gene expression to cell survival and death using cell-cell communication, we can programme the dynamics of a population despite variability in the behaviour of individual cells. Specifically, we have built and characterized a 'population control' circuit that autonomously regulates the density of an Escherichia coli population. The cell density is broadcasted and detected by elements from a bacterial quorum-sensing system(13,14), which in turn regulate the death rate. As predicted by a simple mathematical model, the circuit can set a stable steady state in terms of cell density and gene expression that is easily tunable by varying the stability of the cell-cell communication signal. This circuit incorporates a mechanism for programmed death in response to changes in the environment, and allows us to probe the design principles of its more complex natural counterparts.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	California Institute of Technology; California Institute of Technology; Princeton University; Princeton University	Arnold, FH (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.	frances@cheme.caltech.edu		Arnold, Frances H./0000-0002-4027-364X				Ameisen JC, 2002, CELL DEATH DIFFER, V9, P367, DOI 10.1038/sj.cdd.4400950; Atkinson MR, 2003, CELL, V113, P597, DOI 10.1016/S0092-8674(03)00346-5; Becskei A, 2000, NATURE, V405, P590, DOI 10.1038/35014651; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Bulter T, 2004, P NATL ACAD SCI USA, V101, P2299, DOI 10.1073/pnas.0306484101; CHEN W, 1993, GENE, V130, P15, DOI 10.1016/0378-1119(93)90341-Y; Dong YH, 2001, NATURE, V411, P813, DOI 10.1038/35081101; Egland KA, 1999, MOL MICROBIOL, V31, P1197, DOI 10.1046/j.1365-2958.1999.01261.x; Egland KA, 2001, J BACTERIOL, V183, P382, DOI 10.1128/JB.183.1.382-386.2001; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Engelberg-Kulka H, 1999, ANNU REV MICROBIOL, V53, P43, DOI 10.1146/annurev.micro.53.1.43; Farmer WR, 2000, NAT BIOTECHNOL, V18, P533, DOI 10.1038/75398; Fuqua C, 2001, ANNU REV GENET, V35, P439, DOI 10.1146/annurev.genet.35.102401.090913; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Gerchman Y, 2004, P NATL ACAD SCI USA, V101, P2221, DOI 10.1073/pnas.0400473101; Hasty J, 2002, NATURE, V420, P224, DOI 10.1038/nature01257; Isaacs FJ, 2003, P NATL ACAD SCI USA, V100, P7714, DOI 10.1073/pnas.1332628100; Leadbetter JR, 2000, J BACTERIOL, V182, P6921, DOI 10.1128/JB.182.24.6921-6926.2000; Lewis K, 2000, MICROBIOL MOL BIOL R, V64, P503, DOI 10.1128/MMBR.64.3.503-514.2000; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; Schaefer AL, 2000, METHOD ENZYMOL, V305, P288; Steinmoen H, 2002, P NATL ACAD SCI USA, V99, P7681, DOI 10.1073/pnas.112464599; Wall ME, 2004, NAT REV GENET, V5, P34, DOI 10.1038/nrg1244; Weiss R., 2003, Natural Computing, V2, P47, DOI 10.1023/A:1023307812034; Weiss R, 2000, 6 INT M DNA BAS COMP, V2054, P1; WEISS R, 1999, DIM WORKSH EV COMP, P275; Yokobayashi Y, 2002, P NATL ACAD SCI USA, V99, P16587, DOI 10.1073/pnas.252535999; You LC, 2003, BIOINFORMATICS, V19, P435, DOI 10.1093/bioinformatics/btg009; Zhu J, 1999, P NATL ACAD SCI USA, V96, P4832, DOI 10.1073/pnas.96.9.4832	32	486	513	8	195	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 22	2004	428	6985					868	871		10.1038/nature02491	http://dx.doi.org/10.1038/nature02491			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	814CH	15064770				2022-12-28	WOS:000220952300044
J	Carnes, M; Mahoney, JE				Carnes, M; Mahoney, JE			Update in women's health	ANNALS OF INTERNAL MEDICINE			English	Review							ESTROGEN PLUS PROGESTIN; HEART-FAILURE; TASK-FORCE; ASSOCIATION; GUIDELINES		Univ Wisconsin, Sch Med, Gen Clin Res Ctr, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Carnes, M (corresponding author), Univ Wisconsin, Sch Med, Gen Clin Res Ctr, Dept Med, 1300 Univ Ave, Madison, WI 53706 USA.	mlcarnes@facstaff.wisc.edu						Adams KF, 1999, J CARD FAIL, V5, P357; Berg AO, 2002, ANN INTERN MED, V137, P344, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00011; DIOKNO AC, 1986, J UROLOGY, V136, P1022; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Humphrey LL, 2002, ANN INTERN MED, V137, P347, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00012; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Perry G, 1997, NEW ENGL J MED, V336, P525; Rathore SS, 2003, JAMA-J AM MED ASSOC, V289, P871, DOI 10.1001/jama.289.7.871; Remme WJ, 2001, EUR HEART J, V22, P1527, DOI 10.1053/euhj.2001.2783	12	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 6	2004	140	7					538	544		10.7326/0003-4819-140-7-200404060-00014	http://dx.doi.org/10.7326/0003-4819-140-7-200404060-00014			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808OE	15068982				2022-12-28	WOS:000220577600006
J	Bhutta, ZA; Gupta, I; de'Silva, H; Manandhar, D; Awasthi, S; Hossain, SMM; Salam, MA				Bhutta, ZA; Gupta, I; de'Silva, H; Manandhar, D; Awasthi, S; Hossain, SMM; Salam, MA			Maternal and child health: is South Asia ready for change?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEONATAL-MORTALITY; RANDOMIZED-TRIAL; VITAMIN-A; INFANTS; SUPPLEMENTATION	South Asia still has a long way to go to meet the United Nations' millennium development goals for maternal and child mortality.	Aga Khan Univ, Karachi 74800, Pakistan; Postgrad Inst Med Educ & Res, Chandigarh 160012, India; Sri Lanka Coll Paediatricians, Colombo 7, Sri Lanka; Kathmandu Med Coll, Dept Paediat, Kathmandu, Nepal; King Georges Med Univ, Inst Clin Epidemiol, Lucknow, Uttar Pradesh, India; Unicef, MCHC Sect, Islamabad, Pakistan; ICDDR B, Ctr Hlth & Populat Res, Div Clin Sci, Dhaka 1212, Bangladesh	Aga Khan University; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; King George's Medical University; International Centre for Diarrhoeal Disease Research (ICDDR)	Bhutta, ZA (corresponding author), Aga Khan Univ, Karachi 74800, Pakistan.	zulfiqar.bhutta@aku.edu						Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; Bhandari N, 2003, LANCET, V361, P1418, DOI 10.1016/S0140-6736(03)13134-0; Bhargava SK, 2004, NEW ENGL J MED, V350, P865, DOI 10.1056/NEJMoa035698; Bhutta ZA, 2000, BRIT MED J, V321, P809, DOI 10.1136/bmj.321.7264.809; Bhutta ZA, 2002, BMJ-BRIT MED J, V324, P1405, DOI 10.1136/bmj.324.7351.1405; Bhutta ZA, 2002, BMJ-BRIT MED J, V324, P349, DOI 10.1136/bmj.324.7333.349; BHUTTA ZA, IN PRESS PRIORITIES; BHUTTA ZA, 2003, SHAPING POLICY MATER, P5; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; *CNN, 2001, IND FEM FREEF; DESILVA H, 2001, CHILD ABUSE REV, V10, P125, DOI DOI 10.1002/CAR.669; Ellis M, 2000, BMJ-BRIT MED J, V320, P1229, DOI 10.1136/bmj.320.7244.1229; Fall CHD, 2003, J NUTR, V133, p1747S, DOI 10.1093/jn/133.5.1747S; George SM, 1998, ECON POLIT WEEKLY, V33, P2191; Hill K, 2001, B WORLD HEALTH ORGAN, V79, P182; *INT I POP SCI ORC, 2001, NAT FAM HLTH SURV NF, V2, P178; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Kamal IT, 1998, INT J GYNECOL OBSTET, V63, pS43, DOI 10.1016/S0020-7292(98)00183-0; Kinare AS, 2000, AM J OBSTET GYNECOL, V182, P443, DOI 10.1016/S0002-9378(00)70237-7; Rahbar MH, 2002, B WORLD HEALTH ORGAN, V80, P769; Rahmathullah L, 2003, BMJ-BRIT MED J, V327, P254, DOI 10.1136/bmj.327.7409.254; SACHDEV HPS, 1997, MALNUTRITION S ASIA; *SAV CHILDR, 2001, STAT WORLDS NEWB, P45; Sazawal S, 2001, PEDIATRICS, V108, P1280, DOI 10.1542/peds.108.6.1280; Sein T, 2002, REGIONAL HLTH FORUM, V6, P1; Sinha A, 1999, LANCET, V354, P734, DOI 10.1016/S0140-6736(98)09001-1; UN, MILL DEV GOALS; *UN DEV PROGR, 2003, HUM DEV REP; UNICEF, 2003, STAT WORLDS CHILDR 2; West KP, 1999, BMJ-BRIT MED J, V318, P570, DOI 10.1136/bmj.318.7183.570; *WHO, WORLD HLTH REP 2003; *WHO, VACC IMM BIOL COUNTR; *WHO DEP REPR HLTH, 2001, PER NEON MORT GLOB R; WHO/ UN/ UNICEF, MAT MORT 2000 EST DE; Yasmin S, 2001, B WORLD HEALTH ORGAN, V79, P608; 2004, ECONOMIST       0221, P12; 2003, GLOBAL POLIO ERADICA, P1	37	82	85	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	2004	328	7443					816	819		10.1136/bmj.328.7443.816	http://dx.doi.org/10.1136/bmj.328.7443.816			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	811CG	15070640	Green Published			2022-12-28	WOS:000220749400023
J	Pham, JW; Pellino, JL; Lee, YS; Carthew, RW; Sontheimer, EJ				Pham, JW; Pellino, JL; Lee, YS; Carthew, RW; Sontheimer, EJ			A Dicer-2-dependent 80S complex cleaves targeted mRNAs during RNAi in Drosophila	CELL			English	Article							INITIATION; PROTEIN; MATURATION; SIRNAS	We use native gel electrophoresis to characterize complexes that mediate RNA interference (RNAi) in Drosophila. Our data reveal three distinct complexes (R1, R2, and R3) that assemble on short interfering RNAs (siRNAs) in vitro. To form, all three complexes require Dicer-2 (Dcr-2), which directly contacts siRNAs in the ATP-independent R1 complex. R1 serves as a precursor to both the R2 and R3 complexes. R3 is a large (80S), ATP-enhanced complex that contains unwound siRNAs, cofractionates with known RNAi factors, and binds and cleaves targeted mRNAs in a cognate-siRNA-dependent manner. Our results establish an ordered biochemical pathway for RISC assembly and indicate that siRNAs must first interact with Dcr-2 to reach the R3 "holo-RISC" complex. Dcr-2 does not simply transfer siRNAs to a distinct effector complex, but rather assembles into RISC along with the siRNAs, indicating that its role extends beyond the initiation phase of RNAi.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Sontheimer, EJ (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2205 Tech Dr, Evanston, IL 60208 USA.	erik@northwestern.edu		Sontheimer, Erik/0000-0002-0881-0310	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068743] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM068743-01, R01 GM068743] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Caudy AA, 2003, NATURE, V425, P411, DOI 10.1038/nature01956; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Djikeng A, 2003, RNA, V9, P802, DOI 10.1261/rna.5270203; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Jin P, 2003, TRENDS BIOCHEM SCI, V28, P152, DOI 10.1016/S0968-0004(03)00033-1; Kennerdell JR, 2002, GENE DEV, V16, P1884, DOI 10.1101/gad.990802; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Nadano D, 2001, BIOCHEMISTRY-US, V40, P15184, DOI 10.1021/bi0108397; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100	27	329	362	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	2004	117	1					83	94		10.1016/S0092-8674(04)00258-2	http://dx.doi.org/10.1016/S0092-8674(04)00258-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YV	15066284	Bronze			2022-12-28	WOS:000221500300010
J	Higashida, C; Miyoshi, T; Fujita, A; OcegueraYanez, F; Monypenny, J; Andou, Y; Narumiya, S; Watanabe, N				Higashida, C; Miyoshi, T; Fujita, A; OcegueraYanez, F; Monypenny, J; Andou, Y; Narumiya, S; Watanabe, N			Actin polymerization-driven molecular movement of mDia1 in living cells	SCIENCE			English	Article							CAPPING PROTEIN; FISSION YEAST; FORMIN MDIA1; PROFILIN; NUCLEATION; CYTOKINESIS; FILAMENTS; DYNAMICS; CYTOSKELETON; ELONGATION	mDia1, a Rho effector, belongs to the Formin family of proteins, which shares the conserved tandem FH1-FH2 unit structure. Formins including mDia1 accelerate actin nucleation while interacting with actin. lament fast-growing ends. Here our single-molecule imaging revealed fast directional movement of mDia1 FH1-FH2 for tens of microns in living cells. The movement of mDia1 FH1-FH2 was blocked by actin-perturbing drugs, and the speed of mDia1 FH1-FH2 movement appeared to correlate with actin elongation rates. In vitro, mDia1 FH1-FH2 associated persistently with the growing actin barbed end. mDia1 probably moves processively along the growing end of actin. laments in cells, and Formins may be a molecular motility machinery that is independent from motor proteins.	Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 606, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Watanabe, N (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 606, Japan.	naoki-w@mfour.med.kyoto-u.ac.jp						Adam T, 1996, EMBO J, V15, P3315, DOI 10.1002/j.1460-2075.1996.tb00696.x; Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Bubb MR, 2003, J BIOL CHEM, V278, P24629, DOI 10.1074/jbc.M302796200; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Chang F, 1997, J CELL BIOL, V137, P169, DOI 10.1083/jcb.137.1.169; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; DINUBILE MJ, 1995, MOL BIOL CELL, V6, P1659, DOI 10.1091/mbc.6.12.1659; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965; Theriot JA, 2000, TRAFFIC, V1, P19, DOI 10.1034/j.1600-0854.2000.010104.x; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Watanabe N, 2002, SCIENCE, V295, P1083, DOI 10.1126/science.1067470; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Yang HC, 2002, P NATL ACAD SCI USA, V99, P751, DOI 10.1073/pnas.022462899; Zigmond SH, 2003, CURR BIOL, V13, P1820, DOI 10.1016/j.cub.2003.09.057	29	238	246	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	2004	303	5666					2007	2010		10.1126/science.1093923	http://dx.doi.org/10.1126/science.1093923			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044801	Green Submitted			2022-12-28	WOS:000220429800039
J	Basaria, S; Salvatori, R				Basaria, S; Salvatori, R			Pemberton's sign	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA	Johns Hopkins University	Basaria, S (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA.			Basaria, Shehzad/0000-0003-1749-8549; Basaria, Shehzad/0000-0002-8533-2383					0	10	12	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2004	350	13					1338	1338		10.1056/NEJMicm990287	http://dx.doi.org/10.1056/NEJMicm990287			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VN	15044645				2022-12-28	WOS:000220393900012
J	Ellis, MR				Ellis, MR			Diner on commercial street	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												mark.ellis@coxhealth.com							0	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	2004	291	12					1424	1424		10.1001/jama.291.12.1424	http://dx.doi.org/10.1001/jama.291.12.1424			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805UI	15039393				2022-12-28	WOS:000220390800001
J	Kuppermann, M; Varner, RE; Summitt, RL; Learman, LA; Ireland, C; Vittinghoff, E; Stewart, AL; Lin, F; Richter, HE; Showstack, J; Hulley, SB; Washington, AE				Kuppermann, M; Varner, RE; Summitt, RL; Learman, LA; Ireland, C; Vittinghoff, E; Stewart, AL; Lin, F; Richter, HE; Showstack, J; Hulley, SB; Washington, AE		Ms Res Grp	Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning - The medicine or surgery (Ms) randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-INCONTINENCE; OVARIAN FAILURE; SURVEY SF-36; WOMEN; MENORRHAGIA; AGE; APPROPRIATENESS; OUTCOMES; TESTS	Context Although a quarter of US women undergo elective hysterectomy before menopause, controlled trials that evaluate the benefits and harms are lacking. Objective To compare the effect of hysterectomy vs expanded medical treatment on health-related quality of life. Design, Setting, and Participants A multicenter, randomized controlled trial (August 1997-December 2000) of 63 premenopausal women, aged 30 to 50 years, with abnormal uterine bleeding for a median of 4 years who were dissatisfied with medical treatments, including medroxyprogesterone acetate. The participants, who were patients at gynecology clinics and affiliated practices of 4 US academic medical centers, were followed up for 2 years. Interventions Participants were randomly assigned to undergo hysterectomy or expanded medical treatment with estrogen and/or progesterone and/or a prostaglandin synthetase inhibitor. The hysterectomy route and medical regimen were determined by the participating gynecologist. Main Outcome Measures The primary outcome was mental health measured by the Mental Component Summary (MCS) of the 36-Item Short-Form Health Survey (SF-36). Secondary outcomes included physical health measured by the Physical Component Summary (PCS), symptom resolution and satisfaction, body image, and sexual functioning, as well as other aspects of mental health and general health perceptions. Results At 6 months, women in the hysterectomy group had greater improvement in MCS scores than women in the medicine group (8 vs 2, P=.04). They also had greater improvement in symptom resolution (75 vs 29, P<.001), symptom satisfaction (44 vs 7, P<.001), interference with sex (41 vs 22, P=.003), sexual desire (21 vs 3, P=.01), health distress (33 vs 13, P=.009), sleep problems (13 vs 1, P=.03), overall health (12 vs 2, P=.006), and satisfaction with health (31 vs 14, P=.01). By the end of the study, 17 (53%) of the women in the medicine group had requested and received hysterectomy, and these women reported improvements in quality-of-life outcomes during the 2 years that were similar to those reported by women randomized to the hysterectomy group. Women who continued medical treatment also reported some improvements (P<.001 for within-group change in many outcomes), with the result that most differences between randomized groups at the end of the study were no longer statistically significant in the intention-to-treat analysis. Conclusions Among women with abnormal uterine bleeding and dissatisfaction with medroxyprogesterone, hysterectomy was superior to expanded medical treatment for improving health-related quality-of-life after 6 months. With longer follow-up, half the women randomized to medicine elected to undergo hysterectomy, with similar and lasting quality-of-life improvements; those who continued medical treatment also reported some improvements.	Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Nursing, Inst Hlth & Aging, San Francisco, CA 94143 USA; Univ Alabama Birmingham, Dept Obstet & Gynecol, Birmingham, AL 35294 USA; Univ Tennessee, Dept Obstet & Gynecol, Memphis, TN 38103 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Alabama System; University of Alabama Birmingham; University of Tennessee System; University of Tennessee Health Science Center	Kuppermann, M (corresponding author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, 3333 Calif St,Suite 335, San Francisco, CA 94143 USA.	kuppermannm@obgyn.ucsf.edu	Learman, Lee/ABB-7436-2021; Showstack, Jonathan/L-6556-2013	Showstack, Jonathan/0000-0002-1367-419X; Richter, Holly E/0000-0001-7741-5771	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U01HS009478] Funding Source: NIH RePORTER; AHRQ HHS [UO1 HS09478] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BENTOVIM DI, 1994, J PSYCHOSOM RES, V38, P477, DOI 10.1016/0022-3999(94)90109-0; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P2398, DOI 10.1001/jama.269.18.2398; Bonnar J, 1996, BRIT MED J, V313, P579; Broder MS, 2000, OBSTET GYNECOL, V95, P199, DOI 10.1016/S0029-7844(99)00519-0; Brown JS, 1996, OBSTET GYNECOL, V87, P715, DOI 10.1016/0029-7844(96)00013-0; CARLSON KJ, 1994, OBSTET GYNECOL, V83, P556, DOI 10.1097/00006250-199404000-00012; COULTER A, 1988, SOC SCI MED, V27, P987, DOI 10.1016/0277-9536(88)90289-4; Davies Joanne E, 2002, J Obstet Gynaecol, V22, P523; Davis A, 2000, OBSTET GYNECOL, V96, P913, DOI 10.1016/S0029-7844(00)01029-2; DICKER RC, 1982, AM J OBSTET GYNECOL, V144, P841, DOI 10.1016/0002-9378(82)90362-3; EDLUND M, 1995, BRIT J OBSTET GYNAEC, V102, P913, DOI 10.1111/j.1471-0528.1995.tb10881.x; Farquhar CM, 2002, OBSTET GYNECOL, V99, P229, DOI 10.1016/S0029-7844(01)01723-9; Farrell SA, 2000, OBSTET GYNECOL, V95, P1045, DOI 10.1016/S0029-7844(00)00784-5; FRASER IS, 1990, AUST NZ J OBSTET GYN, V30, P353, DOI 10.1111/j.1479-828X.1990.tb02028.x; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Hurskainen R, 2001, LANCET, V357, P273, DOI 10.1016/S0140-6736(00)03615-1; Kennedy ADM, 2002, JAMA-J AM MED ASSOC, V288, P2701, DOI 10.1001/jama.288.21.2701; Kjerulff KH, 2000, OBSTET GYNECOL, V95, P319, DOI 10.1016/S0029-7844(99)00544-X; Kjerulff KH, 2000, AM J OBSTET GYNECOL, V183, P1440, DOI 10.1067/mob.2000.107731; KOZAK LJ, 2002, SERIES DEP HLTH HUM, V13; Lepine L A, 1997, MMWR CDC Surveill Summ, V46, P1; LORIG K, 1996, MEASURES HLTH ED OTH; LYDICK E, 1993, QUAL LIFE RES, V2, P221, DOI 10.1007/BF00435226; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; McTigue KM, 2002, ANN INTERN MED, V136, P857, DOI 10.7326/0003-4819-136-12-200206180-00006; MILSOM I, 1993, J UROLOGY, V149, P1459, DOI 10.1016/S0022-5347(17)36415-7; Munro MG, 2001, CURR OPIN OBSTET GYN, V13, P475, DOI 10.1097/00001703-200110000-00006; Rhodes JC, 1999, JAMA-J AM MED ASSOC, V282, P1934, DOI 10.1001/jama.282.20.1934; Richter HE, 2003, AM J OBSTET GYNECOL, V189, P37, DOI 10.1067/mob.2003.342; RIEDEL HH, 1986, J REPROD MED, V31, P597; Rolnick SJ, 2001, J REPROD MED, V46, P1; SIDDLE N, 1987, FERTIL STERIL, V47, P94; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART AL, 1992, MEASURING FUNCTIONIN, P449; van der Vaart CH, 2002, BJOG-INT J OBSTET GY, V109, P149, DOI 10.1016/S1470-0328(02)01332-0; Varner RE, 2004, CONTROL CLIN TRIALS, V25, P104, DOI 10.1016/j.cct.2003.08.008; Vuorma S, 2003, PATIENT EDUC COUNS, V49, P125, DOI 10.1016/S0738-3991(02)00069-1; Ware JE, 2001, SF 36 PHYS MENTAL HL; Ware JE, 1993, SF36 HLTH SURVEY MAN; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; WINGO PA, 1985, AM J OBSTET GYNECOL, V152, P803, DOI 10.1016/S0002-9378(85)80067-3; Wyrwich KW, 2003, J GEN INTERN MED, V18, P196, DOI 10.1046/j.1525-1497.2003.20203.x	43	88	95	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	2004	291	12					1447	1455		10.1001/jama.291.12.1447	http://dx.doi.org/10.1001/jama.291.12.1447			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	805UI	15039411	Bronze			2022-12-28	WOS:000220390800025
J	Gollogly, L				Gollogly, L			Ways around the NHS	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		Gollogly, L (corresponding author), Lancet, London NW1 7BY, England.							Gunn J, 2003, LANCET, V361, P2123, DOI 10.1016/S0140-6736(03)13723-3; Lowson K, 2002, DEP HLTH EVALUATION	2	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	2004	363	9413					914	914		10.1016/S0140-6736(04)15822-4	http://dx.doi.org/10.1016/S0140-6736(04)15822-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043957				2022-12-28	WOS:000220308600006
J	Liu, SW; Xiao, GF; Chen, YB; He, YX; Niu, JK; Escalante, CR; Xiong, HB; Farmar, J; Debnath, AK; Tien, P; Jiang, SB				Liu, SW; Xiao, GF; Chen, YB; He, YX; Niu, JK; Escalante, CR; Xiong, HB; Farmar, J; Debnath, AK; Tien, P; Jiang, SB			Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors	LANCET			English	Article							ACUTE RESPIRATORY SYNDROME; GP41 CORE STRUCTURE; INFECTION IN-VITRO; HIV-1 GP41; POTENT INHIBITORS; COILED-COIL; ENVELOPE GLYCOPROTEIN; SYNTHETIC PEPTIDES; MEMBRANE-FUSION; TYPE-1 GP41	Background Studies on the fusion-inhibitory peptides derived from the heptad repeat 1 and 2 (HR1 and HR2) regions of the HIV-1 envelope glycoprotein gp41 provided crucial information on the viral fusogenic mechanism. We used a similar approach to study the fusogenic mechanism of severe-acute-respiratory-syndrome-associated coronavirus (SARS-CoV). Methods We tested the inhibitory activity against infection of two sets of peptides corresponding to sequences of SARS-CoV spike protein HR1 and HR2 regions and investigated the interactions between the HR1 and HR2 peptides by surface plasmon resonance, sedimentation equilibration analysis, circular dichroism, native polyacrylamide-gel electrophoresis, size exclusion high-performance liquid chromatography, and computer-aided homology modelling and molecule docking analysis. Findings One peptide, CP-1, derived from the HR2 region, inhibited SARS-CoV infection in the micromolar range. CP-1 bound with high affinity to a peptide from the HR1 region, NP-1. CIPA alone had low alpha-helicity and self-associated to form a trimer in phosphate buffer (pH 7.2). CP-1 and NP-1 mixed in equimolar concentrations formed a six-helix bundle, similar to the fusogenic core structure of HIV-1 gp41. Interpretation After binding to the target cell, the transmembrane spike protein might change conformation by association between the HR1 and HR2 regions to form an oligomeric structure, leading to fusion between the viral and target-cell membranes. At the prefusion intermediate state, CP-1 could bind to the HR1 region and interfere with the conformational changes, resulting in inhibition of SARS-CoV fusion with the target cells. CP-1 might be modifiable to increase its anti-SARS-CoV activity and could be further developed as an antiviral agent for treatment or prophylaxis of SARS-CoV infection.	New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA; Wuhan Univ, Modern Virol Res Ctr, Wuhan 430072, Peoples R China; Mt Sinai Sch Med, New York, NY USA	New York Blood Center; Wuhan University; Icahn School of Medicine at Mount Sinai	Jiang, SB (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, 310 E 67th St, New York, NY 10021 USA.	SJiang@DNYBloodcenter.org	Jiang, Shibo/L-4500-2014	Jiang, Shibo/0000-0001-8283-7135; Liu, Shuwen/0000-0001-6346-5006				BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003; Cavanagh D, 1995, CORONAVIRIDAE, P73; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Debnath AK, 1999, J MED CHEM, V42, P3203, DOI 10.1021/jm990154t; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Dwyer JJ, 2003, BIOCHEMISTRY-US, V42, P4945, DOI 10.1021/bi027283n; Gallagher TM, 1997, J VIROL, V71, P3129, DOI 10.1128/JVI.71.4.3129-3137.1997; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Holmes KV, 2003, NEW ENGL J MED, V348, P1948, DOI 10.1056/NEJMp030078; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; JIANG SB, 1993, BIOCHEM BIOPH RES CO, V195, P533, DOI 10.1006/bbrc.1993.2078; Jiang SB, 1999, J VIROL METHODS, V80, P85, DOI 10.1016/S0166-0934(99)00041-5; Jiang SB, 2002, CURR PHARM DESIGN, V8, P563; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Jones DK, 1998, BIOCHEM J, V330, P983; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Krueger DK, 2001, J VIROL, V75, P2792, DOI 10.1128/JVI.75.6.2792-2802.2001; Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Liu SW, 2003, PEPTIDES, V24, P1303, DOI 10.1016/j.peptides.2003.07.013; Lombardi S, 1996, VIROLOGY, V220, P274, DOI 10.1006/viro.1996.0315; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Luo ZL, 1999, J VIROL, V73, P8152, DOI 10.1128/JVI.73.10.8152-8159.1999; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Qin E, 2003, CHINESE SCI BULL, V48, P941, DOI [10.1360/03wc0186, 10.1007/BF03184203]; Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399; Rost B, 1996, METHOD ENZYMOL, V266, P525; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vakser IA, 1999, P NATL ACAD SCI USA, V96, P8477, DOI 10.1073/pnas.96.15.8477; Wang EX, 2003, BIOCHEM BIOPH RES CO, V302, P469, DOI 10.1016/S0006-291X(03)00197-9; Watanabe S, 2000, J VIROL, V74, P10194, DOI 10.1128/JVI.74.21.10194-10201.2000; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; World Health Organization (WHO), 2003, SUMM PROB SARS CAS O; Yao QZ, 1996, VIROLOGY, V223, P103, DOI 10.1006/viro.1996.0459; Yu M, 2002, J GEN VIROL, V83, P623, DOI 10.1099/0022-1317-83-3-623; Zhao Q, 2002, AIDS RES HUM RETROV, V18, P989, DOI 10.1089/08892220260235353	50	369	407	3	44	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	2004	363	9413					938	947		10.1016/S0140-6736(04)15788-7	http://dx.doi.org/10.1016/S0140-6736(04)15788-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043961	Green Published, Bronze			2022-12-28	WOS:000220308600010
J	Cheng, CL; Flamarique, IN				Cheng, CL; Flamarique, IN			Opsin expression: New mechanism for modulating colour vision - Single cones start making a different opsin as young salmon move to deeper waters	NATURE			English	Editorial Material							VISUAL PIGMENT COEXPRESSION; RETINA		Simon Fraser Univ, Dept Biol Sci, Burnaby, BC V5A 1S6, Canada	Simon Fraser University	Cheng, CL (corresponding author), Simon Fraser Univ, Dept Biol Sci, Burnaby, BC V5A 1S6, Canada.	inigo@sfu.ca						FEIN A, 1982, PHOTORECEPTORS THEIR; Forsell J, 2001, J EXP BIOL, V204, P2517; Groot C., 1991, PACIFIC SALMON LIFE; KUNZ YW, 1994, VISION RES, V34, P1375, DOI 10.1016/0042-6989(94)90136-8; Lukats A, 2002, INVEST OPHTH VIS SCI, V43, P2468; Makino CL, 1996, J GEN PHYSIOL, V108, P27, DOI 10.1085/jgp.108.1.27; Parry JWL, 2002, INVEST OPHTH VIS SCI, V43, P1662; SZEL A, 1994, NATURE, V370, P336, DOI 10.1038/370336a0; 1986, RETINA MODEL CELL 1, P297	9	90	93	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	2004	428	6980					279	279		10.1038/428279a	http://dx.doi.org/10.1038/428279a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15029185	Bronze			2022-12-28	WOS:000220250200030
J	Wittenstein, B; Rogers, V; Novelli, V; Clayton, PT; Kenny, MB; Peters, MJ				Wittenstein, B; Rogers, V; Novelli, V; Clayton, PT; Kenny, MB; Peters, MJ			"African medicine" and Reye's syndrome	LANCET			English	Editorial Material							ANALOGS		Great Ormond St Hosp Children NHS Trust, Paediat Intens Care Unit, London WC1N 3JH, England; Great Ormond St Hosp Children NHS Trust, Infect Dis & Microbiol Unit, London WC1N 3JH, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Peters, MJ (corresponding author), Great Ormond St Hosp Children NHS Trust, Paediat Intens Care Unit, Great Ormond St, London WC1N 3JH, England.	m.peters@ich.ucl.ac.uk	Clayton, Peter T/C-1523-2008; Peters, Mark/AAD-7518-2019	Peters, Mark/0000-0003-3653-4808; Clayton, Peter/0000-0001-7592-4302				Bonnet F, 2003, REV MED INTERNE, V24, P11, DOI 10.1016/S0248-8663(02)00702-6; BURRIS AS, 1986, SOUTHERN MED J, V79, P647, DOI 10.1097/00007611-198605000-00037; Casteels-Van Daele M, 2000, EUR J PEDIATR, V159, P641, DOI 10.1007/PL00008399; MARTIN JL, 1994, ANTIMICROB AGENTS CH, V38, P2743, DOI 10.1128/AAC.38.12.2743	4	1	2	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	2004	363	9412					860	860		10.1016/S0140-6736(04)15733-4	http://dx.doi.org/10.1016/S0140-6736(04)15733-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15031031				2022-12-28	WOS:000220231500012
J	Chan, CS; De Stasio, G; Welch, SA; Girasole, M; Frazer, BH; Nesterova, MV; Fakra, S; Banfield, JF				Chan, CS; De Stasio, G; Welch, SA; Girasole, M; Frazer, BH; Nesterova, MV; Fakra, S; Banfield, JF			Microbial polysaccharides template assembly of nanocrystal fibers	SCIENCE			English	Article							ELECTRON-MICROSCOPY; IRON; BIOFILMS; ZNS	Biological systems can produce extraordinary inorganic structures and morphologies. The mechanisms of synthesis are poorly understood but are of great interest for engineering novel materials. We use spectromicroscopy to show that microbially generated submicrometer-diameter iron oxyhydroxide (FeOOH). laments contain polysaccharides, providing an explanation for the formation of akaganeite pseudo-single crystals with aspect ratios of similar to1000:1. We infer that the cells extrude the polysaccharide strands to localize FeOOH precipitation in proximity to the cell membrane to harness the proton gradient for energy generation. Characterization of organic compounds with high spatial resolution, correlated with mineralogical information, should improve our understanding of biomineralization mechanisms.	Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; Univ Wisconsin, Dept Phys, Madison, WI 53706 USA; Univ Wisconsin, Dept Geol & Geophys, Madison, WI 53706 USA; Univ Wisconsin, Ctr Synchrotron Radiat, Stoughton, WI 53589 USA; CNR, Ist Struttura Mat, I-00044 Frascati, Italy; Univ Calif Berkeley, Lawrence Berkeley Lab, Adv Light Source, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; Consiglio Nazionale delle Ricerche (CNR); Istituto di Struttura della Materia (ISM-CNR); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	De Stasio, G (corresponding author), Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA.	pupa@src.wisc.edu; jill@eps.berkeley.edu	Gilbert, Pupa/A-6299-2010; GIRASOLE, MARCO/I-6861-2013; Chan, Clara S/B-6420-2011	Gilbert, Pupa/0000-0002-0139-2099; GIRASOLE, MARCO/0000-0001-6146-2979; Chan, Clara S/0000-0003-1810-4994; Banfield, Jill/0000-0001-8203-8771; Welch, Susan/0000-0002-2890-0065				Banfield JF, 2000, SCIENCE, V289, P751, DOI 10.1126/science.289.5480.751; COMBES JM, 1989, PHYSICA B, V158, P419, DOI 10.1016/0921-4526(89)90333-5; Cornell R.M., 1996, CORROS SCI, DOI [DOI 10.1016/S0010-938X(99)00005-0, DOI 10.1016/S0010-938X(97)00096-6]; Debon SJJ, 2001, FOOD CHEM, V73, P401, DOI 10.1016/S0308-8146(00)00312-5; Druschel GK, 2002, ECON GEOL BULL SOC, V97, P1319, DOI 10.2113/97.6.1319; Ehrlich H.L., 1996, GEOMICROBIOLOGY; FRAZER BH, IN PRESS ULTRAMICROS; ISHII I, 1987, J CHEM PHYS, V87, P830, DOI 10.1063/1.453290; Labrenz M, 2000, SCIENCE, V290, P1744, DOI 10.1126/science.290.5497.1744; Lawrence JR, 2003, APPL ENVIRON MICROB, V69, P5543, DOI 10.1128/AEM.69.9.5543-5554.2003; Mann S., 2001, BIOMINERALIZATION PR; Mavrocordatos D, 2002, AM MINERAL, V87, P940; Nicholls D., 2002, BIOENERGETICS; PARKHURST DL, 1999, SPECIATION MODELED U; Sogaard EG, 2000, WATER RES, V34, P2675, DOI 10.1016/S0043-1354(00)00002-6; Stohr J, 2013, SPRINGE SER SURF SCI; Ueshima M, 2001, CLAY CLAY MINER, V49, P292, DOI 10.1346/CCMN.2001.0490403; Wehrli B., 1990, AQUATIC CHEM KINETIC, P311	18	322	345	7	192	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1656	1658		10.1126/science.1092098	http://dx.doi.org/10.1126/science.1092098			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016997				2022-12-28	WOS:000220151400040
J	Riedel, M; Hausleiter, J; Martinoff, S				Riedel, M; Hausleiter, J; Martinoff, S			Scimitar syndrome	LANCET			English	Editorial Material									Tech Univ Munich, German Heart Ctr, Dept Cardiol, D-80636 Munich, Germany; Tech Univ Munich, German Heart Ctr, Dept Radiol, D-80636 Munich, Germany	German Heart Centre Munich; Technical University of Munich; German Heart Centre Munich; Technical University of Munich	Riedel, M (corresponding author), Tech Univ Munich, German Heart Ctr, Dept Cardiol, D-80636 Munich, Germany.		Colombo, Antonio/N-2960-2015; hasanzad, maryam/G-4362-2017; Latib, Azeem/B-4165-2008; Hausleiter, Jörg/V-4206-2019	Colombo, Antonio/0000-0002-2940-2455; hasanzad, maryam/0000-0001-7164-0599; Latib, Azeem/0000-0001-9035-343X; 					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	2004	363	9406					356	356		10.1016/S0140-6736(04)15435-4	http://dx.doi.org/10.1016/S0140-6736(04)15435-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768TQ	15070564	Bronze			2022-12-28	WOS:000188590900009
J	Zaidi, AKM; Awasthi, S; deSilva, HJ				Zaidi, AKM; Awasthi, S; deSilva, HJ			Burden of infectious diseases in South Asia	BMJ-BRITISH MEDICAL JOURNAL			English	Review							NEONATAL-MORTALITY; TYPHOID-FEVER; HEPATITIS-B; SURVEILLANCE; STRATEGIES; INJECTIONS; RESISTANCE; CARE		Aga Khan Univ, Dept Paediat, Karachi 74800, Pakistan; King Georges Med Univ, Dept Paediat, Lucknow, Uttar Pradesh, India	Aga Khan University; King George's Medical University	Zaidi, AKM (corresponding author), Aga Khan Univ, Dept Paediat, Karachi 74800, Pakistan.	Anita.zaidi@aku.edu						Bang A T, 2001, Indian Pediatr, V38, P952; Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; BHUTTA ZA, 1996, ANN TROP PEDIAT  DEC, P299; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; Caulfield LE, COMP QUANTIFICATION; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P107; Claeson M, 2003, LANCET, V362, P323, DOI 10.1016/S0140-6736(03)13977-3; Couper MR, 1997, CLIN INFECT DIS, V24, pS154, DOI 10.1093/clinids/24.Supplement_1.S154; FISHMAN S, IN PRESS COMP QUANTI; Hyder AA, 2003, BJOG-INT J OBSTET GY, V110, P894, DOI 10.1111/j.1471-0528.2003.02446.x; John TJ, 1998, LANCET, V352, P58, DOI 10.1016/S0140-6736(97)10494-9; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Khan AJ, 2000, B WORLD HEALTH ORGAN, V78, P956; KHAN M, 2002, HEPATITIS B C CARRIE, P19; Lopez A. D, 1993, DIS CONTROL PRIORITI; Okeke IN, 1999, EMERG INFECT DIS, V5, P18, DOI 10.3201/eid0501.990103; Qazi SA, 1999, CLIN INFECT DIS, V28, P214, DOI 10.1086/515124; RICE AL, IN PRESS COMP QUANTI; Saha SK, 2001, PEDIATR INFECT DIS J, V20, P521, DOI 10.1097/00006454-200105000-00010; Shears P, 2001, T ROY SOC TROP MED H, V95, P127, DOI 10.1016/S0035-9203(01)90134-8; Sinha A, 1999, LANCET, V354, P734, DOI 10.1016/S0140-6736(98)09001-1; Stoll BJ, 1997, CLIN PERINATOL, V24, P1; *UNICEF, 2001, PROGR WORLD SUMM CHI; Usman HR, 2003, EPIDEMIOL INFECT, V130, P293, DOI 10.1017/S0950268802008178; van Doorn KJ, 2003, NEW ENGL J MED, V348, P1182; *WHO, DENG FEV IND UPD; *WHO, 2003, GLOB TUB CONTR WHO R; *WHO, HEP C GLOB PREV UPD; *WHO, 2001, HIV AIDS AS PAC REG; *WHO, FACTS HIV AIDS SE AS; *WHO UNICEF, 2000, INT MAN CHILDH ILLN; World Health Organization, HEPATITIS B	33	72	73	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	2004	328	7443					811	815		10.1136/bmj.328.7443.811	http://dx.doi.org/10.1136/bmj.328.7443.811			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	811CG	15070639	Green Published, Green Submitted			2022-12-28	WOS:000220749400022
J	Reconditi, M; Linari, M; Lucii, L; Stewart, A; Sun, YB; Boesecke, P; Narayanan, T; Fischetti, RF; Irving, T; Piazzesi, G; Irving, M; Lombardi, V				Reconditi, M; Linari, M; Lucii, L; Stewart, A; Sun, YB; Boesecke, P; Narayanan, T; Fischetti, RF; Irving, T; Piazzesi, G; Irving, M; Lombardi, V			The myosin motor in muscle generates a smaller and slower working stroke at higher load	NATURE			English	Article							FORCE GENERATION; SINGLE; CONTRACTION; FILAMENTS; HEADS; ACTIN; EXTENSIBILITY; REFLECTIONS; TRANSIENTS; DEPENDENCE	Muscle contraction is driven by the motor protein myosin II, which binds transiently to an actin filament, generates a unitary filament displacement or 'working stroke', then detaches and repeats the cycle. The stroke size has been measured previously using isolated myosin II molecules at low load, with rather variable results(1-4), but not at the higher loads that the motor works against during muscle contraction. Here we used a novel X-ray-interference technique(5,6) to measure the working stroke of myosin II at constant load(7) in an intact muscle cell, preserving the native structure and function of the motor. We show that the stroke is smaller and slower at higher load. The stroke size at low load is likely to be set by a structural limit(8,9); at higher loads, the motor detaches from actin before reaching this limit. The load dependence of the myosin II stroke is the primary molecular determinant of the mechanical performance and efficiency of skeletal muscle.	Univ Florence, DBAG, Lab Fisiol, I-50134 Florence, Italy; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02545 USA; Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; European Synchrotron Radiat Facil, F-38043 Grenoble, France; BioCAT Adv Photon Source, Argonne, IL 60439 USA	University of Florence; Brandeis University; University of London; King's College London; European Synchrotron Radiation Facility (ESRF); United States Department of Energy (DOE); Argonne National Laboratory	Lombardi, V (corresponding author), Univ Florence, DBAG, Lab Fisiol, I-50134 Florence, Italy.	vincenzo.lombardi@unifi.it	Sun, Yin-Biao/F-9988-2018	Sun, Yin-Biao/0000-0002-4992-8198; LINARI, MARCO/0000-0001-6512-4897; RECONDITI, MASSIMO/0000-0001-5065-924X; Narayanan, Theyencheri/0000-0003-1957-1041	Telethon [945] Funding Source: Medline	Telethon(Fondazione Telethon)		BOSECKE P, 1995, REV SCI INSTRUM, V66, P1636, DOI 10.1063/1.1145868; Dobbie I, 1998, NATURE, V396, P383, DOI 10.1038/24647; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; HASELGROVE JC, 1975, J MOL BIOL, V92, P113, DOI 10.1016/0022-2836(75)90094-7; Huxley AF, 1996, J MUSCLE RES CELL M, V17, P507, DOI 10.1007/BF00123366; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; Huxley HE, 2003, BIOPHYS J, V84, p139A; HUXLEY HE, 1994, BIOPHYS J, V67, P2411, DOI 10.1016/S0006-3495(94)80728-3; Irving M, 2000, NAT STRUCT BIOL, V7, P482, DOI 10.1038/75890; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; Irving TC, 2000, NUCL INSTRUM METH A, V448, P250, DOI 10.1016/S0168-9002(99)00732-9; Kitamura K, 1999, NATURE, V397, P129, DOI 10.1038/16403; KUSHMERICK MJ, 1969, PROC R SOC SER B-BIO, V174, P315, DOI 10.1098/rspb.1969.0096; Linari M, 2000, P NATL ACAD SCI USA, V97, P7226, DOI 10.1073/pnas.97.13.7226; Linari M, 1998, BIOPHYS J, V74, P2459, DOI 10.1016/S0006-3495(98)77954-8; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; Mehta AD, 1999, SCIENCE, V283, P1689, DOI 10.1126/science.283.5408.1689; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Phillips WC, 2002, J SYNCHROTRON RADIAT, V9, P36; Piazzesi G, 2002, NATURE, V415, P659, DOI 10.1038/415659a; Piazzesi G, 2002, J PHYSIOL-LONDON, V545, P145, DOI 10.1113/jphysiol.2002.028969; PIAZZESI G, 1995, BIOPHYS J, V68, pS92; PODOLSKY RJ, 1960, NATURE, V188, P666, DOI 10.1038/188666a0; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sun YB, 2001, J PHYSIOL-LONDON, V531, P781, DOI 10.1111/j.1469-7793.2001.0781h.x; WAKABAYASHI K, 1994, BIOPHYS J, V67, P2422, DOI 10.1016/S0006-3495(94)80729-5	28	151	159	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					578	581		10.1038/nature02380	http://dx.doi.org/10.1038/nature02380			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15058307				2022-12-28	WOS:000220540100046
J	Light, D; Dixon, M				Light, D; Dixon, M			Making the NHS more like Kaiser Permanente	BRITISH MEDICAL JOURNAL			English	Article									Univ Med & Dent New Jersey, Div Social & Behav Med, Newark, NJ 07103 USA; NHS Alliance, Retford DN22 6JD, Notts, England	Rutgers State University New Brunswick; Rutgers State University Medical Center	Light, D (corresponding author), Univ Med & Dent New Jersey, Div Social & Behav Med, Newark, NJ 07103 USA.	dlight@princeton.edu						BMA, 2001, NAT SURV GP OP; CLEWS G, 2003, HLT SERVICE J, V113, P15; Dixon J, 2004, BRIT MED J, V328, P223, DOI 10.1136/bmj.328.7433.223; Feachem RGA, 2002, BMJ-BRIT MED J, V324, P135, DOI 10.1136/bmj.324.7330.135; Ham C, 2003, BRIT MED J, V327, P1257, DOI 10.1136/bmj.327.7426.1257; Ham C, 2003, LANCET, V361, P1978, DOI 10.1016/S0140-6736(03)13593-3; Ham C., 2003, LEARNING KAISER PERM; Hendricks Rickey, 1993, MODEL NATL HLTH CARE; Klein Rudolf, 1995, NEW POLITICS NHS; Light D, 2000, BRIT MED J, V320, P1349, DOI 10.1136/bmj.320.7245.1349; Light D, 2000, Health Serv J, V110, P24; *NHS ALL, 2001, VIS PRACT; *NHS ALL, 2003, ENG GPS NEW NHS; *NHS ALL, 2003, STAT COMM PRIM CAR T; *NHS DUMFR GALL, 2002, PROP CREAT SINGL DUM; SMILIE JG, 1981, CAN PHYS MANAGE QUAL; SOMERS AR, 1971, KAISER PERMANENTE ME; Webster C., 1998, NATL HLTH SERVICE PO; YATES J, 1995, PRIVATE EYE HEART HI	19	36	36	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 27	2004	328	7442					763	765		10.1136/bmj.328.7442.763	http://dx.doi.org/10.1136/bmj.328.7442.763			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809WH	15044296	Green Published			2022-12-28	WOS:000220666300032
J	Gawande, A				Gawande, A			Notes of a surgeon: On washing hands	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Gawande, A (corresponding author), Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.			Gawande, Atul/0000-0002-1824-9176				Nuland SB, 2003, DOCTORS PLAGUE GERMS	1	35	36	0	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2004	350	13					1283	1286		10.1056/NEJMp048025	http://dx.doi.org/10.1056/NEJMp048025			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VN	15044638				2022-12-28	WOS:000220393900005
J	Li, JS; Ishii, T; Feinstein, P; Mombaerts, P				Li, JS; Ishii, T; Feinstein, P; Mombaerts, P			Odorant receptor gene choice is reset by nuclear transfer from mouse olfactory sensory neurons	NATURE			English	Article							EMBRYONIC STEM-CELLS; MICE; VOMERONASAL; DEFICIENT; GLOMERULI; PROTEINS; CLONING; CODES	Of the,1,000 odorant receptor ( OR) genes in the mouse genome, an olfactory sensory neuron (OSN) is thought to express one gene, from one allele. This is reminiscent of immunoglobulin and T-cell receptor genes, which undergo DNA rearrangements in lymphocytes. Here, we test the hypothesis that OR gene choice is controlled by DNA rearrangements in OSNs. Using permanent genetic marking, we show that the choice by an OSN to express an allele of the OR gene M71 is irreversible. Using M71-expressing OSNs as donors for nuclear transfer, we generate blastocysts, embryonic stem (ntES) cell lines and clonal mice. DNA analysis of these cell lines, whose genome is clonally derived from an M71-expressing OSN, does not reveal DNA rearrangements or sequence alterations at the M71 locus. OSNs that differentiate from ntES cells after injection into blastocysts are not restricted to expression of M71 but can express other OR genes. Thus, M71 gene choice is irreversible but is reset upon nuclear transfer, and is not accompanied by genomic alterations.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Mombaerts, P (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	peter@rockefeller.edu		li, jin song/0000-0003-3456-662X				Bozza T, 2002, J NEUROSCI, V22, P3033, DOI 10.1523/JNEUROSCI.22-08-03033.2002; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Chung YG, 2002, BIOL REPROD, V66, P1178, DOI 10.1095/biolreprod66.4.1178; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; Eggan E, 2004, NATURE, V428, P44, DOI 10.1038/nature02375; Hamana H, 2003, CHEM SENSES, V28, P87, DOI 10.1093/chemse/28.2.87; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; Hochedlinger K, 2002, NATURE, V415, P1035, DOI 10.1038/nature718; Hochedlinger K, 2003, NEW ENGL J MED, V349, P275, DOI 10.1056/NEJMra035397; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HOZUMI N, 1976, P NATL ACAD SCI USA, V73, P3628, DOI 10.1073/pnas.73.10.3628; Ishii T, 2003, CURR BIOL, V13, P394, DOI 10.1016/S0960-9822(03)00092-7; Ishii T, 2001, GENES CELLS, V6, P71, DOI 10.1046/j.1365-2443.2001.00398.x; Lewcock JW, 2004, P NATL ACAD SCI USA, V101, P1069, DOI 10.1073/pnas.0307986100; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Mombaerts P, 2004, CURR OPIN NEUROBIOL, V14, P31, DOI 10.1016/j.conb.2004.01.014; Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mombaerts P, 2003, P NATL ACAD SCI USA, V100, P11924, DOI 10.1073/pnas.1934141100; Mombaerts P, 2001, NAT NEUROSCI, V4, P1192, DOI 10.1038/nn751; Mombaerts P, 1999, SCIENCE, V286, P707, DOI 10.1126/science.286.5440.707; NAGY A, 1990, DEVELOPMENT, V110, P815; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Potter SM, 2001, J NEUROSCI, V21, P9713, DOI 10.1523/JNEUROSCI.21-24-09713.2001; SAUER B, 1990, New Biologist, V2, P441; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; Strotmann J, 2000, J NEUROSCI, V20, P6927, DOI 10.1523/JNEUROSCI.20-18-06927.2000; TONEGAWA S, 1988, CELL DEV BIOL, V24, P235; Tsuboi A, 1999, J NEUROSCI, V19, P8409; Vassalli A, 2002, NEURON, V35, P681, DOI 10.1016/S0896-6273(02)00793-6; Wakayama T, 2001, SCIENCE, V292, P740, DOI 10.1126/science.1059399; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 1999, P NATL ACAD SCI USA, V96, P14984, DOI 10.1073/pnas.96.26.14984; ZHANG X, 2003, GENOMICS, DOI DOI 10.1016/J.YGEN3.2003.10.009; Zheng C, 2000, NEURON, V26, P81, DOI 10.1016/S0896-6273(00)81140-X	39	201	212	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	2004	428	6981					393	399		10.1038/nature02433	http://dx.doi.org/10.1038/nature02433			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042081				2022-12-28	WOS:000220404300033
J	Thomas, J; Paranjothy, S; James, D				Thomas, J; Paranjothy, S; James, D			National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section	BRITISH MEDICAL JOURNAL			English	Article							EPIDURAL-ANESTHESIA; FETAL DISTRESS; TIME	Objective To examine the association between decision to delivery interval and maternal and baby outcomes. Design National cross sectional survey. Setting Maternity units in England and Wales. Subjects reviewed 17 780 singleton births (99% of all births) delivered by emergency caesarean section in England and Wales between I May 2000 and 31 July 2000. Main outcome measures Association between decision to delivery interval and baby outcomes (Apgar scores of < 7 and < 4 at five minutes, and stillbirth) and maternal outcomes (requirement for special care additional to routine care after caesarean section and where care was provided). Results Compared with babies delivered within 15 minutes, there was no difference in maternal or baby outcome for decision to delivery interval between 16 and 75 minutes. After 75 minutes, however, there was a significantly higher odds of a five minute Apgar score of < 7 (odds ratio 1.7, 95% confidence interval .1.2 to 2.4), and 50% increase in odds of special care additional to routine care for mothers. Conclusion A decision to delivery interval of 30 minutes is not an absolute threshold for influencing baby outcome. Decision to delivery intervals of more than 75 minutes are associated with poorer maternal and baby outcomes and should be avoided.	Natl Collaborating Ctr Womens & Childrens Hlth, London NW1 4RG, England; Queens Med Ctr, Sch Human Dev, Nottingham NG7 2UH, England	University of Nottingham	Thomas, J (corresponding author), Natl Collaborating Ctr Womens & Childrens Hlth, London NW1 4RG, England.	JThomas@rcog.org.uk		Paranjothy, Shantini/0000-0002-0528-3121				American College of Obstetricians and Gynecologists, 1995, INT J GYNECOL OBSTET, V51, P65; [Anonymous], 2001, WHY MOTHERS DIE 1997; Chauhan SP, 1997, J REPROD MED, V42, P347; DICK W, 1992, EUR J ANAESTH, V9, P15; DUNPHY B C, 1991, Journal of Obstetrics and Gynaecology (Abingdon), V11, P241, DOI 10.3109/01443619109027807; Eddy JW, 2000, HOSP MED, V61, P204, DOI 10.12968/hosp.2000.61.3.1301; GOODWIN TM, AM J OBSTET GYNAECOL, V167, P1506; Hong JY, 2003, INT J OBSTET ANESTH, V12, P12, DOI 10.1016/S0959-289X(02)00183-8; James D, 2001, BMJ-BRIT MED J, V322, P1316, DOI 10.1136/bmj.322.7298.1316; Kolatat Thrathip, 1999, Journal of the Medical Association of Thailand, V82, P40; Lertakyamanee Jariya, 1999, Journal of the Medical Association of Thailand, V82, P672; MacKenzie IZ, 2002, BJOG-INT J OBSTET GY, V109, P498, DOI 10.1111/j.1471-0528.2002.01323.x; MacKenzie IZ, 2001, BRIT MED J, V322, P1334, DOI 10.1136/bmj.322.7298.1334; ROEMER VM, 1992, Z GEBURTSH PERINATOL, V196, P95; Royal College of Obstetricians and Gynaecologists, 2001, US EL FET MON US INT, V8; SCHAUBERGER CW, 1994, J AM COLL SURGEONS, V179, P151; Thomas J., 2001, NATL SENTINEL CAESAR; WALLACE DH, 1995, OBSTET GYNECOL, V86, P193, DOI 10.1016/0029-7844(95)00139-I; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	19	84	89	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 20	2004	328	7441					665	668		10.1136/bmj.38031.775845.7C	http://dx.doi.org/10.1136/bmj.38031.775845.7C			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VB	15023829	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000220392700015
J	Rakitzis, TP; van den Brom, AJ; Janssen, MHM				Rakitzis, TP; van den Brom, AJ; Janssen, MHM			Directional dynamics in the photodissociation of oriented molecules	SCIENCE			English	Article							ANGULAR-DISTRIBUTIONS; PHOTOFRAGMENTATION; PHOTOELECTRON	We observed directional dynamics in the photodissociation of an oriented molecule. When a laser dissociated hexapole-oriented carbonyl sulfide molecules, the three-dimensional recoil of carbon monoxide fragments, which we measured with ion imaging, was strongly asymmetric. We obtained a microscopic view of molecular bond breaking that revealed both the sign and the magnitude of the deflection angle of the fragment in the molecular frame. This experimental approach can be applied to study and control the three-dimensional dynamics of photoinitiated reactions of fixed molecules or molecules oriented by emerging techniques.	Free Univ Amsterdam, Ctr Laser, NL-1081 HV Amsterdam, Netherlands; Free Univ Amsterdam, Dept Chem, NL-1081 HV Amsterdam, Netherlands; Univ Crete, Dept Phys, Iraklion 71110, Greece; Inst Elect Struct & Laser, Fdn Res & Technol Hellas, Iraklion 71110, Greece	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Janssen, MHM (corresponding author), Free Univ Amsterdam, Ctr Laser, De Boelelaan 1083, NL-1081 HV Amsterdam, Netherlands.	mhmj@chem.vu.nl	Rakitzis, T. Peter/C-5564-2011; Janssen, Maurice/ABG-1431-2020; Rakitzis, Peter/ABA-1640-2021	Rakitzis, T. Peter/0000-0002-0385-3936; 				Crompvoets FMH, 2001, NATURE, V411, P174, DOI 10.1038/35075537; Davies JA, 2000, PHYS REV LETT, V84, P5983, DOI 10.1103/PhysRevLett.84.5983; Dong F, 2002, SCIENCE, V298, P1227, DOI 10.1126/science.1076947; Eppink ATJB, 1997, REV SCI INSTRUM, V68, P3477, DOI 10.1063/1.1148310; Forkey JN, 2003, NATURE, V422, P399, DOI 10.1038/nature01529; FRIEDRICH B, 1991, NATURE, V353, P412, DOI 10.1038/353412a0; Friedrich B, 1999, J PHYS CHEM A, V103, P10280, DOI 10.1021/jp992131w; HECK AJR, 1995, ANNU REV PHYS CHEM, V46, P335, DOI 10.1146/annurev.pc.46.100195.002003; Janssen MHM, 1997, J PHYS CHEM A, V101, P7605, DOI 10.1021/jp971159+; Karczmarek J, 1999, PHYS REV LETT, V82, P3420, DOI 10.1103/PhysRevLett.82.3420; Kong W, 2001, INT J MOD PHYS B, V15, P3471, DOI 10.1142/S0217979201007816; KUIPERS EW, 1988, NATURE, V334, P420, DOI 10.1038/334420a0; Larsen JJ, 1999, PHYS REV LETT, V83, P1123, DOI 10.1103/PhysRevLett.83.1123; Leibscher M, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.213001; LOESCH HJ, 1990, J CHEM PHYS, V93, P4779, DOI 10.1063/1.458668; Rakitzis TP, 2003, CHEM PHYS LETT, V372, P187, DOI 10.1016/S0009-2614(03)00399-3; Sakai H, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.083001; Sato H, 2001, CHEM REV, V101, P2687, DOI 10.1021/cr990403l; Schinke R., 1993, PHOTODISSOCIATION DY; Seideman T, 1996, CHEM PHYS LETT, V253, P279, DOI 10.1016/0009-2614(96)00201-1; SIVAKUMAR N, 1985, J PHYS CHEM-US, V89, P3609, DOI 10.1021/j100263a008; Stapelfeldt H, 2003, REV MOD PHYS, V75, P543, DOI 10.1103/RevModPhys.75.543; Suzuki T, 1998, J CHEM PHYS, V109, P5778, DOI 10.1063/1.477200; TAATJES CA, 1993, CHEM PHYS LETT, V203, P363, DOI 10.1016/0009-2614(93)85582-9; Torres EA, 1999, FARADAY DISCUSS, V113, P279, DOI 10.1039/a903734i; van den Brom AJ, 2002, J CHEM PHYS, V117, P4255, DOI 10.1063/1.1496464; Woutersen S, 2002, J PHYS-CONDENS MAT, V14, pR1035, DOI 10.1088/0953-8984/14/39/202; YANG SC, 1974, J CHEM PHYS, V61, P4400, DOI 10.1063/1.1681757	29	139	142	4	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1852	1854		10.1126/science.1094186	http://dx.doi.org/10.1126/science.1094186			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031501				2022-12-28	WOS:000220281600051
J	Heckmann, JG; Lufti, M				Heckmann, JG; Lufti, M			Images in clinical medicine - Angiomatosis associated with Sneddon's syndrome.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Erlangen Nurnberg, D-9105 Erlangen, Germany	University of Erlangen Nuremberg	Heckmann, JG (corresponding author), Univ Erlangen Nurnberg, D-9105 Erlangen, Germany.								0	4	4	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	2004	350	12					E11	E11		10.1056/ENEJMicm020035	http://dx.doi.org/10.1056/ENEJMicm020035			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803PG	15028838				2022-12-28	WOS:000220242400011
J	Berg, AO; Allan, JD; Orleans, CT; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH				Berg, AO; Allan, JD; Orleans, CT; Siu, AL; Teutsch, SM; Westhoff, C; Woolf, SH		US Preventive Serv Task Force	Screening for hepatitis C virus infection in adults: Recommendation statement	ANNALS OF INTERNAL MEDICINE			English	Article								This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on screening for hepatitis C virus (HCV) infection, which are based on the USPSTF's examination of evidence specific to asymptomatic persons for HCV testing and treatment. The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the summary of the evidence and systematic evidence review on this topic.	US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA; Univ Maryland, Baltimore, MD 21201 USA; Colorado Dept Publ Hlth & Environm, Denver, CO USA; Univ Rochester, Rochester, NY USA; Tri Cty Family Med, Cohocton, NY USA; Pan Amer Hlth Org, Washington, DC USA; Univ N Carolina, Sch Med, Chapel Hill, NC USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Univ Rochester, Sch Med, Rochester, NY USA; Univ Michigan, Ann Arbor, MI 48109 USA; Univ Texas, Houston, TX USA; Robert Wood Johnson Fdn, Princeton, NJ 08540 USA; Mt Sinai Sch Med, New York, NY USA; Merck & Co Inc, West Point, PA USA; Columbia Univ, New York, NY USA; Virginia Commonwealth Univ, Fairfax, VA USA	Agency for Healthcare Research & Quality; University System of Maryland; University of Maryland Baltimore; Colorado Department of Public Health & Environment; University of Rochester; Pan American Health Organization; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Rochester; University of Michigan System; University of Michigan; University of Texas System; Robert Wood Johnson Foundation (RWJF); Icahn School of Medicine at Mount Sinai; Merck & Company; Columbia University; Virginia Commonwealth University	Berg, AO (corresponding author), US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA.							Alter Miriam J, 2003, MMWR Recomm Rep, V52, P1; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; *MAN HEP C, 2002, NIH CONSENS STATE SC, V19, P1	3	43	43	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 16	2004	140	6					462	464		10.7326/0003-4819-140-6-200403160-00013	http://dx.doi.org/10.7326/0003-4819-140-6-200403160-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803AU	15023712				2022-12-28	WOS:000220204800007
J	Hess, C; Altfeld, M; Thomas, SY; Addo, MM; Rosenberg, ES; Allen, TM; Draenert, R; Eldrige, RL; van Lunzen, J; Stellbrink, HJ; Walker, BD; Luster, AD				Hess, C; Altfeld, M; Thomas, SY; Addo, MM; Rosenberg, ES; Allen, TM; Draenert, R; Eldrige, RL; van Lunzen, J; Stellbrink, HJ; Walker, BD; Luster, AD			HIV-1 specific CD8+T cells with an effector phenotype and control of viral replication	LANCET			English	Article							T-LYMPHOCYTES	Most people infected with HIV-1 cannot control viral replication despite the presence of virus-specific CD8+ T cells. It has been postulated that this inability is related to the failure of these cells to mature into fully differentiated effector cells. We tested this hypothesis by comparing the maturation phenotype of virus-specific CD8+ T cells in people who could control viral replication off anti-retroviral therapy with those who could not; In five patients with treated acute HIV-1-infection, structured treatment interruption (STI) induced control of viral replication was associated with expansion of virus-specific CD8+ T cells with a fully differentiated effector phenotype. These effector cells were also expanded in treatment-naive chronically infected individuals who spontaneously controlled viral replication, and augmented expression of perforin was noted in both settings. Our data show that full maturation of virus-specific CD8+ T cells is possible in the context of HIV-1-infection, and suggest that such maturation might be important in viral control.	Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Howard Hughes Med Inst, Partners AIDS Res Ctr, Boston, MA 02114 USA; Harvard Univ, Sch Med, Div AIDS, Cambridge, MA 02138 USA; Univ Hamburg, Hosp Eppendorf, Infect Dis Outpatient Clin, Hamburg, Germany	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; University of Hamburg	Luster, AD (corresponding author), Massachusetts Gen Hosp E, Bldg 149,13th St, Charlestown, MA 02482 USA.	luster@helix.mgh.harvard.edu	Allen, Todd/F-5473-2011; Addo, Marylyn M./GNP-2548-2022; Luster, Andrew/ABE-6504-2020; Altfeld, Marcus/AAE-7306-2019	Allen, Todd/0000-0002-6609-1318; Luster, Andrew/0000-0001-9679-7912; Altfeld, Marcus/0000-0001-5972-2997; Addo, Marylyn/0000-0003-2836-9224; Thomas, Seddon/0000-0003-0075-0744				Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385	5	90	94	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	2004	363	9412					863	866		10.1016/S0140-6736(04)15735-8	http://dx.doi.org/10.1016/S0140-6736(04)15735-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15031033				2022-12-28	WOS:000220231500014
J	Wakefield, A				Wakefield, A			A statement by Dr Andrew Wakefield	LANCET			English	Editorial Material												Wakersa@aol.com						Altmann P, 1999, BMJ-BRIT MED J, V319, P807, DOI 10.1136/bmj.319.7213.807	1	8	8	5	53	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	2004	363	9411					823	824		10.1016/S0140-6736(04)15710-3	http://dx.doi.org/10.1016/S0140-6736(04)15710-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15022650				2022-12-28	WOS:000220092000026
J	Evers, IN; de Valk, HW; Visser, GHA				Evers, IN; de Valk, HW; Visser, GHA			Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GLYCEMIC CONTROL; OUTCOMES; DEFINITION; MORTALITY; INFANT; CARE	Objective To investigate maternal, perinatal, and neonatal outcomes of pregnancies in women with type 1 diabetes in the Netherlands. Design Nationwide prospective cohort study Setting All 118 hospitals in the Netherlands. Participants 323 women with type 1 diabetes who became pregnant between 1 April 1999 and 1 April 2000. Main outcome measures Maternal, perinatal, and neonatal Outcomes of pregnancy Results 84% (n = 271) of the pregnancies were planned. Glycaemic control early in pregnancy was good in most women (HbA(1c) less than or equal to 7.0% in 75% (n = 212) of the population), and folic acid supplementation was adequate in 70% (n = 226). 314 pregnancies that went beyond 24 weeks' gestation resulted in 324 infants. rates of pre-eclampsia (40; 12.7%), preterm delivery (101: 32.2%), caesarean section (139; 44.3%), maternal mortality (2, 0.6%), congenital malformations (29; 8.8%), perinatal mortality (9; 2.8%) and macrosomia (146 - 45.1%) were considerably higher than in the general population. Neonatal morbidity (one or more complications) was extremely high (260; 80.2%). The incidence of major congenital malformations was significantly lower in planned pregnancies than in unplanned pregnancies (4.2% (n = 11) v 12.2% (n = 6); relative risk 0.34, 95% confidence interval 0.13 to 0.88). Conclusion Despite a high frequency of planned pregnancies, resulting in overall good glycaemic control (early) in pregnancy and a high rate of adequate use of folic acid, maternal and perinatal complications were Still increased in women With type 1 diabetes. Neonatal morbidity, especially hypoglycaemia, was also extreme]), high. Near optimal maternal glycaemic control (HbA(1c) less than or equal to 7.0%) apparently is not good enough.	Univ Utrecht, Med Ctr, Dept Obstet, NL-3508 AB Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Internal Med & Endocrinol, NL-3508 AB Utrecht, Netherlands	Utrecht University; Utrecht University	Evers, IN (corresponding author), Univ Utrecht, Med Ctr, Dept Obstet, POB 85090, NL-3508 AB Utrecht, Netherlands.	ingwil@worldonline.nl						Altman D.G., 1991, PRACTICAL STAT MED R; *AMD IAB ASS, 2002, DIABETES CARE S1, V25, pS82; American Diabetes Association, 2002, DIABETES CARE S1, V25, ps85; [Anonymous], 1990, Diabet Med, V7, P360; Anthony S, 2001, PAEDIATR PERINAT EP, V15, P306, DOI 10.1046/j.1365-3016.2001.00355.x; Casson IF, 1997, BRIT MED J, V315, P275, DOI 10.1136/bmj.315.7103.275; Cheyne E, 2002, DIABETES-METAB RES, V18, pS43, DOI 10.1002/dmrr.209; CNATTINGIUS S, 1994, DIABETIC MED, V11, P696, DOI 10.1111/j.1464-5491.1994.tb00335.x; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; *DEP HLTH, 2001, NAT SERV FRAM DIAB; Elferink-Stinkens PM, 2001, EUR J OBSTET GYN R B, V94, P125, DOI 10.1016/S0301-2115(00)00295-5; Evers IM, 2002, DIABETOLOGIA, V45, P1484, DOI 10.1007/s00125-002-0958-7; Fisher BM, 1999, HYPOGLYCAEMIA CLIN D, P55; FUHRMANN K, 1983, DIABETES CARE, V6, P219, DOI 10.2337/diacare.6.3.219; Giedion A, 1973, Pediatr Radiol, V1, P145, DOI 10.1007/BF00974058; GRAVENHORST JB, 2001, NED TIJDSCHR OBSTET, V114, P75; GREGORY JW, 1993, BAILLIERE CLIN ENDOC, V7, P587, DOI 10.1016/S0950-351X(05)80208-3; HANSON U, 1993, AM J PERINAT, V10, P330, DOI 10.1055/s-2007-994754; HANSON U, 1990, DIABETOLOGIA, V33, P100, DOI 10.1007/BF00401047; Hawthorne G, 1997, BRIT MED J, V315, P279, DOI 10.1136/bmj.315.7103.279; Holing EV, 1998, DIABETES CARE, V21, P889, DOI 10.2337/diacare.21.6.889; JERVELL J, 1980, DIABETOLOGIA, V18, P131, DOI 10.1007/BF00290489; Kerssen A, 2003, J Matern Fetal Neonatal Med, V13, P309, DOI 10.1080/jmf.13.5.309.313; Kinnala A, 1999, PEDIATRICS, V103, P724, DOI 10.1542/peds.103.4.724; KITZMILLER JL, 1991, JAMA-J AM MED ASSOC, V265, P731, DOI 10.1001/jama.265.6.731; KLOOSTERMAN GJ, 1970, INT J GYNECOL OBSTET, V8, P895, DOI DOI 10.1002/J.1879-3479.1970.TB00313.X; Kyne-Grzebalski D, 1999, DIABETIC MED, V16, P702, DOI 10.1046/j.1464-5491.1999.00131.x; Platt MJ, 2002, DIABETIC MED, V19, P216, DOI 10.1046/j.1464-5491.2002.00665.x; REECE EA, 1994, SEMIN PERINATOL, V18, P459; Schuitemaker N, 1998, EUR J OBSTET GYN R B, V79, P57, DOI 10.1016/S0301-2115(98)00053-0; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; *SIG ZORG, 1999, LAND VERL REG LVR 19; STEEL JM, 1990, BRIT MED J, V301, P1070, DOI 10.1136/bmj.301.6760.1070; STJAMES PJ, 1993, DIABETES CARE, V16, P1572, DOI 10.2337/diacare.16.12.1572; TAMBORLANE WV, 1985, DIABETES, V34, P22, DOI 10.2337/diab.34.3.S22; Taylor R, 2002, OBSTET GYNECOL, V99, P537, DOI 10.1016/S0029-7844(01)01790-2; Vaarasmaki MS, 2000, EARLY HUM DEV, V59, P61, DOI 10.1016/S0378-3782(00)00087-6; VANEYCK J, 1998, 11 WORLD C INT SOC S; VRAY M, 1991, DIABETES CARE, V14, P994; WILLHOITE MB, 1993, DIABETES CARE, V16, P450, DOI 10.2337/diacare.16.2.450	40	464	474	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	2004	328	7445					915	918A		10.1136/bmj.38043.583160.EE	http://dx.doi.org/10.1136/bmj.38043.583160.EE			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	814SM	15066886	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000220994400014
J	Wright, EB; Holcombe, C; Salmon, P				Wright, EB; Holcombe, C; Salmon, P			Doctors communication of trust, care, and respect in breast cancer: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PATIENT COMMUNICATION; PATIENTS PERSPECTIVE; DECISION-MAKING; BAD-NEWS; SKILLS; WOMEN; TRIAL	Objective To determine how patients with breast cancer want their doctors to communicate With them. Design Qualitative study. Setting Breast unit and patients' homes. Participants 39 Women with breast cancer. Main outcome measure Patients' reports of doctors' characteristics or behaviour that they valued or deprecated. Results Patients were not primarily concerned With doctors' communication skills. Instead they emphasised doctors' enduring characteristics. Specifically, they valued doctors whom they believed were technically expert, had formed individual relationships with diem, and respected them. They therefore valued forms of communication that are currently not emphasised in training and research and did not intrinsically value others that are currently thought important, including provision of information and choice. Conclusions Women with breast cancer seek to regard their doctors as attachment figures who will care for them. They seek communication that does not compromise this view and that enhances confidence that they are cared for. Testing and elaborating our analysis will help to focus communication research and teaching on what patients need rather than on what Professionals think they need.	Univ Liverpool, Dept Clin Psychol, Liverpool L69 3GB, Merseyside, England; Royal Liverpool Univ Hosp, Linda McCartney Ctr, Liverpool L7 8XP, Merseyside, England	University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Salmon, P (corresponding author), Univ Liverpool, Dept Clin Psychol, Liverpool L69 3GB, Merseyside, England.	psalmon@liv.ac.uk	Wright, Emma Burkitt/X-6623-2019; Salmon, Peter/H-5289-2018	Salmon, Peter/0000-0001-6450-5209				BOWLBY J, 1998, MAKING BREAKING AFFE; Brunett PH, 2001, ACAD MED, V76, P390, DOI 10.1097/00001888-200104000-00021; Butow PN, 2002, SUPPORT CARE CANCER, V10, P161, DOI 10.1007/s005200100290; Cegala DJ, 2002, MED EDUC, V36, P1004, DOI 10.1046/j.1365-2923.2002.01331.x; de Haes H, 2003, PATIENT EDUC COUNS, V50, P43, DOI 10.1016/S0738-3991(03)00079-X; Fallowfield L, 1999, EUR J CANCER, V35, P1592, DOI 10.1016/S0959-8049(99)00212-9; Fallowfield L, 2002, LANCET, V359, P650, DOI 10.1016/S0140-6736(02)07810-8; Fallowfield L, 1997, PATIENT EDUC COUNS, V30, P209, DOI 10.1016/S0738-3991(96)00947-0; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; Guba E., 1989, 4 GENERATION EVALUAT; Henman MJ, 2002, PSYCHO-ONCOLOGY, V11, P295, DOI 10.1002/pon.566; Hulsman RL, 2002, MED EDUC, V36, P125, DOI 10.1046/j.1365-2923.2002.01074.x; Jefford M, 2002, LANCET ONCOL, V3, P629, DOI 10.1016/S1470-2045(02)00877-X; Larsson G, 1998, J ADV NURS, V27, P855, DOI 10.1046/j.1365-2648.1998.00583.x; Leydon GM, 2000, BMJ-BRIT MED J, V320, P909, DOI 10.1136/bmj.320.7239.909; Maguire P, 1999, EUR J CANCER, V35, P2058, DOI 10.1016/S0959-8049(99)00301-9; McWilliam CL, 2000, PATIENT EDUC COUNS, V39, P191, DOI 10.1016/S0738-3991(99)00040-3; Rankin N, 2000, EUR J CANCER CARE, V9, P97; Rutter DR, 1996, PSYCHOL HEALTH, V12, P57, DOI 10.1080/08870449608406922; Salander P, 1996, SOC SCI MED, V42, P985, DOI 10.1016/0277-9536(95)00204-9; Salander P, 2002, SOC SCI MED, V55, P721, DOI 10.1016/S0277-9536(01)00198-8; Schofield PE, 2001, ANN ONCOL, V12, P365, DOI 10.1023/A:1011100524076; TARTERSALL MHN, 2002, HEMATOL ONCOL CLIN N, V16, P731; Tattersall MHN, 2002, HEMATOL ONCOL CLIN N, V16, P731, DOI 10.1016/S0889-8588(02)00022-9	24	187	188	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 10	2004	328	7444					864	867		10.1136/bmj.38046.771308.7C	http://dx.doi.org/10.1136/bmj.38046.771308.7C			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	812XE	15054034	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000220871400015
J	Banatvala, JE; Brown, DWG				Banatvala, JE; Brown, DWG			Rubella	LANCET			English	Review							CONGENITAL-RUBELLA; PRENATAL-DIAGNOSIS; ORAL-FLUID; DEVELOPING-COUNTRIES; MATERNAL RUBELLA; E1 GLYCOPROTEIN; SYNDROME CRS; VIRUS; INFECTION; MEASLES	Maternal rubella is now rare in many developed countries that have rubella vaccination programmes. However, in many developing countries congenital rubella syndrome (CRS) remains a major cause of developmental anomalies, particularly blindness and deafness. WHO have provided recommendations for prevention of CRS, and, encouragingly, the number of countries introducing rubella vaccination programmes has risen. However, declining uptake rates due to concerns about the measles-mumps-rubella vaccine in the UK, and increasing numbers of cases in some European countries coupled with poor uptake rates might jeopardise this progress. Surveillance of postnatally and congenitally acquired infection is an essential component of CRS prevention since rubella is difficult to diagnose on clinical grounds alone. Laboratory differentiation of rubella from other rash-causing infections, such as measles, parvovirus B19, human herpesvirus 6, and enteroviruses in developed countries, and various endemic arboviruses is essential. Reverse transcriptase PCR and sequencing for diagnosis and molecular epidemiological investigation and detection of rubella-specific IgG and IgM salivary antibody responses in oral fluid are now available.	Kings Coll London, Dept Infect Dis, Virol Sect, London SE1 7EH, England; Hlth Protect Agcy, Enter Resp & Neurol Virus Lab, London, England	University of London; King's College London; Health Protection Agency	Banatvala, JE (corresponding author), Kings Coll London, Dept Infect Dis, Virol Sect, St Thomas Campus, London SE1 7EH, England.	jangu@btopenworld.co.uk						Akingbade D, 2003, CLIN DIAGN LAB IMMUN, V10, P189, DOI 10.1128/CDLI.10.1.189-190.2003; ALNAKIB W, 1975, CLIN EXP IMMUNOL, V22, P293; ANAND A, 1987, NEW ENGL J MED, V316, P183, DOI 10.1056/NEJM198701223160403; ATKINS MC, 1991, POSTGRAD MED J, V67, P375, DOI 10.1136/pgmj.67.786.375; BAKSHI SS, 1990, PEDIATR CLIN N AM, V37, P651; BANARVALA JE, 2000, PRINCIPLES PRACTICE, P387; Banatvala JE, 1998, LANCET, V351, P849, DOI 10.1016/S0140-6736(05)70283-X; BASS JB, 1995, CLIN INFECT DIS, V21, P9, DOI 10.1093/clinids/21.1.9; BEST JM, 1992, INTERVIROLOGY, V34, P164; BONER A, 1983, PEDIATRICS, V72, P835; BOSMA TJ, 1995, J CLIN MICROBIOL, V33, P1075, DOI 10.1128/JCM.33.5.1075-1079.1995; Bosma TJ, 1996, J GEN VIROL, V77, P2523, DOI 10.1099/0022-1317-77-10-2523; Bosma TJ, 1998, J CLIN MICROBIOL, V36, P3524, DOI 10.1128/JCM.36.12.3524-3526.1998; BOSMA TJ, 1995, J CLIN MICROBIOL, V33, P2881, DOI 10.1128/JCM.33.11.2881-2887.1995; BRINK NS, 2000, PRINCIPLES PRACTICE, P467; BUIMOVICIKLEIN E, 1979, PEDIATRICS, V64, P620; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P1117; Chang YC, 1996, CLIN INFECT DIS, V22, P569, DOI 10.1093/clinids/22.3.569; CHANTLER S, 1982, J VIROL METHODS, V4, P305, DOI 10.1016/0166-0934(82)90055-6; CHAYE H, 1992, VIROLOGY, V189, P483, DOI 10.1016/0042-6822(92)90572-7; COOPER LZ, 1967, ARCH OPHTHALMOL-CHIC, V77, P434; Cooray S, 2003, J GEN VIROL, V84, P1275, DOI 10.1099/vir.0.18785-0; CRADOCKWATSON JE, 1980, J HYG-CAMBRIDGE, V85, P381, DOI 10.1017/S0022172400063452; CUSI MG, 1989, ARCH VIROL, V106, P63, DOI 10.1007/BF01311038; Cutts FT, 1997, B WORLD HEALTH ORGAN, V75, P55; Date Masatsune, 1995, No To Hattatsu, V27, P286; Devi R, 2002, LANCET, V360, P803, DOI 10.1016/S0140-6736(02)09916-6; Domegan LM, 2002, J GEN VIROL, V83, P2135, DOI 10.1099/0022-1317-83-9-2135; Duncan R, 2000, VIROLOGY, V275, P20, DOI 10.1006/viro.2000.0467; Eckstein MB, 1996, BRIT MED J, V312, P161; ENDERS G, 1987, INFECTION, V15, P162, DOI 10.1007/BF01646038; ENDERS G, 1988, LANCET, V1, P1445; ENDERS G, 1998, PRANATAL GEBURTSMEDI; FORBES JA, 1969, AM J DIS CHILD, V118, P5, DOI 10.1001/archpedi.1969.02100040007002; Forrest JM, 2002, MED J AUSTRALIA, V177, P664, DOI 10.5694/j.1326-5377.2002.tb05003.x; FRASER JRE, 1983, CLIN EXP RHEUMATOL, V1, P287; Frey TK, 1997, INTERVIROLOGY, V40, P167, DOI 10.1159/000150543; FREY TK, 1994, ADV VIRUS RES, V44, P69, DOI 10.1016/S0065-3527(08)60328-0; Frey TK, 1998, J INFECT DIS, V178, P642, DOI 10.1086/515370; Gerson AA, 2000, PRINCIPLES PRACTICE, P1708; GINSBERGFELLNER F, 1984, DIABETOLOGIA, V27, P87, DOI 10.1007/BF00275655; Gregg NM, 1941, T OPHTHALMOL SOC AUS, V3, P35; HARCOURT GC, 1979, J HYG-CAMBRIDGE, V83, P405, DOI 10.1017/S0022172400026231; HARCOURT GC, 1980, J INFECT DIS, V142, P145, DOI 10.1093/infdis/142.2.145; Hinman AR, 2002, B WORLD HEALTH ORGAN, V80, P264; Hofmann J, 1999, J GEN VIROL, V80, P1657, DOI 10.1099/0022-1317-80-7-1657; Hudson P, 1996, CLIN DIAGN VIROL, V5, P21, DOI 10.1016/0928-0197(95)00155-7; Hyoty H, 2002, DIABETOLOGIA, V45, P1353, DOI 10.1007/s00125-002-0852-3; *I MED, 2001, IMM SAF REV; *INT C MED, 1881, T INT C MED, P14; JEFFRIES D, 1999, VIRAL INFECT OBSTET; Jin L, 2002, B WORLD HEALTH ORGAN, V80, P76; KAROUNOS DG, 1993, J IMMUNOL, V150, P3080; LIM KO, 1995, BIOL PSYCHIAT, V37, P764, DOI 10.1016/0006-3223(94)00219-S; Martinez LD, 2002, J CLIN VIROL, V25, P309, DOI 10.1016/S1386-6532(02)00023-9; MAURACHER CA, 1993, J IMMUNOL, V151, P2041; *MED RES COUNC, 1998, GROUP CONCL NO REAS; Mehl AL, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.1.e4; MENDIS L, 1989, Ceylon Medical Journal, V34, P73; MENSER MA, 1978, LANCET, V1, P57; MENSER MA, 1967, PEDIATRICS, V40, P901; MENSER MA, 1967, LANCET, V2, P1347; MILLER E, 1982, LANCET, V2, P781; Miller E, 1998, BRIT J OBSTET GYNAEC, V105, P174, DOI 10.1111/j.1471-0528.1998.tb10048.x; Mitchell LA, 2000, J RHEUMATOL, V27, P418; Mitchell LA, 1998, J INFECT DIS, V177, P5, DOI 10.1086/513807; Morgan-Capner P, 2002, Commun Dis Public Health, V5, P59; Morgan-Capner P, 1991, CDR (Lond Engl Rev), V1, pR57; MORGANCAPNER P, 1999, VIRAL INFECT OBSTET, P15; MORTIMER PP, 1988, EPIDEMIOL INFECT, V101, P197, DOI 10.1017/S0950268800054108; NAEYE RL, 1965, J AMER MED ASSOC, V194, P1277, DOI 10.1001/jama.194.12.1277; Nokes DJ, 2001, B WORLD HEALTH ORGAN, V79, P588; Nokes DJ, 1998, T ROY SOC TROP MED H, V92, P679, DOI 10.1016/S0035-9203(98)90811-2; OKADA K, 1993, PEDIATR INFECT DIS J, V12, P204, DOI 10.1097/00006454-199303000-00006; Oliveira SA, 2001, EPIDEMIOL INFECT, V127, P509, DOI 10.1017/S0950268801005908; OSHEA S, 1992, J VIROL METHODS, V37, P139, DOI 10.1016/0166-0934(92)90041-B; OSHEA S, 1983, J INFECT DIS, V148, P639, DOI 10.1093/infdis/148.4.639; OSHEA S, 1988, LANCET, V2, P909; OSHIRO LS, 1969, J GEN VIROL, V5, P205, DOI 10.1099/0022-1317-5-2-205; Ou DW, 1999, HUM IMMUNOL, V60, P652, DOI 10.1016/S0198-8859(99)00037-3; Panagiotopoulos T, 1999, BRIT MED J, V319, P1462, DOI 10.1136/bmj.319.7223.1462; *PHLS, 1982, PHLS MON SER, V16; Public Health Service Advisory Committee on Immunisation Practices, 1969, ANN INTERN MED, V70, P1239, DOI 10.7326/0003-4819-70-6-1239; Pugachev KV, 1998, VIROLOGY, V250, P359, DOI 10.1006/viro.1998.9395; Ramsay M, 2002, ARCH DIS CHILD, V87, P202, DOI 10.1136/adc.87.3.202; RAWLS WE, 1968, P SOC EXP BIOL MED, V129, P477, DOI 10.3181/00379727-129-33348; Reef SE, 2002, JAMA-J AM MED ASSOC, V287, P464, DOI 10.1001/jama.287.4.464; Revello MG, 1997, J CLIN MICROBIOL, V35, P708, DOI 10.1128/JCM.35.3.708-713.1997; Robertson SE, 1997, B WORLD HEALTH ORGAN, V75, P69; Robertson Susan E., 2003, Rev Panam Salud Publica, V14, P306, DOI 10.1590/S1020-49892003001000005; SALISBURY DM, 1991, EPI GLOB ADV GROUP M; SCHOUB BD, 2000, PRINCIPLES PRACTICE, P486; SEVER JL, 1985, REV INFECT DIS, V7, pS164; Sheridan E, 2002, LANCET, V359, P674, DOI 10.1016/S0140-6736(02)07805-4; Skendzel LP, 1996, AM J CLIN PATHOL, V106, P170; SKVORCRANKO R, 1991, CAN MED ASSOC J, V145, P649; SLATER PE, 1995, VACCINE, V13, P1529, DOI 10.1016/0264-410X(95)00096-J; SMITH A, 1999, 5 M WHO STEER COMM E; SMITH CA, 1987, RHEUM DIS CLIN N AM, V13, P265; Spika JS, 2003, J INFECT DIS, V187, pS191, DOI 10.1086/368336; STEEN E, 1956, ARCH DIS CHILD, V31, P470, DOI 10.1136/adc.31.160.470; Tait DR, 1996, BRIT MED J, V312, P101; Tang JW, 2003, PRENATAL DIAG, V23, P509, DOI 10.1002/pd.631; TARDIEU M, 1980, J PEDIATR-US, V97, P370, DOI 10.1016/S0022-3476(80)80183-1; THOMAS HIJ, 1993, J MED VIROL, V41, P196, DOI 10.1002/jmv.1890410305; TONDURY G, 1966, J PEDIATR-US, V68, P867, DOI 10.1016/S0022-3476(66)80204-4; UEDA K, 1985, CLIN PEDIATR, V24, P155, DOI 10.1177/000992288502400309; Uhlmann V, 2002, J CLIN PATHOL-MOL PA, V55, P84, DOI 10.1136/mp.55.2.84; vanStraaten HLM, 1996, EUR J PEDIATR, V155, P702, DOI 10.1007/s004310050472; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; Webster WS, 1998, TERATOLOGY, V58, P13; WELLER TH, 1962, P SOC EXP BIOL MED, V111, P215, DOI 10.3181/00379727-111-27749; *WHO, 2002, WKLY EPIDEMIOL REC, V77, P169; *WHO, 2000, M PREV CONG RUB SYND; *WHO, 1999, WHO EUR REG EUR HLTH, V6; WOLINSKY JS, 1996, FIELDS VIROLOGY, P899; World Health Organization, 2000, WKLY EPIDEMIOL REC, V75, P161; 1993, COMMUN DIS REP CDR W, V3, P125; 2003, COMMUN DIS REP CDR W, V13, P4802	119	187	205	0	49	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	2004	363	9415					1127	1137		10.1016/S0140-6736(04)15897-2	http://dx.doi.org/10.1016/S0140-6736(04)15897-2			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808VB	15064032				2022-12-28	WOS:000220595500021
J	Bishop, DK; Zickler, D				Bishop, DK; Zickler, D			Early decision: Meiotic crossover interference prior to stable strand exchange and synapsis	CELL			English	Review							SYNAPTONEMAL COMPLEX PROTEIN; BREAK REPAIR MODEL; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SYNAPSIS; HOLLIDAY JUNCTIONS; GENE CONVERSION; CROSSING-OVER; RECOMBINATION; MEIOSIS; SEGREGATION		Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Paris 11, Inst Genet & Microbiol, UMR8621, F-91405 Orsay, France	University of Chicago; University of Chicago; UDICE-French Research Universities; Universite Paris Saclay	Bishop, DK (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA.	dbishop@midway.uchicago.edu						Allers T, 2001, CELL, V106, P47, DOI 10.1016/S0092-8674(01)00416-0; BELL LR, 1982, COLD SPRING HARB SYM, V47, P829, DOI 10.1101/SQB.1983.047.01.095; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; Borner GV, 2004, CELL, V117, P29, DOI 10.1016/S0092-8674(04)00292-2; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; Colaiacovo MP, 2003, DEV CELL, V5, P463, DOI 10.1016/S1534-5807(03)00232-6; EGEL R, 1995, TRENDS GENET, V11, P206, DOI 10.1016/S0168-9525(00)89046-0; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; Fung JC, 2004, CELL, V116, P795, DOI 10.1016/S0092-8674(04)00249-1; Gilbertson LA, 1996, GENETICS, V144, P27; Henderson KA, 2004, P NATL ACAD SCI USA, V101, P4519, DOI 10.1073/pnas.0400843101; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Hollingsworth NM, 2004, GENE DEV, V18, P117, DOI 10.1101/gad.1165904; Hunter N, 2001, CELL, V106, P59, DOI 10.1016/S0092-8674(01)00430-5; Jones GH., 1987, MEIOSIS; Kaback DB, 1999, GENETICS, V152, P1475; Lee JY, 2001, ANNU REV CELL DEV BI, V17, P753, DOI 10.1146/annurev.cellbio.17.1.753; Lynn A, 2002, SCIENCE, V296, P2222, DOI 10.1126/science.1071220; MAGUIRE MP, 1994, GENETICS, V137, P281; Mazina OM, 2004, CELL, V117, P47, DOI 10.1016/S0092-8674(04)00294-6; NASSIF N, 1994, MOL CELL BIOL, V14, P1613, DOI 10.1128/MCB.14.3.1613; Osman F, 2003, MOL CELL, V12, P761, DOI 10.1016/S1097-2765(03)00343-5; Page SL, 2001, GENE DEV, V15, P3130, DOI 10.1101/gad.935001; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PORTER SE, 1993, GENETICS, V134, P5; Rabitsch KP, 2003, DEV CELL, V4, P535, DOI 10.1016/S1534-5807(03)00086-8; Rockmill B, 2003, CURR BIOL, V13, P1954, DOI 10.1016/j.cub.2003.10.059; Shinohara M, 2003, GENETICS, V163, P1273; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; Storlazzi A, 1996, P NATL ACAD SCI USA, V93, P9043, DOI 10.1073/pnas.93.17.9043; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1995, J CELL BIOL, V128, P455, DOI 10.1083/jcb.128.4.455; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Tarsounas M, 2001, CURR TOP DEV BIOL, V51, P109, DOI 10.1016/S0070-2153(01)51004-2; Tesse S, 2003, P NATL ACAD SCI USA, V100, P12865, DOI 10.1073/pnas.2034282100; Tsubouchi H, 2003, DEV CELL, V5, P915, DOI 10.1016/S1534-5807(03)00357-5; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603; ZICKLER D, 1992, GENETICS, V132, P135	39	263	278	3	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	2004	117	1					9	15		10.1016/S0092-8674(04)00297-1	http://dx.doi.org/10.1016/S0092-8674(04)00297-1			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YV	15066278	Bronze			2022-12-28	WOS:000221500300004
J	Jaeger, H; Haas, H				Jaeger, H; Haas, H			Harnessing nonlinearity: Predicting chaotic systems and saving energy in wireless communication	SCIENCE			English	Article							BACKPROPAGATION; RECONSTRUCTION; RESPONSES	We present a method for learning nonlinear systems, echo state networks (ESNs). ESNs employ artificial recurrent neural networks in a way that has recently been proposed independently as a learning mechanism in biological brains. The learning method is computationally efficient and easy to use. On a benchmark task of predicting a chaotic time series, accuracy is improved by a factor of 2400 over previous techniques. The potential for engineering applications is illustrated by equalizing a communication channel, where the signal error rate is improved by two orders of magnitude.	Int Jacobs Univ Bremen, D-28759 Bremen, Germany		Jaeger, H (corresponding author), Int Jacobs Univ Bremen, D-28759 Bremen, Germany.	h.jaeger@iu-bremen.de	Haas, Harald/AAD-1660-2019					Beiser DG, 1998, J NEUROPHYSIOL, V79, P3168, DOI 10.1152/jn.1998.79.6.3168; BERSINI H, 1997, P IEEE WORLD C COMP, P2102; Chudy L., 1998, Neural Network World, V8, P481; DEHAENE S, 1987, P NATL ACAD SCI USA, V84, P2727, DOI 10.1073/pnas.84.9.2727; DOYA K, 1989, NEURAL NETWORKS, V2, P375, DOI 10.1016/0893-6080(89)90022-1; DOYA K, 1995, HDB BRAIN THEORY NEU, P796; Feldkamp LA, 1998, NONLINEAR MODELING, P29; FUNAHASHI K, 1993, NEURAL NETWORKS, V6, P801, DOI 10.1016/S0893-6080(05)80125-X; GERS F, 2000, IDSIAIDSIA2200; Hertzberg J, 2002, FRONT ARTIF INTEL AP, V77, P708; Hinton G. E., 1981, PARALLEL MODELS ASS, P161; Jaeger H, 2001, BONN GER GER NATL RE, V148, P13; Jaeger H., 2002, SHORT TERM MEMORY EC; Jaeger H, 2002, 159 GMD GERM NAT RES; Kistler WM, 2002, NEURAL COMPUT, V14, P2597, DOI 10.1162/089976602760407991; Maass W, 2002, NEURAL COMPUT, V14, P2531, DOI 10.1162/089976602760407955; Maass W, 2004, MATH COMP BIOL SER, P575; MACKEY MC, 1977, SCIENCE, V197, P287, DOI 10.1126/science.267326; MARTINETZ TM, 1993, IEEE T NEURAL NETWOR, V4, P558, DOI 10.1109/72.238311; MATHEWS VJ, 1994, ADV SIGNAL PROCESSIN, V5, P317; McNames J, 1999, INT J BIFURCAT CHAOS, V9, P1485, DOI 10.1142/S0218127499001048; Mussa-Ivaldi S, 2000, NATURE, V408, P305, DOI 10.1038/35042670; Stanley GB, 1999, J NEUROSCI, V19, P8036, DOI 10.1523/jneurosci.19-18-08036.1999; Stanley GB, 2001, NEUROCOMPUTING, V38, P1703, DOI 10.1016/S0925-2312(01)00535-5; VESANTO J, 1997, P WSOM 97; WERBOS PJ, 1990, P IEEE, V78, P1550, DOI 10.1109/5.58337; Williams RJ, 1989, NEURAL COMPUT, V1, P270, DOI 10.1162/neco.1989.1.2.270; Yao X, 1997, IEEE T NEURAL NETWOR, V8, P694, DOI 10.1109/72.572107; [No title captured]	30	1863	1980	25	248	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					78	80		10.1126/science.1091277	http://dx.doi.org/10.1126/science.1091277			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15064413	Green Submitted			2022-12-28	WOS:000220567900039
J	Mann, J				Mann, J			Free sugars and human health: sufficient evidence for action?	LANCET			English	Editorial Material							SERUM-LIPIDS; BODY-WEIGHT; SUCROSE; CONSUMPTION		Univ Otago, Dept Human Nutr, Dunedin, New Zealand; Univ Otago, Dept Med, Dunedin, New Zealand; Univ Otago, Edgar Natl Ctr Diabet Res, Dunedin, New Zealand	University of Otago; University of Otago; University of Otago	Mann, J (corresponding author), Univ Otago, Dept Human Nutr, Dunedin, New Zealand.	beth.gray@stonebow.otago.ac.nz						[Anonymous], 2004, LANCET, V363, P339; Brynes AE, 2003, BRIT J NUTR, V89, P207, DOI 10.1079/BJN2002769; Institute of Medicine, DIET REF INT EN CARB; *JOINT FAO WHO EXP, 66 UN FAOWHO EXP CON; *JOINT FAO WHO EXP, 2003, DIET NUTR PREV CHRON; Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1; Mann JI, 2000, EUR J CLIN NUTR, V54, P353, DOI 10.1038/sj.ejcn.1600962; MANN JI, 1970, LANCET, V1, P870; *OXFAM, 27 OXFAM; Poppitt SD, 2002, AM J CLIN NUTR, V75, P11, DOI 10.1093/ajcn/75.1.11; Prentice A M, 2003, Obes Rev, V4, P187, DOI 10.1046/j.1467-789X.2003.00117.x; Raben A, 2002, AM J CLIN NUTR, V76, P721, DOI 10.1093/ajcn/76.4.721; Saris WHM, 2000, INT J OBESITY, V24, P1310, DOI 10.1038/sj.ijo.0801451; Smith JB, 1996, EUR J CLIN NUTR, V50, P498; Steyn NP, 2003, B WORLD HEALTH ORGAN, V81, P599; *USDA, SUG SWEET DAT TABL	16	25	30	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	2004	363	9414					1068	1070		10.1016/S0140-6736(04)15844-3	http://dx.doi.org/10.1016/S0140-6736(04)15844-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15051288				2022-12-28	WOS:000220497300023
J	Neugut, AI				Neugut, AI			Preventive oncology - lessons from preventive cardiology	LANCET			English	Editorial Material							CANCER PREVENTION; CIGARETTE-SMOKING; LUNG-CANCER		Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA; New York Presbyterian Hosp, Canc Prevent Program, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; NewYork-Presbyterian Hospital	Neugut, AI (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.	ain1@columbia.edu			NATIONAL CANCER INSTITUTE [K05CA089155] Funding Source: NIH RePORTER; NCI NIH HHS [K05-CA89155] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja R, 2003, SEMIN ONCOL, V30, P94, DOI 10.1053/sonc.2003.50000; American Society of Clinical Oncology, 2003, J Clin Oncol, V21, P2777; Baron JA, 2003, PROG EXP TUMOR RES, V37, P1; Boyle P, 2003, ANN ONCOL, V14, P1312, DOI 10.1093/annonc/mdg353; Bruinooge SS, 2003, J CLIN ONCOL, V21, P2397, DOI 10.1200/JCO.2003.03.189; CURNEN MGM, 1984, CANCER DETECT PREV, V7, P191; DOYLE JT, 1964, JAMA-J AM MED ASSOC, V190, P886; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Gescher AJ, 2003, LANCET ONCOL, V4, P72, DOI 10.1016/S1470-2045(03)00976-8; Goodwin PJ, 2003, J CLIN ONCOL, V21, P2500, DOI 10.1200/JCO.2003.06.121; Puska P, 1993, Eur J Cancer Prev, V2, P457; Quinn MJ, 2003, JNCI-J NATL CANCER I, V95, P1258, DOI 10.1093/jnci/djg063; Rock CL, 2002, J NUTR, V132, p3504S, DOI 10.1093/jn/132.11.3504S; THOMAS HE, 1966, NEW ENGL J MED, V274, P701, DOI 10.1056/NEJM196603312741302; Videtic GMM, 2003, J CLIN ONCOL, V21, P1544, DOI 10.1200/JCO.2003.10.089; Weir HK, 2003, JNCI-J NATL CANCER I, V95, P1276, DOI 10.1093/jnci/djg040; WILLIAMS RR, 1981, JAMA-J AM MED ASSOC, V245, P247, DOI 10.1001/jama.245.3.247; ZHANG S, 1996, CANCER, V76, P275	18	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	2004	363	9414					1004	1005		10.1016/S0140-6736(04)15878-9	http://dx.doi.org/10.1016/S0140-6736(04)15878-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15051278				2022-12-28	WOS:000220497300004
J	Rakic, P				Rakic, P			Genetic control of cortical convolutions	SCIENCE			English	Editorial Material							NEOCORTEX; FOREBRAIN; NEURONS; ORIGIN; SIZE		Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA	Yale University	Rakic, P (corresponding author), Yale Univ, Sch Med, Dept Neurobiol, 333 Cedar St, New Haven, CT 06520 USA.	pasko.rakic@yale.edu						Anderson SA, 1997, SCIENCE, V278, P474, DOI 10.1126/science.278.5337.474; Bishop KM, 2000, SCIENCE, V288, P344, DOI 10.1126/science.288.5464.344; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Fukuchi-Shimogori T, 2001, SCIENCE, V294, P1071, DOI 10.1126/science.1064252; Haydar TF, 1999, CEREB CORTEX, V9, P621, DOI 10.1093/cercor/9.6.621; Letinic K, 2002, NATURE, V417, P645, DOI 10.1038/nature00779; Miyashita-Lin EM, 1999, SCIENCE, V285, P906, DOI 10.1126/science.285.5429.906; Piao XH, 2004, SCIENCE, V303, P2033, DOI 10.1126/science.1092780; Piao XH, 2002, AM J HUM GENET, V70, P1028, DOI 10.1086/339552; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; Rubenstein JLR, 1999, CEREB CORTEX, V9, P521, DOI 10.1093/cercor/9.6.521	12	85	86	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	2004	303	5666					1983	1984		10.1126/science.1096414	http://dx.doi.org/10.1126/science.1096414			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044793				2022-12-28	WOS:000220429800028
J	Kirkup, BC; Riley, MA				Kirkup, BC; Riley, MA			Antibiotic-mediated antagonism leads to a bacterial game of rock-paper-scissors in vivo	NATURE			English	Article							MOUSE LARGE-INTESTINE; ESCHERICHIA-COLI K-12; PROMOTES BIODIVERSITY; STREPTOMYCIN; COLICINOGENY; COLONIZATION; MICE	Colicins are narrow-spectrum antibiotics produced by and active against Escherichia coli and its close relatives. Colicin-producing strains cannot coexist with sensitive or resistant strains in a well-mixed culture, yet all three phenotypes are recovered in natural populations(1). Recent in vitro results conclude that strain diversity can be promoted by colicin production in a spatially structured, non-transitive interaction(2), as in the classic nontransitive model rock - paper - scissors (RPS). In the colicin version of the RPS model, strains that produce colicins (C) kill sensitive (S) strains, which outcompete resistant (R) strains, which outcompete C strains. Pairwise in vitro competitions between these three strains are resolved in a predictable order ( C beats S, S beats R, and R beats C), but the complete system of three strains presents the opportunity for dynamic equilibrium(2). Here we provide conclusive evidence of an in vivo antagonistic role for colicins and show that colicins ( and potentially other bacteriocins) may promote, rather than eliminate, microbial diversity in the environment.	Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06511 USA	Yale University	Kirkup, BC (corresponding author), Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06511 USA.	bckirkup@post.harvard.edu	Kirkup, Benjamin/C-3610-2009; Riley, Margaret Ann/AAB-9743-2022	Kirkup, Benjamin/0000-0002-8722-6218; 				BERRY RJ, 1981, S ZOOLOGICAL SOC LON, V47, P395; CHAO L, 1981, P NATL ACAD SCI-BIOL, V78, P6324, DOI 10.1073/pnas.78.10.6324; Czaran TL, 2002, P NATL ACAD SCI USA, V99, P786, DOI 10.1073/pnas.012399899; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; Durrett R, 1998, THEOR POPUL BIOL, V53, P30, DOI 10.1006/tpbi.1997.1338; Durrett R, 1997, J THEOR BIOL, V185, P165, DOI 10.1006/jtbi.1996.0292; Feldgarden M, 1999, EVOLUTION, V53, P1019, DOI 10.1111/j.1558-5646.1999.tb04517.x; FREDERICQ P, 1957, ANNU REV MICROBIOL, V11, P7, DOI 10.1146/annurev.mi.11.100157.000255; Gordon DM, 1999, MICROBIOL-SGM, V145, P655, DOI 10.1099/13500872-145-3-655; Gordon DM, 1998, MICROBIOL-SGM, V144, P2233, DOI 10.1099/00221287-144-8-2233; HARDY KG, 1975, BACTERIOL REV, V39, P464, DOI 10.1128/MMBR.39.4.464-515.1975; HENTGES D J, 1990, Microbial Ecology in Health and Disease, V3, P105; Kerr B, 2002, NATURE, V418, P171, DOI 10.1038/nature00823; LAU CYY, 1976, BIOLOGY, P89; Maynard Smith J., 1982, EVOLUTION THEORY GAM; Myhal M L, 1982, Eur J Clin Microbiol, V1, P186, DOI 10.1007/BF02019621; MYHAL ML, 1983, J GEN MICROBIOL, V129, P1549; Pugsley A, 1987, METHODS STUDYING COL; PUGSLEY AP, 1985, J GEN MICROBIOL, V131, P369; QUE JU, 1986, INFECT IMMUN, V53, P116, DOI 10.1128/IAI.53.1.116-123.1986; ROWE FP, 1981, S ZOOL SOC LOND, V47, P575; Sweeney NJ, 1996, INFECT IMMUN, V64, P3497, DOI 10.1128/IAI.64.9.3497-3503.1996; WADOLKOWSKI EA, 1988, INFECT IMMUN, V56, P1030, DOI 10.1128/IAI.56.5.1030-1035.1988; Wald A, 1943, T AM MATH SOC, V54, P426, DOI 10.2307/1990256; Weibull J.W., 1997, EVOLUTIONARY GAME TH; WILSON KH, 1997, GASTROINTESTINAL MIC, P680	26	355	359	0	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 25	2004	428	6981					412	414		10.1038/nature02429	http://dx.doi.org/10.1038/nature02429			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042087				2022-12-28	WOS:000220404300039
J	Lister, TA				Lister, TA			Who should receive myeloablative therapy for lymphoma?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									St Bartholomews Hosp, Dept Med Oncol, London, England	University of London; Queen Mary University London	Lister, TA (corresponding author), St Bartholomews Hosp, Dept Med Oncol, London, England.								0	5	5	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2004	350	13					1277	1278		10.1056/NEJMp048007	http://dx.doi.org/10.1056/NEJMp048007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VN	15044635				2022-12-28	WOS:000220393900002
J	Nishimura, RA; Holmes, DR				Nishimura, RA; Holmes, DR			Hypertrophic obstructive cardiomyopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUB-AORTIC STENOSIS; SUBAORTIC STENOSIS; SUDDEN-DEATH; CLINICAL IMPROVEMENT; OUTFLOW OBSTRUCTION; DOUBLE-BLIND; TERM; PREVENTION; MANAGEMENT; VERAPAMIL		Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA	Mayo Clinic	Nishimura, RA (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.							BONOW RO, 1985, CIRCULATION, V72, P853, DOI 10.1161/01.CIR.72.4.853; BRAUNWALD E, 1964, CIRCULATION, V30, P3; Braunwald E, 2002, CIRCULATION, V106, P1312, DOI 10.1161/01.CIR.0000030314.11999.6A; COHEN LS, 1967, CIRCULATION, V35, P847, DOI 10.1161/01.CIR.35.5.847; Elliott PM, 2001, LANCET, V357, P420, DOI 10.1016/S0140-6736(00)04005-8; EPSTEIN SE, 1981, CIRCULATION, V64, P437, DOI 10.1161/01.CIR.64.3.437; FANANAPAZIR L, 1994, CIRCULATION, V90, P2731, DOI 10.1161/01.CIR.90.6.2731; FLAMM MD, 1968, CIRCULATION, V38, P846, DOI 10.1161/01.CIR.38.5.846; MARIAN AJ, 1995, CIRCULATION, V92, P1336, DOI 10.1161/01.CIR.92.5.1336; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Maron BJ, 2003, NEW ENGL J MED, V349, P1064, DOI 10.1056/NEJMra022783; Maron BJ, 2003, J AM COLL CARDIOL, V42, P882, DOI 10.1016/S0735-1097(03)00855-6; Maron BJ, 2003, CIRCULATION, V107, P2872, DOI 10.1161/01.CIR.0000072343.81530.75; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; Maron BJ, 1998, CIRCULATION, V98, P2505, DOI 10.1161/01.CIR.98.23.2505; Maron BJ, 1999, CIRCULATION, V99, P2927, DOI 10.1161/01.CIR.99.22.2927; Maron BJ, 2000, LANCET, V355, P425, DOI 10.1016/S0140-6736(00)82005-X; Maron BJ, 2003, EUR HEART J, V24, P1965, DOI 10.1016/S0195-668X(03)00479-2; Maron BJ, 2000, NEW ENGL J MED, V342, P365, DOI 10.1056/NEJM200002103420601; McCully RB, 1996, CIRCULATION, V94, P467, DOI 10.1161/01.CIR.94.3.467; MORROW AG, 1978, J THORAC CARDIOV SUR, V76, P423; Nishimura RA, 1997, J AM COLL CARDIOL, V29, P435, DOI 10.1016/S0735-1097(96)00473-1; Nishimura RA, 1996, MAYO CLIN PROC, V71, P1077, DOI 10.4065/71.11.1077; Olivotto I, 2001, CIRCULATION, V104, P2517, DOI 10.1161/hc4601.097997; Ommen SR, 1999, J AM COLL CARDIOL, V34, P191, DOI 10.1016/S0735-1097(99)00173-4; POLLICK C, 1982, NEW ENGL J MED, V307, P997, DOI 10.1056/NEJM198210143071607; ROSING DR, 1981, AM J CARDIOL, V48, P545, DOI 10.1016/0002-9149(81)90086-2; Schulte HD, 1999, THORAC CARDIOV SURG, V47, P213, DOI 10.1055/s-2007-1013146; Seggewiss H, 1998, J AM COLL CARDIOL, V31, P252, DOI 10.1016/S0735-1097(97)00508-1; SIGWART U, 1995, LANCET, V346, P211, DOI 10.1016/S0140-6736(95)91267-3; Singh M, 2001, MAYO CLIN PROC, V76, P799; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6	33	180	190	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2004	350	13					1320	1327		10.1056/NEJMcp030779	http://dx.doi.org/10.1056/NEJMcp030779			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VN	15044643				2022-12-28	WOS:000220393900010
J	Allen, TM; Cullis, PR				Allen, TM; Cullis, PR			Drug delivery systems: Entering the mainstream	SCIENCE			English	Article							PEGYLATED LIPOSOMAL DOXORUBICIN; AMPHOTERICIN-B AMBISOME; PHASE-I; POLYETHYLENE-GLYCOL; TRIAL; RELEASE; PHARMACOKINETICS; LOCALIZATION; THERAPEUTICS; PERMEABILITY	Drug delivery systems (DDS) such as lipid- or polymer-based nanoparticles can be designed to improve the pharmacological and therapeutic properties of drugs administered parenterally. Many of the early problems that hindered the clinical applications of particulate DDS have been overcome, with several DDS formulations of anticancer and antifungal drugs now approved for clinical use. Furthermore, there is considerable interest in exploiting the advantages of DDS for in vivo delivery of new drugs derived from proteomics or genomics research and for their use in ligand-targeted therapeutics.	Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Inex Pharmaceut Corp, Burnaby, BC V5J 5J8, Canada	University of Alberta; University of British Columbia	Allen, TM (corresponding author), Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada.	terry.allen@ualberta.ca						ADLERMOORE J, 1994, BONE MARROW TRANSPL, V14, pS3; Alberts DS, 1997, DRUGS, V54, P30, DOI 10.2165/00003495-199700544-00007; Allen TM, 2002, NAT REV CANCER, V2, P750, DOI 10.1038/nrc903; Batist G, 2001, J CLIN ONCOL, V19, P1444, DOI 10.1200/JCO.2001.19.5.1444; Bolotin Elijah M., 1994, Journal of Liposome Research, V4, P455, DOI 10.3109/08982109409037057; BORY C, 1991, ADV EXP MED BIOL, V309, P173; Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5; Cabanes A, 1998, INT J ONCOL, V12, P1035; Chowdhary RK, 2003, J PHARM PHARM SCI, V6, P13; Cullis PR, 1997, BBA-REV BIOMEMBRANES, V1331, P187, DOI 10.1016/S0304-4157(97)00006-3; DAVIDSON RN, 1994, Q J MED, V87, P75; Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088; Edens HA, 2002, J IMMUNOL, V169, P476, DOI 10.4049/jimmunol.169.1.476; Fang J, 2003, ADV EXP MED BIOL, V519, P29; Gabizon A, 2003, CLIN PHARMACOKINET, V42, P419, DOI 10.2165/00003088-200342050-00002; Gelmon KA, 1999, J CLIN ONCOL, V17, P697, DOI 10.1200/JCO.1999.17.2.697; Glantz MJ, 1999, J CLIN ONCOL, V17, P3110, DOI 10.1200/JCO.1999.17.10.3110; Glantz MJ, 1999, CLIN CANCER RES, V5, P3394; Glue P, 2000, HEPATOLOGY, V32, P647, DOI 10.1053/jhep.2000.16661; Guo X, 2003, ACCOUNTS CHEM RES, V36, P335, DOI 10.1021/ar9703241; Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Huwyler J, 1996, P NATL ACAD SCI USA, V93, P14164, DOI 10.1073/pnas.93.24.14164; JAIN RK, 1987, CANCER METAST REV, V6, P559, DOI 10.1007/BF00047468; Kaminski MS, 2001, J CLIN ONCOL, V19, P3918, DOI 10.1200/JCO.2001.19.19.3918; Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8; LaVan DA, 2003, NAT BIOTECHNOL, V21, P1184, DOI 10.1038/nbt876; Liu MJ, 2000, J CONTROL RELEASE, V65, P121, DOI 10.1016/S0168-3659(99)00245-X; Lotem M, 2000, ARCH DERMATOL, V136, P1475, DOI 10.1001/archderm.136.12.1475; Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5; Mehvar Reza, 2003, Current Pharmaceutical Biotechnology, V4, P283, DOI 10.2174/1389201033489685; Moghimi SM, 2001, PHARMACOL REV, V53, P283; Muggia F, 2001, EUR J CANCER, V37, pS15; Nabhan C, 2002, CLIN LYMPHOMA, V2, pS19, DOI 10.3816/CLM.2002.s.004; Netti PA, 1996, MICROVASC RES, V52, P27, DOI 10.1006/mvre.1996.0041; Northfelt DW, 1996, J CLIN PHARMACOL, V36, P55, DOI 10.1002/j.1552-4604.1996.tb04152.x; Ogris Manfred, 2002, Somatic Cell and Molecular Genetics, V27, P85, DOI 10.1023/A:1022988008131; Olsen E, 2001, J CLIN ONCOL, V19, P376, DOI 10.1200/JCO.2001.19.2.376; Pastorino F, 2003, CLIN CANCER RES, V9, P4595; PETERS BG, 1995, FORMULARY, V30, P388; SAMUELS BL, 1987, CANCER TREAT REP, V71, P971; Schiffelers RM, 2001, PHARMACEUT RES, V18, P780, DOI 10.1023/A:1011080211226; Semple SC, 1996, BIOCHEMISTRY-US, V35, P2521, DOI 10.1021/bi950414i; Senter PD, 2001, ADV DRUG DELIVER REV, V53, P247, DOI 10.1016/S0169-409X(01)00206-X; Seymour LW, 1998, INT J ONCOL, V12, P1217; Siena S, 2003, ONCOL REP, V10, P715; Smith DH, 2002, ANN ONCOL, V13, P1590, DOI 10.1093/annonc/mdf275; Szebeni J, 2002, J LIPOSOME RES, V12, P165, DOI 10.1081/LPR-120004790; Tardi P, 2000, CANCER RES, V60, P3389; Templeton NS, 2003, EXPERT OPIN BIOL TH, V3, P57, DOI 10.1517/eobt.3.1.57.20953; Terwogt JMM, 2002, CANCER CHEMOTH PHARM, V49, P201, DOI 10.1007/s002800100371; TOLLEMAR J, 1992, MYCOSES, V35, P215, DOI 10.1111/j.1439-0507.1992.tb00850.x; TREAT J, 2000, P AN M AM SOC CLIN, V19, pA225; UZIELY B, 1995, J CLIN ONCOL, V13, P1777, DOI 10.1200/JCO.1995.13.7.1777; Vasey PA, 1999, CLIN CANCER RES, V5, P83; Wiseman GA, 2002, BLOOD, V99, P4336, DOI 10.1182/blood.V99.12.4336	56	3411	3554	29	1979	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1818	1822		10.1126/science.1095833	http://dx.doi.org/10.1126/science.1095833			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031496				2022-12-28	WOS:000220281600044
J	Badjic, JD; Balzani, V; Credi, A; Silvi, S; Stoddart, JF				Badjic, JD; Balzani, V; Credi, A; Silvi, S; Stoddart, JF			A molecular elevator	SCIENCE			English	Article							MOTION	We report the incrementally staged design, synthesis, characterization, and operation of a molecular machine that behaves like a nanoscale elevator. The operation of this device, which is made of a platformlike component interlocked with a trifurcated riglike component and is only 3.5 nanometers by 2.5 nanometers in size, relies on the integration of several structural and functional molecular subunits. This molecular elevator is considerably more complex and better organized than previously reported artificial molecular machines. It exhibits a clear-cut on-off reversible behavior, and it could develop forces up to around 200 piconewtons.	Univ Bologna, Dipartimento Chim G Ciamician, I-40126 Bologna, Italy; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA	University of Bologna; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Credi, A (corresponding author), Univ Bologna, Dipartimento Chim G Ciamician, Via Selmi 2, I-40126 Bologna, Italy.	alberto.credi@unibo.it; stoddart@chem.ucla.edu	Badjic, Jovica/H-9134-2013; Credi, Alberto/H-4450-2011; Stoddart, James Fraser/H-1518-2011	Credi, Alberto/0000-0003-2546-9801; Stoddart, James Fraser/0000-0003-3161-3697; Silvi, Serena/0000-0001-9273-4148				ANDERSON S, 1993, ACCOUNTS CHEM RES, V26, P469, DOI 10.1021/ar00033a003; ANELLI PL, 1991, J AM CHEM SOC, V113, P5131, DOI 10.1021/ja00013a096; Ashton PR, 1998, J AM CHEM SOC, V120, P11932, DOI 10.1021/ja982167m; Ashton PR, 2000, CHEM-EUR J, V6, P3558, DOI 10.1002/1521-3765(20001002)6:19<3558::AID-CHEM3558>3.0.CO;2-M; Balzani V, 2003, CHEM-EUR J, V9, P5348, DOI 10.1002/chem.200304979; Balzani V, 2000, ANGEW CHEM INT EDIT, V39, P3348, DOI 10.1002/1521-3773(20001002)39:19<3348::AID-ANIE3348>3.0.CO;2-X; Balzani V., 2003, MOL DEVICES MACHINES, VSecond; Brouwer AM, 2001, SCIENCE, V291, P2124, DOI 10.1126/science.1057886; Cantrill SJ, 2000, J CHEM SOC DALTON, P3715, DOI 10.1039/b003769i; Collin JP, 2001, ACCOUNTS CHEM RES, V34, P477, DOI 10.1021/ar0001766; Kelly TR, 1999, NATURE, V401, P150, DOI 10.1038/43639; Koumura N, 1999, NATURE, V401, P152, DOI 10.1038/43646; Leigh DA, 2003, NATURE, V424, P174, DOI 10.1038/nature01758; Luo Y, 2002, CHEMPHYSCHEM, V3, P519, DOI 10.1002/1439-7641(20020617)3:6<519::AID-CPHC519>3.0.CO;2-2; Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755; MartinezDiaz MV, 1997, ANGEW CHEM INT EDIT, V36, P1904, DOI 10.1002/anie.199719041; Monk P. M. S., 1998, PHYSICOCHEMICAL PROP; Oster G, 2003, TRENDS CELL BIOL, V13, P114, DOI 10.1016/S0962-8924(03)00004-7; Sauvage, 1999, MOL CATENANES ROTAXA; Schliwa M, 2003, NATURE, V422, P759, DOI 10.1038/nature01601; Soong RK, 2000, SCIENCE, V290, P1555, DOI 10.1126/science.290.5496.1555; Steinberg-Yfrach G, 1998, NATURE, V392, P479, DOI 10.1038/33116	22	889	896	12	371	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1845	1849		10.1126/science.1094791	http://dx.doi.org/10.1126/science.1094791			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031499				2022-12-28	WOS:000220281600049
J	Ohnaka, M				Ohnaka, M			Rupture in the laboratory	SCIENCE			English	Editorial Material							EARTHQUAKE RUPTURE; SHEAR; ZONE; TIP		UCL, London WC1E 6BT, England; Univ Tokyo, Bunkyo Ku, Tokyo 113, Japan	University of London; University College London; University of Tokyo	Ohnaka, M (corresponding author), Univ Tokyo, Bunkyo Ku, Tokyo 113, Japan.	ohnaka@g05.itscom.net						AKI K, 1979, J GEOPHYS RES, V84, P6140, DOI 10.1029/JB084iB11p06140; ANDREWS DJ, 1976, J GEOPHYS RES, V81, P5679, DOI 10.1029/JB081i032p05679; Bouchon M, 1997, J GEOPHYS RES-SOL EA, V102, P11731, DOI 10.1029/97JB00623; Das S, 2003, PURE APPL GEOPHYS, V160, P579, DOI 10.1007/PL00012551; IDA Y, 1972, J GEOPHYS RES, V77, P3796, DOI 10.1029/JB077i020p03796; KANAMORI H, 1978, J GEOPHYS RES, V83, P3427, DOI 10.1029/JB083iB07p03427; Madariaga R., 2002, INT HDB EARTHQUAKE A, V81A, P175, DOI DOI 10.1016/S0074-6142%2802%2980215-7; MATSUURA M, 2002, EARTHQUAKE PROCESS 2; MATSUURA M, 2002, EARTHQUAKE PROCESS 1; Ohnaka M, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2000JB000123; OHNAKA M, 1987, TECTONOPHYSICS, V144, P109, DOI 10.1016/0040-1951(87)90011-4; OHNAKA M, 1989, J GEOPHYS RES-SOLID, V94, P4089, DOI 10.1029/JB094iB04p04089; OKUBO PG, 1984, J GEOPHYS RES, V89, P5817, DOI 10.1029/JB089iB07p05817; Xia KW, 2004, SCIENCE, V303, P1859, DOI 10.1126/science.1094022	14	3	5	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1788	1789		10.1126/science.1095765	http://dx.doi.org/10.1126/science.1095765			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031488				2022-12-28	WOS:000220281600036
J	Stevens, CJ; Dise, NB; Mountford, JO; Gowing, DJ				Stevens, CJ; Dise, NB; Mountford, JO; Gowing, DJ			Impact of nitrogen deposition on the species richness of grasslands	SCIENCE			English	Article							SEMINATURAL GRASSLANDS; VEGETATION; LIMITATION; SWEDEN; TRENDS	A transect of 68 acid grasslands across Great Britain, covering the lower range of ambient annual nitrogen deposition in the industrialized world ( 5 to 35 kg N ha(-1) year(-1)), indicates that long-term, chronic nitrogen deposition has significantly reduced plant species richness. Species richness declines as a linear function of the rate of inorganic nitrogen deposition, with a reduction of one species per 4-m(2) quadrat for every 2.5 kg N ha(-1) year(-1) of chronic nitrogen deposition. Species adapted to infertile conditions are systematically reduced at high nitrogen deposition. At the mean chronic nitrogen deposition rate of central Europe (17 kgNha(-1) year(-1)), there is a 23% species reduction compared with grasslands receiving the lowest levels of nitrogen deposition.	Open Univ, Dept Earth Sci, Milton Keynes MK7 6AA, Bucks, England; Open Univ, Dept Biol Sci, Milton Keynes MK7 6AA, Bucks, England; Villanova Univ, Dept Biol, Villanova, PA 19085 USA; NERC, Ctr Ecol & Hydrol, Huntingdon PE17 2LS, England	Open University - UK; Open University - UK; Villanova University; UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Stevens, CJ (corresponding author), Open Univ, Dept Earth Sci, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.	c.j.stevens@open.ac.uk		Stevens, Carly/0000-0002-2390-1763				AERTS R, 1990, OIKOS, V57, P310, DOI 10.2307/3565959; Baumgardner RE, 2002, ENVIRON SCI TECHNOL, V36, P2614, DOI 10.1021/es011146g; Berendse F., 1990, Perspectives on plant competition., P93; Blake L, 1999, EUR J SOIL SCI, V50, P401, DOI 10.1046/j.1365-2389.1999.00253.x; Bobbink R, 1998, J ECOL, V86, P717, DOI 10.1046/j.1365-2745.1998.8650717.x; *CTR EC HYDR, 2001, TRANSB AIR POLL AC E; Diekmann M, 1999, PLANT BIOLOGY, V1, P471, DOI 10.1111/j.1438-8677.1999.tb00730.x; DIRKSE GM, 1992, BIOL CONSERV, V59, P155, DOI 10.1016/0006-3207(92)90576-9; Galloway JN, 1995, WATER AIR SOIL POLL, V85, P15, DOI 10.1007/BF00483685; Gaston KJ, 2000, NATURE, V405, P220, DOI 10.1038/35012228; Goulding KWT, 1998, NEW PHYTOL, V139, P49, DOI 10.1046/j.1469-8137.1998.00182.x; HALL J, 1998, STATUS CRITICAL LOAD; HALLINGBACK T, 1992, BIOL CONSERV, V59, P163, DOI 10.1016/0006-3207(92)90577-A; Hill M.O., 1999, ELLENBERGS INDICATOR; Kent M., 2012, VEGETATION DESCRIPTI, V2nd ed.; Lee JA, 1998, NEW PHYTOL, V139, P127, DOI 10.1046/j.1469-8137.1998.00165.x; MORECROFT MD, 1994, J ECOL, V82, P475, DOI 10.2307/2261256; MOUNTFORD JO, 1993, J APPL ECOL, V30, P321, DOI 10.2307/2404634; Phoenix GK, 2003, GLOBAL CHANGE BIOL, V9, P1309, DOI 10.1046/j.1365-2486.2003.00660.x; RODWELL JS, 1992, GRASSLANDS MONTANE C; SILVERTOWN J, 1980, J APPL ECOL, V17, P491, DOI 10.2307/2402344; VITOUSEK PM, 1991, BIOGEOCHEMISTRY, V13, P87; Wedin DA, 1996, SCIENCE, V274, P1720, DOI 10.1126/science.274.5293.1720; Wright RF, 2001, HYDROL EARTH SYST SC, V5, P299, DOI 10.5194/hess-5-299-2001; 1992, 9243EEC; [No title captured]	26	1029	1162	39	883	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	2004	303	5665					1876	1879		10.1126/science.1094678	http://dx.doi.org/10.1126/science.1094678			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031507				2022-12-28	WOS:000220281600058
J	Schafer, AI				Schafer, AI			Current concepts - Thrombocytosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE MYELOID-LEUKEMIA; BCR-ABL TRANSCRIPTS; C-MPL; THROMBOPOIETIN RECEPTOR; CLINICAL-SIGNIFICANCE; FOLLOW-UP; HYDROXYUREA; EXPRESSION; RISK; COMPLICATIONS		Univ Penn Hlth Syst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Schafer, AI (corresponding author), Univ Penn Hlth Syst, 100 Centrex,3400 Spruce St, Philadelphia, PA 19104 USA.	schafer@uphs.upenn.edu						Aviram A, 1999, LEUKEMIA LYMPHOMA, V33, P77, DOI 10.3109/10428199909093727; Axelrad AA, 2000, BLOOD, V96, P3310; BARBUI T, 1987, AM J MED, V83, P265, DOI 10.1016/0002-9343(87)90696-6; Bazzan M, 1999, ANN HEMATOL, V78, P539, DOI 10.1007/s002770050555; Bernasconi P, 2002, LEUKEMIA, V16, P2078, DOI 10.1038/sj.leu.2402638; BUSS DH, 1994, AM J MED, V96, P247, DOI 10.1016/0002-9343(94)90150-3; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; Cervantes F, 2002, BRIT J HAEMATOL, V118, P786, DOI 10.1046/j.1365-2141.2002.03688.x; CORTELAZZO S, 1995, NEW ENGL J MED, V332, P1132, DOI 10.1056/NEJM199504273321704; Emilia G, 2001, BLOOD, V97, P2187, DOI 10.1182/blood.V97.7.2187; Finazzi G, 2000, BRIT J HAEMATOL, V110, P577, DOI 10.1046/j.1365-2141.2000.02188.x; Folman CC, 2001, BRIT J HAEMATOL, V114, P126, DOI 10.1046/j.1365-2141.2001.02888.x; Griesshammer M, 1999, J INTERN MED, V245, P295, DOI 10.1046/j.1365-2796.1999.00452.x; Hanft VN, 2000, BLOOD, V95, P3589, DOI 10.1182/blood.V95.11.3589.011k38_3589_3593; Harrison CN, 1999, BLOOD, V93, P417, DOI 10.1182/blood.V93.2.417.402a33_417_424; Harrison CN, 2002, BRIT J HAEMATOL, V117, P796, DOI 10.1046/j.1365-2141.2002.03474.x; Heller P, 2001, BLOOD, V98, P1990, DOI 10.1182/blood.V98.6.1990; Hoffman R, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.33753; Horikawa Y, 1997, BLOOD, V90, P4031, DOI 10.1182/blood.V90.10.4031; Hsu HC, 1999, J LAB CLIN MED, V134, P392, DOI 10.1016/S0022-2143(99)90154-3; Ishiguro A, 2002, BRIT J HAEMATOL, V116, P612, DOI 10.1046/j.0007-1048.2001.03304.x; Jurado M, 2001, BRIT J HAEMATOL, V112, P392, DOI 10.1046/j.1365-2141.2001.02584.x; Kaser A, 2001, BLOOD, V98, P2720, DOI 10.1182/blood.V98.9.2720; KAUSHANSKY K, 2003, THROMBOSIS HEMORRHAG, P120; Kesler A, 2000, ACTA NEUROL SCAND, V102, P299, DOI 10.1034/j.1600-0404.2000.102005299.x; Kondo T, 1998, BLOOD, V92, P1091, DOI 10.1182/blood.V92.4.1091.416a36_1091_1096; Landolfi R, 2004, NEW ENGL J MED, V350, P114, DOI 10.1056/NEJMoa035572; Li JZ, 2000, BRIT J HAEMATOL, V111, P943; Liozon E, 1997, HEMATOL CELL THER, V39, P11, DOI 10.1007/s00282-997-0011-x; Liu E, 2003, BLOOD, V101, P3294, DOI 10.1182/blood-2002-07-2287; Mesa RA, 2002, BLOOD, V99, P4131, DOI 10.1182/blood.V99.11.4131; Mesa RA, 1999, AM J HEMATOL, V61, P10, DOI 10.1002/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.3.CO;2-9; Moliterno AR, 1998, NEW ENGL J MED, V338, P572, DOI 10.1056/NEJM199802263380903; Pearson TC, 2002, SEMIN ONCOL, V29, P16, DOI 10.1053/sonc.2002.33756; Picardi M, 2002, BLOOD, V99, P4228, DOI 10.1182/blood.V99.11.4228; Schafer AI, 2001, BLOOD REV, V15, P159, DOI 10.1054/blre.2001.0162; Shih LY, 2002, BLOOD, V100, P1596, DOI 10.1182/blood.V100.5.1596.h81702001596_1596_1601; Sterkers Y, 1998, BLOOD, V91, P616, DOI 10.1182/blood.V91.2.616.616_616_622; Storen EC, 2001, BLOOD, V97, P863, DOI 10.1182/blood.V97.4.863; Takahashi H, 2000, AM J HEMATOL, V64, P120, DOI 10.1002/(SICI)1096-8652(200006)64:2<120::AID-AJH9>3.0.CO;2-M; Teofili L, 2002, BLOOD, V100, P714, DOI 10.1182/blood.V100.2.714; Thiele J, 2002, AM J HEMATOL, V70, P283, DOI 10.1002/ajh.10116; Tomer A, 2002, BLOOD, V99, P1602, DOI 10.1182/blood.V99.5.1602; Wang JC, 1998, AM J MED, V104, P451, DOI 10.1016/S0002-9343(98)00090-4; Wiestner A, 1998, NAT GENET, V18, P49, DOI 10.1038/ng0198-49; Wolber EM, 2001, THROMB HAEMOSTASIS, V86, P1421; Wright CA, 2001, EUR J HAEMATOL, V66, P152, DOI 10.1034/j.1600-0609.2001.00367.x	47	253	272	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 18	2004	350	12					1211	1219		10.1056/NEJMra035363	http://dx.doi.org/10.1056/NEJMra035363			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803PG	15028825				2022-12-28	WOS:000220242400008
J	Raithatha, N; Smith, RD				Raithatha, N; Smith, RD			Disclosure of genetic tests for health insurance: is it ethical not to?	LANCET			English	Editorial Material							LIFE-INSURANCE; DISCRIMINATION; INFORMATION; LEGAL		Univ E Anglia, Ctr Hlth, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Med Hlth Policy & Practice, Hlth Econ & Eth Grp, Norwich NR4 7TJ, Norfolk, England	University of East Anglia; University of East Anglia	Raithatha, N (corresponding author), Univ E Anglia, Ctr Hlth, Norwich NR4 7TJ, Norfolk, England.	N.Raithatha@uea.ac.uk		Smith, Richard/0000-0003-3837-6559				Abbott A, 1996, NATURE, V379, P392; *ASS BRIT INS, 1999, GEN TEST ABI COD PRA; Cook ED, 1999, J MED ETHICS, V25, P157, DOI 10.1136/jme.25.2.157; Cunningham GC, 2000, POSTGRAD MED, V108, P193, DOI 10.3810/pgm.2000.07.1163; *DEP HLTH, GEN INS COMM DEC; Hall MA, 2000, GENET MED, V2, P214, DOI 10.1097/00125817-200007000-00003; HARPER PS, 1993, LANCET, V341, P224, DOI 10.1016/0140-6736(93)90080-Z; Harper PS, 1997, PHILOS T ROY SOC B, V352, P1063, DOI 10.1098/rstb.1997.0086; *HOUS COMM SCI TEC, 2001, 5 HOUS COMM SCI TECH; Hoy M, 2000, J PUBLIC ECON, V78, P235, DOI 10.1016/S0047-2727(99)00118-8; Launis V, 2000, SCI ENG ETHICS, V6, P299, DOI 10.1007/s11948-000-0033-z; LeGrys DJ, 1997, PHILOS T ROY SOC B, V352, P1057; *MED INF INS, JOINT GUID ABI BMA B; Murthy A, 2001, J ROY SOC MED, V94, P57, DOI 10.1177/014107680109400202; Stephens JW, 2003, J INTERN MED, V253, P120, DOI 10.1046/j.1365-2796.2003.01104.x; Vineis P, 2001, LANCET, V357, P709, DOI 10.1016/S0140-6736(00)04136-2; Wilkie D, 1997, PHILOS T ROY SOC B, V352, P1039, DOI 10.1098/rstb.1997.0082; Wolf SM, 1995, J LAW MED ETHICS, V23, P345, DOI 10.1111/j.1748-720X.1995.tb01376.x	18	17	18	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	2004	363	9406					395	396		10.1016/S0140-6736(04)15442-1	http://dx.doi.org/10.1016/S0140-6736(04)15442-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768TQ	15070572				2022-12-28	WOS:000188590900026
J	Craig, NJ; Taylor, JM; Lester, EA; Marcus, CM; Hanson, MP; Gossard, AC				Craig, NJ; Taylor, JM; Lester, EA; Marcus, CM; Hanson, MP; Gossard, AC			Tunable nonlocal spin control in a coupled-quantum dot system	SCIENCE			English	Article							TRANSPORT	The effective interaction between magnetic impurities in metals that can lead to various magnetic ground states often competes with a tendency for electrons near impurities to screen the local moment (known as the Kondo effect). The simplest system exhibiting the richness of this competition, the two-impurity Kondo system, was realized experimentally in the form of two quantum dots coupled through an open conducting region. We demonstrate nonlocal spin control by suppressing and splitting Kondo resonances in one quantum dot by changing the electron number and coupling of the other dot. The results suggest an approach to nonlocal spin control that may be relevant to quantum information processing.	Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA	Harvard University; University of California System; University of California Santa Barbara	Marcus, CM (corresponding author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.	marcus@harvard.edu	Marcus, Charles M./M-4526-2014; Taylor, Jacob M/B-7826-2011; Taylor, Jacob/O-1670-2019	Marcus, Charles M./0000-0003-2420-4692; Taylor, Jacob M/0000-0003-0493-5594; Taylor, Jacob/0000-0003-0493-5594				Aguado R, 2000, PHYS REV LETT, V85, P1946, DOI 10.1103/PhysRevLett.85.1946; Aguado R, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.245307; Aono T, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.125327; CHEN JC, 2003, MATTER, V1; Georges A, 1999, PHYS REV LETT, V82, P3508, DOI 10.1103/PhysRevLett.82.3508; GLAZMAN LI, 1988, JETP LETT+, V47, P452; Goldhaber-Gordon D, 1998, NATURE, V391, P156, DOI 10.1038/34373; Golovach VN, 2003, EUROPHYS LETT, V62, P83, DOI 10.1209/epl/i2003-00365-x; Hewson A C, 1993, KONDO PROBLEM HEAVY; Izumida W, 2000, PHYS REV B, V62, P10260, DOI 10.1103/PhysRevB.62.10260; JAYAPRAKASH C, 1981, PHYS REV LETT, V47, P737, DOI 10.1103/PhysRevLett.47.737; Jeong H, 2001, SCIENCE, V293, P2221, DOI 10.1126/science.1063182; JONES BA, 1987, PHYS REV LETT, V58, P843, DOI 10.1103/PhysRevLett.58.843; JONES BA, 1989, PHYS REV B, V40, P324, DOI 10.1103/PhysRevB.40.324; KASUYA T, 1956, PROG THEOR PHYS, V16, P45, DOI 10.1143/PTP.16.45; Kouwenhoven L, 2001, PHYS WORLD, V14, P33; Loss D, 2000, PHYS REV LETT, V84, P1035, DOI 10.1103/PhysRevLett.84.1035; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; MEIR Y, 1993, PHYS REV LETT, V70, P2601, DOI 10.1103/PhysRevLett.70.2601; NG TK, 1988, PHYS REV LETT, V61, P1768, DOI 10.1103/PhysRevLett.61.1768; Osborne TJ, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.032110; RUDERMAN MA, 1954, PHYS REV, V96, P99, DOI 10.1103/PhysRev.96.99; Saguia A, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.012315; UTSUMI Y, 2003, CONDMAT0310168; van der Wiel WG, 2003, REV MOD PHYS, V75, P1, DOI 10.1103/RevModPhys.75.1; Varma C.M., COMMUNICATION; Verstraete F, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.027901; YOSIDA K, 1957, PHYS REV, V106, P893, DOI 10.1103/PhysRev.106.893	28	313	317	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 23	2004	304	5670					565	567		10.1126/science.1095452	http://dx.doi.org/10.1126/science.1095452			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	814LB	15044752	Green Submitted			2022-12-28	WOS:000220975100042
J	Laurant, MGH; Hermens, RPMG; Braspenning, JCC; Sibbald, B; Grol, RPTM				Laurant, MGH; Hermens, RPMG; Braspenning, JCC; Sibbald, B; Grol, RPTM			Impact of nurse practitioners on workload of general practitioners: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE; SKILL MIX	Objective To examine the impact oil general practitioners' workload of adding nurse practitioners to the general practice team. Design Randomised controlled trial with measurements before and after the introduction Of nurse practitioners. Setting 34 general practices in a Southern region of the Netherlands. Participants 48 general practitioners. Intervention Five nurses were randomly allocated to general practitioners to undertake specific elements of care according to agreed guidelines. The control group received no nurse. Main outcome measures Objective workload, derived from 28 day diaries, included the number of contacts per day for each Of three conditions (chronic obstructive pulmonary disease or asthma, dementia, cancer), by type of consultation (in practice, telephone.. home visit), and by time of day (surgery hours, Out Of hours). Subjective workload was measured by using a validated questionnaire. Outcomes were measured six months before and 18 months after the intervention. Results The number of contacts during surgery hours increased ill the intervention group compared with the control group (P < 0.06), particularly for patients with chronic obstructive pulmonary disease or asthma (P < 0.01). The number of consultations out of hours declined slightly in the intervention group compared with the control group, but this difference did not reach significance. No significant changes became apparent in subjective workload. Conclusion Adding nurse practitioners to general practice teams did not reduce the workload of general practitioners, at least in the short term. This implies that nurse practitioners are used as supplements, rather than Substitutes, for care given by general practitioners.	Univ Nijmegen, Ctr Qual Care Res WOK, Med Ctr, NL-6500 HB Nijmegen, Netherlands; Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	Radboud University Nijmegen; University of Manchester	Laurant, MGH (corresponding author), Univ Nijmegen, Ctr Qual Care Res WOK, Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands.	m.laurant@wok.umcn.nl	Grol, Richard/C-8523-2013; Hermens, Rosella P.M.G./N-3581-2014; Laurant, Miranda/H-6488-2015; Braspenning, Jozé/AAG-7612-2021; Braspenning, Jozé CC/D-4268-2009	Hermens, Rosella P.M.G./0000-0001-7624-7120; Laurant, Miranda/0000-0002-8826-3352; Braspenning, Jozé/0000-0003-0800-0630; Braspenning, Jozé CC/0000-0003-0800-0630				[Anonymous], 1994, BMJ, V308, P313; Aubert RE, 1998, ANN INTERN MED, V129, P605, DOI 10.7326/0003-4819-129-8-199810150-00004; BLISS A, 1977, NEW HLTH PROFESSIONA; BRANDS P, 1998, HUISARTS PRAKTIJKVER; Bruce J, 1998, BRIT J GEN PRACT, V48, P1419; CALNAN M, 2000, HLTH RELATED BEHAV G; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1434, DOI 10.1136/bmj.316.7142.1434; CHARLTON I, 1991, BRIT J GEN PRACT, V41, P227; COULTER A, 1995, BRIT MED J, V310, P1099; Fall M, 1997, BRIT J GEN PRACT, V47, P699; Horrocks S, 2002, BRIT MED J, V324, P819, DOI 10.1136/bmj.324.7341.819; HUTTEN JBF, 1998, THESIS UTRECHT; Jenkins-Clarke S, 1998, J ADV NURS, V28, P1120, DOI 10.1046/j.1365-2648.1997.00388.x; KENENS R, 2001, BROCHUR REGISTRATIE; Kernick D, 2002, BRIT J GEN PRACT, V52, P42; KIRKMAN MS, 1994, DIABETES CARE, V17, P840, DOI 10.2337/diacare.17.8.840; Koperski M, 1997, BRIT J GEN PRACT, V47, P696; Lattimer V, 1998, BMJ-BRIT MED J, V317, P1054; MARSH GN, 1995, BRIT MED J, V310, P778, DOI 10.1136/bmj.310.6982.778; Rethans JJ, 1996, FAM PRACT, V13, P468, DOI 10.1093/fampra/13.5.468; Richardson G, 1999, J Nurs Manag, V7, P265; ROSS T, 1994, EVALUATION NURSE PRA; SALISBURY CJ, 1988, J ROY COLL GEN PRACT, V38, P314; SPITZER WO, 1974, NEW ENGL J MED, V290, P251, DOI 10.1056/NEJM197401312900506; *TOUCH ROSS, 1994, EV NURS PRACT PIL PR; van Dierendonck D., 1992, OPGEBRAND INVENTARIS; VANDENHOMBERGH P, 1997, HUISARTS WETENSCHAP, V40, P193; VANDIERENDONCK D, 1992, EEN INVENTARISEREND; Whitecross L, 1999, Aust Fam Physician, V28, P349	29	67	67	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	2004	328	7445					927	930B		10.1136/bmj.38041.493519.EE	http://dx.doi.org/10.1136/bmj.38041.493519.EE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	814SM	15069024	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000220994400022
J	Nelson, HD				Nelson, HD			Commonly used types of postmenopausal estrogen for treatment of hot flashes - Scientific review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HORMONE REPLACEMENT THERAPY; ESTRADIOL TRANSDERMAL SYSTEM; INITIATIVE RANDOMIZED-TRIAL; VASOMOTOR SYMPTOMS; PLUS PROGESTIN; DOUBLE-BLIND; MENOPAUSAL SYMPTOMS; CONJUGATED ESTROGENS; MATRIX PATCH; WOMEN	Context Recommendations for postmenopausal hormone therapy have changed since the Women's Health Initiative indicated that estrogen was harmful for use in disease prevention; however, treatment of menopausal symptoms with low-dose estrogen remains an approved indication for use. Objective To compare the short-term efficacy and adverse effects of 2 commonly used estrogens, conjugated equine estrogen (CEE) and 17beta-estradiol, for reducing menopausal hot flashes by systematically reviewing randomized controlled trials. Data Sources MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews, and Cochrane Controlled Trials Registry were searched from the database start dates to July 2003 using database-specific key words. Reference lists of published articles, experts, and pharmaceutical manufacturers were also consulted. Study Selection English-language abstracts of double-blind, randomized, placebo-controlled trials and systematic evidence reviews of oral CEE and oral and transdermal 17beta-estradiol, and treatment of menopausal hot flashes and their adverse effects. Data Extraction Study design, population characteristics, eligibility criteria, interventions, withdrawals, adverse effects, and results for each outcome. Study quality was assessed using predefined criteria based on parameters developed with the US Preventive Services Task Force and the UK National Health Services Centre. Data Synthesis A total of 32 trials including 4 head-to-head comparisons met inclusion criteria; 14 trials met criteria for meta-analysis. All estrogen agents significantly reduced the weekly number of hot flashes compared with placebo (CEE, 1 trial: mean change, -19.1; 95% confidence interval [CI], -33.0 to -5.1; oral 17beta-estradiol, 5 trials: pooled weighted mean difference, -16.8; 95% CI, -23.4 to -10.2; transdermal 17beta-estradiol, 6 trials: pooled weighted mean difference, -22.4; 95% CI, -35.9 to -10.4); differences between agents were not significant. Breast tenderness and atypical vaginal bleeding were the most frequently reported adverse effects among estrogen users. The influence of progestin or progesterone use, cyclic and continuous regimens, and differences in adverse effects could not be determined. Conclusion Conjugated equine estrogen and 17beta-estradiol have consistent and comparable effects on treatment of menopausal hot flashes and may have similar short-term adverse effects.	Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Oregon Evidence Based Practice Ctr, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Nelson, HD (corresponding author), Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Oregon Evidence Based Practice Ctr, Mail Code BICC 504,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	nelsonh@ohsu.edu						Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; ARCHER DF, 1992, ADV THER, V9, P21; Austin PC, 2003, JAMA-J AM MED ASSOC, V289, P3241, DOI 10.1001/jama.289.24.3241; BacchiModena A, 1997, MATURITAS, V27, P285, DOI 10.1016/S0378-5122(97)00039-X; Baerug U, 1998, Climacteric, V1, P219; Barnabei VM, 2002, OBSTET GYNECOL, V100, P1209, DOI 10.1016/S0029-7844(02)02369-4; BAUMGARDNER SB, 1978, OBSTET GYNECOL, V51, P445, DOI 10.1097/00006250-197804000-00013; Bech P, 1998, PSYCHOTHER PSYCHOSOM, V67, P259, DOI 10.1159/000012289; CAMPBELL S, 1976, MANAGEMENT MENOPAUSE; Carranza-Lira S, 2001, INT J GYNECOL OBSTET, V73, P169, DOI 10.1016/S0020-7292(00)00332-5; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Chung TKH, 1996, MATURITAS, V25, P115, DOI 10.1016/0378-5122(96)01050-X; CONARD J, 1995, FERTIL STERIL, V64, P957, DOI 10.1016/S0015-0282(16)57909-6; COOPE J, 1975, BRIT MED J, V4, P139, DOI 10.1136/bmj.4.5989.139; De Aloysio D, 2000, ARZNEIMITTELFORSCH, V50, pE293; de Vrijer B, 2000, MATURITAS, V34, P47, DOI 10.1016/S0378-5122(99)00085-7; DERMAN RJ, 1995, INT J FERTIL MENOP S, V40, P73; Freedman RR, 2002, FERTIL STERIL, V77, P487, DOI 10.1016/S0015-0282(01)03009-6; Good W R, 1999, Climacteric, V2, P29, DOI 10.3109/13697139909025560; GORDON SF, 1995, INT J FERTIL MENOP S, V40, P126; Greendale GA, 1998, OBSTET GYNECOL, V92, P982, DOI 10.1016/S0029-7844(98)00305-6; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Humphrey LL, 2002, ANN INTERN MED, V137, P273, DOI 10.7326/0003-4819-137-4-200208200-00012; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; KUPPERMAN H, 1959, JAMA-J AM MED ASSOC, V111, P1627; MACLENNAN A, 2002, ORAL OESTROGEN REPLA; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; MULROW CD, 1997, CONDUCT COCHRANE SYS; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; NHS Centre for Reviews and Dissemination, 2001, 4 CRD NHS CTR REV DI; Notelovitz M, 2000, AM J OBSTET GYNECOL, V182, P7, DOI 10.1016/S0002-9378(00)70483-2; Notelovitz M, 2000, OBSTET GYNECOL, V95, P726, DOI 10.1016/S0029-7844(99)00643-2; Notelovitz M, 2000, MENOPAUSE, V7, P310, DOI 10.1097/00042192-200007050-00005; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Shulman LP, 2002, MENOPAUSE, V9, P385, DOI 10.1097/00042192-200209000-00013; Shulman LP, 2002, MENOPAUSE, V9, P195, DOI 10.1097/00042192-200205000-00008; Speroff L, 1996, OBSTET GYNECOL, V88, P587, DOI 10.1016/0029-7844(96)00272-4; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; Stephenson J, 2003, JAMA-J AM MED ASSOC, V289, P537, DOI 10.1001/jama.289.5.537; STUDD JWW, 1995, MATURITAS, V22, P105, DOI 10.1016/0378-5122(95)00910-D; Utian WH, 1999, AM J OBSTET GYNECOL, V181, P71, DOI 10.1016/S0002-9378(99)70438-2; Utian WH, 2001, FERTIL STERIL, V75, P1065, DOI 10.1016/S0015-0282(01)01791-5; Vastag B, 2003, JAMA-J AM MED ASSOC, V289, P290, DOI 10.1001/jama.289.3.290-a; VIKHLYAEVA E, 1997, J AKUSHERSTVO GINECO, V5, P76; von Holst T, 2002, MATURITAS, V41, P231, DOI 10.1016/S0378-5122(01)00297-3; von Holst T, 2000, MATURITAS, V34, P143, DOI 10.1016/S0378-5122(99)00099-7; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Wells G, 2002, ENDOCR REV, V23, P529, DOI 10.1210/er.2001-5002; WIKLUND I, 1993, AM J OBSTET GYNECOL, V168, P824, DOI 10.1016/S0002-9378(12)90828-5; *WYETH PHARM, WEB SIT	51	157	166	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2004	291	13					1610	1620		10.1001/jama.291.13.1610	http://dx.doi.org/10.1001/jama.291.13.1610			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809PQ	15069049	Bronze			2022-12-28	WOS:000220649000026
J	Belmekki, M				Belmekki, M			Pit latrines for trachoma control	LANCET			English	Editorial Material											Belmekki, M (corresponding author), 12 Albaakili St,Number 3 Agdal, Rabat 10000, Morocco.	belmekki.m@menara.ma						CONRAY RM, 2001, FLY TRAP MADE MASSAI; Dobson R, 2000, B WORLD HEALTH ORGAN, V78, P1282; Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2; FORSEY T, 1981, BRIT J OPHTHALMOL, V65, P147, DOI 10.1136/bjo.65.2.147; KUPPER H, 2003, LANCET, V3, P372; TAYLOR HR, 1985, B WORLD HEALTH ORGAN, V63, P559	6	2	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	2004	363	9415					1088	1089		10.1016/S0140-6736(04)15929-1	http://dx.doi.org/10.1016/S0140-6736(04)15929-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808VB	15064021				2022-12-28	WOS:000220595500002
J	Murchison, CF; Zhang, XY; Zhang, WP; Ming, OY; Lee, A; Thomas, SA				Murchison, CF; Zhang, XY; Zhang, WP; Ming, OY; Lee, A; Thomas, SA			A distinct role for norepinephrine in memory retrieval	CELL			English	Article							POSTTRAUMATIC-STRESS-DISORDER; DOPAMINE-BETA-HYDROXYLASE; LONG-TERM POTENTIATION; CONTEXTUAL FEAR; LOCUS-COERULEUS; ALZHEIMERS-DISEASE; RETROGRADE-AMNESIA; CONDITIONED FEAR; SPATIAL MEMORY; HIPPOCAMPAL CIRCUITRY	A role for norepinephrine in learning and memory has been elusive and controversial. A longstanding hypothesis states that the adrenergic nervous system mediates enhanced memory consolidation of emotional events. We tested this hypothesis in several learning tasks using mutant mice conditionally lacking norepinephrine and epinephrine, as well as control mice and rats treated with adrenergic receptor agonists and antagonists. We find that adrenergic signaling is critical for the retrieval of intermediate-term contextual and spatial memories, but is not necessary for the retrieval or consolidation of emotional memories in general. The role of norepinephrine in retrieval requires signaling through the beta(1)-adrenergic receptor in the hippocampus. The results demonstrate that mechanisms of memory retrieval can vary over time and can be different from those required for acquisition or consolidation. These findings may be relevant to symptoms in several neuropsychiatric disorders as well as the treatment of cardiac failure with beta blockers.	Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Thomas, SA (corresponding author), Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA.	thomas@pharm.med.upenn.edu						Abel T, 2001, CURR OPIN NEUROBIOL, V11, P180, DOI 10.1016/S0959-4388(00)00194-X; Alaniz RC, 1999, P NATL ACAD SCI USA, V96, P2274, DOI 10.1073/pnas.96.5.2274; Anagnostaras SG, 2001, HIPPOCAMPUS, V11, P8; Anagnostaras SG, 1999, J NEUROSCI, V19, P1106; Aston-Jones G, 2000, PROG BRAIN RES, V126, P165; AstonJones G, 1997, NEUROSCIENCE, V80, P697, DOI 10.1016/S0306-4522(97)00060-2; Backman L, 1999, NEUROLOGY, V52, P1861, DOI 10.1212/WNL.52.9.1861; Bergles DE, 1996, J NEUROSCI, V16, P572; Bevilaqua L, 1997, BEHAV PHARMACOL, V8, P331, DOI 10.1097/00008877-199708000-00006; BLIN N, 1994, BRIT J PHARMACOL, V112, P911, DOI 10.1111/j.1476-5381.1994.tb13167.x; Brun VH, 2002, SCIENCE, V296, P2243, DOI 10.1126/science.1071089; CAHILL L, 1994, NATURE, V371, P702, DOI 10.1038/371702a0; Corcoran KA, 2001, J NEUROSCI, V21, P1720, DOI 10.1523/JNEUROSCI.21-05-01720.2001; CROW TJ, 1968, NATURE, V219, P736, DOI 10.1038/219736a0; DAVIS M, 1979, PSYCHOPHARMACOLOGY, V65, P111, DOI 10.1007/BF00433036; Day M, 2003, NATURE, V424, P205, DOI 10.1038/nature01769; de Quervain DJF, 1998, NATURE, V394, P787, DOI 10.1038/29542; DEVAUGES V, 1991, BEHAV BRAIN RES, V43, P93, DOI 10.1016/S0166-4328(05)80056-7; Elrod R, 1997, AM J PSYCHIAT, V154, P25; FAMULARO R, 1988, AM J DIS CHILD, V142, P1244, DOI 10.1001/archpedi.1988.02150110122036; Frankland KBJ, 1997, MOUSE BRAIN STEREOTA; Frankland PW, 2001, NATURE, V411, P309, DOI 10.1038/35077089; Frick KM, 2000, NEUROREPORT, V11, P3461, DOI 10.1097/00001756-200011090-00013; GALA RR, 1986, NEUROENDOCRINOLOGY, V43, P115, DOI 10.1159/000124517; GALLAGHER M, 1977, SCIENCE, V198, P423, DOI 10.1126/science.20664; Geracioti TD, 2001, AM J PSYCHIAT, V158, P1227, DOI 10.1176/appi.ajp.158.8.1227; GORMAN AL, 1993, PHARMACOL BIOCHEM BE, V45, P1; HAGAN JJ, 1983, BEHAV BRAIN RES, V9, P83, DOI 10.1016/0166-4328(83)90015-3; Hensbroek RA, 2003, BEHAV BRAIN RES, V138, P215, DOI 10.1016/S0166-4328(02)00243-7; HICKS PE, 1987, J PHARMACOL EXP THER, V242, P1025; HIRSH R, 1974, BEHAV BIOL, V12, P421, DOI 10.1016/S0091-6773(74)92231-7; Holt W, 1999, J NEUROSCI, V19, P9054, DOI 10.1523/JNEUROSCI.19-20-09054.1999; Homewood J, 1999, ALCOHOL, V19, P75, DOI 10.1016/S0741-8329(99)00027-0; Hoogendijk WJG, 1999, ANN NEUROL, V45, P82, DOI 10.1002/1531-8249(199901)45:1<82::AID-ART14>3.0.CO;2-T; ILSLEY JE, 1995, J AFFECT DISORDERS, V35, P1, DOI 10.1016/0165-0327(95)00032-I; IVERSEN LL, 1983, NEUROSCI LETT, V39, P95, DOI 10.1016/0304-3940(83)90171-4; Izquierdo I, 1997, NEUROBIOL LEARN MEM, V68, P285, DOI 10.1006/nlme.1997.3799; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092-8674(01)00497-4; Kety S. S., 1970, NEUROSCIENCES 2 STUD, P324; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Kolb LC, 1984, POSTTRAUMATIC STRESS, P98; LEE EHY, 1993, SYNAPSE, V14, P144, DOI 10.1002/syn.890140207; Lee HJ, 2001, NEUROSCI LETT, V303, P123, DOI 10.1016/S0304-3940(01)01733-5; Lisman JE, 1999, NEURON, V22, P233, DOI 10.1016/S0896-6273(00)81085-5; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; MCENTEE WJ, 1978, SCIENCE, V202, P905, DOI 10.1126/science.715450; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; MIDDLEMISS DN, 1984, EUR J PHARMACOL, V101, P289, DOI 10.1016/0014-2999(84)90173-0; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; Morris RGM, 2003, PHILOS T R SOC B, V358, P773, DOI 10.1098/rstb.2002.1264; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; Moser EI, 2001, CURR OPIN NEUROBIOL, V11, P745, DOI 10.1016/S0959-4388(01)00279-3; Moser MB, 1998, J NEUROSCI, V18, P7535; Munro CAM, 2001, HIPPOCAMPUS, V11, P322, DOI 10.1002/hipo.1046; Nader K, 2000, NAT REV NEUROSCI, V1, P216, DOI 10.1038/35044580; Nakazawa K, 2002, SCIENCE, V297, P211, DOI 10.1126/science.1071795; NICHOLAS AP, 1993, NEUROSCIENCE, V56, P1023, DOI 10.1016/0306-4522(93)90148-9; NostenBertrand M, 1996, NATURE, V379, P826, DOI 10.1038/379826a0; O'Carroll RE, 1999, PSYCHOL MED, V29, P1083, DOI 10.1017/S0033291799008703; O'Carroll RE, 1999, J PSYCHOPHARMACOL, V13, P32, DOI 10.1177/026988119901300104; PHILLIPS RG, 1994, LEARN MEMORY, V1, P34; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Pitman RK, 2002, BIOL PSYCHIAT, V51, P189, DOI 10.1016/S0006-3223(01)01279-3; Raskind MA, 2003, AM J PSYCHIAT, V160, P371, DOI 10.1176/appi.ajp.160.2.371; Ressler KJ, 1999, BIOL PSYCHIAT, V46, P1219, DOI 10.1016/S0006-3223(99)00127-4; Riedel G, 1999, NAT NEUROSCI, V2, P898, DOI 10.1038/13202; Robbins TW, 1997, BIOL PSYCHOL, V45, P57, DOI 10.1016/S0301-0511(96)05222-2; ROBINSON MB, 1992, PEDIATR RES, V32, P483, DOI 10.1203/00006450-199210000-00021; Rudy JW, 1999, BEHAV NEUROSCI, V113, P867, DOI 10.1037/0735-7044.113.5.867; Sallach JA, 2003, ANN MED, V35, P259, DOI 10.1080/14734220310011716; SARA SJ, 1985, ANN NY ACAD SCI, V444, P178, DOI 10.1111/j.1749-6632.1985.tb37588.x; SARA SJ, 1991, PROG BRAIN RES, V88, P571; Schroeter S, 2000, J COMP NEUROL, V420, P211; SEGAL M, 1991, PROG BRAIN RES, V88, P323; SELDEN NRW, 1990, J NEUROSCI, V10, P531; Shimizu E, 2000, SCIENCE, V290, P1170, DOI 10.1126/science.290.5494.1170; Shouse MN, 2000, BRAIN RES, V860, P181, DOI 10.1016/S0006-8993(00)02013-8; SOLOMON S, 1983, ARCH GEN PSYCHIAT, V40, P1109; Southwick SM, 1999, BIOL PSYCHIAT, V46, P1192, DOI 10.1016/S0006-3223(99)00219-X; Squire LR, 2001, HIPPOCAMPUS, V11, P50, DOI 10.1002/1098-1063(2001)11:1<50::AID-HIPO1019>3.0.CO;2-G; Thomas SA, 1998, J NEUROCHEM, V70, P2468; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; Thomas SA, 1997, BEHAV NEUROSCI, V111, P579, DOI 10.1037/0735-7044.111.3.579; Thomas SA, 1997, CELL, V91, P583, DOI 10.1016/S0092-8674(00)80446-8; Tonegawa S, 2003, PHILOS T R SOC B, V358, P787, DOI 10.1098/rstb.2002.1243; TRICKLEBANK MD, 1987, EUR J PHARMACOL, V133, P47, DOI 10.1016/0014-2999(87)90204-4; WAELBROECK M, 1983, MOL PHARMACOL, V24, P174; Wong ST, 1999, NEURON, V23, P787, DOI 10.1016/S0896-6273(01)80036-2; YOKOO H, 1990, BRAIN RES, V536, P305, DOI 10.1016/0006-8993(90)90039-E; ZHANG WP, 2004, IN PRESS NEUROPHARMA	93	288	293	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	2004	117	1					131	143		10.1016/S0092-8674(04)00259-4	http://dx.doi.org/10.1016/S0092-8674(04)00259-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YV	15066288	Bronze			2022-12-28	WOS:000221500300014
J	Grimwood, J; Gordon, LA; Olsen, A; Terry, A; Schmutz, J; Lamerdin, J; Hellsten, U; Goodstein, D; Couronne, O; Gyamfi, MT; Aerts, A; Altherr, M; Ashworth, L; Bajorek, E; Black, S; Branscomb, E; Caenepeel, S; Carrano, A; Caoile, C; Chan, YM; Christensen, M; Cleland, CA; Copeland, A; Dalin, E; Dehal, P; Denys, M; Detter, JC; Escobar, J; Flowers, D; Fotopulos, D; Garcia, C; Georgescu, AM; Glavina, T; Gomez, M; Gonzales, E; Groza, M; Hammon, N; Hawkins, T; Haydu, L; Ho, I; Huang, W; Israni, S; Jett, J; Kadner, K; Kimball, H; Kobayashi, A; Larionov, V; Leem, SH; Lopez, F; Lou, YL; Lowry, S; Malfatti, S; Martinez, D; McCready, P; Medina, C; Morgan, J; Nelson, K; Nolan, M; Ovcharenko, I; Pitluck, S; Pollard, M; Popkie, AP; Predki, P; Quan, G; Ramirez, L; Rash, S; Retterer, J; Rodriguez, A; Rogers, S; Salamov, A; Salazar, A; She, XW; Smith, D; Slezak, T; Solovyev, V; Thayer, N; Tice, H; Tsai, M; Ustaszewska, A; Vo, N; Wagner, M; Wheeler, J; Wu, K; Xie, G; Yang, J; Dubchak, I; Furey, TS; DeJong, P; Dickson, M; Gordon, D; Eichler, EE; Pennacchio, LA; Richardson, P; Stubbs, L; Rokhsar, DS; Myers, RM; Rubin, EM; Lucas, SM				Grimwood, J; Gordon, LA; Olsen, A; Terry, A; Schmutz, J; Lamerdin, J; Hellsten, U; Goodstein, D; Couronne, O; Gyamfi, MT; Aerts, A; Altherr, M; Ashworth, L; Bajorek, E; Black, S; Branscomb, E; Caenepeel, S; Carrano, A; Caoile, C; Chan, YM; Christensen, M; Cleland, CA; Copeland, A; Dalin, E; Dehal, P; Denys, M; Detter, JC; Escobar, J; Flowers, D; Fotopulos, D; Garcia, C; Georgescu, AM; Glavina, T; Gomez, M; Gonzales, E; Groza, M; Hammon, N; Hawkins, T; Haydu, L; Ho, I; Huang, W; Israni, S; Jett, J; Kadner, K; Kimball, H; Kobayashi, A; Larionov, V; Leem, SH; Lopez, F; Lou, YL; Lowry, S; Malfatti, S; Martinez, D; McCready, P; Medina, C; Morgan, J; Nelson, K; Nolan, M; Ovcharenko, I; Pitluck, S; Pollard, M; Popkie, AP; Predki, P; Quan, G; Ramirez, L; Rash, S; Retterer, J; Rodriguez, A; Rogers, S; Salamov, A; Salazar, A; She, XW; Smith, D; Slezak, T; Solovyev, V; Thayer, N; Tice, H; Tsai, M; Ustaszewska, A; Vo, N; Wagner, M; Wheeler, J; Wu, K; Xie, G; Yang, J; Dubchak, I; Furey, TS; DeJong, P; Dickson, M; Gordon, D; Eichler, EE; Pennacchio, LA; Richardson, P; Stubbs, L; Rokhsar, DS; Myers, RM; Rubin, EM; Lucas, SM			The DNA sequence and biology of human chromosome 19	NATURE			English	Article							SITU HYBRIDIZATION MAP; THYMINE DIMERS; GENE-CLUSTER; LDL RECEPTOR; CHROMOSOME; ORGANIZATION; EVOLUTION; EXPANSION; MOUSE	Chromosome 19 has the highest gene density of all human chromosomes, more than double the genome-wide average. The large clustered gene families, corresponding high G+C content, CpG islands and density of repetitive DNA indicate a chromosome rich in biological and evolutionary significance. Here we describe 55.8 million base pairs of highly accurate finished sequence representing 99.9% of the euchromatin portion of the chromosome. Manual curation of gene loci reveals 1,461 protein-coding genes and 321 pseudogenes. Among these are genes directly implicated in mendelian disorders, including familial hypercholesterolaemia and insulin-resistant diabetes. Nearly one-quarter of these genes belong to tandemly arranged families, encompassing more than 25% of the chromosome. Comparative analyses show a fascinating picture of conservation and divergence, revealing large blocks of gene orthology with rodents, scattered regions with more recent gene family expansions and deletions, and segments of coding and non-coding conservation with the distant fish species Takifugu.	Stanford Univ, Sch Med, Dept Genet, Stanford Human Genome Ctr, Palo Alto, CA 94304 USA; DOEs Joint Genome Inst, Walnut Creek, CA 94598 USA; Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; NCI, Lab Biosyst & Canc, NIH, Bethesda, MD 20892 USA; Case Western Reserve Univ, Sch Med, Ctr Computat Genom, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA; Childrens Hosp Oakland, Oakland, CA 94609 USA; Univ Washington, Howard Hughes Med Inst, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Seattle, WA 98195 USA	Stanford University; United States Department of Energy (DOE); Joint Genome Institute - JGI; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; University of California System; University of California Santa Cruz; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Grimwood, J (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford Human Genome Ctr, 975 Calif Ave, Palo Alto, CA 94304 USA.	jane@shgc.stanford.edu; emrubin@lbl.gov	Solovyev, Victor/C-4614-2013; Grimwood, Jane/ABD-5737-2021; Terry, Astrid Y/A-2538-2011; Schmutz, Jeremy/N-3173-2013; Couronne, Olivier Couronne/G-1244-2012	Solovyev, Victor/0000-0001-8885-493X; Terry, Astrid Y/0000-0002-5234-1224; Schmutz, Jeremy/0000-0001-8062-9172; Pennacchio, Len/0000-0002-8748-3732; Furey, Terry/0000-0001-5546-9672; Rokhsar, Daniel/0000-0002-8704-2224; Goodstein, David/0000-0001-6287-2697; Stubbs, Lisa/0000-0002-9556-1972; Malfatti, Stephanie/0000-0003-4225-9857; christoffersen, catherine/0000-0003-1816-9747	NATIONAL CANCER INSTITUTE [ZIABC010413, Z01BC010413] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; Bailey JA, 2001, GENOME RES, V11, P1005, DOI 10.1101/gr.GR-1871R; Birney E, 2000, GENOME RES, V10, P547, DOI 10.1101/gr.10.4.547; BRANDRIFF BF, 1994, GENOMICS, V23, P582, DOI 10.1006/geno.1994.1546; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; Dehal P, 2001, SCIENCE, V293, P104, DOI 10.1126/science.1060310; DEJONG PJ, 1989, CYTOGENET CELL GENET, V51, P985; Deloukas P, 2001, NATURE, V414, P865, DOI 10.1038/414865a; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Doray B, 1998, HUM MOL GENET, V7, P1449, DOI 10.1093/hmg/7.9.1449; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Eichler EE, 1998, GENOME RES, V8, P791, DOI 10.1101/gr.8.8.791; Felsenfeld A, 1999, GENOME RES, V9, P1; Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641; GORDON LA, 1995, GENOMICS, V30, P187, DOI 10.1006/geno.1995.9886; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Heilig R, 2003, NATURE, V421, P601, DOI 10.1038/nature01348; Hillier LW, 2003, NATURE, V424, P157, DOI 10.1038/nature01782; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; Hoffman SMG, 2001, PHARMACOGENETICS, V11, P687, DOI 10.1097/00008571-200111000-00007; Hsu KC, 2002, IMMUNOL REV, V190, P40, DOI 10.1034/j.1600-065X.2002.19004.x; JUVONEN E, 1991, BLOOD, V78, P3066; Kan ZY, 2002, GENOME RES, V12, P1837, DOI 10.1101/gr.764102; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lewis S.E., 2002, GENOME BIOL, V3; Menashe I, 2003, NAT GENET, V34, P143, DOI 10.1038/ng1160; MOHRENWEISER HW, 1989, CYTOGENET CELL GENET, V52, P11, DOI 10.1159/000132829; Mungall AJ, 2003, NATURE, V425, P805, DOI 10.1038/nature02055; Newman T, 2003, GENOME RES, V13, P781, DOI 10.1101/gr.769003; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; O'Brien TJ, 2002, TUMOR BIOL, V23, P154, DOI 10.1159/000064032; Patrinos A, 1997, J Am Med Womens Assoc (1972), V52, P8; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Rivas E, 2001, BMC BIOINFORMATICS, V2, DOI 10.1186/1471-2105-2-8; Schwartz S, 2003, GENOME RES, V13, P103, DOI 10.1101/gr.809403; SETLOW RB, 1962, P NATL ACAD SCI USA, V48, P1250, DOI 10.1073/pnas.48.7.1250; SETLOW RB, 1964, P NATL ACAD SCI USA, V51, P226, DOI 10.1073/pnas.51.2.226; Shannon M, 2003, GENOME RES, V13, P1097, DOI 10.1101/gr.963903; SOLOVYEV VV, 2002, BIOINFORMATICS GENOM, V1, P59; Trowsdale J, 2001, IMMUNOL REV, V181, P20, DOI 10.1034/j.1600-065X.2001.1810102.x; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184; Yu A, 2001, NATURE, V409, P951, DOI 10.1038/35057185	48	219	1153	1	47	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					529	535		10.1038/nature02399	http://dx.doi.org/10.1038/nature02399			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15057824	Bronze, Green Submitted			2022-12-28	WOS:000220540100034
J	Mukherjee, J				Mukherjee, J			Basing treatment on rights rather than ability to pay: 3 by 5	LANCET			English	Editorial Material							HEALTH		Partners Hlth, Boston, MA 02115 USA	Partners Healthcare System	Mukherjee, J (corresponding author), Partners Hlth, 641 Huntington Ave, Boston, MA 02115 USA.	jmukherjee@pih.org						*GLOB FUND FIGHT A, TUB MAL PLEDG; Hall JJ, 2003, MED J AUSTRALIA, V178, P17, DOI 10.5694/j.1326-5377.2003.tb05033.x; Kritski AL, 2000, INT J TUBERC LUNG D, V4, P622; Wendo C, 2003, LANCET, V361, P942, DOI 10.1016/S0140-6736(03)12794-8; *WHO, TREAT 3 MILL 2005 MA	5	13	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 27	2004	363	9414					1071	1072		10.1016/S0140-6736(04)15846-7	http://dx.doi.org/10.1016/S0140-6736(04)15846-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15065564				2022-12-28	WOS:000220497300025
J	Arzberger, P; Schroeder, P; Beaulieu, A; Bowker, G; Casey, K; Laaksonen, L; Moorman, D; Uhlir, P; Wouters, P				Arzberger, P; Schroeder, P; Beaulieu, A; Bowker, G; Casey, K; Laaksonen, L; Moorman, D; Uhlir, P; Wouters, P			An international framework to promote access to data	SCIENCE			English	Editorial Material							INFORMATION; SCIENCE		Univ Calif San Diego, La Jolla, CA 92093 USA; Minist Educ Culture & Sci, Zoetermeer, Netherlands; Royal Netherlands Acad Arts & Sci, Amsterdam, Netherlands; CSC Sci Comp Ltd, Espoo, Finland; Social Sci & Humanities Res Council, Ottawa, ON, Canada; CNR, Washington, DC 20418 USA	University of California System; University of California San Diego; Finnish IT center for science	Arzberger, P (corresponding author), Univ Calif San Diego, La Jolla, CA 92093 USA.	parzberg@ucsd.edu		Beaulieu, Anne/0000-0002-2431-8975; Wouters, Paul/0000-0002-4324-5732				Atkins D.E., 2003, REVOLUTIONIZING SCI; Butler D, 2004, NATURE, V427, P275, DOI 10.1038/427275b; COLWELL R, NAT AC SCI 25 JAN 20; *COMM EUR COMM, 1999, PUBL SECT INF KEY RE; *COMM PIL STUD DAT, 1995, FIND FOR TREES CHALL, P97; ESANU JM, OP ACC PUBL DOM DIG; ESANU JM, 2003, ROLE SCI TECHNICAL D, P226; *EUR COMM DIR GEN, 2000, COMM EXPL EUR PUBL S; Finkbeiner A, 2001, SCIENCE, V292, P1472, DOI 10.1126/science.292.5521.1472; Koslow SH, 2002, NAT REV NEUROSCI, V3, P311, DOI 10.1038/nrn787; Lubchenco J, 2003, SCIENCE, V301, P1443, DOI 10.1126/science.301.5639.1443; Marshall E, 2003, SCIENCE, V299, P990, DOI 10.1126/science.299.5609.990; Maurer SM, 2000, NATURE, V405, P117, DOI 10.1038/35012169; MCCAIN KW, 1991, SCI TECHNOL HUM VAL, V16, P491, DOI 10.1177/016224399101600404; *NETH I SCI INF SE, 2003, PUBL DOM DIG RES DAT; Newman HB, 2003, COMMUN ACM, V46, P67; *OECD COMM SCI TEC, 2004, SCI TECHN INN 21 CEN; Reichman J., 2003, LAW CONTEMP PROBL, V66, P314; Salzberg S, 2003, NATURE, V422, P801, DOI 10.1038/422801a; SIEBER JE, 1988, LAW HUMAN BEHAV, V12, P199, DOI 10.1007/BF01073128; Stix G, 2001, SCI AM, V284, P80, DOI 10.1038/scientificamerican0101-80; WEISS P, 2002, BORDERS CYBERSPACE C	22	120	121	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1777	1778		10.1126/science.1095958	http://dx.doi.org/10.1126/science.1095958			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031482				2022-12-28	WOS:000220281600030
J	Shen, K; Fetter, RD; Bargmann, CI				Shen, K; Fetter, RD; Bargmann, CI			Synaptic specificity is generated by the synaptic guidepost protein SYG-2 and its receptor, SYG-1	CELL			English	Article							C-ELEGANS; GENETIC PATHWAY; NEPHRIN; EXPRESSION; MOLECULES; VESICLES; RST	Synaptic connections in the nervous system are directed onto specific cellular and subcellular targets. Synaptic guidepost cells in the C. elegans vulval epithelium drive synapses from the HSNL motor neuron onto adjacent target neurons and muscles. Here, we show that the transmembrane immunoglobulin superfamily protein SYG-2 is a central component of the synaptic guidepost signal. SYG-2 is expressed transiently by primary vulval epithelial cells during synapse formation. SYG-2 binds SYG-1, the receptor on HSNL, and directs SYG-1 accumulation and synapse formation to adjacent regions of HSNL. syg-1 and syg-2 mutants have defects in synaptic specificity; the HSNL neuron forms fewer synapses onto its normal targets and forms ectopic synapses onto inappropriate targets. Misexpression of SYG-2 in secondary epithelial cells causes aberrant accumulation of SYG-1 and synaptic markers in HSNL adjacent to the SYG-2-expressing cells. Our results indicate that local interactions between immunoglobulin superfamily proteins can determine specificity during synapse formation.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Bargmann, CI (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA.	cori@itsa.ucsf.edu		Bargmann, Cornelia/0000-0002-8484-0618				ALLENDOERFER KL, 1994, ANNU REV NEUROSCI, V17, P185, DOI 10.1146/annurev.neuro.17.1.185; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Benson DL, 2001, NAT REV NEUROSCI, V2, P899, DOI 10.1038/35104078; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; BRENNER S, 1974, GENETICS, V77, P71; Burdine RD, 1998, DEVELOPMENT, V125, P1083; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; Donoviel DB, 2001, MOL CELL BIOL, V21, P4829, DOI 10.1128/MCB.21.14.4829-4836.2001; Dworak HA, 2002, BIOESSAYS, V24, P591, DOI 10.1002/bies.10115; Dworak HA, 2001, DEVELOPMENT, V128, P4265; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Gerke P, 2003, J AM SOC NEPHROL, V14, P918, DOI 10.1097/01.ASN.0000057853.05686.89; Gupta BP, 2003, DEVELOPMENT, V130, P2589, DOI 10.1242/dev.00500; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; Hao JC, 2001, NEURON, V32, P25, DOI 10.1016/S0896-6273(01)00448-2; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Khoshnoodi J, 2001, EXP NEPHROL, V9, P355; Liu G, 2003, J CLIN INVEST, V112, P209, DOI 10.1172/JCI200318242; Mello C, 1995, METHOD CELL BIOL, V48, P451; Nonet ML, 1999, J NEUROSCI METH, V89, P33, DOI 10.1016/S0165-0270(99)00031-X; Nurrish S, 1999, NEURON, V24, P231, DOI 10.1016/S0896-6273(00)80835-1; Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1; Reist NE, 1998, J NEUROSCI, V18, P7662; Rose D, 2000, MICROSC RES TECHNIQ, V49, P3, DOI 10.1002/(SICI)1097-0029(20000401)49:1<3::AID-JEMT2>3.0.CO;2-E; Ruiz-Gomez M, 2000, CELL, V102, P189, DOI 10.1016/S0092-8674(00)00024-6; Sato T, 1968, J Electron Microsc (Tokyo), V17, P158; SCHNEIDER T, 1995, NEURON, V15, P259, DOI 10.1016/0896-6273(95)90032-2; Shen K, 2003, CELL, V112, P619, DOI 10.1016/S0092-8674(03)00113-2; Somogyi P, 1998, BRAIN RES REV, V26, P113, DOI 10.1016/S0165-0173(97)00061-1; Strunkelnberg M, 2001, DEVELOPMENT, V128, P4229; Tryggvason K, 1999, J AM SOC NEPHROL, V10, P2440; WEINSHENKER D, 1995, J NEUROSCI, V15, P6975; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; Yamagata M, 2002, CELL, V110, P649, DOI 10.1016/S0092-8674(02)00910-8	36	215	226	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 19	2004	116	6					869	881		10.1016/S0092-8674(04)00251-X	http://dx.doi.org/10.1016/S0092-8674(04)00251-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YS	15035988	Bronze			2022-12-28	WOS:000221499900012
J	Hasson, U; Nir, Y; Levy, I; Fuhrmann, G; Malach, R				Hasson, U; Nir, Y; Levy, I; Fuhrmann, G; Malach, R			Intersubject synchronization of cortical activity during natural vision	SCIENCE			English	Article							MONKEY INFEROTEMPORAL CORTEX; HUMAN NEURAL SYSTEM; HUMAN VISUAL-CORTEX; FACE PERCEPTION; RECEPTIVE-FIELDS; OBJECTS; REPRESENTATION; SCENES; AREAS; MOVEMENTS	To what extent do all brains work alike during natural conditions? We explored this question by letting Five subjects freely view half an hour of a popular movie while undergoing functional brain imaging. Applying an unbiased analysis in which spatiotemporal activity patterns in one brain were used to "model" activity in another brain, we found a striking level of voxel-by-voxel synchronization between individuals, not only in primary and secondary visual and auditory areas but also in association cortices. The results reveal a surprising tendency of individual brains to "tick collectively" during natural vision. The intersubject synchronization consisted of a widespread cortical activation pattern correlated with emotionally arousing scenes and regionally selective components. The characteristics of these activations were revealed with the use of an open-ended "reverse-correlation" approach, which inverts the conventional analysis by letting the brain signals themselves "pick up" the optimal stimuli for each specialized cortical area.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Dept Comp Sci, IL-61390 Tel Aviv, Israel; Hebrew Univ Jerusalem, Interdisciplinary Ctr Neural Computat, IL-91904 Jerusalem, Israel	Weizmann Institute of Science; Tel Aviv University; Hebrew University of Jerusalem	Malach, R (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	rafi.malach@weizmann.ac.il		Hasson, Uri/0000-0002-3599-7168; Levy, Ifat/0000-0001-7851-9070; Nir, Yuval/0000-0002-5433-6349; Fuhrmann Alpert, Galit/0000-0003-4778-3754				Aguirre GK, 1998, NEURON, V21, P373, DOI 10.1016/S0896-6273(00)80546-2; Bartels A, 2004, HUM BRAIN MAPP, V21, P75, DOI 10.1002/hbm.10153; Beauchamp MS, 2002, NEURON, V34, P149, DOI 10.1016/S0896-6273(02)00642-6; Brefczynski JA, 1999, NAT NEUROSCI, V2, P370, DOI 10.1038/7280; Cochin S, 1999, EUR J NEUROSCI, V11, P1839, DOI 10.1046/j.1460-9568.1999.00598.x; Critchley HD, 2003, BRAIN, V126, P2139, DOI 10.1093/brain/awg216; Damasio A.R., 2000, FEELING WHAT HAPPENS; DiCarlo JJ, 2000, NAT NEUROSCI, V3, P814, DOI 10.1038/77722; Dijksterhuis A, 2001, ADV EXP SOC PSYCHOL, V33, P1, DOI 10.1016/S0065-2601(01)80003-4; Downing PE, 2001, SCIENCE, V293, P2470, DOI 10.1126/science.1063414; Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402; Grill-Spector K, 2003, CURR OPIN NEUROBIOL, V13, P159, DOI 10.1016/S0959-4388(03)00040-0; Grill-Spector K, 1999, NEURON, V24, P187, DOI 10.1016/S0896-6273(00)80832-6; Hartley T, 2003, NEURON, V37, P877, DOI 10.1016/S0896-6273(03)00095-3; Hasson U, 2003, NEURON, V37, P1027, DOI 10.1016/S0896-6273(03)00144-2; HASSON U, UNPUB; Haxby JV, 2000, TRENDS COGN SCI, V4, P223, DOI 10.1016/S1364-6613(00)01482-0; Haxby JV, 2001, SCIENCE, V293, P2425, DOI 10.1126/science.1063736; Hoffman EA, 2000, NAT NEUROSCI, V3, P80, DOI 10.1038/71152; Ishai A, 1999, P NATL ACAD SCI USA, V96, P9379, DOI 10.1073/pnas.96.16.9379; ITO M, 1995, J NEUROPHYSIOL, V73, P218, DOI 10.1152/jn.1995.73.1.218; Janata P, 2002, SCIENCE, V298, P2167, DOI 10.1126/science.1076262; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Kilner JM, 2003, CURR BIOL, V13, P522, DOI 10.1016/S0960-9822(03)00165-9; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; O'Craven KM, 1999, NATURE, V401, P584, DOI 10.1038/44134; Press WA, 2001, VISION RES, V41, P1321, DOI 10.1016/S0042-6989(01)00074-8; Puce A, 1998, J NEUROSCI, V18, P2188; Ringach DL, 2002, J VISION, V2, P12, DOI 10.1167/2.1.2; Rizzolatti G, 1997, CURR OPIN NEUROBIOL, V7, P562, DOI 10.1016/S0959-4388(97)80037-2; Rizzolatti G, 1996, COGNITIVE BRAIN RES, V3, P131, DOI 10.1016/0926-6410(95)00038-0; Rolls ET, 2003, J NEUROSCI, V23, P339; Sheinberg DL, 2001, J NEUROSCI, V21, P1340; Tootell RBH, 1998, NEURON, V21, P1409, DOI 10.1016/S0896-6273(00)80659-5; Tootell RBH, 1997, J NEUROSCI, V17, P7060; VINCENZONI L, 1966, GOOD BAD UGLY; Zacks JM, 2001, NAT NEUROSCI, V4, P651, DOI 10.1038/88486	38	981	997	42	215	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1634	1640		10.1126/science.1089506	http://dx.doi.org/10.1126/science.1089506			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016991				2022-12-28	WOS:000220151400034
J	Murch, S				Murch, S			A statement by Dr Simon Murch	LANCET			English	Editorial Material									UCL Royal Free & Univ Coll Med Sch, Ctr Paediat Gastroenterol, London NW3 2PF, England	University of London; University College London; UCL Medical School	Murch, S (corresponding author), UCL Royal Free & Univ Coll Med Sch, Ctr Paediat Gastroenterol, London NW3 2PF, England.	s.murch@rfc.ucl.ac.uk							0	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 6	2004	363	9411					821	822		10.1016/S0140-6736(04)15708-5	http://dx.doi.org/10.1016/S0140-6736(04)15708-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801JK	15022648				2022-12-28	WOS:000220092000024
J	Herzog, P; Rieger, CT				Herzog, P; Rieger, CT			Risk of cancer from diagnostic X-rays	LANCET			English	Editorial Material							TUBE CURRENT MODULATION; DOSE REDUCTION; IONIZING-RADIATION; PEDIATRIC CT; OPTIMIZATION; TOMOGRAPHY		Univ Munich, Inst Clin Radiol, D-81377 Munich, Germany; Univ Munich, Dept Internal Med 3, D-81377 Munich, Germany	University of Munich; University of Munich	Herzog, P (corresponding author), Univ Munich, Inst Clin Radiol, Marchioninistr 15, D-81377 Munich, Germany.	mail@pherzog.com						Andronikou S, 2002, SAMJ S AFR MED J, V92, P516; Bacher K, 2003, AM J ROENTGENOL, V181, P923, DOI 10.2214/ajr.181.4.1810923; Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100; BRIX G, 2003, EUR RADIOL, V10, P10; Fleszler F, 2003, AM J MED SCI, V325, P251, DOI 10.1097/00000441-200305000-00001; Gies M, 1999, MED PHYS, V26, P2235, DOI 10.1118/1.598779; Herzog P, 2002, RADIOLOGE, V42, P691, DOI 10.1007/s00117-002-0799-x; Huda W, 2002, PEDIATR RADIOL, V32, P709, DOI 10.1007/S00247-002-0796-2; Kalender WA, 1999, MED PHYS, V26, P2248, DOI 10.1118/1.598738; Kalender WA, 1999, EUR RADIOL, V9, P323, DOI 10.1007/s003300050674; KALENDER WA, 2000, COMPUTERTOMOGRAPHIE, P142; Kaul A, 1997, EUR RADIOL, V7, P1127, DOI 10.1007/s003300050267; McCreath G T, 1999, Health Bull (Edinb), V57, P180; Prokop M, 2001, RADIOLOGE, V41, P269, DOI 10.1007/s001170050987; Suess C, 2002, PEDIATR RADIOL, V32, P729, DOI 10.1007/s00247-002-0800-x	15	30	31	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	2004	363	9406					340	341		10.1016/S0140-6736(04)15470-6	http://dx.doi.org/10.1016/S0140-6736(04)15470-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768TQ	15070557				2022-12-28	WOS:000188590900002
J	Murphy, RT; Mogensen, J; Shaw, A; Kubo, T; Hughes, S; McKenna, WJ				Murphy, RT; Mogensen, J; Shaw, A; Kubo, T; Hughes, S; McKenna, WJ			Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy	LANCET			English	Article								Idiopathic dilated cardiomyopathy is a common cause of heart failure. Half of cases are believed to be hereditary, and mutations in cardiac sarcomeric contractile protein genes have been reported with autosomal dominant inheritance. We used mutation analysis suitable for identification of both dominant and recessive mutations to investigate the sarcomeric gene for cardiac troponin I (TNNI3) in 235 patients with dilated cardiomyopathy. We identified a novel TNNI3 mutation in a family with recessive disease. Functional studies showed impairment of troponin interactions that could lead to diminished myocardial contractility. TNNI3 is the first recessive gene identified for this condition, and we suggest that other such genes could be pinpointed by mutation analyses designed to identify homozygous mutations.	Univ London St Georges Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England; Kochi Med Sch, Dept Med & Geriatr, Kochi, Japan	St Georges University London; Kochi University	Mogensen, J (corresponding author), Skejby Univ Hosp, Dept Cardiol, Brendstupgaardsvej, DK-8200 Aarhus N, Denmark.	jens.mogensen@dadlnet.dk	McKenna, William J/C-3243-2008	McKenna, William J/0000-0001-7994-2460; Mogensen, Jens/0000-0002-8813-573X				Mestroni L, 1999, J AM COLL CARDIOL, V34, P181, DOI 10.1016/S0735-1097(99)00172-2; Mogensen J, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.5.e59; Mogensen J, 2003, J CLIN INVEST, V111, P209, DOI 10.1172/JCI200316336; Rarick HM, 1999, J MOL CELL CARDIOL, V31, P363, DOI 10.1006/jmcc.1998.0870; Towbin J. A., 2001, Current Molecular Medicine (Hilversum), V1, P81, DOI 10.2174/1566524013364077	5	125	133	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	2004	363	9406					371	372		10.1016/S0140-6736(04)15468-8	http://dx.doi.org/10.1016/S0140-6736(04)15468-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768TQ	15070570				2022-12-28	WOS:000188590900015
J	Hossain, SMM; Bhuiya, A; Khan, AR; Uhaa, I				Hossain, SMM; Bhuiya, A; Khan, AR; Uhaa, I			Community development and its impact on health: South Asian experience	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Most South Asian governments have concentrated on emulating a Western style of healthcare service, with the result that an elite few are overmedicalised whereas the majority are neglected. However, community participation in the development of local health services could provide a solution.	Unicef, MCHC Sect, Islamabad, Pakistan; Unicef Reg Off S Asia, Kathmundu, Nepal		Hossain, SMM (corresponding author), Unicef, MCHC Sect, Saudi Pk Tower,Blue Area, Islamabad, Pakistan.	smhossain@unicef.org						[Anonymous], NAT PROGR FAM PLANN; ANTIA NH, 1986, BRIT MED J, V292, P1181, DOI 10.1136/bmj.292.6529.1181; ANTIA NH, 1993, PEOPLES HLTH PEOPLES; Antia NH, 2000, HLTH MED CARE PEOPLE; AROLE R, 1994, JAMKHED COMPREHENSIV; Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; BHUIYA A, 2002, COMMUNITY BASED HLTH, P87; BHUIYA A, 1996, COMMUNITY PARTICIPAT; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Chaulagai C N, 1993, World Health Forum, V14, P16; Paz T. de la, 1983, World Health Forum, V4, P34; el-Katsha S, 1994, World Health Forum, V15, P29; *HLTH NUTR DEV SOC, 2003, HANDS AKF PROJ RED M; HODDY E, 1999, BANWASI SEVA ASHRAM; *MIN HLTH FAM WELF, 2000, MAJ SCHEM PROGR, P160; NAMGYAL P, 1994, EVALUATION VILLAGE H; Perry HB, 2000, HLTH ALL BANGLADESH; Saludung D, 1997, WORLD HEALTH FORUM, V18, P274; Stefanini A, 1995, World Health Forum, V16, P42; *UNICEF, 2004, WHAT WORKS LIT REV C; WALT G, 1989, SOC SCI MED, V29, P599, DOI 10.1016/0277-9536(89)90179-2; *WORLD BANK, 1998, ROAD BETT HLTH COND; *WORLD BANK GROUP, HNPSTATS HLTH NUTR P	23	17	18	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	2004	328	7443					830	833		10.1136/bmj.328.7443.830	http://dx.doi.org/10.1136/bmj.328.7443.830			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	811CG	15070644	Green Accepted, Green Published			2022-12-28	WOS:000220749400027
J	Kamad, D				Kamad, D			Shazia Fatima - the sky's the limit ...	LANCET			English	Editorial Material									Clarke Sch Deaf, Sadhana Unit, Madras, Tamil Nadu, India		Kamad, D (corresponding author), Clarke Sch Deaf, Sadhana Unit, Madras, Tamil Nadu, India.	diptik@md3.vsnl.net.in							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	2004	363	9415					1138	1138		10.1016/S0140-6736(04)15899-6	http://dx.doi.org/10.1016/S0140-6736(04)15899-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808VB	15064034				2022-12-28	WOS:000220595500023
J	Korber, P; Horz, W				Korber, P; Horz, W			SWRred not shaken: Mixing the histones	CELL			English	Review							DNA-SYNTHESIS; CHROMATIN; HETEROCHROMATIN; EXCHANGE; PROMOTER; MEDIATE; COMPLEX; CODE		Univ Munich, Adolf Butenandt Inst Mol Biol, D-80336 Munich, Germany	University of Munich	Horz, W (corresponding author), Univ Munich, Adolf Butenandt Inst Mol Biol, Schillerstr 44, D-80336 Munich, Germany.	hoerz@bio.med.uni-muenchen.de	Korber, Philipp/AAN-7633-2021	Korber, Philipp/0000-0001-7526-6549				Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; Bruno M, 2003, MOL CELL, V12, P1599, DOI 10.1016/S1097-2765(03)00499-4; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kaplan CD, 2003, SCIENCE, V301, P1096, DOI 10.1126/science.1087374; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Langst G, 2004, BBA-GENE STRUCT EXPR, V1677, P58, DOI 10.1016/j.bbaexp.2003.10.011; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Ray-Gallet D, 2002, MOL CELL, V9, P1091, DOI 10.1016/S1097-2765(02)00526-9; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Smith MM, 2002, CURR OPIN CELL BIOL, V14, P279, DOI 10.1016/S0955-0674(02)00331-9; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; van Leeuwen F, 2003, CELL, V112, P591, DOI 10.1016/S0092-8674(03)00152-1; Wolffe A., 1998, CHROMATIN STRUCTURE	20	52	55	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 2	2004	117	1					5	7		10.1016/S0092-8674(04)00296-X	http://dx.doi.org/10.1016/S0092-8674(04)00296-X			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YV	15066277	Bronze			2022-12-28	WOS:000221500300003
J	Ruan, CY; Lobastov, VA; Vigliotti, F; Chen, SY; Zewail, AH				Ruan, CY; Lobastov, VA; Vigliotti, F; Chen, SY; Zewail, AH			Ultrafast electron crystallography of interfacial water	SCIENCE			English	Article							VIBRATIONAL SPECTROSCOPY; SURFACE; ICE; DIFFRACTION; DESORPTION; TRANSITIONS; MOLECULES; DYNAMICS; CRYSTAL	We report direct determination of the structures and dynamics of interfacial water on a hydrophilic surface with atomic-scale resolution using ultrafast electron crystallography. On the nanometer scale, we observed the coexistence of ordered surface water and crystallite-like ice structures, evident in the superposition of Bragg spots and Debye-Scherrer rings. The structures were determined to be dominantly cubic, but each undergoes different dynamics after the ultrafast substrate temperature jump. From changes in local bond distances (OH..O and O...O) with time, we elucidated the structural changes in the far-from-equilibrium regime at short times and near-equilibration at long times.	CALTECH, Arthur Amos Noyes Lab Chem Phys, Lab Mol Sci, Pasadena, CA 91125 USA	California Institute of Technology	Zewail, AH (corresponding author), CALTECH, Arthur Amos Noyes Lab Chem Phys, Lab Mol Sci, Pasadena, CA 91125 USA.	zewail@caltech.edu		gaber, sarah/0000-0002-5995-7291				Bansal A, 2001, J PHYS CHEM B, V105, P10266, DOI 10.1021/jp010284p; BECHTEL JH, 1975, J APPL PHYS, V46, P1585, DOI 10.1063/1.321760; BERRY RS, 1994, CLUSTERS ATOMS MOL, P187; Bonn M, 2000, PHYS REV LETT, V84, P4653, DOI 10.1103/PhysRevLett.84.4653; Cao J, 2003, APPL PHYS LETT, V83, P1044, DOI 10.1063/1.1593831; Clary DC, 2000, ACCOUNTS CHEM RES, V33, P441, DOI 10.1021/ar9800643; Cruzan JD, 1996, SCIENCE, V271, P59, DOI 10.1126/science.271.5245.59; DU Q, 1993, PHYS REV LETT, V70, P2313, DOI 10.1103/PhysRevLett.70.2313; EISENTHAL KB, 1993, ACCOUNTS CHEM RES, V26, P636, DOI 10.1021/ar00036a005; Elsayed-Ali HE, 1997, TIME RESOLVED DIFFRA, P284; Ertl G, 2000, ADV CATAL, V45, P1; Henderson MA, 2002, SURF SCI REP, V46, P1, DOI 10.1016/S0167-5729(01)00020-6; Kubota J, 2003, CHEM PHYS LETT, V377, P217, DOI 10.1016/S0009-2614(03)01087-X; KUHS WF, 1987, J PHYS-PARIS, V48, P631, DOI 10.1051/jphyscol:1987187; Lobastov V. A., 2003, SPRINGER SERIES OPTI, P413; MATERER N, 1995, J PHYS CHEM-US, V99, P6267, DOI 10.1021/j100017a002; MISEWICH JA, 1992, PHYS REV LETT, V68, P3737, DOI 10.1103/PhysRevLett.68.3737; Pal SK, 2002, J PHYS CHEM B, V106, P12376, DOI 10.1021/jp0213506; Ruan CY, 2004, P NATL ACAD SCI USA, V101, P1123, DOI 10.1073/pnas.0307302101; RUAN CY, UNPUB; SEARS VF, 1991, ACTA CRYSTALLOGR A, V47, P441, DOI 10.1107/S0108767391002970; Siwick BJ, 2003, SCIENCE, V302, P1382, DOI 10.1126/science.1090052; Srinivasan R, 2003, HELV CHIM ACTA, V86, P1763; Su XC, 1998, PHYS REV LETT, V80, P1533, DOI 10.1103/PhysRevLett.80.1533; Thomas JM, 1997, CHEM-EUR J, V3, P1557, DOI 10.1002/chem.19970031004; Tulk CA, 2002, SCIENCE, V297, P1320, DOI 10.1126/science.1074178; VIGLIOTTI F, IN PRESS ANGEW CHEM; Whalley E., 1976, Hydrogen bond. Recent developments in theory and experiments. III. Dynamics, thermodynamics and special systems, P1425; Whitesides GM, 2002, SCIENCE, V295, P2418, DOI 10.1126/science.1070821; WILLIAMSON S, 1984, PHYS REV LETT, V52, P2364, DOI 10.1103/PhysRevLett.52.2364; Woutersen S, 1997, SCIENCE, V278, P658, DOI 10.1126/science.278.5338.658; Yalamanchili MR, 1996, LANGMUIR, V12, P4176, DOI 10.1021/la950340b; Yang MC, 2003, J CHEM PHYS, V118, P5106, DOI 10.1063/1.1553793	33	221	225	2	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					80	84		10.1126/science.1094818	http://dx.doi.org/10.1126/science.1094818			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15064414				2022-12-28	WOS:000220567900040
J	Steffan, JS; Agrawal, N; Pallos, J; Rockabrand, E; Trotman, LC; Slepko, N; Illes, K; Lukacsovich, T; Zhu, YZ; Cattaneo, E; Pandolfi, PP; Thompson, LM; Marsh, JL				Steffan, JS; Agrawal, N; Pallos, J; Rockabrand, E; Trotman, LC; Slepko, N; Illes, K; Lukacsovich, T; Zhu, YZ; Cattaneo, E; Pandolfi, PP; Thompson, LM; Marsh, JL			SUMO modification of Huntingtin and Huntington's disease pathology	SCIENCE			English	Article							INTRANUCLEAR INCLUSIONS; POLYGLUTAMINE AGGREGATION; NUCLEAR INCLUSIONS; UBIQUITIN; PROTEIN; LOCALIZATION; DROSOPHILA; NEURODEGENERATION; PATHOGENESIS; INTERACTS	Huntington's disease (HD) is characterized by the accumulation of a pathogenic protein, Huntingtin (Htt), that contains an abnormal polyglutamine expansion. Here, we report that a pathogenic fragment of Htt (Httex1p) can be modified either by small ubiquitin-like modifier (SUMO)-1 or by ubiquitin on identical lysine residues. In cultured cells, SUMOylation stabilizes Httex1p, reduces its ability to form aggregates, and promotes its capacity to repress transcription. In a Drosophila model of HD, SUMOylation of Httex1p exacerbates neurodegeneration, whereas ubiquitination of Httex1p abrogates neurodegeneration. Lysine mutations that prevent both SUMOylation and ubiquitination of Httex1p reduce HD pathology, indicating that the contribution of SUMOylation to HD pathology extends beyond preventing Htt ubiquitination and degradation.	Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92697 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10021 USA; Univ Milan, Ctr Excellence Neurodegenerat Dis, Dept Pharmacol Sci, I-20133 Milan, Italy; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Milan; University of California System; University of California Irvine	Marsh, JL (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, 4444 McGaugh Hall, Irvine, CA 92697 USA.	jlmarsh@uci.edu	Pallos, Judit/AAE-6833-2020	, Namita/0000-0002-9459-385X; CATTANEO, ELENA/0000-0002-0755-4917	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036049, R01HD036081] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA062203] Funding Source: NIH RePORTER; NCI NIH HHS [CA-62203] Funding Source: Medline; NICHD NIH HHS [HD36049, HD36081] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alefantis T, 2003, J BIOL CHEM, V278, P21814, DOI 10.1074/jbc.M211576200; Apostol BL, 2003, P NATL ACAD SCI USA, V100, P5950, DOI 10.1073/pnas.2628045100; Bates G, 2003, LANCET, V361, P1642, DOI 10.1016/S0140-6736(03)13304-1; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Chan HYE, 2002, HUM MOL GENET, V11, P2895, DOI 10.1093/hmg/11.23.2895; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Donaldson KM, 2003, P NATL ACAD SCI USA, V100, P8892, DOI 10.1073/pnas.1530212100; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kazantsev A, 2002, NAT GENET, V30, P367, DOI 10.1038/ng864; Li YH, 2003, P NATL ACAD SCI USA, V100, P9102, DOI 10.1073/pnas.1533062100; Li YH, 2003, P NATL ACAD SCI USA, V100, P259, DOI 10.1073/pnas.0235361100; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Luthi-Carter R, 2003, CLIN NEUROSCI RES, V3, P165, DOI 10.1016/S1566-2772(03)00059-8; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Pichler A, 2002, TRAFFIC, V3, P381, DOI 10.1034/j.1600-0854.2002.30601.x; Pountney DL, 2003, EXP NEUROL, V184, P436, DOI 10.1016/j.expneurol.2003.07.004; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sieradzan KA, 1999, EXP NEUROL, V156, P92, DOI 10.1006/exnr.1998.7005; Sipione S, 2002, HUM MOL GENET, V11, P1953, DOI 10.1093/hmg/11.17.1953; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Steffan JS, 2003, EXPERT OPIN THER TAR, V7, P201, DOI 10.1517/14728222.7.2.201; Sugars KL, 2003, TRENDS GENET, V19, P233, DOI 10.1016/S0168-9525(03)00074-X; Terashima T, 2002, NEUROREPORT, V13, P2359, DOI 10.1097/00001756-200212030-00038; Tobin AJ, 2000, TRENDS CELL BIOL, V10, P531, DOI 10.1016/S0962-8924(00)01853-5; Tsai YC, 2003, J BIOL CHEM, V278, P22044, DOI 10.1074/jbc.M212235200; Ueda H, 2002, BIOCHEM BIOPH RES CO, V293, P307, DOI 10.1016/S0006-291X(02)00211-5; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Zuccato C, 2003, NAT GENET, V35, P76, DOI 10.1038/ng1219	43	526	549	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					100	104		10.1126/science.1092194	http://dx.doi.org/10.1126/science.1092194			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15064418	Green Submitted			2022-12-28	WOS:000220567900046
J	Lipton, SA				Lipton, SA			Turning down, but not off	NATURE			English	Editorial Material							MEMANTINE		Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Lipton, SA (corresponding author), Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA.			Lipton, Stuart/0000-0002-3490-1259				CHEN HSV, 1992, J NEUROSCI, V12, P4427; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lipton SA, 2004, CELL DEATH DIFFER, V11, P18, DOI 10.1038/sj.cdd.4401344; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128	4	56	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 1	2004	428	6982					473	473		10.1038/428473a	http://dx.doi.org/10.1038/428473a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15057811				2022-12-28	WOS:000220540100021
J	Shulenin, S; Nogee, LM; Annilo, T; Wert, SE; Whitsett, JA; Dean, M				Shulenin, S; Nogee, LM; Annilo, T; Wert, SE; Whitsett, JA; Dean, M			ABCA3 gene mutations in newborns with fatal surfactant deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CASSETTE TRANSPORTER 1; PROTEIN-B DEFICIENCY; TANGIER-DISEASE; STARGARDT-DISEASE; MEMBRANE-PROTEIN; II CELLS; ACCUMULATION; LUNG; SITOSTEROLEMIA; DYSTROPHY	BACKGROUND: Pulmonary surfactant forms a lipid-rich monolayer that coats the airways of the lung and is essential for proper inflation and function of the lung. Surfactant is produced by alveolar type II cells, stored intracellularly in organelles known as lamellar bodies, and secreted by exocytosis. The gene for ATP-binding cassette transporter A3 (ABCA3) is expressed in alveolar type II cells, and the protein is localized to lamellar bodies, suggesting that it has an important role in surfactant metabolism. METHODS: We sequenced each of the coding exons of the ABCA3 gene in blood DNA from 21 racially and ethnically diverse infants with severe neonatal surfactant deficiency for which the etiologic process was unknown. Lung tissue from four patients was examined by high-resolution light and electron microscopy. RESULTS: Nonsense and frameshift mutations, as well as mutations in highly conserved residues and in splice sites of the ABCA3 gene were identified in 16 of the 21 patients (76 percent). In five consanguineous families with mutations, each pair of siblings was homozygous for the same mutation and each mutation was found in only one family. Markedly abnormal lamellar bodies were observed by ultrastructural examination of lung tissue from four patients with different ABCA3 mutations, including nonsense, splice-site, and missense mutations. CONCLUSIONS: Mutation of the ABCA3 gene causes fatal surfactant deficiency in newborns. ABCA3 is critical for the proper formation of lamellar bodies and surfactant function and may also be important for lung function in other pulmonary diseases. Since it is closely related to ABCA1 and ABCA4, proteins that transport phospholipids in macrophages and photoreceptor cells, it may have a role in surfactant phospholipid metabolism.	NCI, Human Genet Sect, Lab Genom Divers, Frederick, MD 21702 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center	Dean, M (corresponding author), NCI, Human Genet Sect, Lab Genom Divers, Bldg 560,Rm 21-18, Frederick, MD 21702 USA.	dean@ncifcrf.gov	Dean, Michael/R-7501-2019; Annilo, Tarmo/J-2900-2013; Dean, Michael C/G-8172-2012	Annilo, Tarmo/0000-0002-9588-3058; Dean, Michael C/0000-0003-2234-0631	NATIONAL CANCER INSTITUTE [ZIABC005725, Z01BC005725] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054703, P01HL056387, R29HL054703, P50HL056387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56387, HL-54703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allikmets R, 1997, NAT GENET, V17, P122, DOI 10.1038/ng0997-122b; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Connors TD, 1997, GENOMICS, V39, P231, DOI 10.1006/geno.1996.4500; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; DEMELLO DE, 1994, AM J RESP CELL MOL, V11, P230, DOI 10.1165/ajrcmb.11.2.8049084; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; Lu KM, 2001, AM J HUM GENET, V69, P278, DOI 10.1086/321294; Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685; Mulugeta S, 2002, J BIOL CHEM, V277, P22147, DOI 10.1074/jbc.M201812200; Na C.-L, 1998, Microscopy and Microanalysis, V4, P852, DOI 10.1017/S1431927600024387; Nogee LM, 2000, AM J RESP CRIT CARE, V161, P973, DOI 10.1164/ajrccm.161.3.9903153; Nogee LM, 1997, CHEST, V111, pS129, DOI 10.1378/chest.111.6_Supplement.129S-a; Nogee LM, 2001, NEW ENGL J MED, V344, P573, DOI 10.1056/NEJM200102223440805; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tredano M, 2003, AM J MED GENET A, V119A, P324, DOI 10.1002/ajmg.a.20058; Tryka AF, 2000, PEDIATR DEVEL PATHOL, V3, P335, DOI 10.1007/s100249910048; Wood PG, 2000, AM J PHYSIOL-REG I, V278, pR611, DOI 10.1152/ajpregu.2000.278.3.R611; Yamano G, 2001, FEBS LETT, V508, P221, DOI 10.1016/S0014-5793(01)03056-3; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	26	460	488	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2004	350	13					1296	1303		10.1056/NEJMoa032178	http://dx.doi.org/10.1056/NEJMoa032178			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VN	15044640				2022-12-28	WOS:000220393900007
J	Thorley-Lawson, DA; Gross, A				Thorley-Lawson, DA; Gross, A			Mechanisms of disease - Persistence of the Epstein-Barr virus and the origins of associated lymphomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MEMORY B-CELLS; REED-STERNBERG CELLS; INFECTIOUS-MONONUCLEOSIS; HODGKINS-DISEASE; BURKITTS-LYMPHOMA; IN-VIVO; NUCLEAR ANTIGEN-2; GENETIC-VARIATION; GERMINAL-CENTERS; EPITHELIAL-CELLS		Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Dept Rheumatol, Boston, MA USA	Tufts University; Tufts Medical Center	Thorley-Lawson, DA (corresponding author), Tufts Univ, Sch Med, Dept Pathol, Jaharis Bldg,150 Harrison Ave, Boston, MA 02111 USA.	david.thorley-lawson@tufts.edu						AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; ANAGNOSTOPOULOS I, 1995, BLOOD, V85, P744, DOI 10.1182/blood.V85.3.744.bloodjournal853744; Babcock GJ, 2000, P NATL ACAD SCI USA, V97, P12250, DOI 10.1073/pnas.200366597; Babcock GJ, 2000, IMMUNITY, V13, P497, DOI 10.1016/S1074-7613(00)00049-2; Babcock GJ, 1999, J EXP MED, V190, P567, DOI 10.1084/jem.190.4.567; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Borza CM, 2002, NAT MED, V8, P594, DOI 10.1038/nm0602-594; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Casola S, 2004, NAT IMMUNOL, V5, P317, DOI 10.1038/ni1036; Cohen JI, 2000, NEW ENGL J MED, V343, P481, DOI 10.1056/NEJM200008173430707; Crawford DH, 2001, PHILOS T R SOC B, V356, P461, DOI 10.1098/rstb.2000.0783; de-The G, 1985, IARC Sci Publ, P165; DEACON EM, 1993, J EXP MED, V177, P339, DOI 10.1084/jem.177.2.339; DIEHL V, 1968, J VIROL, V2, P663, DOI 10.1128/JVI.2.7.663-669.1968; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FAHRAEUS R, 1990, P NATL ACAD SCI USA, V87, P7390, DOI 10.1073/pnas.87.19.7390; Glaser SL, 1997, INT J CANCER, V70, P375, DOI 10.1002/(SICI)1097-0215(19970207)70:4&lt;375::AID-IJC1&gt;3.0.CO;2-T; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1987, J IMMUNOL, V139, P313; GULLEY ML, 1992, CANCER, V70, P185, DOI 10.1002/1097-0142(19920701)70:1<185::AID-CNCR2820700129>3.0.CO;2-J; Henle W., 1979, EPSTEINBARR VIRUS, P61; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; Hjalgrim H, 2003, NEW ENGL J MED, V349, P1324, DOI 10.1056/NEJMoa023141; Hochberg D, 2004, P NATL ACAD SCI USA, V101, P239, DOI 10.1073/pnas.2237267100; HOCHBERG D, IN PRESS J VIROL; JONCAS J, 1974, CAN MED ASSOC J, V110, P33; Joseph AM, 2000, J IMMUNOL, V165, P2975, DOI 10.4049/jimmunol.165.6.2975; Joseph AM, 2000, J VIROL, V74, P9964, DOI 10.1128/JVI.74.21.9964-9971.2000; Kelly G, 2002, NAT MED, V8, P1098, DOI 10.1038/nm758; Khanna R, 1999, IMMUNOL REV, V170, P49, DOI 10.1111/j.1600-065X.1999.tb01328.x; Khanna R, 1997, J VIROL, V71, P8340, DOI 10.1128/JVI.71.11.8340-8346.1997; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; Klein G, 1987, ADV VIRAL ONCOL, V7, P207; KLEIN U, 1995, MOL MED, V1, P495, DOI 10.1007/BF03401587; Kuppers R, 1998, ANNU REV IMMUNOL, V16, P471, DOI 10.1146/annurev.immunol.16.1.471; Kurth J, 2000, IMMUNITY, V13, P485, DOI 10.1016/S1074-7613(00)00048-0; Kurth J, 2003, P NATL ACAD SCI USA, V100, P4730, DOI 10.1073/pnas.2627966100; Laichalk LL, 2002, IMMUNITY, V16, P745, DOI 10.1016/S1074-7613(02)00318-7; Leder P, 1985, IARC Sci Publ, P341; Lenoir GM, 1987, ADV VIRAL ONCOL, V7, P173; Liu YJ, 1997, IMMUNOL REV, V156, P111, DOI 10.1111/j.1600-065X.1997.tb00963.x; MACLENNAN ICM, 1988, CURR TOP MICROBIOL, V141, P138; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MANOLOV G, 1972, NATURE, V237, P33, DOI 10.1038/237033a0; Miyashita EM, 1998, J VIROL, V72, P9419, DOI 10.1128/JVI.72.11.9419-9419.1998; NIEDERMAN JC, 1968, J AMER MED ASSOC, V203, P205; Niedobitek G, 1997, BLOOD, V90, P1664, DOI 10.1182/blood.V90.4.1664.1664_1664_1672; NILSSON K, 1979, EPSTEINBARR VIRUS, P225; Oudejans JJ, 1996, J CLIN PATHOL, V49, P897, DOI 10.1136/jcp.49.11.897; PEARSON G, 1970, JNCI-J NATL CANCER I, V45, P989; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Polack A, 1996, P NATL ACAD SCI USA, V93, P10411, DOI 10.1073/pnas.93.19.10411; POPE JH, 1968, INT J CANCER, V3, P857, DOI 10.1002/ijc.2910030619; Staudt LM, 2000, J EXP MED, V191, P207, DOI 10.1084/jem.191.2.207; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; Thorley-Lawson DA, 1999, LIFE SCI, V65, P1433, DOI 10.1016/S0024-3205(99)00214-3; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; THORLEYLAWSON DA, 1985, J IMMUNOL, V134, P3007; THORLEYLAWSON DA, 1982, CELL, V30, P415, DOI 10.1016/0092-8674(82)90239-2; THORLEYLAWSON DA, 2001, SAMPTERS IMMUNOLOGIC, V2, P970; Timms JM, 2003, LANCET, V361, P217, DOI 10.1016/S0140-6736(03)12271-4; Tugizov SM, 2003, NAT MED, V9, P477; Tugizov SM, 2003, NAT MED, V9, P307, DOI 10.1038/nm830; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; WEBSTER RG, 1982, NATURE, V296, P115, DOI 10.1038/296115a0; WEISS LM, 1989, NEW ENGL J MED, V320, P502, DOI 10.1056/NEJM198902233200806; WOOD TA, 1967, AM J MED, V42, P923, DOI 10.1016/0002-9343(67)90073-3; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	74	692	714	2	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2004	350	13					1328	1337		10.1056/NEJMra032015	http://dx.doi.org/10.1056/NEJMra032015			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VN	15044644				2022-12-28	WOS:000220393900011
J	Hurskainen, R; Teperi, J; Rissanen, P; Aalto, AM; Grenman, S; Kivela, A; Kujansuu, E; Vuorma, S; Yliskoski, M; Paavonen, J				Hurskainen, R; Teperi, J; Rissanen, P; Aalto, AM; Grenman, S; Kivela, A; Kujansuu, E; Vuorma, S; Yliskoski, M; Paavonen, J			Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia - Randomized trial 5-year follow-up	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; TRANSCERVICAL ENDOMETRIAL RESECTION; LAPAROSCOPIC HYSTERECTOMIES; ABDOMINAL HYSTERECTOMY; COMPLICATIONS; MANAGEMENT; WOMEN; REGISTER; DEVICE	Context Because menorrhagia is often a reason for seeking medical attention, it is important to consider outcomes and costs associated with alternative treatment modalities. Both the levonorgestrel-releasing intrauterine system (LNG-lUS) and hysterectomy have proven effective for treatment of menorrhagia but there are no long-term comparative studies measuring cost and quality of life. Objective To compare outcomes, quality-of-life issues, and costs of the LNG-IUS vs hysterectomy in the treatment of menorrhagia. Design, Setting, and Participants Randomized controlled trial conducted between October 1, 1994, and October 6, 2002, and enrolling 236 women (mean [SDI age, 43 [3.4] years) referred to 5 university hospitals in Finland for complaints of menorrhagia. Interventions Participants were randomly assigned to treatment with the LNG-I US (n=119) or hysterectomy (n=117) and were monitored for 5 years. Main Outcome Measures Health-related quality of life (H RQQ as measured by the 5-Dimensional EuroQol and the RAND 36-Item Short-Form Health Survey, other measures of psychosocial well-being (anxiety, depression, and sexual function), and costs. Results After 5 years of follow-up, 232 women (99%) were analyzed for the primary outcomes. The 2 groups did not differ substantially in terms of HRQL or psychosocial well-being. Although 50 (42%) of the women assigned to the LNG-IUS group eventually underwent hysterectomy, the discounted direct and indirect costs in the LNG-IUS group ($2817 [95% confidence interval, $2222-$3530] per participant) remained substantially lower than in the hysterectomy group ($4660 [95% confidence interval, $4014-$5180]). Satisfaction with treatment was similar in both groups. Conclusions By providing improvement in HRQL at relatively low cost, the LNG-IUS may offer a wider availability of choices for the patient and may decrease costs due to interventions involving surgery.	Univ Helsinki, Dept Obstet & Gynecol, FIN-00014 Helsinki, Finland; Univ Turku, SF-20500 Turku, Finland; Univ Oulu, Oulu, Finland; Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland; Univ Kuopio, FIN-70211 Kuopio, Finland; STAKES, Natl Res & Dev Ctr Welf & Hlth, Helsinki, Finland	University of Helsinki; University of Turku; University of Oulu; Tampere University; University of Eastern Finland; Finland National Institute for Health & Welfare	Hurskainen, R (corresponding author), Helsinki Univ Hosp, Dept Obstet & Gynecol, Pl 140, Helsinki 0029, Finland.	ritva.hurskainen@stakes.fi		Paavonen, Jorma/0000-0003-4775-606X				Aalto A., 1999, 101 STAKES; BECK AT, 1974, PSYCHOL REP, V34, P1184; Cameron IM, 1996, EUR J OBSTET GYN R B, V70, P87, DOI 10.1016/S0301-2115(96)02558-4; Cooper KG, 1999, BRIT J OBSTET GYNAEC, V106, P258, DOI 10.1111/j.1471-0528.1999.tb08240.x; Crosignani PG, 1997, OBSTET GYNECOL, V90, P257, DOI 10.1016/S0029-7844(97)00226-3; DICKER RC, 1982, AM J OBSTET GYNECOL, V144, P841, DOI 10.1016/0002-9378(82)90362-3; Dorsey JH, 1996, NEW ENGL J MED, V335, P476, DOI 10.1056/NEJM199608153350705; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; FARQUHAR CM, 1992, DRUGS, V44, P578, DOI 10.2165/00003495-199244040-00005; GANNON MJ, 1991, BRIT MED J, V303, P1362, DOI 10.1136/bmj.303.6814.1362; Grant A, 1999, BRIT J OBSTET GYNAEC, V106, P360; HarkkiSiren P, 1997, AM J OBSTET GYNECOL, V176, P118, DOI 10.1016/S0002-9378(97)80023-3; Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305; Hidalgo M, 2002, CONTRACEPTION, V65, P129, DOI 10.1016/S0010-7824(01)00302-X; Hurskainen R, 1998, ACTA OBSTET GYN SCAN, V77, P201, DOI 10.1034/j.1600-0412.1998.770214.x; Hurskainen R, 2001, LANCET, V357, P273, DOI 10.1016/S0140-6736(00)03615-1; Irvine GA, 1998, BRIT J OBSTET GYNAEC, V105, P592, DOI 10.1111/j.1471-0528.1998.tb10172.x; Kittelsen N, 1998, GYNAECOL ENDOSC, V7, P61, DOI 10.1046/j.1365-2508.1998.00165.x; KOOPMANSCHAP MA, 1994, HEALTH ECON, V3, P385, DOI 10.1002/hec.4730030606; Lahteenmaki P, 1998, BMJ-BRIT MED J, V316, P1122, DOI 10.1136/bmj.316.7138.1122; MCCOY NL, 1985, MATURITAS, V7, P203, DOI 10.1016/0378-5122(85)90041-6; Meltomaa SS, 1999, J AM COLL SURGEONS, V189, P389, DOI 10.1016/S1072-7515(99)00170-2; MILSOM I, 1991, AM J OBSTET GYNECOL, V164, P879, DOI 10.1016/S0002-9378(11)90533-X; *MORI, 1990, MORI WOM HLTH 1990 R; MUNRO MG, 1995, CLIN OBSTET GYNECOL, V38, P401; Nagrani R, 2002, BJOG-INT J OBSTET GY, V109, P345, DOI 10.1016/S1470-0328(02)01274-0; Ohinmaa A, 1995, 12 ANN EUROQOL PLEN; Ohinmaa S, 1998, 15 ANN EUROQOL PLEN, P57; *ORG EC COOP DEV, 1993, DEV ECOA, P15; POWELL M, 1998, CURR OBSTET GYNAECOL, V8, P73; *RCOG, 1998, RCOG EV BAS GUID, V1; SCULPHER MJ, 1993, BRIT J OBSTET GYNAEC, V100, P244, DOI 10.1111/j.1471-0528.1993.tb15238.x; Sculpher MJ, 1996, BRIT J OBSTET GYNAEC, V103, P142, DOI 10.1111/j.1471-0528.1996.tb09666.x; Spielberger C., 1983, STAI MANUAL; Stirrat GM, 1999, LANCET, V353, P2175, DOI 10.1016/S0140-6736(99)00132-4; Vuorma S, 1998, ACTA OBSTET GYN SCAN, V77, P770, DOI 10.1034/j.1600-0412.1998.770713.x; WIKLUND I, 1993, ACTA OBSTET GYN SCAN, V72, P648, DOI 10.3109/00016349309021159; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	38	232	245	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	2004	291	12					1456	1463		10.1001/jama.291.12.1456	http://dx.doi.org/10.1001/jama.291.12.1456			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805UI	15039412	Bronze			2022-12-28	WOS:000220390800026
J	Chadwick, D; Mitra, T; Sitoh, YY				Chadwick, D; Mitra, T; Sitoh, YY			Salmonella typhimurium brain abscess	LANCET			English	Editorial Material									James Cook Univ Hosp, Dept Infect & Travel Med, Middlesbrough T4 3BW, Cleveland, England; Natl Inst Neurosci, Dept Neuroradiol, Singapore, Singapore; Tan Tock Seng Hosp, Dept Infect Dis, Singapore, Singapore	James Cook University Hospital; National Neuroscience Institute (NNI); Tan Tock Seng Hospital	Chadwick, D (corresponding author), Tan Tock Seng Hosp, Dept Infect Dis, Singapore, Singapore.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	2004	363	9413					947	947		10.1016/S0140-6736(04)15789-9	http://dx.doi.org/10.1016/S0140-6736(04)15789-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043962	Bronze			2022-12-28	WOS:000220308600011
J	Jeri, C; Gilman, RH; Lescano, AG; Mayta, H; Ramirez, ME; Gonzalez, AE; Nazerali, R; Garcia, HH				Jeri, C; Gilman, RH; Lescano, AG; Mayta, H; Ramirez, ME; Gonzalez, AE; Nazerali, R; Garcia, HH			Species identification after treatment for human taeniasis	LANCET			English	Article							SOLIUM; INFECTIONS	Identification of species of human tapeworms is crucial because the consequences of infection by Taenia solium and T saginata are very different. However, evacuation of species-identifiable tapeworms is uncommon and Taenia spp eggs are indistinguishable under the microscope. Treatment of taeniasis consists of niclosamide followed by a purgative. Recently, we adopted preniclosamide and postniclosamide electrolyte-polyethyleneglycol salt (EPS) purges to improve bowel cleaning. Retrospective comparison of traditional castor oil with EPS purge showed that recovery of the tapeworm scolex was significantly improved (20 of 68 vs none of 46, p=0.0001) in the EPS group. Furthermore, 42 of 68 (62%) individuals receiving EPS excreted identifiable gravid proglottids. EPS treatment helps the visual identification of Taenia spp.	Inst Ciencias Neurol, Cysticercosis Unit, Lima 1, Peru; Univ Peruana Cayetano Heredia San Martin de Porra, Sch Sci, Dept Microbiol, Lima, Peru; Univ Peruana Cayetano Heredia San Martin de Porra, Sch Publ Hlth & Adm, Lima, Peru; Asociac Benefica PRISMA, Lima, Peru; Naval Med Res Ctr Detachment, Global Emerging Infect Syst, Lima, Peru; Univ Nacl Mayor San Marcos, Sch Vet Med, Lima 14, Peru	Universidad Peruana Cayetano Heredia; Universidad Peruana Cayetano Heredia; Universidad Nacional Mayor de San Marcos	Garcia, HH (corresponding author), Inst Ciencias Neurol, Cysticercosis Unit, Jiron Ancash 1271,Barrios Altos, Lima 1, Peru.	hgarcia@jhsph.edu	Mayta, Holger/ABA-4755-2020; Lescano, Andres G./M-9849-2019; Lescano, Andres G/B-8479-2008	Mayta, Holger/0000-0001-5306-628X; Lescano, Andres G./0000-0001-9779-633X; Lescano, Andres G/0000-0001-9779-633X; Gonzalez, Armando/0000-0003-1909-1873; Jeri, Cesar/0000-0002-3368-4918	NIAID NIH HHS [P01 AI51976, U01 AI35894] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI051976, U01AI035894] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Garcia HH, 2003, AM J TROP MED HYG, V68, P268, DOI 10.4269/ajtmh.2003.68.268; Garcia HH, 2003, LANCET, V362, P547, DOI 10.1016/S0140-6736(03)14117-7; Mayta H, 2000, J CLIN MICROBIOL, V38, P133; PEARSON RD, 1985, ANN INTERN MED, V102, P550, DOI 10.7326/0003-4819-102-4-550; Sanchez AL, 1997, ANN TROP MED PARASIT, V91, P163, DOI 10.1080/00034983.1997.11813126	5	48	50	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	2004	363	9413					949	950		10.1016/S0140-6736(04)15791-7	http://dx.doi.org/10.1016/S0140-6736(04)15791-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804OS	15043964				2022-12-28	WOS:000220308600013
J	Johnson, SJ; Beese, LS				Johnson, SJ; Beese, LS			Structures of mismatch replication errors observed in a DNA polymerase	CELL			English	Article							I KLENOW FRAGMENT; CRYSTAL-STRUCTURE; NUCLEOTIDE INCORPORATION; REVERSE-TRANSCRIPTASE; ANGSTROM RESOLUTION; TERNARY COMPLEXES; TEMPLATE-PRIMERS; ALPHA HOLOENZYME; BASE-PAIRS; FIDELITY	Accurate DNA replication is essential for genomic stability. One mechanism by which high-fidelity DNA polymerases maintain replication accuracy involves stalling of the polymerase in response to covalent incorporation of mismatched base pairs, thereby favoring subsequent mismatch excision. Some polymerases retain a "short-term memory" of replication errors, responding to mismatches up to four base pairs in from the primer terminus. Here we a present a structural characterization of all 12 possible mismatches captured at the growing primer terminus in the active site of a polymerase. Our observations suggest four mechanisms that lead to mismatch-induced stalling of the polymerase. Furthermore, we have observed the effects of extending a mismatch up to six base pairs from the primer terminus and find that long-range distortions in the DNA transmit the presence of the mismatch back to the enzyme active site, suggesting the structural basis for the short-term memory of replication errors.	Duke Univ, Ctr Med, Dept Biochem, Durham, NC 27710 USA	Duke University	Beese, LS (corresponding author), Duke Univ, Ctr Med, Dept Biochem, Durham, NC 27710 USA.	lsb@biochem.duke.edu	Johnson, Sean/G-8191-2012; Classen, Scott/AAY-8176-2020; beese, lorena/G-4993-2010	Johnson, Sean/0000-0001-7992-2494; 	NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA92584] Funding Source: Medline; NCRR NIH HHS [RR07707] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAEYENS KJ, 1995, NAT STRUCT BIOL, V2, P56, DOI 10.1038/nsb0195-56; BECKMAN RA, 1993, Q REV BIOPHYS, V26, P225, DOI 10.1017/S0033583500002869; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; CARVER TE, 1994, P NATL ACAD SCI USA, V91, P10670, DOI 10.1073/pnas.91.22.10670; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; Friedberg EC, 2001, CELL, V107, P9, DOI 10.1016/S0092-8674(01)00509-8; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUANG MM, 1992, NUCLEIC ACIDS RES, V20, P4567, DOI 10.1093/nar/20.17.4567; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; JOYCE CM, 1992, J BIOL CHEM, V267, P24485; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KENNARD O, 1989, Q REV BIOPHYS, V22, P327, DOI 10.1017/S0033583500002997; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Li Y, 2001, PROTEIN SCI, V10, P1225, DOI 10.1110/ps.250101; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Lu XJ, 2000, J MOL BIOL, V300, P819, DOI 10.1006/jmbi.2000.3690; Miller H, 1997, BIOCHEMISTRY-US, V36, P15336, DOI 10.1021/bi971927n; NG L, 1989, J BIOL CHEM, V264, P13018; PATEL DJ, 1987, CONFORMATION DNA BAS; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P3085, DOI 10.1073/pnas.86.9.3085; Saenger W., 1989, J MOL BIOL, V205, P787; SKELLY JV, 1993, P NATL ACAD SCI USA, V90, P804, DOI 10.1073/pnas.90.3.804; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; WEISS SJ, 1992, J BIOL CHEM, V267, P18520; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464	39	242	244	1	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 19	2004	116	6					803	816		10.1016/S0092-8674(04)00252-1	http://dx.doi.org/10.1016/S0092-8674(04)00252-1			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YS	15035983	Bronze			2022-12-28	WOS:000221499900007
J	Garg, A				Garg, A			Medical progress - Acquired and inherited lipodystrophies	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FAMILIAL PARTIAL LIPODYSTROPHY; SEIP CONGENITAL LIPODYSTROPHY; DOMINANT-NEGATIVE MUTATIONS; HIV-INFECTED PATIENTS; BODY-FAT DISTRIBUTION; NUCLEAR LAMIN-A; GENERALIZED LIPODYSTROPHY; INSULIN-RESISTANCE; DIABETES-MELLITUS; ADIPOSE-TISSUE		Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Div Nutr & Metab Dis, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Garg, A (corresponding author), Univ Texas, SW Med Ctr, Ctr Human Nutr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	garg@utsouthwestern.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054387] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00633] Funding Source: Medline; NIDDK NIH HHS [R01-DK54387] Funding Source: Medline; PHS HHS [R01-63656, R01-56583] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Agarwal AK, 2003, J CLIN ENDOCR METAB, V88, P4840, DOI 10.1210/jc.2003-030855; Agarwal AK, 2002, J CLIN ENDOCR METAB, V87, P408, DOI 10.1210/jc.87.1.408; Agarwal AK, 2002, NAT GENET, V31, P21, DOI 10.1038/ng880; Agarwal AK, 2003, HUM MOL GENET, V12, P1995, DOI 10.1093/hmg/ddg213; Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Arioglu E, 2000, ANN INTERN MED, V133, P263, DOI 10.7326/0003-4819-133-4-200008150-00009; BARRAQUER L, 2005, NEUROLOG CENTRALBLAT, V26, P1072; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Bastard JP, 2002, LANCET, V359, P1026, DOI 10.1016/S0140-6736(02)08094-7; BERARDINELLI W, 1954, J CLIN ENDOCR METAB, V14, P193, DOI 10.1210/jcem-14-2-193; BILLINGS JK, 1987, ARCH DERMATOL, V123, P1662, DOI 10.1001/archderm.123.12.1662; Bolan C, 2002, J CLIN ENDOCR METAB, V87, P380, DOI 10.1210/jc.87.1.380; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Cao H, 2000, HUM MOL GENET, V9, P109, DOI 10.1093/hmg/9.1.109; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 2000, AIDS, V14, pF25, DOI 10.1097/00002030-200002180-00001; Carr A, 2001, AIDS, V15, P1811, DOI 10.1097/00002030-200109280-00010; Cauble MS, 2001, TRANSPLANTATION, V71, P892, DOI 10.1097/00007890-200104150-00012; Caux F, 2003, J CLIN ENDOCR METAB, V88, P1006, DOI 10.1210/jc.2002-021506; CHANDALIA M, 1995, J CLIN ENDOCR METAB, V80, P3077, DOI 10.1210/jc.80.10.3077; Chen DL, 2002, J CLIN ENDOCR METAB, V87, P4845, DOI 10.1210/jc.2002-020794; CUTLER DL, 1991, J CLIN ENDOCR METAB, V73, P1056, DOI 10.1210/jcem-73-5-1056; Domingo P, 1999, AIDS, V13, P2261, DOI 10.1097/00002030-199911120-00008; Dowell P, 2000, J BIOL CHEM, V275, P41325, DOI 10.1074/jbc.M006474200; Dube MP, 1997, LANCET, V350, P713, DOI 10.1016/S0140-6736(05)63513-1; DUNNIGAN MG, 1974, Q J MED, V43, P33; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Fichtenbaum CJ, 2002, AIDS, V16, P569, DOI 10.1097/00002030-200203080-00008; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FLECKENSTEIN JL, 1992, SKELETAL RADIOL, V21, P381; FLEMING P, 2002, 9 C RETR OPP INF SEA, P56; Gange SJ, 2002, J EPIDEMIOL COMMUN H, V56, P153, DOI 10.1136/jech.56.2.153; GARG A, 1992, J CLIN ENDOCR METAB, V75, P358, DOI 10.1210/jc.75.2.358; Garg A, 1996, DIABETES CARE, V19, P28, DOI 10.2337/diacare.19.1.28; Garg A, 2000, AM J MED, V108, P143, DOI 10.1016/S0002-9343(99)00414-3; Garg A, 2002, AM J MED, V112, P549, DOI 10.1016/S0002-9343(02)01070-7; Garg A, 1999, J CLIN ENDOCR METAB, V84, P170, DOI 10.1210/jc.84.1.170; Garg A, 1999, J CLIN ENDOCR METAB, V84, P3390, DOI 10.1210/jc.84.9.3390; Garg A, 2001, J CLIN ENDOCR METAB, V86, P59, DOI 10.1210/jc.86.1.59; Garg A, 2000, J CLIN ENDOCR METAB, V85, P1776, DOI 10.1210/jc.85.5.1776; GORLIN RJ, 1975, BIRTH DEFECTS, V11, P46; Haque WA, 2003, DIABETES CARE, V26, P1350, DOI 10.2337/diacare.26.5.1350; Haque WA, 2002, DIABETIC MED, V19, P1022, DOI 10.1046/j.1464-5491.2002.00796.x; Haque WA, 2002, J CLIN ENDOCR METAB, V87, P2395, DOI 10.1210/jc.87.5.2395; Heathcote K, 2002, DIABETES, V51, P1291, DOI 10.2337/diabetes.51.4.1291; Hegele RA, 2002, DIABETES, V51, P3586, DOI 10.2337/diabetes.51.12.3586; Herbst KL, 2003, DIABETES CARE, V26, P1819, DOI 10.2337/diacare.26.6.1819; Huemer C, 2001, J RHEUMATOL, V28, P610; IMAMURA S, 1971, ARCH DERMATOL, V104, P291, DOI 10.1001/archderm.104.3.291; James J, 2002, DERMATOL SURG, V28, P979, DOI 10.1046/j.1524-4725.2002.02099.x; JASIN HE, 1979, J RHEUMATOL, V6, P43; KOBBERLING J, 1986, J MED GENET, V23, P120, DOI 10.1136/jmg.23.2.120; Laurin J, 1996, HEPATOLOGY, V23, P1464; Lelliott CJ, 2002, J CLIN ENDOCR METAB, V87, P728, DOI 10.1210/jc.87.2.728; Leung DW, 2001, FRONT BIOSCI, V6, pD944, DOI 10.2741/Leung; LIN F, 1993, J BIOL CHEM, V268, P16321; Lloyd DJ, 2002, HUM MOL GENET, V11, P769, DOI 10.1093/hmg/11.7.769; Lo JC, 1998, J ACQ IMMUN DEF SYND, V19, P307, DOI 10.1097/00042560-199811010-00015; Magre J, 2001, NAT GENET, V28, P365, DOI 10.1038/ng585; Magre J, 2003, DIABETES, V52, P1573, DOI 10.2337/diabetes.52.6.1573; Marchesini G, 2001, LANCET, V358, P893, DOI 10.1016/S0140-6736(01)06042-1; MATHIESON PW, 1993, J EXP MED, V177, P1827, DOI 10.1084/jem.177.6.1827; MATHIESON PW, 1994, AM J KIDNEY DIS, V24, P964, DOI 10.1016/S0272-6386(12)81069-9; Misra A, 2004, MEDICINE, V83, P18, DOI 10.1097/01.md.0000111061.69212.59; Misra A, 2003, MEDICINE, V82, P129, DOI 10.1097/00005792-200303000-00007; Mitchell SW, 1885, AM J MED SCI, V90, P105, DOI [10.1097/00000441-188507000-00006, DOI 10.1097/00000441-188507000-00006]; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Murata H, 2000, J BIOL CHEM, V275, P20251, DOI 10.1074/jbc.C000228200; Nestler JE, 1998, NEW ENGL J MED, V338, P1876, DOI 10.1056/NEJM199806253382603; Novelli G, 2002, AM J HUM GENET, V71, P426, DOI 10.1086/341908; Oral EA, 2002, NEW ENGL J MED, V346, P570, DOI 10.1056/NEJMoa012437; Peters JM, 1998, NAT GENET, V18, P292, DOI 10.1038/ng0398-292; Petersen KF, 2002, J CLIN INVEST, V109, P1345, DOI [10.1172/JCI0215001, 10.1172/JCI200215001]; Pivnick EK, 2000, AM J MED GENET, V90, P131, DOI 10.1002/(SICI)1096-8628(20000117)90:2<131::AID-AJMG9>3.3.CO;2-5; Rosen ED, 2000, GENE DEV, V14, P1293; Savage DB, 2003, DIABETES, V52, P910, DOI 10.2337/diabetes.52.4.910; Schwarz JM, 2002, J CLIN ENDOCR METAB, V87, P942, DOI 10.1210/jc.87.2.942; SEIP M, 1959, Acta Paediatr, V48, P555; Seip M, 1996, ACTA PAEDIATR, V85, P2, DOI 10.1111/j.1651-2227.1996.tb14262.x; Sensenbrenner J A, 1975, Birth Defects Orig Artic Ser, V11, P423; Shackleton S, 2000, NAT GENET, V24, P153, DOI 10.1038/72807; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Simha V, 2003, J CLIN ENDOCR METAB, V88, P5433, DOI 10.1210/jc.2003-030835; Simha V, 2003, DIABETES CARE, V26, P30, DOI 10.2337/diacare.26.1.30; Simha V, 2003, J CLIN ENDOCR METAB, V88, P2821, DOI 10.1210/jc.2002-021575; Simha V, 2002, J CLIN ENDOCR METAB, V87, P776, DOI 10.1210/jc.87.2.776; Simons A, 1911, Z GESAMTE NEUROL PSY, V5, P29, DOI 10.1007/BF02867054; Speckman, 2000, AM J HUM GENET, V67, P775; Speckman RA, 2000, AM J HUM GENET, V66, P1192, DOI 10.1086/302836; Sutinen J, 2002, AIDS, V16, P2183, DOI 10.1097/00002030-200211080-00011; Szczepaniak LS, 1999, AM J PHYSIOL-ENDOC M, V276, pE977, DOI 10.1152/ajpendo.1999.276.5.E977; TORRELO A, 1991, ARCH DERMATOL, V127, P1846, DOI 10.1001/archderm.127.12.1846; *UNAIDS, 2002, REP GLOB HIV AIDS EP; van der Kooi AJ, 2002, NEUROLOGY, V59, P620, DOI 10.1212/WNL.59.4.620; Van Maldergem L, 2002, J MED GENET, V39, P722, DOI 10.1136/jmg.39.10.722; VANMALDERGEM L, 2003, J MED GENET, V40, P150; Vigouroux C, 2000, DIABETES, V49, P1958, DOI 10.2337/diabetes.49.11.1958; Vigouroux C, 2001, J CELL SCI, V114, P4459; West CD, 1999, PEDIATR NEPHROL, V13, P448, DOI 10.1007/s004670050638; West J, 1997, DNA CELL BIOL, V16, P691, DOI 10.1089/dna.1997.16.691; WILLIAMS DG, 1978, CLIN EXP IMMUNOL, V33, P425; YOUNG L W, 1971, Birth Defects Original Article Series, V7, P291	103	589	621	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 18	2004	350	12					1220	1234		10.1056/NEJMra025261	http://dx.doi.org/10.1056/NEJMra025261			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803PG	15028826				2022-12-28	WOS:000220242400009
J	Hsu, LC; Park, JM; Zhang, KZ; Luo, JL; Maeda, S; Kaufman, RJ; Eckmann, L; Guiney, DG; Karin, M				Hsu, LC; Park, JM; Zhang, KZ; Luo, JL; Maeda, S; Kaufman, RJ; Eckmann, L; Guiney, DG; Karin, M			The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4	NATURE			English	Article							TOLL-LIKE RECEPTORS; IKK-BETA; MICE; INTERFERONS; DISRUPTION; INDUCTION; INFECTION; IRF-3	Macrophages are pivotal constituents of the innate immune system, vital for recognition and elimination of microbial pathogens(1). Macrophages use Toll-like receptors (TLRs) to detect pathogen-associated molecular patterns - including bacterial cell wall components, such as lipopolysaccharide or lipoteichoic acid, and viral nucleic acids, such as double-stranded (ds) RNA and in turn activate effector functions, including anti-apoptotic signalling pathways(2). Certain pathogens, however, such as Salmonella spp., Shigellae spp. and Yersiniae spp., use specialized virulence factors to overcome these protective responses and induce macrophage apoptosis(3). We found that the anthrax bacterium, Bacillus anthracis, selectively induces apoptosis of activated macrophages(4) through its lethal toxin, which prevents activation of the anti-apoptotic p38 mitogen-activated protein kinase(4). We now demonstrate that macrophage apoptosis by three different bacterial pathogens depends on activation of TLR4. Dissection of anti- and pro-apoptotic signalling events triggered by TLR4 identified the dsRNA responsive protein kinase PKR as a critical mediator of pathogen-induced macrophage apoptosis. The pro-apoptotic actions of PKR are mediated both through inhibition of protein synthesis and activation of interferon response factor 3.	Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Michigan, Howard Hughes Med Inst, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu		Zhang, Kezhong/0000-0002-6062-235X; Hsu, Li-Chung/0000-0001-7206-5231; Luo, Jun-Li/0000-0002-7625-4766				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Browne SH, 2002, INFECT IMMUN, V70, P7126, DOI 10.1128/IAI.70.12.7126-7135.2002; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783; Durbin RK, 2002, VIRAL IMMUNOL, V15, P41, DOI 10.1089/088282402317340224; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lehner M, 2001, BLOOD, V98, P736, DOI 10.1182/blood.V98.3.736; Li ZW, 2003, J IMMUNOL, V170, P4630, DOI 10.4049/jimmunol.170.9.4630; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rosenberger CM, 2003, NAT REV MOL CELL BIO, V4, P385, DOI 10.1038/nrm1104; Saelens X, 2001, J BIOL CHEM, V276, P41620, DOI 10.1074/jbc.M103674200; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Weinrauch Y, 1999, ANNU REV MICROBIOL, V53, P155, DOI 10.1146/annurev.micro.53.1.155; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zhang Y, 2003, INFECT IMMUN, V71, P1513, DOI 10.1128/IAI.71.3.1513-1519.2003	30	301	320	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	2004	428	6980					341	345		10.1038/nature02405	http://dx.doi.org/10.1038/nature02405			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15029200	Green Published			2022-12-28	WOS:000220250200049
J	Nishibayashi, Y; Saito, M; Uemura, S; Takekuma, S; Takekuma, H; Yoshida, Z				Nishibayashi, Y; Saito, M; Uemura, S; Takekuma, S; Takekuma, H; Yoshida, Z			Buckminsterfullerenes - A non-metal system for nitrogen fixation	NATURE			English	Editorial Material							DINITROGEN; REDUCTION; AMMONIA; C-60		Kyoto Univ, Grad Sch Engn, Dept Energy & Hydrocarbon Chem, Sakyo Ku, Kyoto, Japan; Kinki Univ, Fac Sci & Engn, Dept Appl Chem, Osaka 5778502, Japan	Kyoto University; Kindai University (Kinki University)	Nishibayashi, Y (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Energy & Hydrocarbon Chem, Sakyo Ku, Kyoto, Japan.	uemura@scl.kyoto-u.ac.jp	Nishibayashi, Yoshiaki/E-9230-2010	Nishibayashi, Yoshiaki/0000-0001-9739-9588				Appl, 1999, AMMONIA; CHATT J, 1975, NATURE, V253, P39, DOI 10.1038/253039b0; Guldi DM, 2000, ACCOUNTS CHEM RES, V33, P695, DOI 10.1021/ar990144m; Nishibayashi Y, 1998, SCIENCE, V279, P540, DOI 10.1126/science.279.5350.540; Postgate J., 1998, NITROGEN FIXATION; Solari E, 2001, ANGEW CHEM INT EDIT, V40, P3907, DOI 10.1002/1521-3773(20011015)40:20<3907::AID-ANIE3907>3.0.CO;2-#; Takekuma S, 2000, TETRAHEDRON LETT, V41, P2929, DOI 10.1016/S0040-4039(00)00312-9; Yandulov DV, 2003, SCIENCE, V301, P76, DOI 10.1126/science.1085326; YOSHIDA ZI, 1994, ANGEW CHEM INT EDIT, V33, P1597, DOI 10.1002/anie.199415971	9	98	105	4	102	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 18	2004	428	6980					279	280		10.1038/428279b	http://dx.doi.org/10.1038/428279b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	803SG	15029186				2022-12-28	WOS:000220250200031
J	Haas, CS; Amann, K; Braun, J				Haas, CS; Amann, K; Braun, J			Bone tumour and haemodialysis	LANCET			English	Editorial Material									Univ Erlangen Nurnberg, Dept Internal Med Nephrol, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany; KfH Dialysis Ctr, Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg	Haas, CS (corresponding author), Univ Erlangen Nurnberg, Dept Internal Med Nephrol, D-91054 Erlangen, Germany.								0	1	1	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 13	2004	363	9412					851	851		10.1016/S0140-6736(04)15731-0	http://dx.doi.org/10.1016/S0140-6736(04)15731-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15031029				2022-12-28	WOS:000220231500010
J	Whitby, EH; Griffiths, PD; Rutter, S; Smith, MF; Sprigg, A; Ohadike, P; Davies, NP; Rigby, AS; Paley, MN				Whitby, EH; Griffiths, PD; Rutter, S; Smith, MF; Sprigg, A; Ohadike, P; Davies, NP; Rigby, AS; Paley, MN			Frequency and natural history of subdural haemorrhages in babies and relation to obstetric factors	LANCET			English	Article							INFLICTED HEAD-INJURY; HEMATOMAS; NEUROPATHOLOGY	Background Subdural haematomas are thought to be uncommon in babies born at term. This view is mainly based on findings in symptomatic neonates and babies in whom subdural haemorrhages are detected fortuitously. We aimed to establish the frequency of subdural haemorrhages in asymptomatic term neonates; to study the natural history of such subdural haematomas; and to ascertain which obstetric factors, if any, are associated with presence of subdural haematoma. Methods We did a prospective study in babies who were born in the Jessop wing of the Central Sheffield University Hospitals between March, 2001, and November, 2002. We scanned neonates with a 0.2 T magnetic resonance machine. Findings 111 babies underwent MRI in this study. 49 were born by normal vertex delivery without instrumentation, 25 by caesarean section, four with forceps, 13 ventouse, 18 failed ventouse leading to forceps, one failed ventouse leading to caesarean section, and one failed forceps leading to caesarean section. Nine babies had subdural haemorrhages: three were normal vaginal deliveries (risk 6.1%), five were delivered by forceps after an attempted ventouse delivery (27.8%), and one had a traumatic ventouse delivery (7.7%). All babies with subdural haemorrhage were assessed clinically but no intervention was needed. All were rescanned at 4 weeks and haematomas had completely resolved. Interpretation Presence of unilateral and bilateral subdural haemorrhage is not necessarily indicative of excessive birth trauma.	Univ Sheffield, Sect Acad Radiol, Sheffield, S Yorkshire, England; Sheffield Childrens Hosp, Dept Radiol, Sheffield, S Yorkshire, England; Univ Hull, Dept Cardiol, Kingston Upon Hull, Yorks, England; Cent Sheffield Teaching Hosp, Dept Obstet & Gynaecol, Sheffield, S Yorkshire, England; Cent Sheffield Teaching Hosp, Reg Neonatal Intens Care Unit, Sheffield, S Yorkshire, England	University of Sheffield; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Hull	Whitby, EH (corresponding author), Royal Hallamshire Hosp, MRI Dept, Floor C,Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.	e.whitby@sheffield.ac.uk	Whitby, Elspeth/G-5517-2010; Rigby, Alan/AFM-1194-2022	Rigby, Alan/0000-0001-8331-3907; Whitby, Elspeth/0000-0002-8912-8013				BARKOVICH AJ, 2000, PEDIAT NEUROIMAGING, P239; Breningstall GN, 2000, PEDIATR RADIOL, V30, P630, DOI 10.1007/s002470000256; BROOKS RA, 1989, J COMPUT ASSIST TOMO, V13, P194, DOI 10.1097/00004728-198903000-00002; Chamnanvanakij S, 2002, PEDIATR NEUROL, V26, P301, DOI 10.1016/S0887-8994(01)00420-9; Doward W, 2001, PEDIATR NEUROSURG, V35, P335, DOI 10.1159/000050448; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Geddes JF, 2003, NEUROPATH APPL NEURO, V29, P14, DOI 10.1046/j.1365-2990.2003.00434.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Kemp AM, 2002, ARCH DIS CHILD, V86, P98, DOI 10.1136/adc.86.2.98; Pollina J, 2001, PEDIATR NEUROSURG, V35, P113, DOI 10.1159/000050403; Stephens RP, 1997, PEDIATRICS, V99, P619, DOI 10.1542/peds.99.4.619; Towner D, 1999, NEW ENGL J MED, V341, P1709, DOI 10.1056/NEJM199912023412301; Whitby EH, 2003, ARCH DIS CHILD-FETAL, V88, P203	14	200	205	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	2004	363	9412					846	851		10.1016/S0140-6736(04)15730-9	http://dx.doi.org/10.1016/S0140-6736(04)15730-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803LB	15031028				2022-12-28	WOS:000220231500009
J	Kohara, S; Suzuya, K; Takeuchi, K; Loong, CK; Grimsditch, M; Weber, JKR; Tangeman, JA; Key, TS				Kohara, S; Suzuya, K; Takeuchi, K; Loong, CK; Grimsditch, M; Weber, JKR; Tangeman, JA; Key, TS			Glass formation at the limit of insufficient network formers	SCIENCE			English	Article							FORSTERITE MG2SIO4; DYNAMICS; TRANSITION; PRESSURE; MELTS	Inorganic glasses normally exhibit a network of interconnected, covalent-bonded, structural elements that has no long-range order. In silicate glasses, the network formers are based on SiO4 tetrahedra interconnected through oxygen atoms at the corners. Conventional wisdom implies that alkaline and alkaline-earth orthosilicate materials cannot be vitrified, because they do not contain sufficient network-forming SiO2 to establish the needed interconnectivity. We studied a bulk magnesium orthosilicate glass obtained by containerless melting and cooling. We found that the role of network former was largely taken on by corner and edge sharing of highly distorted, ionic Mg-O species that adopt 4-, 5-, and 6-coordination with oxygen. The results suggest that similar glassy phases may be found in the containerless environment of interstellar space.	Argonne Natl Lab, Argonne, IL 60439 USA; Japan Synchrotron Radiat Res Inst, Sayo, Hyogo 6795198, Japan; Japan Atom Energy Res Inst, Ibaraki 3191195, Japan; Tokyo Univ Sci, Yarmakoshi, Hokkaido 0493514, Japan; Containerless Res Inc, Evanston, IL 60201 USA	United States Department of Energy (DOE); Argonne National Laboratory; Japan Synchrotron Radiation Research Institute; Japan Atomic Energy Agency; Tokyo University of Science	Loong, CK (corresponding author), Argonne Natl Lab, 9700 S Cass Ave, Argonne, IL 60439 USA.	ckloong@anl.gov	Takeuchi, Ken/R-3184-2019; KOHARA, Shinji/J-4255-2015	Takeuchi, Ken/0000-0002-2391-1267; KOHARA, Shinji/0000-0001-9596-2680				BOCKRIS JO, 1956, T FARADAY SOC, V52, P299, DOI 10.1039/tf9565200299; BOCKRIS JO, 1955, T FARADAY SOC, V51, P1734, DOI 10.1039/tf9555101734; BOCKRIS JOM, 1952, T FARADAY SOC, V48, P536, DOI 10.1039/tf9524800536; Choudhury N, 1998, PHYS REV B, V58, P756, DOI 10.1103/PhysRevB.58.756; CHOUDHURY N, 1989, PHYS CHEM MINER, V16, P599, DOI 10.1007/BF00202217; DURBEN DJ, 1993, AM MINERAL, V78, P1143; EMERSON JF, 1989, J NON-CRYST SOLIDS, V113, P253, DOI 10.1016/0022-3093(89)90019-7; George AM, 1998, AM MINERAL, V83, P1022; GHOSE S, 1987, SOLID STATE COMMUN, V63, P1045, DOI 10.1016/0038-1098(87)90658-2; Kohara S, 2003, NUCL INSTRUM METH B, V199, P23, DOI 10.1016/S0168-583X(02)01554-9; KUBICKI JD, 1991, PHYS CHEM MINER, V17, P661, DOI 10.1007/BF00202236; MASSON CR, 1968, J AM CERAM SOC, V51, P134, DOI 10.1111/j.1151-2916.1968.tb11856.x; McGreevy RL, 2001, J PHYS-CONDENS MAT, V13, pR877, DOI 10.1088/0953-8984/13/46/201; Molster FJ, 1999, NATURE, V401, P563, DOI 10.1038/44085; Proffen T, 1999, J APPL CRYSTALLOGR, V32, P572, DOI 10.1107/S0021889899003532; RAM S, 1990, PHILOS MAG B, V61, P299, DOI 10.1080/13642819008208636; RICHET P, 1993, GEOPHYS RES LETT, V20, P1675, DOI 10.1029/93GL01836; Ringwood A.E, 1975, COMPOSITION PETROLOG; SHANNON RD, 1970, ACTA CRYSTALL B-STRU, VB 26, P1046, DOI 10.1107/S0567740870003576; Tangeman JA, 2001, GEOPHYS RES LETT, V28, P2517, DOI 10.1029/2000GL012222; TANGEMAN JA, UNPUB; Trapp H., 1960, PHYS CHEM GLASSES-B, V1, P107; Waseda Y., 1980, STRUCTURE NONCRYSTAL; WILLIAMS Q, 1989, PHYS CHEM MINER, V16, P352	24	141	142	3	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1649	1652		10.1126/science.1095047	http://dx.doi.org/10.1126/science.1095047			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016995				2022-12-28	WOS:000220151400038
J	Maitra, A; Sherriff, A; Griffiths, M; Henderson, J				Maitra, A; Sherriff, A; Griffiths, M; Henderson, J		Avon Longitudinal Study Parents Ch	Pertussis vaccination in infancy and asthma or allergy in later childhood: birth cohort study	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN		Univ Bristol, Dept Community Based Med, Avon Longitudinal Study Parents & Children, Bristol BS8 1TQ, Avon, England; St Michaels Hosp, Dept Ear Nose & Throat, Bristol BS2 8EG, Avon, England; Bristol Royal Hosp Children, Dept Resp Med, Bristol BS2 8BJ, Avon, England	University of Bristol; Bristol Royal Hospital For Children		dramaitra@yahoo.co.uk		sherriff, andrea/0000-0002-1016-037X				Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Henderson J, 1999, BRIT MED J, V318, P1173, DOI 10.1136/bmj.318.7192.1173; Kemp T, 1997, EPIDEMIOLOGY, V8, P678, DOI 10.1097/00001648-199710000-00011; Nilsson L, 1998, ARCH PEDIAT ADOL MED, V152, P734; ODENT MR, 1994, JAMA-J AM MED ASSOC, V272, P592, DOI 10.1001/jama.1994.03520080034035	5	28	28	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 17	2004	328	7445					925	926		10.1136/bmj.38045.858889.EB	http://dx.doi.org/10.1136/bmj.38045.858889.EB			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	814SM	15033878	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000220994400018
J	Patel, V; Rahman, A; Jacob, KS; Hughes, M				Patel, V; Rahman, A; Jacob, KS; Hughes, M			Effect of maternal mental health on infant growth in low income countries: new evidence from South Asia	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; FAILURE-TO-THRIVE; POSTNATAL DEPRESSION; POSTPARTUM DEPRESSION; MOTHERS; CHILDREN; RISK; INTERVENTION; CHILDBIRTH; COMMUNITY	Impaired infant growth, a major problem in South Asia, may require interventions to improve maternal mental health in addition to current interventions targeting infant nutrition.	Sangath, Porvorim 403521, Goa, India; London Sch Hyg & Trop Med, London, England; Univ Manchester, Sch Psychiat & Behav Sci, Manchester M13 9PL, Lancs, England; Christian Med Coll & Hosp, Vellore 632002, Tamil Nadu, India; Inst Psychiat, London, England	University of London; London School of Hygiene & Tropical Medicine; University of Manchester; Christian Medical College & Hospital (CMCH) Vellore; University of London; King's College London	Patel, V (corresponding author), Sangath, 841-1 Alto, Porvorim 403521, Goa, India.	vikpat_goa@sancharnet.in		Patel, Vikram/0000-0003-1066-8584				ANOOP S, IN PRESS ARCH DIS CH; Araya R, 2003, LANCET, V361, P995, DOI 10.1016/S0140-6736(03)12825-5; Baker-Henningham H, 2003, EUR J CLIN NUTR, V57, P786, DOI 10.1038/sj.ejcn.1601611; BETTES BA, 1988, CHILD DEV, V59, P1089, DOI 10.1111/j.1467-8624.1988.tb03261.x; Bhutta ZA, 2000, BRIT MED J, V321, P809, DOI 10.1136/bmj.321.7264.809; Bolton P, 2003, JAMA-J AM MED ASSOC, V289, P3117, DOI 10.1001/jama.289.23.3117; Brugha TS, 2000, PSYCHOL MED, V30, P1273, DOI 10.1017/S0033291799002937; Chandran M, 2002, BRIT J PSYCHIAT, V181, P499, DOI 10.1192/bjp.181.6.499; Cooper PJ, 2002, BRIT J PSYCHIAT, V180, P76, DOI 10.1192/bjp.180.1.76; Cooper PJ, 1999, BRIT J PSYCHIAT, V175, P554, DOI 10.1192/bjp.175.6.554; Copper RL, 1996, AM J OBSTET GYNECOL, V175, P1286, DOI 10.1016/S0002-9378(96)70042-X; Elliott SA, 2000, BRIT J CLIN PSYCHOL, V39, P223, DOI 10.1348/014466500163248; Hay DF, 2001, J CHILD PSYCHOL PSYC, V42, P871, DOI 10.1111/1469-7610.00784; HEDEGAARD M, 1993, BMJ-BRIT MED J, V307, P234, DOI 10.1136/bmj.307.6898.234; HOLDEN JM, 1989, BRIT MED J, V298, P223, DOI 10.1136/bmj.298.6668.223; KOCHANSKA G, 1987, AM J ORTHOPSYCHIAT, V57, P345, DOI 10.1111/j.1939-0025.1987.tb03543.x; LANATA C, 2001, POVERTY INEQUALITY H, P137; LIVINGOOD AB, 1983, J CLIN PSYCHOL, V39, P369, DOI 10.1002/1097-4679(198305)39:3<369::AID-JCLP2270390310>3.0.CO;2-8; Milberger S, 1996, AM J PSYCHIAT, V153, P1138; Montgomery SM, 1997, ARCH DIS CHILD, V77, P326, DOI 10.1136/adc.77.4.326; Murray L, 1997, ARCH DIS CHILD, V77, P99, DOI 10.1136/adc.77.2.99; OHara MW, 1996, INT REV PSYCHIATR, V8, P37, DOI 10.3109/09540269609037816; PAGEL MD, 1990, SOC SCI MED, V30, P597, DOI 10.1016/0277-9536(90)90158-O; Patel V, 2003, LANCET, V361, P33, DOI 10.1016/S0140-6736(03)12119-8; Patel V, 2003, ARCH DIS CHILD, V88, P34, DOI 10.1136/adc.88.1.34; Patel V, 2002, AM J PSYCHIAT, V159, P43, DOI 10.1176/appi.ajp.159.1.43; Rahman A, 2004, CHILD CARE HLTH DEV, V30, P21, DOI 10.1111/j.1365-2214.2004.00382.x; Rahman A, 2003, PSYCHOL MED, V33, P1161, DOI 10.1017/S0033291703008286; Rahman A, 2002, CHILD CARE HLTH DEV, V28, P51, DOI 10.1046/j.1365-2214.2002.00239.x; Ransjo-Arvidson AB, 1998, J EPIDEMIOL COMMUN H, V52, P385, DOI 10.1136/jech.52.6.385; Regmi S, 2002, TROP MED INT HEALTH, V7, P378, DOI 10.1046/j.1365-3156.2002.00866.x; *UNICEF MIN SAL CO, 1998, PLAN DEC PROM PROT L, P16; Wickberg B, 1996, J AFFECT DISORDERS, V39, P209, DOI 10.1016/0165-0327(96)00034-1; Wilensky DS, 1996, ARCH DIS CHILD, V75, P145, DOI 10.1136/adc.75.2.145; Wright CM, 2000, ARCH DIS CHILD, V82, P5, DOI 10.1136/adc.82.1.5	35	223	228	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	2004	328	7443					820	823		10.1136/bmj.328.7443.820	http://dx.doi.org/10.1136/bmj.328.7443.820			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	811CG	15070641	Green Accepted, Green Published			2022-12-28	WOS:000220749400024
J	Arnold, GL; Anbar, AD; Barling, J; Lyons, TW				Arnold, GL; Anbar, AD; Barling, J; Lyons, TW			Molybdenum isotope evidence for widespread anoxia in mid-proterozoic oceans	SCIENCE			English	Article							NORTHERN AUSTRALIA; PROTEROZOIC ATMOSPHERE; MCARTHUR BASIN; SULFUR CYCLE; GEOCHEMISTRY; SEDIMENTS; CHEMISTRY; EVOLUTION; MODEL; SEA	How much dissolved oxygen was present in the mid-Proterozoic oceans between 1.8 and 1.0 billion years ago is debated vigorously. One model argues for oxygenation of the oceans soon after the initial rise of atmospheric oxygen similar to2.3 billion years ago. Recent evidence for H2S in some mid-Proterozoic marine basins suggests, however, that the deep ocean remained anoxic until much later. New molybdenum isotope data from modern and ancient sediments indicate expanded anoxia during the mid-Proterozoic compared to the present-day ocean. Consequently, oxygenation of the deep oceans may have lagged that of the atmosphere by over a billion years.	Univ Rochester, Dept Earth & Environm Sci, Rochester, NY 14627 USA; Univ Rochester, Dept Chem, Rochester, NY 14627 USA; Univ Missouri, Dept Geol Sci, Columbia, MO 65211 USA	University of Rochester; University of Rochester; University of Missouri System; University of Missouri Columbia	Arnold, GL (corresponding author), Univ Rochester, Dept Earth & Environm Sci, 601 Elmwood Ave, Rochester, NY 14627 USA.	gail@earth.rochester.edu	Barling, Jane/F-9443-2015; Arnold, Gail L/A-5572-2010	Barling, Jane/0000-0001-8535-5262; Arnold, Gail L/0000-0001-9631-9830				Anbar AD, 2004, REV MINERAL GEOCHEM, V55, P429, DOI 10.2138/gsrmg.55.1.429; Anbar AD, 2002, SCIENCE, V297, P1137, DOI 10.1126/science.1069651; Barling J, 2004, EARTH PLANET SC LETT, V217, P315, DOI 10.1016/S0012-821X(03)00608-3; Barling J, 2001, EARTH PLANET SC LETT, V193, P447, DOI 10.1016/S0012-821X(01)00514-3; BERTINE KK, 1973, GEOCHIM COSMOCHIM AC, V37, P1415, DOI 10.1016/0016-7037(73)90080-X; Canfield DE, 1999, AM J SCI, V299, P697, DOI 10.2475/ajs.299.7-9.697; Canfield DE, 1998, NATURE, V396, P450, DOI 10.1038/24839; Canfield DE, 1996, NATURE, V382, P127, DOI 10.1038/382127a0; Canfield DE, 1996, AM J SCI, V296, P818, DOI 10.2475/ajs.296.7.818; CRICK IH, 1988, AAPG BULL, V72, P1495; Des Marais DJ, 2002, ASTROBIOLOGY, V2, P153, DOI 10.1089/15311070260192246; DONNELLY TH, 1988, SEDIMENT GEOL, V58, P145, DOI 10.1016/0037-0738(88)90067-X; EMERSON SR, 1991, MAR CHEM, V34, P177, DOI 10.1016/0304-4203(91)90002-E; Erickson BE, 2000, GEOCHIM COSMOCHIM AC, V64, P1149, DOI 10.1016/S0016-7037(99)00423-8; Farquhar J, 2000, SCIENCE, V289, P756, DOI 10.1126/science.289.5480.756; GUTSEV GL, 1987, USP KHIM+, V56, P889; Helz GR, 1996, GEOCHIM COSMOCHIM AC, V60, P3631, DOI 10.1016/0016-7037(96)00195-0; Holland HD., 1984, CHEM EVOLUTION ATMOS; Holland HD., 1999, GEOCHEM NEWS, V100, P20; Kah LC, 2001, PRECAMBRIAN RES, V111, P203, DOI 10.1016/S0301-9268(01)00161-9; Kaufman AJ, 2003, NATURE, V425, P279, DOI 10.1038/nature01902; KLEMME HD, 1991, AAPG BULL, V75, P1809; Knoll A. H, 1992, ORIGIN EARLY EVOLUTI, P53; McManus J, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2002GC000356; Morford JL, 1999, GEOCHIM COSMOCHIM AC, V63, P1735, DOI 10.1016/S0016-7037(99)00126-X; MURRAY JW, 1991, DEEP SEA RES S2, V38, P663; Pavlov AA, 2003, GEOLOGY, V31, P87, DOI 10.1130/0091-7613(2003)031<0087:MRPA>2.0.CO;2; Shen Y, 2003, NATURE, V423, P632, DOI 10.1038/nature01651; Shen YN, 2002, AM J SCI, V302, P81, DOI 10.2475/ajs.302.2.81; Siebert C, 2003, EARTH PLANET SC LETT, V211, P159, DOI 10.1016/S0012-821X(03)00189-4; Zheng Y, 2000, GEOCHIM COSMOCHIM AC, V64, P4165, DOI 10.1016/S0016-7037(00)00495-6	31	472	523	3	164	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					87	90		10.1126/science.1091785	http://dx.doi.org/10.1126/science.1091785			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15066776				2022-12-28	WOS:000220567900042
J	Elmquist, JK; Flier, JS				Elmquist, JK; Flier, JS			The fat-brain axis enters a new dimension	SCIENCE			English	Editorial Material							LEPTIN; OBESITY; GENE		Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Endocrinol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Elmquist, JK (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Endocrinol, Boston, MA 02215 USA.	jflier@bidmc.harvard.edu	Flier, jeffrey/AAG-6223-2019					Ahima RS, 1999, ENDOCRINOLOGY, V140, P2755, DOI 10.1210/en.140.6.2755; Ahima RS, 1998, J CLIN INVEST, V101, P1020, DOI 10.1172/JCI1176; Barker DJP, 2002, TRENDS ENDOCRIN MET, V13, P364, DOI 10.1016/S1043-2760(02)00689-6; Bouret SG, 2004, SCIENCE, V304, P108, DOI 10.1126/science.1095004; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Meaney MJ, 2001, ANNU REV NEUROSCI, V24, P1161, DOI 10.1146/annurev.neuro.24.1.1161; Pinto S, 2004, SCIENCE, V304, P110, DOI 10.1126/science.1089459; Saper CB, 2002, NEURON, V36, P199, DOI 10.1016/S0896-6273(02)00969-8; Simerly RB, 2002, ANNU REV NEUROSCI, V25, P507, DOI 10.1146/annurev.neuro.25.112701.142745; van den Pol AN, 2003, NEURON, V40, P1059, DOI 10.1016/S0896-6273(03)00809-2; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zigman JM, 2003, ENDOCRINOLOGY, V144, P3749, DOI 10.1210/en.2003-0241	15	77	78	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					63	64		10.1126/science.1096746	http://dx.doi.org/10.1126/science.1096746			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15064411				2022-12-28	WOS:000220567900035
J	LaHaye, MD; Buu, O; Camarota, B; Schwab, KC				LaHaye, MD; Buu, O; Camarota, B; Schwab, KC			Approaching the quantum limit of a nanomechanical resonator	SCIENCE			English	Article							SINGLE-ELECTRON TRANSISTOR; INTRINSIC NOISE; SENSITIVITY; AMPLIFIER; MOTION	By coupling a single-electron transistor to a high - quality factor, 19.7-megahertz nanomechanical resonator, we demonstrate position detection approaching that set by the Heisenberg uncertainty principle limit. At millikelvin temperatures, position resolution a factor of 4.3 above the quantum limit is achieved and demonstrates the near-ideal performance of the single-electron transistor as a linear amplifier. We have observed the resonator's thermal motion at temperatures as low as 56 millikelvin, with quantum occupation factors of N-TH = 58. The implications of this experiment reach from the ultimate limits of force microscopy to qubit readout for quantum information devices.	Lab Phys Sci, College Pk, MD 20740 USA; Univ Maryland, Dept Phys, College Pk, MD 20740 USA	University System of Maryland; University of Maryland College Park	Schwab, KC (corresponding author), Lab Phys Sci, 8050 Greenmead Dr, College Pk, MD 20740 USA.	schwab@lps.umd.edu		LaHaye, Matthew/0000-0003-1911-0704				Armour AD, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.125313; Armour AD, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.148301; Blencowe MP, 2000, APPL PHYS LETT, V77, P3845, DOI 10.1063/1.1331090; Braginsky V. B., 1995, QUANTUM MEASUREMENT, P12; CAVES CM, 1982, PHYS REV D, V26, P1817, DOI 10.1103/PhysRevD.26.1817; CAVES CM, 1980, REV MOD PHYS, V52, P341, DOI 10.1103/RevModPhys.52.341; Clerk AA, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.176804; Devoret MH, 2000, NATURE, V406, P1039, DOI 10.1038/35023253; GREYWALL DS, 1994, PHYS REV LETT, V72, P2992, DOI 10.1103/PhysRevLett.72.2992; Hadjar Y, 1999, EUROPHYS LETT, V47, P545, DOI 10.1209/epl/i1999-00422-6; Harry GM, 2000, APPL PHYS LETT, V76, P1446, DOI 10.1063/1.126059; Heisenberg W., 1927, Z PHYS J PHYS, V43, P172; Hopkins A, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.235328; Huang XMH, 2003, NATURE, V421, P496, DOI 10.1038/421496a; Hutchinson AB, 2004, APPL PHYS LETT, V84, P972, DOI 10.1063/1.1646213; Irish EK, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.155311; Knobel RG, 2003, NATURE, V424, P291, DOI 10.1038/nature01773; KOROTKOV AN, 1994, PHYS REV B, V49, P10381, DOI 10.1103/PhysRevB.49.10381; Landau L, 1931, Z PHYS, V69, P56, DOI 10.1007/BF01391513; Leggett AJ, 2002, J PHYS-CONDENS MAT, V14, pR415, DOI 10.1088/0953-8984/14/15/201; Leivo MM, 1998, APPL PHYS LETT, V72, P1305, DOI 10.1063/1.120979; Mozyrsky D, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.018301; Pobell F., 1996, MATTER METHODS LOW T; Roukes M, 2001, PHYS WORLD, V14, P25; Shytov AV, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.228303; Zhang Y, 2002, J APPL PHYS, V91, P4249, DOI 10.1063/1.1453494	26	740	755	3	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 2	2004	304	5667					74	77		10.1126/science.1094419	http://dx.doi.org/10.1126/science.1094419			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15064412				2022-12-28	WOS:000220567900038
J	Devendra, D; Liu, E; Eisenbarth, GS				Devendra, D; Liu, E; Eisenbarth, GS			Type 1 diabetes: recent developments	BMJ-BRITISH MEDICAL JOURNAL			English	Review							BETA-CELL AUTOIMMUNITY; GLUTAMIC-ACID DECARBOXYLASE; AUTOREACTIVE T-CELLS; ISLET AUTOIMMUNITY; NOD MOUSE; FOLLOW-UP; COWS MILK; IMMUNE-RESPONSE; YOUNG DAISY; RISK-FACTOR		Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Eisenbarth, GS (corresponding author), Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA.	George.Eisenbarth@UCHSC.edu			NCRR NIH HHS [M01 RR00069, M01 RR00051] Funding Source: Medline; NIAID NIH HHS [AI95380, AI46374, AI39213, AI50864] Funding Source: Medline; NIDDK NIH HHS [DK62718, DK55969, P30 DK57516, DK50970, DK 06405, DK32082] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000069, M01RR000051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI050864, R01AI039213, N01AI095380, U19AI046374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062718, P30DK057516, R01DK055969] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alleva DG, 2001, J CLIN INVEST, V107, P173, DOI 10.1172/JCI8525; [Anonymous], 2000, Diabetologia, V43, P47; Atkinson MA, 1999, NAT MED, V5, P601, DOI 10.1038/9442; Atkinson MA, 2001, LANCET, V358, P221, DOI 10.1016/S0140-6736(01)05415-0; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; BARKER J, 2003, DIABETES S1, V52, pA188; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; BODANSKY HJ, 1986, LANCET, V2, P1351; Bolli GB, 2000, LANCET, V356, P443, DOI 10.1016/S0140-6736(00)02546-0; Couper JJ, 1999, DIABETES, V48, P2145, DOI 10.2337/diabetes.48.11.2145; DAHLQUIST G, 1995, DIABETOLOGIA, V38, P1371; DAHLQUIST GG, 1990, BMJ-BRIT MED J, V300, P1302, DOI 10.1136/bmj.300.6735.1302; Devendra D, 2003, J ALLERGY CLIN IMMUN, V111, P624, DOI DOI 10.1067/MAI.2003.81); DEVENDRA D, 2004, IN PRESS CLIN IMMUNO; FOULIS AK, 1986, DIABETOLOGIA, V29, P267, DOI 10.1007/BF00452061; Gale EAM, 2002, DIABETOLOGIA, V45, P588, DOI 10.1007/s00125-002-0801-1; Gavin JR, 1997, DIABETES CARE, V20, P1183; Graves PM, 2003, DIABETES RES CLIN PR, V59, P51, DOI 10.1016/S0168-8227(02)00198-5; Graves PM, 1999, DIABETES CARE, V22, P1694, DOI 10.2337/diacare.22.10.1694; Green A, 2000, LANCET, V355, P873; HELMKE K, 1986, DIABETOLOGIA, V29, P30, DOI 10.1007/BF02427277; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; Honeyman MC, 2000, DIABETES, V49, P1319, DOI 10.2337/diabetes.49.8.1319; Hummel M, 2000, DIABETES CARE, V23, P969, DOI 10.2337/diacare.23.7.969; Hyoty H, 2002, DIABETOLOGIA, V45, P1353, DOI 10.1007/s00125-002-0852-3; Imagawa A, 1999, DIABETOLOGIA, V42, P574, DOI 10.1007/s001250051197; Johnson SB, 2001, J PEDIATR ENDOCR MET, V14, P653; Kaufman DL, 2001, DIABETES, V50, P2459, DOI 10.2337/diabetes.50.11.2459; KOSTRABA JN, 1992, DIABETES CARE, V15, P1505, DOI 10.2337/diacare.15.11.1505; Kotani R, 2002, DIABETES CARE, V25, P1390, DOI 10.2337/diacare.25.8.1390; LaGasse JM, 2002, DIABETES CARE, V25, P505, DOI 10.2337/diacare.25.3.505; Lindberg B, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.1.e12; Liu CP, 2000, P NATL ACAD SCI USA, V97, P14596, DOI 10.1073/pnas.250390997; Lonnrot M, 2000, J MED VIROL, V61, P214, DOI 10.1002/(SICI)1096-9071(200006)61:2&lt;214::AID-JMV7&gt;3.0.CO;2-9; Martin S, 2001, NEW ENGL J MED, V345, P1036, DOI 10.1056/NEJMoa010465; Meyer L, 2003, DIABETES CARE, V26, P1655, DOI 10.2337/diacare.26.5.1655-a; MOLBAK AG, 1994, DIABETIC MED, V11, P650, DOI 10.1111/j.1464-5491.1994.tb00327.x; Moriyama H, 2002, P NATL ACAD SCI USA, V99, P5539, DOI 10.1073/pnas.082120099; Norris JM, 2003, JAMA-J AM MED ASSOC, V290, P1713, DOI 10.1001/jama.290.13.1713; Norris JM, 1996, JAMA-J AM MED ASSOC, V276, P609, DOI 10.1001/jama.276.8.609; Onkamo P, 1999, DIABETOLOGIA, V42, P1395, DOI 10.1007/s001250051309; Redondo MJ, 1999, BRIT MED J, V318, P698; Reijonen H, 2003, ANN NY ACAD SCI, V1005, P82, DOI 10.1196/annals.1288.009; Roep BO, 1999, J AUTOIMMUN, V13, P267, DOI 10.1006/jaut.1999.0312; Shannon H, 2000, NEW ENGL J MED, V342, P381; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; Trudeau JD, 2003, J CLIN INVEST, V111, P217, DOI 10.1172/JCI200316409; Turner R, 1997, LANCET, V350, P1288, DOI 10.1016/S0140-6736(97)03062-6; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; Vajo Z, 2000, PHARMACOL REV, V52, P1; Verge CF, 1996, DIABETES, V45, P926, DOI 10.2337/diabetes.45.7.926; Virtanen SM, 1998, DIABETIC MED, V15, P730, DOI 10.1002/(SICI)1096-9136(199809)15:9&lt;730::AID-DIA646&gt;3.0.CO;2-C; Wahlberg J, 2003, ANN NY ACAD SCI, V1005, P404, DOI 10.1196/annals.1288.068; WEGMANN DR, 1994, EUR J IMMUNOL, V24, P1853, DOI 10.1002/eji.1830240820; Wong FS, 1999, NAT MED, V5, P1026, DOI 10.1038/12465; Yu LP, 2000, P NATL ACAD SCI USA, V97, P1701, DOI 10.1073/pnas.040556697; Ziegler AG, 2003, JAMA-J AM MED ASSOC, V290, P1721, DOI 10.1001/jama.290.13.1721	58	190	211	0	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 27	2004	328	7442					750	754		10.1136/bmj.328.7442.750	http://dx.doi.org/10.1136/bmj.328.7442.750			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	809WH	15044291	Green Published			2022-12-28	WOS:000220666300019
J	Rabitz, HA; Hsieh, MM; Rosenthal, CM				Rabitz, HA; Hsieh, MM; Rosenthal, CM			Quantum optimally controlled transition landscapes	SCIENCE			English	Article							2-PHOTON TRANSITIONS; LEARNING CONTROL; LASER-PULSES; FEEDBACK; SYSTEMS; OPTIMIZATION; CONTROLLABILITY; DYNAMICS	A large number of experimental studies and simulations show that it is surprisingly easy to find excellent quality control over broad classes of quantum systems. We now prove that for controllable quantum systems with no constraints placed on the controls, the only allowed extrema of the transition probability landscape correspond to perfect control or no control. Under these conditions, no suboptimal local extrema exist as traps that would impede the search for an optimal control. The identified landscape structure is universal for all controllable quantum systems of the same dimension when seeking to maximize the same transition probability, regardless of the detailed nature of the system Hamiltonian. The presence of weak control field noise or environmental decoherence is shown to preserve the general structure of the control landscape, but at lower resolution.	Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Drexel Univ, Dept Chem, Philadelphia, PA 19104 USA	Princeton University; Drexel University	Rabitz, HA (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.	hrabitz@princeton.edu						Assion A, 1998, SCIENCE, V282, P919, DOI 10.1126/science.282.5390.919; Bardeen CJ, 1997, CHEM PHYS LETT, V280, P151, DOI 10.1016/S0009-2614(97)01081-6; Bartels R, 2000, NATURE, V406, P164, DOI 10.1038/35018029; Brixner T, 2003, J MOD OPTIC, V50, P539, DOI 10.1080/09500340210163817; Daniel C, 2001, CHEM PHYS, V267, P247, DOI 10.1016/S0301-0104(01)00315-9; DEMIRALP M, 1993, PHYS REV A, V47, P809, DOI 10.1103/PhysRevA.47.809; Geremia JM, 2000, J CHEM PHYS, V113, P10841, DOI 10.1063/1.1326905; Girardeau MD, 1998, PHYS REV A, V58, P2684, DOI 10.1103/PhysRevA.58.2684; HEREK JL, 2001, NATURE, V414, P57; Hornung T, 2000, APPL PHYS B-LASERS O, V71, P277, DOI 10.1007/s003400000346; JUDSON RS, 1992, PHYS REV LETT, V68, P1500, DOI 10.1103/PhysRevLett.68.1500; Kunde J, 2001, J OPT SOC AM B, V18, P872, DOI 10.1364/JOSAB.18.000872; Levis RJ, 2001, SCIENCE, V292, P709, DOI 10.1126/science.1059133; Meshulach D, 1998, NATURE, V396, P239, DOI 10.1038/24329; Pearson BJ, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.063412; Rabitz H, 2000, SCIENCE, V288, P824, DOI 10.1126/science.288.5467.824; RABITZ H, UNPUB; RAMAKRISHNA V, 1995, PHYS REV A, V51, P960, DOI 10.1103/PhysRevA.51.960; Rice S. A., 2000, OPTICAL CONTROL MOL; Turinici G, 2003, J PHYS A-MATH GEN, V36, P2565, DOI 10.1088/0305-4470/36/10/316; Weinacht TC, 2001, CHEM PHYS LETT, V344, P333, DOI 10.1016/S0009-2614(01)00788-6; Weiner AM, 2000, REV SCI INSTRUM, V71, P1929, DOI 10.1063/1.1150614; Wu R., UNPUB; Zeidler D, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.023420; Zhu WS, 2003, INT J QUANTUM CHEM, V93, P50, DOI 10.1002/qua.10536	25	326	332	3	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	2004	303	5666					1998	2001		10.1126/science.1093649	http://dx.doi.org/10.1126/science.1093649			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806JI	15044798				2022-12-28	WOS:000220429800036
J	Jancke, D; Chavane, F; Naaman, S; Grinvald, A				Jancke, D; Chavane, F; Naaman, S; Grinvald, A			Imaging cortical correlates of illusion in early visual cortex	NATURE			English	Article							MOTION INDUCTION; LINE-MOTION; ATTENTION; DYNAMICS; FACILITATION; CONNECTIONS; RESPONSES; SPEED; FIELD; AREA	Exploring visual illusions reveals fundamental principles of cortical processing. Illusory motion perception of non-moving stimuli was described almost a century ago by Gestalt psychologists(1,2). However, the underlying neuronal mechanisms remain unknown. To explore cortical mechanisms underlying the 'linemotion' illusion(3), we used real-time optical imaging(4-6), which is highly sensitive to subthreshold activity. We examined, in the visual cortex of the anaesthetized cat, responses to five stimuli: a stationary small square and a long bar; a moving square; a drawnout bar; and the well-known line-motion illusion(3), a stationary square briefly preceding a long stationary bar presentation. Whereas flashing the bar alone evoked the expected localized, short latency and high amplitude activity patterns(7,8), presenting a square 60 - 100 ms before a bar induced the dynamic activity patterns resembling that of fast movement. The preceding square, even though physically non-moving, created gradually propagating subthreshold cortical activity that must contribute to illusory motion, because it was indistinguishable from cortical representations of real motion in this area. These findings demonstrate the effect of spatio-temporal patterns of subthreshold synaptic potentials on cortical processing and the shaping of perception.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Grodetsky Ctr Studies Higher Brain Funct, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Jancke, D (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	jancke@neurobiologie.ruhr-uni-bochum.de	GRINVALD, AMIRAM/AAH-9919-2019; Jancke, Dirk/A-2961-2015; Chavane, Frederic/ABB-1487-2021; Jancke, Dirk/A-6721-2015	Chavane, Frederic/0000-0001-7916-2640; Naaman, Shmuel/0000-0002-5406-6967; Jancke, Dirk/0000-0001-8440-6259				ALBUS K, 1975, EXP BRAIN RES, V24, P159, DOI 10.1007/BF00234061; Bringuier V, 1999, SCIENCE, V283, P695, DOI 10.1126/science.283.5402.695; CAVANAGH P, 1989, VISION RES, V29, P1197, DOI 10.1016/0042-6989(89)90065-5; Downing PE, 1997, J EXP PSYCHOL HUMAN, V23, P768; GRINVALD A, 1994, J NEUROSCI, V14, P2545; GRINVALD A, 1984, NATURE, V308, P848, DOI 10.1038/308848a0; Grinvald A, 1999, MODERN TECHNIQUES NE, P893, DOI 10.1007/978-3-642-58552-4_34; HIKOSAKA O, 1993, PERCEPTION, V22, P517, DOI 10.1068/p220517; HIKOSAKA O, 1993, VISION RES, V33, P1219, DOI 10.1016/0042-6989(93)90210-N; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; Jancke D, 1999, J NEUROSCI, V19, P9016, DOI 10.1523/JNEUROSCI.19-20-09016.1999; KANIZSA G, 1951, ARCH PSICOLOGIA NEUR, V3, P224; Kawahara J, 1996, PERCEPTION, V25, P901, DOI 10.1068/p250901; KENKEL F, 1913, Z PSYCHOL, V67, P358; Kisvarday ZF, 1997, CEREB CORTEX, V7, P605, DOI 10.1093/cercor/7.7.605; NAKAYAMA K, 1989, VISION RES, V29, P1631, DOI 10.1016/0042-6989(89)90144-2; Petersen CCH, 2003, J NEUROSCI, V23, P1298, DOI 10.1523/JNEUROSCI.23-04-01298.2003; Polat U, 1998, NATURE, V391, P580, DOI 10.1038/35372; POSNER MI, 1980, J EXP PSYCHOL GEN, V109, P160, DOI 10.1037/0096-3445.109.2.160; SAGI D, 1986, NATURE, V321, P693, DOI 10.1038/321693a0; Series P, 2002, VISION RES, V42, P2781, DOI 10.1016/S0042-6989(02)00302-4; Shimojo S, 1997, VISION RES, V37, P1575, DOI 10.1016/S0042-6989(96)00313-6; Shoham D, 1999, NEURON, V24, P791, DOI 10.1016/S0896-6273(00)81027-2; STEINMAN BA, 1995, VISION RES, V35, P1859, DOI 10.1016/0042-6989(94)00276-R; Sterkin A, 1998, NEUROSCI LETT, pS41; TUSA RJ, 1979, J COMP NEUROL, V185, P657, DOI 10.1002/cne.901850405; vonGrunau M, 1996, VISION RES, V36, P2447, DOI 10.1016/0042-6989(95)00330-4; VONGRUNAU M, 1994, PERCEPTION, V23, P913, DOI 10.1068/p230913; vonGrunau M, 1996, VISION RES, V36, P2433, DOI 10.1016/0042-6989(95)00326-6; Wertheimer M, 1912, Z PSYCHOL PHYSIOL SI, V61, P161	30	173	174	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	2004	428	6981					423	426		10.1038/nature02396	http://dx.doi.org/10.1038/nature02396			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042090				2022-12-28	WOS:000220404300042
J	La Spina, A; Paolicchi, P; Kryszczynska, A; Pravec, P				La Spina, A; Paolicchi, P; Kryszczynska, A; Pravec, P			Retrograde spins of near-Earth asteroids from the Yarkovsky effect	NATURE			English	Article							FRAGMENTS; ORIGIN	Dynamical resonances in the asteroid belt are the gateway for the production of near-Earth asteroids(1) (NEAs). To generate the observed number of NEAs, however, requires the injection of many asteroids into those resonant regions. Collisional processes have long been claimed as a possible source(1-3), but difficulties with that idea have led to the suggestion that orbital drift arising from the Yarkovsky effect(4-7) dominates the injection process(8-10). ( The Yarkovsky effect is a force arising from differential heating the 'afternoon' side of an asteroid is warmer than the 'morning' side.) The two models predict different rotational properties of NEAs: the usual collisional theories(2) are consistent with a nearly isotropic distribution of rotation vectors, whereas the 'Yarkovsky model' predicts an excess of retrograde rotations. Here we report that the spin vectors of NEAs show a strong and statistically significant excess of retrograde rotations, quantitatively consistent with the theoretical expectations of the Yarkovsky model.	Univ Pisa, Dipartimento Fis, I-56127 Pisa, Italy; Univ Pisa, Dipartimento Matemat, I-56127 Pisa, Italy; Adam Mickiewicz Univ Poznan, Astron Observ, PL-60286 Poznan, Poland; Acad Sci Czech Republ, Astron Inst, CZ-25165 Ondrejov, Czech Republic	University of Pisa; University of Pisa; Adam Mickiewicz University; Czech Academy of Sciences; Astronomical Institute of the Czech Academy of Sciences	Paolicchi, P (corresponding author), Univ Pisa, Dipartimento Fis, Via Buonarroti 2, I-56127 Pisa, Italy.	paolicchi@df.unipi.it	Pravec, Petr/AAE-2695-2019; Pravec, Petr/G-9037-2014	Pravec, Petr/0000-0001-8434-9776; LA SPINA, ALESSANDRA/0000-0002-3377-8199; Kryszczynska, Agnieszka/0000-0002-4421-4663				Bottke WF, 2002, ICARUS, V156, P399, DOI 10.1006/icar.2001.6788; Bottke WF, 2000, SCIENCE, V288, P2190, DOI 10.1126/science.288.5474.2190; Cellino A., 2002, ASTEROIDS, P633; DAVIS DR, 1989, ASTEROIDS, V2, P805; GREENBERG R, 1989, ASTEROIDS, V2, P778; Kaasalainen M, 2004, ICARUS, V167, P178, DOI 10.1016/j.icarus.2003.09.012; KRYSZCZYNSKA A, DATABASE ASTEROID SP; Magnusson P, 1989, ASTEROIDS, VII, P66; Morbidelli A, 2003, ICARUS, V163, P120, DOI 10.1016/S0019-1035(03)00047-2; Pravec P., 2002, ASTEROIDS 3, P113; Rubincam DP, 2000, ICARUS, V148, P2, DOI 10.1006/icar.2000.6485; Spitale J, 2001, ICARUS, V149, P222, DOI 10.1006/icar.2000.6477; Vokrouhlicky D, 2003, NATURE, V425, P147, DOI 10.1038/nature01948; Vokrouhlicky D, 1998, ASTRON ASTROPHYS, V335, P1093; Vokrouhlicky D, 1998, ASTRON J, V116, P2032, DOI 10.1086/300565; Vokrouhlicky D, 1999, ASTRON ASTROPHYS, V344, P362; Zappala V, 1997, ICARUS, V129, P1, DOI 10.1006/icar.1997.5749	17	70	70	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	2004	428	6981					400	401		10.1038/nature02411	http://dx.doi.org/10.1038/nature02411			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	805ZN	15042082				2022-12-28	WOS:000220404300034
J	Yeh, TF; Lin, YJ; Lin, HC; Huang, CC; Hsieh, WS; Lin, CH; Tsai, CH				Yeh, TF; Lin, YJ; Lin, HC; Huang, CC; Hsieh, WS; Lin, CH; Tsai, CH			Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Pediatric-Academic-Societies/Society-for-Pediatric-Research	MAY 03-06, 2003	SEATTLE, WA	Pediat Acad Soc, Amer Pediat Soc, Soc Pediat Res, Ambulatory Pediat Assoc, Tulane Univ Hlth Sci Ctr, Ctr Cont Educ			LOW-BIRTH-WEIGHT; CONTROLLED-TRIAL; PRETERM INFANTS; BRONCHOPULMONARY DYSPLASIA; COGNITIVE-ABILITIES; FOLLOW-UP; GROWTH; PERFORMANCE; RISK	BACKGROUND: We studied the outcomes at school age in children who had participated in a double-blind, placebo-controlled trial of early postnatal dexamethasone therapy (initiated within 12 hours after birth) for the prevention of chronic lung disease of prematurity. METHODS: Of the 262 children included in the initial study, 159 lived to school age. Of these children, 146 (72 in the dexamethasone group and 74 in the control group) were included in our study. All the infants had had severe respiratory distress syndrome requiring mechanical ventilation shortly after birth. In the dexamethasone group, 0.25 mg of dexamethasone per kilogram of body weight was given intravenously every 12 hours for one week, and then the dose was tapered. We evaluated the children's growth, neurologic and motor function, cognition, and school performance. RESULTS: Children in the dexamethasone group were significantly shorter than the controls (P=0.03 for boys, P=0.01 for girls, and P=0.03 for all children) and had a significantly smaller head circumference (P=0.04). Children in the dexamethasone group had significantly poorer motor skills (P<0.001), motor coordination (P<0.001), and visual-motor integration (P=0.02). As compared with the controls, children in the dexamethasone group also had significantly lower full IQ scores (mean [+/-SD], 78.2+/-15.0 vs. 84.4+/-12.6; P=0.008), verbal IQ scores (84.1+/-13.2 vs. 88.4+/-11.8, P=0.04), and performance IQ scores (76.5+/-14.6 vs. 84.5+/-12.7, P=0.001). The frequency of clinically significant disabilities was higher among children in the dexamethasone group than among controls (28 of 72 [39 percent] vs. 16 of 74 [22 percent], P=0.04). CONCLUSIONS: Early postnatal dexamethasone therapy should not be recommended for the routine prevention or treatment of chronic lung disease, because it leads to substantial adverse effects on neuromotor and cognitive function at school age.	China Med Univ, Coll Med, Dept Pediat, Taichung 40421, Taiwan; Natl Chung Kung Univ Hosp, Tainan, Taiwan; Natl Taiwan Univ, Taipei 10764, Taiwan	China Medical University Taiwan; National Cheng Kung University; National Taiwan University	Yeh, TF (corresponding author), China Med Univ, Coll Med, Dept Pediat, 91 Hsueh Shih Rd, Taichung 40421, Taiwan.	master@mail.cmu.edu.tw	Lin, Yuh Jyh/AAK-4314-2020	Huang, Chao-Ching/0000-0003-2799-7181; HSIEH, WU-SHIUN/0000-0002-0609-3311				Anderson ME, 2001, PEDIATRICS, V108, P741, DOI 10.1542/peds.108.3.741; Armstrong DL, 2002, ARCH DIS CHILD-FETAL, V86, P102, DOI 10.1136/fn.86.2.F102; AVERY GB, 1985, PEDIATRICS, V75, P106; Barrington K J, 2001, BMC Pediatr, V1, P1, DOI 10.1186/1471-2431-1-1; BEERY KE, 1997, BEERYBUKTENICA DEV T; Blackmon LR, 2002, PEDIATRICS, V109, P330; Bos AF, 2002, BIOL NEONATE, V82, P155, DOI 10.1159/000063612; COTTERRELL M, 1972, J NEUROCHEM, V19, P2151, DOI 10.1111/j.1471-4159.1972.tb05124.x; CUMMINGS JJ, 1989, NEW ENGL J MED, V320, P1505, DOI 10.1056/NEJM198906083202301; Garland JS, 1999, PEDIATRICS, V104, P91, DOI 10.1542/peds.104.1.91; GIBSON AT, 1993, ARCH DIS CHILD-FETAL, V69, P505, DOI 10.1136/adc.69.5_Spec_No.505; HACK M, 1991, NEW ENGL J MED, V325, P231, DOI 10.1056/NEJM199107253250403; Halliday HL, 2001, PRENAT NEONAT MED, V6, P371; HALLIDAY HL, 2001, COCHRANE DB SYST REV, V1; HALLIDAY HL, 2000, COCHRANE DB SYST REV, V2; HALLIDAY HL, 2000, COCHRANE DB SYST REV, V2; Henderson S., 1992, MOVEMENT ASSESSMENT; JONES R, 1991, PEDIATRICS, V88, P421; JONES R, 1995, PEDIATRICS, V96, P897; Kaufman A. S, 2004, KAUFMAN BRIEF INTELL; Luckasson R., 1992, MENTAL RETARDATION D; MAMMEL MC, 1983, LANCET, V1, P1356; Mayer R. E, 1992, THINKING PROBLEM SOL; Murphy BP, 2001, PEDIATRICS, V107, P217, DOI 10.1542/peds.107.2.217; O'Shea TM, 1999, PEDIATRICS, V104, P15, DOI 10.1542/peds.104.1.15; OSHEA TM, 1993, AM J DIS CHILD, V147, P658, DOI 10.1001/archpedi.1993.02160300064024; Rastogi A, 1996, PEDIATRICS, V98, P204; ROBERTSON CMT, 1992, PEDIATRICS, V89, P365; Romagnoli C, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e85; Romagnoli C, 2002, ARCH DIS CHILD-FETAL, V87, pF55, DOI 10.1136/fn.87.1.F55; SAIGAL S, 1991, J PEDIATR-US, V118, P751, DOI 10.1016/S0022-3476(05)80043-5; Shinwell ES, 2000, ARCH DIS CHILD-FETAL, V83, pF177, DOI 10.1136/fn.83.3.F177; SHYU S, 1998, PSYCHOL TESTING, V45, P137; Stark AR, 2001, NEW ENGL J MED, V344, P95, DOI 10.1056/NEJM200101113440203; WEICHSEL ME, 1974, PEDIATR RES, V8, P843, DOI 10.1203/00006450-197410000-00005; WEICHSEL ME, 1977, ANN NEUROL, V2, P364, DOI 10.1002/ana.410020503; Weiler HA, 1997, EARLY HUM DEV, V47, P271, DOI 10.1016/S0378-3782(96)01783-5; WU WD, 2001, PSYCHOL TESTING, V31, P37; Yeh TF, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.5.e7; Yeh TF, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.4.e3	40	394	416	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 25	2004	350	13					1304	1313		10.1056/NEJMoa032089	http://dx.doi.org/10.1056/NEJMoa032089			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	805VN	15044641	Bronze			2022-12-28	WOS:000220393900008
J	Dalal, H; Evans, PH; Campbell, JL				Dalal, H; Evans, PH; Campbell, JL			Recent developments in secondary prevention and cardiac rehabilitation after acute myocardial infarction	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CORONARY-HEART-DISEASE; RANDOMIZED CONTROLLED-TRIAL; NATIONAL SERVICE FRAMEWORK; GENERAL-PRACTICE; FOLLOW-UP; HIGH-RISK; CARDIOVASCULAR EVENTS; SMOKING-CESSATION; PRIMARY-CARE; DEPRESSION		Lower Lemon St Surg, Truro TR1 2LZ, England; Peninsula Med Sch, Exeter EX2 5DW, Devon, England	University of Exeter	Dalal, H (corresponding author), Lower Lemon St Surg, Truro TR1 2LZ, England.	hmdalal@doctors.net.uk	Campbell, John/A-5792-2011	Campbell, John/0000-0002-6752-3493; Evans, Philip/0000-0002-5277-3545				Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; BEGG A, 2003, GUIDELINES PRACTICE, V9, P45; Berkman LF, 2003, JAMA-J AM MED ASSOC, V289, P3106; Bethell H J, 2001, J Cardiopulm Rehabil, V21, P111, DOI 10.1097/00008483-200103000-00008; BETHELL HJN, 1990, BRIT HEART J, V64, P370; *BMA NHS CONF GP C, 2003, INV GEN PRACT NEW GE; Boersma E, 2003, LANCET, V361, P847, DOI 10.1016/S0140-6736(03)12712-2; Brady AJB, 2001, BMJ-BRIT MED J, V322, P1463, DOI 10.1136/bmj.322.7300.1463; BROWN ATR, 2003, EXERCISE BASED CARDI; Burns P, 2003, BMJ-BRIT MED J, V326, P584, DOI 10.1136/bmj.326.7389.584; Campbell NC, 1998, HEART, V80, P447, DOI 10.1136/hrt.80.5.447; Chin-Dusting JPF, 2003, LANCET, V361, P1925, DOI 10.1016/S0140-6736(03)13601-X; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Critchley JA, 2003, JAMA-J AM MED ASSOC, V290, P86, DOI 10.1001/jama.290.1.86; Cupples ME, 1999, BMJ-BRIT MED J, V319, P687, DOI 10.1136/bmj.319.7211.687; Dalal HM, 2003, BRIT MED J, V326, P481, DOI 10.1136/bmj.326.7387.481; *DEP HLTH, 2000, NAT SERV FRAM COR HE; DeWilde S, 2003, HEART, V89, P417, DOI 10.1136/heart.89.4.417; Dickstein K, 2002, LANCET, V360, P752, DOI 10.1016/S0140-6736(02)09895-1; Feder G, 1999, BRIT MED J, V318, P1522, DOI 10.1136/bmj.318.7197.1522; Ferguson JL, 2002, HEART, V88, P343, DOI 10.1136/heart.88.4.343; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Fox KM, 2003, LANCET, V362, P782; Freeman AC, 2001, BRIT MED J, V323, P1100, DOI 10.1136/bmj.323.7321.1100; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gordon NF, 2002, AM J CARDIOL, V89, P1263, DOI 10.1016/S0002-9149(02)02323-8; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; Gray DP, 2003, MED EDUC, V37, P754, DOI 10.1046/j.1365-2923.2003.01602.x; Gray J, 2000, BMJ-BRIT MED J, V321, P548, DOI 10.1136/bmj.321.7260.548; HEINTZEN MP, 1994, EUR HEART J, V15, P2, DOI 10.1093/eurheartj/15.suppl_C.2; Hippisley-Cox J, 2001, BRIT MED J, V323, P269, DOI 10.1136/bmj.323.7307.269; Hobbs FDR, 2002, FAM PRACT, V19, P596, DOI 10.1093/fampra/19.6.596; Jackevicius CA, 2002, JAMA-J AM MED ASSOC, V288, P462, DOI 10.1001/jama.288.4.462; Jolliffe JA, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001800, DOI 10.1093/eurheartj/ehm316, DOI 10.1002/14651858.CD001800]; Jolly K, 1999, BMJ-BRIT MED J, V318, P706; Joseph AM, 1996, NEW ENGL J MED, V335, P1792, DOI 10.1056/NEJM199612123352402; Kedward J, 2003, BRIT J GEN PRACT, V53, P684; Ko DT, 2002, JAMA-J AM MED ASSOC, V288, P351, DOI 10.1001/jama.288.3.351; Kotseva K, 2001, LANCET, V357, P995, DOI 10.1016/S0140-6736(00)04235-5; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; LEATHERMAN S, 2003, QUEST QUALITY NHS; LEWIN B, 1992, LANCET, V339, P1036, DOI 10.1016/0140-6736(92)90547-G; Marchionni N, 2003, CIRCULATION, V107, P2201, DOI 10.1161/01.CIR.0000066322.21016.4A; Mayou RA, 2000, PSYCHOSOM MED, V62, P212, DOI 10.1097/00006842-200003000-00011; McAlister FA, 2001, BRIT MED J, V323, P957, DOI 10.1136/bmj.323.7319.957; Murchie P, 2003, BRIT MED J, V326, P84, DOI 10.1136/bmj.326.7380.84; National Institute for Clinical Excellence, 2001, PROPH PAT WHO HAV EX; *OFF NAT STAT MORT, 2003, HLTH STAT Q, V18; PEDERSEN TR, 1994, LANCET, V344, P1383; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Salpeter S, 2002, COCHRANE DATABASE SY, DOI [DOI 10.1002/14651858.CD002992, 10.1002/14651858.CD002992]; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; *SCOTT INT GUID NE, 2002, SIGN PUBL, V57; *SCOTT INT GUID NE, 2000, SEC PREV COR HEART D; Summerskill WSM, 2002, FAM PRACT, V19, P605, DOI 10.1093/fampra/19.6.605; Wenger N K, 1995, Clin Pract Guidel Quick Ref Guide Clin, P1; White HD, 2003, LANCET, V362, P755, DOI 10.1016/S0140-6736(03)14295-X; Williams MA, 2002, CIRCULATION, V105, P1735, DOI 10.1161/01.CIR.0000013074.73995.6C; Wood D, 1998, HEART, V80, pS1; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487; Yusuf S, 2001, NEW ENGL J MED, V345, P494; Yusuf S, 2000, NEW ENGL J MED, V342, P145	62	37	39	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 20	2004	328	7441					693	+		10.1136/bmj.328.7441.693	http://dx.doi.org/10.1136/bmj.328.7441.693			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805VB	15031243	Green Published, Green Submitted			2022-12-28	WOS:000220392700025
J	Haramis, APG; Begthel, H; van den Born, M; van Es, J; Jonkheer, S; Offerhaus, GJA; Clevers, H				Haramis, APG; Begthel, H; van den Born, M; van Es, J; Jonkheer, S; Offerhaus, GJA; Clevers, H			De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine	SCIENCE			English	Article							MORPHOGENETIC PROTEIN-RECEPTOR; GERMLINE MUTATIONS; EXPRESSION; CANCER; NOGGIN; CELLS; SMAD4; GENE; DPC4; GASTRULATION	Little is known about the signaling mechanisms that determine the highly regular patterning of the intestinal epithelium into crypts and villi. With the use of mouse models, we show that bone morphogenetic protein (BMP)-4 expression occurs exclusively in the intravillus mesenchyme. Villus epithelial cells respond to the BMP signal. Inhibition of BMP signaling by transgenic expression of noggin results in the formation of numerous ectopic crypt units perpendicular to the crypt-villus axis. These changes phenocopy the intestinal histopathology of patients with the cancer predisposition syndrome juvenile polyposis (JP), including the frequent occurrence of intraepithelial neoplasia. Many JP cases are known to harbor mutations in BMP pathway genes. These data indicate that intestinal BMP signaling represses de novo crypt formation and polyp growth.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1100 DD Amsterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Clevers, H (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	clevers@niob.knaw.nl	van+Es, Johan/ABD-5411-2021					Aaltonen LA, 2000, PATHOLOGY GENETICS T, P130; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Beppu H, 2000, DEV BIOL, V221, P249, DOI 10.1006/dbio.2000.9670; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Entius MM, 1999, HEPATO-GASTROENTEROL, V46, P661; GIARDIELLO FM, 1995, EUR J CANCER, V31A, P1085, DOI 10.1016/0959-8049(95)00139-A; HARAMIS APG, UNPUB; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Houlston R, 1998, HUM MOL GENET, V7, P1907, DOI 10.1093/hmg/7.12.1907; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Jacoby RF, 1997, GASTROENTEROLOGY, V112, P1398, DOI 10.1016/S0016-5085(97)70156-2; Khokha MK, 2003, NAT GENET, V34, P303, DOI 10.1038/ng1178; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lawson KA, 1999, GENE DEV, V13, P424, DOI 10.1101/gad.13.4.424; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Takaku K, 1999, CANCER RES, V59, P6113; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Woodford-Richens K, 2000, CANCER RES, V60, P2477; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zhou XP, 2001, AM J HUM GENET, V69, P704, DOI 10.1086/323703	29	545	577	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1684	1686		10.1126/science.1093587	http://dx.doi.org/10.1126/science.1093587			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15017003				2022-12-28	WOS:000220151400048
J	Shen, Q; Goderie, SK; Jin, L; Karanth, N; Sun, Y; Abramova, N; Vincent, P; Pumiglia, K; Temple, S				Shen, Q; Goderie, SK; Jin, L; Karanth, N; Sun, Y; Abramova, N; Vincent, P; Pumiglia, K; Temple, S			Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells	SCIENCE			English	Article							DIFFERENTIATION; ANGIOGENESIS; GENERATION; PRECURSORS; EXPRESSION; NICHE; BRAIN; HES1	Neural stem cells are reported to lie in a vascular niche, but there is no direct evidence for a functional relationship between the stem cells and blood vessel component cells. We show that endothelial cells but not vascular smooth muscle cells release soluble factors that stimulate the self-renewal of neural stem cells, inhibit their differentiation, and enhance their neuron production. Both embryonic and adult neural stem cells respond, allowing extensive production of both projection neuron and interneuron types in vitro. Endothelial coculture stimulates neuroepithelial cell contact, activating Notch and Hes1 to promote self-renewal. These findings identify endothelial cells as a critical component of the neural stem cell niche.	Albany Med Coll, Ctr Neuropharmacol & Neurosci, Albany, NY 12208 USA; Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College; Albany Medical College; Albany Medical College	Temple, S (corresponding author), Albany Med Coll, Ctr Neuropharmacol & Neurosci, Albany, NY 12208 USA.	TempleS@mail.amc.edu		Pumiglia, Kevin/0000-0003-4655-0334	NCI NIH HHS [R01 CA081419] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081419] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREIER G, 1992, DEVELOPMENT, V114, P521; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Chenn A, 2003, CEREB CORTEX, V13, P599, DOI 10.1093/cercor/13.6.599; Chojnacki A, 2003, J NEUROSCI, V23, P1730; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Herrera DG, 1999, ANN NEUROL, V46, P867, DOI 10.1002/1531-8249(199912)46:6<867::AID-ANA9>3.0.CO;2-Z; Hevner RF, 2001, NEURON, V29, P353, DOI 10.1016/S0896-6273(01)00211-2; Hitoshi S, 2002, GENE DEV, V16, P846, DOI 10.1101/gad.975202; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Lu BW, 2001, NATURE, V409, P522, DOI 10.1038/35054077; Nakamura Y, 2000, J NEUROSCI, V20, P283, DOI 10.1523/JNEUROSCI.20-01-00283.2000; Ohtsuka T, 2001, J BIOL CHEM, V276, P30467, DOI 10.1074/jbc.M102420200; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Qian XM, 1998, DEVELOPMENT, V125, P3143; Qian XM, 2000, NEURON, V28, P69, DOI 10.1016/S0896-6273(00)00086-6; SHEN Q, UNPUB; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0	18	1161	1257	6	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2004	304	5675					1338	1340		10.1126/science.1095505	http://dx.doi.org/10.1126/science.1095505			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824EV	15060285				2022-12-28	WOS:000221669600059
J	Wernet, P; Nordlund, D; Bergmann, U; Cavalleri, M; Odelius, M; Ogasawara, H; Naslund, LA; Hirsch, TK; Ojamae, L; Glatzel, P; Pettersson, LGM; Nilsson, A				Wernet, P; Nordlund, D; Bergmann, U; Cavalleri, M; Odelius, M; Ogasawara, H; Naslund, LA; Hirsch, TK; Ojamae, L; Glatzel, P; Pettersson, LGM; Nilsson, A			The structure of the first coordination shell in liquid water	SCIENCE			English	Article							HYDROGEN-BOND DYNAMICS; MOLECULAR-DYNAMICS; AB-INITIO; SPECTROSCOPY; SCATTERING; SIMULATION; ICE	X-ray absorption spectroscopy and x-ray Raman scattering were used to probe the molecular arrangement in the first coordination shell of liquid water. The local structure is characterized by comparison with bulk and surface of ordinary hexagonal ice Ih and with calculated spectra. Most molecules in liquid water are in two hydrogen-bonded configurations with one strong donor and one strong acceptor hydrogen bond in contrast to the four hydrogen-bonded tetrahedral structure in ice. Upon heating from 25degreesC to 90degreesC, 5 to 10% of the molecules change from tetrahedral environments to two hydrogen-bonded configurations. Our findings are consistent with neutron and x-ray diffraction data, and combining the results sets a strong limit for possible local structure distributions in liquid water. Serious discrepancies with structures based on current molecular dynamics simulations are observed.	Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA; BESSY, D-12489 Berlin, Germany; Stockholm Univ, FYSIKUM, S-10691 Stockholm, Sweden; Stockholm Univ, Dept Chem Phys, S-10691 Stockholm, Sweden; Linkoping Univ, Dept Chem, S-58183 Linkoping, Sweden; Univ Utrecht, Debye Inst, Dept Inorgan Chem & Catalysis, NL-3584 CA Utrecht, Netherlands	Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Helmholtz Association; Helmholtz-Zentrum fuer Materialien und Energie GmbH (HZB); Stockholm University; Stockholm University; Linkoping University; Utrecht University	Nilsson, A (corresponding author), Stanford Synchrotron Radiat Lab, POB 20450, Stanford, CA 94309 USA.	nilsson@slac.stanford.edu	Ogasawara, Hirohito/AAC-8754-2020; Pettersson, Lars GM/J-4925-2013; Nilsson, Anders/E-1943-2011; Glatzel, Pieter/E-9958-2010; Wernet, Philippe/A-7085-2013; Odelius, Michael/J-6142-2019; Pettersson, Lars G.M./F-8428-2011; Nordlund, Dennis/A-8902-2008; Ogasawara, Hirohito/AGU-4579-2022; Ogasawara, Hirohito/D-2105-2009; Cavalleri, Matteo/A-7689-2008; Ojamäe, Lars/C-4974-2015; Odelius, Michael/A-7628-2014	Pettersson, Lars GM/0000-0003-1133-9934; Nilsson, Anders/0000-0003-1968-8696; Glatzel, Pieter/0000-0001-6532-8144; Wernet, Philippe/0000-0001-7011-9072; Nordlund, Dennis/0000-0001-9524-6908; Ogasawara, Hirohito/0000-0001-5338-1079; Ogasawara, Hirohito/0000-0001-5338-1079; Ojamäe, Lars/0000-0002-5341-2637; Odelius, Michael/0000-0002-7023-2486; Cavalleri, Matteo/0000-0002-7925-928X	NCRR NIH HHS [RR-08630] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bergmann U, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.092107; Cavalleri M, 2002, CHEM PHYS LETT, V364, P363, DOI 10.1016/S0009-2614(02)00890-4; Chialvo AA, 1996, J PHYS CHEM-US, V100, P1309, DOI 10.1021/jp951445q; Fecko CJ, 2003, SCIENCE, V301, P1698, DOI 10.1126/science.1087251; Glebov A, 2000, J CHEM PHYS, V112, P11011, DOI 10.1063/1.481741; Head-Gordon T, 2002, CHEM REV, V102, P2651, DOI 10.1021/cr0006831; KUSALIK PG, 1994, SCIENCE, V265, P1219, DOI 10.1126/science.265.5176.1219; LIE GC, 1986, PHYS REV A, V33, P2679, DOI 10.1103/PhysRevA.33.2679; Ludwig R, 2001, ANGEW CHEM INT EDIT, V40, P1808, DOI 10.1002/1521-3773(20010518)40:10<1808::AID-ANIE1808>3.3.CO;2-T; Luzar A, 1996, PHYS REV LETT, V76, P928, DOI 10.1103/PhysRevLett.76.928; Myneni S, 2002, J PHYS-CONDENS MAT, V14, pL213, DOI 10.1088/0953-8984/14/8/106; NARTEN AH, 1969, SCIENCE, V165, P447, DOI 10.1126/science.165.3892.447; NORDLUND D, UNPUB; Nyberg M, 2003, J CHEM PHYS, V119, P12577, DOI 10.1063/1.1625640; OJAMAE L, 1994, J PHYS CHEM-US, V98, P4271, DOI 10.1021/j100067a011; Silvestrelli PL, 1999, J CHEM PHYS, V111, P3572, DOI 10.1063/1.479638; Soper AK, 2000, CHEM PHYS, V258, P121, DOI 10.1016/S0301-0104(00)00179-8; SOPER AK, 1994, J CHEM PHYS, V101, P6888, DOI 10.1063/1.468318; Stenger J, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.027401; STILLINGER FH, 1980, SCIENCE, V209, P451, DOI 10.1126/science.209.4455.451; Stohr J, 2013, SPRINGE SER SURF SCI; TOUKAN K, 1985, PHYS REV B, V31, P2643, DOI 10.1103/PhysRevB.31.2643; Weinhold F, 1998, J CHEM PHYS, V109, P373, DOI 10.1063/1.476574; Wilson KR, 2002, J PHYS-CONDENS MAT, V14, pL221, DOI 10.1088/0953-8984/14/8/107; Woutersen S, 1997, SCIENCE, V278, P658, DOI 10.1126/science.278.5338.658	25	1152	1173	12	532	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	2004	304	5673					995	999		10.1126/science.1096205	http://dx.doi.org/10.1126/science.1096205			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	820IV	15060287	Green Submitted			2022-12-28	WOS:000221383300044
J	Tucker, WC; Weber, T; Chapman, ER				Tucker, WC; Weber, T; Chapman, ER			Reconstitution of Ca2+-regulated membrane fusion by synaptotagmin and SNAREs	SCIENCE			English	Article							PHOSPHOLIPID-BINDING; BOTULINUM TOXIN; T-SNARES; DOMAIN; EXOCYTOSIS; VESICLES; RELEASE; COMPLEX; CORE; CA2+	We investigated the effect of synaptotagmin I on membrane fusion mediated by neuronal SNARE proteins, SNAP-25, syntaxin, and synaptobrevin, which were reconstituted into vesicles. In the presence of Ca2+, the cytoplasmic domain of synaptotagmin I (syt) strongly stimulated membrane fusion when synaptobrevin densities were similar to those found in native synaptic vesicles. The Ca2+ dependence of syt-stimulated fusion was modulated by changes in lipid composition of the vesicles and by a truncation that mimics cleavage of SNAP-25 by botulinum neurotoxin A. Stimulation of fusion was abolished by disrupting the Ca2+-binding activity, or by severing the tandem C2 domains, of syt. Thus, syt and SNAREs are likely to represent the minimal protein complement for Ca2+-triggered exocytosis.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; CUNY Mt Sinai Sch Med, Carl C Icahn Ctr Gene Therapy & Mol Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Mol Cell & Dev Biol, New York, NY 10029 USA	University of Wisconsin System; University of Wisconsin Madison; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Chapman, ER (corresponding author), Univ Wisconsin, Dept Physiol, 1300 Univ Ave, Madison, WI 53706 USA.	chapman@physiology.wisc.edu	Weber, Thomas/A-2363-2008; Weber, Thomas/GLS-9125-2022	Weber, Thomas/0000-0002-0494-0484; Weber, Thomas/0000-0002-0494-0484; Chapman, Edwin/0000-0001-9787-8140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066313, R01GM056827] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56827, GM 66313] Funding Source: Medline; NIMH NIH HHS [MH 61876] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Augustine GJ, 2001, CURR OPIN NEUROBIOL, V11, P320, DOI 10.1016/S0959-4388(00)00214-2; Bagala C, 2003, BIOCHEM BIOPH RES CO, V310, P1041, DOI 10.1016/j.bbrc.2003.09.119; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Craxton M, 1999, FEBS LETT, V460, P417, DOI 10.1016/S0014-5793(99)01382-4; CULLCANDY SG, 1976, J PHYSIOL-LONDON, V260, P177, DOI 10.1113/jphysiol.1976.sp011510; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; Earles CA, 2001, J CELL BIOL, V154, P1117, DOI 10.1083/jcb.200105020; Fernandez I, 2001, NEURON, V32, P1057, DOI 10.1016/S0896-6273(01)00548-7; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; Katz B., 1969, RELEASE NEURAL TRANS; LUNDH H, 1977, J NEUROL SCI, V32, P29, DOI 10.1016/0022-510X(77)90037-5; Mahal LK, 2002, J CELL BIOL, V158, P273, DOI 10.1083/jcb.200203135; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; Tucker WC, 2002, BIOCHEM J, V366, P1, DOI 10.1042/BJ20020776; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Zhang XY, 1998, BIOCHEMISTRY-US, V37, P12395, DOI 10.1021/bi9807512	23	283	290	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	2004	304	5669					435	438		10.1126/science.1097196	http://dx.doi.org/10.1126/science.1097196			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	812NE	15044754				2022-12-28	WOS:000220845400047
J	Whitlock, EP; Polen, MR; Green, CA; Orleans, T; Klein, J				Whitlock, EP; Polen, MR; Green, CA; Orleans, T; Klein, J			Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: A summary of the evidence for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							BRIEF PHYSICIAN ADVICE; RANDOMIZED CONTROLLED-TRIAL; ALL-CAUSE MORTALITY; AT-RISK DRINKING; PROBLEM DRINKERS; GENERAL-PRACTICE; LONG-TERM; FOLLOW-UP; HEAVY DRINKING; USE DISORDERS	Background: Primary health care visits offer opportunities to identify and intervene with risky or harmful drinkers to reduce alcohol consumption. Purpose: To systematically review evidence for the efficacy of brief behavioral counseling interventions in primary care settings to reduce risky and harmful alcohol consumption. Data Sources: Cochrane Database of Systematic Reviews, Database of Research Effectiveness (DARE), MEDLINE, Cochrane Controlled Clinical Trials, PsycINFO, HealthSTAR, CINAHL databases, bibliographies of reviews and included trials from 1994 through April 2002; update search through February 2003. Study Selection: An inclusive search strategy (alcohol* or drink*) identified English-language systematic reviews or trials of primary care interventions to reduce risky/harmful alcohol use. Twelve controlled trials with general adult patients met our quality and relevance inclusion criteria. Data Extraction: Investigators abstracted study design and setting, participant characteristics, screening and assessment procedures, intervention components, alcohol consumption and other outcomes, and quality-related study details. Data Synthesis: Six to 12 months after good-quality, brief, multicontact behavioral counseling interventions (those with up to 15 minutes of initial contact and at least 1 follow-up), participants reduced the average number of drinks per week by 13% to 34% more than controls did, and the proportion of participants drinking at moderate or safe levels was 10% to 19% greater compared with controls. One study reported maintenance of improved drinking patterns for 48 months. Conclusions: Behavioral counseling interventions for risky/ harmful alcohol use among adult primary care patients could provide an effective component of a public health approach to reducing risky/harmful alcohol use. Future research should focus on implementation strategies to facilitate adoption of these practices into routine health care.	Kaiser Permanente Ctr Hlth Res, Oregon Evidencebased Practice Ctr, Portland, OR 97227 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Robert Wood Johnson Fdn, Princeton, NJ USA; Univ Rochester, Rochester, NY USA	Kaiser Permanente; Oregon Health & Science University; Robert Wood Johnson Foundation (RWJF); University of Rochester	Whitlock, EP (corresponding author), Kaiser Permanente Ctr Hlth Res, Oregon Evidencebased Practice Ctr, 3800 N Interstate Ave, Portland, OR 97227 USA.		Green, Carla/D-2534-2017	Green, Carla/0000-0002-0000-4381	PHS HHS [290-97-0018] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aalto M, 2000, ALCOHOL CLIN EXP RES, V24, P1680, DOI 10.1097/00000374-200011000-00010; Aalto M, 2001, ALCOHOL ALCOHOLISM, V36, P224, DOI 10.1093/alcalc/36.3.224; ALLEN JP, 1995, ARCH INTERN MED, V155, P1726, DOI 10.1001/archinte.155.16.1726; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDERSON P, 1992, BRIT J ADDICT, V87, P891; ANDERSON P, 1995, ADDICTION, V90, P481, DOI 10.1111/j.1360-0443.1995.tb02178.x; ANDERSON P, 2003, BMJ             0903; ANTTIPOIKA I, 1988, ALCOHOL ALCOHOLISM, V23, P115; Babor TF, 2000, J STUD ALCOHOL, V61, P55, DOI 10.15288/jsa.2000.61.55; Babor TF, 1996, AM J PUBLIC HEALTH, V86, P948; BABOR TF, 1995, ALCOHOL PUBLIC POLIC, P164; Beich A, 2003, BMJ-BRIT MED J, V327, P536, DOI 10.1136/bmj.327.7414.536; BEICH A, 2003, BMJ             0914; BEICH A, 2003, BMJ             1005; Berglund G, 2000, J INTERN MED, V247, P19, DOI 10.1046/j.1365-2796.2000.00568.x; BLAIR KE, 2000, THESIS PENNSYLVANIA; BLONDELL RD, 2001, J FAM PRACTICE, V50, P447; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; Bondy SJ, 1999, CAN J PUBLIC HEALTH, V90, P264, DOI 10.1007/BF03404129; Bradley KA, 1998, JAMA-J AM MED ASSOC, V280, P166, DOI 10.1001/jama.280.2.166; BURTON LC, 1995, PREV MED, V24, P492, DOI 10.1006/pmed.1995.1078; CAMACHO TC, 1987, J CHRON DIS, V40, P229, DOI 10.1016/0021-9681(87)90158-5; CHERPITEL CJ, 1995, ACCIDENT ANAL PREV, V27, P651, DOI 10.1016/0001-4575(95)00011-N; *COCHR DRUG ALC GR, 2003, GUID ASS STUD QUAL; Cordoba R, 1998, FAM PRACT, V15, P562, DOI 10.1093/fampra/15.6.562; Corrao G, 2000, ADDICTION, V95, P1505, DOI 10.1046/j.1360-0443.2000.951015056.x; Corrao G, 1999, ADDICTION, V94, P1551, DOI 10.1046/j.1360-0443.1999.9410155111.x; Curry SJ, 2003, HEALTH PSYCHOL, V22, P156, DOI 10.1037/0278-6133.22.2.156; Dawson DA, 2000, ALCOHOL CLIN EXP RES, V24, P72, DOI 10.1097/00000374-200001000-00012; Del Boca FK, 2000, ADDICTION, V95, pS347; DIGUISEPPI C, 1996, US PREVENTIVE SERVIC, P567; Dimeff LA, 2000, COGN BEHAV PRACT, V7, P82, DOI 10.1016/S1077-7229(00)80010-3; DIMEFF LA, 1998, BRIEF INTERVENTION H; Dinh-Zarr T, 1999, ALCOHOL ALCOHOLISM, V34, P609, DOI 10.1093/alcalc/34.4.609; ELVY GA, 1988, BRIT J ADDICT, V83, P83; Fiellin DA, 2000, ARCH INTERN MED, V160, P1977, DOI 10.1001/archinte.160.13.1977; Fillmore KM, 1998, ADDICTION, V93, P183, DOI 10.1046/j.1360-0443.1998.9321834.x; Fillmore KM, 1998, ADDICTION, V93, P219, DOI 10.1046/j.1360-0443.1998.9322196.x; FIORE MC, 2000, TREATING TOBACCO USE; Fleming MF, 2002, ALCOHOL CLIN EXP RES, V26, P36, DOI 10.1111/j.1530-0277.2002.tb02429.x; Fleming MF, 2001, RECENT DEV ALCOHOL, V15, P393; Fleming MF, 1999, J FAM PRACTICE, V48, P378; Fleming MF, 1998, AM J PUBLIC HEALTH, V88, P90, DOI 10.2105/AJPH.88.1.90; Fleming MF, 2000, MED CARE, V38, P7, DOI 10.1097/00005650-200001000-00003; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; Forsberg L, 2000, ADDICT BEHAV, V25, P471, DOI 10.1016/S0306-4603(99)00005-2; Friedmann PD, 2000, J GEN INTERN MED, V15, P84, DOI 10.1046/j.1525-1497.2000.03379.x; Friedmann PD, 2001, J STUD ALCOHOL, V62, P234, DOI 10.15288/jsa.2001.62.234; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; GENTILELLO LM, 1997, ABSTR BOOK ASS HLTH, V14, P226; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hays WL, 1988, STATISTICS; HEATHER N, 1987, J ROY COLL GEN PRACT, V37, P358; Heather N, 1996, DRUG ALCOHOL REV, V15, P29, DOI 10.1080/09595239600185641; HEATHER N, 1987, BRIT J CLIN PSYCHOL, V26, P279, DOI 10.1111/j.2044-8260.1987.tb01361.x; HEATHER N, 2003, COMMUNICATION; Holman CDJ, 1996, MED J AUSTRALIA, V164, P141, DOI 10.5694/j.1326-5377.1996.tb122011.x; Israel Y, 1996, ALCOHOL CLIN EXP RES, V20, P1443, DOI 10.1111/j.1530-0277.1996.tb01147.x; KAHAN M, 1995, CAN MED ASSOC J, V152, P851; Kaner EFS, 1999, BRIT J GEN PRACT, V49, P699; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; Kraemer KL, 2002, J GEN INTERN MED, V17, P382, DOI 10.1046/j.1525-1497.2002.10613.x; KRISTENSON H, 1983, ALCOHOL CLIN EXP RES, V7, P203, DOI 10.1111/j.1530-0277.1983.tb05441.x; Kristenson H, 2002, ALCOHOL CLIN EXP RES, V26, P478, DOI 10.1097/00000374-200204000-00007; Leino EV, 1998, ADDICTION, V93, P205, DOI 10.1046/j.1360-0443.1998.9322055.x; Lock CA, 2000, J EVAL CLIN PRACT, V6, P345, DOI 10.1046/j.1365-2753.2000.00268.x; LOGSDON DN, 1989, AM J PREV MED, V5, P249, DOI 10.1016/S0749-3797(18)31065-1; Maisto SA, 2001, J STUD ALCOHOL, V62, P605, DOI 10.15288/jsa.2001.62.605; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; McIntosh MC, 1997, CAN FAM PHYSICIAN, V43, P1959; Monti PM, 1999, J CONSULT CLIN PSYCH, V67, P989, DOI 10.1037/0022-006X.67.6.989; Moyer A, 2002, ADDICTION, V97, P279, DOI 10.1046/j.1360-0443.2002.00018.x; *NAT AC PR, 1996, COMM FUT PRIM CAR AM; *NIAAA, 1997, NIH PUBL; *NIAAA, 1995, NIH PUBL; NIAAA, 2003, NIH PUBL, V03-3745; *NIAAA, 2000, NIH PUBL; *NIAAA, 1995, ALC AL 30 DIAGN CRIT; NILSSEN O, 1991, PREV MED, V20, P518, DOI 10.1016/0091-7435(91)90049-A; O'Connor PG, 1998, NEW ENGL J MED, V338, P592, DOI 10.1056/NEJM199802263380907; Ockene JK, 1999, ARCH INTERN MED, V159, P2198, DOI 10.1001/archinte.159.18.2198; OLIANSKY DM, 1997, SUBST ABUS, V18, P95; Perreira KM, 2002, ADDICTION, V97, P301, DOI 10.1046/j.1360-0443.2002.00067.x; PERSSON J, 1989, ALCOHOL, V6, P403, DOI 10.1016/0741-8329(89)90011-6; Poikolainen K, 1999, PREV MED, V28, P503, DOI 10.1006/pmed.1999.0467; POIKOLAINEN K, 1995, J CLIN EPIDEMIOL, V48, P455, DOI 10.1016/0895-4356(94)00174-O; Reid MC, 1999, ARCH INTERN MED, V159, P1681, DOI 10.1001/archinte.159.15.1681; Reinert DF, 2002, ALCOHOL CLIN EXP RES, V26, P272, DOI 10.1111/j.1530-0277.2002.tb02534.x; RICHMOND R, 1995, ADDICTION, V90, P119, DOI 10.1046/j.1360-0443.1995.90111915.x; ROMELSJO A, 1989, BRIT J ADDICT, V84, P1319; Sacco RL, 1998, STROKE, V29, P380, DOI 10.1161/01.STR.29.2.380; Saitz R, 2003, ANN INTERN MED, V138, P372, DOI 10.7326/0003-4819-138-5-200303040-00006; SAITZ R, 2003, BMJ; Scott E, 1991, Drug Alcohol Rev, V10, P313; Senft RA, 1997, AM J PREV MED, V13, P464, DOI 10.1016/S0749-3797(18)30143-0; SERDULA MK, 1995, J STUD ALCOHOL, V56, P233, DOI 10.15288/jsa.1995.56.233; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1990, BR J ADDICT, V85, P849; Spandorfer JM, 1999, J FAM PRACTICE, V48, P899; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; Tomson Y, 1998, SCAND J PRIM HEALTH, V16, P188; *US DEP HHS, 2000, HEALTH PEIPL 2010; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; WATERSON E J, 1990, Health Education Research, V5, P53, DOI 10.1093/her/5.1.53; Watson HE, 1999, INT J NURS STUD, V36, P425, DOI 10.1016/S0020-7489(99)00028-0; Welte JW, 1998, ADDICTION, V93, P573, DOI 10.1046/j.1360-0443.1998.93457312.x; Whitlock EP, 2002, AM J PREV MED, V22, P267, DOI 10.1016/S0749-3797(02)00415-4; WHITLOCK EP, 2003, DISCUSSION, V327, pE265; WHITLOCK EP, 2004, BEHAV COUNS INT PRIM; Whitlock Evelyn P, 2003, BMJ, V327, pE263, DOI 10.1136/bmj.327.7429.E263; Wilk AI, 1997, J GEN INTERN MED, V12, P274; Wutzke SE, 2002, ADDICTION, V97, P665, DOI 10.1046/j.1360-0443.2002.00080.x; Wutzke SE, 2001, SOC SCI MED, V52, P863, DOI 10.1016/S0277-9536(00)00189-1	114	547	556	0	39	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 6	2004	140	7					557	568		10.7326/0003-4819-140-7-200404060-00017	http://dx.doi.org/10.7326/0003-4819-140-7-200404060-00017			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	808OE	15068985				2022-12-28	WOS:000220577600009
J	Mirza, I; Jenkins, R				Mirza, I; Jenkins, R			Risk factors, prevalence, and treatment of anxiety and depressive disorders in Pakistan: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC-DISORDER; MENTAL-DISORDERS; HEALTH-CARE; COMMUNITY; STRESS; WOMEN; RAWALPINDI; PUNJAB	Objectives To assess the available evidence on the prevalence, aetiology, treatment, and prevention of anxiety and depressive disorders in Pakistan. Design Systematic review of published literature: Studies reviewed 20 studies, of which 17 gave prevalence estimates and 11 discussed risk factors.. Main outcome measures Prevalence of anxiety and depressive disorders, risk factors, effects of treatment. Results Factors positively associated with anxiety and depressive disorders were female sex, middle age, low , level of education, financial difficulty, being a housewife, and relationship problems. Arguments with husbands and relational problems with in-laws were positively associated in 3/11 studies. Those who had close confiding relationships were less likely to have anxiety and depressive disorders. Mean overall prevalence of anxiety and depressive disorders in the community population was 34% (range 29-66% for women and 10-33% for men). There were no rigorously controlled trials of treatments for these disorders. Conclusions Available evidence suggests a major social cause for anxiety and depressive disorders in Pakistan. This evidence is limited because of methodological problems, so caution must be exercised in generalising this to the whole of the population of Pakistan.	Royal London Hosp St Clements, London E3 4LL, England; Inst Psychiat, WHO Collaborating Ctr Mental Htlh, London SE5 8AF, England	Barts Health NHS Trust; Royal London Hospital; University of London; King's College London	Mirza, I (corresponding author), Thorpe Coombe Hosp, Larkswood Ctr, London E17 3HP, England.	ilyasmirza@blueyonder.co.uk	Jenkins, Rachel/E-4287-2010; Jenkins, Rachel/H-2953-2019	Jenkins, Rachel/0000-0002-2958-0331; Jenkins, Rachel/0000-0002-2958-0331; mirza, ilyas/0000-0003-2804-1173				Abas MA, 1997, PSYCHOL MED, V27, P59, DOI 10.1017/S0033291796004163; Ali B., 1993, JPMA (Journal of the Pakistan Medical Association), V43, P69; Ali B. S., 2000, JCPSP, Journal of the College of Physicians and Surgeons - Pakistan, V10, P4; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Baig L, 2001, J Pak Med Assoc, V51, P206; Bender KG, 2001, INT J SOC PSYCHIATR, V47, P32, DOI 10.1177/002076400104700304; Bhagwanjee A, 1998, PSYCHOL MED, V28, P1137, DOI 10.1017/S0033291798006965; Broadhead JC, 1998, PSYCHOL MED, V28, P29, DOI 10.1017/S0033291797005618; Desjarlis R, 1995, WORLD MENTAL HLTH PR; DODANI D, 2000, J PAK MED ASS, V50, P138; GADIT A, 1998, J COLL PHYS SURG PK, V8, P262; Gadit A. A., 2001, JCPSP, Journal of the College of Physicians and Surgeons Pakistan, V11, P706; GREENHALGH T, 1999, READ PAPER BASIS EVI; HARDING TW, 1980, PSYCHOL MED, V10, P231, DOI 10.1017/S0033291700043993; Husain N, 2000, PSYCHOL MED, V30, P395, DOI 10.1017/S0033291700001707; Institute of Medicine,, 2001, NEUR PSYCH DEV DIS M; JAVED M, 1991, PAK J CLIN PSYCHIAT, V1, P127; Javed Muhammad Afzal, 1994, JPMA (Journal of the Pakistan Medical Association), V44, P85; Jenkins R, 2001, ACTA PSYCHIAT SCAND, V103, P2, DOI 10.1034/j.1600-0447.2001.00004.x; Khalid Saeed, 2000, JCPSP, Journal of the College of Physicians and Surgeons - Pakistan, V10, P7; Malik S. B., 1999, JCPSP, Journal of the College of Physicians and Surgeons - Pakistan, V9, P359; Malik SB, 2001, PSYCHIAT B, V25, P273, DOI [DOI 10.1192/pb.25.7.273, DOI 10.1192/PB.25.7.273]; MEHMOOD S, 2000, PAKISTAN POLITICAL R; Minhas F. A., 2001, JCPSP, Journal of the College of Physicians and Surgeons Pakistan, V11, P224; Mirza I, 2001, BRIT J PSYCHIAT, V178, P475, DOI 10.1192/bjp.178.5.475-a; Mumford DB, 2000, BRIT J PSYCHIAT, V177, P557, DOI 10.1192/bjp.177.6.557; Mumford DB, 1997, BRIT J PSYCHIAT, V170, P473, DOI 10.1192/bjp.170.5.473; Mumford DB, 1996, BRIT J PSYCHIAT, V168, P299, DOI 10.1192/bjp.168.3.299; Naeem Shifa, 1992, JPMA (Journal of the Pakistan Medical Association), V42, P137; *POP DIV DEP EC SO, 1999, WORLD 6 BILL, P12; Rabbani Fauziah, 1999, JPMA (Journal of the Pakistan Medical Association), V49, P139; RABBANI R, 2000, J PAK MED ASS, V49, P306; Rahman A, 1998, LANCET, V352, P1022, DOI 10.1016/S0140-6736(98)02381-2; Saeed K, 2000, SOC PSYCH PSYCH EPID, V35, P480, DOI 10.1007/s001270050267; TAREEN E, 2000, THESIS U ESSEX COLCH; Winkvist A, 1997, SOC SCI MED, V45, P1483, DOI 10.1016/S0277-9536(97)00078-6; World Health Organization, 2001, MACR HLTH INV HLTH E	37	294	298	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	2004	328	7443					794	797		10.1136/bmj.328.7443.794	http://dx.doi.org/10.1136/bmj.328.7443.794			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	811CG	15070634	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000220749400017
J	Traggiai, E; Chicha, L; Mazzucchelli, L; Bronz, L; Piffaretti, JC; Lanzavecchia, A; Manz, MG				Traggiai, E; Chicha, L; Mazzucchelli, L; Bronz, L; Piffaretti, JC; Lanzavecchia, A; Manz, MG			Development of a human adaptive immune system in cord blood cell-transplanted mice	SCIENCE			English	Article							RECEPTOR-GAMMA CHAIN; SCID-HU MICE; CD34(+) CELLS; NOD/SCID MICE; MOUSE MODEL; T-CELLS; ENGRAFTMENT; LYMPHOCYTES; SUBSETS; DEFICIENT	Because ethical restrictions limit in vivo studies of the human hematolymphoid system, substitute human to small animal xenotransplantation models have been employed. Existing models, however, sustain only limited development and maintenance of human lymphoid cells and rarely produce immune responses. Here we show that intrahepatic injection of CD34(+) human cord blood cells into conditioned newborn Rag2(-/-) gamma(c)(-/-) mice leads to de novo development of B, T, and dendritic cells; formation of structured primary and secondary lymphoid organs; and production of functional immune responses. This provides a valuable model to study development and function of the human adaptive immune system in vivo.	IRB, CH-6500 Bellinzona, Switzerland; Inst Pathol, CH-6600 Locarno, Switzerland; Osped San Giovanni Bellinzona, Dept Gynecol & Obstet, CH-6500 Bellinzona, Switzerland; Inst Microbiol, CH-6501 Bellinzona, Switzerland	Universita della Svizzera Italiana; Regional Hospital of Bellinzona & Valleys, San Giovanni	Manz, MG (corresponding author), IRB, Via Vela 6, CH-6500 Bellinzona, Switzerland.	manz@irb.unisi.ch	Manz, Markus G/C-7588-2011; traggiai, elisabetta/A-2316-2009; Serei, Virian D/B-4616-2015	Manz, Markus/0000-0002-4676-7931				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Carballido JM, 2000, NAT MED, V6, P103, DOI 10.1038/71434; Delhem N, 1998, J IMMUNOL, V161, P2060; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Goldman JP, 1998, BRIT J HAEMATOL, V103, P335, DOI 10.1046/j.1365-2141.1998.00980.x; Greiner DL, 1998, STEM CELLS, V16, P166, DOI 10.1002/stem.160166; Hiramatsu H, 2003, BLOOD, V102, P873, DOI 10.1182/blood-2002-09-2755; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Kerre TCC, 2002, BLOOD, V99, P1620, DOI 10.1182/blood.V99.5.1620; Kollet O, 2000, BLOOD, V95, P3102, DOI 10.1182/blood.V95.10.3102.010k14_3102_3105; Liu YJ, 2001, CELL, V106, P259, DOI 10.1016/S0092-8674(01)00456-1; MANZ M, UNPUB; Mazurier F, 1999, J INTERF CYTOK RES, V19, P533, DOI 10.1089/107999099313983; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; McCutchen D, 1996, EDUC PSYCHOL REV, V8, P187, DOI 10.1007/BF01464072; Mosier DE, 2000, VIROLOGY, V271, P215, DOI 10.1006/viro.2000.0336; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; Palucka AK, 2003, BLOOD, V102, P3302, DOI 10.1182/blood-2003-02-0384; Ramirez M, 1998, EXP HEMATOL, V26, P332; Rossi MID, 2001, J IMMUNOL, V167, P3033, DOI 10.4049/jimmunol.167.6.3033; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; SANDHU J, 1994, J IMMUNOL, V152, P3806; SHULTZ LD, 1995, J IMMUNOL, V154, P180	25	744	800	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 2	2004	304	5667					104	107		10.1126/science.1093933	http://dx.doi.org/10.1126/science.1093933			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808KL	15064419				2022-12-28	WOS:000220567900047
J	Gharehbaghian, A; Haque, KMG; Truman, C; Evans, R; Morse, R; Newman, J; Bannister, G; Rogers, C; Bradley, BA				Gharehbaghian, A; Haque, KMG; Truman, C; Evans, R; Morse, R; Newman, J; Bannister, G; Rogers, C; Bradley, BA			Effect of autologous salvaged blood on postoperative natural killer cell precursor frequency	LANCET			English	Article							KNEE REPLACEMENT SURGERY; WHOLE-BLOOD; INFLAMMATORY CYTOKINES; RANDOMIZED-TRIAL; MAJOR SURGERY; NK CELLS; T-CELLS; TRANSFUSION; ARTHROPLASTY; INTERLEUKIN-10	Background Immunosuppression after major surgery increases the risk of infections. Natural killer cells play a pivotal part in defence against infection. We aimed to investigate the immunomodulatory effects of different types of postoperative blood transfusion by use of a new assay for measuring the frequency of peripheral blood natural killer precursor cells (NKpf assay). Methods We measured the natural killer cell precursor (NKp) frequency before and 5 days after surgery in 120 patients undergoing joint replacement surgery. The patients were assigned to one of five groups according to the type of transfusion received: non-transfused (n=32), allogeneic non-leukodepleted blood (eight), allogeneic leukodepleted blood (30), autologous predeposited blood (ten), and autologous salvaged blood collected within the first 24 h after surgery (40). We also measured interferon gamma and interleukin 10 concentrations before and after surgery. Findings The mean postoperative NKp frequency for all patients was lower than the preoperative values, except in patients receiving autologous salvaged blood, which was higher than all other groups (p<0.0001). Postoperative NKp frequencies for patients receiving allogeneic or autologous predeposited blood responded similarly (p=0.99), but these patients had lower NKp frequencies than did the nontransfused group (p<0.0001). Postoperative interferon gamma concentrations were higher in the autologous salvaged blood group (p<0.0001) than in other groups, which did not differ from each other. Interleukin 10 concentrations were similar across ail groups (p=0.49). Interpretation Immunosuppression associated with surgery and blood loss was reflected in a reduced frequency of NKp and decreased interferon gamma. This immunosuppression was reversed by transfusion of autologous salvaged blood, suggesting that this fluid contained immunostimulants.	Univ Bristol, Transplantat Sci Grp, Bristol BS8 1TH, Avon, England; Univ Bristol, Bristol Heart Inst, Bristol BS8 1TH, Avon, England; N Bristol NHS Trust, Avon Orthopaed Ctr, Bristol, Avon, England; Iranian Blood Transfus Serv, Tehran, Iran	University of Bristol; University of Bristol; North Bristol NHS Trust	Bradley, BA (corresponding author), Univ Bristol, Southmead Hosp, Transplantat Sci Grp, Paul OGorman Lifeline Ctr, Bristol BS10 5NB, Avon, England.	ben.bradley@bris.ac.uk	Gharehbaghian, Ahmad/ABA-5947-2020	Bannister, Gordon/0000-0001-6068-2320				Andersson I, 2001, CAN J ANAESTH, V48, P251, DOI 10.1007/BF03019754; Andrews DM, 2003, NAT IMMUNOL, V4, P175, DOI 10.1038/ni880; Beckman N, 1999, TRANSFUS SCI, V21, P147, DOI 10.1016/S0955-3886(99)00089-2; Berguer R, 1999, ARCH SURG-CHICAGO, V134, P540, DOI 10.1001/archsurg.134.5.540; Biron CA, 2001, CURR OPIN IMMUNOL, V13, P458, DOI 10.1016/S0952-7915(00)00241-7; Case CP, 2001, CLIN CHEM, V47, P275; Gharehbaghian A, 2002, J IMMUNOL METHODS, V260, P69, DOI 10.1016/S0022-1759(01)00534-8; Godshall CJ, 2003, SHOCK, V19, P144, DOI 10.1097/00024382-200302000-00010; HEDDLE NM, 1992, TRANSFUSION, V32, P742, DOI 10.1046/j.1537-2995.1992.32893032102.x; HENDERSON MC, 1996, NETH MIL ACAD J, V49, P116; Hensler T, 1997, INFECT IMMUN, V65, P2283, DOI 10.1128/IAI.65.6.2283-2291.1997; Innerhofer P, 1999, TRANSFUSION, V39, P1089, DOI 10.1046/j.1537-2995.1999.39101089.x; Jacobi KE, 2000, J CLIN ANESTH, V12, P94, DOI 10.1016/S0952-8180(00)00122-7; Krohn CD, 1999, TRANSFUSION MED, V9, P125; Lausten SB, 1999, DIGEST SURG, V16, P471, DOI 10.1159/000018772; Leung KL, 2000, ANN SURG, V231, P506, DOI 10.1097/00000658-200004000-00008; MARQUET RL, 1993, TRANSFUSION, V33, P368, DOI 10.1046/j.1537-2995.1993.33593255594.x; MARSHALL WH, 1969, J EXP MED, V130, P327, DOI 10.1084/jem.130.2.327; Mehrotra PT, 1998, J IMMUNOL, V160, P2637; Mendes R, 2000, CYTOMETRY, V39, P72, DOI 10.1002/(SICI)1097-0320(20000101)39:1<72::AID-CYTO10>3.0.CO;2-R; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Newman JH, 1997, J BONE JOINT SURG BR, V79B, P630, DOI 10.1302/0301-620X.79B4.7272; Opelz G, 1997, TRANSPLANTATION, V63, P964, DOI 10.1097/00007890-199704150-00010; PETERS WR, 1989, DIS COLON RECTUM, V32, P749, DOI 10.1007/BF02562122; Quintiliani L, 1997, HAEMATOLOGICA, V82, P318; Ramirez G, 2002, TRANSFUSION, V42, P66, DOI 10.1046/j.1537-2995.2002.00005.x; Roy S, 2001, SURGERY, V130, P304, DOI 10.1067/msy.2001.116033; Shenolikar A, 1997, TRANSFUSION MED, V7, P277, DOI 10.1046/j.1365-3148.1997.d01-43.x; Thomas D, 2001, BRIT J ANAESTH, V86, P669, DOI 10.1093/bja/86.5.669; Tylman M, 2001, INTENS CARE MED, V27, P1379, DOI 10.1007/s001340101025; 2001, GUIDELINES BLOOD SER	31	54	57	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	2004	363	9414					1025	1030		10.1016/S0140-6736(04)15837-6	http://dx.doi.org/10.1016/S0140-6736(04)15837-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15051282				2022-12-28	WOS:000220497300008
J	Singh, B; Sung, LK; Matusop, A; Radhakrishnan, A; Shamsul, SSG; Cox-Singh, J; Thomas, A; Conway, DJ				Singh, B; Sung, LK; Matusop, A; Radhakrishnan, A; Shamsul, SSG; Cox-Singh, J; Thomas, A; Conway, DJ			A large focus of naturally acquired Plasmodium knowlesi infections in human beings	LANCET			English	Article							MALARIA DETECTION; SIMIAN MALARIAS; TRANSMISSION; PARASITES; PROTEINS; SEQUENCE	Background About a fifth of malaria cases in 1999 for the Kapit division of Malaysian Borneo had routinely been identified by microscopy as Plasmodium malariae, although these infections appeared atypical and a nested PCR assay failed to identify P malariae DNA. We aimed to investigate whether such infections could be attributable to a variant form of P malariae or a newly emergent Plasmodium species. Methods We took blood samples from 208 people with malaria in the Kapit division between March, 2000, and November, 2002. The small subunit ribosomal RNA and the circumsporozoite protein genes were sequenced for eight isolates that had been microscopically identified as P malariae. All blood samples were characterised with a genus-specific and species-specific nested PCR assay together with newly designed P knowlesi-specific primers. Findings All DNA sequences were phylogenetically indistinguishable from those of P knowlesi, a malaria parasite of long-tailed macaque monkeys, but were significantly different from other malaria parasite species. By PCR assay, 120 (58%) of 208 people with malaria tested positive for P knowlesi, whereas none was positive for P malariae. P knowlesi parasites in human erythrocytes were difficult to distinguish from P malariae by microscopy. Most of the P knowlesi infections were in adults and we did not note any clustering of cases within communities. P knowlesi infections were successfully treated with chloroquine and primaquine. Interpretation Naturally acquired P knowlesi infections, misdiagnosed by microscopy mainly as P malariae, accounted for over half of all malaria cases in our study. Morphological similarities between P knowlesi and P malariae necessitate the use of molecular methods for correct identification. Further work is needed to determine whether human P knowlesi infections in the Kapit division are acquired from macaque monkeys or whether a host switch to human beings has occurred.	Univ Malaysia Sarawak, Fac Med & Hlth Sci, Kuching 93150, Sarawak, Malaysia; Sarawak State Hlth Dept, Kuching, Sarawak, Malaysia; Biomed Primate Res Ctr, Dept Parasitol, Rijswijk, Netherlands; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England	University of Malaysia Sarawak; University of London; London School of Hygiene & Tropical Medicine	Singh, B (corresponding author), Univ Malaysia Sarawak, Fac Med & Hlth Sci, Kuching 93150, Sarawak, Malaysia.	bsingh@fmhs.unimas.my	Cox-Singh, Janet/A-3608-2009; Singh, Balbir/A-3610-2009; Janet Cox, Janet Cox/GLU-3838-2022	Janet Cox, Janet Cox/0000-0003-4878-5188; Singh, Balbir/0000-0002-9143-3965; Conway, David/0000-0002-8711-3037				CHIN W, 1965, SCIENCE, V149, P865, DOI 10.1126/science.149.3686.865; CHIN W, 1968, AM J TROP MED HYG, V17, P355, DOI 10.4269/ajtmh.1968.17.355; CHITNIS CE, 1994, J EXP MED, V180, P497, DOI 10.1084/jem.180.2.497; Ciuca M., 1937, Archives Roumaines de Pathologie Experimentale, V10, P5; COATNEY GR, 1968, AM J TROP MED HYG, V17, P147, DOI 10.4269/ajtmh.1968.17.147; Coatney RG., 1971, PRIMATE MALARIAS; COLLINS WE, 1967, J PARASITOL, V53, P841, DOI 10.2307/3276783; Cox-Singh J, 1997, INT J PARASITOL, V27, P1575, DOI 10.1016/S0020-7519(97)00147-1; DEANS JA, 1988, PARASITE IMMUNOL, V10, P535, DOI 10.1111/j.1365-3024.1988.tb00241.x; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; Felsenstein J, PHYLIP PHYLOGENY INF; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; FONG YL, 1971, T ROY SOC TROP MED H, V65, P839, DOI 10.1016/0035-9203(71)90103-9; Garnham PCC., 1966, MALARIA PARASITES OT; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Kawamoto F, 2002, J PARASITOL, V88, P350, DOI 10.1645/0022-3395(2002)088[0350:UPMLPI]2.0.CO;2; Knowles R, 1932, Ind Med Gaz, V67, P301; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Liu Q, 1998, J CLIN MICROBIOL, V36, P3378, DOI 10.1128/JCM.36.11.3378-3381.1998; McCutchan TF, 1996, P NATL ACAD SCI USA, V93, P11889, DOI 10.1073/pnas.93.21.11889; Nicol W. D., 1935, British Medical Journal, V1935, P760, DOI 10.1136/bmj.2.3902.760; Ozwara H, 2003, INFECT IMMUN, V71, P4375, DOI 10.1128/IAI.71.8.4375-4381.2003; Rogers WO, 2002, INFECT IMMUN, V70, P4329, DOI 10.1128/IAI.70.8.4329-4335.2002; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sandosham A., 1959, MALARIOLOGY SPECIAL; Singh B, 1997, INT J PARASITOL, V27, P1135, DOI 10.1016/S0020-7519(97)00111-2; Singh B, 1999, AM J TROP MED HYG, V60, P687, DOI 10.4269/ajtmh.1999.60.687; Singh B, 2001, TRENDS PARASITOL, V17, P597, DOI 10.1016/S1471-4922(01)02148-1; TRAPE JF, 1985, T ROY SOC TROP MED H, V79, P181, DOI 10.1016/0035-9203(85)90329-3; WARREN M, 1963, J PARASITOL, V49, P892, DOI 10.2307/3275715	30	715	748	1	70	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 27	2004	363	9414					1017	1024		10.1016/S0140-6736(04)15836-4	http://dx.doi.org/10.1016/S0140-6736(04)15836-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807JH	15051281	Green Submitted			2022-12-28	WOS:000220497300007
J	Rowe, S; MacLean, CH; Shekelle, PG				Rowe, S; MacLean, CH; Shekelle, PG			Preventing visual loss from chronic eye disease in primary care - Scientific review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							TREATMENT DIABETIC-RETINOPATHY; ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE; CAUSE-SPECIFIC PREVALENCE; AGE-RELATED MACULOPATHY; OPEN-ANGLE GLAUCOMA; RISK-FACTORS; DIETARY-FAT; COST-EFFECTIVENESS; MICROVASCULAR COMPLICATIONS; CATARACT-EXTRACTION	Context Vision loss is common in the United States and its prevalence increases with age. Visual disability significantly impacts quality of life and increases the risk of injury. Although at least 40% of blindness in the United States is either preventable or treatable with timely diagnosis and intervention, many people with vision loss are undiagnosed and untreated. Objective To review the evidence regarding screening and management of eye disorders and visual disability among adults in the primary care setting. Data Sources and Study Selection MEDLINE, HealthSTAR, EMBASE, The Cochrane Database of Systematic Reviews, and the National Guidelines Clearinghouse were searched for articles and practice guidelines about screening and management of eye diseases and vision loss among adults in the primary care setting using key words and free-text terms, such as vision screening, glaucoma prevention and control, from 1985 to 2003. References in these articles and those suggested by experts in eye care, vision loss, and vision screening were reviewed as well. Data Extraction Articles were Searched for the most clinically important information and emphasized randomized controlled trials where available. Data Synthesis Most major guidelines recommend periodic referral of older adults to an eye care professional for comprehensive evaluation to detect eye diseases and visual disability. The value of routine screening for vision loss in the primary care setting has not been established. Timely identification and treatment of eye diseases can substantially reduce the incidence and prevalence of visual disability among-older adults. Optimizing management of systemic diseases, such as diabetes, hypertension, and hyperlipidemia, significantly reduces the risk of related eye disorders. Conclusions Primary care clinicians can play a vital role in preserving vision in their patients by managing systemic diseases that impact eye health and by ensuring that patients undergo periodic evaluations by eye care professionals and receive needed eye care.	Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02119 USA; RAND Hlth, Santa Monica, CA USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; Greater Los Angeles Vet Affairs Hlth Care Syst, Dept Med, Los Angeles, CA USA	Boston University; RAND Corporation; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Rowe, S (corresponding author), Boston Univ, Sch Med, Dept Ophthalmol, Room L-907,720 Harrison Ave, Boston, MA 02119 USA.	srowe@bu.edu		Rowe, Susannah/0000-0002-2061-6828				Adler AI, 2000, BMJ-BRIT MED J, V321, P412, DOI 10.1136/bmj.321.7258.412; Aiello LP, 1998, DIABETES CARE, V21, P143, DOI 10.2337/diacare.21.1.143; Aiello LP, 2001, AM J OPHTHALMOL, V132, P760, DOI 10.1016/S0002-9394(01)01124-2; *AM AC FAM PHYS, 2001, SUMM AAFP POL REC PE; *AM AC OPHTH, 2000, PRIM OP ANGL GLAUC; *AM AC OPHTH, 2000, COMPR AD MED EYE EV; *AM AC OPHTH, 1997, REFR ERR; *AM AC OPHTH, REC SCREEN CHLOR HYP; *AM AC OPHTH, 1998, PREF PRACT PATT DIAB; *AM AC OPHTH, 2003, AG REL MAC DEG; *AM AC OPHTH, 2001, CAT AD EYE; *AM ASS CLIN END, 2002, ENDOCR PRACT S1, V8, P40; *AM DIAB ASS, 1929, DIABETES CARE, V25, pS90; *AM OPT ASS CONS P, COMPR AD EYE VIS; American Diabetes Association, 1999, DIABETES CARE, V22, pS1; American Optometric Association, 2002, OPT CLIN PRACT GUID; Anand R, 2000, OPHTHALMOLOGY, V107, P2224; [Anonymous], 1991, Ophthalmology, V98, P823; Arroyo JG, 2002, BRIT J OPHTHALMOL, V86, P3, DOI 10.1136/bjo.86.1.3; BARTALENA L, 1989, J ENDOCRINOL INVEST, V12, P733, DOI 10.1007/BF03350047; BERTELSEN JB, 1994, THYROID, V4, P327, DOI 10.1089/thy.1994.4.327; Bursell SE, 2001, OPHTHALMOLOGY, V108, P572, DOI 10.1016/S0161-6420(00)00604-7; Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509; Cheng A. C. K., 2000, Hong Kong Medical Journal, V6, P195; Chew EY, 1996, ARCH OPHTHALMOL-CHIC, V114, P1079, DOI 10.1001/archopht.1996.01100140281004; Cho E, 2001, AM J CLIN NUTR, V73, P209; Christen WG, 2000, JAMA-J AM MED ASSOC, V284, P713, DOI 10.1001/jama.284.6.713; Congdon NG, 2001, BRIT J OPHTHALMOL, V85, P516, DOI 10.1136/bjo.85.5.516; CRUICKSHANKS KJ, 1992, AM J PUBLIC HEALTH, V82, P1658, DOI 10.2105/AJPH.82.12.1658; Davis MD, 1998, INVEST OPHTH VIS SCI, V39, P233; *DEP VET AFF, 2000, SCREEN GLAUC PRIM CA; Diabetes Control and Complications, 2000, DIABETES CARE, V23, P1084; Eastman RC, 1997, DIABETES CARE, V20, P735, DOI 10.2337/diacare.20.5.735; EVA PR, 1982, BRIT J OPHTHALMOL, V66, P500, DOI 10.1136/bjo.66.8.500; Ferris FL, 1996, DIABETES CARE, V19, P1291, DOI 10.2337/diacare.19.11.1291; Fong DS, 2001, ARCH OPHTHALMOL-CHIC, V119, P758, DOI 10.1001/archopht.119.5.758; Friedman DS, VISION PROBLEMS US P; GOLDBLOOM R, 1995, CAN MED ASSOC J, V152, P1211; Guerci B, 1999, DIABETES METAB, V25, P412; Guven D, 1999, EUR J OPHTHALMOL, V9, P43; GUYER DR, 1985, ARCH OPHTHALMOL-CHIC, V103, P1136; GWINUP G, 1976, DIABETES, V25, P29, DOI 10.2337/diabetes.25.1.29; Hagedoorn A, 1966, Arch Ophthalmol, V76, P604; HAYREH SS, 1994, AM J OPHTHALMOL, V117, P603, DOI 10.1016/S0002-9394(14)70067-4; Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833; HILLER R, 1983, AM J EPIDEMIOL, V118, P239, DOI 10.1093/oxfordjournals.aje.a113631; *I CLINSYST IMPR, HLTH CAR GUID PREV S; *INT DIAB CTR, 2001, TYP 2 DIAB PRACT GUI; JAKOBIEC FA, 1999, PRINCIPLES PRACTICE; Javitt JC, 2000, JAMA-J AM MED ASSOC, V284, P437, DOI 10.1001/jama.284.4.437; Javitt JC, 1996, ANN INTERN MED, V124, P164, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00017; Javitt JC, 1996, ANNU REV PUBL HEALTH, V17, P159; JAVITT JC, 1991, NEW ENGL J MED, V325, P1418, DOI 10.1056/NEJM199111143252005; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; Katz J, 1997, INVEST OPHTH VIS SCI, V38, P334; KLEIN BEK, 1991, OPHTHALMOLOGY, V98, P1261; Klein BEK, 1997, AM J OPHTHALMOL, V123, P338, DOI 10.1016/S0002-9394(14)70129-1; Klein BEK, 1999, AM J OPHTHALMOL, V128, P652, DOI 10.1016/S0002-9394(99)00222-6; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P244, DOI 10.1001/archopht.1989.01070010250031; Klein R, 1998, AM J EPIDEMIOL, V147, P103; KLEIN R, 1985, OPHTHALMOLOGY, V92, P485; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023; KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310; Klein R, 2002, BRIT J OPHTHALMOL, V86, P84, DOI 10.1136/bjo.86.1.84; Lee SC, 2001, ARCH OPHTHALMOL-CHIC, V119, P509; Leibowitz HM, 2000, NEW ENGL J MED, V343, P345, DOI 10.1056/NEJM200008033430507; Lotan R, 1999, J NATL CANCER I, V91, P7, DOI 10.1093/jnci/91.1.7; Maberley DAL, 2002, OPHTHAL EPIDEMIOL, V9, P153, DOI 10.1076/opep.9.3.153.1515; Mann K, 1999, EXP CLIN ENDOCR DIAB, V107, pS164, DOI 10.1055/s-0029-1212176; MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034; Margulies L J, 1995, Curr Opin Ophthalmol, V6, P97, DOI 10.1097/00055735-199512000-00017; McCarty CA, 1999, AM J OPHTHALMOL, V128, P446, DOI 10.1016/S0002-9394(99)00218-4; Miki E, 2001, DIABETOLOGIA, V44, pS31, DOI 10.1007/PL00002937; Moss SE, 1998, OPHTHALMOLOGY, V105, P998, DOI 10.1016/S0161-6420(98)96025-0; Moss SE, 2000, ARCH OPHTHALMOL-CHIC, V118, P1264; MOSS SE, 1985, OPHTHALMOLOGY, V92, P62; Munoz B, 1999, ANN EPIDEMIOL, V9, P53, DOI 10.1016/S1047-2797(98)00026-X; *NAT COMM QUAL ASS, DIAB QUAL IMPR PROJ; *NAT EYE I, NEI STAT VIS SCREEN; *NAT GUID CLEAR, GUID TITL MAN DIAB M; Okamoto F, 2000, BRIT J OPHTHALMOL, V84, P1097, DOI 10.1136/bjo.84.10.1097; Paolini M, 1999, NATURE, V398, P760, DOI 10.1038/19655; PRUMMEL MF, 1993, JAMA-J AM MED ASSOC, V269, P479, DOI 10.1001/jama.269.4.479; Quigley HA, 1997, INVEST OPHTH VIS SCI, V38, P83; Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1; Recchia F M, 2000, Curr Opin Ophthalmol, V11, P462, DOI 10.1097/00055735-200012000-00013; SALIVE ME, 1992, OPHTHALMOLOGY, V99, P1840; Salomon O, 1999, OPHTHALMOLOGY, V106, P739, DOI 10.1016/S0161-6420(99)90159-8; SANDSTEAD HH, 1995, AM J CLIN NUTR, V61, p621S, DOI 10.1093/ajcn/61.3.621S; Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHINGLETON BJ, 1991, NEW ENGL J MED, V325, P408; Sims RV, 1998, J AM GERIATR SOC, V46, P556, DOI 10.1111/j.1532-5415.1998.tb01070.x; SINGER DE, 1992, ANN INTERN MED, V116, P660, DOI 10.7326/0003-4819-116-8-660; SMEETH L, 2003, COCHRANE DB SYST REV, V1; Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; Sommer A, 1996, Curr Opin Ophthalmol, V7, P93, DOI 10.1097/00055735-199604000-00016; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Stellingwerf C, 2001, DIABETES CARE, V24, P2086, DOI 10.2337/diacare.24.12.2086; Stratton IM, 2001, DIABETOLOGIA, V44, P156, DOI 10.1007/s001250051594; Talks SJ, 1996, EYE, V10, P321, DOI 10.1038/eye.1996.67; TALLSTEDT L, 1993, ACTA ENDOCRINOL-COP, V129, P147, DOI 10.1530/acta.0.1290147; Taylor H R, 1989, Trans Am Ophthalmol Soc, V87, P802; TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369; TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806; TROBE J, 2001, PHYS GUIDE EYE CARE; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Vijan S, 2000, JAMA-J AM MED ASSOC, V283, P889, DOI 10.1001/jama.283.7.889; Vijan S, 1997, ANN INTERN MED, V127, P788, DOI 10.7326/0003-4819-127-9-199711010-00003; VINGER PF, 1970, AM J OPHTHALMOL, V70, P563, DOI 10.1016/0002-9394(70)90890-1; Wake N, 2000, DIABETES RES CLIN PR, V48, P201, DOI 10.1016/S0168-8227(00)00122-4; WANG F, 1994, ARCH INTERN MED, V154, P1821, DOI 10.1001/archinte.154.16.1821; Weintraub JM, 2002, AM J EPIDEMIOL, V155, P72, DOI 10.1093/aje/155.1.72; WEST S, 1989, ARCH OPHTHALMOL-CHIC, V107, P1166, DOI 10.1001/archopht.1989.01070020232031; West SK, 1997, INVEST OPHTH VIS SCI, V38, P72; WINSA B, 1993, ACTA ENDOCRINOL-COP, V128, P156, DOI 10.1530/acta.0.1280156; Yannuzzi LA, 1996, ARCH OPHTHALMOL-CHIC, V114, P545; YANNUZZI LA, 1993, AM J OPHTHALMOL, V116, P286; ZADNIK K, 1994, JAMA-J AM MED ASSOC, V271, P1323, DOI 10.1001/jama.271.17.1323	121	70	72	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 24	2004	291	12					1487	1496		10.1001/jama.291.12.1487	http://dx.doi.org/10.1001/jama.291.12.1487			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805UI	15039416				2022-12-28	WOS:000220390800030
J	Bennett, CH; Shor, PW				Bennett, CH; Shor, PW			Quantum channel capacities	SCIENCE			English	Editorial Material									IBM Corp, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA; MIT, Dept Math, Cambridge, MA 02139 USA	International Business Machines (IBM); Massachusetts Institute of Technology (MIT)	Bennett, CH (corresponding author), IBM Corp, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA.	shor@math.mit.edu	Bennett, Charles H. H/G-9082-2013	Bennett, Charles H. H/0000-0003-0921-2643				BENNETT CH, 1992, PHYS REV LETT, V69, P2881, DOI 10.1103/PhysRevLett.69.2881; BENNETT CH, 1993, PHYS REV LETT, V70, P1895, DOI 10.1103/PhysRevLett.70.1895; Collins D, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.032321; DEVETAK I, UNPUB; Holevo A. S., 1973, PROBL INF T, V9, P177; Holevo AS, 1998, IEEE T INFORM THEORY, V44, P269, DOI 10.1109/18.651037; JOZSA R, 1995, PHYS REV A, V51, P2738; Pomeransky AA, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.032317; Schumacher B, 1997, PHYS REV A, V56, P131, DOI 10.1103/PhysRevA.56.131; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x	11	16	16	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1784	+		10.1126/science.1092381	http://dx.doi.org/10.1126/science.1092381			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031486				2022-12-28	WOS:000220281600034
J	Ma, LS; Bi, ZY; Bartels, A; Robertsson, L; Zucco, M; Windeler, RS; Wilpers, G; Oates, C; Hollberg, L; Diddams, SA				Ma, LS; Bi, ZY; Bartels, A; Robertsson, L; Zucco, M; Windeler, RS; Wilpers, G; Oates, C; Hollberg, L; Diddams, SA			Optical frequency synthesis and comparison with uncertainty at the 10(-19) level	SCIENCE			English	Article							CLOCKWORK	A femtosecond laser-based optical frequency synthesizer is referenced to an optical standard, and we use it to demonstrate the generation and control of the frequency of electromagnetic fields over 100 terahertz of bandwidth with fractional uncertainties approaching 1 part in 10(19). The reproducibility of this performance is verified by comparison of different types of femtosecond laser based frequency synthesizers from three laboratories.	Natl Inst Stand & Technol, Boulder, CO 80305 USA; Bur Int Poids & Mesures, F-92312 Sevres, France; E China Normal Univ, Dept Phys, Shanghai 200062, Peoples R China; OFS Labs, Murray Hill, NJ 07974 USA	National Institute of Standards & Technology (NIST) - USA; East China Normal University; Furukawa Electric	Ma, LS (corresponding author), Natl Inst Stand & Technol, 325 Broadway, Boulder, CO 80305 USA.	lsma@phy.ecnu.edu.cn; sdiddams@boulder.nist.gov	Bartels, Albrecht O/B-3456-2009; Bartels, Albrecht/N-5801-2019; Zucco, Massimo/E-7614-2011; Diddams, Scott A/L-2819-2013	Zucco, Massimo/0000-0002-3187-6852; Diddams, Scott A/0000-0002-2144-0764				ALLAN DW, 1987, IEEE T ULTRASON FERR, V34, P647, DOI 10.1109/T-UFFC.1987.26997; Bartels A, 2003, OPT LETT, V28, P663, DOI 10.1364/OL.28.000663; Bize S, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.150802; DEHMELT HG, 1982, IEEE T INSTRUM MEAS, V31, P83, DOI 10.1109/TIM.1982.6312526; Diddams SA, 2002, OPT LETT, V27, P58, DOI 10.1364/OL.27.000058; Diddams SA, 2001, SCIENCE, V293, P825, DOI 10.1126/science.1061171; ECKSTEIN JN, 1978, PHYS REV LETT, V40, P847, DOI 10.1103/PhysRevLett.40.847; GILL P, 2002, P 6 S FREQ STAND MET, P12703; Holzwarth R, 2000, PHYS REV LETT, V85, P2264, DOI 10.1103/PhysRevLett.85.2264; Karshenboim SG, 2000, CAN J PHYS, V78, P639, DOI 10.1139/cjp-78-7-639; LIRA I, 2002, AH MEAS SCI, pR11; Marion H, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.150801; Oates CW, 2000, OPT LETT, V25, P1603, DOI 10.1364/OL.25.001603; PRESTAGE JD, 1995, PHYS REV LETT, V74, P3511, DOI 10.1103/PhysRevLett.74.3511; Sen Gupta A., 1999, Proceedings of the 1999 Joint Meeting of the European Frequency and Time Forum and the IEEE International Frequency Control Symposium (Cat. No.99CH36313), P615, DOI 10.1109/FREQ.1999.841382; Shelton RK, 2001, SCIENCE, V293, P1286, DOI 10.1126/science.1061754; Stenger J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.073601; Udem T, 2002, NATURE, V416, P233, DOI 10.1038/416233a; Udem T, 1999, OPT LETT, V24, P881, DOI 10.1364/OL.24.000881; Udem T, 1999, PHYS REV LETT, V82, P3568, DOI 10.1103/PhysRevLett.82.3568; Webb JK, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.091301; Ye J, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.270801; Young BC, 1999, PHYS REV LETT, V82, P3799, DOI 10.1103/PhysRevLett.82.3799; Zimmermann M, 2004, OPT LETT, V29, P310, DOI 10.1364/OL.29.000310	24	253	271	4	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1843	1845		10.1126/science.1095092	http://dx.doi.org/10.1126/science.1095092			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031498	Green Submitted			2022-12-28	WOS:000220281600048
J	Leung, C; Lingbeek, M; Shakhova, O; Liu, J; Tanger, E; Saremaslani, P; van Lohuizen, M; Marino, S				Leung, C; Lingbeek, M; Shakhova, O; Liu, J; Tanger, E; Saremaslani, P; van Lohuizen, M; Marino, S			Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas	NATURE			English	Article							SONIC HEDGEHOG; STEM-CELLS; N-MYC; C-MYC; PROLIFERATION; MICE; TRANSFORMATION; EXPRESSION; MUTATIONS; BIOLOGY	Overexpression of the polycomb group gene Bmi1 promotes cell proliferation and induces leukaemia through repression of Cdkn2a (also known as ink4a/Arf) tumour suppressors(1,2). Conversely, loss of Bmi1 leads to haematological defects and severe progressive neurological abnormalities in which de-repression of the ink4a/Arf locus is critically implicated(1,3). Here, we show that Bmi1 is strongly expressed in proliferating cerebellar precursor cells in mice and humans. Using Bmi1-null mice we demonstrate a crucial role for Bmi1 in clonal expansion of granule cell precursors both in vivo and in vitro. Deregulated proliferation of these progenitor cells, by activation of the sonic hedgehog (Shh) pathway, leads to medulloblastoma development(4). We also demonstrate linked overexpression of BMI1 and patched (PTCH), suggestive of SHH pathway activation, in a substantial fraction of primary human medulloblastomas. Together with the rapid induction of Bmi1 expression on addition of Shh or on overexpression of the Shh target Gli1 in cerebellar granule cell cultures, these findings implicate BMI1 overexpression as an alternative or additive mechanism in the pathogenesis of medulloblastomas, and highlight a role for Bmi1-containing polycomb complexes in proliferation of cerebellar precursor cells.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Univ Zurich, Dept Pathol, Inst Clin Pathol, CH-8091 Zurich, Switzerland	Netherlands Cancer Institute; University of Zurich	Marino, S (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	m.v.lohuizen@nki.nl; silvia.marino@usz.ch		Marino, Silvia/0000-0002-9612-2883; Liu, James/0000-0002-1907-7150				Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dong J, 2000, Hum Mutat, V16, P89, DOI 10.1002/1098-1004(200007)16:1<89::AID-HUMU18>3.3.CO;2-Z; Herms J, 2000, INT J CANCER, V89, P395; Huard JMT, 1999, DEVELOPMENT, V126, P1927; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Lee Y, 2003, CANCER RES, V63, P5428; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Marino S, 2000, GENE DEV, V14, P994; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Pietsch T, 1997, CANCER RES, V57, P2085; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Rubin JB, 2002, CANCER CELL, V2, P7, DOI 10.1016/S1535-6108(02)00090-9; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Smith KS, 2003, MOL CELL, V12, P393, DOI 10.1016/S1097-2765(03)00277-6; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; TOMLINSON FH, 1994, MAYO CLIN PROC, V69, P359, DOI 10.1016/S0025-6196(12)62221-6; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V	25	439	475	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	2004	428	6980					337	341		10.1038/nature02385	http://dx.doi.org/10.1038/nature02385			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15029199				2022-12-28	WOS:000220250200048
J	Torre, R; Bartolini, P; Righini, R				Torre, R; Bartolini, P; Righini, R			Structural relaxation in supercooled water by time-resolved spectroscopy	NATURE			English	Article							MODE-COUPLING THEORY; KERR-EFFECT MEASUREMENTS; GLASS-FORMING LIQUID; DYNAMICS; TRANSITION	Water has many kinetic and thermodynamic properties that exhibit an anomalous dependence on temperature(1-5), in particular in the supercooled phase. These anomalies have long been interpreted in terms of underlying structural causes, and their experimental characterization points to the existence of a singularity at a temperature of about 225 K. Further insights into the nature and origin of this singularity might be gained by completely characterizing the structural relaxation in supercooled water(6). But until now, such a characterization has only been realized in simulations(7-9) that agree with the predictions of simple mode-coupling theory(10); unambiguous experimental support for this surprising conclusion is, however, not yet available(11-14). Here we report time-resolved optical Kerr effect measurements(15) that unambiguously demonstrate that the structural relaxation of liquid and weakly supercooled water follows the behaviour predicted by simple mode-coupling theory. Our findings thus support the interpretation(7-9) of the singularity as a purely dynamical transition. That is, the anomalous behaviour of weakly supercooled water can be explained using a fully dynamic model and without needing to invoke a thermodynamic origin. In this regard, water behaves like many other, normal molecular liquids that are fragile glass-formers.	Univ Florence, European Lab Nonlinear Spect, I-50019 Florence, Italy; Univ Florence, Inst Nazl Fis Mat, I-50019 Florence, Italy; Univ Florence, Dipartimento Fis, I-50019 Florence, Italy; Univ Florence, Dipartimento Chim, I-50019 Florence, Italy	University of Florence; University of Florence; University of Florence; University of Florence	Torre, R (corresponding author), Univ Florence, European Lab Nonlinear Spect, Polo Sci, I-50019 Florence, Italy.	torre@lens.unifi.it	Torre, Renato/G-6313-2012; bartolini, paolo/R-2900-2016; de la Torre, Rafael/D-3561-2018; Righini, Roberto/C-8968-2014	Torre, Renato/0000-0003-3182-9906; de la Torre, Rafael/0000-0002-6765-1866; Righini, Roberto/0000-0003-0260-0248; Bartolini, Paolo/0000-0002-5447-9868				ANGELL CA, 1983, ANNU REV PHYS CHEM, V34, P593, DOI 10.1146/annurev.pc.34.100183.003113; ANGELL CA, 1981, WATER COMPREHENSIVE, V7, P1; Bartolini P, 1999, J CHEM PHYS, V110, P8653, DOI 10.1063/1.478773; Bellissent-Funel MC, 2000, PHYS REV LETT, V85, P3644, DOI 10.1103/PhysRevLett.85.3644; CASTNER EW, 1995, J CHEM PHYS, V102, P653, DOI 10.1063/1.469177; Debenedetti P. G., 1996, METASTABLE LIQUIDS, P305; Debenedetti PG, 2001, NATURE, V410, P259, DOI 10.1038/35065704; Debenedetti PG, 2003, PHYS TODAY, V56, P40, DOI 10.1063/1.1595053; Fabbian L, 1999, PHYS REV E, V60, P5768, DOI 10.1103/PhysRevE.60.5768; Foggi P, 1997, J PHYS CHEM A, V101, P7029, DOI 10.1021/jp962760v; Franzese G, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.011103; GOTZE W, 1992, REP PROG PHYS, V55, P241, DOI 10.1088/0034-4885/55/3/001; MISHINA O, 1995, NATURE, V396, P329; Palese S, 1996, J PHYS CHEM-US, V100, P10380, DOI 10.1021/jp960266l; PALESE S, 1994, J PHYS CHEM-US, V98, P6308, DOI 10.1021/j100076a013; POOLE PH, 1992, NATURE, V360, P324, DOI 10.1038/360324a0; RICCI MA, 1989, MOL PHYS, V67, P19, DOI 10.1080/00268978900100901; RIGHINI R, 1993, SCIENCE, V262, P1386, DOI 10.1126/science.262.5138.1386; Ronne C, 1999, PHYS REV LETT, V82, P2888, DOI 10.1103/PhysRevLett.82.2888; Sastry S, 2003, NAT MATER, V2, P739, DOI 10.1038/nmat994; Sciortino F, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.155701; Sciortino F, 1996, PHYS REV E, V54, P6331, DOI 10.1103/PhysRevE.54.6331; Sciortino F, 2000, CHEM PHYS, V258, P307, DOI 10.1016/S0301-0104(00)00188-9; SOKOLOV AP, 1995, PHYS REV B, V51, P12865, DOI 10.1103/PhysRevB.51.12865; SPEEDY RJ, 1976, J CHEM PHYS, V65, P851, DOI 10.1063/1.433153; Torre R, 2000, EUROPHYS LETT, V52, P324, DOI 10.1209/epl/i2000-00442-2; Torre R, 1998, PHYS REV E, V57, P1912, DOI 10.1103/PhysRevE.57.1912; Winkler K, 2000, J CHEM PHYS, V113, P4674, DOI 10.1063/1.1288690; Winkler K, 2002, PHYS CHEM CHEM PHYS, V4, P2144, DOI 10.1039/b200299j	29	225	227	2	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 18	2004	428	6980					296	299		10.1038/nature02409	http://dx.doi.org/10.1038/nature02409			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803SG	15029190	Green Submitted			2022-12-28	WOS:000220250200037
J	Fagiolini, M; Fritschy, JM; Low, K; Mohler, H; Rudolph, U; Hensch, TK				Fagiolini, M; Fritschy, JM; Low, K; Mohler, H; Rudolph, U; Hensch, TK			Specific GABA(A) circuits for visual cortical plasticity	SCIENCE			English	Article							EXPERIENCE-DEPENDENT PLASTICITY; ACID(A) RECEPTOR SUBTYPES; ALPHA-SUBUNITS; PYRAMIDAL CELLS; CRITICAL-PERIOD; CORTEX; INHIBITION; MOUSE; LOCALIZATION; PHARMACOLOGY	Weak inhibition within visual cortex early in life prevents experience-dependent plasticity. Loss of responsiveness to an eye deprived of vision can be initiated prematurely by enhancing gamma-aminobutyric acid (GABA)-mediated transmission with benzodiazepines. Here, we use a mouse "knockin" mutation to alpha subunits that renders individual GABA type A(GABA(A)) receptors insensitive to diazepam to show that a particular inhibitory network controls expression of the critical period. Only alpha1-containing circuits were found to drive cortical plasticity, whereas alpha2-enriched connections separately regulated neuronal. ring. This dissociation carries implications for models of brain development and the safe design of benzodiazepines for use in infants.	RIKEN, Brain Sci Inst, Lab Neuronal Circuit Dev, Wako, Saitama 3510198, Japan; Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, Dept Chem & Appl Biosci, CH-8057 Zurich, Switzerland	RIKEN; University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Hensch, TK (corresponding author), RIKEN, Brain Sci Inst, Lab Neuronal Circuit Dev, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	hensch@postmn.riken.go.jp	Hensch, Takao/L-4182-2019	Fritschy, Jean-Marc/0000-0002-8552-3702; Low, Karin/0000-0002-5052-3892; fagiolini, michela/0000-0003-2807-803X				Benson JA, 1998, FEBS LETT, V431, P400, DOI 10.1016/S0014-5793(98)00803-5; Bi GQ, 2001, ANNU REV NEUROSCI, V24, P139, DOI 10.1146/annurev.neuro.24.1.139; Bosman LWJ, 2002, J PHYSIOL-LONDON, V545, P169, DOI 10.1113/jphysiol.2002.026534; Buzas P, 2001, J COMP NEUROL, V437, P259, DOI 10.1002/cne.1282; Chen L, 2001, MOL BRAIN RES, V88, P135, DOI 10.1016/S0169-328X(01)00042-0; Crestani F, 2002, P NATL ACAD SCI USA, V99, P8980, DOI 10.1073/pnas.142288699; DAW N, 1995, VISUAL DEV; Dunning DD, 1999, J NEUROPHYSIOL, V82, P3286, DOI 10.1152/jn.1999.82.6.3286; Fagiolini M, 2000, NATURE, V404, P183, DOI 10.1038/35004582; Feldman DE, 2000, NAT NEUROSCI, V3, P303, DOI 10.1038/73849; Fritschy JM, 1998, J COMP NEUROL, V390, P194; Galarreta M, 2001, SCIENCE, V292, P2295, DOI 10.1126/science.1061395; Gordon JA, 1996, J NEUROSCI, V16, P3274; Hensch TK, 2004, SCIENCE, V303, P1678, DOI 10.1126/science.1091031; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; Klausberger T, 2002, J NEUROSCI, V22, P2513, DOI 10.1523/JNEUROSCI.22-07-02513.2002; Kralic JE, 2002, J PHARMACOL EXP THER, V302, P1037, DOI 10.1124/jpet.102.036665; Low K, 2000, SCIENCE, V290, P131, DOI 10.1126/science.290.5489.131; Matsuda Yuji, UNPUB; Nusser Z, 1996, P NATL ACAD SCI USA, V93, P11939, DOI 10.1073/pnas.93.21.11939; Pouille F, 2001, SCIENCE, V293, P1159, DOI 10.1126/science.1060342; Prusky GT, 2003, EUR J NEUROSCI, V17, P167, DOI 10.1046/j.1460-9568.2003.02420.x; Rudolph U, 2001, TRENDS PHARMACOL SCI, V22, P188, DOI 10.1016/S0165-6147(00)01646-1; Rudolph U, 1999, NATURE, V401, P796, DOI 10.1038/44579; Sanna E, 2002, EUR J PHARMACOL, V451, P103, DOI 10.1016/S0014-2999(02)02191-X; SHAW C, 1987, DEV BRAIN RES, V37, P67, DOI 10.1016/0165-3806(87)90229-X; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Somogyi P, 1998, BRAIN RES REV, V26, P113, DOI 10.1016/S0165-0173(97)00061-1	29	352	355	3	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1681	1683		10.1126/science.1091032	http://dx.doi.org/10.1126/science.1091032			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15017002				2022-12-28	WOS:000220151400047
J	Anderson, HR; Ruggles, R; Strachan, DP; Austin, JB; Burr, M; Jeffs, D; Standring, P; Steriu, A; Goulding, R				Anderson, HR; Ruggles, R; Strachan, DP; Austin, JB; Burr, M; Jeffs, D; Standring, P; Steriu, A; Goulding, R			Trends in prevalence of symptoms of asthma, hay fever, and eczema in 12-14 year olds in the British Isles, 1995-2002: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD; ALLERGIES; ISAAC		St George Hosp, Sch Med, Dept Community Hlth Sci, London SW17 0RE, England; Univ Aberdeen, Highlands & Isl Hlth Res Inst, Inverness IV2 3ED, Scotland; Univ Wales Coll Med, Dept Epidemiol State & PUbl Hlth, Cardiff CF14 4XN, S Glam, Wales; Board Hlth, St Martins GY4 6UU, Guernsey, England; Dept Hlth & Social Secur, Douglas IM1 3QA, Isle Of Man, England; Harvey Educ Ctr, St Helier JE1 3QZ, Jersey, England	St Georges University London; UHI Millennium Institute; University of Aberdeen; Cardiff University	Anderson, HR (corresponding author), St George Hosp, Sch Med, Dept Community Hlth Sci, London SW17 0RE, England.	r.anderson@sghms.ac.uk	Anderson, Hugh R/A-7417-2016; Steriu, Andreea/AAQ-5127-2021	Steriu, Andreea/0000-0002-2998-8644				ANDERSON HR, 2002, EFFECTIVE MANAGEMENT; Asher MI, 1998, EUR RESPIR J, V12, P315; Jeffs D, 2000, J R SOC PROMO HEALTH, V120, P236, DOI 10.1177/146642400012000411; Kaur B, 1998, BRIT MED J, V316, P118; MAN KGN, 2001, THORAX, V56, P312	5	136	139	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 1	2004	328	7447					1052	1053		10.1136/bmj.38057.583727.47	http://dx.doi.org/10.1136/bmj.38057.583727.47			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817JT	15028634	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000221174500018
J	Bellanne-Chantelot, C; Chauveau, D; Gautier, JF; Dubois-Laforgue, D; Clauin, S; Beaufils, S; Wilhelm, JM; Boitard, C; Noel, LH; Velho, G; Timsit, J				Bellanne-Chantelot, C; Chauveau, D; Gautier, JF; Dubois-Laforgue, D; Clauin, S; Beaufils, S; Wilhelm, JM; Boitard, C; Noel, LH; Velho, G; Timsit, J			Clinical spectrum associated with hepatocyte nuclear factor-1 beta mutations	ANNALS OF INTERNAL MEDICINE			English	Article							HYPOPLASTIC GLOMERULOCYSTIC KIDNEY; FRAMESHIFT MUTATION; INSULIN-SECRETION; RENAL DYSFUNCTION; DIABETES-MELLITUS; JAPANESE SUBJECTS; HNF-1-BETA GENE; GENITAL-TRACT; DISEASE; IDENTIFICATION	Background: maturity-onset diabetes of the young type 5 (MODY5), a type of dominantly inherited diabetes mellitus and nephropathy, has been associated with mutations of the hepatocyte nuclear factor-1beta (HNF-1beta) gene, mostly generating truncated protein. Various phenotypes, including urogenital malformations, are related to HNF-1beta mutations. Objective: To describe clinical and genetic findings in 13 patients with 8 novel HNF-1beta mutations. Design: Multicenter, descriptive study. Setting: 2 departments of diabetes, 1 department of internal medicine, and 1 department of nephrology. Participants: 8 probands with diabetes diagnosed before 40 years of age and nondiabetic kidney disease who were selected independent of their family history of diabetes, and 5 offspring. Measurements: Characteristics of diabetes, renal function and structure, genital tract abnormalities, pancreas structure, insulin secretion, exocrine pancreas function, and liver test results. Results: All mutations, including 5 missense changes, were found in the DNA-binding domain. Cosegregation of the mutation and MODY5 phenotype was observed in 4 families. Occurrence of a de novo mutation was demonstrated in 2 families. Diabetes was present in 10 of 13 mutation carriers. It was clinically overt in 5 participants and found by screening at age 19 to 38 years in 5 participants. Pancreas atrophy was observed in 5 of 6 probands, and pancreas exocrine insufficiency was observed in 6 of 7 probands. Renal involvement, consisting of structural changes and slowly progressive renal failure, was recognized in 9 patients at 18 to 41 years of age. Dysplastic kidneys were found by ultrasonography in 3 fetuses who subsequently showed transient neonatal renal failure. Genital tract abnormalities were present in 5 probands and liver enzyme levels were abnormal in 11 of 13 patients. Limitations: since the study was small and not populationbased, it could not estimate the prevalence of MODY5. Other phenotypes might be associated with HNF-1beta mutations. Conclusions: Maturity-onset diabetes of the young type 5 encompasses a wide clinical spectrum. Analysis for mutations of HNF-1beta is warranted, even without a family history of diabetes, in nonobese patients with diabetes and slowly progressive nondiabetic nephropathy, particularly when pancreatic atrophy or genital abnormalities are present.	Hop St Antoine, Lab Biol Mol, Federat Serv Biochim, F-75012 Paris, France; Hop St Vincent De Paul, Paris, France; Hop St Morand, Altkirch, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Bellanne-Chantelot, C (corresponding author), Hop St Antoine, Lab Biol Mol, Federat Serv Biochim, 184 Rue Faubourg, F-75012 Paris, France.	christine.bellanne@sat.ap-hop-paris.fr	Velho, Gilberto/Q-6724-2017	Velho, Gilberto/0000-0001-8811-363X; BOITARD, Christian/0000-0003-3985-9405; Dubois-Laforgue, Daniele/0000-0003-3287-6309				ASSAN R, 1990, DIABETES, V39, P768, DOI 10.2337/diabetes.39.7.768; BARNES DJ, 1995, TXB CLIN NEPHROLOGY, P723; Bingham C, 2001, AM J HUM GENET, V68, P219, DOI 10.1086/316945; Bingham C, 2000, KIDNEY INT, V57, P898, DOI 10.1046/j.1523-1755.2000.057003898.x; Bingham C, 2002, KIDNEY INT, V61, P1243, DOI 10.1046/j.1523-1755.2002.00272.x; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Carbone I, 2002, DIABETOLOGIA, V45, P153; Clocquet AR, 2000, DIABETES, V49, P1856, DOI 10.2337/diabetes.49.11.1856; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Coffinier C, 1999, MECH DEVELOP, V89, P211, DOI 10.1016/S0925-4773(99)00221-X; Coffinier C, 2002, DEVELOPMENT, V129, P1829; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; Furuta H, 2002, J CLIN ENDOCR METAB, V87, P3859, DOI 10.1210/jc.87.8.3859; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; Iwasaki N, 1998, DIABETES CARE, V21, P2144, DOI 10.2337/diacare.21.12.2144; Iwasaki N, 2001, DIABETOLOGIA, V44, P387; KAPLAN BS, 1989, AM J MED GENET, V34, P569, DOI 10.1002/ajmg.1320340423; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Kolatsi-Joannou M, 2001, J AM SOC NEPHROL, V12, P2175, DOI 10.1681/ASN.V12102175; Lehto M, 1997, J CLIN INVEST, V99, P582, DOI 10.1172/JCI119199; Lindner TH, 1999, HUM MOL GENET, V8, P2001, DOI 10.1093/hmg/8.11.2001; Mache CJ, 2002, PEDIATR NEPHROL, V17, P1021, DOI 10.1007/s00467-002-0975-2; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; Moller AM, 1998, DIABETOLOGIA, V41, P1528, DOI 10.1007/s001250051101; Montoli A, 2002, AM J KIDNEY DIS, V40, P397, DOI 10.1053/ajkd.2002.34538; Nishigori H, 1998, DIABETES, V47, P1354, DOI 10.2337/diabetes.47.8.1354; Reber M, 2001, MECH DEVELOP, V100, P75, DOI 10.1016/S0925-4773(00)00493-7; RIZZONI G, 1982, CLIN NEPHROL, V18, P263; Shih DQ, 2001, P NATL ACAD SCI USA, V98, P14189, DOI 10.1073/pnas.251558998; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Vaxillaire M, 1999, J BIOL CHEM, V274, P35639, DOI 10.1074/jbc.274.50.35639; Waller SC, 2002, AM J KIDNEY DIS, V40, P1325, DOI 10.1053/ajkd.2002.36915; Yamada S, 1999, DIABETES, V48, P645, DOI 10.2337/diabetes.48.3.645; Yamada S, 1997, DIABETES, V46, P1643, DOI 10.2337/diabetes.46.10.1643; Yoshiuchi I, 2002, DIABETOLOGIA, V45, P154	35	247	254	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 6	2004	140	7					510	517		10.7326/0003-4819-140-7-200404060-00009	http://dx.doi.org/10.7326/0003-4819-140-7-200404060-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808OE	15068978				2022-12-28	WOS:000220577600002
J	Brown, R; Silva, AJ				Brown, R; Silva, AJ			Molecular and cellular cognition: The unraveling of memory retrieval	CELL			English	Editorial Material									Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Silva, AJ (corresponding author), Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA.		Silva, Alcino/ABD-7684-2021	Silva, Alcino/0000-0002-1587-4558; Silva, Alcino/0000-0001-5525-0494				Barros DM, 2001, BEHAV BRAIN RES, V124, P1, DOI 10.1016/S0166-4328(01)00208-X; Bontempi B, 1999, NATURE, V400, P671, DOI 10.1038/23270; Cahill L, 1998, TRENDS NEUROSCI, V21, P294, DOI 10.1016/S0166-2236(97)01214-9; Mansuy IM, 1998, NEURON, V21, P257, DOI 10.1016/S0896-6273(00)80533-4; Matynia A, 2002, ANNU REV GENET, V36, P687, DOI 10.1146/annurev.genet.36.062802.091007; Murchison CF, 2004, CELL, V117, P131, DOI 10.1016/S0092-8674(04)00259-4; Nader K, 2003, TRENDS NEUROSCI, V26, P65, DOI 10.1016/S0166-2236(02)00042-5; SARA SJ, 1994, BRAIN RES BULL, V35, P457, DOI 10.1016/0361-9230(94)90159-7; STANTON PK, 1985, J NEUROSCI, V5, P2169	9	10	12	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 2	2004	117	1					3	4		10.1016/S0092-8674(04)00295-8	http://dx.doi.org/10.1016/S0092-8674(04)00295-8			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YV	15066276	Bronze			2022-12-28	WOS:000221500300002
J	Loizou, JI; El-Khamisy, SF; Zlatanou, A; Moore, DJ; Chan, DW; Qin, J; Sarno, S; Meggio, F; Pinna, LA; Caldecott, KW				Loizou, JI; El-Khamisy, SF; Zlatanou, A; Moore, DJ; Chan, DW; Qin, J; Sarno, S; Meggio, F; Pinna, LA; Caldecott, KW			The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks	CELL			English	Article							FHA DOMAIN; POLY(ADP-RIBOSE) POLYMERASE; XRCC1; PHOSPHORYLATION; DAMAGE; BETA; ATP; 4,5,6,7-TETRABROMOBENZOTRIAZOLE; REQUIREMENT; DISRUPTION	CK2 was the first protein kinase identified and is required for the proliferation and survival of mammalian cells. Here, we have identified an unanticipated role for CK2. We show that this essential protein kinase phosphorylates the scaffold protein XRCC1 and thereby enables the assembly and activity of DNA single-strand break repair protein complexes in vitro and at sites of chromosomal breakage. Moreover, we show that inhibiting XRCC1 phosphorylation by mutation of the CK2 phosphorylation sites or preventing CK2 activity using a highly specific inhibitor ablates the rapid repair of cellular DNA single-strand breaks by XRCC1. These data identify a direct role for CK2 in the repair of chromosomal DNA strand breaks and in maintaining genetic integrity.	Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England; Baylor Coll Med, Houston, TX 77030 USA; Univ Padua, I-35121 Padua, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy	University of Sussex; Baylor College of Medicine; University of Padua; Veneto Institute Molecular Medicine	Caldecott, KW (corresponding author), Univ Sussex, Genome Damage & Stabil Ctr, Sci Pk Rd,Falmer, Brighton BN1 9RQ, E Sussex, England.	k.w.caldecott@sussex.ac.uk	Caldecott, Keith/S-4245-2019	Caldecott, Keith/0000-0003-4255-9016; , Sherif/0000-0003-2721-7763; Loizou, Joanna/0000-0003-1853-0424	MRC [G0001259] Funding Source: UKRI; Medical Research Council [G0001259] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Barz T, 2003, J CELL SCI, V116, P1563, DOI 10.1242/jcs.00352; Battistutta R, 2001, PROTEIN SCI, V10, P2200, DOI 10.1110/ps.19601; Buchou T, 2003, MOL CELL BIOL, V23, P908, DOI 10.1128/MCB.23.3.908-915.2003; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Caldecott KW, 2001, BIOESSAYS, V23, P447, DOI 10.1002/bies.1063; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kadkhodayan S, 1996, SOMAT CELL MOLEC GEN, V22, P453, DOI 10.1007/BF02369437; Keller DM, 2002, J BIOL CHEM, V277, P50206, DOI 10.1074/jbc.M209820200; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Li PF, 2002, MOL CELL, V10, P247, DOI 10.1016/S1097-2765(02)00600-7; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Marintchev A, 1999, NAT STRUCT BIOL, V6, P884; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MEGGIO F, 1976, ANAL BIOCHEM, V71, P583, DOI 10.1016/S0003-2697(76)80028-0; Miyata Y, 1997, P NATL ACAD SCI USA, V94, P14500, DOI 10.1073/pnas.94.26.14500; Moore DJ, 2000, P NATL ACAD SCI USA, V97, P13649, DOI 10.1073/pnas.250477597; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Sarno S, 2002, PHARMACOL THERAPEUT, V93, P159, DOI 10.1016/S0163-7258(02)00185-7; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Taylor RM, 2000, MOL CELL BIOL, V20, P735, DOI 10.1128/MCB.20.2.735-740.2000; Taylor RM, 2002, MOL CELL BIOL, V22, P2556, DOI 10.1128/MCB.22.8.2556-2563.2002; Thomas M C, 2000, BMC Nephrol, V1, P1, DOI 10.1186/1471-2369-1-1; THOMPSON LH, 1982, MUTAT RES, V95, P427, DOI 10.1016/0027-5107(82)90276-7; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m	45	267	281	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 2	2004	117	1					17	28		10.1016/S0092-8674(04)00206-5	http://dx.doi.org/10.1016/S0092-8674(04)00206-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YV	15066279	Bronze			2022-12-28	WOS:000221500300005
J	Minokoshi, Y; Alquier, T; Furukawa, N; Kim, YB; Lee, A; Xue, BZ; Mu, J; Foufelle, F; Ferre, P; Birnbaum, MJ; Stuck, BJ; Kahn, BB				Minokoshi, Y; Alquier, T; Furukawa, N; Kim, YB; Lee, A; Xue, BZ; Mu, J; Foufelle, F; Ferre, P; Birnbaum, MJ; Stuck, BJ; Kahn, BB			AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus	NATURE			English	Article							ACTIVATED PROTEIN-KINASE; CENTRAL-NERVOUS-SYSTEM; BODY-WEIGHT; GLUCOSE-PRODUCTION; GENE-EXPRESSION; MALONYL-COA; IN-VITRO; LEPTIN; NEURONS; INHIBITION	Obesity is an epidemic in Western society, and causes rapidly accelerating rates of type 2 diabetes and cardiovascular disease. The evolutionarily conserved serine/threonine kinase, AMP-activated protein kinase (AMPK), functions as a 'fuel gauge' to monitor cellular energy status(1). We investigated the potential role of AMPK in the hypothalamus in the regulation of food intake. Here we report that AMPK activity is inhibited in arcuate and paraventricular hypothalamus (PVH) by the anorexigenic hormone leptin, and in multiple hypothalamic regions by insulin, high glucose and refeeding. A melanocortin receptor agonist, a potent anorexigen(2), decreases AMPK activity in PVH, whereas agouti-related protein, an orexigen(2), increases AMPK activity. Melanocortin receptor signalling is required for leptin and refeeding effects on AMPK in PVH. Dominant negative AMPK expression in the hypothalamus is sufficient to reduce food intake and body weight, whereas constitutively active AMPK increases both. Alterations of hypothalamic AMPK activity augment changes in arcuate neuropeptide expression induced by fasting and feeding. Furthermore, inhibition of hypothalamic AMPK is necessary for leptin's effects on food intake and body weight, as constitutively active AMPK blocks these effects. Thus, hypothalamic AMPK plays a critical role in hormonal and nutrient-derived anorexigenic and orexigenic signals and in energy balance.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Cox Inst, Philadelphia, PA 19104 USA; Ctr REch Biomed Cordeliers, INSERM, U465, F-75270 Paris 6, France	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Pennsylvania; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Kahn, BB (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA.	bkahn@bidmc.harvard.edu	Alquier, Thierry/Z-1917-2019; Ferré, Pascal/K-1250-2013	Alquier, Thierry/0000-0001-8171-802X; Ferré, Pascal/0000-0003-0115-7045; Birnbaum, Morris/0000-0001-9972-8680; Minokoshi, Yasuhiko/0000-0002-7119-4805; FOUFELLE, Fabienne/0000-0002-0752-622X; Mu, James/0000-0001-8081-2401				Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Cowley MA, 1999, NEURON, V24, P155, DOI 10.1016/S0896-6273(00)80829-6; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Hu ZY, 2003, P NATL ACAD SCI USA, V100, P12624, DOI 10.1073/pnas.1834402100; Levin BE, 2001, INT J OBESITY, V25, pS68, DOI 10.1038/sj.ijo.0801916; Light PE, 2003, CIRCULATION, V107, P1962, DOI 10.1161/01.CIR.0000069269.60167.02; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; Obici S, 2002, DIABETES, V51, P271, DOI 10.2337/diabetes.51.2.271; Obici S, 2002, NAT MED, V8, P1376, DOI 10.1038/nm798; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Spanswick D, 1997, NATURE, V390, P521, DOI 10.1038/37379; Spanswick D, 2000, NAT NEUROSCI, V3, P757, DOI 10.1038/77660; Turnley AM, 1999, J NEUROCHEM, V72, P1707, DOI 10.1046/j.1471-4159.1999.721707.x; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Xavier GD, 2003, BIOCHEM J, V371, P761; Zhao AZ, 2002, NAT NEUROSCI, V5, P727, DOI 10.1038/nn885	31	1251	1309	4	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2004	428	6982					569	574		10.1038/nature02440	http://dx.doi.org/10.1038/nature02440			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	807ZT	15058305				2022-12-28	WOS:000220540100044
J	Webster, MA; Kaping, D; Mizokami, Y; Duhamel, P				Webster, MA; Kaping, D; Mizokami, Y; Duhamel, P			Adaptation to natural facial categories	NATURE			English	Article							FACE RECOGNITION; PERCEPTION; EXPRESSIONS; MECHANISMS; RACE	Face perception is fundamentally important for judging the characteristics of individuals, such as identification of their gender, age, ethnicity or expression. We asked how the perception of these characteristics is influenced by the set of faces that observers are exposed to. Previous studies have shown that the appearance of a face can be biased strongly after viewing an altered image of the face, and have suggested that these aftereffects reflect response changes in the neural mechanisms underlying object or face perception(1-5). Here we show that these adaptation effects are pronounced for natural variations in faces and for natural categorical judgements about faces. This suggests that adaptation may routinely influence face perception in normal viewing, and could have an important role in calibrating properties of face perception according to the subset of faces populating an individual's environment.	Univ Nevada, Dept Psychol, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	Webster, MA (corresponding author), Univ Nevada, Dept Psychol, Reno, NV 89557 USA.	mwebster@unr.nevada.edu	Mizokami, Yoko/R-6982-2016	Mizokami, Yoko/0000-0001-7678-5463; Webster, Michael/0000-0001-8262-7525	NATIONAL EYE INSTITUTE [R01EY010834] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY010834] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BEALE JM, 1995, COGNITION, V57, P217, DOI 10.1016/0010-0277(95)00669-X; DIAMOND R, 1986, J EXP PSYCHOL GEN, V115, P107, DOI 10.1037/0096-3445.115.2.107; EKMAN P, 1994, PSYCHOL BULL, V115, P268, DOI 10.1037/0033-2909.115.2.268; ETCOFF NL, 1992, COGNITION, V44, P227, DOI 10.1016/0010-0277(92)90002-Y; Farah MJ, 1998, PSYCHOL REV, V105, P482, DOI 10.1037/0033-295X.105.3.482; Furl N, 2002, COGNITIVE SCI, V26, P797, DOI 10.1016/S0364-0213(02)00084-8; Gauthier I, 1997, VISION RES, V37, P1673, DOI 10.1016/S0042-6989(96)00286-6; Kanwisher N, 2000, NAT NEUROSCI, V3, P759, DOI 10.1038/77664; Leopold DA, 2001, NAT NEUROSCI, V4, P89, DOI 10.1038/82947; Levin DT, 2000, J EXP PSYCHOL GEN, V129, P559, DOI 10.1037//0096-3445.129.4.559; Matsumoto D, 1988, JAPANESE CAUCASIAN F; McKone E, 2001, J EXP PSYCHOL HUMAN, V27, P573, DOI 10.1037/0096-1523.27.3.573; Moscovitch M, 1997, J COGNITIVE NEUROSCI, V9, P555, DOI 10.1162/jocn.1997.9.5.555; Rhodes G, 2003, PSYCHOL SCI, V14, P558, DOI 10.1046/j.0956-7976.2003.psci_1465.x; Watson TL, 2003, PERCEPTION, V32, P1109, DOI 10.1068/p5082; Webster MA, 1999, PSYCHON B REV, V6, P647, DOI 10.3758/BF03212974; Young AW, 1997, COGNITION, V63, P271, DOI 10.1016/S0010-0277(97)00003-6; Zhao L, 2001, VISION RES, V41, P2979, DOI 10.1016/S0042-6989(01)00202-4	18	486	492	1	201	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 1	2004	428	6982					557	561		10.1038/nature02420	http://dx.doi.org/10.1038/nature02420			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	807ZT	15058304				2022-12-28	WOS:000220540100041
J	Lohmann, JU; Weigel, D				Lohmann, JU; Weigel, D			From tough nuts to touch-me-nots	CELL			English	Editorial Material							ARABIDOPSIS; GENE	An intricate arrangement of different cell types is required for the spring-loaded mechanism of spontaneous seed dispersal typical for many fruits. LiIjegren and colleagues (2004 [this issue of Cell]) describe a nonlinear network of transcription factor genes controlling this process.	Max Planck Inst Dev Biol, Dept Biol Mol, D-72076 Tubingen, Germany; Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA	Max Planck Society; Salk Institute	Lohmann, JU (corresponding author), Max Planck Inst Dev Biol, Dept Biol Mol, D-72076 Tubingen, Germany.		Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/GSJ-0799-2022; Lohmann, Jan/T-3776-2019; Weigel, Detlef/C-1418-2008	Weigel, Detlef/0000-0002-2114-7963; Lohmann, Jan/0000-0003-3667-187X; Weigel, Detlef/0000-0002-2114-7963				Ferrandiz C, 2000, SCIENCE, V289, P436, DOI 10.1126/science.289.5478.436; Heisler MGB, 2001, DEVELOPMENT, V128, P1089; Liljegren SJ, 2004, CELL, V116, P843, DOI 10.1016/S0092-8674(04)00217-X; Rajani S, 2001, CURR BIOL, V11, P1914, DOI 10.1016/S0960-9822(01)00593-0; Sessions A, 1997, DEVELOPMENT, V124, P4481	5	6	6	1	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 19	2004	116	6					763	764		10.1016/S0092-8674(04)00254-5	http://dx.doi.org/10.1016/S0092-8674(04)00254-5			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YS	15035977	Bronze			2022-12-28	WOS:000221499900001
J	Tomari, Y; Du, TT; Haley, B; Schwarz, DS; Bennett, R; Cook, HA; Koppetsch, BS; Theurkauf, WE; Zamore, PD				Tomari, Y; Du, TT; Haley, B; Schwarz, DS; Bennett, R; Cook, HA; Koppetsch, BS; Theurkauf, WE; Zamore, PD			RISC assembly defects in the Drosophila RNAi mutant armitage	CELL			English	Article							DOUBLE-STRANDED-RNA; MESSENGER-RNA; GENETIC INTERFERENCE; MEIOTIC DRIVE; GERM-LINE; C-ELEGANS; TRANSGENE; HELICASE; INITIATION; EXPRESSION	The putative RNA helicase, Armitage (Armi), is required to repress oskar translation in Drosophila oocytes; armi mutant females are sterile and armi mutations disrupt anteroposterior and dorsoventral patterning. Here, we show that armi is required for FINAL armi mutant male germ cells fail to silence Stellate, a gene regulated endogenously by RNAi, and lysates from armi mutant ovaries are defective for RNAi in vitro. Native gel analysis of protein-siRNA complexes in wild-type and armi mutant ovary lysates suggests that armi mutants support early steps in the RNAi pathway but are defective in the production of active RNA-induced silencing complex (RISC), which mediates target RNA destruction in RNAi. Our results suggest that armi is required for RISC maturation.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Theurkauf, WE (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA.	william.theurkauf@umassmed.edu; phillip.zamore@umassmed.edu	Zamore, Phillip D/A-8941-2013; Tomari, Yukihide/A-8009-2009	Tomari, Yukihide/0000-0001-8442-0851; Zamore, Phillip/0000-0002-4505-9618; Theurkauf, William/0000-0001-7342-1912	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062862, R37GM062862, R01GM065236] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62862-01, GM65236-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; Aravin AA, 2001, CURR BIOL, V11, P1017, DOI 10.1016/S0960-9822(01)00299-8; Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Belloni M, 2002, GENETICS, V161, P1551; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; Boutla A, 2001, CURR BIOL, V11, P1776, DOI 10.1016/S0960-9822(01)00541-3; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Catalanotto C, 2002, GENE DEV, V16, P790, DOI 10.1101/gad.222402; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Celotto AM, 2002, RNA, V8, P718, DOI 10.1017/S1355838202021064; Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Cox DN, 1998, GENE DEV, V12, P3715, DOI 10.1101/gad.12.23.3715; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; Dalmay T, 2001, EMBO J, V20, P2069, DOI 10.1093/emboj/20.8.2069; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fagard M, 2000, P NATL ACAD SCI USA, V97, P11650, DOI 10.1073/pnas.200217597; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Gvozdev VA, 2003, GENETICA, V117, P239, DOI 10.1023/A:1022952315467; Haley B, 2003, METHODS, V30, P330, DOI 10.1016/S1046-2023(03)00052-5; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Himber C, 2003, EMBO J, V22, P4523, DOI 10.1093/emboj/cdg431; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Jorgensen Richard A., 2003, P5; Kennerdell JR, 2002, GENE DEV, V16, P1884, DOI 10.1101/gad.990802; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90338-A; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Lohmann JU, 1999, DEV BIOL, V214, P211, DOI 10.1006/dbio.1999.9407; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Morel JB, 2002, PLANT CELL, V14, P629, DOI 10.1105/tpc.010358; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Pal-Bhadra M, 2002, MOL CELL, V9, P315, DOI 10.1016/S1097-2765(02)00440-9; Ratcliff FG, 1999, PLANT CELL, V11, P1207, DOI 10.1105/tpc.11.7.1207; Roignant JY, 2003, RNA, V9, P299, DOI 10.1261/rna.2154103; Saxena S, 2003, J BIOL CHEM, V278, P44312, DOI 10.1074/jbc.M307089200; Schmidt A, 1999, GENETICS, V151, P749; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Schwarz DS, 2002, MOL CELL, V10, P537, DOI 10.1016/S1097-2765(02)00651-2; Sijen T, 2003, NATURE, V426, P310, DOI 10.1038/nature02107; Stapleton W, 2001, CHROMOSOMA, V110, P228, DOI 10.1007/s004120100136; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; THEURKAUF WE, 1994, METHOD CELL BIOL, V44, P489, DOI 10.1016/S0091-679X(08)60928-0; Tijsterman M, 2002, SCIENCE, V295, P694, DOI 10.1126/science.1067534; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Wianny F, 2000, NAT CELL BIOL, V2, P70, DOI 10.1038/35000016; Williams RW, 2002, P NATL ACAD SCI USA, V99, P6889, DOI 10.1073/pnas.072190799; Wu-Scharf D, 2000, SCIENCE, V290, P1159, DOI 10.1126/science.290.5494.1159; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	68	302	333	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 19	2004	116	6					831	841		10.1016/S0092-8674(04)00218-1	http://dx.doi.org/10.1016/S0092-8674(04)00218-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	821YS	15035985	Bronze			2022-12-28	WOS:000221499900009
J	Xia, KW; Rosakis, AJ; Kanamori, H				Xia, KW; Rosakis, AJ; Kanamori, H			Laboratory earthquakes: The sub-Rayleigh-to-supershear rupture transition	SCIENCE			English	Article							IMPERIAL-VALLEY EARTHQUAKE; SHEAR CRACKS; SLIP-PULSE; FAULT; PROPAGATION; SIMULATION	We report on the experimental observation of spontaneously nucleated supershear rupture and on the visualization of sub-Rayleigh-to-supershear rupture transitions in frictionally held interfaces. The laboratory experiments mimic natural earthquakes. The results suggest that under certain conditions supershear rupture propagation can be facilitated during large earthquake events.	CALTECH, Seismol Lab, Pasadena, CA 91125 USA; CALTECH, Grad Aeronaut Labs, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Kanamori, H (corresponding author), CALTECH, Seismol Lab, MC 252-21, Pasadena, CA 91125 USA.	hiroo@gps.caltech.edu		Rosakis, Ares/0000-0003-0559-0794				Abraham FF, 2000, PHYS REV LETT, V84, P3113, DOI 10.1103/PhysRevLett.84.3113; ANDREWS DJ, 1976, J GEOPHYS RES, V81, P5679, DOI 10.1029/JB081i032p05679; Andrews DJ, 1997, J GEOPHYS RES-SOL EA, V102, P553, DOI 10.1029/96JB02856; ARCHULETA RJ, 1984, J GEOPHYS RES, V89, P4559, DOI 10.1029/JB089iB06p04559; Bouchon M, 2003, SCIENCE, V301, P824, DOI 10.1126/science.1086832; Bouchon M, 2001, GEOPHYS RES LETT, V28, P2723, DOI 10.1029/2001GL013112; Bowden F. P., 1986, FRICTION LUBRICATION, P374; Broberg K.B., 1999, CRACKS FRACTURE, P752; BURRIDGE R, 1973, GEOPHYS J ROY ASTR S, V35, P439, DOI 10.1111/j.1365-246X.1973.tb00608.x; BURRIDGE R, 1979, J GEOPHYS RES, V84, P2210, DOI 10.1029/JB084iB05p02210; Cochard A, 2000, J GEOPHYS RES-SOL EA, V105, P25891, DOI 10.1029/2000JB900230; DAS S, 1977, GEOPHYS J ROY ASTR S, V50, P643, DOI 10.1111/j.1365-246X.1977.tb01339.x; DAY SM, 1982, B SEISMOL SOC AM, V72, P1881; Dunham EM, 2003, SCIENCE, V299, P1557, DOI 10.1126/science.1080650; Ellsworth W. L., 2004, 11 INT C SOIL DYN EA; Freund L. B., 1990, DYNAMIC FRACTURE MEC, P563; Ide S, 1997, J GEOPHYS RES-SOL EA, V102, P27379, DOI 10.1029/97JB02675; Lin AM, 2002, SCIENCE, V296, P2015, DOI 10.1126/science.1070879; Madariaga R, 2000, PURE APPL GEOPHYS, V157, P1981, DOI 10.1007/PL00001071; Ohnaka M, 2003, J GEOPHYS RES, V108; Olsen KB, 1997, SCIENCE, V278, P834, DOI 10.1126/science.278.5339.834; PALMER AC, 1973, P ROY SOC LOND A MAT, V332, P527, DOI 10.1098/rspa.1973.0040; Rosakis AJ, 1999, SCIENCE, V284, P1337, DOI 10.1126/science.284.5418.1337; Rosakis AJ, 2002, ADV PHYS, V51, P1189, DOI 10.1080/00018730210122328; SPUDICH P, 1984, B SEISMOL SOC AM, V74, P2083	25	260	269	10	156	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	2004	303	5665					1859	1861		10.1126/science.1094022	http://dx.doi.org/10.1126/science.1094022			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	804EI	15031503				2022-12-28	WOS:000220281600053
J	Murakami, A; Miyashita, H; Iseki, M; Adachi, K; Mimuro, M				Murakami, A; Miyashita, H; Iseki, M; Adachi, K; Mimuro, M			Chlorophyll d in an epiphytic cyanobacterium of red algae	SCIENCE			English	Article									Kobe Univ, Res Ctr Inland Seas, Awaji, Hyogo 6562401, Japan; Kobe Univ, Grad Sch Sci & Technol, Kobe, Hyogo 6578501, Japan; Kyoto Univ, Dept Technol & Ecol, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Human & Environm Studies, Kyoto 6068501, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan; Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan; Marine Biotechnol Inst, Kamaishi, Iwate 0260001, Japan	Kobe University; Kobe University; Kyoto University; Kyoto University; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Murakami, A (corresponding author), Kobe Univ, Res Ctr Inland Seas, Awaji, Hyogo 6562401, Japan.	akiomura@kobe-u.ac.jp						[Anonymous], 2002, PHOTOSYNTHETICA; Buchanan B.B., 2000, BIOCH MOL BIOL PLANT; ESTIGNEEV VB, 1970, BIOCHEMISTRY-US, V35, P48; HOLT A. STANLEY, 1961, CANADIAN JOUR BOT, V39, P327; HOLT AS, 1959, CAN J CHEM, V37, P507, DOI 10.1139/v59-069; LEY RE, 1999, PHYCOLOGY; Manning WM, 1943, J BIOL CHEM, V151, P1; Miyashita H, 1996, NATURE, V383, P402, DOI 10.1038/383402a0; Strain HH, 1958, CHLOROPLAST PIGMENTS	9	121	129	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	2004	303	5664					1633	1633		10.1126/science.1095459	http://dx.doi.org/10.1126/science.1095459			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802GG	15016990				2022-12-28	WOS:000220151400033
J	Raitakari, OT				Raitakari, OT			Arterial abnormalities in children with familial hypercholesterolaemia	LANCET			English	Editorial Material							CARDIOVASCULAR RISK-FACTORS; INTIMA-MEDIA THICKNESS; PLACEBO-CONTROLLED TRIAL; CHILDHOOD; EFFICACY; SAFETY; ADULTHOOD; DISEASE		Univ Turku, Cardioresp Res Unit, FIN-20520 Turku, Finland	University of Turku	Raitakari, OT (corresponding author), Univ Turku, Cardioresp Res Unit, FIN-20520 Turku, Finland.	olli.raitakari@utu.fi	Raitakari, Olli/AAQ-7389-2021					Davis PH, 2001, CIRCULATION, V104, P2815, DOI 10.1161/hc4601.099486; de Jongh S, 2002, CIRCULATION, V106, P2231, DOI 10.1161/01.CIR.0000035247.42888.82; Jarvisalo MJ, 2001, CIRCULATION, V104, P2943, DOI 10.1161/hc4901.100522; Li SX, 2003, JAMA-J AM MED ASSOC, V290, P2271, DOI 10.1001/jama.290.17.2271; McCrindle BW, 2003, J PEDIATR-US, V143, P74, DOI 10.1016/S0022-3476(03)00186-0; Raitakari OT, 2003, JAMA-J AM MED ASSOC, V290, P2277, DOI 10.1001/jama.290.17.2277; SLACK J, 1969, LANCET, V2, P1380; Stein EA, 1999, JAMA-J AM MED ASSOC, V281, P137, DOI 10.1001/jama.281.2.137; STONE NJ, 1974, CIRCULATION, V49, P476, DOI 10.1161/01.CIR.49.3.476; Tonstad S, 1996, ARTERIOSCL THROM VAS, V16, P984, DOI 10.1161/01.ATV.16.8.984	10	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	2004	363	9406					342	343		10.1016/S0140-6736(04)15472-X	http://dx.doi.org/10.1016/S0140-6736(04)15472-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768TQ	15070559				2022-12-28	WOS:000188590900004
J	Ridley, AJ				Ridley, AJ			Pulling back to move forward	CELL			English	Editorial Material							ACTIN; KINASE		UCL, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London W1W 7BS, England	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Ridley, AJ (corresponding author), UCL, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.			Ridley, Anne/0000-0001-8186-5708				ALENGHAT FJ, 2002, SCI STKE 2002; Chew TL, 2002, J CELL BIOL, V156, P543, DOI 10.1083/jcb.200110161; Giannone G, 2004, CELL, V116, P431, DOI 10.1016/S0092-8674(04)00058-3; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4; Zhang XF, 2003, NEURON, V40, P931, DOI 10.1016/S0896-6273(03)00754-2; Zicha D, 2003, SCIENCE, V300, P142, DOI 10.1126/science.1082026	10	27	27	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 6	2004	116	3					357	358		10.1016/S0092-8674(04)00123-0	http://dx.doi.org/10.1016/S0092-8674(04)00123-0			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	772DR	15016370	Bronze			2022-12-28	WOS:000188825800004
